Last active
November 13, 2025 21:56
-
-
Save mnarayan/033696fbf92edad56e066960f2980b2d to your computer and use it in GitHub Desktop.
NIH Biomarker Research Funding Analysis (Oct 2024)
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| <!DOCTYPE html> | |
| <html lang="en"> | |
| <head> | |
| <meta charset="UTF-8"> | |
| <meta name="viewport" content="width=device-width, initial-scale=1.0"> | |
| <title>All Biomarker Research: Top 10 Institutes by Total Funding</title> | |
| <script src="https://cdn.jsdelivr.net/npm/[email protected]/dist/chart.umd.min.js"></script> | |
| <style> | |
| body { | |
| font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Arial, sans-serif; | |
| margin: 0; | |
| padding: 20px; | |
| background-color: #f5f5f5; | |
| } | |
| .container { | |
| max-width: 1200px; | |
| margin: 0 auto; | |
| background: white; | |
| padding: 30px; | |
| border-radius: 8px; | |
| box-shadow: 0 2px 4px rgba(0,0,0,0.1); | |
| } | |
| h1 { | |
| color: #333; | |
| margin-bottom: 30px; | |
| font-size: 24px; | |
| } | |
| #chartContainer { | |
| position: relative; | |
| height: 600px; | |
| } | |
| </style> | |
| </head> | |
| <body> | |
| <div class="container"> | |
| <h1>All Biomarker Research: Top 10 Institutes by Total Funding</h1> | |
| <div id="chartContainer"> | |
| <canvas id="myChart"></canvas> | |
| </div> | |
| </div> | |
| <script> | |
| const ctx = document.getElementById('myChart').getContext('2d'); | |
| const myChart = new Chart(ctx, { | |
| type: 'bar', | |
| data: { | |
| labels: ["NCI", "NIA", "NINDS", "NIAID", "NIDDK", "NHLBI", "NIMH", "NIGMS", "NICHD", "NIBIB"], | |
| datasets: [{ | |
| label: 'Total Funding (Millions $)', | |
| data: [1893.19, 1488.02, 730.75, 465.63, 382.74, 367.3, 304.71, 141.74, 139.76, 115.5], | |
| backgroundColor: 'rgba(46, 134, 171, 0.8)', | |
| borderColor: 'rgba(46, 134, 171, 1)', | |
| borderWidth: 2 | |
| }] | |
| }, | |
| options: { | |
| responsive: true, | |
| maintainAspectRatio: false, | |
| scales: { | |
| y: { | |
| beginAtZero: true, | |
| ticks: { | |
| callback: function(value) { | |
| return '$' + value.toFixed(0) + 'M'; | |
| } | |
| } | |
| } | |
| }, | |
| plugins: { | |
| legend: { | |
| display: false | |
| }, | |
| tooltip: { | |
| callbacks: { | |
| label: function(context) { | |
| return '$' + context.parsed.y.toFixed(1) + 'M'; | |
| } | |
| } | |
| } | |
| } | |
| } | |
| }); | |
| </script> | |
| </body> | |
| </html> |
We can't make this file beautiful and searchable because it's too large.
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
| NIH Spending Categorization,Project Terms,Project Title,Public Health Relevance,Administering IC,Application ID,Award Notice Date,Opportunity Number,Project Number,Type,Activity,IC,Serial Number,Support Year,Suffix,Program Official Information,Project Start Date,Project End Date,Study Section,Subproject Number,Contact PI Person ID,Contact PI / Project Leader,Other PI or Project Leader(s),Congressional District,Department,Primary DUNS,Primary UEI,DUNS Number,UEI,FIPS,Latitude,Longitude,Organization ID (IPF),Organization Name,Organization City,Organization State,Organization Type,Organization Zip,Organization Country,ARRA Indicator,Budget Start Date,Budget End Date,CFDA Code,Funding Mechanism,Fiscal Year,Total Cost,Total Cost (Sub Projects),Funding IC(s),Direct Cost IC,InDirect Cost IC,NIH COVID-19 Response,Total Cost IC,Unnamed: 52,Total Cost Numeric | |
| No NIH Category available, ,Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer,Project NarrativeThe current standard of care treatment for men with newly diagnosed oligometastatic prostate cancer (PCa) isnon-curative and this disease remains near uniformly fatal. The use of metastasis-directed therapy (MDT) incombination with systemic therapy and treatment of the primary has the potential to cure a subset of thesemen but currently there is no biomarker to identify which men may benefit from this approach. The lack ofimaging and molecular biomarkers to address this problem is a critical unmet need and by leveraging the firstphase 3 randomized trial assessing the benefit of MDT as part of the international STAMPEDE trial we plan toquantify the benefit of MDT and produce predictive imaging and molecular biomarkers to personalizetreatment decisions and maximize each individuals treatment response to MDT.,NCI,10488573,7/24/2024 12:00:00 AM,PAR-18-951,5U01CA257638-02,5,U01,CA,257638,02, ,"VIKRAM, BHADRASAIN",9/14/2021 12:00:00 AM,8/31/2028 12:00:00 AM,ZCA1-SRB-K(O2), ,14212803,"SPRATT, DANIEL EIDELBERG","SUN, YILUN ",11,RADIATION-DIAGNOSTIC/ONCOLOGY,077758407,HJMKEF7EJW69,077758407,HJMKEF7EJW69,US,41.502739,-81.607334,218601,CASE WESTERN RESERVE UNIVERSITY,CLEVELAND,OH,SCHOOLS OF MEDICINE,441061712,UNITED STATES,N,9/1/2024 12:00:00 AM,8/31/2025 12:00:00 AM,395,Non-SBIR/STTR,2024,445266, ,NCI,351904,93362, ,445266,,445266.0 | |
| No NIH Category available,Address;Animal Model;Antineoplastic Agents;Aspirin;Biogenesis;Blood specimen;Cancer Control;Cancer Etiology;Cancer Intervention;Cancer Patient;Cardiovascular system;Cessation of life;Characteristics;Clinic;Clinical;Clinical Trials;Colorectal;Colorectal Cancer;Data;Development;Disease;Distant;Distant Metastasis;Dose;Experimental Animal Model;FDA approved;Familial Adenomatous Polyposis Syndrome;Forms Controls;Future;General Population;Generic Drugs;Genes;Healthcare;Human;Incidence;Individual;Invaded;Lead;Lesion;Liver;Longevity;Lung;Malignant Neoplasms;Mediating;Mediator;Medical center;Meta-Analysis;Metastatic Adenocarcinoma;MicroRNAs;Military Personnel;Modeling;Molecular;Mus;Neoplasm Metastasis;Non-Steroidal Anti-Inflammatory Agents;Organ;Patients;Pharmaceutical Preparations;Physicians;Plasma;Polyps;Prostaglandin Inhibition;Prostaglandin-Endoperoxide Synthase;Randomized Controlled Clinical Trials;Regulation;Reporting;Resources;Risk;Role;Safety;Sampling;Specimen;Sulindac;Survival Rate;System;Therapeutic;Time;Tissue Microarray;Tissues;Toxic effect;Treatment Efficacy;Tumor Suppressor Proteins;Tumor-Derived;United States;United States Department of Veterans Affairs;Veterans;Xenograft Model;adenoma;advanced disease;biomarker validation;cancer cell;cancer chemoprevention;cell motility;colon cancer patients;colorectal cancer metastasis;colorectal cancer prevention;colorectal cancer progression;exosome;implantation;improved;in vivo;innovation;insight;interest;metastatic colorectal;mortality risk;mouse model;novel;patient derived xenograft model;peripheral blood;pharmacokinetics and pharmacodynamics;preclinical study;premalignant;pressure;prevent;success;systemic toxicity;transcriptome sequencing;tumor;tumor progression;tumorigenesis,MiR-17 mediates sulindac anti-metastatic activity in human colorectal cancer,PROJECT NARRATIVE:Approximately 11% of cancer patients treated by the Veterans Affairs Medical Centers (VAMCs) are colorectalcancer; however there are very few drugs that have been approved by the FDA to treat advanced colorectalcancer. In this project we aim to study a non-toxic mechanism to understand the anti-metastatic activity ofsulindac with the intent to support a new indication of this FDA approved generic drug in the treatment ofmetastatic colorectal cancer. The success of this project will endorse an efficacious safe and affordable optionto benefit the veterans with advanced colorectal cancer and eventually reduce the pressure on the VAMCs dueto the increasing needs for VA health care.,VA,10513297,11/3/2023 12:00:00 AM,RFA-BX-20-001,5I01BX005094-02,5,I01,BX,005094,02, , ,9/30/2022 12:00:00 AM,9/30/2027 12:00:00 AM,ZRD1-ONCC-Y(01), ,9508072,"XI, YAGUANG ",Not Applicable,02,Unavailable,828108790,R7FQBD9KMR63,828108790,R7FQBD9KMR63,US,29.952324,-90.079238,481038,SOUTHEAST LOUISIANA VETERANS HEALTH CARE,NEW ORLEANS,LA,Independent Hospitals,70119,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Bacteria;Bacterial Vaginosis;Binding;Biochemical;Categories;Clinical;Clinical Data;Collection;Communities;Consumption;DNA Sequence;Data;Development;Disease;Enzymes;Epithelial Cells;Epithelium;Excision;Feeds;Functional disorder;Funding;Gardnerella;Gardnerella vaginalis;Genes;Genetic;Growth;Human;In Vitro;Lactobacillus;Longitudinal cohort;Measures;Modeling;Molecular;Mucous body substance;Mus;Mutate;Neuraminidase;Paper;Pathogenesis;Phenotype;Play;Polysaccharides;Pregnancy Complications;Pregnant Women;Premature Birth;Publishing;Reproductive Tract Infections;Ribosomal RNA;Risk;Role;Sampling;Sialic Acids;Specimen;Stretching;Swab;Taxonomy;Testing;Vagina;Woman;adverse outcome;biomarker identification;biomarker validation;dysbiosis;experience;experimental study;human model;intrauterine infection;metaplastic cell transformation;microbial;microbiome;mouse model;mutant;novel;pathogen;prevent;repository;reproductive;tool;vaginal infection;vaginal microbiota,Roles of sialidase in G. vaginalis-host interactions during bacterial vaginosis,PROJECT NARRATIVE:Bacterial vaginosis is an imbalance of the vaginal flora that occurs in 1/3 of U.S. women and is associated withpreterm birth and other reproductive complications. Successful completion of this project will result in a molecularunderstanding of the role played by specific subtypes of Gardnerella in the pathophysiology of BV and will helpidentify biomarkers that may be useful predictors of preterm birth.,NIAID,10545026,12/12/2023 12:00:00 AM,PA-19-056,5R01AI114635-09,5,R01,AI,114635,09, ,"VINCENT, LEAH REBECCA",12/1/2014 12:00:00 AM,11/30/2025 12:00:00 AM,Clinical Research and Field Studies of Infectious Diseases Study Section[CRFS], ,10181621,"LEWIS, AMANDA L.","LEWIS, WARREN G",50,OBSTETRICS & GYNECOLOGY,804355790,UYTTZT6G9DT1,804355790,UYTTZT6G9DT1,US,32.876991,-117.24087,577507,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",LA JOLLA,CA,SCHOOLS OF MEDICINE,920930621,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,855,Non-SBIR/STTR,2024,570002, ,NIAID,368783,201219, ,570002,,570002.0 | |
| No NIH Category available,3-Dimensional;ABCC9 gene;Affect;Age;Aging;Agonist;Alzheimer's Disease;Alzheimer's disease related dementia;Alzheimers disease biomarker;Amyloid;Amyloid beta-Protein;Autopsy;Biological Assay;Biological Markers;Brain;Cardiovascular system;Clinical;Clinical Trials;Cognition;Complement;Congestive Heart Failure;Data;Degenerative Disorder;Dementia;Diagnosis;Differential Diagnosis;Diffusion Magnetic Resonance Imaging;Disease;Double-Blind Method;Elderly;Future;Genes;Genetic;Heart failure;Hippocampus;Human;Impaired cognition;Individual;Kentucky;Life;Link;Longitudinal cohort;Magnetic Resonance Imaging;Magnetic Resonance Spectroscopy;Measures;Metabolic;Morbidity - disease rate;Nerve Degeneration;Neurocognitive;Neurofibrillary Tangles;Nicorandil;Outcome Measure;Participant;Pathology;Pathway interactions;Persons;Pharmaceutical Preparations;Pharmacotherapy;Phase;Placebo Control;Placebos;Population;Populations at Risk;Prevention trial;Probability;Prospective cohort;Proteins;Proteomics;Publishing;Randomized;Research;Risk;Running;Safety;Techniques;Testing;Universities;Urea;Work;aging population;arterial spin labeling;biomarker validation;cognitive testing;cohort;cost;design;disease diagnosis;drug discovery;drug repurposing;early phase clinical trial;efficacy outcomes;genetic risk factor;high risk;hippocampal atrophy;hippocampal sclerosis;magnetic resonance imaging biomarker;neurocognitive test;neuroimaging;neuropathology;novel;novel therapeutics;pharmacologic;prevent;primary endpoint;primary outcome;randomized placebo-controlled clinical trial;rational design;receptor;safety testing;sex;tau Proteins;tau-1;treatment duration;trial design;volunteer,Safety and modulation of ABCC9 pathways by nicorandil for the treatment of hippocampal sclerosis of aging (SMArTHS),NarrativeThis proposal seeks (through drug repurposing) a novel drug therapy as a potential treatment forhippocampal sclerosis dementia. There is no current treatment for this disease that affects approximately1/4th of the elderly but which is seldom recognized clinically because it mimics Alzheimer's disease. As suchthe proposed study represents a cutting-edge data-driven low-cost exploration of a novel disease relevantpathway that may hold promise for our global efforts targeting late life dementia.,NIA,10547764,2/21/2024 12:00:00 AM,PAR-18-175,5R01AG061111-04,5,R01,AG,061111,04, ,"CLARKE, AKANNI YAO",2/1/2019 12:00:00 AM,11/30/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-BBBP-Z(55)R], ,1900844,"JICHA, GREGORY A","NELSON, PETER T.",06,NEUROSCIENCES,939017877,H1HYA8Z1NTM5,939017877,H1HYA8Z1NTM5,US,38.040959,-84.505885,2793601,UNIVERSITY OF KENTUCKY,LEXINGTON,KY,SCHOOLS OF MEDICINE,405260001,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,703505, ,NIA,459807,243698, ,703505,,703505.0 | |
| No NIH Category available,Address;Adolescent;Adult;Age;Aging;Area;Biochemistry;Biological Aging;Biological Assay;Biological Markers;Birth;Blood Chemical Analysis;Blood Pressure;Body mass index;Cells;Child Welfare;Childhood;Cities;Cognition;Communities;DNA Methylation;Data;Data Set;Detection;Disease;Disease Progression;Early Diagnosis;Elderly;Environment;Ethnic Origin;Exposure to;Family;GDF15 gene;Gene Expression;Generations;Glycosylated hemoglobin A;Health;Health and Retirement Study;Healthcare;Immune;Individual;Insulin-Like Growth Factor I;Interleukin-6;Intervention;Life;Life Cycle Stages;Link;Longevity;Longitudinal Studies;Measures;Mediating;Mental Health;Methods;Methylation;National Longitudinal Survey of Adolescent to Adult Health;Outcome;Patient Self-Report;Phenotype;Physiological;Population;Poverty;Prevalence;Prevention;Process;Production;Quality Control;RNA;Race;Research;Research Personnel;Sampling;Signal Transduction;Social Environment;Societies;Socioeconomic Status;Subgroup;Surveys;Symptoms;Testing;Trauma;age related;biobank;biological specimen archives;biomarker validation;blood-based biomarker;clinical practice;cohort;contextual factors;cost;data harmonization;demographics;family structure;insight;middle age;post gamma-globulins;pro-brain natriuretic peptide (1-76);secondary analysis;sex;social adversity;sociodemographics;transcriptome sequencing;traumatic event,Biological Aging Across the Life Course: Harmonizing Cohort Biospecimen Archives,Aging blood-based biomarkers (assays: IL-6 TNFa CRP GDF15 IGF-1 Cystatin C NT-proBNP and hbA1c)DNA methylation (Illumina EPIC chip) and gene expression (RNA Seq) provide an opportunity to detect agingrelated diseases and identify mechanisms linking earlier exposures to later life health. However little is knownabout how these aging biomarkers correlate with each other the environment or health over the life course.This project uses data from three large nationally representative panel studies to examine these associationsover the life course: the Health and Retirement Study (biomarker data for ages 51-110) the NationalLongitudinal Study of Adolescent to Adult Health (biomarker data ages 24-42) and the Fragile Families andChild Wellbeing Study (biomarker data ages 9-22).,NIA,10578833,3/11/2024 12:00:00 AM,PA-17-088,5R01AG071071-03,5,R01,AG,071071,03, ,"BRAUDT, DAVID BRUCE",3/15/2021 12:00:00 AM,2/28/2027 12:00:00 AM,Special Emphasis Panel[ZRG1-PSE-C(02)], ,11514880,"MITCHELL, COLTER M.S.","FAUL, JESSICA ; GAYDOSH, LAUREN M",06,BIOSTATISTICS & OTHER MATH SCI,073133571,GNJ7BBP73WE9,073133571,GNJ7BBP73WE9,US,42.275494,-83.743038,1506502,UNIVERSITY OF MICHIGAN AT ANN ARBOR,ANN ARBOR,MI,ORGANIZED RESEARCH UNITS,481091276,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,615735, ,NIA,494137,121598, ,615735,,615735.0 | |
| No NIH Category available,3-Dimensional;Address;Adult;Algorithms;Archives;Asthma;Cause of Death;Chest;Chest imaging;Chronic Obstructive Pulmonary Disease;Chronic lung disease;Clinical;Collaborations;Computer software;Computerized Medical Record;Data;Development;Diagnosis;Diagnostic tests;Disease;Disease Management;Disease susceptibility;Electronic Health Record;Elements;Enrollment;Environment;Environmental Exposure;Epidemiology;Exposure to;Fibrosis;Foundations;Funding;Future;General Population;Genes;Genetic Diseases;Genetic Markers;Genetic study;Genomics;Health;Heterogeneity;Image;Individual;Inhalation;International;International Classification of Disease Codes;Interstitial Lung Diseases;Investigation;Knowledge;Lung;Lung Diseases;Manuals;Measurement;Medical Imaging;Methods;Modernization;Natural Language Processing;Outcome;Pathogenesis;Pathologic;Patient Self-Report;Persons;Pharmacogenomics;Phenotype;Population Heterogeneity;Probability;Pulmonary Emphysema;Reporting;Research;Research Personnel;Resolution;Retrieval;Risk;Secure;Smoking;Smoking Status;Spirometry;Subgroup;System;Technology;Test Result;Testing;Toxic Environmental Substances;Toxin;United States;Validation;Veterans;Veterans Health Administration;Visual;Work;X-Ray Computed Tomography;adjudication;biobank;blood-based biomarker;case control;chest computed tomography;cohort;computer program;disability;disease diagnosis;disease phenotype;electronic structure;environmental enrichment for laboratory animals;epidemiologic data;epidemiology study;ethnic diversity;firewall;gene environment interaction;genetic epidemiology;genetic variant;genome wide association study;health care service utilization;idiopathic pulmonary fibrosis;imaging modality;imaging platform;information gathering;interstitial;military veteran;mortality;multi-ethnic;multimodality;novel;participant enrollment;personalized medicine;pharmacologic;phenotyping algorithm;polygenic risk score;programs;prospective;prototype;quantitative imaging;radiological imaging;radiologist;respiratory;risk stratification;risk variant;tool,Chronic lung disease phenotyping and genomics in the Veterans Health Administration,Veterans have higher rates of smoking and exposure to inhaled toxins. Veterans also have higher rates ofchronic lung diseases such as asthma chronic obstructive pulmonary disease (COPD) and interstitial lungdisease. However the risk for developing lung disease is different for every person. Genetic studies mayhelp to us understand risk among Veterans. Genetic studies require large numbers of people with and withoutchronic lung disease this has been challenging because tests for diagnosing lung diseases are not alwaysperformed or the information is hard to retrieve. In this project we use advanced technologies to gatherinformation from the VAs electronic medical records and new computer programs to analyze chest CATscans to identify Veterans with and without lung disease. We will then identify differences is genetic markersbetween Veterans with and without lung disease in the Million Veteran Program. Findings from this study willhelp us understand risk and develop personalized treatments in the future.,VA,10583622,12/21/2023 12:00:00 AM,RFA-BX-22-001,1I01BX005957-01A1,1,I01,BX,005957,01,A1, ,1/1/2024 12:00:00 AM,12/31/2027 12:00:00 AM,ZRD1-PULM-N(01)1, ,10328945,"WAN, EMILY S",Not Applicable,07,Unavailable,034432265,DNXEHSXERCX7,034432265,DNXEHSXERCX7,US,42.326771,-71.110172,481041,VA BOSTON HEALTH CARE SYSTEM,BOSTON,MA,Independent Hospitals,021304817,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,3' Untranslated Regions;Address;Axon;Biological Markers;Biological Process;Catalytic Domain;Cells;Characteristics;Co-Immunoprecipitations;Complex;Data;Dependence;Development;Diagnostic;Disease;Embryo;Environmental Exposure;Etiology;Exposure to;Health;Hela Cells;Human;Investigation;Kidney;Length;Link;Literature;Mass Spectrum Analysis;Mediating;Mental disorders;Metabolism;Methodology;Methods;Methylation;Methyltransferase;Modification;Molecular;Nervous System Disorder;Nervous System control;Neurodegenerative Disorders;Neurons;Oxidative Stress;Oxidative Stress Induction;Pathogenesis;Pathogenicity;Pathologic;Pathway interactions;Pattern;Physiological;Play;Predisposition;Prevention strategy;Process;Protein Isoforms;RNA;RNA Transport;Regulation;Regulatory Element;Research;Risk;Role;Shapes;Signaling Molecule;Specific qualifier value;Stimulus;Stress;Synapses;System;Toxic Environmental Substances;Toxicant exposure;Transcript;Validation;Work;adverse outcome;biological adaptation to stress;biomarker identification;design;disorder risk;epitranscriptome;epitranscriptomics;gene environment interaction;genome-wide;human disease;innovation;insight;interest;methylation pattern;novel;protein TDP-43;response;sodium arsenite;toxicant;transcriptome;treatment strategy,Systems-wide analysis of oxidative stress-responsive m6A epitranscriptome,PROJECT NARRATIVEElucidating the action of m6A remodeling complex and the resulting m6A epitranscriptome will reveal how them6A machinery is dysregulated by environmental exposures. This will ultimately aid in the design of effectivediagnostics and facilitate prevention and treatment strategies for exposure-associated disease development.,NIEHS,10600102,3/28/2024 12:00:00 AM,RFA-ES-19-001,5R01ES031511-04,5,R01,ES,031511,04, ,"TYSON, FREDERICK L",6/15/2020 12:00:00 AM,3/31/2026 12:00:00 AM,ZES1-LWJ-D(01), ,14089727,"WENG, YI-LAN ",Not Applicable,09,Unavailable,185641052,XJUCJAYJWYV1,185641052,XJUCJAYJWYV1,US,29.707454,-95.399168,10005742,METHODIST HOSPITAL RESEARCH INSTITUTE,HOUSTON,TX,Other Domestic Non-Profits,77030,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,113,Non-SBIR/STTR,2024,402308, ,NIEHS,307663,94645, ,402308,,402308.0 | |
| No NIH Category available,Abate;Acetic Acids;Algorithms;Blinded;Cervical;Cervical Cancer Screening;Cervical Intraepithelial Neoplasia;Clinical;Colorectal Cancer;Communities;Complex;Country;Cytology;DNA Markers;DNA Methylation;DNA Sequence;Disease;Disparity;Enrollment;Epigenetic Process;Ethnic Origin;Evaluation;Federally Qualified Health Center;Fright;Future;Goals;Guidelines;HPV-High Risk;Health;Health Insurance;Health Promotion;High Risk Woman;Human Papillomavirus;Human papilloma virus infection;Incidence;Income;Insurance Coverage;Knowledge;Laboratories;Laboratory Research;Language;Latina;Latina Population;Left;Lesion;Low Income Population;Low income;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of cervix uteri;Medicaid;Medical;Methylation;Montana;Oncogenic;Pap smear;Patients;Perception;Performance;Phase;Policies;Predictive Value;Prevalence;Preventive;Privatization;Prospective Studies;Puerto Rico;Race;Retrospective Studies;Risk;Sampling;Screening for cancer;Services;Small Business Innovation Research Grant;Specificity;Squamous intraepithelial lesion;Swab;Technology;Testing;Time;Transportation;Uninsured;United States;United States Preventative Services Task Force;Universities;Vagina;Validation;Viral;Visit;Visual;Woman;World Health Organization;advanced disease;aged;biomarker development;cancer health disparity;clinical risk;cohort;commercialization;cost;ethnic diversity;feasibility testing;high risk;intraepithelial;low income country;medical schools;methylation testing;mortality;multiplex assay;novel;personalized screening;phase 1 testing;precision medicine;premalignant;prevent;programs;screening;screening guidelines;social health determinants;tool;treatment guidelines;trial comparing;tumor,Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas,Narrative The goal of this project is to demonstrate the feasibility for the commercialization of the CervicalMethDxTest a precision methylation test in self-collected samples to stratify Latina women for high risk of cervical cancer. Latinas have the highest cervical cancer prevalence and incidence rates in United States and Puerto Rico. A highly sensitive and specific risk test on self-collected samples will enable a novel precision medicine paradigm enabling a reduction in cervical cancer disparities in US and ex-US communities.,NIMHD,10601924,4/22/2024 12:00:00 AM,RFA-MD-22-003,1R42MD018231-01,1,R42,MD,018231,01, ,"WHITE, DOLLY PENN",6/1/2024 12:00:00 AM,11/30/2024 12:00:00 AM,ZMD1-JT(A1)R, ,8374819,"GUERRERO-PRESTON, RAFAEL ",Not Applicable,98,Unavailable,968756119,GGR9ABCTBGG5,968756119,GGR9ABCTBGG5,US,18.417375,-66.061221,10029873,"LIFEGENE-BIOMARKS, INC.",SAN JUAN,PR,Domestic For-Profits,009091833,UNITED STATES,N,6/1/2024 12:00:00 AM,11/30/2024 12:00:00 AM,307,SBIR/STTR,2024,275767, ,NIMHD,184090,73636, ,275767,,275767.0 | |
| No NIH Category available,Affect;Anti-Inflammatory Agents;Antineoplastic Agents;Arginine;Aspirin;Biodistribution;Blood;Caspase;Cell division;Cell membrane;Cells;Cellular Membrane;Chemical Agents;Chemicals;Colon Carcinoma;Contrast Media;DNA Methylation;DNA Methylation Inhibition;DU145;Data;Detection;Drug Efflux;Drug Exposure;Drug resistance;Enzymes;FDA approved;Failure;Formulation;Glutathione;Goals;Hour;Human;Hydroxyl Radical;Image;Image Enhancement;In Vitro;Injectable;Intravenous;Kidney;LNCaP;Label;Length;Liver;MRI Scans;Magnetic Resonance Imaging;Malignant - descriptor;Malignant Neoplasms;Malignant neoplasm of prostate;Measurement;Measures;Mediating;Membrane Proteins;Modeling;Modification;Mus;Nanostructures;Near-infrared optical imaging;Optics;Organ;Penetration;Peptides;Permeability;Pharmaceutical Preparations;Physical condensation;Prediction of Response to Therapy;Property;Proprotein Convertases;Prostate;Prostate Cancer therapy;Protons;Reaction;Salicylic Acids;Signal Transduction;Spleen;Testing;Therapeutic;Time;Toxic effect;Transgenic Mice;Treatment Efficacy;Validation;Visualization;Xenograft Model;asparaginylendopeptidase;biomaterial compatibility;cancer cell;cancer imaging;chemical reaction;clinical translation;clinically relevant;contrast enhanced;efflux pump;imaging biomarker;imaging platform;in vivo;inhibitor;mouse model;nanoformulation;nanoparticle;nanotheranostics;near infrared dye;neoplastic cell;novel;novel anticancer drug;overexpression;pharmacologic;prognostic;prostate cancer cell;prostate cancer cell line;prostate cancer model;protein aminoacid sequence;self assembly;single molecule;small molecule;subcutaneous;success;theranostics;transgenic adenocarcinoma of mouse prostate;treatment response;tumor;tumor growth;tumor initiation;uptake,Intracellular Self-Assembly of Theranostic Nanoparticles for Enhanced Imaging and Tumor Therapy,We propose to develop a novel theranostic formulation of nanoparticles that accumulates in prostate cancercells through a specific chemical reaction initiated by the tumor-specific enzyme legumain. The formulationconsists of self-assembled olsalazine molecules that can provide contrast on MRI scans and simultaneouslyinhibits cell division which allows us to see if the tumor takes up the drug and if this uptake leads to inhibitionof tumor growth. This is important as we may then be able to predict early on if the tumor will eventuallyrespond to treatment.,NIBIB,10606546,5/2/2024 12:00:00 AM,PA-19-056,5R01EB030376-04,5,R01,EB,030376,04, ,"ATANASIJEVIC, TATJANA",7/10/2020 12:00:00 AM,3/31/2025 12:00:00 AM,Imaging Probes and Contrast Agents Study Section[IPCA], ,7039588,"BULTE, JEFF W.",Not Applicable,07,RADIATION-DIAGNOSTIC/ONCOLOGY,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,286,Non-SBIR/STTR,2024,519965, ,NIBIB,388944,131021, ,519965,,519965.0 | |
| No NIH Category available,Acceleration;Address;Aducanumab;Affect;Affective;Alleles;Alzheimer disease prevention;Alzheimer's Disease;Alzheimer's disease patient;Alzheimer's disease risk;Alzheimers disease biomarker;Amyloid;Amyloid beta-Protein;Antibodies;Antibody Therapy;Binding;Biological;Biological Markers;Biological Testing;Blinded;Characteristics;Clinical;Cognition;Cognitive;Collaborations;Communication;Data;Disclosure;Dose;Double-Blind Method;Elderly;Excision;Financial Support;Functional disorder;Genetic;Genetic Risk;Goals;Health;Image;Impaired cognition;Impairment;Incidence;Intervention;Learning;Licensing;Life;Magnetic Resonance Imaging;Measurement;Memory Loss;Modeling;Moods;Nature;Outcome;Participant;Pathology;Persons;Pharmaceutical Preparations;Phase;Phase Ib Clinical Trial;Phase Ib Trial;Placebo Control;Placebos;Populations at Risk;Positron-Emission Tomography;Prevention Guidelines;Prevention therapy;Prevention trial;Procedures;Quality of life;Randomized;Reporting;Resources;Risk;Safety;Sampling;Secure;Senile Plaques;Surrogate Endpoint;Surrogate Markers;Test Result;Testing;Time;Titrations;United States National Institutes of Health;Visit;abeta oligomer;apolipoprotein E-4;asymptomatic Alzheimer's disease;behavioral outcome;clinical effect;cognitive benefits;cost;data resource;industry partner;open label;phase III trial;placebo group;post-market;pre-clinical;prevent;primary outcome;programs;public-private partnership;social relationships;tau Proteins;therapy adverse effect;treatment group,API A4 Alzheimer's Prevention Trial,Project NarrativeLeaders from the Alzheimers Prevention Initiative (API) and Anti-Amyloid Treatment in AsymptomaticAlzheimers (A4) Trials have come together to conduct a potentially license-enabling prevention trial usingclinically informative Alzheimers disease biomarkers and other assessments to evaluate the promising amyloidplaque-busting antibody treatment aducanumab in cognitively unimpaired 65-80 year-old persons with a positiveamyloid PET scan. The deliberately ambitious proposal is intended to 1) find an approved Alzheimers preventiontherapy as early as 2023 ahead of the National Plan to Address Alzheimers Disease goal to preventAlzheimers disease by 2025; 2) introduce the use of these biomarkers to test and approve prevention therapiesin almost everyone who based on their biological tests or genetic risk are at increased risk; and 3) help make itpossible to conduct prevention trials in at risk persons even before they have extensive amyloid plaques whensome treatments may have their greatest benefit. It is intended to capitalize on a public-private partnership withthe makers of aducanumab NIH support $5-10 million dollars in philanthropy; enable us to secure access tothis promising drug and secure most of the financial support from our industry partner; provide a public resourceof data and biological samples to help the field find even better ways to test prevention therapies; have themaximum public benefit; and prevent Alzheimers disease as soon as possible.,NIA,10618803,1/23/2024 12:00:00 AM,PA-16-160,5R01AG058468-04,5,R01,AG,58468,4, ,"RYAN, LAURIE M",9/1/2018 12:00:00 AM,11/30/2025 12:00:00 AM,Basic Neuroscience of Aging Study Section[NIA-N], ,2092025,"REIMAN, ERIC MICHAEL","AISEN, PAUL S.; ALEXANDER, ROBERT C; JOHNSON, KEITH A.; LANGBAUM, JESSICA BROOKE; SPERLING, REISA A.",3.0,Unavailable,071753982,SB35ENJFKK14,071753982,SB35ENJFKK14,US,33.433422,-112.087594,2202601,BANNER HEALTH,PHOENIX,AZ,Other Domestic Non-Profits,850122700,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,6538660, ,NIA,8931574,3730002, ,6538660,,6538660.0 | |
| No NIH Category available,Antigen Presentation;Antigen-Presenting Cells;Antigens;Area;CD8-Positive T-Lymphocytes;CRISPR screen;Cancer Patient;Cell Line;Cell surface;Cells;Cellular biology;Clinic;Clinical;Clinical Research;Clinical Trials Design;Coculture Techniques;Collaborations;Combination immunotherapy;Combined Modality Therapy;Computational Biology;Data;Defect;Dependence;Development Plans;Disease remission;Doctor of Philosophy;Down-Regulation;Environment;Epigenetic Process;Fellowship;Foundations;Gene Expression Regulation;Genetic;Genetic Transcription;Goals;Immune;Immune response;Immunotherapy;In Vitro;Knowledge;Leadership;Machine Learning;Major Histocompatibility Complex;Malignant Neoplasms;Mediating;Melanoma;Melanoma Cell;Modeling;Neoplasm Transplantation;Outcome;Pathway interactions;Patients;Phase I/II Clinical Trial;Phenotype;Play;Production;Regulation;Research;Resistance;Resources;Role;Sampling;Schedule;T-Lymphocyte;Testing;Therapeutic;Training Activity;Transition Career Development Award (K22);Translational Research;Trust;Tumor Antigens;Up-Regulation;Validation;Work;anti-PD-1;cancer cell;cancer immunotherapy;cancer therapy;cancer type;career;career development;cell type;cytokine;cytotoxicity;data mining;efficacy evaluation;epigenetic marker;feature selection;genome-wide;immune checkpoint blockade;immune function;immunoregulation;improved;in vivo;inhibitor-of-apoptosis protein;mathematical model;mimetics;multiple omics;personalized strategies;response;response biomarker;single cell technology;skills;small molecule;transcriptome;transplant model;tumor;tumor immunology;tumor microenvironment;tumor progression,Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics,PROJECT NARRATIVESMAC mimetics can boost antigen presentation in some cancer cells and enhance their response toimmunotherapy but it is unclear which subset of cancer patients can benefit from SMAC mimetic treatment inthe clinic. This proposal will address the context dependencies of SMAC mimetics effects on cancer cells andidentify the optimal combination with immunotherapy. The results from this study can enable effective use ofSMAC mimetics for cancer treatment in the clinic.,NCI,10642113,11/14/2023 12:00:00 AM,PAR-21-128,1K22CA279077-01,1,K22,CA,279077,01, ,"JAKOWLEW, SONIA B",12/1/2023 12:00:00 AM,11/30/2026 12:00:00 AM,ZCA1-RTRB-R(J1), ,15044837,"GU, SHENGQING ",Not Applicable,09,NONE,800772139,S3GMKS8ELA16,800772139,S3GMKS8ELA16,US,29.706319,-95.397195,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,HOUSTON,TX,HOSPITALS,770304009,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,398,Other Research-Related,2024,192240, ,NCI,178000,14240, ,192240,,192240.0 | |
| No NIH Category available,Address;Adoption;Adverse event;Autoantibodies;Autoimmune;Autoimmune Diseases;Autoimmune Process;Autoimmunity;B-Lymphocytes;Biological;Blood;Blood specimen;CD19 gene;CD4 Positive T Lymphocytes;Cancer Patient;Cardiac;Cardiopulmonary;Cells;Chest;Clinical;Clinical Research;Collaborations;Combined Modality Therapy;Diagnosis;Diagnostic tests;Discipline;Early Diagnosis;Excess Mortality;Exposure to;Foundations;Goals;Heart;Humoral Immunities;IL17 gene;Immune;Immunologist;Immunotherapy;Inflammatory;Injury;Innate Immune Response;Institution;Intervention;Investigation;Knockout Mice;Laboratories;Lead;Life;Link;LoxP-flanked allele;Lung;Malignant neoplasm of lung;Measures;Mediating;Modeling;Monitor;Mus;Natural Immunity;Outcome;PD-1 blockade;Patients;Pre-Clinical Model;Production;Quality of life;Radiation Oncologist;Radiation therapy;Role;Sampling;Serum;Structure of parenchyma of lung;T-Lymphocyte;Testing;Therapeutic;Toxic effect;Toxicity Attenuation;Universities;Validation;Wild Type Mouse;Work;adaptive immune response;adaptive immunity;anti-CD20;anti-PD-1;anti-PD1 therapy;autoimmune toxicity;bench to bedside;cytokine;humoral immunity deficiency;immune checkpoint;improved;improved outcome;inhibitor;irradiation;mouse model;neutrophil;new therapeutic target;novel;novel diagnostics;novel marker;pharmacologic;pre-clinical;predictive marker;prevent;programmed cell death protein 1;prospective;response;therapeutic target;translational study,Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy andImmunotherapy,Project NarrativeIn this proposal we will investigate autoimmune mechanisms of cardiac and lung toxicities from thoracicirradiation in the presence of PD-1 blockade. Outcomes of the proposed studies will help to identify novelbiomarkers for early diagnosis of serious and fatal adverse events and novel therapeutic targets for managingthe toxicities and improving therapeutic ratio.,NCI,10643954,5/22/2024 12:00:00 AM,PAR-19-325,5R01CA252484-05,5,R01,CA,252484,05, ,"SOMMERS, CONNIE L",8/1/2020 12:00:00 AM,5/31/2026 12:00:00 AM,Radiation Therapeutics and Biology Study Section[RTB], ,1943281,"LU, BO ",Not Applicable,03,RADIATION-DIAGNOSTIC/ONCOLOGY,153890272,SZPJL5ZRCLF4,153890272,SZPJL5ZRCLF4,US,38.948231,-92.327335,578002,UNIVERSITY OF MISSOURI-COLUMBIA,COLUMBIA,MO,SCHOOLS OF MEDICINE,652110001,UNITED STATES,N,6/1/2024 12:00:00 AM,5/31/2025 12:00:00 AM,395,Non-SBIR/STTR,2024,584575, ,NCI,411503,173072, ,584575,,584575.0 | |
| No NIH Category available,Acceleration;Address;Adenosine Diphosphate Ribose;Adoption;Antibodies;Antibody Therapy;Area;BRCA1 Mutation;BRCA1 gene;BRCA2 Mutation;Biological Markers;Blood specimen;CD8-Positive T-Lymphocytes;CTLA4 blockade;CTLA4 gene;Cancer Biology;Cancer Model;Cell Cycle;Cell Death;Cells;Clinical;Clinical Data;Clinical Trials;Collaborations;Correlative Study;Cytotoxic agent;Data;Death Rate;Development;Disease;Disease Outcome;Environment;Failure;Gene Expression;Goals;Immune;Immunobiology;Immunologic Memory;Immunologic Monitoring;Immunotherapy;In Vitro;Interferon Type II;Interferons;Knowledge;Leukocytes;Link;Lymphocyte;Macrophage;Malignant Neoplasms;Malignant neoplasm of ovary;Mediating;Melanoma;Modeling;Mus;PARP inhibition;Patient Selection;Patient-Focused Outcomes;Patients;Phase;Poly(ADP-ribose) Polymerase Inhibitor;Polymerase;Production;Publishing;Recurrence;Recurrent disease;Regimen;Resistance;Sampling Studies;Signal Transduction;Solid Neoplasm;T-Lymphocyte;Testing;Therapeutic;Translations;Treatment Efficacy;Treatment outcome;Tumor Immunity;Woman;Work;antibody inhibitor;blood treatment;cancer cell;cancer therapy;candidate validation;clinical translation;combinatorial;cytotoxic;cytotoxicity;efficacy evaluation;genetic signature;immune checkpoint;immune checkpoint blockade;immunogenic;immunogenic cell death;immunoregulation;in vivo;inhibitor;mutation carrier;novel;ovarian neoplasm;participant enrollment;pre-clinical;predicting response;predictive marker;recruit;response;response biomarker;synergism;therapy resistant;treatment effect;treatment response;tumor;tumor microenvironment,Mechanisms of Selective Therapeutic Synergy of PARP-inhibition and CTLA4 Blockade Engaged by Interferon-gamma in the Ovarian Tumor Microenvironment,Project Narrative:The high mortality rate associated with ovarian cancer results from the failure of tumor-directedtherapy to produce lasting treatment responses. Published work from our lab demonstrates thatcombining PARP-inhibitors with immune checkpoint blockade can achieve long-term survival inovarian cancer models and may overcome treatment resistance in patients with recurrentdisease. Here we will investigate the mechanisms responsible for the therapeutic synergy ofthis combination to enable the optimal integration of immune therapy with cytotoxic regimens forlong-term benefit in women with ovarian cancer.,NCI,10655058,2/27/2024 12:00:00 AM,PAR-21-138,4R37CA229221-06,4,R37,CA,229221,06, ,"SOMMERS, CONNIE L",2/18/2019 12:00:00 AM,1/31/2026 12:00:00 AM, , ,9617704,"ADAMS, SARAH FOSTER",Not Applicable,01,OBSTETRICS & GYNECOLOGY,829868723,G389MFAYJNG9,829868723,G389MFAYJNG9,US,35.090968,-106.617544,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,ALBUQUERQUE,NM,SCHOOLS OF MEDICINE,871310001,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,395,Non-SBIR/STTR,2024,334312, ,NCI,238200,96112, ,334312,,334312.0 | |
| No NIH Category available,Action Research;Acute;Address;Affect;Biological Markers;Caring;Categories;Cerebral hemisphere hemorrhage;Classification;Clinical;Clinical Treatment;Corticospinal Tracts;Data;Data Set;Decision Making;Dimensions;Enrollment;Fiber;Future;Health;Hospitalization;Impairment;Individual;Injury;International;Ischemic Stroke;Lesion;Location;Magnetic Resonance Imaging;Measures;Motor;Motor Activity;Motor Cortex;Motor Evoked Potentials;Outcome;Patient Selection;Patient-Focused Outcomes;Patients;Performance;Physiological;Process;Randomized Controlled Trials;Recommendation;Recovery;Rehabilitation therapy;Reperfusion Therapy;Reporting;Research;Residual state;Sampling;Severities;Site;Stroke;System;Testing;Transcranial magnetic stimulation;Triage;Upper Extremity;Validation;World Health Organization;acute stroke;arm;biomarker validation;clinical practice;clinically relevant;cohort;cost;disability;functional outcomes;improved;individual patient;individualized medicine;innovation;international health organization;magnetic resonance imaging biomarker;motor deficit;motor impairment;motor recovery;neuroimaging;neurophysiology;outcome prediction;patient stratification;patient subsets;post stroke;predictive tools;prevent;primary outcome;prognostic;prospective;response;stroke recovery;stroke rehabilitation;stroke survivor;treatment effect,Validation of Early Prognostic Data for Recovery Outcomes after Stroke for Future Higher Yield Trials (VERIFY),Arm strength is important for taking care ones self. Predicting whether arm weakness due to a stroke will or will not improve would allow for more efficient and effective testing of new treatments and more individualized treatment decisions. The VERIFY study will establish the ability of noninvasive transcranial magnetic stimulation and MRI to reliably predict patient outcomes in the important early period of stroke recovery.,NINDS,10675060,1/31/2024 12:00:00 AM,PAR-18-561,5U01NS120910-03,5,U01,NS,120910,03, ,"AFZAL, MARIAM MASHEEB",9/1/2021 12:00:00 AM,1/31/2027 12:00:00 AM,ZNS1-SRB-G(33), ,8779645,"KHATRI, POOJA ","CRAMER, STEVEN C.; STINEAR, CATHY ; VAGAL, ACHALA SAMEER",01,NEUROLOGY,041064767,DZ4YCZ3QSPR5,041064767,DZ4YCZ3QSPR5,US,39.129719,-84.520554,1523902,UNIVERSITY OF CINCINNATI,CINCINNATI,OH,SCHOOLS OF MEDICINE,452210001,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,2595998, ,NINDS,2242366,353632, ,2595998,,2595998.0 | |
| No NIH Category available, ,Understanding the molecular mechanism of a protein-recycling complex in small cell lung cancer treatment resistance.,PROJECT NARRATIVESmall cell lung cancer (SCLC) patients frequently suffer from relapse and resistant disease with a largenumber of these resistance mechanisms remaining elusive. From a genetic screen followed by functionalvalidation and clinical genomic correlation we identified a putative resistance biomarker in SCLC for bothcurrent and novel drug therapies (i.e. cisplatin and PARP inhibitors respectively). This proposal aims tounderstand how this biomarker works in a protein-recycling pathway (i.e. ubiquitin-proteasome pathway) andDNA repair with identification of novel treatments for treatment resistant/relapsed SCLC dependent on thisbiomarker to improve outcomes for afflicted patients.,NCI,10684226,7/9/2024 12:00:00 AM,PAR-19-361,5U01CA253383-04,5,U01,CA,253383,04, ,"JOHNSON, RONALD L",9/25/2020 12:00:00 AM,8/31/2026 12:00:00 AM,ZCA1-RPRB-7(M1), ,15616955,"LOK, BENJAMIN H","RAUGHT, BRIAN ",,Unavailable,208469486,ENZFJ8Q5KX39,208469486,ENZFJ8Q5KX39,CA,43.70011,-79.4163,3836301,UNIVERSITY HEALTH NETWORK,TORONTO,ON,Unavailable,M5G 2C4,CANADA,N,9/1/2024 12:00:00 AM,8/31/2025 12:00:00 AM,393,Non-SBIR/STTR,2024,276338, ,NCI,255869,20469, ,276338,,276338.0 | |
| No NIH Category available,Accident and Emergency department;Acute;Adolescent;Affect;Algorithms;American;Anxiety;Axon;Behavioral;Biochemical;Biological;Biological Markers;Blood;Brain;Brain Concussion;Cardiovascular system;Categories;Childhood;Chronic;Clinic;Clinical;Clinical Trials;Cognitive;Collaborations;Common Data Element;Data;Detection;Development;Diffusion Magnetic Resonance Imaging;Early Intervention;Early identification;Early treatment;Enrollment;Foundations;Functional impairment;Future;Goals;Headache;Image;Impairment;Individual;Injury;Intervention;Lesion;Longitudinal cohort study;Magnetic Resonance Imaging;Measurement;Measures;Membrane;Migraine;Molecular;Moods;Movement;National Institute of Neurological Disorders and Stroke;Neurobehavioral Manifestations;Neurocognitive;Neurologic;Neuropsychology;Phenotype;Phospholipids;Physiological;Population;Post-Concussion Syndrome;Postural adjustments;Prevention;Psychophysiology;Radiology Specialty;Registries;Research;Resolution;Risk;Science;Site;Sports Medicine;Symptoms;Techniques;Testing;Time;Traumatic Brain Injury;Validation;Work;Youth;biological adaptation to stress;biomarker development;biomarker panel;biomarker validation;candidate validation;cohort;cytokine;endophenotype;imaging biomarker;imaging modality;innovation;medical specialties;mild traumatic brain injury;molecular marker;neurobehavioral;neuroimaging;neuroinflammation;novel;patient subsets;prediction algorithm;predictive marker;primary care clinic;prospective;recruit;respiratory;risk stratification;screening;symptom cluster;symptom treatment;symptomatology;trait;vestibular system,Endophenotypes of Persistent Post-Concussive Symptoms in Adolescents: CARE4Kids,PROJECT NARRATIVE OverallConcussions affect nearly 3 million Americans annually with up to 30% not recovered 3 months after injury andthe risk for adolescents is even greater. Persistent post-concussive impairments such as migrainous headacheabnormal stress responses and mood dysregulation are common. In this work we will determine the best markersthat predict these symptoms in order to provide a firm foundation for future clinical trials to treat these symptoms.,NINDS,10701858,4/4/2024 12:00:00 AM,RFA-NS-20-016,5U54NS121688-03,5,U54,NS,121688,03, ,"UMOH, NSINI ALEASE",9/8/2021 12:00:00 AM,3/31/2027 12:00:00 AM,ZNS1-SRB-N(23), ,2047464,"GIZA, CHRISTOPHER C","GIOIA, GERARD A.; RIVARA, FREDERICK P.",36,PEDIATRICS,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,SCHOOLS OF MEDICINE,900952000,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,853,Research Centers,2024,3030561, ,NINDS,2617687,412874, ,3030561,,3030561.0 | |
| No NIH Category available,Adherence;Adolescent;Adult;Affect;Algorithms;Biological;Biological Markers;Biometry;Blood;Blood Proteins;Blood Specimen Collection;Blood specimen;Brain Concussion;Child;Clinic;Clinic Visits;Clinical;Clinical Data;Clinical Research;Collection;Common Data Element;Data;Data Collection;Data Coordinating Center;Development;Distal;Education;Emergency department visit;Enrollment;Ensure;Goals;Health;Image;Individual;Informatics;Injury;Leadership;Longevity;Measures;Methods;Minority;Monitor;Morbidity - disease rate;National Institute of Neurological Disorders and Stroke;Neuropsychology;Outcome;Participant;Phase;Population;Post-Concussion Syndrome;Protocols documentation;Public Health;Qualifying;Recovery;Registries;Reporting;Research;Research Support;Resources;Risk;Site;Surveys;Symptoms;System;Technical Expertise;Text;Text Messaging;Time;Traumatic Brain Injury;United States;Universities;Utah;Youth;biomarker development;biomarker validation;cohort;concussive symptom;cost;data management;data quality;data sharing;data standards;design;disability;endophenotype;experience;imaging biomarker;medical specialties;mild traumatic brain injury;neurobehavioral;neuroimaging;oculomotor;predictive marker;predictive tools;prospective;risk prediction;risk stratification;symptom cluster,CARE4Kids: Data Coordinating Core,,NINDS,10701860,4/4/2024 12:00:00 AM,RFA-NS-20-016,5U54NS121688-03,5,U54,NS,121688,03, , ,9/8/2021 12:00:00 AM,3/31/2027 12:00:00 AM,ZNS1-SRB-N,8442,10004759,"COOK, LAWRENCE JOSEPH",Not Applicable,36,Unavailable,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,Domestic Higher Education,900952000,UNITED STATES,N,9/1/2023 12:00:00 AM,8/31/2024 12:00:00 AM, ,Research Centers,2024, ,418791, ,414463,4328, , ,, | |
| No NIH Category available,Acute;Address;Adolescent;Age;Autonomic Dysfunction;Autonomic nervous system;Autonomic nervous system disorders;Biological Factors;Biological Markers;Blood Pressure;Brain;Brain Concussion;Brain Injuries;Brain imaging;Breathing;Cardiovascular system;Central Nervous System;Chronic;Clinical;Cognitive;Congenital neurologic anomalies;Data;Data Analyses;Development;Educational Status;Equipment;Functional disorder;Gender;Goals;Heart Rate;Hour;Link;Literature;Longitudinal Studies;Manuals;Measures;Methodology;Nervous System Physiology;Neurobiology;Patients;Phase;Physiological;Pilot Projects;Post-Concussion Syndrome;Postural adjustments;Prognosis;Protocols documentation;Quality Control;Recovery;Research Assistant;Research Project Grants;Research Training;Rest;Sample Size;Signs and Symptoms;Site;Standardization;Structure;Symptoms;Testing;Time;Training;Validation;Variant;analytical method;axon injury;blood-based biomarker;clinical decision-making;cohort;concussive symptom;design;detection sensitivity;endophenotype;heart rate variability;imaging biomarker;imaging modality;innovation;molecular marker;neuroinflammation;neuropsychiatric disorder;predictive marker;psychological stressor;respiratory;response;systematic review,CARE4Kids: Autonomic Biomarker Core,,NINDS,10701861,4/4/2024 12:00:00 AM,RFA-NS-20-016,5U54NS121688-03,5,U54,NS,121688,03, , ,9/8/2021 12:00:00 AM,3/31/2027 12:00:00 AM,ZNS1-SRB-N,8443,1894466,"ASARNOW, ROBERT F",Not Applicable,36,Unavailable,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,Domestic Higher Education,900952000,UNITED STATES,N,9/1/2023 12:00:00 AM,8/31/2024 12:00:00 AM, ,Research Centers,2024, ,160545, ,109955,50590, , ,, | |
| No NIH Category available,3-Dimensional;Administrative Supplement;Adolescent;Affect;Anatomy;Biological Markers;Blood;Brain;Brain Concussion;Brain imaging;Brain region;Brain scan;Calibration;Cerebrovascular Circulation;Child;Clinical;Clinical assessments;Collection;Common Data Element;Communities;Data;Data Adjustments;Data Analyses;Data Collection;Data Coordinating Center;Detection;Development;Diffusion Magnetic Resonance Imaging;Ensure;Feedback;Functional Magnetic Resonance Imaging;Funding;Genetic study;Geometry;Goals;Hemorrhage;Image;Individual;Inflammation;Information Theory;International;Machine Learning;Magnetic Resonance Imaging;Maps;Measurable;Measures;Methods;Modality;Modeling;Monitor;Motion;Multimodal Imaging;National Institute of Neurological Disorders and Stroke;Nervous System Trauma;Outcome;Outcome Measure;Participant;Perfusion;Phase;Post-Concussion Syndrome;Predisposition;Process;Productivity;Prognosis;Protocols documentation;Qualifying;Quality Control;Recommendation;Research;Resolution;Rest;Running;Sample Size;Scanning;Site;Standardization;Structure;Subgroup;Testing;Time;Training;Travel;United States;United States National Institutes of Health;Universities;Utah;Validation;White Matter Hyperintensity;Work;arterial spin labeling;biobank;blood perfusion;brain magnetic resonance imaging;brain volume;cognitive development;cohort;combat;cost;data collection site;data harmonization;data quality;design;endophenotype;experience;falls;functional outcomes;imaging biomarker;imaging facilities;imaging study;indexing;injured;innovation;mild traumatic brain injury;multimodality;neuroimaging;neuropathology;outcome prediction;patient population;patient subsets;phenotypic data;predict clinical outcome;tool;volunteer;white matter,CARE4Kids: Imaging Biomarker Core,,NINDS,10701862,4/4/2024 12:00:00 AM,RFA-NS-20-016,5U54NS121688-03,5,U54,NS,121688,03, , ,9/8/2021 12:00:00 AM,3/31/2027 12:00:00 AM,ZNS1-SRB-N,8444,6111760,"THOMPSON, PAUL M",Not Applicable,36,Unavailable,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,Domestic Higher Education,900952000,UNITED STATES,N,9/1/2023 12:00:00 AM,8/31/2024 12:00:00 AM, ,Research Centers,2024, ,171508, ,165941,5567, , ,, | |
| No NIH Category available,Acute;Adolescence;Adolescent;Affect;Age;Algorithms;American;Biochemical;Biological;Biological Markers;Blood;Blood specimen;Brain;Brain Concussion;Caring;Categories;Clinical;Clinical Management;Clinical Treatment;Clinical Trials;Collection;Common Data Element;Data;Dedications;Development;Dizziness;Early identification;Evaluation;Future;Goals;Headache;Human Resources;Image;Inflammation;Inflammatory;Injury;Intervention;Lipids;Long term disability;Measurement;Measures;Membrane;Memory;Methods;Mission;Molecular;Monitor;National Institute of Neurological Disorders and Stroke;Neurons;Neuropeptides;Neurotransmitters;Oxidative Stress;Pathway interactions;Peptides;Phenotype;Physiological;Physiological Processes;Populations at Risk;Post-Concussion Syndrome;Procedures;Process;Protein Analysis;Proteins;Protocols documentation;Psychophysiology;Publishing;Quality Control;Radiology Specialty;Recovery;Reporting;Reproducibility;Research Personnel;Research Project Grants;Resources;Risk;Schools;Site;Standardization;Symptoms;Technical Expertise;Techniques;Time;Training;Work;Youth;age group;axon injury;biobank;blood-based biomarker;cognitive function;critical period;cytokine;data quality;design;emotional functioning;endophenotype;executive function;experience;falls;genetic analysis;high risk;imaging biomarker;improved;medical specialties;neurodevelopment;neuroimaging;neurotransmission;novel;peripheral blood;prediction algorithm;prevent;preventive intervention;prospective;repository;risk prediction;risk stratification;sample collection;social;specific biomarkers;success;targeted treatment;trait;white matter change;young adult,CARE4Kids: Blood Biomarker Core,,NINDS,10701863,4/4/2024 12:00:00 AM,RFA-NS-20-016,5U54NS121688-03,5,U54,NS,121688,3, , ,9/8/2021 12:00:00 AM,3/31/2027 12:00:00 AM,ZNS1-SRB-N,8445,6713741,"BAZARIAN, JEFFREY JOHN",Not Applicable,36.0,Unavailable,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,Domestic Higher Education,900952000,UNITED STATES,N,9/1/2023 12:00:00 AM,8/31/2024 12:00:00 AM, ,Research Centers,2024, ,558661, ,379070,179591, , ,, | |
| No NIH Category available,Accident and Emergency department;Acute;Adolescent;Age;Agreement;Algorithms;Anxiety;Area Under Curve;Behavioral;Biochemical;Biological;Biological Markers;Blood;Blood flow;Brain Concussion;Brain Injuries;Cardiovascular system;Centers for Disease Control and Prevention (U.S.);Childhood Injury;Chronic;Clinic;Clinical;Collaborations;Common Data Element;Detection;Development;Diagnostic;Dysautonomias;Early identification;Functional disorder;Functional impairment;Future;Goals;Guidelines;Image;Immune;Impairment;Individual;Inflammation;Injury;Lesion;Lipids;Long term disability;Longitudinal cohort study;Measures;Medical;Mental Depression;Migraine;Monitor;Multivariate Analysis;National Institute of Neurological Disorders and Stroke;Nature;Neurobiology;Neurologic;Neurologic Symptoms;Neuropsychology;Neurotransmitters;Outcome;Pain;Phase;Phenotype;Physiological;Physiology;Post-Concussion Syndrome;Prevention;Prevention strategy;Public Health;Radiology Specialty;Recovery;Research;Research Project Grants;Resolution;Resources;Sampling;Science;Site;Symptoms;Techniques;Testing;Time;Traumatic Brain Injury;Validation;Youth;biological adaptation to stress;biomarker development;biomarker validation;blood-based biomarker;cell injury;clinical phenotype;cognitive performance;cohort;common symptom;disability;endophenotype;experience;imaging biomarker;improved;mild traumatic brain injury;multidisciplinary;multimodality;neurobehavioral;neuroimaging;novel therapeutics;prediction algorithm;preventive intervention;primary care clinic;prognostic tool;prognostication;programs;prospective;recruit;research clinical testing;risk stratification;sex;symptom cluster;trait,Endophenotypes of Persistent Post-Concussive Symptoms in Adolescents: CARE4Kids,,NINDS,10701866,4/4/2024 12:00:00 AM,RFA-NS-20-016,5U54NS121688-03,5,U54,NS,121688,03, , ,9/8/2021 12:00:00 AM,3/31/2027 12:00:00 AM,ZNS1-SRB-N,8446,2047464,"GIZA, CHRISTOPHER C",Not Applicable,36,Unavailable,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,Domestic Higher Education,900952000,UNITED STATES,N,9/1/2023 12:00:00 AM,8/31/2024 12:00:00 AM, ,Research Centers,2024, ,1479915, ,1372310,107605, , ,, | |
| No NIH Category available,3-Dimensional;Accounting;Activities of Daily Living;Affect;Animal Model;Animal Testing;Artificial Intelligence;Autoantibodies;Award;Axon;Big Data;Biological;Biological Markers;Blood;Brain;Brain imaging;Chronic;Cities;Clinical Research;Cognitive;Computer Models;Contusions;Data;Data Analyses;Data Commons;Data Element;Data Science;Data Set;Dimensions;Drops;Ensure;Explosion;Exposure to;Eye;FAIR principles;Functional disorder;Healthcare;High Prevalence;Histology;Human;Image;Impairment;Individual;Informatics;Infrastructure;Ingestion;Injury;Iowa;Laboratories;Link;Machine Learning;Magnetic Resonance Imaging;Measures;Mediating;Methods;Modeling;Monitor;Motor;Multiple Trauma;Mus;Nerve Degeneration;Nervous System Trauma;Neurocognition;Neurological outcome;Neuronal Dysfunction;Neurons;Optic Disk;Optic Nerve;Optic tract structure;Outcome;Output;Pathology;Pattern;Pattern Recognition;Percussion;Personality;Phase;Precision therapeutics;Proteomics;Quality Control;Rattus;Reproducibility;Research;Research Personnel;Resources;Retina;Retinal Diseases;Rodent Model;Sampling;San Francisco;Scientist;Serum;Severities;Shock;Signal Transduction;Site;Statistical Data Interpretation;Statistical Models;Stress;Structure;Testing;Therapeutic;Tissue Model;Tissues;Traumatic Brain Injury;Tube;Validation;Veterans;Visual;Weight;Well in self;Work;advanced analytics;animal data;assay development;base;bench-to-bedside translation;big data management;biomarker discovery;biomarker identification;biomarker validation;biomechanical model;blast trauma;blood-based biomarker;candidate validation;cognitive function;cohort;complex data;cytokine;data dictionary;data ingestion;data integration;data management;data modeling;data sharing;diverse data;ex vivo imaging;experimental study;functional outcomes;imaging modality;improved;information model;military veteran;neuroimaging marker;open data;potential biomarker;pre-clinical;precision medicine;predictive marker;predictive signature;protein expression;sensor;statistics;therapeutic development;therapeutic target;tool;translational medicine;translational therapeutics;transmission process,BCCMA: Predicting TBI Pathology with Visual and Blood-based Biomarkers,Traumatic brain injury (TBI) is a condition with higher prevalence in the veteran population than civilians and isassociated with multi-dimensional impairments in function impacting neurocognition psychological well-beingpersonality motor function and activities of daily living. These impairments have diverse biological causesproducing a challenge for both scientific reproducibly of therapeutic discoveries as well as bench-to-bedsidetranslation of discoveries into veteran healthcare. Project 4 of the proposed linked merit will take a data-scienceapproach to TBI biomarker discovery integrating data on retinal function and structure blood biomarkersbiomechanical modeling and outcomes in multiple rodent models of TBI (blast contusion percussion weightdrop injuries) produced by Projects 1-3. Harnessing data science and machine intelligence tools we will helpidentify biomarker signatures predicting TBI impairment and help validate biomarker measures for translationand precision medicine.,VA,10702037,10/13/2023 12:00:00 AM,RFA-BX-22-007,1I01BX005871-01A2,1,I01,BX,005871,01,A2, ,10/1/2023 12:00:00 AM,9/30/2027 12:00:00 AM,ZRD1-NURF-C(01), ,8203706,"FERGUSON, ADAM R",Not Applicable,11,Unavailable,078763885,DHRRHTDZBGA4,078763885,DHRRHTDZBGA4,US,37.781241,-122.503638,481016,VETERANS AFFAIRS MED CTR SAN FRANCISCO,SAN FRANCISCO,CA,Independent Hospitals,941211545,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available, ,Validation of a novel cortical biomarker signature for pain,NarrativeBecause of the difficulty in treating chronic pain development of brain signal predictive biomarkers is ofgrowing interest. Here we propose to develop a predictive biomarker signature of pain severity and durationusing two commonly available techniques electroencephalogram (EEG) and transcranial magneticstimulation (TMS) and perform initial clinical validation in first onset temporomandibular disorder (TMD). Thebiomarker could have utility in identifying patients at high risk of transitioning from acute to chronic pain andhas additional potential for clinical application in the treatment and prevention of chronic pain.,NINDS,10709408,9/16/2024 12:00:00 AM,RFA-NS-18-041,4R33NS113269-02,4,R33,NS,113269,02, ,"ARUDCHANDRAN, RAMACHANDRAN NMN",8/1/2019 12:00:00 AM,7/31/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-ETTN-C(50)R], ,15497866,"DA SILVA, JOYCE TEIXEIRA","SCHABRUN, SIOBHAN ; SEMINOWICZ, DAVID ",07,OTHER BASIC SCIENCES,188435911,Z9CRZKD42ZT1,188435911,Z9CRZKD42ZT1,US,39.292248,-76.625629,820104,UNIVERSITY OF MARYLAND BALTIMORE,BALTIMORE,MD,SCHOOLS OF DENTISTRY/ORAL HYGN,212011508,UNITED STATES,N,8/1/2024 12:00:00 AM,7/31/2026 12:00:00 AM,279,Non-SBIR/STTR,2024,854352, ,NINDS,617784,236568, ,854352,,854352.0 | |
| No NIH Category available,Accountability;Adherence;Adult;Adverse event;Advocacy;Ancillary Study;Awareness;Biological Assay;Biometry;Blood Glucose;Caregivers;Cessation of life;Clinical Research;Clinical Trials;Collaborations;Collection;Coma;Communication;Conduct Clinical Trials;Conflict of Interest;Continuous Glucose Monitor;Data;Data Analyses;Data Coordinating Center;Data Management Resources;Development;Devices;Diabetes Mellitus;Digestive System Disorders;Enrollment;Ensure;Evaluation;Exclusion;Family member;Funding;Glucose;Glycosylated hemoglobin A;Health Sciences;Healthcare Systems;Heterogeneity;Hypoglycemia;Impairment;Individual;Institutional Review Boards;Insulin-Dependent Diabetes Mellitus;Internet;Investigational New Drug Application;Kidney Diseases;Laboratories;Lead;Manuals;Manuscripts;Measures;Medical;Medicine;Monitor;National Institute of Diabetes and Digestive and Kidney Diseases;Patient Self-Report;Patients;Pennsylvania;Predisposition;Preparation;Procedures;Process;Protocols documentation;Psychometrics;Public Health;Publications;Quality Control;Questionnaires;Randomized;Reporting;Request for Applications;Research;Research Design;Safety;Safety Management;Sample Size;Security;Site Visit;Statistical Data Interpretation;Support System;System;Technology;Time;United States Food and Drug Administration;United States National Institutes of Health;Universities;Validation;Vendor;Visit;acute pancreatitis;biomarker selection;clinical center;college;cost;data exchange;data management;data submission;design;drug distribution;experience;improved;member;participant enrollment;programs;quality assurance;recruit;repository;response;restoration;web site,The Biostatistics Research Center for the Impaired Awareness of Hypoglycemia Consortium,PROJECT NARRATIVEIndividuals with Type 1 Diabetes (T1D) are susceptible to repeated episodes of hypoglycemia which can resultin impaired awareness of hypoglycemia (IAH). As a consequence IAH contributes to diminished recognition ofthe need for external glucose. This can be a very risky situation for T1D individuals with IAH possibly leadingto coma and in some circumstances death. The NIDDK is forming the IAH Consortium which will conductstudies to determine if the most up-to-date management strategies using diabetes technology will restoreawareness of hypoglycemia.,NIDDK,10709601,4/10/2024 12:00:00 AM,RFA-DK-21-036,5U01DK135126-02,5,U01,DK,135126,02, ,"ARREAZA-RUBIN, GUILLERMO",9/25/2022 12:00:00 AM,12/31/2027 12:00:00 AM,ZDK1-GRB-9(O2), ,1864645,"CHINCHILLI, VERNON M",Not Applicable,10,PUBLIC HEALTH & PREV MEDICINE,129348186,TNKGNDAWB445,129348186,TNKGNDAWB445,US,40.264414,-76.674014,1524204,PENNSYLVANIA STATE UNIV HERSHEY MED CTR,HERSHEY,PA,SCHOOLS OF MEDICINE,170332360,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,2361429, ,NIDDK,1442099,919330, ,2361429,,2361429.0 | |
| No NIH Category available,ALS patients;Affect;Alzheimer's Disease;Amyotrophic Lateral Sclerosis;Apoptosis;Area;Autopsy;Back;Blood Vessels;Brain;Brain Diseases;Cell Aging;Cell Death;Cell Death Process;Cells;Cellular Morphology;Cellular Stress;Central Nervous System;Chronic;Communities;Complex;Cytoplasm;Data;Data Set;Deposition;Development;Diagnosis;Disease;Disease Progression;Environment;Family history of;Functional disorder;Future;Goals;Health;Histologic;Human;Immunohistochemistry;Individual;Investigation;Lateral;Limb structure;Link;Location;Maps;Mitochondria;Molecular;Molecular Profiling;Motor;Motor Cortex;Motor Neurons;Movement;Muscle;Muscle function;Nerve Degeneration;Nervous System;Neurodegenerative Disorders;Neuronal Dysfunction;Neurons;Nuclear;Outcome;Pathogenicity;Pathologic;Pathology;Pathway interactions;Process;Proteins;RNA;Research;Research Proposals;Resolution;Role;Site;Spinal Cord;Spinal Cord Column;Spinal Diseases;Stress;Structure;Symptoms;Technology;Testing;Therapeutic Intervention;Time;Tissue Donors;Tissues;Transcript;Transgenic Mice;Validation;Veterans;analytical method;biobank;biological adaptation to stress;biomarker discovery;biomarker validation;brain tissue;candidate identification;candidate marker;case control;cell injury;cell type;cellular resilience;digital;effective therapy;experience;experimental study;extracellular;human tissue;improved;method development;military veteran;mouse model;muscle form;neuropathology;new therapeutic target;novel;pharmacologic;preservation;protein TDP-43;protein expression;proteostasis;research clinical testing;screening;senescence;single cell analysis;stress resilience;tau Proteins;tau aggregation;therapeutic target;tissue degeneration;transcriptomics,High Resolution Profiling of Senescent Cells in ALS Brain and Spinal Cord,Project NarrativeRegardless of family history site of onset and sequence of symptoms and progression all Amyotrophic LateralSclerosis (ALS) patients lose muscle function as central nervous system cells stop working and eventually die.This proposal will perform comprehensive analyses on 1000s of individual cells from dozens of central nervoussystem tissues donated by veterans with ALS. The results will provide an unprecedented depth of informationon stresses experienced at the cellular level and how this stress relates to the health of the tissue. Data derivedfrom this project will unveil numerous new directions of research to better understand ALS disease processeswith the goal of developing effective therapies.,VA,10721824,10/13/2023 12:00:00 AM,RFA-BX-21-004,5I01BX005717-02,5,I01,BX,005717,02, , ,10/1/2022 12:00:00 AM,9/30/2026 12:00:00 AM,ZRD1-NURE-E(01), ,8961421,"ORR, MIRANDA ETHEL",Not Applicable,08,Unavailable,023298611,WKXDGLW4LMV5,023298611,WKXDGLW4LMV5,US,35.684204,-80.488788,481066,W G HEFNER VA MEDICAL CENTER,SALISBURY,NC,Independent Hospitals,281442515,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Acceleration;Affect;Alzheimer's Disease;Animal Model;Award;Bacteria;Binding;Bioinformatics;Biological Markers;Biology;CDC2 gene;California;Cardiovascular Diseases;Cardiovascular system;Cell Proliferation;Cells;Chromosome Mapping;Chromosomes;Chromosomes Human Y;Clinical;Clinical Management;Cloning;Cloning Vectors;Code;Collaborations;Cyclin B;DNA Library;Databases;Development;Diagnosis;Disease;Disease Progression;Ectopic Expression;Educational workshop;Elderly man;Embryo;Epithelial Cells;Equipment;Family;Feedback;Foundations;Funding;Gene Activation;Genes;Genetic;Genetic Materials;Genetic Models;Genetic Predisposition to Disease;Genetic Transcription;Genome;Genomic Instability;Genomics;Gonadal structure;Gonadoblastoma;Health;Health Services Research;Healthcare;Healthcare Systems;Hepatocyte;Histones;Homologous Gene;Hormone Receptor;Human;Human Genome;Immunologic Surveillance;Impairment;Incidence;Inhibition of Cell Proliferation;International;Journals;Knowledge;Laboratories;Laboratory Finding;Link;Lysine;Malignant Neoplasms;Malignant neoplasm of liver;Malignant neoplasm of lung;Malignant neoplasm of prostate;Mammalian Cell;Maps;Mediating;Medical;Methods;Molecular;Molecular Genetics;Myocardial Infarction;Nature;Neurodegenerative Disorders;Oncogenes;Oncogenic;Outcome;Pharmaceutical Preparations;Physiology;Pilot Projects;Population;Predisposition;Prognosis;Property;Prostate;Proteins;Proto-Oncogenes;Publishing;Recombinant DNA;Reporting;Research;Research Personnel;Risk;Role;San Francisco;Science;Scientist;Screening procedure;Series;Sex Chromosomes;Sex Differences;Signal Pathway;Somatic Cell;Stem Cell Factor;Stimulation of Cell Proliferation;System;TK Gene;TSPY1 gene;Techniques;Technology;Testing;Testis;Therapeutic;Time;Tissues;Transactivation;Transgenes;Transgenic Mice;Treatment outcome;Tumor Suppressor Proteins;United States National Academy of Sciences;Universities;Validation;Variant;Veterans;Work;X Chromosome;Y Chromosome;authority;biomarker identification;career;chromosome Y loss;design;differential expression;dosage;effective therapy;experimental study;gender disparity;germline stem cells;health care delivery;human disease;human model;improved;insight;interest;lung development;male;male sex hormones;member;mortality;mosaic loss;mouse model;neurogenesis;new technology;next generation sequencing;non-alcoholic fatty liver disease;older men;peripheral blood;postnatal;precision medicine;professor;programs;research and development;sex;sex determination;sexual dimorphism;sry Genes;targeted treatment;therapeutic target;tool;transcription factor;translational applications;translational potential;treatment planning;treatment response;tumorigenesis,BLR&D Research Career Scientist Award Application,Dr. Lau is a key and contributing member of the San Francisco VA Health Care System. He is a world authorityin the genetics of the male-specific Y chromosome and an expert in molecular genetics and animal modeling ofhuman diseases. He has developed a vigorous research program to investigate the contributions of the male-specific portion of the human genome (genetic materials) to gender disparities in various cancers anddiseases. He correlates the laboratory results to the clinical features and outcomes and identifies biomarkersfor precise diagnosis and prognosis in prostate and liver cancers cardiovascular and neurodegenerativediseases. He establishes animal models for various cancer and human diseases affecting many of ourVeterans. His studies have shed critical insights on the disease mechanisms and provided therapeutic targetsfor development of effective treatment plans for human cancers and diseases. His research has providedsignificant translational potentials to improve the healthcare of our Veterans in the twenty-first century.,VA,10724264,10/6/2023 12:00:00 AM,RFA-BX-19-022,5IK6BX004854-05,5,IK6,BX,004854,05, , ,10/1/2019 12:00:00 AM,9/30/2024 12:00:00 AM,ZRD1-RCSR-K(01)1, ,1859953,"LAU, YUN-FAI CHRIS ",Not Applicable,11,Unavailable,078763885,DHRRHTDZBGA4,078763885,DHRRHTDZBGA4,US,37.781241,-122.503638,481016,VETERANS AFFAIRS MED CTR SAN FRANCISCO,SAN FRANCISCO,CA,Independent Hospitals,941211545,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Other,2024, , , , , , , ,, | |
| No NIH Category available,Adult;Afghanistan;Aromatic Amines;Awareness;BCG Live;Bacillus Calmette-Guerin Therapy;Benign;Biological;Biological Markers;Bladder;Blood;Cancer Detection;Cancer Patient;Cessation of life;Chemical Exposure;Clinical;Clinical Trials;Clinical Trials Design;Clinics and Hospitals;Collaborations;Cystoscopy;Cytology;Data;Decision Making;Development;Diagnosis;Diagnostic;Diagnostic Sensitivity;Disease;Doctor of Philosophy;Emotional;Environmental Exposure;Epidemiologist;Exposure to;Foundations;General Population;Goals;Health;Health Services Accessibility;Hematuria;High-Throughput RNA Sequencing;Iraq;Lesion;Liquid substance;Malignant Neoplasms;Malignant neoplasm of urinary bladder;Measurement;Measures;Medical;Messenger RNA;Microfluidics;Microscopic;Modeling;Molecular;Monitor;Morbidity - disease rate;Nucleic Acids;Operative Surgical Procedures;Particulate;Patients;Performance;Population;Prediction of Response to Therapy;Procedures;Recording of previous events;Recurrence;Research;Research Design;Research Personnel;Residual Cancers;Risk;Risk Assessment;Risk Factors;Sampling;Scientist;Screening for cancer;Services;Smoke;Smoking;Solid;Staging;Symptoms;Technology;Testing;Therapeutic Intervention;Tobacco use;Translations;Transurethral Resection;Tumor-Derived;Urine;Urologic Diseases;Urologic Oncology;Urologic Surgeon;Validation;Veterans;Vietnam;agent orange;biomarker discovery;biomarker panel;burden of illness;burn pit;cancer risk;cancer type;clinical translation;diagnostic strategy;diagnostic tool;experience;falls;high risk;improved;improved outcome;intravesical;molecular diagnostics;molecular marker;non-muscle invasive bladder cancer;patient stratification;personalized approach;personalized medicine;personalized therapeutic;prospective;response;risk stratification;screening;tool;treatment response;treatment strategy;tumor;urinary;validation studies,Personalized assessment of bladder cancer treatment response using urinary molecular biomarkers,As the sixth most common cancer in the U.S. bladder cancer is a major health burden for veterans. Veterans areat a higher risk for bladder cancer due to increased exposures to risk factors including tobacco use and service-related chemical exposure. There are significant unmet diagnostic needs for bladder cancer across all stages.Particularly for patients with early stage disease current diagnostic approaches are either invasive (e.g.cystoscopy) or lack sensitivity (e.g. urine cytology). We propose to develop non-invasive molecular diagnosticsbased on urinary biomarkers that will lead to more effective and personalized therapeutic strategies for patientswith localized bladder cancer. Successful completion of the studies proposed here will serve as a foundation forincorporating urine-based biomarkers in bladder cancer surveillance and into prospective clinical trials to assesstherapeutic interventions with the long-term goal to reduce surveillance-related morbidity and improveoutcomes for veterans with bladder cancer.,VA,10725120,10/6/2023 12:00:00 AM,RFA-BX-19-013,5I01BX004962-04,5,I01,BX,004962,04, , ,10/1/2020 12:00:00 AM,9/30/2025 12:00:00 AM,ZRD1-CAMM-P(01), ,7594907,"LIAO, JOSEPH C",Not Applicable,16,Unavailable,046017455,ZN2TPL7TCAY7,046017455,ZN2TPL7TCAY7,US,37.400877,-122.138324,481014,VETERANS ADMIN PALO ALTO HEALTH CARE SYS,PALO ALTO,CA,Independent Hospitals,943041207,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Address;Animal Model;Baltimore;Biological;Biological Assay;Biological Markers;Blood;Cancer Cluster;Cancer Relapse;Carcinoma;Cell Surface Receptors;Cells;Chemoresistance;Clinic;Clinical;Collaborations;Colon;Colon Carcinoma;Colonic Neoplasms;Colorectal;Colorectal Cancer;Development;Disease remission;Distal;Drug Kinetics;Epidermal Growth Factor Receptor;Exhibits;FGF2 gene;FGFR1 gene;Fiber;Fibroblast Growth Factor Receptors;Fluorouracil;Genomics;Glycobiology;Glycosaminoglycans;Goals;Growth Factor;HT29 Cells;Human;Immunotherapy;In Vitro;Insulin-Like-Growth Factor I Receptor;Intestines;Invaded;Knowledge;Malignant Neoplasms;Mediator;Methods;Modeling;Molecular;Molecular Mechanisms of Action;Nature;Neoplasm Metastasis;Organ;Organoids;Outcome;Pathology;Pharmaceutical Preparations;Phenotype;Play;Polysaccharides;Process;Property;Receptor Signaling;Regulation;Reproducibility;Reproducibility of Results;Research;Research Personnel;Resources;Role;Sampling;Serum;Signal Transduction;Site;Specificity;Stem Cell Assay;System;Testing;Therapeutic;Tissue Sample;Toxic effect;Validation;Xenograft Model;Xenograft procedure;adult stem cell;analog;anti-cancer;cancer cell;cancer immunotherapy;cancer recurrence;cancer stem cell;cancer therapy;carcinogenesis;chemotherapy;colon cancer patients;colorectal cancer treatment;efficacy evaluation;efficacy testing;genetic variant;improved;in silico;in vivo;in vivo Model;inhibitor;innovation;metabolomics;migration;mimetics;mortality;mutant;novel;oxaliplatin;p38 Mitogen Activated Protein Kinase;patient derived xenograft model;personalized medicine;pleiotropism;polysulfated glycosaminoglycan;predictive marker;prototype;receptor;response;scaffold;self-renewal;stem cell biology;stem cell biomarkers;stem cell growth;stem cell self renewal;stem cells;transcriptomics;treatment strategy;tumor growth,Unique Non-Saccharide Mimetics of Sulfated Glycosaminoglycan Target Colon Cancer Stem Cells,Glycosaminoglycans (GAGs) are ubiquitous in nature and play important role in cancer. They have beenfound to regulate critical properties of cancer stem cells (CSCs) which are responsible for cancer recurrenceand mortality. We have discovered that a non-sugar mimetic called G2.2 and its analogs selectively inhibitCSCs. We propose to generate more effective analogs of G2.2 with improved drug-like properties and studytheir molecular mechanisms of action to decipher CSC biology especially glycobiology and develop novelanti-cancer therapies that address the issues of remission and/or cure.,VA,10725160,10/11/2023 12:00:00 AM,RFA-BX-19-001,5I01BX004584-04,5,I01,BX,004584,04, , ,10/1/2020 12:00:00 AM,9/30/2024 12:00:00 AM,ZRD1-ONCC-Y(01), ,9130462,"PATEL, BHAUMIK B",Not Applicable,04,Unavailable,146678115,Y2L8GM7QZJD5,146678115,Y2L8GM7QZJD5,US,37.493539,-77.470293,481091,VA VETERANS ADMINISTRATION HOSPITAL,RICHMOND,VA,Independent Hospitals,232490001,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Algorithms;Anesthesia procedures;Architecture;Attention;Biological Markers;Boston;Brain;Clinic;Clinical;Collaborations;Complex;Coupling;Deep Brain Stimulation;Devices;Disease;Electrophysiology (science);Evoked Potentials;Excision;Frequencies;Future;General Anesthesia;Generations;Globus Pallidus;Goals;Human;Individual;Industry Collaboration;Investigation;Lead;Link;Location;Maps;Measures;Methods;Morphologic artifacts;Motor;Movement Disorders;Neurons;Operative Surgical Procedures;Outcome;Parkinson Disease;Patients;Phase;Physiologic pulse;Physiological;Physiology;Population;Radial;Refractory;Research;Severity of illness;Shapes;Signal Transduction;Site;Specific qualifier value;Stimulus;Structure;Structure of subthalamic nucleus;Symptoms;System;Technology;Testing;Thalamic structure;Vision;Visualization;Work;analytical method;awake;biomarker validation;clinical decision-making;clinical efficacy;clinical predictors;clinically relevant;design;experimental study;implantable device;improved;industry partner;interest;motor symptom;neural;neurocognitive disorder;neuroregulation;new technology;next generation;novel;novel marker;point of care;prediction algorithm;predictive marker;predictive modeling;prospective;recruit;response;spatiotemporal,Stimulus-evoked directional field potentials to guide subthalamic and pallidal DBS for PD,Despite intense and ongoing investigations there are no established biomarkers to identify the optimal location intensity or parameters for emerging DBS device technologies. Here we will use a novel 16-contact directional lead in tandem with advanced stimulation and acquisition hardware to create detailed spatiotemporal maps of globus pallidus interna and subthalamic nucleus electrophysiology in patients with advanced Parkinsons disease. Our vision is for this work to advance the design of future DBS systems that can stimulate and sense interactions between DBS and human brain circuits and inform clinical decision-making related to directional stimulation for Parkinsons disease and other complex neurocognitive disorders.,NINDS,10728552,12/18/2023 12:00:00 AM,RFA-NS-21-021,1UG3NS130202-01A1,1,UG3,NS,130202,01,A1,"FRANKOWSKI, MEGAN MICHELLE",12/18/2023 12:00:00 AM,11/30/2024 12:00:00 AM,ZNS1-SRB-G(59), ,3105390,"WALKER, HARRISON CARROLL",Not Applicable,07,NEUROLOGY,063690705,YND4PLMC9AN7,063690705,YND4PLMC9AN7,US,33.50591,-86.799772,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,BIRMINGHAM,AL,SCHOOLS OF MEDICINE,352940001,UNITED STATES,N,12/18/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Non-SBIR/STTR,2024,1232410, ,NINDS,969286,263124, ,1232410,,1232410.0 | |
| No NIH Category available,Adaptive Immune System;Affect;Alzheimer's Disease;Anatomy;Animal Model;Astrocytes;Autopsy;Binding;Biological Markers;Blood;Brain;Brain Diseases;Brain imaging;Brain region;Calcium Binding;Caring;Cell Fraction;Cells;Cellularity;Cerebrospinal Fluid;Clinical;Clinical Trials;Clonal Expansion;Cognition Disorders;Cognitive;Cyclotrons;Data;Dementia;Development;Diffusion;Disease;Disease Progression;Edema;Elderly;Encephalitis;Evaluation;Flow Cytometry;Formalin;Functional disorder;Genetic Transcription;Glial Fibrillary Acidic Protein;Gliosis;Goals;Histologic;Histopathology;Hospitals;Human;Imaging Techniques;Immune Targeting;Immune response;Immune system;Immunohistochemistry;Impaired cognition;Impairment;Inflammation;Inflammatory;Inflammatory Response;Innate Immune Response;Innate Immune System;Investigation;Life;Link;Magnetic Resonance Imaging;Measurement;Measures;Methods;Microglia;Mobility decline;Monitor;Motor;Movement;Multiple Sclerosis;Nerve Degeneration;Nervous System Disorder;Outcome;Parkinson Disease;Parkinsonian Disorders;Participant;Pathogenesis;Pathologic;Pathologic Processes;Pathology;Persons;Phenotype;Play;Population;Positron-Emission Tomography;Proteins;Radiation exposure;Research;Role;Severity of illness;Source;Specimen;Staging;Stains;Standardization;Structure;Substantia nigra structure;Surrogate Markers;T cell response;T-Lymphocyte;Testing;Thinking;Tissues;Tremor;United States Department of Veterans Affairs;United States Food and Drug Administration;Variant;Veterans;adaptive immune response;age related neurodegeneration;alpha synuclein;axon injury;biomarker validation;brain tissue;catalyst;clinical application;clinical predictors;cognitive function;cognitive impairment in Parkinson's;diagnostic biomarker;dopaminergic neuron;experience;glial activation;imaging biomarker;imaging modality;immunohistochemical markers;improved;in vivo;interest;ionization;motor disorder;motor symptom;neuroimaging;neuroinflammation;neuropathology;new therapeutic target;non-demented;non-motor symptom;novel;novel therapeutics;patient stratification;peripheral blood;progressive neurodegeneration;prospective;recruit;response;single-cell RNA sequencing;spectrograph;targeted agent;therapy development;tool,Diffusion Basis Spectrum Imaging for Measurement of Neuroinflammation in Parkinson Disease,Project NarrativeParkinson disease (PD) is a progressive neurological disorder strongly linked to advancing age that ultimatelyresults in decline in mobility and thinking. Approximately 100000 veterans with PD receive care from theDepartment of Veterans Affairs and this number is expected to grow in the coming decades. Inflammation inthe brain may play an important role in the progression of these impairments but we lack easily accessibletools to identify and measure inflammation in the brain. The main goal of this project is to use a novel brainimaging test diffusion basis spectrum imaging (DBSI) to examine brain inflammation in veterans with PD. Wewill compare DBSI to other measures of inflammation and use it to predict clinical progression in PD. This willhelp us understand the role of inflammation in PD and lead to development of a readily-available noninvasivebrain imaging measure of inflammation which will be useful in clinical trials of agents that target the immunesystem.,VA,10731359,11/6/2023 12:00:00 AM,RFA-CX-20-001,5I01CX002316-03,5,I01,CX,002316,03, , ,10/1/2021 12:00:00 AM,3/31/2027 12:00:00 AM,ZRD1-NURE-E(01), ,7551841,"WHITE, ROBERT L",Not Applicable,01,Unavailable,033986766,K6GERM8557E6,033986766,K6GERM8557E6,US,38.641405,-90.229956,481050,ST. LOUIS VA MEDICAL CENTER,St. Louis,MO,Independent Hospitals,631061621,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Acute;Address;Advanced Glycosylation End Products;Affect;Animals;Antioxidants;Blood Circulation;Cardiovascular Models;Cardiovascular system;Cell Cycle Arrest;Cell Death;Cell Death Induction;Cell Line;Cell Physiology;Cell model;Cells;Cellular Stress;Chronic;DNA Damage;DNA Repair;Dihydroxyacetone;Dihydroxyacetone Phosphate;Disease;Dose;Electronic cigarette;Endothelial Cells;Epidemiology;Epithelial Cells;Equilibrium;Exposure to;Free Radicals;Future;Genetic Transcription;Glycerol;Glycolysis;Goals;Homeostasis;Human;Inhalation;Inhalation Exposure;Ion Channel;Isotope Labeling;Kidney;Link;Liver;Lung;Measures;Metabolic;Metabolic Pathway;Metabolic dysfunction;Metabolic stress;Metabolism;Mitochondria;Modeling;Organelles;Outcome;Oxidation-Reduction;Oxidative Stress;Oxidative Stress Induction;Permeability;Propylene Glycols;Protein Glycosylation;Proteins;Public Health;Reactive Oxygen Species;Research;Schedule;Signal Transduction;Skin;Skin tanning;Testing;Time;Tissues;Translating;Umbilical vein;Work;absorption;biomarker validation;cofactor;cytotoxic;e-cigarette aerosols;electronic cigarette use;electronic cigarette user;electronic liquid;genotoxicity;innovation;kidney cell;lung microvascular endothelial cells;meter;mitochondrial dysfunction;oxidation;programs;stress reduction;sugar;vaper;vaping,Dihydroxyacetone exposure induces metabolic reprogramming and mitochondrial dysfunction,The proposed research is relevant to public health because it focuses on measuring the cellulareffects of dihydroxyacetone (DHA) exposure in pulmonary and cardiovascular models to betterunderstand the inhalation exposure effects of DHA. DHA generated by e-cigarettes is inhaled byvapers enters cells and is incorporated into metabolic pathways causing metabolic changesand mitochondrial damage. This work will establish critical links between DHA exposure anddisease for e-cigarette users by understanding DHAs ability to alter cell homeostasis causesevere declines in cellular function and induce cell death..,NIEHS,10731728,10/30/2023 12:00:00 AM,PA-19-056,5R01ES032450-04,5,R01,ES,032450,04, ,"SHAUGHNESSY, DANIEL",11/19/2021 12:00:00 AM,10/31/2025 12:00:00 AM,Xenobiotic and Nutrient Disposition and Action Study Section[XNDA], ,9303574,"GASSMAN, NATALIE ROSE",Not Applicable,07,PHARMACOLOGY,063690705,YND4PLMC9AN7,063690705,YND4PLMC9AN7,US,33.50591,-86.799772,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,BIRMINGHAM,AL,SCHOOLS OF MEDICINE,352940001,UNITED STATES,N,11/1/2023 12:00:00 AM,10/31/2024 12:00:00 AM,113,Non-SBIR/STTR,2024,306275, ,NIEHS,225000,81275, ,306275,,306275.0 | |
| No NIH Category available,Acceleration;Affect;Aging;Ataxia;Autoimmunity;Autophagocytosis;Autopsy;Basic Science;Biochemical Pathway;Biological;Biological Models;Birds;Brain;Candidate Disease Gene;Categories;Chorea;Chromosome Mapping;Clinical;Collaborations;Collection;Copy Number Polymorphism;DNA;Data;Data Set;Development;Diagnosis;Disease;Drosophila genus;Dystonia;Dystonic Disorder;Etiology;Evaluation;Family;Family member;Gene Expression Profiling;Genes;Genetic;Genetic Diseases;Genetic Research;Genomic Segment;Genotype;Goals;Health;Hereditary Dystonia;Hereditary Spastic Paraplegia;Heritability;Human;Idiopathic Parkinson Disease;Impairment;In Vitro;Individual;Inherited;Intervention;Knowledge;Lead;Massive Parallel Sequencing;Mission;Modeling;Molecular;Movement;Movement Disorders;Mutation;Nerve Degeneration;Nervous System Disorder;Neurodegenerative Disorders;Neuroglia;Neurons;Pancytopenia;Parkinson Disease;Parkinsonian Disorders;Pathogenesis;Pathogenicity;Pathologic;Pathology;Pathway interactions;Patients;Pattern;Phenotype;Preventive;Productivity;Proteins;Research Personnel;Research Project Grants;Research Proposals;Resolution;Resources;Role;SNP array;Sampling;Spastic Paraplegia;Syndrome;Tauopathies;Techniques;Technology;Tissues;United States;Validation;Variant;Veterans;analytical method;bioinformatics tool;biomarker panel;causal variant;cell type;cost;diagnostic accuracy;disease-causing mutation;exome;exome sequencing;fascinate;gene discovery;gene product;genetic risk factor;genetic technology;genome sequencing;identity by descent;improved;in vivo Model;induced pluripotent stem cell;interest;member;military veteran;mutant;neurogenetics;neuronal survival;next generation sequencing;parkinson's disease registry;patient - derived stem cells;pharmacologic;proband;protein complex;protein protein interaction;recruit;repository;research study;sample collection;spasticity;stem cell model;success;synucleinopathy;targeted treatment;tau Proteins;trafficking;transcriptome sequencing;transmission process;vacuolar H+-ATPase,Genetic Movement Disorders: Etiologies and Pathogeneses,The goals of this proposal are to identify genes responsible for neurologic disorders that affect movementincluding ataxias parkinsonian disorders hereditary spastic paraplegias choreas and dystonias and deciferthe steps that lead from the altered genes to disease. Genetic diseases of the nervous system are relativelycommon in the Veteran population and the diseases studied in this research project are directly relevant toVeterans health. These disorders and especially parkinsonian disorders and ataxia disproportionately affectthe aging Veteran population. By itself Parkinson's disease affects approximately one million individuals in theUnited States at an estimated annual cost of $52 billion. Knowledge gained from studies on the biologic causesof the inherited forms of diseases will also increase understanding of more common neurologic disorders andaccelerate improvement in diagnosis management and treatment of these and related conditions. Thereforea better understanding of genetic diseases is pertinent to the long-term VHA mission.,VA,10732221,11/1/2023 12:00:00 AM,RFA-CX-21-001,5I01CX001702-06,5,I01,CX,001702,06, , ,10/1/2022 12:00:00 AM,9/30/2026 12:00:00 AM,ZRD1-NURE-E(01), ,6720078,"ZABETIAN, CYRUS P",Not Applicable,09,Unavailable,020232971,W6J8APWKL9J1,020232971,W6J8APWKL9J1,US,47.562198,-122.311185,481094,VA PUGET SOUND HEALTHCARE SYSTEM,SEATTLE,WA,Independent Hospitals,981081532,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,A549;Adverse reactions;Aftercare;Antineoplastic Agents;Apoptosis;Arachidonate 15-Lipoxygenase;Biological Availability;Biological Markers;Biological Monitoring;Biopsy;Blood;Bronchoalveolar Lavage;Bronchoalveolar Lavage Fluid;Bronchoscopy;C-reactive protein;CASP3 gene;Cancer Etiology;Cancer Patient;Cause of Death;Cells;Cessation of life;Chest;Clinic;Clinical;Clinical Research;Clinical Trials;Colorectal Cancer;Common Terminology Criteria for Adverse Events;Complex;Consent;Country;Data;Development;Diagnosis;Diagnostic Procedure;Dinoprostone;Down-Regulation;Drug Kinetics;Early treatment;Eicosanoids;Enrollment;Epigenetic Process;Epoprostenol;Excision;Food Supplements;Future;Gene Expression Profile;Growth;Health Food;Human;Hydroxyeicosatetraenoic Acids;IGF Type 2 Receptor;Interleukin-10;Interleukin-12;Interleukin-6;Label;Lesion;Lung;Lung Neoplasms;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of lung;Malignant neoplasm of prostate;Measures;Mediating;MicroRNAs;Monitor;Needles;Neoadjuvant Therapy;Newly Diagnosed;Non-Small-Cell Lung Carcinoma;Nude Mice;Operative Surgical Procedures;Oral;Oral Administration;Outcome;PTEN gene;Participant;Pathologic;Pathway interactions;Patients;Pharmacodynamics;Phase;Phospholipids;Phosphorylation;Physiological;Pilot Projects;Plasma;Probability;Procyanidins;Production;Proliferation Marker;Property;Prostaglandins I;Proto-Oncogene Proteins c-akt;Qualifying;Questionnaires;RNA;Recurrence;Resectable;Role;Safety;Sampling;Serum;Smoking;Specimen;Standardization;Structure of parenchyma of lung;Surrogate Endpoint;Telephone;Testing;Therapeutic;Time;Tissues;Toxic Environmental Substances;Tumor Immunity;Tumor Suppressor Proteins;Up-Regulation;Urine;Veterans;Visit;Xenograft procedure;anti-cancer;arm;aspirate;biological specimen archives;cancer chemoprevention;cancer therapy;capsule;carcinogenicity;cardiovascular health;confirmatory clinical trial;confirmatory trial;effective therapy;follow-up;former smoker;grape seed;high risk;improved;indexing;inflammatory marker;insight;lymph nodes;neoplastic cell;oncoprotein p21;pharmacokinetics and pharmacodynamics;pre-clinical;predicting response;recruit;response;soy;treatment strategy;tumor;tumor xenograft,Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer,Lung cancer is the leading cause of cancer death in the country surpassing deaths caused by colorectalprostate and breast cancers combined. Veterans are at higher risk of lung cancer due to the higher rate ofsmoking and environmental toxin exposures. The lack of effective therapy provides the impetus to search foralternative safe and efficacious anticancer agents to improve treatment strategy against lung cancer enhancethe probability of a cure and reduce recurrence. Based on encouraging preclinical and clinical findings in a lungcancer chemoprevention pilot study the purpose of this new CSR&D Merit Review proposal is to evaluate thefeasibility of a standardized grape seed procyanidin extract with enhanced bioavailabilities leucoselectphytosome for neoadjuvant treatment of resectable stage I and II lung cancer in a phase IIa clinical trial toestablish safety feasibility define and validate mechanisms of action identify suitable surrogate endpointbiomarkers and set the stage for larger confirmatory trials in the near future.,VA,10732772,2/26/2024 12:00:00 AM,RFA-CX-19-006,5I01CX002028-05,5,I01,CX,2028,5, , ,10/1/2020 12:00:00 AM,12/31/2026 12:00:00 AM,ZRD1-ONCB-A(01)1, ,1950401,"MAO, JENNY T",Not Applicable,50.0,Unavailable,073358855,KCGNRLSGU6F3,073358855,KCGNRLSGU6F3,US,32.871751,-117.231953,481156,VA SAN DIEGO HEALTHCARE SYSTEM,SAN DIEGO,CA,Independent Hospitals,921610002,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Accounting;American;Antibodies;Antigens;Autoantibodies;Autoantigens;Biological Assay;Breast;Cancer Center;Cancer Etiology;Cancer Patient;Central Nervous System;Cessation of life;Clinic;Clinical;Colon Carcinoma;Complex;Data Set;Detection;Development;Diagnosis;Diagnostic;Disease;Early Diagnosis;Extensive Stage;Generations;Goals;Human;Hybrids;Image;Length;Lesion;Limited Stage;Lung;Malignant Neoplasms;Malignant neoplasm of lung;Methodology;Minority;Modality;Modeling;Molecular;Nodule;Non-Small-Cell Lung Carcinoma;Outcome;Ovarian;Pancreas;Paraneoplastic Syndromes;Patients;Plasma;Prevention;Process;Prostate Lung Colorectal and Ovarian Cancer Screening Trial;Proteins;Proteomics;Reproducibility;Sampling;Screening for cancer;Specimen;Survival Rate;Testing;Time;Translating;Validation;Variant;Women's Health;X-Ray Computed Tomography;biomarker panel;candidate marker;cardiovascular health;case control;chemotherapy;clinical diagnosis;clinical practice;cohort;computed tomography screening;detection method;detection platform;early detection biomarkers;high dimensionality;implementation strategy;improved;lung cancer screening;novel;screening;small cell lung carcinoma;statistics;tumor,Tumor-specific autoantibodies for SCLC early detection,PROJECT NARRATIVESmall cell lung cancer (SCLC) accounts for >30000 American lives each year and portends five-year survivalrates of just ~7%. Detection of SCLC at early stage drastically improves these survival metrics. We propose toleverage molecular features unique to SCLC such as the development of autoantibody-antigen complexes tovalidate a plasma biomarker panel capable of SCLC early detection to allow for early initiation of potentiallycurative chemotherapy.,NCI,10732773,11/15/2023 12:00:00 AM,PA-19-056,5R01CA243328-06,5,R01,CA,243328,06, ,"MARQUEZ, GUILLERMO",12/17/2019 12:00:00 AM,11/30/2024 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,6786529,"HOUGHTON, A MCGARRY","LAMPE, PAUL D.",07,Unavailable,806433145,TJFZLPP6NYL6,806433145,TJFZLPP6NYL6,US,47.626482,-122.329606,10068583,FRED HUTCHINSON CANCER CENTER,SEATTLE,WA,Other Domestic Non-Profits,981094433,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,406116, ,NCI,237076,169040, ,406116,,406116.0 | |
| No NIH Category available,Address;Auditory Hallucination;Award;BRAIN initiative;Behavior;Biological;Brain;Brain region;Cerebellar Cortex;Cerebellar Diseases;Cerebellum;Clinic;Clinical;Data;Disabling;Disparate;Functional Magnetic Resonance Imaging;Functional disorder;Goals;Hallucinations;Human;Image;Intervention;Link;Location;Magnetic Resonance Imaging;Mental disorders;Modeling;National Institute of Mental Health;Observational Study;Participant;Pattern;Phenotype;Psychotic Disorders;Publishing;Recording of previous events;Role;Schizophrenia;Severities;Symptoms;Technology;Testing;Thalamic structure;Therapeutic;Translations;Validation;cohort;debilitating symptom;experimental study;imaging biomarker;imaging study;individual variation;neural circuit;neuroimaging;neuroregulation;novel strategies;outcome disparities;psychiatric symptom;psychotic symptoms;recruit;reduce symptoms;restoration;severe mental illness;sham-controlled study;standard care;translational applications,Empirical validation of a cerebellar-cortical hallucination circuit,Project NarrativeSchizophrenia is characterized by the presence of psychotic symptoms such as hallucinations. We still lack anunderstanding of how brain circuit dysfunction gives rise to hallucinations. In this project we seek to identify thebrain circuit that causes these debilitating symptoms.,NIMH,10735879,10/31/2023 12:00:00 AM,PA-20-184,5R01MH126000-03,5,R01,MH,126000,03, ,"ANKUDOWICH, ELIZABETH",1/1/2022 12:00:00 AM,10/31/2026 12:00:00 AM,"Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]", ,9563233,"HALKO, MARK A","BRADY, ROSCOE O.",05,Unavailable,046514535,MCKWJYCWNVN3,046514535,MCKWJYCWNVN3,US,42.393619,-71.191142,1876801,MCLEAN HOSPITAL,BELMONT,MA,Independent Hospitals,024781064,UNITED STATES,N,11/1/2023 12:00:00 AM,10/31/2024 12:00:00 AM,242,Non-SBIR/STTR,2024,671484, ,NIMH,443786,227698, ,671484,,671484.0 | |
| No NIH Category available,Acute;Back;Basal Ganglia;Behavioral;Biochemical;Biological Markers;Blood Vessels;Brain;Chronic;Clinical;Clinical Trials;Contrast Sensitivity;Control Groups;Coupled;Coupling;Detection;Development;Disease;Disease Progression;Dopamine;Dorsal;Early Diagnosis;Etiology;Functional Magnetic Resonance Imaging;Functional disorder;Future;Genetic;Genetic Techniques;Goals;Healthcare;Imaging Techniques;Intervention;L-DOPA induced dyskinesia;Levodopa;Link;Magnetic Resonance Imaging;Measures;Methods;Modality;Modeling;Motor;Nature;Neurodegenerative Disorders;Neurons;Neurotransmitters;Oxidopamine;Parkinson Disease;Parkinsonian Disorders;Pathologic;Patients;Perfusion;Play;Population;Pre-Clinical Model;Progressive Disease;Research;Rest;Rodent Model;Role;Sensitivity and Specificity;Signal Transduction;Structure;Techniques;Technology;Testing;Therapeutic;Time;Translations;Validation;alpha synuclein;base;clinical phenotype;clinical translation;diagnostic value;disease model;dopaminergic neuron;genetic manipulation;imaging biomarker;imaging modality;improved;insight;locus ceruleus structure;magnetic resonance imaging biomarker;motor symptom;network dysfunction;neuronal circuitry;neuropathology;neurophysiology;neurovascular coupling;non-motor symptom;noradrenergic;novel;pharmacologic;potential biomarker;pre-clinical;pre-formed fibril;preclinical study;prognostic value;receptor;side effect;standard care;synuclein;synucleinopathy;translational therapeutics,Multi-scale functional connectivity in preclinical models of Parkinson's disease,PROJECT NARRATIVE:This goal of this proposal is to investigate Parkinsons-related changes in brain networks using a robustfunctional magnetic resonance imaging method which increases sensitivity to brain activity and informs onmicrovascular function. This method will be used to characterize changes with Parkinsons disease in preclinicalmodels as well as investigate changes in brain networks with specific biochemical modulations. These studieswill provide insight into the underlying causes of altered brain networks observed in Parkinsons disease.,NINDS,10738268,11/20/2023 12:00:00 AM,PAR-21-038,5R01NS124575-03,5,R01,NS,124575,03, ,"SIEBER, BETH-ANNE",1/1/2022 12:00:00 AM,11/30/2026 12:00:00 AM,Emerging Imaging Technologies in Neuroscience Study Section[EITN], ,11854360,"STOKES, ASHLEY M",Not Applicable,03,Unavailable,131606022,SKX6AXF9ZTM3,131606022,SKX6AXF9ZTM3,US,37.775975,-122.392972,2052813,ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER,PHOENIX,AZ,Independent Hospitals,850134409,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Non-SBIR/STTR,2024,387399, ,NINDS,242500,144899, ,387399,,387399.0 | |
| No NIH Category available,3-Dimensional;Affect;Anatomy;Binding;Biomechanics;Bone Density;Bone Diseases;Bone remodeling;Bone structure;Brain imaging;Cadaver;Calcium;Clinical;Clinical Treatment;Clinical assessments;Complex;Computing Methodologies;Death Rate;Densitometry;Diagnosis;Disease;Dual-Energy X-Ray Absorptiometry;Enrollment;Europe;Evaluation;Fatty acid glycerol esters;Femur;Fracture;Functional disorder;Funding;Future;Gold;Health;Hip Fractures;Hip region structure;Human;Image;Intervention;Intervention Studies;Ionizing radiation;Lumbar Regions;Magic;Magnetic Resonance Imaging;Magnetism;Maps;Marrow;Measurement;Measures;Mechanics;Metals;Methods;Minerals;Modeling;Morbidity - disease rate;Morphology;Network-based;Neural Network Simulation;Obesity;Observational Study;Organ;Osteoclasts;Osteoporosis;Osteoporotic;Participant;Pelvis;Persons;Pharmacologic Substance;Physiologic pulse;Porosity;Postmenopause;Predisposition;Property;Protocols documentation;Radiation;Reproducibility;Research;Research Design;Sampling;Scanning;Site;Specimen;Structure;Techniques;Testing;Time;Tissues;United States;United States National Institutes of Health;Validation;Water;Woman;Work;X-Ray Computed Tomography;Zoledronic Acid;absorption;age related;bone;bone health;bone quality;bone strength;clinical translation;clinically relevant;cohort;cone-beam computed tomography;convolutional neural network;deep learning;efficacy evaluation;experience;experimental study;falls;fracture risk;health assessment;imaging biomarker;improved;in vivo;inhibitor;lumbar vertebra bone structure;magnetic field;mortality;novel;osteoporosis with pathological fracture;pharmacologic;radiological imaging;skeletal disorder;success;tibia;treatment effect;validation studies,Bone health assessment through magnetic susceptibility mapping,Project NarrativeOsteoporosis is a disease that effects around 200 million people worldwide and causes catastrophic hipfractures which have a one-year mortality rate of 20% and are associated with substantial morbidity. Clinicalmethods of bone densitometry have many limitations and are poor predictors of osteoporotic fracture. I proposea method to quantify bone material composition in the hip which could help to better inform clinicians treatingosteoporosis and improve research efforts investigating the progression of bone disease.,NIAMS,10738296,2/22/2024 12:00:00 AM,PA-21-051,5F31AR079925-03,5,F31,AR,079925,03, ,"VINCENT, ISAAH S",12/1/2021 12:00:00 AM,2/26/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-F10B-B(20)L], ,15695512,"JONES, BRANDON CLINTON",Not Applicable,03,BIOMEDICAL ENGINEERING,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,BIOMED ENGR/COL ENGR/ENGR STA,191046205,UNITED STATES,N,2/27/2024 12:00:00 AM,2/26/2025 12:00:00 AM,846,"Training, Individual",2024,48974, ,NIAMS,48974,0, ,48974,,48974.0 | |
| No NIH Category available,Antibodies;Binding;Biological Markers;Cell membrane;Cholesterol;Classification;Clinical;Clinical Data;Clinical Research;Clinical Trials;Combined Modality Therapy;Copy Number Polymorphism;Cytotoxic Chemotherapy;Data;Disease Progression;Dose;Drug Kinetics;Drug resistance;ERBB2 gene;Endocytosis;Exhibits;Fluorine;Foundations;Future;Goals;Heterogeneity;Human;Image;Incidence;Investigation;Label;Lovastatin;Lutetium;Malignant Neoplasms;Mediating;Medical Records;Membrane;Methods;Modeling;Molecular;Mus;Mutation;Organoids;Patient Selection;Patients;Pharmaceutical Preparations;Pharmacodynamics;Population;Positron-Emission Tomography;Protein Overexpression;Proteins;Radiation Dose Unit;Radiation therapy;Radiolabeled;Radionuclide therapy;Randomized;Resistance;Resistance development;Saline;Sampling;Site;Stains;Structure;Surface;Survival Analysis;Testing;Therapeutic;Therapeutic antibodies;Time;Tissues;Translations;Trastuzumab;Treatment Efficacy;Validation;Xenograft procedure;Zirconium;cancer cell;caveolin 1;clinical imaging;clinical translation;dosimetry;drug sensitivity;gastroesophageal cancer;humanized antibody;improved;molecular imaging;neoplastic cell;non-invasive imaging;novel;patient response;pharmacologic;pre-clinical;preclinical study;prevent;protein expression;radioligand;receptor;receptor internalization;resistance mechanism;response;targeted imaging;therapy resistant;treatment response;tumor;uptake;young man,Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin,PROJECT NARRATIVEThis proposal seeks to validate caveolin-1 as a complementary biomarker of HER2 and to determine sensitivity orresistance of the tumor-targeting anti-HER2 antibody trastuzumab when administrated in combination with thecommon cholesterol-depleting drug lovastatin in the treatment of esophagogastric cancer. Retrospective clinicaland preclinical analyses will be performed using patient HER2+ tumor samples and patient-derived EG xenograftstreated with statin alone trastuzumab alone or the combination of the two. The long-term goal will be to informfuture therapeutic strategies that can prevent or delay the emergence of trastuzumab resistance.,NCI,10738727,11/1/2023 12:00:00 AM,PA-19-056,5R01CA244233-04,5,R01,CA,244233,04, ,"WU, YICONG",12/1/2020 12:00:00 AM,11/30/2025 12:00:00 AM,Imaging Probes and Contrast Agents Study Section[IPCA], ,7614079,"LEWIS, JASON S.","JANJIGIAN, YELENA Y",12,Unavailable,064931884,KUKXRCZ6NZC2,064931884,KUKXRCZ6NZC2,US,40.764045,-73.956024,5079202,SLOAN-KETTERING INST CAN RESEARCH,NEW YORK,NY,Research Institutes,100656007,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,660915, ,NCI,373399,287516, ,660915,,660915.0 | |
| No NIH Category available,Address;Affect;Agonist;Airway Disease;Area;Asthma;Award;Basal Cell;Bioinformatics;Biology;Bone Marrow;Brush Cell;Calcium Signaling;Cell Culture Techniques;Cell Differentiation process;Cell Physiology;Cells;Complex;Coupled;Cyclic AMP;Data;Defensins;Disease;Epithelial Cells;Epithelial Physiology;Epithelium;Flow Cytometry;Foundations;Funding;GTP-Binding Proteins;Gene Expression;Gene Expression Profiling;Genes;Goals;Head and Neck Surgery;Helminths;Histopathology;Human;Immunity;Immunofluorescence Immunologic;Immunology;Inflammation;Inflammatory;Inflammatory Response;Interleukin-13;Intestines;Ion Channel;Knock-out;Knowledge;Lavage;Lentivirus;Ligands;Mechanics;Mediating;Medical;Membrane;Mentors;Mentorship;Modeling;Mouse Strains;Mucosal Immune Responses;Mucous Membrane;Mus;Nasal Polyps;Nose;Nose Diseases;Observational Study;Otolaryngology;Paracrine Communication;Pathway interactions;Patients;Pennsylvania;Persons;Phosphotransferases;Physiological Processes;Polyps;Population;Potassium;Potassium Channel;Property;Proteins;Protocols documentation;Pyroglyphidae;Regulation;Research;Research Personnel;Resistance;Role;Sampling;Sensory;Signal Pathway;Signal Transduction;Sinus;Sorting;Stimulus;Surgical Management;TRPM5 gene;Taste Buds;Taste Perception;Testing;Tissues;Tongue;Trachea;Training;United States;Universities;Work;X Chromosome;airway inflammation;airway repair;anti-microbial peptide;biomarker validation;career;channel blockers;chronic rhinosinusitis;clinical practice;cohort;epithelial repair;experience;experimental study;immune function;improved;inflammatory marker;injured;insight;interest;medical attention;medical schools;multidisciplinary;new therapeutic target;novel;paracrine;patient subsets;phenotypic biomarker;phosphoric diester hydrolase;professor;rat Gnat3 protein;repaired;respiratory;respiratory health;response;single-cell RNA sequencing;skills;small hairpin RNA;taste transduction;transcription factor;transcriptome sequencing;wound;wound closure,Solitary Chemosensory Cell Regulation of Airway Inflammation and Repair,Project Narrative Chronic rhinosinusitis affects up to 16% of the population in the United States and is among the mostcommon reasons people seek medical attention. Solitary chemosensory cells (SCCs) akin to type II tastecells in the tongue (responsible for taste transduction) and tuft cells in the mouse gut (responsible for localinflammation) are enriched in the sinus epithelium in those with chronic rhinosinusitis with nasal polypshowever little is known about their role in human mucosal inflammatory diseases. This proposal willcharacterize and identify taste and inflammatory pathways related to SCC differentiation and expansion inchronic rhinosinusitis and explore how SCC signaling through epithelial ion channels affects mucosal immunefunction which may reveal novel therapeutic targets for the treatment of chronic rhinosinusitis.,NHLBI,10738762,11/28/2023 12:00:00 AM,PA-19-117,5K08HL151911-04,5,K08,HL,151911,04, ,"LU, JINING",12/20/2020 12:00:00 AM,11/30/2025 12:00:00 AM,NHLBI Mentored Clinical and Basic Science Study Section[MCBS(OA)], ,9712688,"KOHANSKI, MICHAEL AARON",Not Applicable,03,OTOLARYNGOLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,838,Other Research-Related,2024,152896, ,NHLBI,141570,11326, ,152896,,152896.0 | |
| No NIH Category available,Abdomen;Address;Animals;Benchmarking;Biodiversity;Biological Markers;Biology;Biopsy;Brain;Breast;Cancer Patient;Citric Acid Cycle;Clinic;Clinical;Clinical assessments;Collaborations;Computer software;Data;Development;Disease;Disseminated Malignant Neoplasm;Echo-Planar Imaging;Foundations;Future;Glycolysis;Goals;Heart;Histologic;Human;Human body;Image;Industrialization;Infrastructure;Infusion procedures;Label;Lesion;Magnetic Resonance;Magnetic Resonance Imaging;Malignant Neoplasms;Malignant neoplasm of prostate;Metabolic;Metabolism;Metastatic Prostate Cancer;Methods;Monitor;Motivation;Mutation;Oncogenic;PSA level;Pathology;Patients;Perfusion;Pharmacotherapy;Phenotype;Physiologic pulse;Population;Prostate;Pyruvate;Pyruvate Metabolism Pathway;Radioactive Tracers;Research;Research Personnel;Role;Scientist;Sensitivity and Specificity;Site;Support System;Surface;System;Systems Biology;Techniques;Technology;Therapeutic Intervention;Time;Translating;Transrectal Ultrasound;Up-Regulation;Validation;Visualization;Work;androgen deprivation therapy;animal imaging;bone;cancer site;cancer therapy;castration resistant prostate cancer;cohort;design;first-in-human;follow-up;human study;image reconstruction;imaging biomarker;imaging capabilities;imaging modality;improved;in vivo;individualized medicine;industry partner;innovation;interest;men;metabolic abnormality assessment;metabolic imaging;molecular imaging;non-invasive imaging;non-invasive monitor;novel;novel therapeutic intervention;novel therapeutics;patient population;response;serum PSA;software development;tool;transmission process;treatment effect;treatment planning;treatment response;tumor;tumor metabolism;virtual,Development of large-field-of-view hyperpolarized MRI,PROJECT NARRATIVEThe over-arching goal of the proposed research is to translate a new MRI technology hyperpolarized (HP) MRto the clinic in the setting of large-field-of-view (FOV) MRI which utilizes both the agents HP [1-13C] pyruvateand [2-13C] pyruvate in metastatic prostate cancer patients. Prostate cancer demonstrates tremendous biologicdiversity and there is an urgent need to develop more sensitive and specific imaging biomarkers to characterizethe disease. We aim to develop a large-body transmit/receive system and pulse sequences for large FOV andapply them to a cohort of prostate cancer patients: this work will aid in future patient-specific treatment planningfacilitate earlier assessment of response to therapy and facilitate the development of novel experimentalstrategies for cancer treatment.,NCI,10739293,11/7/2023 12:00:00 AM,PAR-18-009,5R01CA237466-05,5,R01,CA,237466,05, ,"ZHANG, HUIMING",12/1/2019 12:00:00 AM,11/30/2024 12:00:00 AM,Special Emphasis Panel[ZRG1-SBIB-Q(57)R], ,10451505,"KESHARI, KAYVAN R","CUNNINGHAM, CHARLES H.; HRICAK, HEDVIG ",12,Unavailable,064931884,KUKXRCZ6NZC2,064931884,KUKXRCZ6NZC2,US,40.764045,-73.956024,5079202,SLOAN-KETTERING INST CAN RESEARCH,NEW YORK,NY,Research Institutes,100656007,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,546632, ,NCI,376177,170455, ,546632,,546632.0 | |
| No NIH Category available,Adult;Age;Alzheimer disease prevention;Alzheimer's Disease;Alzheimer's disease patient;Alzheimers disease biomarker;American;Amino Acids;Amyloid;Amyloid Proteins;Amyloid beta-Protein;Animals;Antibodies;Apolipoprotein E;Binding;Cell membrane;Cells;Chemicals;Chemistry;Clinical;Collaborations;Complement;Complex;Coupled;Cryoelectron Microscopy;Data;Dependence;Deuterium;Development;Device or Instrument Development;Disease;Entropy;Family;Fibroblasts;Field Flow Fractionation;Filament;Foundations;Free Radicals;Functional disorder;Goals;Grant;Heterogeneity;Human;Hydrogen;Hydrogen Bonding;In Vitro;Individual;Kinetics;Label;Laboratories;Ligand Binding;Lipids;Mass Spectrum Analysis;Measures;Membrane;Methods;Modeling;Modification;Molecular;Molecular Sieve Chromatography;Morphology;Nature;Nerve Degeneration;Neurodegenerative Disorders;Neurons;Outcome;Parkinson Disease;Pathogenesis;Patients;Peptides;Physiologic pulse;Pluripotent Stem Cells;Population;Preventive;Protein Footprinting;Protein Isoforms;Proteins;Proteomics;Protocols documentation;Qualifying;Rationalization;Reagent;Research;Resolution;Role;Site;Solvents;Specificity;Structure;System;Techniques;Testing;Therapeutic;Thinking;Time;United States National Institutes of Health;Validation;abeta accumulation;aggregation pathway;apolipoprotein E-4;carbene;computerized data processing;density;disorder prevention;experience;experimental study;in vivo;inhibitor;insight;instrumentation;invention;kinetic model;mathematical model;method development;monomer;mouse model;neurotoxic;novel;novel strategies;novel therapeutics;oxidation;protein aggregation;sensor;small molecule;small molecule inhibitor;solid state;solid state nuclear magnetic resonance;stem;stem cell model;theories;tool,Mass Spectrometry-Based Protein Footprinting: A New Tool for Amyloid Protein Aggregation,The lack of cures and prevention of Alzheimers disease (AD) stems in part from an incomplete understandingof the aggregation of plaque-forming Amyloid beta protein and by the role of another protein ApoE a biomarkerof AD. We seek to understand these proteins in vitro and in reprogrammed neurons from individuals who haveAD.,NIA,10739659,5/10/2024 12:00:00 AM,PAR-22-093,1R01AG079283-01A1,1,R01,AG,079283,01,A1,"YANG, AUSTIN JYAN-YU",5/15/2024 12:00:00 AM,4/30/2029 12:00:00 AM,Special Emphasis Panel[ZRG1-MCST-B(80)S], ,1870813,"GROSS, MICHAEL L",Not Applicable,01,CHEMISTRY,068552207,L6NFUM28LQM5,068552207,L6NFUM28LQM5,US,38.664368,-90.323797,9083901,WASHINGTON UNIVERSITY,SAINT LOUIS,MO,SCHOOLS OF ARTS AND SCIENCES,631304862,UNITED STATES,N,5/15/2024 12:00:00 AM,4/30/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,748641, ,NIA,498891,249750, ,748641,,748641.0 | |
| No NIH Category available,3-Dimensional;Alanine;Binding Proteins;Biochemical;Biochemical Pathway;Bioenergetics;Biological Markers;Breast Cancer Cell;Cancer Cell Growth;Cancerous;Cell Nucleus;Cell Proliferation;Cells;Cholesterol;Cholesterol Homeostasis;Chromatin;Citric Acid Cycle;Confocal Microscopy;Coupled;DEK gene;Data;Deglutition;Development;Drug Targeting;Early Diagnosis;Early identification;Energy Supply;Enzyme Activation;Enzymes;Epidermis;Epithelium;Fermentation;Fibroblasts;Fractionation;Genetic Transcription;Genus Hippocampus;Glucose;Glycolysis;Growth;HPV-negative head and neck cancer;Head and Neck Cancer;Head and Neck Squamous Cell Carcinoma;Human;Human Activities;Human Papillomavirus;Human papilloma virus infection;Hyperplasia;Intervention;Invaded;Knock-out;Laboratories;Literature;Longevity;Malignant Neoplasms;Maps;Mass Spectrum Analysis;Messenger RNA;Metabolic;Metabolic Control;Metabolic Pathway;Metabolism;Mitochondria;Modeling;Molecular;Neoplasm Metastasis;Neoplastic Cell Transformation;Normal Cell;Nuclear;Nuclear Pore Complex Proteins;Oncogenes;Oncogenic;Outcome;Oxidative Phosphorylation;Pathway interactions;Patients;Phenotype;Prevention strategy;Process;Production;Proliferating;Proteins;Reporting;Resolution;Role;Signal Transduction;Smoking;Source;Specimen;Technology;Testing;Therapeutic;Time;Treatment Protocols;Tumor Promotion;Xenograft procedure;aerobic glycolysis;beta catenin;biomarker identification;biomarker validation;cancer cell;cancer type;cell transformation;cell type;cholesterol biosynthesis;diagnostic biomarker;drinking;enzyme biosynthesis;experimental study;gain of function;head and neck cancer prevention;human model;improved outcome;inhibitor;innovation;keratinocyte;knock-down;leukemia;loss of function;macromolecule;metabolomics;mutant;new therapeutic target;novel;nucleic acid binding protein;overexpression;prevent;programs;protein expression;reconstitution;stable isotope;targeted biomarker;three-dimensional modeling;transcriptome sequencing;treatment strategy;tumor;tumor growth;tumor progression;tumorigenesis,New activities of the human DEK oncogene,NARRATIVE.For a cell to become cancerous it must reprogram its metabolism in order to fuel unrestrained growth andprogression to metastasis. Head and neck cancer is one of the most common cancers with low survival andtreatment regimens that can leave patients (sometimes quite young) disfigured and unable to swallow or speak.As experts on a human protein known as DEK we have performed experiments that strongly suggest that DEKcontrols metabolic reprogramming in order to promote cancer development and metastatic dissemination. Theproposed studies will determine whether this is the case while also revealing and testing new metabolism-basedstrategies for head and neck cancer prevention and treatment.,NCI,10740849,11/21/2023 12:00:00 AM,PA-19-056,5R01CA239605-05,5,R01,CA,239605,05, ,"WILLIS, KRISTINE AMALEE",12/1/2019 12:00:00 AM,11/30/2024 12:00:00 AM,Cancer Prevention Study Section[CPSS], ,6436782,"WELLS, SUSANNE I",Not Applicable,01,Unavailable,071284913,JZD1HLM2ZU83,071284913,JZD1HLM2ZU83,US,39.140663,-84.501007,615001,CINCINNATI CHILDRENS HOSP MED CTR,CINCINNATI,OH,Independent Hospitals,452293039,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,396,Non-SBIR/STTR,2024,344256, ,NCI,228538,115718, ,344256,,344256.0 | |
| No NIH Category available,Acceleration;Address;Algorithms;Biological Markers;Cancer Detection;Characteristics;Clinical;Cohort Analysis;Cohort Studies;Consumption;Cost efficiency;Data;Data Analyses;Development;Diabetes Mellitus;Diagnosis;Early Detection Research Network;Early Diagnosis;Eligibility Determination;Failure;Future;Guidelines;Hybrids;Laboratories;Lead;Malignant Neoplasms;Malignant neoplasm of pancreas;Medical Research;Methodology;Methods;Modality;Participant;Phase;Procedures;Process;Prostate Lung Colorectal and Ovarian Cancer Screening Trial;Research;Research Design;Research Personnel;Resources;Sampling;Scientific Advances and Accomplishments;Screening for cancer;Specimen;Statistical Methods;Target Populations;Testing;Time;Translating;Validation;Work;anti-cancer research;biomarker development;biomarker panel;biomarker performance;biomarker validation;cancer biomarkers;cancer site;cancer therapy;clinical application;clinical diagnosis;clinical practice;cohort;computed tomography screening;design;dissemination trial;efficacy evaluation;improved;innovation;low dose computed tomography;lung cancer screening;novel;phase 3 study;phase 4 study;phase IV trial;precision medicine;primary endpoint;programs;prospective;screening;screening guidelines;software development;tool;user-friendly;validation studies,Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies,Project NarrativeThis work aims to develop innovative statistical methods for analyzing phase III and IV biomarker studiesto accelerate biomarker development for cancer early detection. The proposed research is essential foranalyzing two high-impact collaborative studies for pancreatic cancer and lung cancer early detection; it willalso yield guidelines for addressing several critical issues in current practice including: 1) primary endpointselection and proper strategies to assess screening efcacy in phase IV trials 2) utilization of phase IVstudies in phase III biomarker panel development and 3) combination of studies with differential screeningmodalities and eligibility criteria when estimating design parameters for biomarker clinical utility trials.,NCI,10740870,11/29/2023 12:00:00 AM,PA-20-185,5R01CA277133-02,5,R01,CA,277133,02, ,"HODGES, NICHOLAS AARON",12/1/2022 12:00:00 AM,11/30/2027 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,9297264,"HUANG, YING ",Not Applicable,07,Unavailable,806433145,TJFZLPP6NYL6,806433145,TJFZLPP6NYL6,US,47.626482,-122.329606,10068583,FRED HUTCHINSON CANCER CENTER,SEATTLE,WA,Other Domestic Non-Profits,981094433,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,381633, ,NCI,230908,150725, ,381633,,381633.0 | |
| No NIH Category available,AIDS prevention;Address;Antigens;Binding;Biological Markers;Blood;Bone Marrow;CCR5 gene;CD8-Positive T-Lymphocytes;CXCR4 gene;Cell Therapy;Cells;Chronic;Clinical;Containment;Couples;Data;Development;Disease;Disease remission;Epigenetic Process;Epitopes;Evaluation;Functional disorder;Gene Expression Profile;Gene Expression Profiling;Genes;Genetic Transcription;HIV;HIV Infections;Heterogeneity;Immune response;Immunobiology;Immunotherapy;Impairment;In Situ;Individual;Infection;Intervention;Intrinsic factor;Knowledge;Lymphocyte Activation;Lymphocyte Function;Lymphoid Tissue;Maintenance;Malignant Neoplasms;Mediating;Mission;Molecular;Molecular Target;Monitor;Mutation;Outcome;Pathway interactions;Patients;Pharmaceutical Preparations;Population;Prevention;Prevention strategy;Provirus Integration;Public Health;Regulation;Regulatory Pathway;Research;Resolution;Risk;Sampling;Signal Transduction;Specimen;Systemic infection;Systems Biology;T-Cell Development;T-Lymphocyte;Therapeutic Intervention;Tissue Stains;Tissues;Transplantation;United States National Institutes of Health;Validation;Variant;Viral;Viral reservoir;Viremia;antiretroviral therapy;biobank;checkpoint receptors;chronic infection;clinical trial participant;combat;comparative;cost;cytotoxic CD8 T cells;epigenetic profiling;exhaustion;experimental study;human disease;immune activation;immune checkpoint;immune checkpoint blockade;improved;innovation;insight;multiple omics;novel;pharmacologic;posttranscriptional;predictive marker;prevent;rational design;response;restoration;specific biomarkers;success;superinfection;viral rebound,Understanding and Reversing T Cell Dysfunction to Control and Eliminate Persistent HIV Reservoirs,PROJECT NARRATIVEThe proposed research is relevant to public health because it will elucidate molecular regulation of HIV-specificT cell dysfunction which will inform development of T cell-based HIV cure approaches facilitate evaluation ofimmune responses in patients and clinical trial participants improve clinical monitoring for risk of HIV reboundand provide fundamental insights into immunobiology that can also be applied to the treatment of other infectionsand cancer. Thus the proposed research is relevant to the NIHs mission because it will generate fundamentalknowledge that will advance the prevention and cure of human diseases.,NIAID,10741772,11/14/2023 12:00:00 AM,RFA-AI-18-053,5R01AI149704-05,5,R01,AI,149704,05, ,"REFSLAND, ERIC WILLIAM",12/23/2019 12:00:00 AM,11/30/2024 12:00:00 AM,Special Emphasis Panel[ZRG1-AARR-Q(50)R], ,1890766,"WALKER, BRUCE D",Not Applicable,08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,855,Non-SBIR/STTR,2024,420000, ,NIAID,250000,170000, ,420000,,420000.0 | |
| No NIH Category available,Affect;Benign;Bilateral;Biological;Biological Assay;Biological Markers;Calcium;Cancer Diagnostics;Cellular Morphology;Classification;Clinical;Clinical Management;Clinical Trials;Cytopathology;DNA Methylation;Data;Decision Making;Development;Diagnostic;Diagnostic Procedure;Diagnostic Specificity;Epigenetic Process;Evaluation;Excision;Failure;Fine needle aspiration biopsy;Gene Expression;Gene Fusion;Gene Mutation;Knowledge;Laboratories;Malignant - descriptor;Malignant Neoplasms;Malignant neoplasm of thyroid;Medical center;Molecular;Morbidity - disease rate;Mutation;Nodule;Operative Surgical Procedures;Papillary thyroid carcinoma;Parathyroid gland;Pathologic;Patients;Performance;Physicians;Pilot Projects;Predictive Value;Prospective cohort;Publishing;Recurrent Laryngeal Nerve;Reproducibility;Sensitivity and Specificity;Specialist;Specimen;Surgeon;Testing;Thyroid Gland;Thyroid Hormones;Thyroid Nodule;Thyroidectomy;Tissues;Tracheostomy procedure;United States;Validation;Vocal Cord Paralysis;aspirate;cancer risk;clinical decision-making;diagnostic accuracy;diagnostic strategy;diagnostic value;epigenetic marker;epigenomics;genome-wide;improved;inter-institutional;internal control;methylation pattern;molecular diagnostics;pilot trial;prospective;ultrasound,Validation of epigenomic biomarkers for thyroid cancer diagnostics,PROJECT NARRATIVEAs many as 50000 unnecessary thyroidectomies are performed in the United States each year because thyroidnodules are deemed indeterminate preoperatively when they are indeed benign. We have developed a newmolecular test based on assessing DNA methylation in thyroid nodules that is accurate in preliminary tests andmust be tested in the proposed clinical trial.,NCI,10744177,11/22/2023 12:00:00 AM,PAR-18-560,5R01CA241845-03,5,R01,CA,241845,03, ,"MCKEE, TAWNYA C",6/15/2021 12:00:00 AM,11/30/2026 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,10420726,"HAHN, MARIA ","YIM, JOHN H",31,Unavailable,027176833,NPH1VN32EWN5,027176833,NPH1VN32EWN5,US,34.127716,-117.972442,3058203,BECKMAN RESEARCH INSTITUTE/CITY OF HOPE,DUARTE,CA,Research Institutes,910103012,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,779408, ,NCI,566841,212567, ,779408,,779408.0 | |
| No NIH Category available,Adult;Affect;Animal Model;Area;Biological Markers;Brain;Chemosensitization;Chronic;Cognitive;Coma;Conscious;Data;Data Set;Disease;Doctor of Philosophy;Down-Regulation;Electroencephalography;Epilepsy;Excision;Frequencies;Functional disorder;Homeostasis;Hour;Human;Impaired cognition;Injury;Innovative Therapy;Link;Medical;Methods;Microelectrodes;Mission;Nervous System Disorder;Neurons;Normal Range;Operative Surgical Procedures;Outcome;Partial Epilepsies;Patients;Pattern;Peripheral;Pharmaceutical Preparations;Population;Procedures;Public Health;Recurrence;Refractory;Research;Research Personnel;Resolution;Risk;Seizures;Sleep;Slow-Wave Sleep;Synapses;Technical Expertise;United States;United States National Institutes of Health;Universities;density;diagnostic biomarker;diagnostic tool;improved;improvement on sleep;innovation;insight;neuromechanism;neuroprotection;novel;novel diagnostics;novel therapeutic intervention;novel therapeutics;recruit;spatiotemporal;validation studies,electroencephalography and single-unit recordings,Project NarrativeThe proposed research has a direct relevance to public health given that epilepsy is one of the mostcommon neurological disorders in the United States affecting about 3 million adults among which 30-40% have seizures that are medically intractable. The present application is in line with the mission ofthe NIH to develop innovative research strategies to improve public health through an understanding ofthe basic mechanisms of diseases. It may lead to completely novel insights concerning thepathophysiology of epileptic disease and pave the way to innovative therapies improving sleephomeostasis in order to decrease seizure burden and improve cognitive outcomes in patients withepilepsy.,NINDS,10744203,11/28/2023 12:00:00 AM,PA-19-119,5K23NS112473-04,5,K23,NS,112473,04, ,"WHITTEMORE, VICKY R",12/15/2020 12:00:00 AM,11/30/2025 12:00:00 AM,NST-1 Study Section[NST-1], ,12266280,"BOLY, MELANIE ",Not Applicable,02,NEUROLOGY,161202122,LCLSJAGTNZQ7,161202122,LCLSJAGTNZQ7,US,43.068519,-89.400858,578503,UNIVERSITY OF WISCONSIN-MADISON,MADISON,WI,SCHOOLS OF MEDICINE,537151218,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Other Research-Related,2024,163080, ,NINDS,151000,12080, ,163080,,163080.0 | |
| No NIH Category available,Alleles;Amino Acids;Antigen Presentation;Antigen-Presenting Cells;Antigens;Berylliosis;Beryllium;Biological Markers;Bronchoalveolar Lavage;CD4 Positive T Lymphocytes;COVID-19;Cell Culture Techniques;Cell Differentiation process;Cell Line;Cells;Cellular Indexing of Transcriptomes and Epitopes by Sequencing;Chromatin;Chronic berylliosis;DNA Methylation;DNA analysis;Data;Development;Disease;Drug Targeting;Environment;Environmental Exposure;Epigenetic Process;Epitopes;Etiology;Exposure to;Flow Cytometry;Future;Gene Expression;Genes;Genetic;Genetic Polymorphism;Genetic Predisposition to Disease;Genomic approach;Glutamic Acid;Goals;Granuloma;Granulomatous;HLA-DPB1 gene;Health;Heritability;Hour;Immune;Immune Response Genes;Immune response;Inflammation;Inhalation;Inherited;Innate Immune Response;Investigation;Life;Lung;Macrophage;Measures;Mediating;Methods;Methylation;Modification;Molecular;Organ;Pathogenesis;Pathogenicity;Pathway interactions;Persons;Population;Positioning Attribute;Predisposition;Prevalence;Proliferating;Proteins;Pulmonary Fibrosis;Regulation;Regulatory Pathway;Risk;Risk Factors;Sampling;Site;Structure of parenchyma of lung;System;T-Lymphocyte;Technology;Testing;Time;Transcriptional Regulation;Validation;Variant;Work;XCL1 gene;airway epithelium;asthmatic airway;biomarker identification;chemokine;cytokine;disorder risk;epigenome;fibrotic lung;granulomatous lung disease;histone modification;member;multiple omics;neoantigens;novel;peripheral blood;recruit;response;single cell ATAC-seq;single cell sequencing;targeted treatment;transcriptome;transcriptome sequencing,Using Multi-Omics to Define Regulators and Drivers of Granulomatous Inflammation and Chronic Beryllium Disease,PROJECT NARRATIVEThe reason why some develop exposure related diseases such as the scarring lung disease chronic berylliumdisease while others do not is not well understood. This proposal may help explain why some people get CBDwhile also defining drivers and new genes important in the development of this and other similar diseases aswell as helping us understand how beryllium exposure may change these drivers and genes. In future studiesthese factors may serve as biomarkers or predictors of disease and ultimately even targets for therapy.,NIEHS,10744774,11/29/2023 12:00:00 AM,PA-20-185,5R01ES033678-03,5,R01,ES,033678,03, ,"MCALLISTER, KIMBERLY A",2/9/2022 12:00:00 AM,11/30/2026 12:00:00 AM,Systemic Injury by Environmental Exposure[SIEE], ,2134517,"MAIER, LISA A","YANG, IVANA V",01,Unavailable,076443019,VLQKFEEJ3NE9,076443019,VLQKFEEJ3NE9,US,39.739206,-104.941874,5720901,NATIONAL JEWISH HEALTH,DENVER,CO,Independent Hospitals,802062761,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,113,Non-SBIR/STTR,2024,646640, ,NIEHS,490097,156543, ,646640,,646640.0 | |
| No NIH Category available,ARID1A gene;Address;Adjuvant Therapy;Adult;Affinity;African American;Area;Award;Basic Science;Biological Assay;Biological Markers;Biological Response Modifier Therapy;California;Cancer Burden;Cancer Center Support Grant;Cancer Control Research Program;Cancer Patient;Catchment Area;Chest;Clinical;Clinical Research;Clinical Sciences;Clinical Trials;Clinical Trials Network;Collaborations;Combined Modality Therapy;Community Outreach;Companions;Comprehensive Cancer Center;County;DNA Methylation;Data;Development;Disease;Disparity;Disseminated Malignant Neoplasm;Doctor of Philosophy;Drug Targeting;Dysmyelopoietic Syndromes;Early Diagnosis;Enrollment;Epigenetic Process;Evolution;Ewings sarcoma;Fostering;Funding;GRP78 gene;Genitourinary system;Genomics;Gills;Grant;Hematologic Neoplasms;Hematology;Immune checkpoint inhibitor;Immunologics;Immunotherapy;Institution;Intervention Trial;Investigational Therapies;Journals;Last Name;Lead;Leadership;Liver diseases;Los Angeles;Malignant Breast Neoplasm;Malignant Childhood Neoplasm;Malignant Neoplasms;Malignant neoplasm of gastrointestinal tract;Malignant neoplasm of liver;Malignant neoplasm of prostate;Methods;Minority;Mission;Molecular;Molecular Profiling;Monitor;Mutation;NCI Center for Cancer Research;Names;National Clinical Trials Network;Outcome;Paper;Patients;Peer Review;Pharmacodynamics;Phase;Pre-Clinical Model;Predictive Cancer Model;Process;Prognostic Marker;Publishing;RNA;Regulation;Research;Research Project Grants;Resource Sharing;Science;Signal Transduction;Solid;Strategic Planning;Therapeutic Intervention;Tissues;Translational Research;Underrepresented Minority;Universities;University of Southern California Norris Cancer Center;Validation;Woman;Work;anti-cancer research;artemis;cancer biomarkers;cancer diagnosis;cancer epidemiology;cancer genome;cancer health disparity;cancer risk;cancer therapy;candidate validation;cell free DNA;circulating biomarkers;community engagement;design;diagnostic biomarker;diagnostic strategy;dietary restriction;drug development;epigenomics;faculty mentor;gastrointestinal;genome sciences;genomic profiling;health equity;improved;in vivo;inhibitor;innovation;investigator-initiated trial;leukemia;liquid biopsy;meetings;member;men;metastatic colorectal;multidisciplinary;new therapeutic target;novel;novel marker;novel therapeutic intervention;preclinical efficacy;predictive marker;programs;prostate cancer model;repository;therapeutic biomarker;therapeutic candidate;therapeutic target;translational progress;treatment response;tumor;tumor microenvironment,Translational and Clinical Sciences,,NCI,10744805,12/22/2023 12:00:00 AM,PAR-20-043,5P30CA014089-48,5,P30,CA,014089,48, , ,12/1/1996 12:00:00 AM,11/30/2026 12:00:00 AM,ZCA1-RTRB-C,8686,6545166,"LENZ, HEINZ JOSEF ",Not Applicable,37,Unavailable,072933393,G88KLJR3KYT5,072933393,G88KLJR3KYT5,US,34.017282,-118.281254,7636101,UNIVERSITY OF SOUTHERN CALIFORNIA,Los Angeles,CA,Domestic Higher Education,900894304,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM, ,Research Centers,2024, ,109954, ,66639,43315, , ,, | |
| No NIH Category available,Address;Adjuvant;Adjuvant Study;Adjuvant Therapy;Angiogenesis Inhibitors;Angiomyolipoma;BAY 54-9085;Biological Markers;Blood;Blood Tests;Blood specimen;Case/Control Studies;Cessation of life;Clear Cell;Clinical;Clinical Trials;Cohort Studies;Collection;Cyst;Data;Diagnosis;Disease;Disease-Free Survival;Early Diagnosis;Eastern Cooperative Oncology Group;Enrollment;European;Excision;Future;Gene Expression Profile;Goals;Histologic;Immunoglobulins;Immunotherapy;Individual;Injury to Kidney;Integral Membrane Protein;International;International Agency for Research on Cancer;Kidney Neoplasms;Lead;Localized Disease;Measures;Medical center;Metastatic Renal Cell Cancer;Monitor;Mucins;Nephrectomy;Operative Surgical Procedures;Outcome;Papillary;Pathologic;Pathology;Patients;Phase;Phase III Clinical Trials;Plasma;Prediction of Response to Therapy;Prognosis;Prognostic Factor;Prognostic Marker;RNA;Randomized;Recurrence;Renal Cell Carcinoma;Renal Mass;Resected;Retrospective cohort;Risk;Risk Assessment;Sampling;Screening for cancer;T-Lymphocyte;Testing;Time;Validation;Work;blood-based biomarker;checkpoint therapy;circulating biomarkers;clinical prognostic;cohort;diagnostic biomarker;high risk;immune checkpoint;immunoregulation;improved;mortality;outcome prediction;participant enrollment;patient population;predict clinical outcome;prognostic;prospective;rat KIM-1 protein;relapse prediction;relapse risk;risk stratification;targeted treatment;treatment response;tumor,Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma,Project NarrativeTo date there is no known circulating biomarker for RCC. This project will interrogate samples from six clinicalcohorts for KIM-1/TIM-1 as a potential blood test for RCC. Settings in which his will be tested includedifferentiating clear cell and papillary RCC from other renal masses recurrence prediction in the adjuvantsetting and following patients with metastatic RCC treated with targeted and immune therapies.,NCI,10745282,12/18/2023 12:00:00 AM,PA-20-185,5R01CA258442-03,5,R01,CA,258442,03, ,"MCKEE, TAWNYA C",12/15/2021 12:00:00 AM,11/30/2026 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,9223203,"MCDERMOTT, DAVID ",Not Applicable,07,Unavailable,071723621,C1CPANL3EWK4,071723621,C1CPANL3EWK4,US,42.33982,-71.10568,758101,BETH ISRAEL DEACONESS MEDICAL CENTER,BOSTON,MA,Independent Hospitals,022155400,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,374169, ,NCI,247679,155696, ,374169,,374169.0 | |
| No NIH Category available,Address;Adolescence;Alzheimer's Disease;Anterior;Autopsy;Axon;Biological;Brain;Brain Diseases;Cellularity;Characteristics;Child;Complement;Corpus Callosum;Data;Delusions;Demyelinations;Development;Diffusion;Encephalitis;Etiology;Future;Genes;Genetic;Goals;Hallucinations;Hippocampus;Imaging Techniques;Inflammation;Inflammatory;Internal Capsule;Investigation;Limb structure;Longitudinal Studies;Magnetic Resonance Imaging;Major Histocompatibility Complex;Mediating;Methods;Microglia;Multiple Sclerosis;Nerve Degeneration;Pathogenesis;Patients;Persons;Phase;Positron-Emission Tomography;Prefrontal Cortex;Psychoses;Psychotic Disorders;Quality of life;Radiation;Radiation exposure;Risk;Risk Marker;Role;Sampling;Schizophrenia;Serum;Specificity;Temporal Lobe;Testing;Tissues;United States;United States National Institutes of Health;Validation;Variant;Water;Work;aged;axon injury;brain abnormalities;comparison control;complement system;cost;density;drug development;emerging adult;extracellular;functional decline;genome wide association study;genomic locus;gray matter;histological specimens;imaging biomarker;imaging modality;improved;improved outcome;in vivo;in vivo imaging;neuroimaging;neuroinflammation;neuropathology;new therapeutic target;novel;prevent;recruit;risk variant;schizophrenia risk;spectrograph;synaptic pruning;white matter,Validation of Diffusion Basis Spectrum Imaging of Neuroinflammation in Schizophrenia,PROJECT NARRATIVEAbout 3% of those in the United States will have a psychotic disorder like schizophrenia which greatly diminishestheir quality of life and costs billions of dollars per year to treat. Brain inflammation is thought to be one of themajor findings in those with schizophrenia. This proposal validates a safe new inflammation imaging method inbrain samples and then characterizes brain findings in schizophrenia patients. If this method proves effectivethen in the long term it could be used to predict which young people will develop psychosis and facilitate drugdevelopment to treat or even prevent psychotic disorders.,NIMH,10745333,10/26/2023 12:00:00 AM,PA-21-235,5R21MH131962-02,5,R21,MH,131962,02, ,"MEINECKE, DOUGLAS L",12/1/2022 12:00:00 AM,10/31/2024 12:00:00 AM,"Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]", ,8454086,"MAMAH, DANIEL ","WANG, YONG ",01,PSYCHIATRY,068552207,L6NFUM28LQM5,068552207,L6NFUM28LQM5,US,38.664368,-90.323797,9083901,WASHINGTON UNIVERSITY,SAINT LOUIS,MO,SCHOOLS OF MEDICINE,631304862,UNITED STATES,N,11/1/2023 12:00:00 AM,10/31/2024 12:00:00 AM,242,Non-SBIR/STTR,2024,194375, ,NIMH,125000,69375, ,194375,,194375.0 | |
| No NIH Category available,Acceleration;Acute;Acute-Phase Proteins;Address;Age;Aging;Alzheimer's Disease;Alzheimer's disease related dementia;Alzheimer's disease risk;Biological;Biological Aging;Biological Specimen Banks;Blood;Brain;Cessation of life;Characteristics;Chronology;Clinical;Clinical Data;Complex;Confusion;Delirium;Development;Elderly;Enzyme-Linked Immunosorbent Assay;Functional disorder;Funding;Future;Hyperactivity;Impaired cognition;Individual;Inflammation;Inflammatory;Inflammatory Response;Intervention;Investments;Measures;Memory;Modeling;Molecular;National Institute on Aging;Neuronal Injury;Nursing Homes;Operative Surgical Procedures;Outcome;Pathogenesis;Pathway interactions;Patients;Plasma;Plasma Proteins;Postoperative Period;Predisposing Factor;Predisposition;Prevention;Proteins;Proteome;Proteomics;Risk;Schedule;Surgical complication;Techniques;Testing;Thinking;Validation;biomarker discovery;blood-based biomarker;cohort;follow-up;hospital readmission;improved outcome;insight;multiple omics;older patient;postoperative delirium;precision medicine;predictive panel;predictive signature;prognostication;programs;proteomic signature;risk prediction;tetrahydrobiopterin,AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline,Project NarrativeDelirium (acute confusion) a major complication of surgery in older patients is often followed by long termdecline in memory and thinking ultimately leading to Alzheimer's dementia in some individuals. To shed lighton the mechanisms underlying these associations our project will use proteomics a technique measuringlevels of 7000 proteins in blood and previously collected clinical data and biospecimens from the SuccessfulAging after Elective Surgery (SAGES) I and II studies to determine whether a panel of proteins associatedwith future development of Alzheimer's Disease and separate protein panels associated with acceleratedaging predict delirium and delirium with cognitive decline. We will also develop (SAGES I) and independentlytest (SAGES II) new protein predictor panels for delirium and long term decline after delirium.,NIA,10745347,12/21/2023 12:00:00 AM,PA-20-185,5R01AG051658-06,5,R01,AG,051658,06, ,"ROBERTS, LUCI",12/1/2015 12:00:00 AM,11/30/2027 12:00:00 AM,Aging Systems and Geriatrics Study Section[ASG], ,1884321,"MARCANTONIO, EDWARD R","LIBERMANN, TOWIA A.",07,Unavailable,071723621,C1CPANL3EWK4,071723621,C1CPANL3EWK4,US,42.33982,-71.10568,758101,BETH ISRAEL DEACONESS MEDICAL CENTER,BOSTON,MA,Independent Hospitals,022155400,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,870666, ,NIA,534472,336194, ,870666,,870666.0 | |
| No NIH Category available,Adrenergic beta-Antagonists;Allografting;Appearance;Autologous;Bioinformatics;Biological Models;Biology;Cancer Model;Cetuximab;Cisplatin;Clinical;Coculture Techniques;Collaborations;Comprehensive Cancer Center;Credentialing;Critical Pathways;Critiques;Data;Development;Disease;Dissection;Drug Screening;Evaluation;Exhibits;FDA approved;Functional Imaging;Future;Gene Expression Profile;Genomics;Goals;Head and Neck Cancer;Head and Neck Squamous Cell Carcinoma;Heterogeneity;Histone Deacetylase Inhibitor;Human;Human Papillomavirus;Immunocompetent;Immunological Models;In Vitro;Investigation;Malignant Neoplasms;Mediating;Modeling;Molecular;Molecular Profiling;Multimodal Imaging;Mus;Mutation;Neoplasms;Organoids;Pathogenesis;Patients;Pharmaceutical Preparations;Propranolol;Publishing;Quality of life;Radiation;Radiation therapy;Radiogenomics;Radiology Specialty;Research Personnel;Resistance;Respiratory physiology;Safety;Siblings;Speech;System;T-Lymphocyte;Testing;Therapeutic;Therapeutic Trials;Treatment Efficacy;Treatment Protocols;Validation;Valproic Acid;Work;Xenograft procedure;biobank;biomarker discovery;cancer imaging;chemoradiation;comparative;drug candidate;drug efficacy;drug repurposing;efficacy evaluation;experience;high-throughput drug screening;human disease;image guided;imaging biomarker;imaging modality;immune checkpoint blockade;immunological status;immunoregulation;in vivo;in vivo Model;innovation;insight;mouse model;multimodality;novel;novel strategies;novel therapeutics;patient derived xenograft model;patient population;patient response;pre-clinical;precision medicine;radiation response;research clinical testing;resistance mechanism;response;screening;standard of care;targeted agent;transcriptome sequencing;treatment response;treatment strategy;tumor;tumor immunology;tumor xenograft,Radiogenomic Credentialing of Head and Neck Cancer Models,Project NarrativeThe overall goal of this application is to enhance the translational applicability of mammalian tumor models byperforming a cross-comparative evaluation of in vitro (organoids) and in vivo (xenograft/allograft) models ofhead and neck cancer. Consistent with the objectives of PAR-17-245 we propose to perform a systematic in-depth comparison of histopathologic radiologic genomic and therapeutic response profiles across thesemultiple preclinical platforms. In addition to testing standard of care treatment regimens paired in vitro and invivo models will be used to screen the activity of novel and FDA-approved agents targeting critical pathwaysimplicated in the pathogenesis of HNSCC.,NCI,10745671,11/9/2023 12:00:00 AM,PAR-17-245,5R01CA243456-04,5,R01,CA,243456,04, ,"WATSON, JOANNA M",12/1/2020 12:00:00 AM,11/30/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-OTC-N(55)R], ,8807436,"SESHADRI, MUKUND ",Not Applicable,26,Unavailable,824771034,YDWAYVVQHNK5,824771034,YDWAYVVQHNK5,US,42.873378,-78.869243,3934901,ROSWELL PARK CANCER INSTITUTE CORP,BUFFALO,NY,Independent Hospitals,142630001,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,396,Non-SBIR/STTR,2024,552668, ,NCI,328578,224090, ,552668,,552668.0 | |
| No NIH Category available,ADP ribosylation;Action Potentials;Address;Affect;Antineoplastic Agents;Cancer cell line;Catalysis;Cause of Death;Cell Proliferation;Cells;Cessation of life;Chemicals;Colon;Colorectal Cancer;Complex;DNA Sequence Alteration;Development;Dimerization;Epithelial Cells;Genetic;Goals;Hand;Homeostasis;Human;Hyperactivity;Imaging Techniques;Intercept;Investigation;Link;Liquid substance;Malignant Neoplasms;Mass Spectrum Analysis;Metabolic;Methods;Molecular;Mus;Mutation;Neoplasm Metastasis;Oncogenic;Outcome;Pathway interactions;Penetration;Pharmaceutical Preparations;Phase;Phenocopy;Polymerase;Population;Property;Protac;Protein Dynamics;Protein Family;Proteins;Proteome;Proteomics;Reporting;Research;Residual state;Resistance;Series;Signal Pathway;Signal Transduction;Site;Specificity;Tankyrase;Therapeutic;Therapeutic Agents;Time;Toxic effect;Validation;WNT Signaling Pathway;Work;Writing;anti-cancer;beta catenin;cancer cell;clinical investigation;colon cancer cell line;drug action;improved;in vivo;inhibitor;interest;knock-down;live cell imaging;new technology;novel therapeutic intervention;novel therapeutics;potential biomarker;preclinical study;prevent;programs;protein degradation;response;scaffold;small molecule;therapeutic target;tool;tumorigenesis,Therapeutic targeting of Wnt signaling in cancer,Project NarrativeDrugging the oncogenic Wnt/-catenin pathway is a prominent yet unsolved problem. We have previouslyfound targeting tankyrases a viable approach and now present a solution to address the unexpected resistanceissue. This study will cover the development of a new therapeutic agent a thorough investigation of its mode ofaction and the validation of its anticancer potential in mice.,NCI,10745732,11/3/2023 12:00:00 AM,PA-20-185,5R01CA269377-02,5,R01,CA,269377,02, ,"GREENBERG, WILLIAM A",12/1/2022 12:00:00 AM,11/30/2027 12:00:00 AM,Drug Discovery and Molecular Pharmacology Study Section[DMP], ,8576057,"CHEN, CHUO ",Not Applicable,30,BIOCHEMISTRY,800771545,YZJ6DKPM4W63,800771545,YZJ6DKPM4W63,US,32.811963,-96.837534,578404,UT SOUTHWESTERN MEDICAL CENTER,DALLAS,TX,SCHOOLS OF MEDICINE,753909105,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,395,Non-SBIR/STTR,2024,616283, ,NCI,375783,240500, ,616283,,616283.0 | |
| No NIH Category available,Adjuvant;Adjuvant Chemotherapy;Adjuvant Study;Adjuvant Therapy;Biological Assay;Biological Markers;Blood;Breast;Breast Cancer Patient;Breast-Conserving Surgery;Cancer Burden;Characteristics;Clinical;Clinical Trials;Correlative Study;DNA analysis;Data;Detection;Diagnosis;Disease;Disease-Free Survival;Distant;Drug Evaluation;ERBB2 gene;Eligibility Determination;Exposure to;Functional Magnetic Resonance Imaging;Genetic Fingerprintings;Genomics;Goals;Hormone Receptor;Image;In complete remission;Infrastructure;Magnetic Resonance Imaging;Malignant Breast Neoplasm;Measures;Metastatic to;Metastatic/Recurrent;Modality;Molecular;Monitor;Mutation;Neoadjuvant Therapy;Nodal;Operative Surgical Procedures;Outcome;Pathologic;Patient risk;Patient-Focused Outcomes;Patients;Performance;Prediction of Response to Therapy;Primary Neoplasm;Probability;Randomized;Recurrence;Residual Cancers;Residual Neoplasm;Risk;Risk Assessment;Risk Marker;Serial Magnetic Resonance Imaging;Testing;Therapeutic;Time;Toxic effect;Treatment outcome;Tumor Burden;Tumor Volume;Validation;advanced disease;cancer subtypes;cohort;companion diagnostics;deep sequencing;diagnostic biomarker;drug efficacy;efficacy evaluation;experience;high risk;improved;improved outcome;liquid biopsy;multimodality;novel therapeutics;patient response;phase II trial;predicting response;predictive marker;predictive tools;primary endpoint;prognostic model;prognostic tool;prognostic value;real time monitoring;relapse risk;response;risk stratification;standard of care;treatment choice;treatment response;tumor;tumor DNA,Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer,PROJECT NARRATIVE Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is strongly associated withimproved outcomes thus the major challenges of NAC are (1) to bring each patient to pCR; and (2) to identifythose who are at risk of metastatic recurrence in patients who do not achieve pCR. To this end biomarkers forprediction of treatment response and accurate estimation of patients risk of early metastatic recurrenceare needed to guide escalation or de-escalation of treatment in the neoadjuvant and adjuvant settings. In thisproposed study our overarching goal is to develop strategies for combining liquid biopsy (i.e. circulatingtumor DNA) and MRI-based (i.e. functional tumor volume) measures of tumor burden to build robustpredictors of response and metastatic recurrence with the ultimate goal of improving outcomes in high-riskearly breast cancer patients receiving NAC.,NCI,10746093,11/9/2023 12:00:00 AM,PAR-19-363,5R01CA255442-04,5,R01,CA,255442,04, ,"KIM, BOKLYE",12/3/2020 12:00:00 AM,11/30/2025 12:00:00 AM,Clinical Translational Imaging Science Study Section[CTIS], ,10469779,"VAN'T VEER, LAURA J","LI, WEN ; MAGBANUA, MARK JESUS",11,PATHOLOGY,094878337,KMH5K9V7S518,094878337,KMH5K9V7S518,US,37.767442,-122.413937,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",SAN FRANCISCO,CA,SCHOOLS OF MEDICINE,941432510,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,636712, ,NCI,394249,242463, ,636712,,636712.0 | |
| No NIH Category available,Biological Assay;Biological Markers;CD8-Positive T-Lymphocytes;Cancer Control;Cells;Cessation of life;Clinical;Clinical Trials;Combination Drug Therapy;Combined Modality Therapy;Complex;Consensus;Data;Development;Disease;Early Intervention;Enrollment;External Beam Radiation Therapy;Financial Hardship;Future;Glycolysis;Image;Immune;Immune checkpoint inhibitor;Immune response;Immuno-Chemotherapy;Immunologic Markers;Immunophenotyping;Immunotherapy;Intervention;Lesion;Ligands;Link;Malignant neoplasm of lung;Metabolic;Monitor;Newly Diagnosed;Non-Small-Cell Lung Carcinoma;Observational Study;Outcome;Patient Selection;Patient-Focused Outcomes;Patients;Pattern;Peripheral;Phenotype;Positron-Emission Tomography;Precision Medicine Initiative;Precision therapeutics;Progression-Free Survivals;Progressive Disease;Proteins;Radiation;Radiation therapy;Radio;Risk;Site;Standardization;Systemic Therapy;Systemic disease;T-Cell Receptor;Therapeutic;Toxic effect;Treatment Efficacy;Treatment-related toxicity;Tumor Volume;United States National Institutes of Health;Validation;X-Ray Computed Tomography;anti-PD-1;biomarker identification;biomarker signature;burden of illness;cancer survival;chemotherapy;circulating biomarkers;clinical imaging;cytokine;disorder control;fluorodeoxyglucose positron emission tomography;high risk;imaging biomarker;improved;improved outcome;individual patient;individual response;irradiation;learning strategy;monocyte;multidisciplinary;outcome prediction;patient stratification;peripheral blood;phase II trial;predictive marker;prognostic value;prognostication;programmed cell death ligand 1;prospective;quantitative imaging;radiation response;radiomics;randomized trial;response;response biomarker;risk stratification;standard of care;support tools;survival outcome;synergism;treatment response;tumor;uptake,Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays,NARRATIVEPatients with metastatic non-small cell lung cancer undergo complex combinations of treatments includingchemotherapy immunotherapy and radiation therapy; and while some patients have prolonged cancer controlfrom therapy others develop rapid progression. We propose to assess and monitor treatment response withpositron emission tomography imaging and circulating immunologic biomarkers to improve patient outcomes byquickly detecting patients who are not benefiting from standard of care chemo-immunotherapy and selecting forpatients whose outcomes can be improved with the addition of radiation therapy. Development and validationof combined imaging and circulating biomarkers can support treatments that are adapted to the response ofindividual patients with metastatic non-small cell lung cancer and improve clinical outcomes.,NCI,10746779,11/27/2023 12:00:00 AM,PAR-19-363,5R01CA258997-03,5,R01,CA,258997,03, ,"VIKRAM, BHADRASAIN",12/20/2021 12:00:00 AM,11/30/2026 12:00:00 AM,Clinical Translational Imaging Science Study Section[CTIS], ,11513463,"BOWEN, STEPHEN R.","ZENG, JING ",07,RADIATION-DIAGNOSTIC/ONCOLOGY,605799469,HD1WMN6945W6,605799469,HD1WMN6945W6,US,47.660307,-122.315168,9087701,UNIVERSITY OF WASHINGTON,SEATTLE,WA,SCHOOLS OF MEDICINE,981959472,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,395,Non-SBIR/STTR,2024,577989, ,NCI,407201,170788, ,577989,,577989.0 | |
| No NIH Category available,Acute;Address;Age;Anti-Inflammatory Agents;Antioxidants;Binding;Biological;Birth;Bronchiectasis;Caring;Cell Survival;Cells;Chemotactic Factors;Chlorides;Chlorine;Clinical;Clinical Research;Cystic Fibrosis;Cystic Fibrosis Transmembrane Conductance Regulator;Cystic Fibrosis sputum;Cytoplasmic Granules;Data;Defect;Disease;Disease Progression;Enzymes;Epithelial Cells;Epithelium;Event;Exhibits;Exocytosis;Experimental Designs;Generations;Glucose;Glutathione;Goals;Human;Hydrogen Peroxide;Hypochlorous Acid;Immunobiology;In Vitro;Incubated;Inflammation;Inflammatory;Intervention;Knowledge;Label;Leukotriene B4;Longevity;Lung;Lung Diseases;Mediating;Membrane Proteins;Metabolic;Metabolism;Modeling;Molecular;Monitor;Mus;Nutrient;Organ;Oxidants;Oxidation-Reduction;Oxygen;Pathway interactions;Patients;Peroxidases;Phenotype;Physiological;Prevalence;Production;Proteins;Proteomics;Pseudomonas aeruginosa;Pulmonary Cystic Fibrosis;Pulmonary Inflammation;Pulmonary Pathology;Reaction;Reactive Oxygen Species;Research;Resistance;Role;Sampling;Series;Signal Transduction;Specimen;Sputum;Stains;Staphylococcus aureus;Testing;Therapeutic;Thiocyanates;Tissues;VX-770;Validation;Vesicle;airway epithelium;airway inflammation;analytical method;anti-microbial drug;antioxidant therapy;autooxidation;cell injury;chlorination;clinical development;cystic fibrosis airway;cystic fibrosis airway epithelia;cystic fibrosis patients;cytotoxicity;design;detection method;drug development;early cystic fibrosis;experimental study;extracellular;extracellular vesicles;glucose production;healthspan;immunoregulation;improved;inflammatory lung disease;inhibitor;lung injury;metabolomics;methionine sulfoxide;migration;mortality;mutant;neutrophil;next generation;novel;oxidation;pathogen;pharmacologic;rational design;research and development;response;standard of care;targeted biomarker;targeted treatment;trafficking;translational model,Neutrophil hyperexocytosis and hypochlorous acid exposure in early cystic fibrosis lung disease,PROJECT NARRATIVEThe aim of this project is to determine mechanism(s) by which neutrophils in cystic fibrosis airways contributeto increased chlorine bleach production by an enzyme called myeloperoxidase. We will use highly translationalmodels of airway neutrophils and epithelial cells test mechanisms including excessive secretion ofmyeloperoxidase (hyperexocytosis) validate our findings using clinical airway samples and consider clinicalvariables such as use of CFTR modulators. We anticipate knowledge generated during this study will pave theway for rational anti-inflammatory and antioxidant therapies filling current gaps in cystic fibrosis care andbenefiting patients with related inflammatory lung diseases.,NHLBI,10746859,11/3/2023 12:00:00 AM,PA-20-185,5R01HL150658-02,5,R01,HL,150658,02, ,"LACHOWICZ-SCROGGINS, MARRAH ELIZABETH",12/1/2022 12:00:00 AM,11/30/2026 12:00:00 AM,"Lung Cellular, Molecular, and Immunobiology Study Section[LCMI]", ,12626632,"CHANDLER, JOSHUA D",Not Applicable,05,PEDIATRICS,066469933,S352L5PJLMP8,066469933,S352L5PJLMP8,US,33.791247,-84.3249,2384501,EMORY UNIVERSITY,ATLANTA,GA,SCHOOLS OF MEDICINE,303221007,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,838,Non-SBIR/STTR,2024,385205, ,NHLBI,250000,135205, ,385205,,385205.0 | |
| No NIH Category available,Acute Lymphocytic Leukemia;Adherence;Age;Behavior assessment;Behavioral;Biological Markers;Cancer Relapse;Cause of Death;Cessation of life;Child;Child Behavior;Child Rearing;Child health care;Childhood;Classification;Code;Conflict (Psychology);Data;Data Collection;Deglutition;Disease;Dose;Drops;Drug Prescriptions;Education;Educational process of instructing;Electronics;Enrollment;Ensure;Equation;Family;Goals;Health Care Costs;Home;Hospitalization;Ingestion;Intervention;Learning;Life;Malignant Childhood Neoplasm;Malignant Neoplasms;Measurement;Measures;Medical;Medication Management;Medicine;Methodology;Methods;Modeling;Monitor;Morbidity - disease rate;Nurses;Oral;Parents;Participant;Patient Self-Report;Patients;Pediatric Oncology Group;Pediatrics;Pharmaceutical Preparations;Procedures;Public Health;Randomized Controlled Trials;Research;Resistance;Risk;Schedule;Scheme;Shapes;Specific qualifier value;Stress;Surveys;Techniques;Testing;Time;Treatment Failure;Treatment outcome;United States National Institutes of Health;behavior measurement;biomarker validation;cancer care;cancer risk;caregiving;chemotherapy;clinical care;clinically significant;diaries;efficacy evaluation;experience;health disparity;improved;innovation;medication administration;medication compliance;medication nonadherence;mortality;novel;pharmacologic;pill;programs;recruit;restraint;retention rate;risk prediction;satisfaction;screening;secondary outcome;side effect;skills;translational impact;treatment as usual;usability,Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence,Public Health SignificanceRecent landmark studies from the Childrens Oncology Group (COG) highlight adherence to home-based oralchemotherapy as an enduring problem in pediatric cancer care. Yet little is known about why some familieshave difficulty adhering to their childs home-based oral chemotherapy while others do not. Through the novelexamination of how behavioral parenting skills shape adherence at the episode and daily levels the proposedprogram of research has potential to lead to a paradigm shift in pediatric cancer adherence risk prediction andinterventions moving away from blunt demographic-based risk prediction and identifying behavioral parentingskills that are easily amenable to screening modifiable and may be more precise predictors of non-adherencerisk.,NCI,10747297,12/1/2023 12:00:00 AM,PA-18-722,5R01CA258337-03,5,R01,CA,258337,03, ,"FERRER, REBECCA",12/15/2021 12:00:00 AM,11/30/2026 12:00:00 AM,Clinical Management in General Care Settings Study Section[CMGC], ,10654598,"BOUCHARD, ELIZABETH ",Not Applicable,26,Unavailable,824771034,YDWAYVVQHNK5,824771034,YDWAYVVQHNK5,US,42.873378,-78.869243,3934901,ROSWELL PARK CANCER INSTITUTE CORP,BUFFALO,NY,Independent Hospitals,142630001,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,393,Non-SBIR/STTR,2024,621705, ,NCI,419778,201927, ,621705,,621705.0 | |
| No NIH Category available,Acute;Acute Disease;Address;Affect;Benchmarking;Biological Markers;Brain;Brain Death;Brain Injuries;Cardiopulmonary;Cardiopulmonary Physiology;Caring;Cephalic;Cerebrum;Cessation of life;Clinical;Clinical Research;Critical Care;Critical Illness;Data;Data Analytics;Data Science;Data Set;Development;Diagnostic;Disease;Dose;Electroencephalography;Electrophysiology (science);Foundations;Functional disorder;Goals;Head;Heart Arrest;Heterogeneity;Hospitalization;Hypoxic-Ischemic Brain Injury;Image;Individual;Injury;Intervention;Knowledge;Lead;Learning;Life;Measurable;Measures;Methods;Modality;Molecular;Monitor;Morbidity - disease rate;Nervous System Trauma;Neurologic;Neurologic Examination;Neurosciences;Organ;Organ failure;Outcome;Patient-Focused Outcomes;Patients;Pattern;Performance;Physiological;Physiology;Positioning Attribute;Prediction of Response to Therapy;Public Health;Pupil light reflex;Random Allocation;Recovery;Recovery of Function;Research;Research Personnel;Resolution;Rewarming;Role;Sampling;Severities;Severity of illness;Source;Specificity;Standardization;Subgroup;Survivors;Temperature;Testing;Time;Titrations;Translating;United States National Institutes of Health;Validation;Work;advanced analytics;arm;biomarker signature;candidate marker;clinical care;clinical predictors;design;disability;improved;improved outcome;individual patient;innovation;long term recovery;mortality;multidisciplinary;multimodal data;multimodality;natural hypothermia;neuroprotection;novel;novel marker;outcome prediction;patient subsets;personalized care;personalized medicine;precision medicine;predictive marker;predictive modeling;prognostic;prognostic value;prospective;radiological imaging;random forest;response;supervised learning;tool;treatment arm;treatment effect;treatment response;unsupervised learning,PREcision Care In Cardiac ArrEst - ICECAP (PRECICECAP),Project NarrativePost-cardiac arrest injury affects the brain and other critical organs and is a major public health problemcausing significant death and disability. This project will use novel data-driven approaches to collect highresolution monitoring data from patients in the critical care unit and will use that multi-parametric data todevelop newly defined patient sub-groups with differing clinical trajectories and responses to therapies. Thisproject will have a major impact on public health by allowing treatment of the right patient at the right timewith the right therapy thereby reducing disability and saving lives.,NINDS,10747352,5/9/2024 12:00:00 AM,PA-19-056,5R01NS119825-04,5,R01,NS,119825,04, ,"SCOTT, GRETCHEN CARLYLE",12/15/2020 12:00:00 AM,4/30/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-BDCN-L(90)S], ,6270502,"HIRSCH, KAREN G","ELMER, JONATHAN ",16,NEUROLOGY,009214214,HJD6G4D6TJY5,009214214,HJD6G4D6TJY5,US,37.426852,-122.17047,8046501,STANFORD UNIVERSITY,STANFORD,CA,SCHOOLS OF MEDICINE,943052004,UNITED STATES,N,5/1/2024 12:00:00 AM,4/30/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,1155493, ,NINDS,942376,213117, ,1155493,,1155493.0 | |
| No NIH Category available,Address;Adult;Algorithms;Allogenic;Archives;B-Cell Activation;Biological;Biological Markers;Biology;Blood;Blood Tests;Blood specimen;Bone Marrow Transplantation;CCR5 gene;CD276 gene;CSF1 gene;CXCL10 gene;CXCR3 gene;Cells;Child;Childhood;Clinical;Clinical Trials Network;Complication;Cryopreservation;Cytometry;Dana-Farber Cancer Institute;Data;Dendritic Cells;Development;Dimensions;Disease;Disease susceptibility;Enzyme-Linked Immunosorbent Assay;FOXP3 gene;Frequencies;Helper-Inducer T-Lymphocyte;Hematologic Neoplasms;Hematopoietic Stem Cell Transplantation;Hispanic;IL17 gene;Immunosuppression;Incidence;Inherited;Interleukins;Ligands;MCAM gene;Machine Learning;Malignant - descriptor;Measures;Modeling;Patients;Peripheral Blood Mononuclear Cell;Plasma;Plasma Proteins;Population;Positioning Attribute;Proteomics;Publishing;RANTES;Random Allocation;Regimen;Regulatory T-Lymphocyte;Relapse;Research;Risk;Sample Size;Sampling;Sensitivity and Specificity;Steroids;Stromelysin 1;Symptoms;T-Lymphocyte;Techniques;Testing;Thinness;Tissue Banks;Training;Transplant Recipients;Trees;Validation;biobank;biomarker identification;biomarker panel;biomarker validation;candidate identification;chemokine;chronic graft versus host disease;cohort;curative treatments;deep learning;disorder control;disorder risk;experimental study;high dimensionality;high risk;improved;machine learning algorithm;novel;novel marker;osteopontin;personalized medicine;predictive marker;receptor;risk prediction;risk stratification;statistics;success;tandem mass spectrometry,Machine Learning to identify Biomarkers for Risk of Chronic Graft-Versus-Host Disease,NARRATIVE (PUBLIC RELEVANCE)Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for many inheritedand malignant diseases whose applicability has been impeded by the development of one of its mostserious complication chronic graft versus host disease (cGVHD). Unfortunately there is no validatedblood test for predicting the risk of developing cGVHD. Strategies that identify and validate biomarkersfor risk of cGVHD occurrence will allow for personalized therapies that will be more efficient if introducedearly in the course of the disease in many patients with hematological cancers.,NCI,10747384,12/15/2023 12:00:00 AM,PA-20-185,5R01CA264921-03,5,R01,CA,264921,03, ,"SHELBURNE, NONNIEKAYE F",12/2/2021 12:00:00 AM,11/30/2026 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,8911469,"PACZESNY, SOPHIE ","LOGAN, BRENT R",06,PHARMACOLOGY,183710748,NHV3GTWSALA7,183710748,NHV3GTWSALA7,US,32.786754,-79.947265,7575301,MEDICAL UNIVERSITY OF SOUTH CAROLINA,CHARLESTON,SC,SCHOOLS OF MEDICINE,294074636,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,393,Non-SBIR/STTR,2024,215348, ,NCI,152998,62350, ,215348,,215348.0 | |
| No NIH Category available,ASCL1 gene;ATAC-seq;Ablation;Advisory Committees;Atlases;Automobile Driving;BETA2 protein;Cancer Center;Cancer Histology;Cancer Model;Cell Nucleus;Cells;Chemoresistance;Classification;Clinical;Collaborations;Computing Methodologies;Doctor of Philosophy;Drug Targeting;ELF3 gene;Environment;Epidermal Growth Factor Receptor;Epigenetic Process;Faculty;Funding;Genes;Genetic Markers;Genetic Transcription;Genomics;Goals;Histologic;Histology;Human;In Vitro;Knock-out;Lasers;Libraries;Lung;Lung Adenocarcinoma;Machine Learning;Malignant Neoplasms;Malignant neoplasm of lung;Medical Oncology;Memorial Sloan-Kettering Cancer Center;Mentors;Modeling;Molecular;Mus;Mutation;Neoplasm Metastasis;Neurosecretory Systems;Non-Small-Cell Lung Carcinoma;Oncogenic;Patient Care;Patients;Phenotype;Physicians;Play;Population;Pre-Clinical Model;Preparation;Process;RB1 gene;RNA;Recurrence;Relapse;Research;Research Proposals;Resistance;Resources;Risk;Role;Sampling;Scientist;Signal Transduction;TP53 gene;Therapeutic;Training;Validation;Variant;biomarker identification;cancer cell;cancer subtypes;cancer type;career;career development;cell transformation;cohort;epigenetic regulation;experience;experimental study;genetic manipulation;in vivo;in vivo Model;innovation;laboratory experience;molecular marker;notch protein;novel drug class;overexpression;patient derived xenograft model;pre-clinical;preclinical study;pressure;prevent;programs;research and development;single cell sequencing;single-cell RNA sequencing;skills;small cell lung carcinoma;targeted treatment;tenure track;therapeutic target;therapy resistant;transcription factor;transcriptomics;tumor;tumor heterogeneity;whole genome,Uncovering Epigenetic and Transcriptional Drivers of Neuroendocrine Plasticity at Single-Cell Level in Patients with Small Cell Lung Cancer Transformation,PROJECT NARRATIVEHistological transformation from lung adenocarcinoma (LUAD) to small cell lung cancer (SCLC)and subsequent diversification into more aggressive SCLC subtypes are examples ofneuroendocrine lineage plasticity a process that promotes metastasis and treatment resistancein lung cancer. This proposal uses 1) single-cell sequencing in patient tumors of combinedLUAD/SCLC histology and 2) functional experiments in preclinical models of SCLC transformationto identify transcriptomic and epigenetic changes driving lineage plasticity. These moleculardrivers may identify a novel class of drug targets that ablate lineage plasticity with therapeuticimplications in not just lung cancer but also any cancer type where small cell transformation mayarise.,NCI,10747402,12/1/2023 12:00:00 AM,PA-20-203,5K08CA259161-03,5,K08,CA,259161,03, ,"BIAN, YANSONG",12/15/2021 12:00:00 AM,11/30/2026 12:00:00 AM,Career Development Study Section (J)[NCI-J], ,15624212,"CHAN, JOSEPH MINHOW",Not Applicable,12,Unavailable,064931884,KUKXRCZ6NZC2,064931884,KUKXRCZ6NZC2,US,40.764045,-73.956024,5079202,SLOAN-KETTERING INST CAN RESEARCH,NEW YORK,NY,Research Institutes,100656007,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,398,Other Research-Related,2024,197198, ,NCI,182591,14607, ,197198,,197198.0 | |
| No NIH Category available,ALS patients;Age;Amyotrophic Lateral Sclerosis;Animal Model;Biological Markers;Brain;Brain Injuries;Cessation of life;Clinic;Clinical;Clinical Trials;Data;Diagnosis;Disease;Disease Progression;Electromyography;Eligibility Determination;Enrollment;Environment;Equipment;Ethnic Origin;Evaluation;Frequencies;Future;Health Services Accessibility;Human;Measurement;Measures;Methods;Monitor;Motor;Motor Cortex;Motor Neurons;Multicenter Studies;Multicenter Trials;Muscle;Neurodegenerative Disorders;Neurology;Neuronal Dysfunction;Painless;Patients;Progressive Disease;Race;Reporting;Respiratory Failure;Sensitivity and Specificity;Signal Transduction;Specificity;Speed;Spinal;Spinal Cord;Subgroup;Surface;Symptoms;System;Testing;Therapeutic Intervention;Time;age effect;amyotrophic lateral sclerosis therapy;clinical development;cohort;diagnostic criteria;drug development;improved;in vivo;neuron loss;neurophysiology;nonhuman primate;novel marker;potential biomarker;sex;validation studies,Intermuscular coherence: A novel biomarker for upper motor neuron dysfunction in ALS,Project Narrative Amyotrophic lateral sclerosis is a uniformly fatal neurodegenerative disease that is difficult to diagnose inlarge part because there is no way to objectively measure the loss of the brain's signals to muscles. In thisproposal we will test the validity of a quick inexpensive and painless biomarker of ALS known asintermuscular coherence in the real-world environment of the neurology clinic. If validated intermuscularcoherence could speed the diagnosis of ALS and the initiation of treatment allow for objective measures ofdisease progression and provide a way of quantifying the effects of future therapies in clinical trials.,NINDS,10747852,12/4/2023 12:00:00 AM,PA-19-056,5R01NS116262-04,5,R01,NS,116262,04, ,"GUBITZ, AMELIE",1/1/2021 12:00:00 AM,12/31/2025 12:00:00 AM,Clinical Neuroscience and Neurodegeneration Study Section[CNN], ,9260754,"REZANIA, KOUROSH ","ISSA, NAOUM P",01,NEUROLOGY,005421136,ZUE9HKT2CLC9,005421136,ZUE9HKT2CLC9,US,41.789554,-87.601172,1413601,UNIVERSITY OF CHICAGO,CHICAGO,IL,SCHOOLS OF MEDICINE,606372612,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,853,Non-SBIR/STTR,2024,580434, ,NINDS,478392,102042, ,580434,,580434.0 | |
| No NIH Category available,16S ribosomal RNA sequencing;Acids;Advisory Committees;Age;Age Years;Allergic;Allergic Disease;Allergic inflammation;Antibiotics;Antigens;Area;Atopic Dermatitis;Award;Biological;Biological Markers;Biometry;Child;Childhood;Clinical;Clinical Research;Clinical Sciences;Clinical effectiveness;Cohort Studies;Colonic inflammation;Complex;Computer Models;Data;Development;Diagnosis;Diet;Disease;Doctor of Philosophy;Enrollment;Ensure;Enterobacteriaceae;Environment;Environmental Risk Factor;Eosinophil-Derived Neurotoxin;Epidemiology;Food;Food Hypersensitivity;Foundations;Functional disorder;Funding;Gastroenterologist;Gastroenterology;Gastrointestinal Diseases;Gastrointestinal Physiology;Gastrointestinal tract structure;General Hospitals;Goals;Hypersensitivity;IgE;Immune Tolerance;Immune response;Immunology;Incidence;Infant;Inflammatory;Innate Immune System;Leukocyte L1 Antigen Complex;Life;Longitudinal Studies;Massachusetts;Master of Public Health;Mediating;Mentors;Mentorship;Metadata;Modeling;Mucosal Immune System;Mucous Membrane;Onset of illness;Outcome;Pathway interactions;Pediatrics;Pharmaceutical Preparations;Phenotype;Physicians;Positioning Attribute;Prevalence;Prevention;Proctocolitis;Prospective Studies;Proteins;Research;Research Design;Research Personnel;Resources;Risk;Role;Sampling;Scientist;Shotguns;Symptoms;System;Systems Biology;Testing;Training;United States;United States National Institutes of Health;Universities;Work;atopy;biomarker validation;candidate identification;candidate marker;cohort;design;dietary;dysbiosis;eosinophil;experience;food antigen;gastrointestinal;gut inflammation;gut microbiome;infancy;insight;instructor;leadership development;medical schools;metagenomic sequencing;method development;microbial;microbiome;microbiome analysis;novel;novel marker;post-doctoral training;prospective;research and development;success,Systems approach to elucidate the microbiome's influence on the development of food allergies early in life,PROJECT NARRATIVEFood allergy prevalence in children is dramatically rising and can be life-threatening while the biologicalexplanations remain unclear. Utilizing a large prospective longitudinal healthy infant cohort I built to identifypediatric mucosal and allergic diseases I propose to study the role of the intestinal microbiome in thedevelopment of one of the earliest manifestations of food allergy in children. Integrated analyses ofcomprehensive prospective clinical metadata dense longitudinal biological sampling and carefully definedallergic outcomes will allow us to identify important microbial and inflammatory pathways and immunologicresponses useful biomarkers and novel targets for food allergy prevention.,NIAID,10747903,11/14/2023 12:00:00 AM,PA-19-119,5K23AI151556-04,5,K23,AI,151556,04, ,"GONDRE-LEWIS, TIMOTHY A",12/14/2020 12:00:00 AM,11/30/2025 12:00:00 AM,"Allergy, Immunology, and Transplantation Research Committee[AITC]", ,14290868,"MARTIN, VICTORIA MACKENZIE",Not Applicable,08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,855,Other Research-Related,2024,199600, ,NIAID,185000,14600, ,199600,,199600.0 | |
| No NIH Category available,3-Dimensional;3D Print;4D MRI;Acceleration;Address;Adult;American;Anatomy;Anesthesia procedures;Biological;Biological Markers;Blood;Blood Platelets;Blood Vessels;Blood flow;Caring;Catheters;Circulation;Cirrhosis;Clinical;Clinical Management;Clinical Practice Guideline;Complex;Complication;Data;Detection;Development;Diagnostic;Diagnostic tests;Early identification;Esophagogastroduodenoscopy;Esophagus;Future;Gastroenterologist;Goals;Guidelines;Health;Hemorrhage;Hepatic;Hepatology;Intervention;Left;Length;Life;Ligation;Liver;Liver diseases;Magnetic Resonance Imaging;Maps;Measurement;Measures;Methods;Mission;Monitor;National Institute of Diabetes and Digestive and Kidney Diseases;Non-Invasive Detection;Patient Triage;Patients;Performance;Portal Hypertension;Portal Pressure;Preventive treatment;Procedures;Prophylactic treatment;Radial;Recommendation;Reference Standards;Reproducibility;Research;Resistance;Risk;Rupture;Sedation procedure;Sensitivity and Specificity;Serum;Severities;Shunt Device;Societies;Specificity;Spleen;Submucosa;Surface;Testing;Therapeutic;Time;Translating;Translations;Validation;Varicosity;Venous;Venous Pressure level;Visualization;Work;biomarker validation;blood flow measurement;clinically relevant;design;diagnostic accuracy;end stage liver disease;follow-up;gastric vein;hemodynamics;high risk;improved;innovation;liver stiffness;mortality;novel;pre-clinical;predictive marker;prevent;prophylactic;response;risk stratification;specific biomarkers;ultrasound;validation studies;vector,Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis,PROJECT NARRATIVE:The broad long-term objective of our research is to improve the health of the nearly 1 million Americans withadvanced liver disease (cirrhosis). One of the most important complications of cirrhosis is the development ofenlarged fragile blood vessels in the wall of the lower esophagus which can rupture without warning leadingto life-threatening bleeding. We aim to develop non-invasive MRI methods that can detect this complicationbefore bleeding occurs to facilitate preventative treatment that can reduce cirrhosis-associated mortality.,NIDDK,10747919,1/4/2024 12:00:00 AM,PA-20-185,5R01DK125783-04,5,R01,DK,125783,04, ,"SHERKER, AVERELL H",4/1/2021 12:00:00 AM,12/31/2024 12:00:00 AM,Clinical Translational Imaging Science Study Section[CTIS], ,8546939,"REEDER, SCOTT B.","WIEBEN, OLIVER ",02,RADIATION-DIAGNOSTIC/ONCOLOGY,161202122,LCLSJAGTNZQ7,161202122,LCLSJAGTNZQ7,US,43.068519,-89.400858,578503,UNIVERSITY OF WISCONSIN-MADISON,MADISON,WI,SCHOOLS OF MEDICINE,537151218,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,557551, ,NIDDK,362172,195379, ,557551,,557551.0 | |
| No NIH Category available,Acute;Acute Lung Injury;Adult;Affect;Binding;Biological Markers;Blood Cells;Blood Vessels;Blood specimen;CD14 gene;Cell surface;Cells;Characteristics;Chronic lung disease;Clinical;Clinical Research;Collaborations;Data;Deacetylase;Death Rate;Development;Disease;Disease susceptibility;Engineering;Enzyme-Linked Immunosorbent Assay;Epigenetic Process;Event;Flow Cytometry;Functional disorder;Funding;Gene Expression;Genetic Transcription;Genetic Variation;HDAC6 gene;Histones;Hour;Hypoxemia;Immune;Immunity;Immunologics;In Vitro;Inflammatory;Infrastructure;Injury;Ischemia;Longterm Follow-up;Lung;Lung Diseases;Lung Transplantation;Messenger RNA;Modeling;Morbidity - disease rate;Mus;Natural Immunity;Operative Surgical Procedures;Outcome;Parents;Pathogenesis;Pathogenicity;Pathway interactions;Patients;Peripheral Blood Mononuclear Cell;Phenotype;Population;Postoperative Period;Process;Production;Proteins;Publishing;Pulmonary Edema;Regulation;Reperfusion Injury;Research;Research Personnel;Risk;Risk Factors;Role;Sample Size;Source;TLR4 gene;Testing;Therapeutic;Training;Transplant Recipients;Transplantation;Ubiquitin;United States National Institutes of Health;Up-Regulation;Zinc Fingers;adaptive immunity;biomarker validation;cytokine;genomic locus;graft dysfunction;in vivo;individual variation;inhibitor;inhibitor therapy;lung ischemia;monocyte;mortality;mouse model;novel;novel diagnostics;novel therapeutics;overexpression;participant enrollment;pathogen;predicting response;prognostic;response;small molecule inhibitor;transcriptome;transcriptome sequencing;translational study;treatment response,Pre-Transplant Monocyte HDAC6 Expression and Risk of Primary Graft Dysfunction in Clinical Lung Transplant Recipients,Project NarrativeWe will determine whether abnormalities in a key population of circulating blood cells called monocytes affects the veryearly outcomes of lung transplants in patients with severe lung diseases. We will assess whether problems with monocytescan be detected pre-transplant using blood samples already being collected as part of an NIH-funded clinical study of lungtransplant recipients. Our studies may identify new diagnostic or therapeutic options to decrease the high morbidity andmortality rates currently associated with clinical lung transplantation.,NHLBI,10748292,11/21/2023 12:00:00 AM,PA-19-056,5R01HL154241-04,5,R01,HL,154241,04, ,"MONGODIN, EMMANUEL FRANCK",12/15/2020 12:00:00 AM,11/30/2024 12:00:00 AM,"Transplantation, Tolerance, and Tumor Immunology Study Section[TTT]", ,1868761,"HANCOCK, WAYNE WILLIAM",Not Applicable,03,Unavailable,073757627,G7MQPLSUX1L4,073757627,G7MQPLSUX1L4,US,39.946632,-75.196604,1499101,CHILDREN'S HOSP OF PHILADELPHIA,PHILADELPHIA,PA,Independent Hospitals,191462305,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,838,Non-SBIR/STTR,2024,435274, ,NHLBI,271880,163394, ,435274,,435274.0 | |
| No NIH Category available,Adverse event;Benchmarking;Biological;Biological Assay;Black race;Blood;Blood specimen;Caring;Characteristics;Chronic Disease;Chronic Kidney Failure;Clinical;Clinical Practice Guideline;Collaborations;Creatinine;Cystatins;Data;Development;Diet;Disease;Dose;Epidemiology;Equation;Ethnic Origin;Evaluation;Filtration;Foundations;Geography;Glomerular Filtration Rate;Goals;Health;Health Services Accessibility;Heart failure;Hospitalization;Individual;Inflammation;Investigation;Joints;Kidney Diseases;Knowledge;Laboratories;Liquid Chromatography;Liver Failure;Mass Spectrum Analysis;Measures;Methods;Modeling;Muscular Atrophy;Obesity;Outcome;Participant;Patients;Persons;Pharmaceutical Preparations;Physiological;Population;Population Heterogeneity;Prognosis;Property;Public Health;Race;Renal function;Research;Research Design;Science;Serum;Statistical Methods;Techniques;Testing;United States;Validation;Weight;Work;access restrictions;analytical method;biomarker evaluation;biomarker panel;candidate selection;clinical decision-making;clinical practice;cohort;cost efficient;demographics;design;experience;improved;innovation;marginalization;mass spectrometer;metabolomics;multiplex assay;novel;novel strategies;outcome prediction;patient population;post gamma-globulins;predictive modeling;racial diversity;reduced muscle mass,Improving Kidney Function Assessment in Health and Disease,NarrativeKidney function is usually estimated from markers that are measured in the blood but current estimates areless accurate for people with chronic illness such as those with heart or liver failure or diverse racial ethnicand geographic groups. The current project will fill this important gap in knowledge by developing a simplemethod to estimate kidney function from markers that can be easily measured from a single blood draw andthat is more accurate than current estimates for all people across the continuum of health and disease. Moreaccurate kidney function estimates will enable better clinical decision making for patients more rigorousresearch designs and better estimates of the public health burden of chronic kidney disease in the UnitedStates.,NIDDK,10748364,11/7/2023 12:00:00 AM,PA-19-056,5R01DK116790-04,5,R01,DK,116790,04, ,"CHAN, KEVIN E",12/15/2020 12:00:00 AM,11/30/2024 12:00:00 AM,"Kidney, Nutrition, Obesity and Diabetes Study Section[KNOD]", ,8074386,"INKER, LESLEY ANN",Not Applicable,07,Unavailable,079532263,MY2ERHGDV956,079532263,MY2ERHGDV956,US,42.349512,-71.063308,130301,TUFTS MEDICAL CENTER,BOSTON,MA,Independent Hospitals,021111552,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,685739, ,NIDDK,579534,106205, ,685739,,685739.0 | |
| No NIH Category available,Antigens;Bioinformatics;Biological Assay;Biometry;Blood specimen;California;Caring;Catchment Area;Center for Translational Science Activities;Clinic;Clinical;Clinical Data;Clinical Management;Clinical Research;Clinical Sciences;Clinical Trials;Coccidioides;Coccidioidomycosis;Collaborations;Collection;Communicable Diseases;Communities;Computerized Medical Record;Conduct Clinical Trials;Consent;Data;Data Coordinating Center;Data Set;Databases;Diagnosis;Diagnostic;Diagnostic tests;Disease;Drug Industry;Enrollment;Evaluation;Genomics;Health;Human;Immune;Incidence;Infection;Infrastructure;Internal Medicine;Intervention;Investigation;Laboratories;Lead;Life;Link;Lung infections;Medical History;Metabolic;Molecular;Monitor;Morbidity - disease rate;Outcome;Participant;Pathogenesis;Pathogenicity;Pathway interactions;Patients;Peripheral Blood Mononuclear Cell;Pharmacy facility;Play;Predisposition;Procedures;Public Health;Pulmonology;Reagent;Research;Research Personnel;Research Support;Resources;Retrieval;Role;Sampling;Serodiagnoses;Serology;Serum;Severity of illness;Source;Technology;Therapeutic;Translational Research;Treatment outcome;United States National Institutes of Health;Validation;Vulnerable Populations;Work;anti-fungal agents;base;biobank;biomarker identification;biosignature;candidate identification;clinical care;desert fever;diagnostic assay;diagnostic tool;empowerment;exome sequencing;experience;metabolomics;mortality;novel diagnostics;participant enrollment;pathogen;peripheral blood;preservation;programs;radiological imaging;repository;research study;response;sample collection;transcriptomics;validation studies,Clinical and Diagnostics Core,,NIAID,10750976,12/26/2023 12:00:00 AM,RFA-AI-20-056,5U19AI166798-03,5,U19,AI,166798,03, , ,1/1/2022 12:00:00 AM,12/31/2026 12:00:00 AM,ZAI1-AWA-M,6530,10715496,"THOMPSON, GEORGE RICHARD",Not Applicable,11,Unavailable,094878337,KMH5K9V7S518,094878337,KMH5K9V7S518,US,37.767442,-122.413937,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",SAN FRANCISCO,CA,Domestic Higher Education,941432510,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM, ,Non-SBIR/STTR,2024, ,230833, ,230833,0, , ,, | |
| No NIH Category available,3-Dimensional;Area;Biopsy;Breast;Breast Cancer Detection;Breast Cancer Risk Factor;Breast Magnetic Resonance Imaging;Cancer Detection;Clinical;Consult;Data Set;Development;Digital Breast Tomosynthesis;Digital Mammography;Financial cost;Future;Goals;Image;Imaging Techniques;Individual;Lateral;Laws;Lead;Left;Letters;Magnetic Resonance Imaging;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Gland Parenchyma;Mammographic screening;Mammography;Methods;Modality;Modeling;Notification;Physicians;Process;ROC Curve;Radon;Recommendation;Research;Research Personnel;Risk;Scanning;Sensitivity and Specificity;Signal Transduction;Slice;Specificity;Target Populations;Techniques;Testing;Thick;Three-Dimensional Imaging;Tissues;Training;Translating;Validation;Woman;artificial intelligence method;base;biomarker validation;breast density;breast imaging;convolutional neural network;cost;digital;high risk;imaging biomarker;imaging facilities;novel;screening;supplemental screening;tomosynthesis;ultrasound,Detecting Mammographically-Occult Cancer in Women with Dense Breasts Using Digital Breast Tomosynthesis,Over ten million women each year receive a notification letter informing them that they have dense breasttissue and that they should consider having supplemental screening with ultrasound or MRI. Unfortunatelythere is insufficient information available to help women determine whether the benefits for them as anindividual outweigh the known harms of getting supplemental screening. Our research goal is to develop atechnique that can detect breast cancers missed on screening digital breast tomosynthesis images in womenwith dense breast tissue and thus giving women additional information to help them make better informeddecisions regarding supplemental screening.,NCI,10751019,12/1/2023 12:00:00 AM,PA-20-185,5R01CA269540-02,5,R01,CA,269540,02, ,"FU, SIDNEY WANG",12/8/2022 12:00:00 AM,11/30/2027 12:00:00 AM,Emerging Imaging Technologies and Applications Study Section[EITA], ,14162892,"LEE, JUHUN ",Not Applicable,12,RADIATION-DIAGNOSTIC/ONCOLOGY,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,SCHOOLS OF MEDICINE,152133320,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,330868, ,NCI,208093,122775, ,330868,,330868.0 | |
| No NIH Category available,Accounting;Age;Alcohol consumption;Algorithmic Analysis;Amnesia;Animals;Archives;Blood Pressure;Blood Vessels;Blood specimen;Board Certification;Body mass index;Brain;Brain Injuries;Cardiovascular Diseases;Categories;Cerebrum;Cholesterol;Chronic;Clinical;Clinical Data;Cohort Studies;Coupled;Data;Dementia;Development;Diabetes Mellitus;Diagnosis;Diffusion Magnetic Resonance Imaging;Elderly;Goals;Health behavior;Healthcare;Healthcare Systems;Hyperlipidemia;Impaired cognition;Incidence;Injury;Joints;Knowledge;Laboratories;Leadership;Life;Literature;Longitudinal cohort study;Measures;Medical center;Medicine;Mentorship;Military Personnel;Mission;Modality;Modernization;Multiple Trauma;Nervous System Trauma;Neurologic;Outcome;Pathology;Patients;Pennsylvania;Physical Medicine;Physical Rehabilitation;Physical activity;Physicians;Positioning Attribute;Pre-Clinical Model;Prevalence;Recording of previous events;Research;Research Design;Research Methodology;Research Proposals;Resource Sharing;Retrospective cohort study;Risk;Risk Factors;Secondary to;Severities;Sleep;Smoking;Subgroup;Techniques;Testing;Therapeutic Intervention;Time;Training;Translational Research;Traumatic Brain Injury;Unconscious State;Universities;Veterans;Water;White Matter Hyperintensity;age related neurodegeneration;cardiovascular health;cardiovascular risk factor;care systems;career;career development;classification algorithm;clinically relevant;combat veteran;design;early detection biomarkers;endophenotype;follow-up;healing;indexing;lifestyle intervention;longitudinal prospective study;marine;microvascular pathology;mild traumatic brain injury;military veteran;multidisciplinary;neuroimaging;professor;repaired;secondary analysis;sex;skills;sleep quality;translational approach;translational medicine;translational therapeutics;whole health,Traumatic and Treatable Vascular Pathology in the Outcome of TBI,Long-term neurological consequences of traumatic brain injury (TBI) may be the most critical issue facingVeterans over the next 50 years given that TBI has become a signature injury of modern warfare. Largecohort studies in both civilian and Veteran populations have clearly demonstrated an association between TBIand an increased incidence of dementia diagnosis with advancing age. Thus there is a critical need to identifypathophysiological mechanism(s) underlying progressive age-related neurodegeneration which are amenableto modifiable lifestyle and/or therapeutic interventions decades before the clinical presentation of cognitiveimpairment or dementia. This proposal aims to investigate the impact of modifiable cardiovascular risk factorson chronic TBI-related sequelae a goal in-line with the VAs strategic mission to implement Whole Health forLife the radical redesign of healthcare within the VA.,VA,10752608,3/13/2024 12:00:00 AM,RFA-RX-20-006,5IK2RX003651-03,5,IK2,RX,003651,03, , ,2/1/2022 12:00:00 AM,1/31/2026 12:00:00 AM,Career Development Program - Panel I[RRD8], ,14373848,"SWANSON, RANDEL L",Not Applicable,03,Unavailable,071609291,SUDELFB4VGM7,071609291,SUDELFB4VGM7,US,39.963766,-75.198203,481078,PHILADELPHIA VA MEDICAL CENTER,PHILADELPHIA,PA,Independent Hospitals,191044551,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,999,Other,2024, , , , , , , ,, | |
| No NIH Category available,Adult;Antibiotic Resistance;Antibiotic Therapy;Antibiotics;Bacteria;Bacterial Genome;Base Sequence;Big Data;Bioinformatics;Biological Markers;Biological Models;Centers for Disease Control and Prevention (U.S.);Clinical;Clostridium;Clostridium difficile;Complement;Data;Data Analyses;Data Set;Disease;Electronic Health Record;Epidemiology;Exhibits;Genes;Genetic;Genetic Variation;Genome;Genomics;Germination;Health;Healthcare Systems;Immune;Immune response;In Vitro;Incidence;Individual;Infection;Integration Host Factors;Investigation;Knowledge;Machine Learning;Measurement;Measures;Mediating;Medicine;Metadata;Methods;Michigan;Morbidity - disease rate;Outcome;Pathogenesis;Pathway interactions;Patient Care;Patient risk;Patient-Focused Outcomes;Patients;Performance;Phylogeny;Predictive Value;Process;Recording of previous events;Reporting;Reproduction spores;Resolution;Risk Factors;Role;Sampling;Serum;Severities;Structure;Symptoms;Testing;Toxin;Training;Validation;Variant;Virulence Factors;Work;adverse outcome;bacterial genetics;biomarker identification;cost;cytokine;data repository;experience;genetic makeup;genetic strain;genetic variant;genome wide association study;gut colonization;gut inflammation;gut microbiome;gut microbiota;healthcare burden;healthcare-associated infections;improved;in vivo;insight;microbiome;mouse model;new therapeutic target;novel;novel therapeutics;pathogen;predictive modeling;repository;response;treatment strategy;whole genome,Elucidating genetic mechanisms of Clostridioides difficile pathogenesis and patient immune manipulation,Project NarrativeThe interplay between a patients immune response and the genetic background of their infecting strain can leadto severe Clostridioides difficile infection. Identifying features of C. difficile genetic background that directlyinfluence patient immune response to infection and those factors that act independently of patient immuneresponse to cause severe disease could provide insights into novel mechanisms leading to severe infections.Using bacterial genomics in combination with patient health histories and clinical factors this proposal aims toidentify markers of C. difficile infection severity and novel pathways of bacterial pathogenesis and then validatepredictive performance using in vitro and in vivo methods.,NIAID,10752619,10/24/2023 12:00:00 AM,PA-21-048,5F32AI169765-02,5,F32,AI,169765,02, ,"GLOCK, JONATHAN A",12/1/2022 12:00:00 AM,12/2/2023 12:00:00 AM,Special Emphasis Panel[ZRG1-F07B-U(20)], ,15345315,"MAGGIONCALDA, EMILY ",Not Applicable,06,MICROBIOLOGY/IMMUN/VIROLOGY,073133571,GNJ7BBP73WE9,073133571,GNJ7BBP73WE9,US,42.275494,-83.743038,1506502,UNIVERSITY OF MICHIGAN AT ANN ARBOR,ANN ARBOR,MI,SCHOOLS OF MEDICINE,481091276,UNITED STATES,N,12/1/2023 12:00:00 AM,12/2/2023 12:00:00 AM,855,"Training, Individual",2024,8801, ,NIAID,8801,0, ,8801,,8801.0 | |
| No NIH Category available,Acceleration;Accident and Emergency department;Accounting;Acute;Acute Respiratory Distress Syndrome;Address;Adrenal Cortex Hormones;Airway Resistance;Asthma;Automobile Driving;Biological;Biological Markers;Biological Response Modifier Therapy;Bronchodilator Agents;Caring;Child;Childhood;Childhood Asthma;Chronic;Clinical;Clinical Research;Development Plans;Effectiveness;Emergency Care;Emergency Medicine;Emergency department visit;Enrollment;Ensure;Epithelial Cells;Funding;Future;Genes;Goals;Home;Hospitalization;Individual;Infrastructure;Inhalation;Institution;Interferons;K-Series Research Career Programs;Knowledge;Laboratories;Lead;Leadership;Length of Stay;Measures;Mentors;Mentorship;Methods;Modeling;Molecular Genetics;Morbidity - disease rate;Nasal Epithelium;Nose;Oscillometry;Outcome;Outpatients;Physicians;Physiological;Positioning Attribute;Prediction of Response to Therapy;Predictive Analytics;Prospective Studies;Research;Research Methodology;Resources;Scientist;Spirometry;Testing;Therapeutic Intervention;Time;Training;Translational Research;Validation;Variant;Work;asthma exacerbation;career;career development;clinical practice;clinical predictive model;clinical predictors;diagnostic biomarker;experience;feasibility trial;hospital readmission;improved;improved outcome;individualized medicine;innovation;mortality;multidisciplinary;novel;novel diagnostics;novel marker;pediatric emergency;personalized approach;predictive modeling;prospective;pulmonary function;response;skills;success;targeted treatment;therapy development;tool;transcriptome;transcriptome sequencing;transcriptomics;treatment response;treatment strategy;unnecessary treatment,Novel Markers of Treatment Responsiveness for Pediatric Acute Asthma Exacerbations,PROJECT NARRATIVE This proposal will leverage an improved understanding of an individual's biologic and physiologicresponse to emergent asthma therapies to inform biomarker-directed individualized asthma therapy; aparadigm shift in the Emergency Department (ED) management of pediatric acute asthma exacerbations. Aclinical prediction model incorporating objective markers of ED treatment response will be developed to guideclinical decisions facilitate timely and appropriate therapeutic interventions and disposition decisions andimprove clinical outcomes for children acute asthma exacerbations.,NHLBI,10752625,12/1/2023 12:00:00 AM,PA-20-205,5K23HL161354-03,5,K23,HL,161354,03, ,"LU, QING",1/15/2022 12:00:00 AM,12/31/2026 12:00:00 AM,NHLBI Mentored Patient-Oriented Research Study Section[MPOR(OA)], ,15219931,"NAVANANDAN, NIDHYA ",Not Applicable,06,PEDIATRICS,041096314,MW8JHK6ZYEX8,041096314,MW8JHK6ZYEX8,US,39.745098,-104.837605,1199905,UNIVERSITY OF COLORADO DENVER,Aurora,CO,SCHOOLS OF MEDICINE,800452571,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,838,Other Research-Related,2024,184470, ,NHLBI,172937,11533, ,184470,,184470.0 | |
| No NIH Category available,Address;Affect;Age;Aging;Alzheimer disease detection;Alzheimer's Disease;Alzheimer's disease brain;Alzheimer's disease model;Alzheimer's disease patient;Alzheimer's disease risk;Alzheimers disease biomarker;Anatomy;Animal Experimentation;Animal Model;Area;Biological;Biological Markers;Biophysics;Blood Vessels;Blood capillaries;Blood flow;Brain;Cellular Stress;Cerebrovascular Circulation;Cerebrum;Circulation;Clinical;Cognitive;Computer Simulation;Core-Binding Factor;Data;Deterioration;Diagnosis;Diagnostic Imaging;Disease;Disease Progression;Early Diagnosis;Endothelium;Event;Exhibits;Functional disorder;Future;Goals;Health;Hemodynamic Processes;Heterogeneity;Homeostasis;Human;Image;Immune;Impaired cognition;Individual;Infarction;Intervention;Kinetics;Lead;Length;Leukocytes;Link;Magnetic Resonance Imaging;Maps;Mathematics;Measures;Mediating;Medicine;Metabolic;Metabolic Diseases;Metabolism;Methods;Microcirculation;Microscopic;Microvascular Dysfunction;Modeling;Monitor;Mus;Nerve Degeneration;Neurologic;Outcome;Oxygen;Pathologic;Pattern;Perfusion;Physiological;Physiological Processes;Predictive Value;Predisposition;Process;Property;Protocols documentation;Research;Resources;Risk;Rodent;Signal Transduction;Specificity;Symptoms;Techniques;Testing;Time;Tissues;Tracer;Translating;Translations;Validation;Vascular blood supply;age effect;age related;age related neurodegeneration;aged;aging brain;animal data;biomarker identification;cerebral hemodynamics;cerebrovascular;cerebrovascular pathology;cohort;computational platform;computer framework;digital;early detection biomarkers;experimental study;hemodynamics;human data;human disease;imaging biomarker;improved;insight;mathematical methods;microscopic imaging;models and simulation;morphometry;multi-scale modeling;network models;neuroimaging;neuron loss;noninvasive diagnosis;novel;pharmacologic;predictive modeling;prodromal Alzheimer's disease;simulation;solute;spatiotemporal;theories;tissue oxygenation,Image-based cerebrovascular network snythesis(iCNS) to model Alzheimer's Disease,NARRATIVEThe project will quantify both healthy and deteriorated cerebral metabolic function in order to precisely correlatebiological conditions with age and Alzheimer-related decline. As the main thrust a computational frameworkfully validated by advanced imaging at the cellular level will be created for translating research data acquired inanimal models to human. This computational platform will remove the guesswork from the interpretation offindings obtained in mouse as they relate to aging in humans ultimately leading to the ability to accuratelymonitor diagnose and treat metabolic disorders causing decline.,NIA,10752693,3/1/2024 12:00:00 AM,PAR-19-158,5R01AG079894-02,5,R01,AG,079894,02, ,"NEWMAN, ELIZABETH",12/15/2022 12:00:00 AM,11/30/2027 12:00:00 AM,Modeling and Analysis of Biological Systems Study Section[MABS], ,8024997,"LINNINGER, ANDREAS A",Not Applicable,07,BIOMEDICAL ENGINEERING,098987217,W8XEAJDKMXH3,098987217,W8XEAJDKMXH3,US,41.871509,-87.667721,577703,UNIVERSITY OF ILLINOIS AT CHICAGO,Chicago,IL,SCHOOLS OF MEDICINE,606124305,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,710620, ,NIA,586228,124392, ,710620,,710620.0 | |
| No NIH Category available,Address;Adult;Advisory Committees;Affect;Age;Agreement;Animal Disease Models;Architecture;Area;Atmosphere;Atrophic;Bilateral;Biological Markers;Biometry;Biopsy;Blinded;Brain;Clinical;Clinical Research;Clinical Trials;Collaborations;Computing Methodologies;DNA;Data;Development;Diagnosis;Disease;Disease Progression;Distal;Environment;Fatty acid glycerol esters;Fingers;Flexor;Forearm;Foundations;Frequencies;Future;General Hospitals;Genes;Goals;Heart;Image;In Vitro;Infiltration;Inherited;Leg;Limb structure;Longitudinal cohort;Magnetic Resonance Imaging;Massachusetts;Measurement;Measures;Mediating;Medical Research;Mentors;Monitor;Muscle;Muscle Fibers;Muscle Weakness;Muscle relaxation phase;Muscular Atrophy;Muscular Dystrophies;Myography;Myopathy;Myotonia;Myotonic Dystrophy;Neuromuscular Diseases;Neuromuscular conditions;Nucleotides;Ocimum basilicum;Organ;Pacemakers;Painless;Patients;Pattern;Persons;Phase;Physiologic pulse;Pilot Projects;Population;Positioning Attribute;Prevalence;Probability;Publications;RNA;Readiness;Relaxation;Reporting;Research;Research Personnel;Research Proposals;Resistance;Role;Sampling Biases;Scientist;Severity of illness;Skeletal Muscle;Specialist;Sum;System;Testing;Thick;Thigh structure;Time;Toxic effect;Training;Transcript;Translational Research;Ultrasonography;Validation;Visit;Walking;arm;autosome;candidate marker;career;career development;catalyst;data acquisition;design;disability;efficacy evaluation;electric impedance;grasp;lectures;medical schools;meetings;molecular marker;mouse model;muscle strength;musculoskeletal imaging;musculoskeletal ultrasound;mutant;neuromuscular;new technology;patient oriented research;patient response;portability;response;responsible research conduct;sex;time interval;tool;transcriptomics;ultrasound,Clinical and Non-Invasive Biomarkers of Myotonic Dystrophy,PROJECT NARRATIVEMyotonic dystrophy (DM) is the most frequent muscular dystrophy in adults with a prevalence of 1 in 8000people it affects several organs such as skeletal muscle heart and brain it is inherited in an autosomaldominant fashion and no cure exists to date. Promising therapies are in current development to target theexpanded RNA-mediated toxicity associated with this disease; however reliable biomarkers to monitor diseaseactivity and response to upcoming treatments are lacking. For this purpose this research proposal aims atidentifying non-invasive painless and quantitative biomarkers of DM muscle disease by using in parallel butindependently muscle ultrasound and MRI and electrical impedance myography at two-year interval in thesepatients.,NINDS,10753512,11/27/2023 12:00:00 AM,PA-20-205,5K23NS118048-02,5,K23,NS,118048,02, ,"NUCKOLLS, GLEN H",12/15/2022 12:00:00 AM,11/30/2027 12:00:00 AM,ZNS1-SRB-B(02), ,15203166,"GONZALEZ-PEREZ, PALOMA ",Not Applicable,08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Other Research-Related,2024,200880, ,NINDS,186000,14880, ,200880,,200880.0 | |
| No NIH Category available,3-Dimensional;Address;Aminolevulinic Acid;Binding;Biopsy;Brain Neoplasms;Brain scan;Clinical;Clinical Protocols;Clinical Research;Clinical Trials;Collaborations;Comprehensive Cancer Center;Computer software;Consumption;Country;Development;Diagnosis;Drops;Ensure;Environment;Excision;Fingerprint;Future;Glioblastoma;Glioma;Goals;Healthcare;Image;Image Analysis;Imaging Device;Imaging Techniques;Infiltration;Institution;Licensing;MRI Scans;Machine Learning;Magnetic Resonance Imaging;Malignant Neoplasms;Malignant neoplasm of brain;Maps;Marketing;Measurement;Measures;Multi-Institutional Clinical Trial;Neurosurgeon;Newly Diagnosed;Operative Surgical Procedures;Pathologic;Pathology;Patient Care;Patient-Focused Outcomes;Patients;Performance;Physicians;Physiological;Property;Radiation Dose Unit;Radiation Oncologist;Radiation therapy;Radiogenomics;Radiology Specialty;Recurrence;Relaxation;Reproducibility;Research;Sampling;Scanning;Site;Standardization;System;Techniques;Testing;Therapy trial;Time;Tissue Sample;Tissues;Translating;Travel;Validation;Variant;Vendor;brain tumor imaging;cancer imaging;clinical application;clinical care;clinical imaging;clinical implementation;clinical research site;clinical translation;computerized data processing;digital;experience;imaging biomarker;imaging platform;improved;improved outcome;industry partner;interest;neurosurgery;next generation;novel;outcome prediction;performance site;personalized medicine;predictive modeling;predictive tools;prospective;quantitative imaging;radiologist;radiomics;reconstruction;recruit;synergism;targeted treatment;tool;treatment planning;trial comparing;trial planning;tumor;volunteer,MR Fingerprinting based Quantitative Imaging and Analysis Platform (MRF-QIA) for brain tumors.,Project Narrative:Almost all clinical magnetic resonance imaging (MRI) scans are inherently qualitative which leads to subjectiveanalysis and poor center-to-center reproducibility. This project is to develop and clinically translate a novelquantitative MR scan called MR Fingerprinting and a quantitative image analysis software called MRF-QIA intothe clinical workflow through an academic and industry partnership. We will also clinically validate a specializedapplication for predicting tumor infiltration in glioblastoma patients that will eventually allow personalizedtreatment planning to improve patient outcomes.,NCI,10753556,1/3/2024 12:00:00 AM,PAR-20-155,5R01CA269604-02,5,R01,CA,269604,02, ,"KIM, BOKLYE",1/1/2023 12:00:00 AM,12/31/2027 12:00:00 AM,Special Emphasis Panel[ZRG1-SBIB-S(57)R], ,12566494,"MA, DAN ","BADVE, CHAITRA ; DAVATZIKOS, CHRISTOS ",11,BIOMEDICAL ENGINEERING,077758407,HJMKEF7EJW69,077758407,HJMKEF7EJW69,US,41.502739,-81.607334,218601,CASE WESTERN RESERVE UNIVERSITY,CLEVELAND,OH,SCHOOLS OF MEDICINE,441061712,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,531269, ,NCI,353663,177606, ,531269,,531269.0 | |
| No NIH Category available,Acceleration;Acute;Acute Brain Injuries;American;Anesthetics;Anticonvulsants;Area;Big Data Methods;Biological Markers;Biomedical Technology;Biometry;Brain;Brain Injuries;Brain imaging;California;Caring;Categories;Cause of Death;Cerebrum;Clinical;Clinical Trials;Clinical Trials Design;Collaborations;Coma;Complication;Computing Methodologies;Critical Care;Data;Data Scientist;Data Set;Decision Making;Development;Development Plans;Diagnosis;Diffusion Magnetic Resonance Imaging;Early identification;Educational Curriculum;Electroencephalography;Environment;Epilepsy;Epileptogenesis;Evolution;Feedback;Frequencies;Future;Goals;Heart Arrest;Hospitals;Hour;Human;Hypoxic-Ischemic Brain Injury;Individual;Infusion procedures;Injury;International;Intervention Trial;K-Series Research Career Programs;Knowledge;MRI Scans;Machine Learning;Magnetic Resonance Imaging;Mediating;Mentors;Methods;Modeling;Monitor;Morphology;Nervous System Disorder;Neurological disability;Neurological outcome;Neurologist;Outcome;Patient Selection;Patients;Performance;Phenotype;Physiology;Positioning Attribute;Prediction of Response to Therapy;Propofol;Publishing;Recovery;Recovery of Function;Recurrence;Refractory;Research;Research Personnel;Resuscitation;San Francisco;Scientist;Seizures;Selection for Treatments;Series;Specificity;Survivors;Techniques;Testing;Therapeutic;Therapeutic Intervention;Time;Titrations;Training;Universities;Validation;Weaning;Work;authority;biomarker driven;brain magnetic resonance imaging;career development;cohort;deep learning;deep learning algorithm;epileptiform;hands-on learning;improved;improved outcome;innovation;insight;magnetic resonance imaging biomarker;multidisciplinary;natural hypothermia;neuroimaging;neurological recovery;neurophysiology;outcome prediction;personalized medicine;predictive marker;prevent;prognostication;programs;resilience;response biomarker;skills;technological innovation;treatment effect;treatment response;treatment strategy;trend,Physiology-driven seizure management post-cardiac arrest,PROJECT NARRATIVECardiac arrest impacts the lives of 500000 Americans every year and nearly half of patientssurviving the initial resuscitation will develop seizures or seizure-like brain activity as a complication ofhypoxic-ischemic brain injury. We aim to reduce secondary brain injury and neurological disabilityfrom seizures after cardiac arrest by personalizing seizure treatment using EEG and brain MRIbiomarkers of neuro-recovery. We expect that the outcome of the proposed studies will providecritical knowledge about epileptogenesis after hypoxic-ischemic brain injury andguide thedevelopment of goal-directed seizure treatment and patient selection in future clinical trials.,NINDS,10754261,12/8/2023 12:00:00 AM,PA-19-119,5K23NS119794-04,5,K23,NS,119794,04, ,"WHITTEMORE, VICKY R",1/1/2021 12:00:00 AM,12/31/2025 12:00:00 AM,NST-1 Study Section[NST-1], ,14200522,"AMORIM DE CERQUEIRA, EDILBERTO ",Not Applicable,11,NEUROLOGY,094878337,KMH5K9V7S518,094878337,KMH5K9V7S518,US,37.767442,-122.413937,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",SAN FRANCISCO,CA,SCHOOLS OF MEDICINE,941432510,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,853,Other Research-Related,2024,225652, ,NINDS,208937,16715, ,225652,,225652.0 | |
| No NIH Category available,Address;Affect;Agreement;Anxiety Disorders;Attention deficit hyperactivity disorder;Behavioral;Biological Markers;Black race;Brain;Brain imaging;Brain region;Categories;Child;Clinical;Clinical Data;Collaborations;Complex;Country;Data;Data Analyses;Data Set;Databases;Development;Diagnostic;Disease;Environmental Risk Factor;Etiology;Functional Magnetic Resonance Imaging;Functional disorder;Future;Generations;Genetic;Genetic Risk;Genetic study;Genomics;Gilles de la Tourette syndrome;Goals;Heterogeneity;Hispanic;Impairment;Individual;Infrastructure;International;Lead;Light;Magnetic Resonance Imaging;Maintenance;Major Depressive Disorder;Maps;Mental disorders;Meta-Analysis;Motor Tics;Neurobiology;Obsessive-Compulsive Disorder;Participant;Pathway interactions;Patients;Phenotype;Play;Population Heterogeneity;Publishing;Quality Control;Quality of life;Reproducibility;Research Personnel;Resources;Role;Sample Size;Sampling;Site;Standardization;Structure;Testing;Vocal Tics;analysis pipeline;autism spectrum disorder;biobank;biomarker identification;biomarker validation;cohort;comorbidity;gene interaction;genetic association;genetic information;genome wide association study;genomic locus;improved;individual patient;individualized medicine;neuroimaging;neuropsychiatric disorder;novel;outcome prediction;personalized management;population based;portability;psychiatric genomics;recruit;risk variant;structural imaging;success;working group,Tourette Syndrome genetics and neuroimaging international collaborative study,PROJECT NARRATIVETourette Syndrome (TS) is a complex disorder for which there is no cure and efforts to develop novel treatmentsare hampered by our limited understanding of the neurobiology and brain structural and functional deficits thatunderlie the disorder. TS is also highly heterogeneous and often comorbid with Obsessive Compulsive Disorder(OCD) Attention Deficit and Hyperactivity Disorder (ADHD) Autism Spectrum Disorder (ASD) Major DepressiveDisorder (MDD) and Anxiety Disorder (AXD) further complicating our efforts. Leveraging ties to ENIGMA andan international network of collaborators we will pursue the largest neuroimaging and genetics studies for TS todate pooling harmonizing and jointly analyzing worldwide datasets for TS and highly comorbid disordersshedding light into TS neurobiology and identifying biomarkers that could help tailor individualized managementapproaches.,NIMH,10754289,1/2/2024 12:00:00 AM,PA-20-185,5R01MH126213-03,5,R01,MH,126213,03, ,"PEVSNER, JONATHAN",3/4/2022 12:00:00 AM,12/31/2026 12:00:00 AM,"Neurological, Aging and Musculoskeletal Epidemiology Study Section[NAME]", ,14386255,"PASCHOU, PERISTERA ",Not Applicable,04,BIOLOGY,072051394,YRXVL4JYCEF5,072051394,YRXVL4JYCEF5,US,40.41872,-86.910361,1481402,PURDUE UNIVERSITY,WEST LAFAYETTE,IN,SCHOOLS OF ARTS AND SCIENCES,47906,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,242,Non-SBIR/STTR,2024,491596, ,NIMH,421123,70473, ,491596,,491596.0 | |
| No NIH Category available,Acceleration;Address;Adult;Age;Aging;Alleles;Alveolar;Anabolism;Apoptosis;Architecture;Automobile Driving;Autophagocytosis;Biological Markers;Bronchoalveolar Lavage Fluid;Cells;Cellular Stress;Cellular biology;Cessation of life;Characteristics;Chronic;Cicatrix;Clinical;Communities;Complication;Coupled;Data;Dependence;Development;Disease;Disease Progression;Distal;Elderly;Elements;Epithelium;Evolution;Fibrosis;Foundations;Functional disorder;Gases;Gene Expression Profile;Gene Mutation;Generations;Genes;Goals;Hand;High Resolution Computed Tomography;Histology;Human;Impairment;Injury;Interstitial Lung Diseases;Investigation;Knock-in;Knock-in Mouse;Ligands;Lung;Lung Transplantation;Maps;Medical;Medicine;Mesenchymal;Modeling;Morbidity - disease rate;Mus;Mutant Strains Mice;Mutation;Organelles;Organoids;Outcome;Pathogenesis;Pathway interactions;Patients;Pattern;Peripheral;Phenotype;Physiological;Physiology;Pirfenidone;Population;Pre-Clinical Model;Process;Protein Isoforms;Proteomics;Published Comment;Publishing;Pulmonary Fibrosis;Pulmonary Surfactant-Associated Protein C;Quality Control;Refractory;Reporting;Research;Resources;Respiratory Failure;Sampling;Serum;Signal Pathway;Stress;Structure of parenchyma of lung;Syndrome;Testing;Therapeutic;Time;Transplantation;Usual Interstitial Pneumonia;Validation;Work;aged;alveolar epithelium;biobank;biomarker identification;candidate marker;cohort;endoplasmic reticulum stress;fibrogenesis;fibrotic lung;genetic variant;high resolution imaging;idiopathic pulmonary fibrosis;in vivo;inhibition of autophagy;injury and repair;insight;lung repair;mortality;mouse model;mutant;new therapeutic target;nintedanib;non-Native;novel;novel therapeutics;patient subsets;pre-clinical;primary endpoint;programs;radiological imaging;receptor;response;secondary endpoint;segregation;sex;single-cell RNA sequencing;therapeutic development;therapy outcome;trafficking;transcriptomics;validation studies;wound healing,Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary Fibrosis,NARRATIVEIdiopathic Pulmonary fibrosis (IPF) a devastating form of interstitial lung disease in adults is marked byprogressive scarring of lung tissue respiratory failure and death for which there is a significant unmet need foreffective medical therapies. To overcome one of the current barriers in IPF research (a dearth of preclinicalmodels) and to facilitate a better understanding of the fibrotic processes for the identification of new therapeutictargets we developed two novel mouse models expressing mutations in the Surfactant Protein C (SP-C) genethat are associated with an IPF like syndrome in humans. These highly relevant preclinical models used inconjunction with human IPF lung and serum samples will serve as a comprehensive preclinical platform toidentify cell populations signaling pathways biomarkers and the contributions of age and sex on IPFdevelopment towards the goal of accelerating the discovery of new IPF treatments.,NHLBI,10754510,1/5/2024 12:00:00 AM,RFA-HL-20-007,5U01HL152970-04,5,U01,HL,152970,04, ,"GOMEZ, CHRISTIAN RENE",1/1/2021 12:00:00 AM,12/31/2024 12:00:00 AM,ZHL1-CSR-A(M1), ,1871720,"BEERS, MICHAEL FRANCIS",Not Applicable,03,INTERNAL MEDICINE/MEDICINE,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,838,Non-SBIR/STTR,2024,765307, ,NHLBI,470958,294349, ,765307,,765307.0 | |
| No NIH Category available,3-Dimensional;Affect;Basic Science;Biological Assay;Biological Markers;Biology;Cancer Therapy Evaluation Program;Cell Differentiation process;Cells;Cholesterol;Clinical;Clinical Trials;Clonal Evolution;Combination Drug Therapy;Combined Modality Therapy;Data;Disease;Dose;Drug Interactions;Drug Kinetics;Electromagnetic Energy;Fatty Acids;Gene Expression Profiling;Generations;Glioblastoma;Glioma;Goals;Hypoxia;In Vitro;Level of Evidence;Literature;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of brain;Metabolic;Modality;Modeling;Nitric Oxide;Pathway interactions;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Phenotype;Population;Process;Publishing;Radiation;Radiation Dose Unit;Radiation Oncology;Radiation therapy;Recurrence;Reporting;Resources;Scheme;Specimen;Surgical Oncology;Testing;Time;Toxic effect;Transgenic Mice;Treatment Failure;United States National Institutes of Health;biomarker identification;biomarker validation;blood-brain barrier crossing;cancer cell;cancer stem cell;chemotherapeutic agent;cholesterol biosynthesis;disorder control;drug development;effective therapy;imaging system;improved;in vivo;induced pluripotent stem cell;inhibitor;innovation;mevalonate;mouse model;neoplastic cell;nerve stem cell;nestin protein;neurogenesis;novel;patient derived xenograft model;prevent;radiation resistance;radioresistant;responders and non-responders;self-renewal;standard of care;stem cells;synergism;targeted agent;targeted treatment;temozolomide;therapy outcome;therapy resistant;tool;trait;tumor;tumor initiation,Use of CTEP portfolio compounds to counteract phenotype conversion in GBM,Project NarrativeThis proposal will study novel combination therapies against glioblastoma. It targets a pathwayglioma cells use to escape radiotherapy and aims to uncover novel ways to improve the efficacyof radiation treatment for glioblastoma patients.,NCI,10754534,12/13/2023 12:00:00 AM,PA-20-185,5R01CA260886-03,5,R01,CA,260886,03, ,"FORRY, SUZANNE L",1/1/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Radiation Therapeutics and Biology Study Section[RTB], ,8453323,"PAJONK, FRANK ",Not Applicable,36,RADIATION-DIAGNOSTIC/ONCOLOGY,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,SCHOOLS OF MEDICINE,900952000,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,395,Non-SBIR/STTR,2024,439519, ,NCI,281743,157776, ,439519,,439519.0 | |
| No NIH Category available,Afferent Neurons;Auditory;Brain;Brain Stem;Categories;Cell Communication;Cell Nucleus;Cells;Cephalic;Chromium;Code;Data;Detection;Diet;Eating;Electrophysiology (science);Entropy;Feeding behaviors;Food Selections;Funding;Ganglia;Gene Expression Profile;Genetic;Genomics;Goals;Image;Insulin;Label;Laboratories;Lasers;Measures;Mediating;Methods;Molecular;Molecular Profiling;Mouse Strains;Mus;Neural Pathways;Neurons;Noise;Pathway interactions;Phase;Physiological;Process;Reflex action;Reticular Formation;Retina;Retinal Ganglion Cells;Signal Transduction;Stimulus;Structure of geniculate ganglion;System;Taste Bud Cell;Taste Buds;Taste Perception;Testing;Visual;biomarker validation;cell type;combinatorial;designer receptors exclusively activated by designer drugs;food consumption;glucose tolerance;in vivo;molecular marker;nutrition;prototype;response;single-cell RNA sequencing;somatosensory;taste stimuli;transcriptome;transmission process,Functions of gustatory afferent neuron types.,Project NarrativeOur selection of foods we consume is governed in large part by taste pathways in the periphery (sweetsalty sour etc). However there is a paucity of information about the molecular identities of afferent sensoryneurons that process taste signals and transmit these signals to the brain. Understanding how basic tastes areencoded by sensory neurons whose molecular profiles are known is key for understanding diet selection andmaking rational choices of what we eat.,NIDCD,10754866,12/26/2023 12:00:00 AM,PA-19-056,5R01DC018733-04,5,R01,DC,018733,04, ,"SABRI, MERAV",7/10/2020 12:00:00 AM,12/31/2025 12:00:00 AM,Chemosensory Systems Study Section[CSS], ,1863767,"ROPER, STEPHEN D.","CHAUDHARI, NIRUPA ",27,PHYSIOLOGY,052780918,F8THLJQSAF93,052780918,F8THLJQSAF93,US,25.713468,-80.277246,5221250,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,CORAL GABLES,FL,SCHOOLS OF MEDICINE,331462926,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,173,Non-SBIR/STTR,2024,595147, ,NIDCD,387718,207429, ,595147,,595147.0 | |
| No NIH Category available,Antibodies;B lymphoid malignancy;B-Cell Development;B-Lymphocytes;Biological Markers;Blood Circulation;Blood Vessels;Blood flow;Blood specimen;CAR T cell therapy;Cell Communication;Cells;Characteristics;Circulation;Clinic;Clinical Trials;Complex;Computer software;Data;Data Science;Data Set;Detection;Development;Devices;Diagnostic;Disease remission;Dose;Ear;Engineering;Flow Cytometry;Fluorescence;Frequencies;Goals;Hematologic Neoplasms;Hematology;Human;In Vitro;Infusion procedures;Intervention;Label;Leukemic Cell;Leukocytes;Machine Learning;Measurement;Methods;Microfluidic Microchips;Microfluidics;Miniaturization;Monitor;Mus;Oncology;Optics;Outcome;Patient Monitoring;Patients;Precursor B-Lymphoblast;Proteins;Protocols documentation;Refractory;Relapse;Resolution;Sensitivity and Specificity;Signal Transduction;Signaling Protein;Solid Neoplasm;Source;Survival Rate;System;T-Lymphocyte;TCR Activation;Technology;Temperature;Testing;Time;Toxic effect;Translating;Treatment Protocols;Treatment-related toxicity;Tumor Burden;Validation;Variant;Whole Blood;blood-based biomarker;cellular engineering;chimeric antigen receptor;chimeric antigen receptor T cells;early onset;expectation;improved;in vivo;individual patient;individual response;innovation;insight;instrumentation;light scattering;monitoring device;multidisciplinary;non-invasive monitor;novel;novel marker;patient response;patient safety;personalized approach;point of care;precision medicine;predicting response;response;signal processing;standard care;targeted treatment;therapy outcome;tool;translational potential;treatment optimization;treatment response;tumor,Development of a novel platform for label-free monitoring of CAR-T cell interactions in vivo,We propose the development of a new non-invasive method that may be used to optimize and monitor treatmentresponses in patients that are receiving CAR-T cell therapy. The approach is relatively simple and theinstrumentation amenable to miniaturization. Thus if successful it should be possible to translate the technologyto the clinic or as point of care device for monitoring human patients with the frequency that is needed to optimizetherapeutic outcomes.,NCI,10755335,1/12/2024 12:00:00 AM,PAR-22-091,5R21CA271679-02,5,R21,CA,271679,02, ,"MCKEE, TAWNYA C",1/1/2023 12:00:00 AM,12/31/2024 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,2442066,"GEORGAKOUDI, IRENE ",Not Applicable,07,ENGINEERING (ALL TYPES),073134835,WL9FLBRVPJJ7,073134835,WL9FLBRVPJJ7,US,42.40117,-71.125362,8422701,TUFTS UNIVERSITY MEDFORD,Boston,MA,BIOMED ENGR/COL ENGR/ENGR STA,021111817,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,177279, ,NCI,119812,57467, ,177279,,177279.0 | |
| No NIH Category available,Adverse effects;Affect;Antibodies;Autopsy;Binding;Biological Assay;Blindness;Blood Vessels;Blood capillaries;Cell Line;Cell Surface Proteins;Cells;Chronic;Clinical Research Protocols;Clinical Trials;Data;Developed Countries;Development;Diabetes Mellitus;Diabetic Retinopathy;Down-Regulation;Electroretinography;Embryo;Endothelial Cells;Enzyme-Linked Immunosorbent Assay;Eye;FRAP1 gene;Finland;Gene Targeting;Glucose;Glycosylated hemoglobin A;Grant;Hyperglycemia;Individual;Inflammatory;Injections;Insulin-Dependent Diabetes Mellitus;Interleukin-6;Intervention;Intervention Studies;KDR gene;Length;Lentivirus;Mass Spectrum Analysis;Medicine;Microvascular Dysfunction;Modality;Muller's cell;Nuclear;Paper;Pathway interactions;Patients;Persons;Photoreceptors;Plasma;Population Study;Protein Isoforms;Proteins;Proteomics;Protocols documentation;Recombinants;Regulation;Reporting;Retina;Retinal Photoreceptors;Retinol Binding Proteins;Rhodopsin;Rodent;SLC2A1 gene;Science;Serum;Severities;Structure;Structure-Activity Relationship;Therapeutic Agents;Therapeutic Intervention;Tissues;Toxic effect;Transgenes;Translational Research;Validation;Vascular Endothelial Growth Factors;Vascular Permeabilities;cohort;diabetic;diabetic rat;glucose uptake;glycemic control;in vivo;inhibitor;interstitial retinol-binding protein;laser photocoagulation;mRNA Expression;macular edema;new therapeutic target;non-diabetic;novel;novel therapeutic intervention;novel therapeutics;overexpression;potential biomarker;prevent;proliferative diabetic retinopathy;promoter;prospective;protective factors;protein activation;protein expression;protein kinase C-delta;subretinal injection;therapeutic target;transcription factor;translational medicine;type I and type II diabetes,Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration,PROJECT NARRATIVEIn studies involving the Medalist cohort composed of people with insulin-dependent diabetes for50 years as well as their donated retinal tissues we have identified a retina-specific proteinretinol binding protein 3 (RBP3) which can neutralize the toxic effects of hyperglycemia anddiabetes on the retinal tissues and blood vessels. In this application we will evaluate whetherretinal and serum RBP3 levels correlate with severity of diabetic retinopathy in a wide range ofpatients and investigate the regulation of its expression and its protective mechanisms onretinal cells. These findings have identified RBP3 as a potential new therapeutic agent fordiabetic retinopathy.,NEI,10755665,1/16/2024 12:00:00 AM,PA-19-056,5R01EY026080-07,5,R01,EY,026080,07, ,"SHEN, GRACE L",3/1/2016 12:00:00 AM,12/31/2024 12:00:00 AM,Diseases and Pathophysiology of the Visual System Study Section[DPVS], ,1892882,"KING, GEORGE L",Not Applicable,07,Unavailable,071723084,UUUMQVGJNNX1,071723084,UUUMQVGJNNX1,US,42.338497,-71.108264,2133701,JOSLIN DIABETES CENTER,BOSTON,MA,Research Institutes,022155306,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,867,Non-SBIR/STTR,2024,471383, ,NEI,278925,192458, ,471383,,471383.0 | |
| No NIH Category available,Acute Graft Versus Host Disease;Address;Advisory Committees;Allogenic;Anti-Infective Agents;Antibiotics;Behavior;Bioinformatics;Biological Markers;Biology;Carbapenems;Cell Physiology;Cells;Child;Childhood;Childhood Leukemia;Clinical;Clinical Research;Complex;Concentration measurement;Data;Development;Dimensions;Disease;Drug Kinetics;Drug Targeting;Engraftment;Ensure;Environment;Epidemiologist;Epidemiology;Event;Exposure to;Foundations;Future;Gastrointestinal tract structure;Goals;Healthcare;Hematological Disease;Hematopoietic System;Hemoglobinopathies;Human;Immune;Immune System Diseases;Immune system;Immunity;Immunologic Deficiency Syndromes;Immunologics;Individual;Infection;Intervention;Intervention Studies;Investigation;Kinetics;Knowledge;Leukocytes;Life;Link;Longitudinal Studies;Longitudinal cohort;Lymphopenia;Measurement;Measures;Mediating;Mentored Patient-Oriented Research Career Development Award;Mentorship;Metagenomics;Methods;Modeling;Nature;Neutropenia;Outcome;Pathogenesis;Patient-Focused Outcomes;Patients;Pediatric Hospitals;Pediatric Oncologist;Pediatric Oncology Group;Pediatric cohort;Pennsylvania;Peripheral;Pharmaceutical Preparations;Pharmacoepidemiology;Philadelphia;Physicians;Physiological;Population;Prospective cohort;Quality of life;Recovery;Research;Research Personnel;Research Project Grants;Residual state;Resources;Risk;Sampling;Scientist;Signal Transduction;Statistical Methods;Stem cell transplant;Supportive care;System;Systems Development;Therapeutic;Time;Training;Transplant Recipients;Transplantation and Immune System;Universities;Validation;Work;adverse outcome;behavioral study;bone marrow failure syndrome;career;clinically relevant;clinically significant;cohort;deep sequencing;experience;graft vs host disease;host microbiome;immune reconstitution;improved;infection risk;interpatient variability;kinetic model;leukemia;longitudinal analysis;microbiome;microbiome analysis;microbiome research;microbiome sequencing;microbiota;neutrophil;novel marker;patient oriented research;patient variability;pharmacodynamic model;pharmacologic;prevent;rational design;response;skills;stem cells;success;therapy design,Understanding longitudinal microbiome change in relation to immunologic outcomes in pediatric SCT recipients.,PROJECT NARRATIVEAllogeneic stem cell transplant (SCT) is a life-saving treatment for children with leukemia immunodeficienciesand other disorders of the hematopoietic system yet its success is limited by aberrant or delayed developmentof the new immune system. The gastrointestinal tract microbiota and microbiome disruption that occurs over thecourse of SCT may predict or even contribute to the pathogenesis of these immune-related outcomes includinggraft-versus-host disease and time to immune cell recovery. This study will further define the relationshipbetween microbiome disruption and immunologic outcomes of SCT laying the foundation to develop newbiomarkers and therapeutic approaches to improve the success of this treatment.,NHLBI,10755685,12/14/2023 12:00:00 AM,PA-20-205,5K23HL161309-03,5,K23,HL,161309,03, ,"FRANK, DANIEL J",1/1/2022 12:00:00 AM,12/31/2026 12:00:00 AM,NHLBI Mentored Patient-Oriented Research Study Section[MPOR(OA)], ,14586377,"ELGARTEN, CAITLIN WALFOORT",Not Applicable,03,Unavailable,073757627,G7MQPLSUX1L4,073757627,G7MQPLSUX1L4,US,39.946632,-75.196604,1499101,CHILDREN'S HOSP OF PHILADELPHIA,PHILADELPHIA,PA,Independent Hospitals,191462305,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,839,Other Research-Related,2024,185652, ,NHLBI,171900,13752, ,185652,,185652.0 | |
| No NIH Category available,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol;4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone;Alleles;Asian;Biological Markers;Black race;Blood specimen;Cancer Burden;Cancer Etiology;Carcinogens;Cells;Cessation of life;Chemopreventive Agent;Chinese;Cohort Studies;Communities;Complex;Copy Number Polymorphism;Cytochrome P450;Cytosol;Data;Development;Drug Metabolic Detoxication;Enzymes;Exhibits;Genes;Genetic Markers;Genetic Polymorphism;Genetic Variation;Genotype;Glucuronides;Glucuronosyltransferase;Goals;Health;Human;Isomerism;Liver;Lung;Malignant neoplasm of lung;Mediating;Metabolic;Metabolism;Microsomes;Nicotine;Nitrosamines;Oxidoreductase;Pathway interactions;Pattern;Phenotype;Play;Population;Predisposition;Prevention strategy;Prospective cohort;Prospective cohort study;Protein Isoforms;Risk;Role;SNP genotyping;Singapore;Smoker;Smoking;Tissues;Tobacco;Tobacco smoke;Tobacco-Associated Carcinogen;Urine;Validation;Variant;Women's Health;cancer risk;carcinogenesis;carcinogenicity;cigarette smoking;cohort;cost effective;enantiomer;genetic variant;genome wide association study;genome-wide;high risk;improved;insight;lung cancer prevention;lung cancer screening;lung carcinogenesis;lung development;mortality;novel;novel strategies;phenotypic biomarker;precision cancer prevention;prospective;protective pathway;recruit;sample collection;screening;smoking cessation;targeted sequencing;urinary,Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention,Project NarrativeThe major mode of metabolism of NNK a major contributor to the induction of lung cancer in smokers is viathe formation of its pro-carcinogenic metabolite NNAL. Two enantiomers of NNAL are formed -- (R)-NNAL and(S)-NNAL with (R)-NNAL the major isoform formed in the lung and both enantiomers detoxified byglucuronidation. We provide novel preliminary data demonstrating a strong and statistically significant inverseassociation between the ratio of urinary (R)-NNAL-glucuronide (Gluc)/(S)-NNAL-Gluc and lung cancer risk insmokers from two independent large cohort studies and this novel stable biomarker of lung cancer riskreflects the potential importance of (R)-NNAL in the carcinogenicity of NNK and strongly supports the goals ofthis proposal which is to evaluate the importance of different NNAL enantiomers and glucuronides in lungcancer carcinogenesis and to elucidate novel urinary biomarkers of lung cancer risk focusing on the NNALformation and elimination pathways.,NCI,10755737,11/7/2023 12:00:00 AM,PA-20-185,5R01CA269223-02,5,R01,CA,269223,02, ,"SIMONDS, NAOKO ISHIBE",12/16/2022 12:00:00 AM,11/30/2027 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,1901170,"LAZARUS, PHILIP ","YUAN, JIAN-MIN ",05,PHARMACOLOGY,041485301,XRJSGX384TD6,041485301,XRJSGX384TD6,US,46.728892,-117.155742,9082001,WASHINGTON STATE UNIVERSITY,PULLMAN,WA,SCHOOLS OF PHARMACY,991641060,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,393,Non-SBIR/STTR,2024,605270, ,NCI,488513,116757, ,605270,,605270.0 | |
| No NIH Category available,3-Dimensional;Acceleration;Adoption;Affect;Age;Aging;Biological;Biological Markers;Biomechanics;Blood Tests;Breathing;Cardiac;Cardiac Volume;Cardiovascular Diseases;Cause of Death;Clinical;Data;Development;Diagnostic;Diastole;Disease;Dyspnea;EFRAC;Echocardiography;Enrollment;Evolution;Failure;Follicle Stimulating Hormone;Functional disorder;Future;Goals;Heart;Heart failure;Hormonal Change;Image;Intervention;Left;Left Ventricular Ejection Fraction;Longitudinal Studies;Magnetic Resonance Elastography;Measurement;Measures;Mechanics;Menopausal Status;Menopause;Methods;Modeling;Monitor;Motion;Myocardial;Myocardial tissue;Participant;Patients;Perimenopause;Phase;Pilot Projects;Postmenopause;Premenopause;Prevalence;Prevention;Prognosis;Radial;Resolution;Risk;Risk Factors;Sampling;Sex Bias;Sex Differences;Shortness of Breath;Slice;Symptoms;System;Systole;Techniques;Technology;Testing;Therapeutic Trials;Time;Validation;Ventricular;Woman;age effect;cardiac magnetic resonance imaging;cardiovascular disorder risk;clinical biomarkers;clinical examination;clinical imaging;critical period;disorder prevention;follow-up;hospitalization rates;imaging biomarker;improved;in vivo;men;patient population;preservation;pressure;prevent;preventive intervention;quantitative imaging;reconstruction;reproductive;respiratory;response;routine imaging;sex;sex as a biological variable;tool;trend;volunteer,Evaluating the natural evolution of myocardial stiffness in aging sex differences and through menopause transition in women using a free-breathing magnetic resonance elastography approach,PROJECT NARRATIVEWhile cardiovascular disease (CVD) is the leading cause of death in men and women substantial sexdifferences exist in disease prevalence and prognosis. Elevated myocardial stiffness is a precursor and abiological response to a spectrum of cardiovascular diseases and is highly likely to be affected by hormonalchanges during menopause but quantitative non-invasive in vivo measurements have not been realizedclinically to make these measurements. In this project we will develop a non-invasive magnetic resonanceelastography (MRE) method that quantitatively measures myocardial stiffness and will use it to evaluate theinfluence of natural aging sex and menopause transition on myocardial stiffness.,NHLBI,10756128,12/25/2023 12:00:00 AM,PA-20-185,5R01HL151379-02,5,R01,HL,151379,02, ,"DANTHI, NARASIMHAN",1/1/2023 12:00:00 AM,12/31/2027 12:00:00 AM,Imaging Technology Development Study Section[ITD], ,12250032,"FORGHANIAN-ARANI, ARVIN ",Not Applicable,01,Unavailable,006471700,Y2K4F9RPRRG7,006471700,Y2K4F9RPRRG7,US,44.02432,-92.46011,4976101,MAYO CLINIC ROCHESTER,ROCHESTER,MN,Other Domestic Non-Profits,559050001,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,837,Non-SBIR/STTR,2024,572414, ,NHLBI,413015,159399, ,572414,,572414.0 | |
| No NIH Category available,Address;Antibodies;Archives;Artificial Intelligence;B-Lymphocytes;Biological Markers;Biopsy;Biopsy Specimen;Cells;Certification;Chemistry;Clinical;Clinical Laboratory Improvement Amendments;Consumption;Core Biopsy;Diagnostic;Emerging Technologies;Engineering;Evaluation;Evolution;Fine needle aspiration biopsy;Fresh Tissue;Goals;Head and Neck Squamous Cell Carcinoma;Human;Image Guided Biopsy;Immune;Immune response;Immunotherapeutic agent;Immunotherapy;Laboratories;Malignant Neoplasms;Methods;Modification;Morbidity - disease rate;Needles;Pathologist;Patients;Physiologic Monitoring;Quality Control;Recurrence;Research;Sampling;Sedation procedure;Site;Specimen;Stains;System;T-Lymphocyte;Technology;Testing;Time;Tissue Harvesting;Tissues;Training;Translating;Treatment Efficacy;Treatment Protocols;United States Food and Drug Administration;Validation;anti-PD-1;biomarker discovery;biomarker validation;cancer cell;chemotherapy;clinical application;clinical predictors;companion diagnostics;cost;experimental study;innovation;molecular marker;mouse model;novel;predictive marker;programmed cell death ligand 1;prospective;response;response biomarker;single-cell RNA sequencing;therapy outcome;translational goal;tumor;tumor microenvironment,FAST-FNA immune cell profiling in HNSCC,Existing analysis of HNSCC cancer tissues obtained by core biopsy is limited in many aspects. We havedeveloped a new immune and cancer cell profiling technology based on cellular immunocycling. Using fineneedle aspirates (FNA) rather than more invasive core biopsies this method allows frequent and serial profiling onthe composition of the tumor microenvironment in HNSCC patients undergoing immunotherapy.,NCI,10756133,1/17/2024 12:00:00 AM,PA-19-056,5R01CA257623-04,5,R01,CA,257623,04, ,"OSSANDON, MIGUEL",1/26/2021 12:00:00 AM,12/31/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-OTC-M(08)F], ,1887033,"WEISSLEDER, MD, PHD, RALPH ","PAI, SARA ISABEL",08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,637189, ,NCI,379279,257910, ,637189,,637189.0 | |
| No NIH Category available,Acceleration;Adjuvant Chemotherapy;Assessment tool;Benchmarking;Biological Process;Blood Vessels;Breast;Breast Cancer Treatment;Breast Cancer therapy;Breast Magnetic Resonance Imaging;Cancer Burden;Cell membrane;Clinical;Clinical Data;Clinical Decision Support Systems;Clinical Trials;Computer software;Contrast Media;Data;Data Analyses;Data Set;Diffusion;Diffusion Magnetic Resonance Imaging;Dimensions;Drug Kinetics;Evaluation;Future;Goals;Head and Neck Cancer;Health;Image;Imaging Device;In complete remission;Kinetics;MRI Scans;Magnetic Resonance Imaging;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;Maps;Measurement;Measures;Metabolic;Methods;Modeling;Multicenter Studies;Neoadjuvant Therapy;Online Systems;Oregon;Outcome;Pathologic;Patients;Performance;Perfusion;Permeability;Physiological;Prediction of Response to Therapy;Procedures;Prospective Studies;Protocols documentation;Research;Residual Cancers;Science;Signal Transduction;Site;Software Tools;Solid Neoplasm;Speed;System;Testing;Therapy Evaluation;Time;Tissues;Training;Translations;Treatment Protocols;Treatment-related toxicity;Universities;Validation;Variant;Vendor;Water;cancer imaging;cancer therapy;cancer type;clinical application;clinical decision support;clinical decision-making;clinical practice;clinical translation;contrast enhanced;data acquisition;digital;early phase clinical trial;human data;imaging biomarker;imaging modality;improved;individual patient;individual response;magnetic resonance imaging biomarker;molecular marker;non-invasive imaging;patient subsets;pharmacokinetic model;precision medicine;predicting response;predictive marker;predictive modeling;predictive tools;prospective;quantitative imaging;research clinical testing;response;treatment response;tumor,Multicenter Quantitative MRI Assessment of Breast Cancer Therapy Response,Project NarrativeThis application proposes to validate the robustness of Shutter-Speed Model (SSM) dynamic contrast-enhanced (DCE) MRI as a quantitative imaging biomarker for assessment of cancer therapy response in amulticenter prospective study using the setting of breast cancer response to neoadjuvant chemotherapy as theclinical test platform. Validation of this quantitative imaging method in a multi-site and multi-MR scannerplatform setting and making the associated software tools publicly available will accelerate the translation intoclinical trials and ultimately clinical practice to improve prediction and evaluation of cancer therapy responsefor individual patients in the emerging era of precision medicine.,NCI,10756473,5/7/2024 12:00:00 AM,PA-19-056,5R01CA248192-04,5,R01,CA,248192,04, ,"TATA, DARAYASH B",12/1/2020 12:00:00 AM,5/31/2026 12:00:00 AM,Imaging Guided Interventions and Surgery Study Section[IGIS], ,8358335,"HUANG, WEI ","HOLMES, JAMES H; PARTRIDGE, SAVANNAH CORRINA",01,NONE,096997515,NPSNT86JKN51,096997515,NPSNT86JKN51,US,45.49882,-122.685647,6297007,OREGON HEALTH & SCIENCE UNIVERSITY,PORTLAND,OR,OVERALL MEDICAL,972393098,UNITED STATES,N,6/1/2024 12:00:00 AM,5/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,552149, ,NCI,447347,104802, ,552149,,552149.0 | |
| No NIH Category available,25-hydroxyvitamin D;Academic Medical Centers;Achievement;Address;Affect;Age;Asthma;Biological;Biological Markers;Biometry;Blood;Blood specimen;Body mass index;Child;Childhood Asthma;Clinical;Clinical Research;Code;Comparative Genomic Analysis;Complex;Data;Development;Disease;Doctor of Philosophy;Early Diagnosis;Epidemiology;Essential Genes;Future;Gene Expression;Genes;Genomics;Goals;Grant;Health;High-Throughput Nucleotide Sequencing;Hospitals;Hypertension;Inflammation;Investigation;Late pregnancy;Life;Maternal-Fetal Exchange;Maternal-fetal medicine;Measurement;Measures;Medical;Medicine;Mentors;Messenger RNA;MicroRNAs;Molecular;Morbidity - disease rate;Mothers;Multiomic Data;Neonatal Mortality;Netherlands;Pathway interactions;Pharmacogenetics;Pharmacogenomics;Phase;Physiological;Placenta;Pre-Eclampsia;Pregnancy;Pregnant Women;Prevalence;Prevention;Preventive;RNA;Records;Research;Research Personnel;Risk;Risk Factors;Role;Sampling;Science;Scientist;Systems Biology;Time;Tissues;Training;Translational Research;Translations;Umbilical Cord Blood;Validation;Vitamin D;Wheezing;Woman;antenatal;asthmatic;biomarker identification;biomedical informatics;career;circulating microRNA;clinical practice;cohort;developmental plasticity;differential expression;early childhood;early pregnancy;fetal;gene environment interaction;genetic signature;genomic data;genomic signature;high risk;immunoregulation;in utero;insight;instructor;interest;maternal condition;medical schools;miRNA expression profiling;mortality;multidisciplinary;neonatal morbidity;neonate;next generation sequencing;novel;offspring;pathophysiology of preeclampsia;peripheral blood;pre-clinical;preclinical development;pregnancy disorder;prenatal;prenatal risk factor;preservation;prevention practice;protein protein interaction;respiratory;transcriptome;transcriptomics,Integrative Longitudinal Genomics of Maternal Asthma-Preeclampsia Overlap and Risk of Childhood Asthma,Project NarrativePreeclampsia (PE) causes maternal-fetal physiologic imbalance with maternal fetal and neonatal morbidityand mortality. Maternal asthma also increases the risk of PE and childhood asthma. The genomic overlap ofthe two conditions could help to elucidate their early origins and potential prevention of both disorders andchildhood asthma.,NHLBI,10756475,12/12/2023 12:00:00 AM,PA-19-126,5K01HL146977-05,5,K01,HL,146977,05, ,"SHENOY, SIDDHARTH KAUP",1/3/2020 12:00:00 AM,12/31/2024 12:00:00 AM,NHLBI Mentored Clinical and Basic Science Study Section[MCBS(OA)], ,12486066,"MIRZAKHANI, HOOMAN ",Not Applicable,07,Unavailable,030811269,QN6MS4VN7BD1,030811269,QN6MS4VN7BD1,US,42.336107,-71.107481,1080401,BRIGHAM AND WOMEN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021156110,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,838,Other Research-Related,2024,174960, ,NHLBI,162000,12960, ,174960,,174960.0 | |
| No NIH Category available,Acceleration;Actins;Acute;Address;Attention;Attenuated;Biochemical Process;Biophysics;Calcium;Cardiac;Catheterization;Clinical;Contracts;Data;Dependence;Diagnosis;Diagnostic;Disease;EFRAC;Excision;Filament;Fructose;Functional disorder;Goals;Head;Heart;Heart Diseases;Heart failure;Impairment;In Vitro;Individual;Isometric Exercise;Kinetics;Length;Link;Mechanics;Mediating;Mediator;Methods;Modeling;Modification;Molecular;Motion;Myocardial;Myocardium;Myofibrils;Myosin ATPase;Outcome Study;Patients;Peripheral Resistance;Pharmaceutical Preparations;Physiological;Positioning Attribute;Property;Protein Isoforms;Rattus;Regulation;Relaxation;Research;Role;Sodium Chloride;Stretching;Techniques;Testing;Thick Filament;Thin Filament;Tissues;Translating;Translations;Validation;Work;X ray diffraction analysis;arm;attenuation;biomechanical test;biophysical properties;clinical practice;clinically relevant;connectin;experimental study;hemodynamics;imaging biomarker;improved;in vivo;indexing;new therapeutic target;novel;pharmacologic;preservation;pressure;response;tau Proteins;ultrasound,Leveraging Mechanical Control of Relaxation to Improve Diastolic Function,8. PROJECT NARRATIVEThe proposed research addresses the critical need to determine new molecular mechanisms that underlie howthe heart relaxes a key component of diastolic dysfunction and Heart Failure with preserved Ejection Fraction(HFpEF). We investigate a unique strain-rate (stretch) dependent mechanism to accelerate the relaxation ofheart muscle. We utilize novel biomechanical tests to discover new drug targets and diagnostic indexes fordiastolic dysfunction that can be translated into clinical practice.,NHLBI,10756481,1/5/2024 12:00:00 AM,PA-19-056,5R01HL151738-04,5,R01,HL,151738,04, ,"ADHIKARI, BISHOW B",1/1/2021 12:00:00 AM,12/31/2025 12:00:00 AM,"Cardiac Contractility, Hypertrophy, and Failure Study Section[CCHF]", ,10887280,"CHUNG, CHARLES S",Not Applicable,13,PHYSIOLOGY,001962224,M6K6NTJ2MNE5,001962224,M6K6NTJ2MNE5,US,42.357466,-83.065294,9110501,WAYNE STATE UNIVERSITY,DETROIT,MI,SCHOOLS OF MEDICINE,482024000,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,837,Non-SBIR/STTR,2024,373081, ,NHLBI,248519,124562, ,373081,,373081.0 | |
| No NIH Category available,Affect;Alternative Splicing;Apoptosis;Awareness;Biological;Biological Assay;Biological Process;Biopsy;Biopsy Specimen;Brain;Brain Neoplasms;Cell Separation;Data;Development;Event;Excision;Exons;Future;Genes;Genetic Transcription;Glioblastoma;Glioma;Goals;Growth;Invaded;Investigation;Malignant - descriptor;Malignant Neoplasms;Mass Spectrum Analysis;Methodology;Methods;Molecular;Molecular Analysis;Molecular Weight;Normal tissue morphology;Operative Surgical Procedures;Pathogenesis;Pathway interactions;Patients;Pattern;Process;Prognosis;Protein Isoforms;Proteins;Proteomics;RNA;RNA Splicing;Radiation therapy;Research;Resolution;Reverse Transcriptase Polymerase Chain Reaction;Sampling;Source;Spliced Genes;Survival Rate;Techniques;Technology;Testing;Time;Tissues;Transcript;Tumor Antigens;Validation;Variant;Western Blotting;Work;biobank;cancer survival;cancer type;candidate identification;chemotherapy;diagnostic biomarker;differential expression;experimental study;follow-up;large scale data;mRNA sequencing;neoplastic cell;new therapeutic target;novel;novel marker;novel strategies;personalized medicine;potential biomarker;precision medicine;protein folding;proteogenomics;public database;side effect;small hairpin RNA;standard of care;stem cells;therapeutic target;transcriptome sequencing;transcriptomics;translational study;tumor;tumor initiation;variant detection,Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma,PROPOSAL NARRATIVEGlioblastoma (GBM) is the most aggressive type of glioma characterized by fast growth and poor prognosiswith an average survival of 15 months. Here we will apply a systematic molecular analysis to identifyalternatively spliced genes in GBMs and then validate the biological function of those splice forms in patient-derived glioma stem cells. Our main goal is to identify putative alternative splicing genes as therapeutic targetsfor future studies in personalized medicine.,NCI,10756532,11/22/2023 12:00:00 AM,PAR-20-292,5R21CA267394-02,5,R21,CA,267394,02, ,"GANGULY, ANIRUDDHA",1/1/2023 12:00:00 AM,12/31/2024 12:00:00 AM,ZCA1-SRB-P(O1)S, ,7320385,"COBBS, CHARLES S","SEARLE, BRIAN CHIH-SENG",09,Unavailable,079264420,GZ5WW5GZY2A5,079264420,GZ5WW5GZY2A5,US,47.608392,-122.322135,10001759,"SWEDISH MEDICAL CENTER, FIRST HILL",SEATTLE,WA,Independent Hospitals,981224307,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,218604, ,NCI,156855,61749, ,218604,,218604.0 | |
| No NIH Category available,3D Print;Alzheimer's Disease;Anesthesia procedures;Anesthetics;Angiogenesis Inhibitors;Animals;Arteries;Biological Markers;Blood Vessels;Brain Neoplasms;Brain imaging;CD47 gene;Cells;Central Nervous System;Cerebrovascular Circulation;Clinical;Data;Development;Devices;Disease;Drug Delivery Systems;Dyes;Electroencephalography;Exhibits;Fluorescence;Gene Expression;Glioblastoma;Glioma;Goals;Histologic;Histology;Hour;Image;Imaging Device;Immune Evasion;Immune response;Immunocompetent;Immunosuppression;Immunotherapy;Knock-out;Lasers;Life Cycle Stages;Lighting;Magnetic Resonance Imaging;Malignant neoplasm of brain;Maps;Measurement;Mediating;Microscope;Mission;Modeling;Morphology;Motivation;Mus;Optics;Pathway interactions;Patients;Perfusion;Phenotype;Physiological;Play;Public Health;Quail;Research;Resistance;Resolution;Role;Signal Transduction;Stroke;Structure;System;Time;Treatment Efficacy;Tumor-associated macrophages;United States National Institutes of Health;Validation;Vascular remodeling;Veins;Wireless Technology;Xenograft procedure;angiogenesis;anti-cancer research;awake;behavioral study;biomarker identification;blood vessel development;brain tumor imaging;cancer imaging;cellular engineering;cerebral blood volume;cerebral microvasculature;clinically relevant;design;fabrication;fluorescence imaging;fluorophore;imaging capabilities;imaging modality;imaging system;immune cell infiltrate;immunoregulation;in vivo;in vivo imaging;insight;meter;miniaturize;neoplastic cell;neuroimaging;novel therapeutics;operation;optogenetics;overexpression;patient derived xenograft model;pre-clinical;real-time images;recruit;sensor;structural imaging;therapy resistant;transmission process;treatment response;treatment strategy;tumor;tumor growth;tumor microenvironment;tumor progression;tumor-immune system interactions;wireless;wireless fidelity;wireless transmission,A Wireless Multi-function Microscope for Lifetime Imaging of the Brain Tumor Vasculome,The proposed research is relevant to public health because the development of imaging tools capable ofassessing structural and functional changes in the brains microvessels (i.e. vasculome) over the life cycle ofa brain tumor model will yield invaluable insight into their role in brain cancer progression tumor spreadand treatment efficacy. The proposed research is relevant to the NIHs mission because the assessmentof changes in the vasculome of patient-derived brain tumor models over their entire lifetime would helpelucidate the role of non-angiogenic brain tumor growth in resistance to antiangiogenic therapies vascularmodulation associated with immunosuppression of the brain tumor microenvironment and help identify newbiomarkers and treatment strategies for patients with brain cancer.,NCI,10756969,1/3/2024 12:00:00 AM,PAR-19-158,5R01CA237597-05,5,R01,CA,237597,05, ,"OSSANDON, MIGUEL",12/12/2019 12:00:00 AM,11/30/2024 12:00:00 AM,Special Emphasis Panel[ZRG1-ETTN-K(02)M], ,8765367,"PATHAK, ARVIND P",Not Applicable,07,RADIATION-DIAGNOSTIC/ONCOLOGY,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,398030, ,NCI,256976,141054, ,398030,,398030.0 | |
| No NIH Category available,Address;Animal Model;Archives;Awareness;Biological Specimen Banks;Biomedical Engineering;Biometry;Biostatistics Core;Cancer Center;Cancer Research Project;Centers of Research Excellence;Certification;Clinical;Clinical Data;Clinical Research;Collaborations;Communities;Computer software;Cost effectiveness research;Data;Data Analyses;Databases;Development;Educational workshop;Engineering;Ensure;Evaluation Indexes;Experimental Designs;Faculty;Goals;Health Sciences;Histopathology;Image;Imaging technology;Infrastructure;Institutional Review Boards;Joints;Knowledge;Leadership;Learning;Link;Machine Learning;Magnetic Resonance Imaging;Medical Imaging;Medical center;Metadata;Methodology;Methods;Modeling;Monitor;Oklahoma;Pathologist;Performance;Policies;Prospective Studies;Protocols documentation;Publishing;Regulation;Research;Research Methodology;Research Personnel;Research Project Grants;Research Support;Resources;Retrospective Studies;Sample Size;Sampling;Sampling Studies;Secure;Services;Slide;Stains;Statistical Data Interpretation;Study models;Testing;The Cancer Imaging Archive;Training;Translational Research;Treatment outcome;United States National Institutes of Health;Universities;Validation;Vertebrates;Writing;biomedical imaging;cancer diagnosis;central database;clinical biomarkers;clinical imaging;clinical translation;college;commercialization;cost effectiveness;data resource;design;digital;graphical user interface;human subject;human subject protection;imaging biomarker;imaging study;informatics infrastructure;machine learning method;machine learning model;member;operation;performance tests;programs;quantitative imaging;radiological imaging;radiologist;radiomics;shared database;statistics;success;translational cancer research;welfare,Clinical Imaging and Data Resources Core,,NIGMS,10756998,1/3/2024 12:00:00 AM,PAR-19-313,5P20GM135009-03,5,P20,GM,135009,03, , ,2/15/2022 12:00:00 AM,12/31/2026 12:00:00 AM,ZGM1-RCB-2,8617,10799161,"MOORE, KATHLEEN N.",Not Applicable,04,Unavailable,848348348,EVTSTTLCEWS5,848348348,EVTSTTLCEWS5,US,35.209223,-97.443781,1524002,UNIVERSITY OF OKLAHOMA,NORMAN,OK,Domestic Higher Education,730199705,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM, ,Research Centers,2024, ,288437, ,271607,72753, , ,, | |
| No NIH Category available,Address;Algorithms;BRCA mutations;Bayesian Modeling;Biological Markers;CA-125 Antigen;Cancer Center;Cancer Patient;Cancer Prognosis;Characteristics;Clinical;Clinical Markers;Confusion;Data;Data Analyses;Data Set;Databases;Decision Making;Diagnosis;Engineering;Evaluation;Guidelines;Gynecologic Oncology;Histopathology;Hybrids;Image;Learning;Machine Learning;Malignant Female Reproductive System Neoplasm;Malignant Neoplasms;Malignant neoplasm of ovary;Medical Imaging;Medical center;Methods;Modeling;Network-based;Oklahoma;Oncologist;Outcome;Pathologic;Pathology;Patients;Performance;Pharmaceutical Preparations;Physicians;Prediction of Response to Therapy;Progression-Free Survivals;Prospective Studies;ROC Curve;Radiology Specialty;Recurrence;Research;Research Personnel;Research Project Grants;Research Support;Sampling;Scheme;Statistical Data Interpretation;Statistical Methods;Technology;Testing;Toxic effect;Training;Treatment Efficacy;Tumor Volume;United States National Institutes of Health;Universities;Validation;X-Ray Computed Tomography;cancer cell;cancer imaging;cancer therapy;chemotherapy;clinical practice;college;computer aided detection;deep neural network;digital;feature selection;graphical user interface;hazard;image processing;imaging biomarker;improved;interest;machine learning model;multidisciplinary;multimodality;novel;overtreatment;particle;pathology imaging;patient prognosis;patient response;patient stratification;patient subsets;personalized chemotherapy;predictive modeling;predictive tools;prognostic;prognostic value;prospective;quantitative imaging;radiological imaging;radiologist;radiomics;response;side effect;support tools;support vector machine;technology development;technology validation;tool;transfer learning;translational cancer research;treatment response;treatment strategy;tumor;tumor heterogeneity;vector,Early Evaluation of Ovarian Cancer Prognosis by Fusing Radiographic and Histopathologic Imaging Information,,NIGMS,10757005,1/3/2024 12:00:00 AM,PAR-19-313,5P20GM135009-03,5,P20,GM,135009,03, , ,2/15/2022 12:00:00 AM,12/31/2026 12:00:00 AM,ZGM1-RCB-2,8620,12614733,"QIU, YUCHEN ",Not Applicable,04,Unavailable,848348348,EVTSTTLCEWS5,848348348,EVTSTTLCEWS5,US,35.209223,-97.443781,1524002,UNIVERSITY OF OKLAHOMA,NORMAN,OK,Domestic Higher Education,730199705,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM, ,Research Centers,2024, ,228844, ,209191,62725, , ,, | |
| No NIH Category available,Age;Antibiotics;Bacteria;Biological Assay;Bronchoalveolar Lavage;Bronchoalveolar Lavage Fluid;Clinical;Communities;Complication;Computer Models;Data;Death Rate;Dedications;Deterioration;Development;Disease;Disease Outcome;Enrollment;Failure;Flow Cytometry;Funding;Future;Genetic;Genome;Goals;Hospitalization;Hospitals;Immune response;Immunosuppression;Infection;Inflammatory Response;Intervention;Intervention Studies;Klebsiella;Knowledge;Lung;Mechanical ventilation;Metadata;Modeling;Morbidity - disease rate;Multi-Drug Resistance;Multiomic Data;Nosocomial pneumonia;Outcome;Pathogenesis;Pathogenicity;Patient-Focused Outcomes;Patients;Pattern;Pneumonia;Pseudomonas aeruginosa;Research;Research Project Grants;Resources;Respiratory Failure;Ribosomal RNA;Sampling;Shotguns;Staphylococcus aureus;Systems Biology;Techniques;Testing;Therapeutic Intervention;Unfavorable Clinical Outcome;Validation;Work;biobank;biomarker identification;biosignature;clinical predictors;cohort;community acquired pneumonia;cytokine;humanized mouse;improved;insight;lung microbiome;metagenomic sequencing;microbiome;microbiota;mortality;mouse model;multiple omics;novel;novel therapeutic intervention;outcome prediction;pathogen;pathogenic bacteria;pneumonia model;pneumonia treatment;predict clinical outcome;predictive modeling;predictive test;response;single-cell RNA sequencing;transcriptome;transcriptomics;ventilator-associated pneumonia,Systems Biology Modeling of Severe Hospital-Acquired Pneumonia,,NIAID,10757344,1/22/2024 12:00:00 AM,RFA-AI-21-065,5U19AI135964-07,5,U19,AI,135964,07, , ,1/17/2018 12:00:00 AM,12/31/2027 12:00:00 AM,ZAI1-LG-M,7274,2101796,"HAUSER, ALAN R",Not Applicable,05,Unavailable,005436803,KG76WYENL5K1,005436803,KG76WYENL5K1,US,42.050479,-87.680046,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,CHICAGO,IL,Domestic Higher Education,606114579,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM, ,Non-SBIR/STTR,2024, ,400789, ,353716,200291, , ,, | |
| No NIH Category available,Academy;Adherence;African American;African American population;Albuminuria;Ambulatory Blood Pressure Monitoring;Aorta;Area;Behavior Therapy;Blood Pressure;Blood Vessels;Cardiac;Cardiovascular Diseases;Cardiovascular system;Chronic Disease;Chronic Kidney Failure;Clinic Visits;Clinical;Cohort Studies;Control Groups;Diet;Dietary Sodium;Dietitian;Disease Outcome;EFRAC;Endothelium;Etiology;Event;Exclusion Criteria;Femur;Heart;Heart Atrium;Hour;Hypertension;Impairment;Incidence;Intake;Intention;Intervention;Knowledge;Left;Left Ventricular Ejection Fraction;Left Ventricular Hypertrophy;Left Ventricular Mass;Measures;Mediating;Medicine;Observational Study;Organ;Outcome;Outcome Study;Participant;Patients;Physiologic pulse;Play;Potassium;Protocols documentation;Quality Control;Randomized;Randomized Controlled Trials;Recommendation;Recording of previous events;Reporting;Risk Factors;Role;Side;Sodium;Standardization;State Medicine;Structure;Testing;Ventricular;Woman;aged;arterial stiffness;biomarker validation;blood pressure control;blood pressure elevation;blood pressure reduction;cardiac magnetic resonance imaging;cardiovascular disorder prevention;cardiovascular disorder risk;cardiovascular risk factor;clinical risk;clinically significant;dietary;endothelial dysfunction;high risk;improved;indexing;men;mortality;primary outcome;recruit;renal damage;risk prediction;secondary analysis;targeted biomarker,A Mechanistic Trial of Dietary Sodium Reduction on Vascular Structure and Function in African Americans,Project NarrativeThe proposed mechanistic trial will test the effect of dietary sodium reduction on cardiac and vascular structureand function in African Americans with elevated blood pressure or hypertension. Findings from this study will fillthe knowledge gap on the underlying mechanisms of dietary sodium intake on cardiovascular disease risk inaddition to blood pressure and could provide further evidence on sodium reduction for the prevention ofcardiovascular disease.,NHLBI,10757365,12/26/2023 12:00:00 AM,PA-20-183,5R01HL155559-03,5,R01,HL,155559,03, ,"REID, DIANE M",1/17/2022 12:00:00 AM,12/31/2026 12:00:00 AM,"Cancer, Heart, and Sleep Epidemiology A Study Section[CHSA]", ,12158465,"MILLS, KATHERINE TERESA",Not Applicable,01,PUBLIC HEALTH & PREV MEDICINE,053785812,XNY5ULPU8EN6,053785812,XNY5ULPU8EN6,US,29.935429,-90.12279,8424601,TULANE UNIVERSITY OF LOUISIANA,NEW ORLEANS,LA,SCHOOLS OF PUBLIC HEALTH,701185665,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,837,Non-SBIR/STTR,2024,671070, ,NHLBI,453799,217271, ,671070,,671070.0 | |
| No NIH Category available,Abate;Address;Adult;Affect;Agonist;Alveolar Bone Loss;Animals;Anti-Inflammatory Agents;Biological;Biological Assay;Biological Markers;Bone Marrow;Bone Resorption;CD4 Positive T Lymphocytes;Cells;Classification;Clinical;Clinical Research;Communities;Complex;Control Animal;Coronary heart disease;Cyclic GMP;Cytokine Network Pathway;Data;Diabetes Mellitus;Disease;Disease Progression;Family member;Flow Cytometry;Genes;Genetic Transcription;Gingiva;Gingival Crevicular Fluid;Goals;Health;Heterogeneity;Human;IFNAR1 gene;IFNAR2 gene;IL17 gene;Incidence;Infiltration;Inflammation;Inflammatory;Inflammatory Response;Innate Immune Response;Interferon Type I;Interferon-beta;Interferons;Interleukin-6;Knock-out;Knockout Mice;Ligation;Ligature;Lipopolysaccharides;LoxP-flanked allele;Macrophage;Measurement;Measures;Mediating;Mediator;Microinjections;Modeling;Mouth Diseases;Multiple Sclerosis;Mus;Myelogenous;Nature;Neutrophil Activation;Neutrophil Infiltration;Osteoclasts;Pathway interactions;Patients;Pattern;Periodontal Diseases;Periodontitis;Phenotype;Play;Population;Predisposition;Prevalence;Production;Proteomics;Research;Research Proposals;Role;Signal Transduction;Staging;Staging System;Stroke;System;Systemic disease;Testing;Therapeutic;Time;Tissues;Tooth Loss;Tooth structure;Validation;Viral Physiology;Wild Type Mouse;adaptive immune response;anakinra;bone loss;cell type;clay;clinically relevant;cohort;conditional knockout;cytokine;disease classification;disease phenotype;follow-up;improved;in vivo;indexing;insight;member;monocyte;nano;nanoparticle;neutrophil;novel;osteoclastogenesis;patient subsets;precursor cell;receptor;response;tool;translational research program,Assessing the role of Type I Interferon (IFN-I) in Periodontal Disease,Project NarrativePeriodontitis is one of the most prevalent inflammatory diseases in humans and harbors heterogeneousdisease phenotypes. A biomarker analysis in stages of a new periodontal profile classification which improvedthe homogeneity within each disease stage identified that Type I interferon played a novel regulatory role inperiodontitis. This translational research program will delineate the mechanism of Type I interferon indampening excess innate and adaptive immune response involved in periodontitis and evaluate the effect of ananoparticle-mediated sustained delivery system that activates and releases Type I IFN locally in periodontitis.,NIDCR,10757654,11/20/2023 12:00:00 AM,PA-20-185,5R01DE032307-02,5,R01,DE,032307,02, ,"CHANDER, PREETHI",1/1/2023 12:00:00 AM,12/31/2027 12:00:00 AM,"Oral, Dental and Craniofacial Sciences Study Section[ODCS]", ,12382584,"ZHANG, SHAOPING ",Not Applicable,01,DENTISTRY,062761671,Z1H9VJS8NG16,062761671,Z1H9VJS8NG16,US,41.664405,-91.542152,3972901,UNIVERSITY OF IOWA,IOWA CITY,IA,SCHOOLS OF DENTISTRY/ORAL HYGN,522421320,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,121,Non-SBIR/STTR,2024,380975, ,NIDCR,245000,135975, ,380975,,380975.0 | |
| No NIH Category available,Address;Algorithms;Architecture;Bayesian Analysis;Bayesian Method;Benchmarking;Biological;Biological Markers;Biological Testing;Cancer Biology;Cancer Patient;Cells;Clinical;Code;Collection;Communities;Complement;Computer software;Computing Methodologies;Cytometry;Data;Data Analyses;Data Set;Development;Dimensions;Generations;Genetic Transcription;Goals;Image;Immunofluorescence Immunologic;In Situ;Individual;Intestines;Investigation;Location;Lung;Machine Learning;Malignant Neoplasms;Malignant neoplasm of ovary;Measurement;Measures;Melanoma;Methodology;Methods;Modality;Modeling;Molecular Profiling;Morbidity - disease rate;Neoplasm Metastasis;Ovarian;Pathologist;Patient-Focused Outcomes;Patients;Pattern;Phenotype;Property;Proteins;Proteomics;Recurrence;Research Project Grants;Resolution;Sampling;Signal Transduction;Software Tools;Spatial Design;Specimen;Statistical Algorithm;Statistical Methods;Statistical Models;Techniques;Technology;Testing;Tissues;Tumor Biology;Validation;Visualization software;Woman;base;cancer type;cell community;cohort;computer framework;data integration;experimental study;improved;innovation;insight;large scale data;malignant phenotype;mortality;multi-scale modeling;multidisciplinary;next generation;novel;open source;patient biomarkers;patient response;patient stratification;programs;rational design;simulation;single-cell RNA sequencing;technology development;theories;tool;transcriptome;transcriptomics;treatment response;tumor;tumor microenvironment;web interface,Probabilistic Multiscale Modeling of the Tumor Microenvironment,Project narrativeBasic patterns in the spatial layout of cells in a tumor can influence patients response to therapy and metastasisand while significant technology development to measure the properties of cells in intact tissues have advancedat pace detailed and robust investigations have been limited by a lack of computational methods for analyzingspatial tumor data. This proposal addresses this gap by developing and validating new statistical methods andalgorithms capable of (i) extracting rich patterns from spatial tumor data (ii) generalizing across multiple spatialtechnologies and (iii) validating on real-world data from ovarian cancer patients. Addressing this gap will lead tonew fundamental discoveries in cancer biology and enable the rational design of spatial biomarkers to enablebiological discovery and a new generation of single cell spatial properties of tumors.,NCI,10757716,12/21/2023 12:00:00 AM,PA-20-185,5R37CA271186-02,5,R37,CA,271186,02, ,"MILLER, DAVID J",1/1/2023 12:00:00 AM,12/31/2027 12:00:00 AM,Modeling and Analysis of Biological Systems Study Section[MABS], ,77906454,"TANSEY, WESLEY ",Not Applicable,12,Unavailable,064931884,KUKXRCZ6NZC2,064931884,KUKXRCZ6NZC2,US,40.764045,-73.956024,5079202,SLOAN-KETTERING INST CAN RESEARCH,NEW YORK,NY,Research Institutes,100656007,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,396,Non-SBIR/STTR,2024,619118, ,NCI,442020,177098, ,619118,,619118.0 | |
| No NIH Category available,Activated Partial Thromboplastin Time measurement;Acute;Address;Admission activity;Adverse effects;Affect;Age;Alternative Therapies;Anticoagulants;Anticoagulation;Antiplatelet Drugs;Biological;Biological Markers;Blood Cell Count;Cerebral Edema;Child;Classification;Clinical;Clinical/Radiologic;Coagulation Process;Coma;Dependence;Depressed mood;Deterioration;Development;Disabled Persons;Disease;Early identification;Edema;Epidemiology;Ethnic Origin;Female of child bearing age;Glasgow Coma Scale;Goals;Headache;Heparin;Hospitals;Hour;Image;Incidence;Infarction;Injury;Intracranial Hemorrhages;Intracranial Sinus Thrombosis;Intravenous;Iowa;Laboratories;Lasso;Left;Life;Logistic Regressions;Lymphocyte;Magnetic Resonance Imaging;Measures;Metabolic;Methodology;Methods;Modeling;Morbidity - disease rate;Nature;Neurologic Examination;Outcome;Patients;Performance;Persons;Phase;Physiological;Population;Predictive Value;Process;ROC Curve;Randomized Controlled Trials;Refractory;Regression Analysis;Reproducibility;Research;Risk;Sampling;Sampling Studies;Seizures;Specific qualifier value;Specificity;Stratification;Stroke;Symptoms;Techniques;Testing;Therapeutic;Thrombophilia;Thrombus;United States National Institutes of Health;Universities;Validation;Venous;Work;X-Ray Computed Tomography;advanced analytics;alternative treatment;analytical method;cerebral vein;clinical biomarkers;clinical practice;cohort;conventional therapy;cost;cytotoxic;design;efficacy evaluation;follow-up;functional outcomes;gradient boosting;high risk;high risk population;imaging biomarker;inflammatory marker;innovation;machine learning method;mental state;model building;mortality;neuroimaging marker;neutrophil;novel;novel marker;novel therapeutics;patient subsets;predictive modeling;prevent;productivity loss;prognostic;prognostic model;prospective;regression trees;response;risk stratification;sex;statistical and machine learning;tool;validation studies;young adult;young woman,Novel risk stratification score for patients presenting with acute Cerebral Venous Sinus Thrombosis,Project NarrativeCVST has a high morbidity and mortality in young adults despite anticoagulation treatment. Herein we proposethe development of a predictive score for early identification of high-risk patients using novel biomarkers andadvanced analytic methods. The score will be potentially used as a stratification tool to evaluate new therapies.,NINDS,10757948,12/30/2023 12:00:00 AM,PA-20-200,5R03NS126804-02,5,R03,NS,126804,02, ,"KOENIG, JAMES I",1/1/2023 12:00:00 AM,12/31/2024 12:00:00 AM,"Neurological, Aging and Musculoskeletal Epidemiology Study Section[NAME]", ,12494734,"ORTEGA-GUTIERREZ, SANTIAGO ",Not Applicable,01,NEUROLOGY,062761671,Z1H9VJS8NG16,062761671,Z1H9VJS8NG16,US,41.664405,-91.542152,3972901,UNIVERSITY OF IOWA,IOWA CITY,IA,SCHOOLS OF MEDICINE,522421320,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,853,Non-SBIR/STTR,2024,77874, ,NINDS,50080,27794, ,77874,,77874.0 | |
| No NIH Category available,American;Aneuploidy;Area;Barrett Esophagus;Benign;Bile Reflux;Biological Assay;Biological Markers;Biometry;Biopsy;Case/Control Studies;Chronic;Clinical;Clinical Management;Collaborations;Collection;Computational Biology;Computational Technique;Coupled;Credentialing;DNA Sequence Alteration;Detection;Development;Devices;Diagnosis;Disease;Dysplasia;Early Diagnosis;Endoscopic Biopsy;Endoscopy;Epithelium;Esophageal Adenocarcinoma;Esophageal Tissue;Esophagus;Evaluation;Functional disorder;Funding;Gastroenterologist;Gastroenterology;Gastroesophageal reflux disease;Genome;Genomics;Goals;Head;High Prevalence;Histologic;Incidence;Institution;Intestines;Left;Lesion;Malignant Neoplasms;Malignant neoplasm of esophagus;Methylation;Modeling;Mutation;Mutation Detection;Outcome;Pathology;Patients;Persons;Ploidies;Positioning Attribute;Precancerous Conditions;Procedures;Process;Prospective cohort;Publishing;Recommendation;Reporting;Research;Resources;Risk;Sampling;Side;Stratification;Structure;TP53 gene;Talents;Testing;Time;Tissue Banks;Tissue Sample;Tissues;Validation;advanced disease;biomarker identification;biomarker panel;cancer genomics;clinical implementation;clinically relevant;clinically significant;cohort;cost;cost effective;disorder risk;epigenomics;genomic biomarker;high risk;improved;innovation;methylation biomarker;novel;novel therapeutics;patient population;patient stratification;predictive marker;premalignant;prevent;progression risk;response;risk stratification;screening;subclonal heterogeneity;surveillance strategy;targeted sequencing;tool,Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagus,PROJECT NARRATIVEWhile millions of Americans harbor the pre-cancerous lesion Barretts esophagus putting them at elevated riskof esophageal cancer many will not develop cancer and this progression is poorly understood. This proposedresearch will determine important contributors to progression and identify how they can be used to predictprogression risk.,NCI,10757959,11/15/2023 12:00:00 AM,PA-20-185,5R37CA269649-02,5,R37,CA,269649,02, ,"YOUNG, MATTHEW R",12/28/2022 12:00:00 AM,11/30/2027 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,11752706,"STACHLER, MATTHEW D",Not Applicable,11,PATHOLOGY,094878337,KMH5K9V7S518,094878337,KMH5K9V7S518,US,37.767442,-122.413937,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",SAN FRANCISCO,CA,SCHOOLS OF MEDICINE,941432510,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,582600, ,NCI,402032,180568, ,582600,,582600.0 | |
| No NIH Category available,ATAC-seq;Accounting;Acetylation;Acetyltransferase;Affect;Alleles;Antigen Presentation Pathway;Antigen-Presenting Cells;B-Cell Antigen Receptor;B-Cell Lymphomas;B-Lymphocytes;BCL2 gene;Biological Assay;Biological Markers;Biology;CREBBP gene;Cancer Etiology;Cell Separation;Cells;ChIP-seq;Chromatin;Clinical;Complex;Coupled;DNA Sequence Alteration;Data;Dependence;Development;Diagnosis;Diagnostic;Disease;Disease remission;Enhancers;Epigenetic Process;Event;Evolution;Fluorescence Microscopy;Follicular Lymphoma;Frequencies;Gene Expression Profile;Genetic;Genetic Transcription;Goals;Human;Incidence;Indolent;Induced Mutation;Inferior;Knock-in Mouse;Knock-out;Knockout Mice;Lesion;Link;Lymphoma;Lymphomagenesis;Maintenance;Malignant - descriptor;Malignant Neoplasms;Malignant lymphoid neoplasm;Mass Spectrum Analysis;Mediating;Memory B-Lymphocyte;Missense Mutation;Modeling;Modification;Molecular;Mouse Strains;Mus;Mutate;Mutation;Nature;Neoplastic Cell Transformation;Non-Hodgkin's Lymphoma;Non-Malignant;Oncogenic;Outcome;Outcome Study;Pathogenesis;Patients;Pattern;Phenotype;Phylogenetic Analysis;Plasma Cells;Proteins;RNA Decay;Recurrence;Relapse;Reporting;Research;Research Proposals;Role;Sampling;Signal Transduction;Somatic Mutation;Structure;Structure of germinal center of lymph node;TNFRSF5 gene;Therapeutic;Therapeutic Intervention;Tumor Suppressor Proteins;United States;Validation;Work;conventional therapy;dosage;founder mutation;improved;in vivo;insight;large cell Diffuse non-Hodgkin's lymphoma;microscopic imaging;mortality;mouse model;mutant;neoplastic;novel therapeutic intervention;patient population;precursor cell;programs;protein expression;recruit;response;single cell analysis;single-cell RNA sequencing;stem cells;synergism;targeted treatment;therapeutic target;transcriptome sequencing;tumor;tumor-immune system interactions,Role of CREBBP missense mutations in lymphomagenesis,RESEARCH NARRATIVEFollicular lymphoma and diffuse large B-cell lymphoma represent the two most common forms of human B celllymphoma and remain incurable in a significant fraction of patients. This research proposal seeks to elucidatehow missense mutations of the CREBBP acetyltransferase the second most frequent genetic alteration inthese tumors contribute to malignant transformation by reprogramming the pre-neoplastic germinal center Bcells as well as the immune microenvironment. The outcome of these studies is expected to further ourunderstanding of the biology of these common cancers and to pave the basis for the development of improvedbiomarkers and therapeutic approaches.,NCI,10758222,12/22/2023 12:00:00 AM,PA-20-185,5R01CA260176-03,5,R01,CA,260176,03, ,"JHAPPAN, CHAMELLI",1/1/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Cancer Molecular Pathobiology Study Section[CAMP], ,9313443,"PASQUALUCCI, LAURA ",Not Applicable,13,PATHOLOGY,621889815,QHF5ZZ114M72,621889815,QHF5ZZ114M72,US,40.8415,-73.9414,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NEW YORK,NY,SCHOOLS OF MEDICINE,100323725,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,396,Non-SBIR/STTR,2024,451334, ,NCI,278601,172733, ,451334,,451334.0 | |
| No NIH Category available,African American;African American population;Anatomy;Benchmarking;Biological;Biological Markers;Cancer Center;Cancer Center Support Grant;Catchment Area;Classification;Clinic;Clinical;Clinical Drug Development;Clinical Investigator;Clinical Trials;Clinical effectiveness;Collaborations;Communities;Conduct Clinical Trials;Disparity;Dose;Drug Combinations;Drug Design;Enrollment;Family;Funding;Genetic;Genetic Transcription;Goals;Immunologic Markers;Incidence;Industry;Institution;International;Intervention;Laboratories;Laboratory Finding;Lead;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of lung;Malignant neoplasm of prostate;Manuscripts;Michigan;Minority Groups;Mission;Molecular;NCI Center for Cancer Research;New Agents;Nuclear;Pathway interactions;Patients;Peer Review;Pharmaceutical Chemistry;Pharmaceutical Preparations;Phase;Phase II Clinical Trials;Population Study;Prediction of Response to Therapy;Process;Publishing;Research;Research Personnel;Research Project Grants;Schools;Scientist;Signal Pathway;Stromal Cells;Stromal Neoplasm;Testing;Therapeutic;Therapeutic Agents;Toxic effect;Traditional Medicine;Translating;Tumor Biology;Tumor Markers;Tumor-infiltrating immune cells;Universities;Work;base;cancer health disparity;cancer therapy;cancer type;chemotherapy;clinical translation;clinical trial enrollment;clinically relevant;drug development;drug discovery;early phase trial;effectiveness validation;follow-up;genomic biomarker;genomic profiling;high throughput screening;improved;interest;member;molecular imaging;molecular marker;multidisciplinary;novel;novel strategies;novel therapeutic intervention;novel therapeutics;patient oriented;personalized medicine;pharmacodynamic biomarker;pharmacokinetics and pharmacodynamics;phase 2 study;phase II trial;phase III trial;programs;psychosocial;racial difference;response;small molecule libraries;structural biology;translational cancer research;translational study;treatment response;treatment trial;tumor;tumor metabolism;tumor microenvironment,Molecular Therapeutics,,NCI,10758226,12/1/2023 12:00:00 AM,PAR-20-043,5P30CA022453-42,5,P30,CA,022453,42, , ,8/8/1997 12:00:00 AM,11/30/2025 12:00:00 AM,ZCA1-RTRB-C,8818,9609623,"AZMI, ASFAR S",Not Applicable,13,Unavailable,001962224,M6K6NTJ2MNE5,001962224,M6K6NTJ2MNE5,US,42.357466,-83.065294,9110501,WAYNE STATE UNIVERSITY,DETROIT,MI,Domestic Higher Education,482024000,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM, ,Research Centers,2024, ,66034, ,42879,23155, , ,, | |
| No NIH Category available,Adult;Age Years;Algorithms;Anhedonia;Artificial Intelligence;Behavior;Behavioral;Biological;Biological Markers;Brain;Clinical;Communities;Computational Technique;Computer Models;Coupling;Data;Decision Making;Diagnosis;Diagnostic;Diffusion;Dimensions;Disease;Economic Burden;Episodic memory;Female;Functional Magnetic Resonance Imaging;Functional disorder;Goals;Health Care Costs;Hippocampus;Impairment;Individual;Intervention;Knowledge;Learning;Libraries;Link;Magnetic Resonance Imaging;Major Depressive Disorder;Maps;Measurement;Measures;Mediating;Memory;Mental Depression;Mental disorders;National Institute of Mental Health;Neurobiology;Neurosciences;Outcome;Patient Selection;Patient Self-Report;Pattern;Positive Valence;Post-Traumatic Stress Disorders;Prevention;Probability;Process;Psychiatry;Psychological reinforcement;Psychophysiology;Public Health;Quality of life;Regulation;Research;Research Domain Criteria;Resistance;Resolution;Rest;Rewards;Risk;Sampling;Schizophrenia;Severities;Signal Transduction;Stimulus;Structure;Symptoms;Techniques;Testing;Time;Unemployment;Ventral Striatum;artificial intelligence algorithm;biomarker validation;brain based;candidate marker;clinical decision-making;clinical practice;cognitive system;cognitive task;experience;flexibility;gray matter;heart rate variability;imaging modality;improved;innovation;mathematical model;memory process;multimodality;neurobiological mechanism;neuroimaging;neuromechanism;novel;pharmacologic;pleasure;predictive marker;preservation;rapid growth;recruit;reward circuitry;reward processing;suicidal risk;therapy resistant;tool;treatment response;white matter,Testing a Memory-Based Hypothesis for Anhedonia,PUBLIC HEALTH NARRATIVEAnhedonia is a transdiagnostic symptom of multiple psychiatric disorders including depression schizophreniaand post-traumatic stress disorder which are linked with increasingly high levels of economic burden related tosubstantial health care costs and unemployment. Anhedonia is independently associated with substantiallyincreased risk of suicide treatment resistance and reduced quality of life yet its biological basis remains elusive.We will use computational models of behavior and cutting-edge neuroimaging techniques in combination withartificial intelligence approaches to biologically define anhedonia with the ultimate goal of improving clinicalpractice for anhedonia through biologically informed clinical decision-making.,NIMH,10758260,10/17/2023 12:00:00 AM,PA-20-185,5R01MH128306-02,5,R01,MH,128306,02, ,"WIJTENBURG, ANDREA",1/1/2023 12:00:00 AM,10/31/2027 12:00:00 AM,Human Complex Mental Function Study Section[HCMF], ,9818424,"YASSA, MICHAEL A","THAYER, JULIAN F.",47,ANATOMY/CELL BIOLOGY,046705849,MJC5FCYQTPE6,046705849,MJC5FCYQTPE6,US,33.64852,-117.82136,577504,UNIVERSITY OF CALIFORNIA-IRVINE,IRVINE,CA,SCHOOLS OF MEDICINE,926970001,UNITED STATES,N,11/1/2023 12:00:00 AM,10/31/2024 12:00:00 AM,242,Non-SBIR/STTR,2024,767246, ,NIMH,488692,278554, ,767246,,767246.0 | |
| No NIH Category available,2019-nCoV;Animal Model;Animals;Anti-viral Response;Appearance;Bioinformatics;Biological;Biological Markers;Blood;COVID-19;COVID-19 pandemic;COVID-19 severity;Cells;Cessation of life;Chiroptera;Clinical;Clinical Trials;Communities;Coronavirus Infections;Data;Data Set;Diabetes Mellitus;Disease;Disease Outcome;Disease Progression;Epigenetic Process;Experimental Models;Generations;Genes;Genetic Screening;Human;Immune response;Infection;Influenza;Influenza A virus;Integration Host Factors;Intervention;Lighting;Link;Measurement;Modeling;Molecular;Molecular Profiling;Mus;Obesity;Outcome;Pathogenesis;Pathogenicity;Pathway interactions;Patients;Pharmaceutical Preparations;Process;Progress Reports;Proteome;Proteomics;Research;Risk Assessment;SARS coronavirus;SARS-CoV-2 infection;Sampling;Severity of illness;Source;Specific qualifier value;System;Systems Biology;Technology;Testing;Therapeutic Intervention;Tissues;Tropism;Vaccination;Validation;Variant;Viral;Viral Proteins;Virus;Virus Diseases;Virus Replication;Zoonoses;biomarker identification;clinically relevant;cohort;companion diagnostics;cross-species transmission;data integration;data management;disease model;epigenome;functional genomics;immunological status;improved;in vivo;induced pluripotent stem cell;influenza infection;influenzavirus;insight;lens;machine learning algorithm;metabolome;mouse model;multidisciplinary;multiple omics;mutant;network models;new therapeutic target;next generation;novel;novel therapeutics;novel virus;pandemic disease;pathogen;personalized medicine;predictive marker;predictive modeling;programs;protein expression;respiratory;response;targeted treatment;therapeutic target;transcriptome;transcriptomics;virus host interaction,SARS-CoV adaptations through a Systems Biology Lens (SYBIL),We propose a systematic approach to study SARS-CoV adaptations through a Systems Biology Lens(SYBIL) in order to generate predictive models of SARS-CoV pathogenesis which will a) allow us to identifybiomarkers for predicting disease outcome b) reveal changes associated with human adaptation and c)provide avenues to explore for new host-directed therapeutic interventions.,NIAID,10758529,1/3/2024 12:00:00 AM,RFA-AI-21-065,5U19AI135972-07,5,U19,AI,135972,07, ,"KWON, KEEHWAN",1/20/2018 12:00:00 AM,12/31/2027 12:00:00 AM,ZAI1-LG-M(S1), ,2104524,"GARCIA-SASTRE, ADOLFO ",Not Applicable,13,MICROBIOLOGY/IMMUN/VIROLOGY,078861598,C8H9CNG1VBD9,078861598,C8H9CNG1VBD9,US,40.790284,-73.946781,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NEW YORK,NY,SCHOOLS OF MEDICINE,100296574,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,855,Non-SBIR/STTR,2024,2534738, ,NIAID,2361792,317874, ,2534738,,2534738.0 | |
| No NIH Category available,2019-nCoV;Ablation;Address;Animal Model;Animals;Biological;Biological Markers;COVID-19 pandemic;COVID-19 patient;Cells;Characteristics;Clinical;Clinical Data;Cohort Studies;Collection;Communities;Coronavirus Infections;Data;Data Collection;Data Set;Dimensions;Disease;Disease Outcome;Early identification;Economics;Elderly;Experimental Animal Model;Generations;Genes;Genetic;Goals;Hamsters;Healthcare Systems;Human;Hypertension;Immune;Immune response;Immunity;Immunization;In Vitro;Individual;Infection;Integration Host Factors;Intervention;Knockout Mice;Licensing;Mediating;Metadata;Modeling;Molecular Profiling;Morbidity - disease rate;Multiomic Data;Mus;Mutation;Nature;Non-Insulin-Dependent Diabetes Mellitus;Obesity;Outcome;Pathology;Patients;Persons;Population;Predisposition;RNA vaccine;Recombinants;Research;Retrospective cohort;SARS coronavirus;SARS-CoV-2 immunity;SARS-CoV-2 infection;SARS-CoV-2 variant;Sampling;Severity of illness;Specimen;Stress;Study models;System;Systems Biology;Testing;Therapeutic Intervention;Training;Vaccinated;Vaccination;Validation;Variant;Viral;Viral Vector;Virus;animal data;bench to bedside;biomarker identification;cohort;comorbidity;data integration;disorder risk;emerging virus;genetic signature;human data;immunological status;in vivo;interest;lens;medical schools;molecular marker;multiple omics;new therapeutic target;pandemic disease;pharmacologic;prospective;recruit;severe COVID-19;sex;transmission process,Project 1 - A systems biology approach to identify early networks and signatures associated with mild and severe SARS-CoV-2 infections in vivo,,NIAID,10758545,1/3/2024 12:00:00 AM,RFA-AI-21-065,5U19AI135972-07,5,U19,AI,135972,07, , ,1/20/2018 12:00:00 AM,12/31/2027 12:00:00 AM,ZAI1-LG-M,7320,2104524,"GARCIA-SASTRE, ADOLFO ",Not Applicable,13,Unavailable,078861598,C8H9CNG1VBD9,078861598,C8H9CNG1VBD9,US,40.790284,-73.946781,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NEW YORK,NY,Domestic Higher Education,100296574,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM, ,Non-SBIR/STTR,2024, ,403954, ,344807,80305, , ,, | |
| No NIH Category available,2019-nCoV;A549;ATAC-seq;Affect;Anti-viral Therapy;Appearance;Biochemical;Biological;Biological Models;COVID-19;COVID-19 pandemic;COVID-19 severity;CRISPR/Cas technology;Candidate Disease Gene;Cell Line;Cells;Cessation of life;ChIP-seq;Chemicals;Chiroptera;Clinical;Clinical Data;Clinical Research;Clustered Regularly Interspaced Short Palindromic Repeats;Coronavirus;Data;Development;Disease;Disease Outcome;Disease Progression;Epigenetic Process;Epithelial Cells;Generations;Genes;Genetic;Genetic Transcription;Hi-C;Human;Immune;Immune response;Infection;Inflammatory;Life Cycle Stages;Link;Lung;Maps;Measurement;Mediating;Modeling;Molecular;Molecular Profiling;Mus;Mutation;Network-based;Outcome;Pathogenicity;Pathway interactions;Post-Translational Protein Processing;Production;Proteins;Proteomics;Role;SARS coronavirus;SARS-CoV-2 variant;Sampling;Sarbecovirus;Severity of illness;Systems Biology;Tertiary Protein Structure;Testing;Tropism;Validation;Variant;Viral;Viral Proteins;Virus;Virus Diseases;Virus Replication;Zoonoses;candidate marker;cell type;clinical biomarkers;cross-species transmission;cytokine;data integration;data modeling;design;epigenomics;experimental study;improved;in silico;in vivo;in vivo Model;induced pluripotent stem cell;insight;knockout gene;lens;loss of function;machine learning algorithm;mutant;novel;novel therapeutics;pandemic disease;pathogen;pneumocyte;post SARS-CoV-2 infection;predictive marker;predictive modeling;protein expression;proteomic signature;receptor;response;single-cell RNA sequencing;small molecule;therapeutic target;transcriptome sequencing;transcriptomics;transmission process;virus host interaction,Project 2 - Ex Vivo Analysis of Coronavirus Tropism Adaptation Replication and Host Response,,NIAID,10758552,1/3/2024 12:00:00 AM,RFA-AI-21-065,5U19AI135972-07,5,U19,AI,135972,07, , ,1/20/2018 12:00:00 AM,12/31/2027 12:00:00 AM,ZAI1-LG-M,7322,2104524,"GARCIA-SASTRE, ADOLFO ",Not Applicable,13,Unavailable,078861598,C8H9CNG1VBD9,078861598,C8H9CNG1VBD9,US,40.790284,-73.946781,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NEW YORK,NY,Domestic Higher Education,100296574,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM, ,Non-SBIR/STTR,2024, ,702405, ,584344,153918, , ,, | |
| No NIH Category available,Accident and Emergency department;Ambulances;Bacterial Infections;Binding;Biological;Biological Assay;Biological Markers;Biosensor;Blood;Blood specimen;Body Fluids;Brain;Cerebrospinal Fluid;Cerebrospinal Fluid Proteins;Cerebrospinal Fluid Rhinorrhea;Cessation of life;Chemistry;Clinical;Color;Craniocerebral Trauma;Decision Making;Detection;Development;Devices;Diagnosis;Diagnostic;Diagnostic tests;Distress;Ear;Emergency Medical Technicians;Emergency medical service;Ensure;Equipment;Evaluation;Extravasation;Eye;Frequencies;Future;Health Care Costs;Healthcare;Hospitalization;Human Resources;In Transferrin;In Vitro;Infection;Instruction;Laboratories;Left;Life;Liquid substance;Medical;Membrane;Meningitis;Methods;Modification;Morbidity - disease rate;Nanostructures;Nose;Operative Surgical Procedures;Optical reporter;Optics;Otorhinolaryngologic Surgical Procedures;Otorrhea;Pathology;Patient risk;Patient-Focused Outcomes;Patients;Performance;Phase;Physicians;Postoperative Care;Process;Property;Proteins;Quality Control;Reporter;Reproducibility;Research;Risk;Rupture;Sampling;Sensitivity and Specificity;Specificity;Specimen;Spinal Puncture;Spine surgery;Stroke;Surface;Surgeon;Surgical complication;TBI Patients;Technology;Testing;Time;Training;Transferrin;Traumatic Brain Injury;Validation;Vendor;Vertebral column;Work;aptamer;commercial prototype;design;digital media;emergency settings;experimental study;improved;in-vitro diagnostics;infection risk;large scale production;manufacturing process;manufacturing scale-up;nanophotonic;novel;phase 2 study;point of care;point-of-care diagnostics;prevent;protein biomarkers;prototype;rapid diagnosis;receptor;scale up;sensor;skull base;standard of care;success;technology platform;trauma surgery;usability,Development of a Colorimetric Sensor for Detection of Cerebrospinal Fluid Leaks,PROJECT NARRATIVECerebrospinal fluid (CSF) leaks occur when the protective fluid surrounding the brain and spine escapes throughtears caused during traumatic brain injuries spinal surgeries and otolaryngological surgeries and if leftundiagnosed increase a patients risk for infections meningitis stroke and death. Chemeleon Inc. is developingan easy-to-use colorimetric biosensor that rapidly changes color in minutes in the presence of CSF a significantadvancement from current detection technologies which require sending samples to external labs for results in4-7 days. Chemeleons CSF biosensor will be operated by physicians and EMTs at the point-of-care providingnear-instantaneous results to help prevent future complications and improve patient outcomes.,NINDS,10758856,12/13/2023 12:00:00 AM,PA-21-259,5R44NS130769-02,5,R44,NS,130769,02, ,"AUBRECHT, TARYN GRACE",1/2/2023 12:00:00 AM,12/31/2024 12:00:00 AM,Special Emphasis Panel[ZRG1-ETTN-C(10)B], ,15669069,"HU, MIN ",Not Applicable,08,Unavailable,079200058,CCJ3QZXNPMN4,079200058,CCJ3QZXNPMN4,US,42.340888,-71.050742,10045397,"DRINKSAVVY, INC.",BOSTON,MA,Domestic For-Profits,021271219,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,853,SBIR/STTR,2024,840440, ,NINDS,562181,224872, ,840440,,840440.0 | |
| No NIH Category available,Applications Grants;Award;Binding;Biological Markers;Biological Process;Biomedical Engineering;Cancer Patient;Cancerous;Cell Line;Cell Physiology;Cells;Chemicals;Collaborations;Color;Compensation;DU145;Data;Disease;Evolution;Failure;Flow Cytometry;Functional disorder;Genetic;Glutamine;Goals;Grant;Histology;Human;Image;Imaging technology;Immune;Immune Evasion;Immunity;Immunologic Monitoring;Immunosuppression;Immunotherapy;In Vitro;Infiltration;LNCaP;Label;Learning;Leucocytic infiltrate;Leukocytes;Magnetic Resonance Imaging;Malignant Neoplasms;Malignant neoplasm of prostate;Mentored Research Scientist Development Award;Mentors;Mentorship;Methods;Modeling;Monitor;Natural regeneration;Optical Methods;PC3 cell line;Peptides;Play;Preparation;Prostate;Protons;Regimen;Reporter Genes;Research;Research Personnel;Safety;Salicylic Acids;Scheme;Selection for Treatments;Signal Transduction;Surface;Testing;Therapeutic;Training;Translating;Tumor Escape;Tumor Immunity;Validation;Visualization;Work;biomaterial compatibility;cancer therapy;career;cell behavior;clinical translation;cytokine;design;detection method;imaging agent;imaging biomarker;imaging detection;immune cell infiltrate;in vivo;insight;molecular imaging;mouse model;new technology;non-invasive imaging;patient response;programmed cell death ligand 1;programs;prostate cancer cell;prostate cancer cell line;prostate cancer model;prostate cancer progression;quantitative imaging;radio frequency;spatiotemporal;success;symposium;therapeutic gene;translational potential;treatment response;tumor;tumor progression;uptake,Imaging Prostate Cancer Immune Evasion using Chemical Exchange Saturation Transfer MRI,NARRATIVEThis award will support Dr. Aline Thomas to obtain an independent research career developing clinically-translatable noninvasive imaging biomarkers to evaluate cell behavior in disease and in response to therapy.Dr. Thomas aims to enhance the utility of MRI (1) by developing imaging agents that can detect immuneevasion and (2) by developing post-processing methods to monitor and quantify these agents when imagedsimultaneously.,NIBIB,10759454,12/28/2023 12:00:00 AM,PA-19-126,5K01EB030612-04,5,K01,EB,030612,04, ,"GATLIN, TINA L",4/1/2021 12:00:00 AM,12/31/2024 12:00:00 AM,ZEB1-OSR-E(O1)S, ,12153149,"THOMAS, ALINE ",Not Applicable,07,RADIATION-DIAGNOSTIC/ONCOLOGY,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,286,Other Research-Related,2024,132303, ,NIBIB,122503,9800, ,132303,,132303.0 | |
| No NIH Category available,Address;Algorithms;Attention;Basal Ganglia;Behavioral;Biological;Biological Markers;Brain;Brain imaging;Brain scan;Caregivers;Caring;Characteristics;Classification;Clinical;Clinical Data;Clinical Treatment;Clinical Trials;Cognition Disorders;Cognitive;Communities;Data;Development;Diagnosis;Eating;Elements;Enrollment;Home;Hospitalization;Hospitals;Lateral;Left;Lesion;Life;Maps;Measures;Medical center;Modeling;Motor;Movement;Neurobiology;Neurology;Optics;Outcome;Paralysed;Parietal;Parietal Lobe;Pathologic;Pathway interactions;Patients;Perception;Prediction of Response to Therapy;Process;Prospective Studies;Quality of life;Recovery;Recovery of Function;Rehabilitation therapy;Reporting;Research;Research Personnel;Scientist;Self Care;Series;Side;Specificity;Sterile coverings;Stroke;Supervision;Symptoms;System;Techniques;Testing;Training;Treatment outcome;Uncertainty;Veterans;Visual;Wheelchairs;Work;behavior prediction;biomarker identification;biomarker validation;candidate identification;candidate marker;care systems;cognitive rehabilitation;effective therapy;evidence base;expectation;experience;fall risk;frontal lobe;frontal lobe cortex;functional disability;functional improvement;functional independence;functional outcomes;hospital readmission;imaging biomarker;improved;innovation;motor recovery;neuroimaging;neuroimaging marker;personalized approach;personalized health care;post stroke;precision medicine;predicting response;predictive marker;prevent;prognostic model;recruit;rehabilitation research;spatial neglect;stroke rehabilitation;stroke survivor;targeted treatment;treatment responders;treatment response;visual motor;white matter,Prism adaptation treatment (PAT) for right brain stroke rehabilitation,After a right brain stroke >50% of veterans experience problems with dressing eating self-careor steering their wheelchairs because their ability to move orient and respond toward the leftside is limited: spatial neglect. Spatial neglect prevents them from functioning independentlyand their needs in the hospital and at home are greatly increased. An effective treatment forspatial neglect is 10 days of visuomotor training while wearing optical prisms (PAT) howevermany clinicians [fail to diagnose spatial neglect and use this approach. In this study we willdevelop a brain scanning test that could objectively identify the veterans with spatial neglectafter stroke who are the best candidates to receive PAT and recover their ability to function.When the research is complete we expect that brain scans done in the hospital can guide theteam to refer veterans to PAT rehabilitation: improving daily life function] and quality of life.,VA,10762944,3/13/2024 12:00:00 AM,RFA-RX-20-003,5I01RX003662-02,5,I01,RX,003662,02, , ,1/1/2023 12:00:00 AM,12/31/2026 12:00:00 AM,Sensory Systems & Communication Disorders[RRD3], ,2792366,"BARRETT, A. M.",Not Applicable,02,Unavailable,079219093,NLLYTWUN5PM5,079219093,NLLYTWUN5PM5,US,42.345187,-72.682919,10033013,NORTHAMPTON VA MEDICAL CENTER,LEEDS,MA,Independent Hospitals,010539764,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Acute Renal Failure with Renal Papillary Necrosis;Anti-viral Agents;Antibiotics;Antimycin A;Aromatic Polycyclic Hydrocarbons;Benchmarking;Biological Markers;Biological Models;Cardiolipins;Cell Physiology;Cell Survival;Cells;Chemical Exposure;Chemicals;Chronic Kidney Failure;Cisplatin;Cysteine;Cytoplasm;Cytoskeleton;Data;Dependence;Dialysis procedure;Disease;Dose Limiting;Environment;Environmental Pollutants;Environmental and Occupational Exposure;Exhibits;Experimental Models;Exposure to;Fumarates;Heat-Shock Proteins 90;Heavy Metals;High Pressure Liquid Chromatography;Human;Incubated;Injury;Injury to Kidney;Keratin;Kidney;Kidney Diseases;Label;Link;Lipids;Mass Spectrum Analysis;Measures;Mercuric chloride;Methods;Mitochondria;Modeling;Modification;Molecular Weight;Non-Steroidal Anti-Inflammatory Agents;Organ Transplantation;Patients;Pattern;Pharmaceutical Preparations;Phenotype;Plasma;Polymyxin B;Proteins;Proteomics;Public Health;Rattus;Recovery;Renal Replacement Therapy;Resolution;Shotguns;Solvents;Source;Spectrometry Mass Electrospray Ionization;Supporting Cell;Tenofovir;Testing;Therapeutic;Therapeutic Agents;Therapeutic Uses;Time;Toxic effect;Trichloroethylene;Tubular formation;Urine;Validation;adduct;anti-cancer;biomarker validation;chemotherapeutic agent;cytotoxicity;environmental agent;exosome;exposed human population;extracellular;halogenation;improved;in vivo;kidney cell;lipidomics;mitochondrial dysfunction;multiple reaction monitoring;nephrotoxicity;novel;novel marker;potential biomarker;protein biomarkers;renal damage;side effect;sulfite oxidase;tandem mass spectrometry;toxicant,Mitochondrial and Cellular Biomarkers of Renal Injury from Environmental and Therapeutic Agents,Project Narrative:The kidneys are frequent targets of both environmental contaminants and several classes oftherapeutic agents that exhibit dose-limiting nephrotoxicity. We will use primary cultures of proximaltubular cells from fresh human kidneys in targeted studies to identify protein lipid and low-molecular-weight metabolite patterns that are associated with exposure to a diverse array of nephrotoxicchemicals. We anticipate validating biomarkers that are linked to chemical mechanism of action arespecific and highly sensitive and correspond to exposure prior to or after onset of only minimal renalinjury.,NIEHS,10762966,1/29/2024 12:00:00 AM,PA-19-056,5R01ES031584-04,5,R01,ES,031584,04, ,"SHAUGHNESSY, DANIEL",4/9/2021 12:00:00 AM,1/31/2025 12:00:00 AM,Systemic Injury by Environmental Exposure[SIEE], ,1877339,"LASH, LAWRENCE H.",Not Applicable,13,PHARMACOLOGY,001962224,M6K6NTJ2MNE5,001962224,M6K6NTJ2MNE5,US,42.357466,-83.065294,9110501,WAYNE STATE UNIVERSITY,DETROIT,MI,SCHOOLS OF MEDICINE,482024000,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,113,Non-SBIR/STTR,2024,368984, ,NIEHS,263892,105092, ,368984,,368984.0 | |
| No NIH Category available,Address;Adjuvant Chemotherapy;Algorithms;Artificial Intelligence;Award;Benign;Bioinformatics;Biopsy;Breast;COVID-19 severity;Cancer Patient;Cardiovascular Diseases;Chemotherapy and/or radiation;Clinical;Collaborations;Communities;Computer Vision Systems;Computer-Assisted Diagnosis;Data;Development;Diagnosis;Diagnostic;Disease;Environment;Exposure to;Eye diseases;Funding;Genomics;Head and neck structure;Health;Image;Image Analysis;Immunotherapy;Journals;Kidney;Kidney Diseases;Legal patent;Life Style;Lung;Machine Learning;Magnetic Resonance Imaging;Malignant - descriptor;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of lung;Malignant neoplasm of prostate;Manuscripts;Marketing;Medicine;Modernization;Multimodal Imaging;National Cancer Institute;Nodule;Oncologist;Ophthalmology;Oropharyngeal;Outcome;Paper;Pathologic;Pathology;Patients;Pattern;Pattern Recognition;Peer Review;Population;Populations at Risk;Prediction of Response to Therapy;Prognosis;Prostate;Proteomics;Publications;Publishing;Radiation therapy;Radiogenomics;Radiology Specialty;Recurrence;Research;Research Personnel;Resources;Risk;Risk Assessment;Risk Marker;San Francisco;Scanning;Scientist;Series;Site;Technology;Tissues;Toxic effect;Translating;Tumor-Infiltrating Lymphocytes;Urologist;Validation;Veterans;Work;X-Ray Computed Tomography;aggressive therapy;artificial intelligence algorithm;cancer diagnosis;cancer immunotherapy;cancer type;career;clinical decision support;clinical investigation;cohort;companion diagnostics;computer infrastructure;computerized;computerized tools;diagnostic tool;digital;digital pathology;disease diagnosis;disease phenotype;experience;head and neck cancer patient;high risk;imaging biomarker;lung basal segment;lung cancer screening;malignant oropharynx neoplasm;military veteran;molecular phenotype;multimodality;novel;oncology program;oral HPV-positive head and neck cancers;pathology imaging;patient subsets;precision medicine;precision oncology;predicting response;prognostication;prostate cancer risk;racial disparity;radiological imaging;radiologist;radiomics;risk prediction;risk stratification;service programs;standard of care;support tools;symposium;tool;treatment response,BLRD Research Career Scientist Award Application,Project Narrative: Dr Madabhushi's pioneering work on artificial intelligence (AI) has enabled the developmentof decision support tools to aid clinicians in treating patients suffering from a variety of cancers (breast prostatelung head and neck) but also cardiovascular kidney and eye disease. Most recently his group adapted AI andradiomics technologies developed for their VA merit project on lung cancer screening for Veterans to digitallyanalyze CT scans to identify the severity of COVID19 disease. His work has recently focused on the use of AIto help eliminate racial disparities in medicine by identifying disease patterns that might be specific to certainpopulations in turn enabling development of population-specific personalized risk calculators. He is applying thisAI approach to disease diagnosis risk stratification outcome and treatment response prediction in Veteranswhere their unique exposure to wartime environments and particular lifestyle choices engenders differentdisease phenotypes compared to the civilian population.,VA,10762980,10/13/2023 12:00:00 AM,RFA-BX-22-022,5IK6BX006185-02,5,IK6,BX,006185,02, , ,10/1/2022 12:00:00 AM,9/30/2027 12:00:00 AM,ZRD1-RCSR-K(01)1, ,8352708,"MADABHUSHI, ANANT ",Not Applicable,05,Unavailable,824835805,JN4QJ2LB2S13,824835805,JN4QJ2LB2S13,US,33.80276,-84.310515,481023,VETERANS HEALTH ADMINISTRATION,Decatur,GA,Independent Hospitals,30033,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Other,2024, , , , , , , ,, | |
| No NIH Category available,Acceleration;Antibody-drug conjugates;Basic Science;Biological Markers;Biopsy;Breast Cancer Cell;Breast Cancer Patient;CRISPR screen;Cell model;Cells;Clinical;Clinical Sciences;Clinical Trials;Combined Modality Therapy;Complement;Complex;Coupled;DNA Damage;DNA Repair;Data;Disease;Dose;Drug Combinations;Drug Targeting;Exhibits;FDA approved;Funding;Immunohistochemistry;Lead;Link;Malignant Breast Neoplasm;Mediating;Modeling;Molecular Analysis;Morbidity - disease rate;Organoids;PARP inhibition;PIK3CG gene;Pathway interactions;Patients;Pharmaceutical Preparations;Phase;Phase Ib/II Clinical Trial;Preclinical Testing;Prediction of Response to Therapy;Prognosis;Progression-Free Survivals;Refractory;Research Personnel;Resistance;SN-38;Sampling;Schedule;Series;Testing;Therapeutic;Therapeutic Trials;Therapeutic Uses;Topoisomerase;Toxic effect;Translational Research;Treatment-related toxicity;Triplet Multiple Birth;Tumor Antigens;Validation;Work;cancer subtypes;chemotherapy;clinical biomarkers;clinical development;clinical trial analysis;clinically relevant;combinatorial;druggable target;exome sequencing;experience;homologous recombination;humanized monoclonal antibodies;improved;improved outcome;in vivo;in vivo evaluation;inhibitor;innovation;irinotecan;mortality;new combination therapies;new therapeutic target;next generation;novel;novel therapeutic intervention;objective response rate;optimal treatments;patient derived xenograft model;patient subsets;pharmacodynamic biomarker;predicting response;repaired;resistance mechanism;response;success;synergism;transcriptome sequencing;translational goal;treatment response;triple-negative invasive breast carcinoma;tumor,Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer,Project NarrativeOur team recently led the clinical development of Sacituzumab Govitecan (SG aka Trodelvy) the first FDA-approved antibody-drug conjugate (ADC) for triple-negative breast cancer (TNBC) leading to substantiallyimproved outcomes for this most aggressive and poor-prognosis breast cancer subtype. Here we propose tobuild on this success by testing a new targeted drug combination incorporating SG for resistant tumors and bydeveloping biomarkers and additional combinations to guide rational use of this new treatment approach. Weseek to move potentially transformative new combination therapies rapidly into clinical trials.,NCI,10763002,12/29/2023 12:00:00 AM,PA-20-185,5R01CA260890-03,5,R01,CA,260890,03, ,"SONG, MIN-KYUNG H",1/1/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Developmental Therapeutics Study Section[DT], ,1980799,"ELLISEN, LEIF W","BARDIA, ADITYA ",08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,395,Non-SBIR/STTR,2024,531794, ,NCI,316544,215250, ,531794,,531794.0 | |
| No NIH Category available,Aging;Aliquot;Amino Acids;Animal Model;Animals;Antibodies;Aotus primate;Area;Behavior;Binding;Biological;Biological Assay;Biological Markers;Biomedical Research;Biotechnology;Breeding;C-reactive protein;CXCL10 gene;CXCR3 gene;Callithrix;Callithrix jacchus jacchus;Cebidae;Cells;Cercopithecidae;Chronic Disease;Clinical;Clinical Trials;Cognition;Communicable Diseases;Data;Development;Enzyme-Linked Immunosorbent Assay;Epitope Mapping;Epitopes;Eukaryotic Cell;Exposure to;Gastrointestinal Hormones;Generations;Genes;Goals;Granzyme;Haplorhini;Health;Homologous Gene;Hormones;Human;Immunologic Techniques;Immunologics;Immunology procedure;Infection;Inflammation;Inflammatory;Institution;Insulin;Interferon Type II;Interleukin-10;Interleukin-4;Interleukin-6;Intervention;Leptin;Longevity;Longitudinal Studies;Macaca;Macaca mulatta;Malaria;Membrane Glycoproteins;Metabolic;Metabolic hormone;Metabolic syndrome;Metabolism;Modeling;Monkeys;Monoclonal Antibodies;Multiple Sclerosis;Mus;National Institute of Allergy and Infectious Disease;National Institute of Mental Health;Neurodegenerative Disorders;Neurology;Neurosciences;Night Monkey;Obesity;Outcome;Pathology;Plasma;Pre-Clinical Model;Primates;Process;Production;Proteins;Protocols documentation;R24;Reagent;Recombinant Proteins;Recombinants;Recommendation;Reporting;Reproduction;Research;Research Personnel;Resources;Rodent;Saimiri;Sampling;Science;Scientist;Social Behavior;South America;South American;Specificity;Stains;Techniques;Technology;Testing;Transfection;Transgenic Organisms;United States;United States National Academy of Sciences;United States National Institutes of Health;Validation;Vision;Western Blotting;adiponectin;age related neurodegeneration;assay development;biomarker identification;cross reactivity;cytokine;enzyme linked immunospot assay;genetic manipulation;human disease;human model;improved;interest;murine monoclonal antibody;nonhuman primate;preclinical study;tool;validation studies;web site,Development of Immunological Reagents for the Identification of New World Monkey Biomarkers,PROJECT NARRATIVEMarmosets squirrel monkeys and owl monkeys are small South American monkeys used in reproductionmetabolism infectious disease aging and neuroscience studies. Identification of biomarkers of inflammationand metabolic hormones is critical for validation of animal models in biomedical research; however availableimmunological reagents for biomarkers from these New World Monkeys are scarce. This application proposesto fill this void by generating recombinant NWM proteins producing mouse monoclonal antibodies againstthem validating immunological assays using these reagents and distributing reagents and related scientificinformation to interested investigators.,OD,10763409,1/23/2024 12:00:00 AM,RFA-OD-19-027,5R24OD030215-03,5,R24,OD,030215,03, ,"TANDON, RITESH",3/15/2022 12:00:00 AM,1/31/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-GGG-A(55)R], ,1891662,"GIAVEDONI, LUIS DAVID",Not Applicable,35,NONE,008133456,U4SCDG6B6NM8,008133456,U4SCDG6B6NM8,US,29.478611,-98.487222,8398001,TRINITY UNIVERSITY,SAN ANTONIO,TX,UNIVERSITY-WIDE,782127200,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,351,Other Research-Related,2024,406228, ,OD,352753,53475, ,406228,,406228.0 | |
| No NIH Category available,Aging;Archives;Biological Assay;Biological Markers;Blood;Blood specimen;Budgets;Cardiovascular Diseases;Cognition;Collection;Country;Data;Data Analyses;Data Collection;Data Reporting;Databases;Diabetes Mellitus;Disease;Dryness;Economic Conditions;Economics;Europe;European;Event;Fostering;Funding;Hand Strength;Health;Health Status;Health Surveys;Health and Retirement Study;Health behavior;Healthcare;Healthcare Systems;Household;Impaired cognition;Income;Individual;Inflammation;International;Intervention;Laboratories;Legal;Life;Life Cycle Stages;Life Style;Link;Lipids;Longitudinal Studies;Measurement;Measures;Mental Health;Non-Insulin-Dependent Diabetes Mellitus;Patient Self-Report;Population;Process;Recording of previous events;Reporting;Respondent;Retirement;Sampling;Spottings;Statistical Data Interpretation;Study models;Testing;Universities;Validation;Variant;Venous;Venous blood sampling;Washington;Work;aged;blood-based biomarker;clinical diagnosis;data harmonization;health care quality;health difference;human old age (65+);instrumental activity of daily living;life history;response;social;socioeconomics;user-friendly,Understanding Cross-National Health Differences at Older Ages and Their Causes,OTHER PROJECT INFORMATION Project NarrativeThe general aim of this project is to exploit the large international variations in health and lifecircumstances in the US and Europe to better understand the causes for these large differences. Theproject specifically analyzes health status as indicated by analyses of a very large set of blood samplescollected from donors in 13 European countries and links that data to the large differences in socio-economic conditions and health care systems at the national level and at the individual level to bio-medical and socio-economic events over the life course.,NIA,10763800,4/18/2024 12:00:00 AM,PA-18-484,5R01AG063944-05,5,R01,AG,063944,05, ,"CHATTERJI, MINKI",9/15/2019 12:00:00 AM,12/31/2024 12:00:00 AM,Social Sciences and Population Studies A Study Section[SSPA], ,2795023,"BOERSCH-SUPAN, AXEL H","CRIMMINS, EILEEN M; WENER, MARK HOWARD",05,Unavailable,054552435,GT28BRBA2Q49,054552435,GT28BRBA2Q49,US,42.369899,-71.113046,1589901,NATIONAL BUREAU OF ECONOMIC RESEARCH,CAMBRIDGE,MA,Research Institutes,021385359,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,608922, ,NIA,462515,146407, ,608922,,608922.0 | |
| No NIH Category available,Ablation;Acute;Arrhythmia;Atrial Fibrillation;Atropine;Autonomic nervous system;Biochemical;Biochemical Markers;Biological Markers;Blood specimen;Cardiovascular system;Chronic;Clinical;Clinical Trials;Coronary sinus structure;Crossover Design;Data;Dose;EKG P Wave;Electrocardiogram;Electrophysiology (science);Experimental Models;Frequencies;Heart Atrium;Hour;Human;Inflammatory;Infusion procedures;Isoproterenol;Laboratories;Lead;Measures;Modality;Monitor;Morbidity - disease rate;Morphology;Myocardial;Neuromodulator;Pathogenesis;Patient Participation;Patient Selection;Patient-Focused Outcomes;Patients;Peripheral;Pharmaceutical Preparations;Physiological;Play;Population;Randomized;Refractory;Regimen;Research Personnel;Role;Sampling;Series;Serum;Surrogate Markers;Testing;Treatment Protocols;Variant;Veins;clinical practice;clinically significant;cytokine;experience;health care delivery;heart rate variability;improved;improved outcome;individual patient;insight;metabolomics;mortality;multidisciplinary;neuropeptide Y;novel;patient subsets;placebo group;randomized clinical trials;response;response biomarker;side effect;smart watch;success;tool;treatment optimization;vagus nerve stimulation,Biomarker-guided optimization of transcutaneous vagal stimulation for atrial fibrillation,NarrativeTranscutaneous vagal stimulation is an emerging promising modality for atrial fibrillation yet patient selectionand stimulation parameters have not been optimized. This proposal will address these unmet needs by aimingto optimize the stimulation parameters of transcutaneous vagal stimulation and guide selection of the idealcandidates for this novel noninvasive therapy for atrial fibrillation using physiological and biochemicalbiomarkers. By introducing an optimized treatment protocol for transcutaneous vagal stimulation thisapproach has the potential to impact clinical practice and improve outcomes among a large number of patients.,NHLBI,10764702,12/15/2023 12:00:00 AM,PA-20-183,5R01HL161008-03,5,R01,HL,161008,3, ,"TINSLEY, EMILY",1/15/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Clinical Integrative Cardiovascular and Hematological Sciences Study Section[CCHS], ,11336331,"STAVRAKIS, STAVROS ",Not Applicable,5.0,INTERNAL MEDICINE/MEDICINE,878648294,GY8NMUZQXVS7,878648294,GY8NMUZQXVS7,US,35.47459,-97.505034,1524003,UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR,OKLAHOMA CITY,OK,SCHOOLS OF MEDICINE,731043609,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,837,Non-SBIR/STTR,2024,379983, ,NHLBI,329616,50367, ,379983,,379983.0 | |
| No NIH Category available,Address;Adopted;Adult;Age;Aging;Alzheimer's Disease;Alzheimer's disease risk;Amyloid beta-Protein;Bayesian Analysis;Behavioral;Biological Assay;Biological Markers;Clinical;Clinical Distribution;Clinical Research;Clinical Trials;Cognitive;Consent;Data;Data Collection;Databases;Dementia;Development;Devices;Discrimination;Disease;Disease Progression;Early identification;Elderly;Encapsulated;Ethnic Origin;Evaluation;Exercise;Exhibits;Functional disorder;Goals;Healthcare;Hippocampus;Impairment;Individual;Investigation;Japanese;Levetiracetam;Link;Longevity;Magnetic Resonance Imaging;Measures;Medicare;Memory;Memory Loss;Memory impairment;Methods;Modeling;Monitor;Neuropsychological Tests;Neuropsychology;Pattern;Performance;Persons;Pharmacologic Substance;Population;Publications;Race;Reporting;Research;Sampling;Screening procedure;Standardization;Stimulus;Structure;Surveys;Tablets;Testing;Time;Training;Treatment Effectiveness;Validation;Variant;age group;age related;clinical development;clinically relevant;cognitive testing;cohort;design;diagnostic screening;diagnostic value;early detection biomarkers;effectiveness evaluation;healthy aging;high risk;human old age (65+);improved;laptop;large scale data;longitudinal design;memory recognition;mild cognitive impairment;object recognition;tau Proteins;tool;touchscreen;wellness visit,Development of the mnemonic similarity task as a tool to address age and dementia-related memory decline,Project NarrativeFor those over 65 age represents the highest risk factor for Alzheimers disease (AD) and our National Plan toAddress Alzheimers Disease makes clear the need for early identification and monitoring of the disease itsprogress and any treatments. There is a critical need for a highly sensitive measure of hippocampal function toassess change in memory and hippocampal function over time both for monitoring of disease progression andto evaluate the effectiveness of treatment approaches. The development of the clinical Mnemonic SimilarityTask will improve sensitivity compared to existing neuropsychological assessments making it an extremelyvaluable tool for tracking progression of disease or decline and critical for determining the effectiveness oftreatments both pharmaceutical and behavioral.,NIA,10764932,2/8/2024 12:00:00 AM,PA-19-056,5R01AG066683-05,5,R01,AG,066683,05, ,"TREVINO, MELISSA",5/1/2020 12:00:00 AM,1/31/2025 12:00:00 AM,Adult Psychopathology and Disorders of Aging Study Section[APDA], ,1906960,"STARK, CRAIG E",Not Applicable,47,OTHER BASIC SCIENCES,046705849,MJC5FCYQTPE6,046705849,MJC5FCYQTPE6,US,33.64852,-117.82136,577504,UNIVERSITY OF CALIFORNIA-IRVINE,IRVINE,CA,SCHOOLS OF ARTS AND SCIENCES,926970001,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,379237, ,NIA,250000,129237, ,379237,,379237.0 | |
| No NIH Category available,Affect;Award;Biological;Biological Assay;Biological Markers;Biomedical Technology;Blood;Characteristics;Chronic;Clinic;Clinical Trials;Communities;Complement;Complex;DNA Modification Process;Data;Data Set;Databases;Development;Diagnosis;Disease;Distress;Epigenetic Process;Etiology;Exanthema;Fatigue;Genes;Genetic;Genetic Markers;Genetic Variation;Genome;Genomics;Genotype;Goals;Gulf War;Gulf War veteran;Headache;Health;Individual;Inflammation;Laboratories;Life;Lipids;Machine Learning;Measures;Medical;Metabolic;Metabolic Pathway;Methods;Methylation;Modernization;Molecular;Neurocognitive;Pain;Participant;Pathway interactions;Patients;Persian Gulf;Persian Gulf Syndrome;Phenotype;Physiological;Preparation;Quality Control;Research;Research Personnel;Research Project Grants;Research Proposals;Resources;Sample Size;Science;Subgroup;Surveys;Symptoms;Systems Biology;Techniques;Testing;Therapeutic Research;Therapeutic Trials;Tissues;Treatment Efficacy;Uncertainty;Validation;Veterans;Work;affective disturbance;analytical tool;biobank;biological systems;biomarker discovery;biomarker identification;biomarker validation;cohort;comorbidity;data integration;data repository;design;effective therapy;epidemiology study;experience;experimental study;gastrointestinal;genetic variant;genome wide association study;genome-wide;immune function;instrument;liquid chromatography mass spectrometry;machine learning method;medical complication;metabolome;metabolomics;mitochondrial dysfunction;persistent symptom;programs;research and development;response;small molecule;symptom cluster,Integrating genomics and metabolomics data to identify molecular characteristics of Gulf War Veterans' illnesses,Gulf War Illness (GWI) is a chronic debilitating illness suffered by Veterans of the 1990-1991 Gulf War.Veterans suffering from GWI are often subject to years of medical uncertainty as they make their way throughmultiple clinics to try to diagnose and ultimately treat their chronic symptoms if possible. Complicating thismedical journey is the absence of biomarkers that can be used to diagnose the conditions and that mightprovide clues as to treatments and etiology. We will use the Gulf War Era Cohort and Biorepository to testmetabolomic biomarkers and combine metabolomics data with genetic variation to identify pathways importantin Gulf War Veterans Illnesses. Our results hold promise for rapid incorporation of findings into biomarkerdiscovery and validation and ultimately treatment studies and clinical trials.,VA,10765603,5/30/2024 12:00:00 AM,RFA-BX-21-011,5I01BX005902-02,5,I01,BX,005902,02, , ,1/1/2023 12:00:00 AM,12/31/2026 12:00:00 AM,ZRD1-SPLD-B(01), ,2499987,"HAUSER, ELIZABETH R",Not Applicable,04,Unavailable,043241082,FWJ7MMLUN2M1,043241082,FWJ7MMLUN2M1,US,36.00896,-78.937364,481065,DURHAM VA MEDICAL CENTER,DURHAM,NC,Independent Hospitals,277053875,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Acceleration;Address;Affect;Age;Alzheimer's Disease;Alzheimer's disease related dementia;Alzheimer's disease risk;Amyloid;Amyloid beta-Protein;Animal Model;Animal Testing;Area;Astrocytes;Atrophic;Attenuated;Automobile Driving;Behavior;Biochemical;Biological Availability;Biological Markers;Blocking Antibodies;Blood;Blood - brain barrier anatomy;Blood Vessels;Brain;Brain-Derived Neurotrophic Factor;Breeding;Budgets;Caregivers;Cerebral small vessel disease;Cerebrovascular Disorders;Characteristics;Chronic;Clinical;Clinical Data;Combined Modality Therapy;Complement;Complement 3 Convertase;Complement 3b;Complement 5a;Complement Activation;Complement Receptor;Complex;Data;Dementia;Demyelinations;Development;Diagnosis;Disease;Dissection;Drug Design;Encephalitis;Euthanasia;Executive Dysfunction;Exhibits;Extravasation;Feedback;Female;Funding;Genes;Genetic Transcription;Glial Fibrillary Acidic Protein;Gliosis;Health;Hemorrhage;Hippocampus;Histologic;Histology;Human;Hypertension;Hypoxia;Image;Impaired cognition;Inflammation;Inflammatory;K-18 conjugate;Knowledge;Label;Lasers;Lesion;Letters;Liquid substance;Longitudinal Studies;Magnetic Resonance Imaging;Measures;Mediating;Medicare;Methods;Microglia;Microscopy;Microvascular Dysfunction;Minor;Modeling;Mus;Nerve Degeneration;Neurons;Oral;Oral Administration;Outcome;Pathogenesis;Pathogenicity;Pathology;Pathway interactions;Patients;Peptides;Pharmaceutical Preparations;Plasma;Play;Prefrontal Cortex;Process;Protein Isoforms;Proteins;Randomized;Rat Transgene;Rattus;Receptor Activation;Resistance;Risk;Risk Factors;Role;Scanning;Serial Magnetic Resonance Imaging;Serum;Signal Transduction;Solid;Stroke;Structure;Study models;Subarachnoid Hemorrhage;Tauopathies;Testing;Thalamic structure;Therapeutic;Time;Transgenic Organisms;Treatment Efficacy;Validation;Vascular Cognitive Impairment;Vascular Dementia;Veterans;aged;antagonist;behavior test;biomarker validation;complement C5b;complement pathway;design;differential expression;drug development;early onset;familial Alzheimer disease;global health;hypertensive;improved;inflammatory marker;inhibitor;insight;interest;male;mitochondrial dysfunction;mixed dementia;monomer;mouse model;multidisciplinary;myelination;neuroimaging;neuroinflammation;neuron loss;neuropathology;neuroprotection;neurotoxic;neurovascular unit;normotensive;novel;novel therapeutics;pharmacokinetics and pharmacodynamics;putamen;response;sex;small molecule inhibitor;synergism;tau Proteins;tau aggregation;transcriptome sequencing;white matter;white matter damage,Role of Complement Receptor Activation in a Mixed Dementia Model,Uncontrolled hypertension is present in 37% of veterans posing several risks to health includingcerebrovascular disease (CBVD) which increases the risk for Alzheimers dementia (AD). In fact 80%of AD patients have some degree of CBVD which can worsen response to drugs designed to targetpure AD which may be one reason why billions of dollars of investiment in drug development fordementia has had little impact on therapies. In addition to the 750000 veterans who currently havedementia there are predicted to be nearly 900000 new cases by 2030 so we validate a new animalmodels and test two drugs to understand how to treat the complexity of this devastating disease whichhas a catastrophic toll on Veteran patients and their caregivers global health Medicare and the USeconomy and Federal budgets that fund the VA.,VA,10765658,5/30/2024 12:00:00 AM,RFA-BX-22-001,5I01BX005919-02,5,I01,BX,005919,02, , ,1/1/2023 12:00:00 AM,12/31/2026 12:00:00 AM,ZRD1-NURD-E(01), ,1899154,"FRAUTSCHY, SALLY ANN",Not Applicable,32,Unavailable,066689118,DL46AKJ5YD48,066689118,DL46AKJ5YD48,US,34.054858,-118.453774,481012,VA GREATER LOS ANGELES HEALTHCARE SYSTEM,LOS ANGELES,CA,Independent Hospitals,900731003,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Address;Affect;Age-associated memory impairment;Alzheimer's Disease;Alzheimer's disease patient;Apolipoprotein E;Biological Markers;Blood Platelets;Brain;CCL2 gene;Carbohydrates;Citrate (si)-Synthase;Clinic;Clinical;Clinical Trials;Clinical dementia rating scale;Cognition;Cognitive;Controlled Study;Data;Development;Diet;Dietary Intervention;Energy Metabolism;Energy-Generating Resources;Enrollment;Eotaxin;Fasting;Fatty acid glycerol esters;Feedback;Funding Opportunities;Future;Generations;Glucose;High Density Lipoproteins;Homeostasis;Human;Hydroxycholesterols;Inflammation;Inflammatory;Insulin;Intake;Intervention;Ketone Bodies;Ketones;Ketosis;Lead;Life Style;Lipids;Literature;Low-Density Lipoproteins;Magnetic Resonance Spectroscopy;Measurement;Measures;Memory;Metabolic;Metabolism;Mitochondria;N-acetylaspartate;Nature;Outcome;Participant;Physiological;Physiology;Plasma;Prevention;Production;Randomized;Research;Research Personnel;Serum;Single-Blind Study;Strenuous Exercise;Stress;Sum;Symptoms;TNF gene;Testing;Therapeutic;Translating;Treatment Efficacy;Triglycerides;Validation;adiponectin;clinical effect;cognitive performance;cognitive testing;cytochrome c oxidase;cytokine;design;feasibility trial;improved;insight;insulin sensitivity;insulin signaling;interest;ketogenic diet;mental state;pharmacologic;post intervention;primary endpoint;randomized controlled study;secondary endpoint;systemic inflammatory response;therapeutic lifestyle change;treatment program,Validation and Mechanistic Interrogation of Metabolism Targeting for AD,PROJECT NARRATIVE We hypothesize manipulating brain energy metabolism through a ketogenic diet (KD) will benefitAlzheimer's disease (AD) patients. To test this we will randomize AD participants to a three-month KD orTherapeutic Lifestyles Changes (TLC) diet intervention. We additionally include biomarker-based measures todefine how a KD affects participant physiology and to identify KD-related mechanisms of action.,NIA,10766114,11/10/2023 12:00:00 AM,PAR-18-175,5R01AG060733-05,5,R01,AG,060733,05, ,"MCLINDEN, KRISTINA",2/1/2019 12:00:00 AM,11/30/2024 12:00:00 AM,Special Emphasis Panel[ZRG1-BBBP-Z(55)R], ,1884835,"SWERDLOW, RUSSELL H.","SULLIVAN, DEBRA K",03,NEUROLOGY,016060860,YXJGGNC5J269,016060860,YXJGGNC5J269,US,39.026584,-94.636347,1484303,UNIVERSITY OF KANSAS MEDICAL CENTER,KANSAS CITY,KS,SCHOOLS OF MEDICINE,661608500,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,641177, ,NIA,689649,365514, ,641177,,641177.0 | |
| No NIH Category available,Adult;Age;Antigen-Presenting Cells;Biological;Biological Markers;Childhood;Cutaneous;DNA Repair;Detection;Epithelium;Event;Exposure to;External Beam Radiation Therapy;Gene Expression;Genetic;Goals;Hour;Human;Immune system;Immunocompromised Host;Immunodeficient Mouse;Immunologic Deficiency Syndromes;Immunologics;Individual;Intervention;Measures;Medical;Modality;Modeling;Morphology;Mus;Neonatal;Nuclear Accidents;Phase;Phenotype;Population;Population Heterogeneity;Probability;Proteins;Proxy;Radiation;Radiation Accidents;Radiation Tolerance;Radiation exposure;Rapid screening;Reactive Oxygen Species;Risk;Sampling;Site;Skin;Skin graft;T-Lymphocyte;Testing;Tissues;Validation;Visual;biomarker discovery;biomarker identification;biomarker validation;cohort;innovation;irradiation;medical attention;mouse model;neonatal human;penis foreskin;point of care testing;predictive marker;radiation detector;radiation effect;radiation risk;radiation-induced injury;radiation-induced tissue damage;risk prediction;stem cell population;tissue injury;vascular bed,Using human skin grafted mice to identify biomarkers of exposure and study effects of radiation on skin,Project Narrative:We propose to study the effects of cutaneous radiation on immunodeficient mice grafted with livingimmunologically intact human skin to identify biomarkers that detect radiation exposure and predict radiationinduced tissue injury. We will develop point-of-care tests to rapidly screen potentially exposed populations andidentify individuals at risk for tissue damage who will require further medical attention.,NIAID,10766675,1/26/2024 12:00:00 AM,RFA-AI-18-045,5U01AI148306-05,5,U01,AI,148306,05, ,"VEDAMONY, MERRILINE M",2/21/2020 12:00:00 AM,1/31/2025 12:00:00 AM,ZAI1-TC-I(S1), ,1879756,"CLARK, RACHAEL ANN",Not Applicable,07,Unavailable,030811269,QN6MS4VN7BD1,030811269,QN6MS4VN7BD1,US,42.336107,-71.107481,1080401,BRIGHAM AND WOMEN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021156110,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,506157, ,OD,364432,141725, ,506157,,506157.0 | |
| No NIH Category available,Adult;Alzheimer's Disease;Anterior;Attention;Behavior;Chronic;Cognitive;Computer Models;Cost Analysis;Costs and Benefits;Cues;Decision Making;Development;Diagnosis;Diagnostic;Diagnostic Factor;Disease;Dissociation;Dorsal;Electroencephalography;Environment;Evaluation;Event-Related Potentials;Feedback;Functional Magnetic Resonance Imaging;Future;General Population;Goals;Impairment;Incentives;Individual;Individual Differences;Investments;Learning;Major Depressive Disorder;Measures;Mental Depression;Mental disorders;Modeling;Motivation;Multivariate Analysis;Nervous System Disorder;Outcomes Research;Output;Parkinson Disease;Participant;Pattern;Personal Satisfaction;Persons;Population;Productivity;Prognosis;Psyche structure;Research;Rewards;Risk Assessment;Schizophrenia;Severities;Signal Transduction;Source;Stimulus;Techniques;Testing;Treatment Efficacy;Treatment outcome;Update;Work;career;cingulate cortex;cognitive control;daily functioning;disorder risk;efficacy testing;endophenotype;expectation;experience;functional magnetic resonance imaging/electroencephalography;health goals;improved;indexing;information processing;insight;neural;neural circuit;novel;potential biomarker;programs;response,Neural and computational mechanisms of motivation and cognitive control,PROJECT NARRATIVEOur findings have the potential to describe the neural computations that form the basis for amotivation a knowntransdiagnostic factor across several psychiatric and neurological disorders including depression andschizophrenia. This research can therefore enable endophenotypic assessment of risk for these disorders andseverity of motivational impairments in subclinical populations providing a potential biomarker to aid in diagnosisand treatment outcome research and facilitating development of and tests of efficacy for therapies aimed atreducing these impairments. This work carries promising future directions for studying motivational impairmentsin depression schizophrenia Alzheimers and Parkinsons and to improve well-being and increase productivityin the general population.,NIMH,10766721,12/22/2023 12:00:00 AM,PA-19-056,5R01MH124849-04,5,R01,MH,124849,04, ,"ROSSI, ANDREW",3/2/2021 12:00:00 AM,6/30/2024 12:00:00 AM,Cognition and Perception Study Section[CP], ,9379674,"SHENHAV, AMITAI ",Not Applicable,01,SOCIAL SCIENCES,001785542,E3FDXZ6TBHW3,001785542,E3FDXZ6TBHW3,US,41.826136,-71.404513,1003201,BROWN UNIVERSITY,PROVIDENCE,RI,SCHOOLS OF ARTS AND SCIENCES,029034202,UNITED STATES,N,1/1/2024 12:00:00 AM,6/30/2024 12:00:00 AM,242,Non-SBIR/STTR,2024,62763, ,NIMH,39350,23413, ,62763,,62763.0 | |
| No NIH Category available,Acute;Adult;Algorithmic Software;Algorithms;Animal Model;Bioinformatics;Biological Assay;Biological Markers;Biometry;Body System;Brain;Clinical;Clinical Management;Collaborations;Data;Decision Analysis;Development;Early Diagnosis;Early identification;Exposure to;Female;Foundations;Future;Gamma Rays;General Population;Genetic;Guidelines;Heart;High-LET Radiation;Inbreeding;Individual;Injury;Injury to Kidney;Interdisciplinary Study;Ionizing radiation;Kidney;Late Effects;Leg;Linear Energy Transfer;Low Dose Radiation;Lung;Mass Spectrum Analysis;Metabolic;Modeling;Neutrons;Nuclear Warfare;Organ;Outcome;Plasma;Practice Guidelines;Predictive Value;Predisposition;Procedures;Radiation;Radiation Accidents;Radiation Injuries;Radiation exposure;Radiobiology;Rattus;Research Design;Resolution;Risk;Risk Assessment;Roentgen Rays;Sampling;Science;Source;Specificity;Sprague-Dawley Rats;Symptoms;Terrorism;Testing;Time;Tissues;United States Food and Drug Administration;Urine;Validation;Water;Whole-Body Irradiation;Work;biomarker development;biomarker identification;biomarker panel;biomarker validation;biosignature;circulating biomarkers;classification algorithm;clinical care;clinical diagnosis;clinical translation;cohort;diagnostic platform;good laboratory practice;improved;in vivo;indexing;irradiation;lipidomics;male;metabolomics;minimally invasive;multiple reaction monitoring;nonhuman primate;novel;organ growth;organ injury;prediction algorithm;predictive marker;predictive panel;predictive test;prototype;radiation risk;sex;software development;stable isotope;tissue injury;validation studies,Development of a minimally invasive biomarker assay to detect delayed radiation injury,PROJECT NARRATIVEThere is a need for rapid accurate and sensitive assays or diagnostic platforms that can confirm exposure andpredict acute and delayed radiation injury to different organs and tissues. While metabolomics has beenproven effective in identifying biomarkers of acute radiation injury there is a paucity of studies focused oncirculating biomarkers that predict the development of organ-specific or delayed radiation injuries. This projectaims to identify metabolic biomarkers of radiation injury to three major organs at risk: kidney heart and brainfollowing exposure to low- and high-linear energy transfer radiation and develop a kit-based assay forassessing and predicting injury in these organ systems.,NIAID,10766742,2/5/2024 12:00:00 AM,RFA-AI-18-045,5U01AI148308-05,5,U01,AI,148308,05, ,"VEDAMONY, MERRILINE M",2/1/2020 12:00:00 AM,1/31/2025 12:00:00 AM,ZAI1-TC-I(S1), ,8876998,"BOERMA, MARJAN ","CHEEMA, AMRITA KAUR",02,PHARMACOLOGY,122452563,VDFYLZPJEAV6,122452563,VDFYLZPJEAV6,US,34.749005,-92.320097,1471106,UNIV OF ARKANSAS FOR MED SCIS,LITTLE ROCK,AR,SCHOOLS OF PHARMACY,722057101,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,395650, ,OD,347227,48423, ,395650,,395650.0 | |
| No NIH Category available,18 year old;Accident and Emergency department;Address;Adult;Antibiotics;Anxiety;Applied Research;Area;Atelectasis;Attention;Behavior;Binding;Biological Markers;Biometry;Blood Pressure;Blood capillaries;C-reactive protein;Calibration;Caring;Chest;Child;Child Care;Childhood;Clinical;Clinical Research;Communicable Diseases;Complement;Confidence Intervals;Decision Making;Derivation procedure;Deterioration;Development;Diagnostic tests;Disease;Disease Progression;Early Intervention;Emergency Care;Emergency research;Enrollment;Ensure;Epidemiology;Evaluation;Goals;Guidelines;Health;Hospitalization;Hospitalized Child;Hospitals;Hour;Infection;Infrastructure;Inpatients;Institution;Intervention;Judgment;Knowledge;Lung Diseases;Machine Learning;Medical;Medical Errors;Medicine;Mentored Patient-Oriented Research Career Development Award;National Heart Lung and Blood Institute;Nosocomial Infections;Observational Study;Outcome;Outpatients;Patients;Pediatric Hospitals;Performance;Phase;Pleural effusion disorder;Pneumonia;Pneumonia Severity Index;Prospective cohort study;Provider;ROC Curve;Recommendation;Research;Resources;Risk;Risk Estimate;Risk Factors;Schools;Severities;Severity of illness;Societies;Standardization;Targeted Research;Testing;Thoracic Radiography;Time;United States;Validation;Variant;Work;adverse outcome;biomarker selection;clinical decision-making;clinical risk;cohort;community acquired pneumonia;cost;evidence base;experience;high risk;hospitalization rates;implementation research;improved;innovation;mortality;multidisciplinary;novel;novel diagnostics;novel therapeutic intervention;pediatric emergency;personalized approach;predictive modeling;predictive tools;prevent;procalcitonin;prognostic tool;prognostication;prospective;respiratory;risk prediction;risk stratification;success;tool;viral detection;virus testing,Derivation and Validation of the Pediatric Community-Acquired Pneumonia Severity (PedCAPS) Score,PROJECT NARRATIVECommunity-acquired pneumonia is the most common serious pediatric infection and a leading cause ofhospitalization for children in the United States yet wide variation in care and limitations of currentmanagement approaches suggest that evidence-based tools are necessary to improve clinical decision-making. This proposal will improve health outcomes for children with pneumonia by developing and broadlyvalidating a risk prediction rule that will make care safer and more effective by minimizing hospitalization andresource use in children who are at low risk of severe disease while targeting more intensive management tothose at higher risk to prevent progression to severe outcomes. Thus the proposed research is relevant to thestrategic objectives of NHLBI to develop novel diagnostic and therapeutic strategies to prevent treat and curelung diseases and to optimize clinical and implementation research to improve health and reduce disease.,NHLBI,10766760,2/14/2024 12:00:00 AM,PA-20-185,5R01HL163692-02,5,R01,HL,163692,02, ,"NATARAJAN, ARUNA R",2/1/2023 12:00:00 AM,1/31/2028 12:00:00 AM,"Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Study Section[IRAP]", ,11510402,"FLORIN, TODD ADAM",Not Applicable,05,Unavailable,074438755,XJ7MMPHBMGM7,074438755,XJ7MMPHBMGM7,US,41.896663,-87.622919,1525701,LURIE CHILDREN'S HOSPITAL OF CHICAGO,CHICAGO,IL,Independent Hospitals,606112991,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,838,Non-SBIR/STTR,2024,1182683, ,NHLBI,976254,206429, ,1182683,,1182683.0 | |
| No NIH Category available,Algorithms;Animal Model;Area;Bile Acids;Biopsy;Cells;Collaborations;Complex;Consultations;Core Facility;Data;Data Analyses;Databases;Dedications;Deoxycholic Acid;Development;Dietary Factors;Dimensions;Elements;Ensure;Environment;Experimental Designs;Gastric Tissue;Genome;Gerbils;Goals;Helicobacter Infections;Helicobacter pylori;Histopathology;Homeostasis;Human Resources;Image;Immunohistochemistry;In Vitro;Individual;Inductively Coupled Plasma Mass Spectrometry;Inflammation;Institution;Iron;Label;Lesion;Lipids;Location;Mass Spectrum Analysis;Measurement;Measures;Metabolic;Methodology;Methods;Modeling;Modification;Molecular;Molecular Analysis;Mus;Organoids;Pathogenicity;Patients;Peptides;Performance;Play;Post-Translational Protein Processing;Predisposing Factor;Preparation;Protein Analysis;Proteins;Proteome;Proteomics;Research;Research Personnel;Resolution;Rodent;Role;Running;Sampling;Services;Sodium Chloride;Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization;Speed;Stomach;Technology;Tissue Microarray;Tissue Sample;Tissue imaging;Tissues;Training;Validation;biological systems;cancer biomarkers;carcinogenesis;experimental study;flexibility;gastric carcinogenesis;gastric organoids;human tissue;imaging modality;informatics tool;inhibitor;instrumentation;lipidomics;malignant stomach neoplasm;mass spectrometer;mass spectrometric imaging;metabolome;metabolomics;molecular imaging;molecular marker;multiple reaction monitoring;new technology;new therapeutic target;novel strategies;premalignant;protein expression;protein metabolite;response;stable isotope;synergism;therapeutic target;tool;treatment response;uptake,Proteomics and Metabolomics,PROTEOMICS AND METABOLOMICS CORE B NARRATIVEThe use of state-of-the-art proteomics metabolomics and imaging mass spectrometry technologies in thethree Projects will identify protein lipid and metabolite changes in gastric cells and bacterial cells that playimportant roles in gastric cancer.,NCI,10767089,4/1/2024 12:00:00 AM,PAR-20-077,2P01CA116087-17,2,P01,CA,116087,17, , ,1/1/2009 12:00:00 AM,2/28/2029 12:00:00 AM,ZCA1-RPRB-T(O1)P,6703,1901713,"SCHEY, KEVIN L",Not Applicable,07,Unavailable,079917897,GYLUH9UXHDX5,079917897,GYLUH9UXHDX5,US,36.143784,-86.800995,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,NASHVILLE,TN,Independent Hospitals,372320011,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,194950, ,176200,18750, , ,, | |
| No NIH Category available,3-Dimensional;Acceleration;Affect;Age;Algorithms;Alzheimer's Disease;Anatomy;Area;Atrophic;Biological Assay;Biological Markers;Brain;Brain Mapping;Brain region;Cadaver;Clinical;Clinical Protocols;Compensation;Data;Data Set;Dependence;Development;Disease;Disease Progression;Early Diagnosis;Elderly;Evolution;Goals;Graph;Hippocampus;Human;Image;Joint repair;Joints;Learning;Life Expectancy;Machine Learning;Magnetic Resonance Imaging;Manuals;Maps;Measures;Methods;Modeling;Morphologic artifacts;Motion;Mutation;Nervous System Disorder;Neurodegenerative Disorders;Patients;Performance;Pharmaceutical Preparations;Phase;Positron-Emission Tomography;Protocols documentation;Public Health;Radial;Radiation exposure;Recovery;Reproducibility;Resolution;Sampling;Scanning;Scheme;Screening procedure;Shapes;Thick;Time;Training;Translating;Treatment Efficacy;Validation;Variant;brain magnetic resonance imaging;brain shape;cerebral atrophy;cognitive testing;convolutional neural network;data analysis pipeline;deep learning algorithm;deep learning model;direct application;entorhinal cortex;follow-up;high risk;high risk population;imaging biomarker;improved;in vivo;innovation;meter;mild cognitive impairment;neuropathology;novel;pre-clinical;reconstruction;respiratory;screening;segmentation algorithm;sex;treatment response;ultra high resolution,Model Based Deep Learning Framework for Ultra-High Resolution Multi-Contrast MRI,Alzheimers disease (AD) is now a major public health concern with life expectancy at an all-timehigh. In US alone the number of affected patients is expected to triple to 13.8 million by the year2050. This proposal focuses on the development of an ultra-high resolution multicontrast MRIprotocol with the objective of improving the accuracy of brain atrophy rates in early AD subjects.The successful completion of this proposal will yield a biomarker that is sensitive to early brainchanges in AD which can facilitate early detection in high risk population measure progressionand quantify the efficacy of brain sparing drugs.,NIA,10767273,12/20/2023 12:00:00 AM,PA-19-056,5R01AG067078-04,5,R01,AG,067078,04, ,"HSIAO, JOHN",1/1/2021 12:00:00 AM,12/31/2025 12:00:00 AM,Emerging Imaging Technologies in Neuroscience Study Section[EITN], ,9043925,"JACOB, MATHEWS ",Not Applicable,01,ENGINEERING (ALL TYPES),062761671,Z1H9VJS8NG16,062761671,Z1H9VJS8NG16,US,41.664405,-91.542152,3972901,UNIVERSITY OF IOWA,IOWA CITY,IA,BIOMED ENGR/COL ENGR/ENGR STA,522421320,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,665142, ,NIA,437364,227778, ,665142,,665142.0 | |
| No NIH Category available,Affect;Algorithm Design;Algorithms;Autoimmune Diseases;Awareness;Biological;Biological Markers;Biometry;Cardiopulmonary;Cause of Death;Characteristics;Clinical;Clinical Management;Complex;Coupling;Data;Depressed mood;Detection;Development;Diagnosis;Disease;Dyspnea;Early Diagnosis;Early Intervention;Early identification;Early treatment;Echocardiography;Fibrosis;Guidelines;Heart failure;Heterogeneity;Image;Imaging Techniques;Machine Learning;Measurement;Measures;Methodology;Methods;Modeling;Morbidity - disease rate;Myocardial;Nature;Outcome;Patients;Performance;Phenotype;Physiological;Population;Positioning Attribute;Process;Prognosis;Pulmonary Heart Disease;Pulmonary Hypertension;Recommendation;Research;Rest;Right Ventricular Dysfunction;Right Ventricular Function;Risk;Secondary to;Stress;Subgroup;Systemic Scleroderma;Technical Expertise;Techniques;Testing;Therapeutic;Therapeutic Intervention;Tissues;Validation;Vascular Diseases;Ventricular;adverse event risk;case control;clinical application;clinical phenotype;clinically relevant;cohort;design;disability;hemodynamics;high risk;imaging biomarker;improved;improved outcome;indexing;innovation;mortality;novel;patient population;patient stratification;patient subsets;predicting response;pressure;prognostic;prospective;pulmonary arterial hypertension;pulmonary vascular disorder;quantitative imaging;rate of change;recruit;response;right ventricular failure;screening;systemic autoimmune disease;targeted treatment,Early Detection of Right Ventricular Dysfunction and Emerging Pulmonary Hypertension in Systemic Sclerosis,PROJECT NARRATIVEIn the current proposal we will (1) employ innovative Bayesian trajectory analyses with machine-learningtechniques to determine if novel strain-based measures of right ventricular (RV) contractile function improvesprediction of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) by identifying at-riskphenotypes earlier in the disease course (2) establish the relationship between strain-based measures of RVcontractility and contractile reserve with direct pressure-volume hemodynamic chamber-level assessmentsand (3) develop a new multivariate algorithm that utilizes innovative imaging based techniques therebyallowing for an early detection strategy that improves upon existing techniques in identifying SSc patients atrisk for emerging RV dysfunction and PAH.,NHLBI,10767319,1/24/2024 12:00:00 AM,PA-20-185,5R01HL162851-02,5,R01,HL,162851,02, ,"XIAO, LEI",2/1/2023 12:00:00 AM,1/31/2028 12:00:00 AM,Respiratory Integrative Biology and Translational Research Study Section[RIBT], ,12012526,"MUKHERJEE, MONICA ",Not Applicable,07,INTERNAL MEDICINE/MEDICINE,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,838,Non-SBIR/STTR,2024,680843, ,NHLBI,421423,259420, ,680843,,680843.0 | |
| No NIH Category available,Acceleration;Acute;Address;Age;Age Years;Alzheimer's Disease;Alzheimer's disease related dementia;Alzheimers disease biomarker;Amyloidosis;Anesthesia procedures;Biological Markers;Brain;CD14 gene;Cerebrum;Characteristics;Clinical;Cognition;Cognitive;Confusion;Data;Delirium;Dementia;Development;Diagnosis;Distress;Elderly;Future;Glial Fibrillary Acidic Protein;Immune response;Impaired cognition;Impairment;Inflammation;Inflammatory Response;Injury;Lead;Light;Magnetic Resonance Imaging;Measures;Morbidity - disease rate;Nerve Degeneration;Neurobehavioral Manifestations;Neurobiology;Neurodegenerative Disorders;Neuropathogenesis;Observational Study;Operative Surgical Procedures;Outcome;Pathogenicity;Pathology;Patients;Perioperative Care;Plan B;Plasma;Positron-Emission Tomography;Postoperative Period;Predisposition;Prevalence;Principal Investigator;Procedures;Proteome;Proxy;Recovery of Function;Research;Risk Assessment;Risk Factors;Severities;Spinal Puncture;Spine surgery;Surgical complication;Symptoms;Syndrome;Tauopathies;Testing;Time;UCHL1 gene;Validation;Work;axon injury;blood-based biomarker;brain magnetic resonance imaging;cerebral atrophy;cost;human old age (65+);improved;improved outcome;innovation;monocyte;nerve injury;neural;neurofilament;neuroinflammation;neuropathology;novel;older patient;postoperative delirium;primary outcome;programs;prospective;risk prediction;secondary outcome;surgical risk;systemic inflammatory response;tau Proteins;transcriptome,Preoperative Occult Neurodegeneration and Postoperative Delirium,Program Director/Principal Investigator (Last First Middle): Crosby Gregory J.NarrativeDelirium is the most common complication of surgery and anesthesia in older patients and is associated withserious morbidity including accelerated decline to dementia. Using biomarkers in plasma as well as MR imagingof cerebral volume this proposal will investigate occult cerebral neurodegeneration pathology characteristic ofAlzheimers disease and related disorders as a risk factor for postoperative delirium and whether surgery-induced inflammation and delirium lead to neural injury that accelerates neurodegeneration and cognitivedecline. By elucidating mechanisms of and plasma biomarkers for postoperative delirium this work will helpimprove risk prediction and the cognitive outcomes of vulnerable older surgical patients.OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page,NIA,10767354,2/1/2024 12:00:00 AM,PA-20-185,5R01AG071741-03,5,R01,AG,071741,03, ,"ROBERTS, LUCI",3/15/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Aging Systems and Geriatrics Study Section[ASG], ,1925757,"CROSBY, GREGORY ","CULLEY, DEBORAH J",07,Unavailable,030811269,QN6MS4VN7BD1,030811269,QN6MS4VN7BD1,US,42.336107,-71.107481,1080401,BRIGHAM AND WOMEN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021156110,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,890922, ,NIA,497722,393200, ,890922,,890922.0 | |
| No NIH Category available,Affinity;Animals;Anti-Bacterial Agents;Antibodies;Antigens;Area;Bioinformatics;Biological;Biological Assay;Biological Markers;Biosensor;Blood;Centers for Disease Control and Prevention (U.S.);Central America;Clinical;Clinical Trials;Coccidioides;Coccidioides immitis;Coccidioides posadasii;Coccidioidomycosis;Coupled;Data;Data Analyses;Dependence;Detection;Development;Diagnosis;Diagnostic;Diagnostic tests;Disease;Engineering;Escherichia coli;Evaluation;Filtration;Future;Gene Proteins;Genes;Genomics;Goals;Harvest;Health Care Costs;Human;Hydrocortisone;Imagery;Immune response;In Vitro;Incidence;Industry;Infection;Intellectual Property;Laboratories;Length of Stay;Marketing;Methodology;Methods;Molecular;Mus;Mycoses;Outcome Study;Patient-Focused Outcomes;Patients;Performance;Phase;Polymers;Process;Protein Secretion;Proteins;Provider;Rapid diagnostics;Recombinant Proteins;Recombinants;Reporting;Reproducibility;Research;Resource-limited setting;Sampling;Serodiagnoses;Serum;Soil;South America;Southwestern United States;Specificity;Structure of parenchyma of lung;Symptoms;System;Techniques;Testing;Transcript;United States;Up-Regulation;Validation;accurate diagnosis;anti-fungal agents;antibody test;antigen diagnostic;antigen test;bacterial community;bioelectronics;biomarker validation;candidate selection;community acquired pneumonia;cost;desert fever;design;detection limit;diagnostic assay;diagnostic development;diagnostic tool;effective therapy;experimental study;fungus;genomic data;imprint;improved;in silico;in vivo;innovation;interdisciplinary approach;manufacture;model organism;novel;novel diagnostics;novel strategies;pathogenic fungus;peripheral blood;radiological imaging;rapid diagnosis;rational design;reagent testing;screening;sensor;statistics;synthetic antibodies;synthetic biology;time use;transcriptome sequencing,Rational design of a novel rapid diagnostic tool for coccidioidomycosis,The incidence of coccidioidomycosis (Valley Fever) caused by the highly infectious soil fungiCoccidioides posadasii and C. immitis has been rapidly growing for decades with currentstatistics estimating 150000 new cases annually in the United States. Serological diagnosis isthe most common method typically detecting the presence of antibodies (four tests on the market)or antigens (one test on the market) and both types of diagnostic tests are based on intellectualproperty owned by companies and thus no commercial provider of antigens or antibodies isavailable. Advanced diagnostic development approaches can help improve our ability to detectand diagnose infection and we propose to use both well-validated methodologies and innovativenovel approaches to improve Valley Fever diagnostics.,NIAID,10767360,12/21/2023 12:00:00 AM,PA-20-195,5R21AI166614-02,5,R21,AI,166614,02, ,"RITCHIE, ALEC",1/23/2023 12:00:00 AM,12/31/2024 12:00:00 AM,"Etiology, Diagnostic, Intervention and Treatment of Infectious Diseases Study Section[EDIT]", ,10429603,"BARKER, BRIDGET MARIE","CATANZARO, DONALD G; WANG, JOSEPH ",02,MISCELLANEOUS,806345542,MXHAS3AKPRN1,806345542,MXHAS3AKPRN1,US,35.192568,-111.656765,482601,NORTHERN ARIZONA UNIVERSITY,FLAGSTAFF,AZ,ORGANIZED RESEARCH UNITS,860114130,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,855,Non-SBIR/STTR,2024,195569, ,NIAID,164973,30596, ,195569,,195569.0 | |
| No NIH Category available,Acetates;Acetylcysteine;Adoption;Affect;Alzheimer's Disease;Amino Acids;Antioxidants;Ascorbic Acid;Autopsy;Biological Assay;Biopsy;Brain;Cancer Model;Caring;Cerebrum;Clinical;Clinical Management;Cysteine;Detection;Diabetes Mellitus;Disease Progression;Disease remission;Etiology;Evaluation;Fumarates;Glutathione;Homeostasis;Image;Imaging Device;Immunohistochemistry;Inflammation;Inflammatory;Injections;Injury to Kidney;Lead;Lesion;Light;Link;Magnetic Resonance Imaging;Measures;Metabolic;Metabolism;Methods;Monitor;Multiple Sclerosis;Mus;Nervous System Disorder;Neurologic;Noise;Non-Invasive Detection;Organ;Outcome;Oxidation-Reduction;Oxidative Stress;Oxidative Stress Pathway;Pancreas;Parkinson Disease;Patients;Penetration;Peripheral;Persons;Play;Population;Pre-Clinical Model;Process;Production;Prognostic Marker;Quality of life;Reaction;Reactive Oxygen Species;Regimen;Relapse;Relapsing-Remitting Multiple Sclerosis;Reporting;Research;Resolution;Role;Scheme;Secondary Progressive Multiple Sclerosis;Signal Transduction;Structure;Techniques;Testing;Therapeutic;Tissues;Toxic effect;Validation;alternative treatment;clinical practice;clinical translation;clinically relevant;cognitive function;data quality;detection method;effective therapy;glucose metabolism;imaging approach;imaging modality;immunomodulatory therapies;improved;in vivo;in vivo imaging;innovation;magnetic resonance spectroscopic imaging;metabolic imaging;multimodality;multiple sclerosis patient;novel;patient population;personalized therapeutic;precision medicine;public health relevance;respiratory;targeted biomarker;targeted treatment;theranostics;tool;translational potential;treatment response;treatment strategy,Theranostic Metabolic Imaging of Oxidative Stress in Multiple Sclerosis.,Public Health Relevance Statement (Project Narrative)The proposed research will validate a new metabolic imaging approach allowing for non-invasive assessment ofoxidative stress in Multiple Sclerosis (MS). Upon clinical translation the methods developed in this proposal willserve to ameliorate clinical management of MS patients help refine therapeutic regimens and ultimately leadto better outcome and patient quality of life.,NIAID,10767368,11/30/2023 12:00:00 AM,PA-20-195,5R21AI171144-02,5,R21,AI,171144,02, ,"GUERAU, MIREIA",1/23/2023 12:00:00 AM,12/31/2024 12:00:00 AM,Emerging Imaging Technologies in Neuroscience Study Section[EITN], ,11399629,"CHAUMEIL, MYRIAM MARIANNE",Not Applicable,11,PHYSICAL MEDICINE & REHAB,094878337,KMH5K9V7S518,094878337,KMH5K9V7S518,US,37.767442,-122.413937,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",SAN FRANCISCO,CA,SCHOOLS OF MEDICINE,941432510,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,855,Non-SBIR/STTR,2024,201875, ,NIAID,125000,76875, ,201875,,201875.0 | |
| No NIH Category available,Achievement;Awareness;Back;Basic Science;Biological Markers;Biological Models;Black race;Breast Cancer Patient;Burkitt Lymphoma;Cancer Burden;Cancer Center;Cancer Center Support Grant;Cancer Control;Catchment Area;Cell Cycle Checkpoint;Cell Death;Cell Survival;Classification;Clinic;Clinical;Clinical Research;Clinical Trials;Collaborations;Communities;Community Outreach;DNA Repair;Dedications;Defect;Development;Ethnic Origin;FGFR2 gene;Funding;Genomic Instability;Genomics;Glucose;Goals;Grant;Human;Image Analysis;Immune Targeting;Immuno-Chemotherapy;Individual;Investigation;Isotopes;Journals;Leadership;Malignant Neoplasms;Malignant neoplasm of lung;Malignant neoplasm of pancreas;Malignant neoplasm of prostate;Medical Oncology;Metabolic;Methodology;Modeling;Molecular;Mutation;NCI-Designated Cancer Center;Neoadjuvant Therapy;Neuroendocrine Tumors;New Jersey;Non-Small-Cell Lung Carcinoma;Oncogenes;Outcome;Paper;Pathway interactions;Patients;Peer Review;Phage Display;Population;Population Sciences;Pre-Clinical Model;Precision therapeutics;Prevention;Productivity;Proteins;Publications;Publishing;Radiation Oncology;Regimen;Research;Research Personnel;Resistance;Sampling;Schools;Science;Screening for cancer;Site Visit;Solid Neoplasm;Specimen;Surgical Oncology;Systems Biology;Therapeutic;Therapeutic Research;Translating;Translations;United States National Institutes of Health;Universities;Validation;bench-to-bedside translation;biomarker identification;cancer biomarkers;cancer genetics;cancer health disparity;cancer immunotherapy;cancer pharmacology;cancer prevention;cancer surgery;cancer therapy;checkpoint therapy;clinical development;clinical investigation;clinical prognostic;clinical translation;clinically actionable;community engagement;early phase clinical trial;early phase trial;first-in-human;imaging approach;immune checkpoint;improved;inhibitor;meetings;member;multidisciplinary;novel diagnostics;novel strategies;novel therapeutic intervention;precision oncology;prognostic index;programs;rational design;recruit;response;response biomarker;targeted treatment;triple-negative invasive breast carcinoma;tumor;tumor immunology;tumor metabolism;tumor-immune system interactions,Clinical Investigation and Precision Therapy,PROJECT NARRATIVENot required per PAR-21-321 (Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers(P30 Clinical Trial Optional),NCI,10767725,2/29/2024 12:00:00 AM,PAR-21-321,2P30CA072720-25,2,P30,CA,072720,25, , ,3/1/1997 12:00:00 AM,2/28/2029 12:00:00 AM,Cancer Centers Study Section (A)[NCI-A],6849,1930337,"GANESAN, SHRIDAR ",Not Applicable,10,Unavailable,090299830,YVVTQD8CJC79,090299830,YVVTQD8CJC79,US,40.520984,-74.473247,10034168,RUTGERS BIOMEDICAL AND HEALTH SCIENCES,Newark,NJ,Domestic Higher Education,071073001,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Research Centers,2024, ,9429, ,6006,3423, , ,, | |
| No NIH Category available,Address;Adverse effects;Afghanistan;Air Pollutants;Alloys;Area;Asia;Asthma;Biological Markers;Breath Tests;Bronchiolitis;California;Cell Culture Techniques;Cells;Chronic Obstructive Pulmonary Disease;Clinic;Clinical Research;Data;Development;Devices;Disease;Disease Management;Down-Regulation;Eicosanoids;Engineering;Enrollment;Environmental Exposure;Environmental Science;Epithelial Cells;Epithelium;Equipment and supply inventories;Exhalation;Exposure to;Fire - disasters;Funding;Goals;Health;Healthcare;Healthcare Systems;Human;In Vitro;Inflammatory;Iraq;Laboratories;Lung;Lung Diseases;Mass Spectrum Analysis;Measures;Mediating;Medicine;Metals;Methods;Military Personnel;Monitor;Newly Diagnosed;Oils;Particulate;Particulate Matter;Pathway interactions;Patients;Physical condensation;Population;Positioning Attribute;Prevention;Recording of previous events;Research;Research Personnel;Respiratory Disease;Respiratory Signs and Symptoms;Risk;Sampling;Site;Soldier;Source;System;Technology;Time;Tracheobronchial;Up-Regulation;Veterans;active duty;airway epithelium;asthma prevention;asthmatic;asthmatic patient;biobank;biomarker discovery;biomarker validation;burn pit;cohort;combustion product;disease phenotype;epidemiology study;experimental study;human tissue;improved;in vivo;metabolomics;mobile sensor;novel;personalized medicine;pilot test;portability;portable monitoring;pulmonary function;research clinical testing;research study;respiratory health;sensor;tool;toxicant;volatile organic compound,Defining Breath VOC Biomarkers to Improve Respiratory Health of Exposed Veterans,The past two decades have seen a high respiratory health burden for military personnel returning fromdeployments in Afghanistan and Iraq. Veterans have developed a variety of respiratory symptoms and beennewly diagnosed with chronic obstructive pulmonary disease asthma and constrictive bronchiolitis.Environmental exposures including volatile organic compounds (VOCs) and particulate matter from burn pitsoil field fires and metal alloys are thought to be causes; however it has been challenging to concurrentlymeasure and associate health metrics with environmental exposures. Breath testing of exhaled VOCbiomarkers has the potential to transform healthcare for veterans in this regard. This project will bring a suite ofportable sensors forward into development and clinical testing with the aim of identifying breath VOCsignatures of exposures and help establish a personalized exposure and medicine platform for veterans.,VA,10767845,5/29/2024 12:00:00 AM,RFA-BX-19-001,5I01BX004965-04,5,I01,BX,004965,04, , ,1/1/2021 12:00:00 AM,9/30/2027 12:00:00 AM,ZRD1-PULM-Y(01), ,7745756,"KENYON, NICHOLAS J.","HARPER, RICHART W",06,Unavailable,127349889,MTB2MR9MAA99,127349889,MTB2MR9MAA99,US,38.571712,-121.297376,10019212,VA NORTHERN CALIFORNIA HEALTH CARE SYS,MATHER,CA,Independent Hospitals,956554200,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Animals;Antibodies;Aromatic Hydrocarbons;Aromatic Polycyclic Hydrocarbons;Award;Biological Assay;Bronchopulmonary Dysplasia;Cancer Center Support Grant;ChIP-seq;Chromatin;Chronic lung disease;Clinical;Communities;Computers and Advanced Instrumentation;Consultations;Core Facility;DNA Methylation;Data;Data Analyses;Data Set;Detection;Development;Dose;Educational workshop;Ensure;Enzymes;Epigenetic Process;Experimental Designs;Experimental Models;Exposure to;Faculty;Funding;Genetic;Genomics;Goals;Grant;Human;Individual;Infrastructure;Institution;Mass Fragmentography;Mass Spectrum Analysis;Measures;Mentors;Metabolic;Methods;Molecular;Molecular Profiling;Neurocognitive Deficit;Outcome;Oxidation-Reduction;Phase;Postdoctoral Fellow;Pregnant Women;Premature Birth;Prevention;Procedures;Progress Reports;Protein Array;Proteomics;Protocols documentation;Research;Research Institute;Research Personnel;Research Project Summaries;Research Support;Resources;Rice;Services;Signal Recognition Particle;Site;Superfund;Techniques;Technology;Training;Validation;Work;analytical method;anti-cancer research;biomarker identification;biomarker signature;bisulfite sequencing;cancer prevention;data management;design;doctoral student;early life exposure;epigenetic profiling;epigenomics;experience;genome sequencing;genome-wide;genomic platform;graduate student;high risk;histone modification;investigator training;metabolomics;multiple omics;neurobehavioral;novel;organizational structure;postnatal;prenatal;preterm newborn;remediation;skills;superfund site;supplemental oxygen;technology platform;training opportunity;transcriptome sequencing;transcriptomics;whole genome,Core D: Research Support Core,Project Narrative Pregnant women living in the vicinity of superfund sites who may be exposed to polyclicaromatic hydrocarbons (PAHs) that emanate from these sites are at a higher risk for pretermdelivery. We hypothesize that prenatal PAH exposure will exacerbate the effects of postnatalsupplemental oxygen in preterm neonates. Accomplishments of the aims of this project shouldbe beneficial to stakeholders such as EPA and ASTDR as we will be able to extrapolate thedoses we give in animals to humans who might be exposed to PAHs.,NIEHS,10767868,1/26/2024 12:00:00 AM,RFA-ES-18-002,5P42ES027725-05,5,P42,ES,027725,05, , ,2/28/2020 12:00:00 AM,1/31/2025 12:00:00 AM,ZES1-JAB-D,6887,1877170,"EDWARDS, DEAN P",Not Applicable,09,Unavailable,051113330,FXKMA43NTV21,051113330,FXKMA43NTV21,US,29.70926,-95.400851,481201,BAYLOR COLLEGE OF MEDICINE,HOUSTON,TX,Domestic Higher Education,770303411,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM, ,Research Centers,2024, ,123761, ,63961,59800, , ,, | |
| No NIH Category available,Academy;Adjuvant;Adjuvant Therapy;American;Automobile Driving;BRAF gene;Biological Markers;Categories;Classification;Clinic;Clinical;Collaborations;Colon Carcinoma;Cutaneous Melanoma;DNA;Data;Data Set;Decision Making;Dermatology;Diagnostic Neoplasm Staging;Disease;Enrollment;Epigenetic Process;Event;Excision;Gene Mutation;Genes;Germ-Line Mutation;Goals;Guidelines;Histopathology;Immunotherapeutic agent;Immunotherapy;Infiltration;Inherited;Malignant Breast Neoplasm;Measurement;Measures;Melanoma;Melanoma patient;Metastatic Melanoma;Methods;Methylation;Mitosis;Modeling;Molecular;Multicenter Trials;Mutation;NF1 gene;National Comprehensive Cancer Network;Nucleic Acid Regulatory Sequences;Operative Surgical Procedures;Outcome;Pathogenicity;Patient Selection;Patient risk;Patients;Pharmaceutical Preparations;Placebos;Population;Primary Neoplasm;Probability;Prognostic Marker;Promoter Regions;Prospective cohort;Publications;Publishing;RNA-Directed DNA Polymerase;Recommendation;Recurrence;Recurrent tumor;Resected;Risk;Sampling;Site;Staging System;Standardization;Subgroup;Techniques;Telomerase;Testing;Therapeutic;Thick;Toxic effect;Treatment Effectiveness;Treatment-related toxicity;Tumor-Derived;Ulcer;Validation;Variant;anti-PD-1;biomarker validation;candidate marker;clinical biomarkers;cohort;cost;disease prognosis;follow-up;genetic variant;high risk;improved;interest;molecular pathology;mutational status;neoplastic cell;overtreatment;pembrolizumab;placebo group;predictive modeling;prevent;prognostic;prognostic tool;prognostic value;prognostication;promoter;prospective;randomized placebo-controlled clinical trial;randomized clinical trials;relapse risk;standard of care;survival outcome;tool;tumor;validation studies,TERT epigenetic and genomic variants in stage II melanoma as biomarkers of outcome,PROJECT NARRATIVEThe recent approval of adjuvant immunotherapy for stage II melanoma has brought a new urgency to improvingour methods to accurately identify patients who may benefit from adjuvant therapy and distinguish them fromsurgically cured patients who could only be potentially harmed by the treatment. Treatment can reduce thechance of tumor recurrence; however most stage II melanoma patients are surgically cured and will never recurso adjuvant therapy is unnecessary. The goal of this project is to test the ability of candidate biomarkers toimprove our current methods of distinguishing surgically cured patients from those at significant risk of post-surgical recurrence.,NCI,10767943,12/26/2023 12:00:00 AM,PAR-20-292,5R21CA277480-02,5,R21,CA,277480,02, ,"THURIN, MAGDALENA",2/1/2023 12:00:00 AM,1/31/2025 12:00:00 AM,ZCA1-SRB-P(O1)S, ,1895872,"POLSKY, DAVID ",Not Applicable,12,DERMATOLOGY,121911077,M5SZJ6VHUHN8,121911077,M5SZJ6VHUHN8,US,40.669895,-73.974354,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NEW YORK,NY,SCHOOLS OF MEDICINE,10016,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,188198, ,NCI,111031,77167, ,188198,,188198.0 | |
| No NIH Category available,Analytical Biochemistry;Aromatic Polycyclic Hydrocarbons;Bioinformatics;Biological Assay;Biological Markers;Blood;Cancer Center;Cancer Center Support Grant;Carcinogens;Chemical Exposure;Chemicals;Chemoprevention;Chromatography;Complex;Computer software;Cotinine;Coupled;DNA;DNA Adducts;DNA-protein crosslink;Data;Data Analyses;Data Set;Dedications;Educational process of instructing;Facility Accesses;Funding;Gas Chromatography;Goals;Hemoglobin;Hour;Human;Laboratories;Liquid Chromatography;Maintenance;Mass Spectrum Analysis;Measures;Methods;Nicotine;Nitrosamines;Nucleic Acids;Nucleosides;Oligonucleotides;Peptides;Plasma;Postdoctoral Fellow;Prevention program;Process;Proteins;Proteome;Proteomics;Research Personnel;Resource Sharing;Resources;Running;Saliva;Services;Software Tools;Speed;Supervision;Tobacco;Training;Urine;Vendor;Work;adduct;bioinformatics tool;biomarker validation;carcinogenesis;experience;frontier;graduate student;instrument;instrumentation;mass spectrometer;member;metabolomics;method development;operation;small molecule;tobacco products;volatile organic compound,Analytical Biochemistry Shared Resource,,NCI,10768157,3/21/2024 12:00:00 AM,PAR-21-321,2P30CA077598-26,2,P30,CA,077598,26, , ,6/1/1998 12:00:00 AM,1/31/2029 12:00:00 AM,Cancer Centers Study Section (A)[NCI-A],6980,7069558,"VILLALTA, PETER WILLIAM",Not Applicable,05,Unavailable,555917996,KABJZBBJ4B54,555917996,KABJZBBJ4B54,US,44.975143,-93.227003,1450402,UNIVERSITY OF MINNESOTA,MINNEAPOLIS,MN,Domestic Higher Education,554552070,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM, ,Research Centers,2024, ,91797, ,59224,32573, , ,, | |
| No NIH Category available,Amino Acid Sequence;Analytical Biochemistry;Antibodies;Applications Grants;Base Sequence;Basic Science;Bioinformatics;Biological Markers;Cancer Center Support Grant;Clinical;Clinical Research;Collaborations;Coupled;DNA;DNA Sequence;Data;Development;Diagnosis;Doctor of Philosophy;Environment;Experimental Designs;Follow-Up Studies;Funding;Galaxy;Generations;Genetic;Genomics Shared Resource;Immune response;Immune system;Immunooncology;Immunotherapeutic agent;Informatics;Malignant Neoplasms;Mass Spectrum Analysis;Metagenomics;Microbe;Minnesota;Molecular;Multiomic Data;Peptides;Proteins;Proteome;Proteomics;RNA Sequences;Records;Research;Research Design;Research Personnel;Resolution;Resource Sharing;Resources;Sampling;Services;Software Validation;Supercomputing;Technology;Translational Research;Universities;Variant;Work;anti-cancer research;bioinformatics tool;cancer genomics;cancer type;carcinogenesis;data integration;diagnostic biomarker;flexibility;genomic locus;host-microbe interactions;immunogenicity;improved;member;metabolomics;metaproteomics;microbial community;microbiome;microbiome research;multiple omics;neoantigens;next generation;next generation sequencing;novel;predictive tools;programs;proteogenomics;research study;success;tool;transcriptome sequencing;translational study,Proteogenomics Shared Resource,,NCI,10768165,3/21/2024 12:00:00 AM,PAR-21-321,2P30CA077598-26,2,P30,CA,077598,26, , ,6/1/1998 12:00:00 AM,1/31/2029 12:00:00 AM,Cancer Centers Study Section (A)[NCI-A],6988,6363230,"GRIFFIN, TIMOTHY J.",Not Applicable,05,Unavailable,555917996,KABJZBBJ4B54,555917996,KABJZBBJ4B54,US,44.975143,-93.227003,1450402,UNIVERSITY OF MINNESOTA,MINNEAPOLIS,MN,Domestic Higher Education,554552070,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM, ,Research Centers,2024, ,79081, ,51020,28061, , ,, | |
| No NIH Category available,Academic Medical Centers;Acute;Age;Algorithms;Benchmarking;Biological Assay;Biological Markers;Blood;Blood Proteins;Blood specimen;Bone Marrow;Bone Marrow Stem Cell;Burn injury;Cell Culture Techniques;Cellular Structures;Color;Computer software;Confidence Intervals;Data;Data Analyses;Detection;Development;Devices;Diagnostic Equipment;Dose;Exposure to;FDA approved;Flow Cytometry;Fluorescence;Future;Hematology;Hematopoietic;Human;Image;Imagery;Immune;Immunoassay;In Vitro;Individual;Industrial Accidents;Inflammation;Inherited;Injury;Ionizing radiation;Kinetics;Laboratories;Leukocytes;Linear Regressions;Lymphocyte;Machine Learning;Mass Screening;Measures;Medical;Medical center;Modeling;Mus;Noise;Nuclear Accidents;Patients;Performance;Persons;Physiological;Population;Process;Proteins;Protocols documentation;Radiation;Radiation Accidents;Radiation Dose Unit;Radiation Tolerance;Radiation exposure;Reproducibility;Research Design;Roentgen Rays;Saliva;Screening procedure;Surface Antigens;System;Techniques;Testing;Time;Toxic effect;Trauma;Triage;Uncertainty;Urine;Variant;Vision;White Blood Cell Count procedure;absorption;biodosimetry;biomarker identification;biomarker panel;biomarker performance;biomarker validation;brca gene;data exploration;design;dirty bomb;disease-causing mutation;dosimetry;humanized mouse;in vitro testing;in vivo;in-vitro diagnostics;ionization;irradiation;machine learning algorithm;mathematical model;medical countermeasure;micronucleus;nonhuman primate;nonlinear regression;performance tests;peripheral blood;point of care;predictive modeling;protein biomarkers;response;response biomarker;sex;stem;stem cells,Development of FAST-DOSE assay system for the rapid assessment of acute radiation exposure individual radiosensitivity and injury in victims for a large-scale radiological incident,NARRATIVEWe have developed a high-throughput biodosimetry device the FAST-DOSE (FluorescentAutomated Screening Tool for Dosimetry) assay system to measure radiation-responsiveproteins in human blood leukocytes for retrospective estimation of radiation dose. Studies aredesigned to validate and test the performance of the blood protein biomarker panel to accuratelypredict absorbed dose after ionizing radiation exposure. We will correlate biomarker expressionlevels and time kinetics with hematopoietic injury based on peripheral blood leukocyte countsand bone marrow toxicity in humanized mice.,NIAID,10768565,1/5/2024 12:00:00 AM,RFA-AI-18-045,5U01AI148309-05,5,U01,AI,148309,05, ,"VEDAMONY, MERRILINE M",2/1/2020 12:00:00 AM,1/31/2025 12:00:00 AM,ZAI1-TC-I(S1), ,8290655,"TURNER, HELEN C",Not Applicable,13,RADIATION-DIAGNOSTIC/ONCOLOGY,621889815,QHF5ZZ114M72,621889815,QHF5ZZ114M72,US,40.8415,-73.9414,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NEW YORK,NY,SCHOOLS OF MEDICINE,100323725,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,484150, ,OD,298858,185292, ,484150,,484150.0 | |
| No NIH Category available,AR gene;Acceleration;Acetates;Address;African American;Androgen Receptor;Androgens;Armenia;Attention;Biological Models;Biological Process;Biostatistics Core;CDK4 gene;Cancer Center;Cancer Center Support Grant;Cancer Patient;Castrate sensitive prostate cancer;Catchment Area;Cells;ChIP-seq;Clinical;Clinical Investigator;Clinical Trials;Collaborations;Community Outreach;Data;Data Science;Detection;Development;Direct Costs;Early treatment;Elements;Enhancers;Epigenetic Process;Funding;Genes;Genets;Institution;International;Length;Link;Malignant Neoplasms;Malignant neoplasm of prostate;Massachusetts;Mediating;Mission;Mutate;Mutation;Nature;Neoadjuvant Therapy;Neoplasm Metastasis;Nonmetastatic;PD-1 blockade;Paper;Patients;Peer Review Grants;Phenotype;Prostate;Publishing;RNA Splicing;Reporting;Repression;Research;Research Design;Research Personnel;Resistance;Resource Sharing;Resources;Sampling;Series;Signal Transduction;Structure;Surrogate Endpoint;Training;Tumor Suppressor Genes;Upstream Enhancer;Variant;abiraterone;androgen deprivation therapy;antagonist;biomarker driven;cancer biomarkers;cancer cell;cancer epidemiology;cancer genetics;castration resistant prostate cancer;clinical practice;clinical translation;collaborative trial;community engagement;constitutive expression;efficacy evaluation;enzalutamide;exome sequencing;gene repression;genome sequencing;genome wide association study;genome-wide;genomic biomarker;improved;improved outcome;in vivo;inhibitor;inter-institutional;member;men;multidisciplinary;next generation;novel;patient population;phase II trial;phase III trial;programmed cell death ligand 1;programs;prostate cancer risk;resistance mechanism;risk stratification;transcriptome;tumor;tumor progression;whole genome,Program 03 Prostate Cancer,Project NarrativeNot Applicable.,NCI,10768660,11/22/2023 12:00:00 AM,PAR-20-043,5P30CA006516-59,5,P30,CA,6516,59, , ,3/10/1997 12:00:00 AM,11/30/2026 12:00:00 AM,Cancer Centers Study Section (A)[NCI-A],7149,1863884,"BALK, STEVEN P.",Not Applicable,7.0,Unavailable,076580745,DPMGH9MG1X67,076580745,DPMGH9MG1X67,US,42.337593,-71.108279,1464901,DANA-FARBER CANCER INST,BOSTON,MA,Independent Hospitals,022155450,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM, ,Research Centers,2024, ,40622, ,40622,0, , ,, | |
| No NIH Category available,Address;American Society of Clinical Oncology;Award;Basic Science;Biological;Biology;CTLA4 gene;Cancer Center;Cancer Center Support Grant;Catchment Area;Cells;Classification;Clear cell renal cell carcinoma;Clinical Trials;Collaborations;Combined Modality Therapy;Community Health Education;Core Facility;Dana-Farber Cancer Institute;Development;Direct Costs;Disease;EZH2 gene;Early Diagnosis;Ensure;Funding;Future;Goals;Grant;Immunologics;Incidence;Infrastructure;Institution;International;Kidney Neoplasms;Malignant Neoplasms;Massachusetts;Medicine;Mission;Molecular;Nature;New Agents;Nivolumab;Nobel Prize;Oxygen;PD-1 blockade;Paper;Pathway interactions;Patient-Focused Outcomes;Patients;Peer Review Grants;Phenotype;Play;Population;Positioning Attribute;Pre-Clinical Model;Prognosis;Publishing;Randomized;Renal Carcinoma;Research Personnel;Research Training;Rewards;Role;Seminal;Series;Signal Transduction;Strategic Planning;Structure;Surrogate Markers;System;Testing;Training;Training and Education;Validation;Vascular Endothelial Growth Factors;Work;antagonist;anti-PD-1/PD-L1;anti-cancer research;bevacizumab;cancer infiltrating T cells;cancer prevention;clinical development;community engagement process;disparity reduction;drug development;early detection biomarkers;effective therapy;genetic signature;improved;inhibitor;innovation;inter-institutional;member;new therapeutic target;novel;pembrolizumab;phase I trial;phase II trial;phase III trial;predictive marker;programmed cell death ligand 1;programmed cell death protein 1;programs;standard of care;symposium;treatment response;tumor,Program 52: Kidney Cancer,Project NarrativeNot Applicable.,NCI,10768696,11/22/2023 12:00:00 AM,PAR-20-043,5P30CA006516-59,5,P30,CA,006516,59, , ,3/10/1997 12:00:00 AM,11/30/2026 12:00:00 AM,Cancer Centers Study Section (A)[NCI-A],7164,10412700,"CHOUEIRI, TONI ",Not Applicable,07,Unavailable,076580745,DPMGH9MG1X67,076580745,DPMGH9MG1X67,US,42.337593,-71.108279,1464901,DANA-FARBER CANCER INST,BOSTON,MA,Independent Hospitals,022155450,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM, ,Research Centers,2024, ,41121, ,36778,4343, , ,, | |
| No NIH Category available,Address;Benign;Biological Markers;Blinded;Blood;Blood Plasma Volume;Blood Tests;CA-19-9 Antigen;Cancer Detection;Cancer Patient;Categories;Circulation;Clinic;Clinical;Cohort Studies;Collection;Cyst;Cytolysis;Data;Death Rate;Dependence;Detection;Development;Diagnosis;Diagnostic;Diagnostic Procedure;Disease;Endoscopic Ultrasonography;Evaluation;Financial cost;Fine needle aspiration biopsy;Frequencies;Health;High Resolution Computed Tomography;Hypoxia;Image;Imaging Techniques;Individual;Investigation;Knowledge;Label;Lesion;Lipids;Magnetic Resonance Imaging;Malignant Neoplasms;Malignant neoplasm of pancreas;Methods;Microelectrodes;Microfluidic Microchips;Monitor;Necrosis;Organelles;Pancreas;Pancreatic Cyst;Pancreatic Diseases;Pancreatic Ductal Adenocarcinoma;Patients;Plasma;Probability;Procedures;Proteins;Recovery;Research;Research Personnel;Retrospective cohort;Risk;Sampling;Source;Symptoms;Techniques;Technology;Time;Translating;Tumor-Derived;Validation;Work;acute pancreatitis;biomarker panel;blood-based biomarker;cancer type;candidate marker;clinical development;cost;early detection biomarkers;efficacy evaluation;exosome;extracellular vesicles;follow-up;nanoparticle;novel;pancreatic cancer patients;particle;patient stratification;premalignant;protein biomarkers;screening;technology platform;tumor,Distinguishing Pancreatic Cancer from Benign Pancreatic Disease using Nanoparticle-based Biomarkers,Project NarrativeThis project evaluates biomarkers carried by tumor-derived extracellular vesicles for efficacy in stratifyingpatients with pancreatic cysts into categories of high-probability and low-probability for the presence ofpancreatic cancer thereby identifying patients who would benefit from an invasive fine needle aspiration biopsyof the pancreas. The use of label-free high conductance dielectrophoresis technology will enable simultaneousrecovery of these different nanoparticle types from plasma for biomarker detection. This research will generatenew knowledge supporting the development of a nanoparticle-based biomarker panel for the detection ofpancreatic cancer while also helping to enable the use of nanoparticle-based biomarkers for diagnosticapplications in the clinic.,NCI,10769729,12/13/2023 12:00:00 AM,PAR-20-053,5R37CA258787-03,5,R37,CA,258787,03, ,"YOUNG, MATTHEW R",1/1/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,8795495,"IBSEN, STUART DUNCAN",Not Applicable,01,INTERNAL MEDICINE/MEDICINE,096997515,NPSNT86JKN51,096997515,NPSNT86JKN51,US,45.49882,-122.685647,6297007,OREGON HEALTH & SCIENCE UNIVERSITY,PORTLAND,OR,SCHOOLS OF MEDICINE,972393098,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,448091, ,NCI,292074,156017, ,448091,,448091.0 | |
| No NIH Category available,Affect;Aftercare;Biological;Biological Markers;Biopsy;Cancer Model;Cancer Patient;Cell Line;Cell Physiology;Cell Transplantation;Cells;Cellular Metabolic Process;Chemicals;Citric Acid Cycle;Clinic;Clinical;Clinical Trials;Cytostatics;Data;Detection;Diagnosis;Disease;Enzymes;Evaluation;Exhibits;FRAP1 gene;Fatty Acids;Future;Gene Expression;Gene Expression Profile;Gene Expression Profiling;Genes;Genomics;Glycolysis;Goals;Hexokinase 2;Hour;Hyperactivity;Hypoxia;Image;Imaging Techniques;Immune system;In Vitro;Knowledge;Lactic acid;Lymphoma;Lymphoma cell;Malignant Neoplasms;Measurement;Measures;Metabolic;Metabolic Pathway;Metabolism;Methods;Mission;Modeling;Monitor;Mus;Neoplasms;Non-Invasive Detection;Outcome;Pathway interactions;Patients;Pentosephosphate Pathway;Pharmaceutical Preparations;Phosphorylation;Phosphotransferases;Physiologic pulse;Positron-Emission Tomography;Preclinical Testing;Protein-Serine-Threonine Kinases;Proteins;Proteome;Proteomics;Public Health;Radiation;Reporting;Research;SDZ RAD;Serine;Signal Pathway;Signal Transduction;Sirolimus;Staging;Standardization;Sterols;System;Testing;Therapeutic Effect;Therapeutic Intervention;Tumor Markers;Tumor Volume;United States National Institutes of Health;Work;Xenograft Model;Xenograft procedure;biomarker selection;biomarker validation;cancer cell;cancer therapy;cancer type;candidate identification;candidate marker;cell growth;early detection biomarkers;fluorodeoxyglucose positron emission tomography;genome-wide;imaging biomarker;imaging detection;imaging modality;in vivo;in vivo Model;indexing;inhibitor;inhibitor therapy;insight;kinase inhibitor;large cell Diffuse non-Hodgkin's lymphoma;mTOR Inhibitor;mTOR inhibition;metabolic abnormality assessment;metabolic imaging;metabolomics;mouse model;neoplastic cell;non-invasive imaging;novel;patient response;personalized medicine;phosphoproteomics;potential biomarker;pre-clinical;preclinical study;predicting response;predictive marker;protein expression;research clinical testing;response;response biomarker;small molecule;targeted treatment;transcriptome sequencing;translational potential;treatment response;tumor;tumor metabolism,Metabolic Imaging of Targeted Therapies in Cancer,Metabolic Imaging of Targeted Therapies in CancerPROJECT NARRATIVEThe proposed research is relevant to public health because additional criteria are needed besides tumorvolume to accurately determine treatment response when cancer is treated using new cytostatic drugs (i.e.drugs that affect cellular functions without major effect on tumor volume). This project proposes investigatingthe metabolism of a neoplasm of the immune system called diffuse large B-cell lymphoma or DLBCL usingimaging methods that are fast (i.e. results can be reported in a few hours) and noninvasive (i.e. do not needbiopsies or radiation). This project is relevant to NIH's mission because it aims to: (1) assess metabolicchanges produced by cytostatic drugs in DLBCL; (2) evaluate if early changes in metabolites predict the finalresponse to therapy regarding these metabolites as predictive biomarkers of response; and (3) determine theaccuracy of the metabolic biomarkers to help evaluate the treatment response of DLBCL to cytostatic drugs.,NCI,10769781,2/2/2024 12:00:00 AM,PA-20-185,5R01CA268601-03,5,R01,CA,268601,03, ,"WANG, YISONG",1/17/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-OTC-L(02)M], ,10450142,"NATH, KAVINDRA ","WASIK, MARIUSZ A.",03,RADIATION-DIAGNOSTIC/ONCOLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,579363, ,NCI,439013,140350, ,579363,,579363.0 | |
| No NIH Category available,Adult;Age;Albumins;Ambulatory Blood Pressure Monitoring;Anti-Hypertensive Agents;Asian;Black race;Blood Pressure;Blood Pressure Monitors;Cardiovascular Diseases;Creatinine;Data;Detection;Devices;Diagnosis;Diastolic blood pressure;Echocardiography;Elderly;Enrollment;Ethnic Origin;Ethnic Population;Guidelines;Health;Hispanic;Home Blood Pressure Monitoring;Hour;Hypertension;Individual;Left Ventricular Mass;Los Angeles;Measurement;Measures;Medical;Methods;Minority;New York;Not Hispanic or Latino;Office Visits;Organ;Outcome;Participant;Pharmaceutical Preparations;Public Health;Race;Randomized;Recommendation;Reference Standards;Reporting;Reproducibility;Research Design;Risk Factors;Sampling;Site;Testing;Visit;Woman;age difference;age group;awake;biomarker validation;blood pressure control;disability-adjusted life years;hypertension control;hypertensive;improved;indexing;modifiable risk;primary outcome;screening;secondary outcome;sex;urinary;years of life lost;young adult,Improving the Detection of Hypertension and its Control,Project NarrativeThe best approach to measure blood pressure is unclear. This study will compare 3 approaches for measuringblood pressure including 3 visits to a medical office setting over 24 hours with a device that automaticallymeasures blood pressure every 30 minutes and one week of the self-measurement of blood pressure.,NHLBI,10769808,1/23/2024 12:00:00 AM,PA-20-185,5R01HL160929-03,5,R01,HL,160929,03, ,"EINHORN, PAULA T",2/15/2022 12:00:00 AM,1/31/2026 12:00:00 AM,"Cancer, Heart, and Sleep Epidemiology B Study Section[CHSB]", ,7120933,"SHIMBO, DAICHI ","REYNOLDS, KRISTI ",13,INTERNAL MEDICINE/MEDICINE,621889815,QHF5ZZ114M72,621889815,QHF5ZZ114M72,US,40.8415,-73.9414,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NEW YORK,NY,SCHOOLS OF MEDICINE,100323725,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,837,Non-SBIR/STTR,2024,2014325, ,NHLBI,1701333,312992, ,2014325,,2014325.0 | |
| No NIH Category available,Affect;Age;Age of Onset;Attention;Australia;Bayesian Method;Behavioral;Bipolar Disorder;Bipolar I;Brain;Brain imaging;Brain region;Brazil;Canada;Capital;Categories;Chronic;Clinical;Collection;Complex;Corpus Callosum;Country;Data;Data Collection;Data Element;Diagnosis;Diagnostic;Diffuse;Diffusion;Diffusion Magnetic Resonance Imaging;Disease;Disease Progression;Dose;Emotions;Ethnic Origin;Evaluation;Family;First Degree Relative;France;Functional Magnetic Resonance Imaging;Functional disorder;Functional impairment;General Population;Genetic;Genetic Predisposition to Disease;Genetic Risk;Genomics;Germany;Image;Impairment;Individual;Infrastructure;International;Investigation;Japan;Letters;Life;Life Expectancy;Link;Longevity;Major Depressive Disorder;Manic;Maps;Measures;Mental Depression;Modeling;Monitor;Moods;Netherlands;Neurobiology;Neurosciences;New York;Norway;Obesity;Outcome;Patients;Pattern;Personal Satisfaction;Pharmaceutical Preparations;Phenotype;Power Sources;Predictive Value;Prefrontal Cortex;Productivity;Prognosis;Protocols documentation;Recovery;Reporting;Reproducibility;Research;Research Domain Criteria;Resources;Rest;Rewards;Risk;Sampling;Scanning;Severities;Site;Sleep disturbances;South Africa;Standardization;Structure;Suicide attempt;Susceptibility Gene;Symptoms;System;Talents;Testing;Therapeutic;Thick;Woman;Work;anti-depressive agents;associated symptom;biomarker validation;biotypes;clinical imaging;cohort;comorbidity;comparison control;cost;cost effective;crowdsourcing;data harmonization;data-driven model;demographics;depressive symptoms;design;disorder subtype;emotion dysregulation;follow-up;functional outcomes;genetic variant;genomic biomarker;genomic data;imaging biomarker;imaging detection;imaging study;improved;innovation;men;multimodality;neuroimaging;outcome prediction;patient subsets;polygenic risk score;psychosocial;resilience;social relationships;suicide rate;tool;treatment effect;treatment response;white matter;working group,ENIGMA Bipolar Initiative: A Global Study of Imaging Genomics & Clinical Outcomes,NARRATIVEBipolar disorder is a devastating illness - its burden exceeds $202 billion a year in direct treatment societal andfamily costs. With no known cure and limited therapeutic options 50% of patients attempt suicide at least onceand the disease is poorly understood; our ENIGMA Bipolar Initiative offers a new cost-effective innovative globalapproach - a new source of power to unblock this logjam - by merging resources imaging and genomic datacapital infrastructure and talents of leading BD centers from 15 countries across the world.,NIMH,10769818,1/25/2024 12:00:00 AM,PA-20-185,5R01MH129742-03,5,R01,MH,129742,03, ,"WIJTENBURG, ANDREA",4/1/2022 12:00:00 AM,1/31/2027 12:00:00 AM,"Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]", ,6111760,"THOMPSON, PAUL M","ANDREASSEN, OLE A",37,OPHTHALMOLOGY,072933393,G88KLJR3KYT5,072933393,G88KLJR3KYT5,US,34.017282,-118.281254,7636101,UNIVERSITY OF SOUTHERN CALIFORNIA,Los Angeles,CA,SCHOOLS OF MEDICINE,900894304,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,242,Non-SBIR/STTR,2024,588592, ,NIMH,518394,70198, ,588592,,588592.0 | |
| No NIH Category available,Advocate;Affinity;Antibodies;Area;Back;Bacteriophages;Binding;Biological Markers;Biophysics;Biotechnology;Capital;Capital Financing;Catalogs;Cells;Consumption;Cost Savings;Data;Development;Directed Molecular Evolution;Employment;Engineering;Enzyme-Linked Immunosorbent Assay;Epitopes;Escherichia coli;Failure;Flow Cytometry;Future;Generations;Genes;Genetic Recombination;Immunization Schedule;Immunoglobulin G;Integrase;Kinetics;Libraries;Measurement;Measures;Methods;Molecular Biology;Monoclonal Antibodies;Pain;Peptide Sequence Determination;Phage Display;Phase;Plasmids;Principal Investigator;Production;Protein Engineering;Proteins;Publications;Publishing;Qualifying;Reagent;Recombinants;Resources;Risk;Robotics;Site;Specificity;Surface;System;Systems Integration;T-Cell Receptor;Technology;Testing;Time;Validation;Work;Yeasts;biophysical analysis;biophysical properties;commercialization;cost;expectation;experience;falls;improved;innovation;instrumentation;pressure;promoter;protein expression;scale up;screening;single molecule;technology validation;timeline;tool;vector,Platform for the High Throughput Generation and Validation of Affinity Reagents,NARRATIVEImproved methods for deriving high quality affinity reagents will be needed to keep up with the pendingimpact when single molecule protein sequencing instrumentation comes online in the next few years.When that time comes it is not a realistic expectation to be able to go to an existing Ab catalog for mAbsthat are well-validated cloned and sequenced and that work in specific applications against newlydiscovered biomarkers. The high costs and low throughput of current antibody-generating technologiesrepresent significant roadblocks to the development of a comprehensive and broadly available resource ofrenewable affinity reagents. Thus there is an urgent need for all Abs to be defined by their sequences andmade recombinant.,NIGMS,10769854,1/12/2024 12:00:00 AM,PA-21-259,5R44GM148998-02,5,R44,GM,148998,02, ,"ASLAN, KADIR",2/1/2023 12:00:00 AM,1/31/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-BCMB-G(10)B], ,78106439,"WEINER, MICHAEL P",Not Applicable,03,Unavailable,117787837,G7S7M6L41EX5,117787837,G7S7M6L41EX5,US,41.291635,-72.689631,10062716,"ABBRATECH, INC.",Branford,CT,Domestic For-Profits,06405,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,859,SBIR/STTR,2024,1080240, ,NIGMS,771600,308640, ,1080240,,1080240.0 | |
| No NIH Category available,Actins;Address;Aging;Alzheimer's Disease;Antibodies;Antibody Affinity;Autopsy;BLNK gene;Biological Assay;Biological Markers;Biology;Biophysics;Brain;Cell Line;Cell model;Cells;Cellular biology;Characteristics;Client;Clustered Regularly Interspaced Short Palindromic Repeats;Cytoplasm;Cytoskeleton;Data;Disease;Engineering;Enzymes;Epitopes;Equipment and supply inventories;Fluorescence Recovery After Photobleaching;Functional disorder;Future;Genes;Genetic study;Human;Immunofluorescence Immunologic;In Situ;Investigation;Knowledge;Ligands;Ligation;Liquid substance;Location;Mass Spectrum Analysis;Mediating;Membrane;Microglia;Molecular;Molecular Target;Monitor;Mutation;Nature;Nucleoplasm;PLCG2 gene;Pathogenesis;Pathway interactions;Phagocytosis;Phase;Phase Transition;Phospho-Specific Antibodies;Physical condensation;Physiological;Play;Post-Translational Protein Processing;Proteins;Proteomics;Protocols documentation;Reagent;Resources;Risk;Role;Signal Pathway;Specificity;TREM2 gene;TYROBP gene;Testing;Therapeutic;Validation;Variant;Western Blotting;Work;abeta oligomer;brain tissue;cell type;design;experimental study;human induced pluripotent stem cells;induced pluripotent stem cell;migration;neurotransmission;novel;potential biomarker;protein purification;receptor;resilience;response;scaffold;targeted biomarker;therapeutic target;tool,Critical tools enabling analysis of biomolecular condensates in microglial signaling and function in aging and Alzheimer Disease,Project Narrative:This project focuses on generating two critical tools to characterize newly identified protein assemblies (termedbiomolecular condensates) that regulate the function of microglia (brain-resident cleaning cells) in aging andAlzheimer Disease (AD). Specifically we will develop and validate: i) a CRISPR engineered microglial cell linethat allows us to monitor these condensates in living cells; and ii) novel workflows to identify additional proteincomponents of these condensates. These tools which will be shared with the field will enable future work tounderstand how these condensates regulate microglial function - knowledge that will be pivotal in designingprecision biomarkers and therapeutics to manage microglial dysfunction in aging and AD.,NIA,10769869,1/9/2024 12:00:00 AM,RFA-AG-23-002,5R21AG080464-02,5,R21,AG,080464,02, ,"BARRETT, PAUL JOHN",2/1/2023 12:00:00 AM,1/31/2025 12:00:00 AM,ZAG1-ZIJ-8(O1), ,15827204,"ST GEORGE-HYSLOP, PETER HENRY",Not Applicable,13,NEUROLOGY,621889815,QHF5ZZ114M72,621889815,QHF5ZZ114M72,US,40.8415,-73.9414,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NEW YORK,NY,SCHOOLS OF MEDICINE,100323725,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,240438, ,NIA,186903,53535, ,240438,,240438.0 | |
| No NIH Category available,Affinity;Algorithms;Alternative Splicing;Amino Acids;Analytical Chemistry;Antibodies;Antibody Binding Sites;Big Data;Binding;Biological Assay;Biological Markers;Biology;CA-125 Antigen;Cancer Patient;Cell Line;Cells;Centers of Research Excellence;Chemicals;Cisplatin;Clinical;Clinical Management;Complex;Core Facility;Detection;Development;Diagnosis;Disease remission;Early Diagnosis;Epitopes;Exposure to;Failure;Funding;Glycoproteins;Goals;Gynecologic Oncologist;Immunoassay;Individual;Knowledge;Life Cycle Stages;Location;Malignant Neoplasms;Malignant neoplasm of ovary;Maps;Masks;Mass Spectrum Analysis;Measures;Mentors;Messenger RNA;Modification;Molecular;Monitor;Mucins;Patients;Performance;Phenotype;Platinum;Play;Polysaccharides;Positioning Attribute;Protein Glycosylation;Proteins;Proteomics;Publishing;RNA Splicing;Race;Reagent;Recurrence;Reporting;Research;Research Personnel;Research Project Grants;Risk;Role;Screening for Ovarian Cancer;Serous;Serum;Serum Markers;Source;Spectrum Analysis;Surface Plasmon Resonance;System;Tandem Repeat Sequences;Tertiary Protein Structure;Testing;Tracer;United States National Institutes of Health;Variant;Woman;Women's Health;Work;analytical tool;aptamer;biomarker validation;black patient;black women;cancer biomarkers;cancer care;cancer cell;cancer recurrence;cell type;diagnostic value;ethnic difference;glycosylation;immunogenicity;improved;individual variation;innovation;invention;novel;ovarian neoplasm;programs;racial difference;research clinical testing;tool;treatment response;tumor,Clarifying the roles of glycoprotein sequence and cancer cell phenotype on the immunogenicity of ovarian cancer biomarker CA125,,NIGMS,10770247,4/12/2024 12:00:00 AM,PAR-22-250,1P20GM152280-01,1,P20,GM,152280,01, , ,4/15/2024 12:00:00 AM,2/28/2029 12:00:00 AM,ZGM1-RCB-9(C1),7736,9299422,"WHELAN, REBECCA JEAN",Not Applicable,01,Unavailable,076248616,SSUJB3GSH8A5,076248616,SSUJB3GSH8A5,US,38.951542,-95.265562,1484302,UNIVERSITY OF KANSAS LAWRENCE,LAWRENCE,KS,Domestic Higher Education,660457552,UNITED STATES,N,4/15/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Research Centers,2024, ,218761, ,150000,68761, , ,, | |
| No NIH Category available,Address;American Heart Association;Anti-Retroviral Agents;Autopsy;Biological Markers;Biological Specimen Banks;Biology;CD4 Lymphocyte Count;CD8B1 gene;Cardiac;Cardiovascular Diseases;Cells;Clinical;Clinical Data;Complex;Data;Diabetes Mellitus;Diagnosis;EFRAC;Endothelium;Epidemiology;Event;Female;Fibroblasts;Freezing;Functional disorder;Funding;Gene Expression;General Population;Genes;Goals;HIV;Heart Rate;Heart failure;High Prevalence;Hispanic;Hypertension;Immune;Immune System Diseases;Immune response;Immunologics;Impairment;Individual;Inflammation;Inflammatory;Inflammatory Response;Intervention;Investigation;Knowledge;Link;Longevity;Maps;Methods;Modernization;Multicenter Studies;Myocardial;Myocardial tissue;National Heart Lung and Blood Institute;National Institute of Allergy and Infectious Disease;Obesity;Pathogenesis;Patient Outcomes Assessments;Patients;Pattern;Peripheral;Peripheral Blood Mononuclear Cell;Persons;Pharmaceutical Preparations;Phenotype;Predisposition;Prevention;Proteins;Proteomics;Protocols documentation;RNA;Recovery;Regulation;Regulatory T-Lymphocyte;Request for Proposals;Research;Research Priority;Resolution;Risk;Risk Factors;Role;Sampling;Specimen;Structural defect;Syndrome;T-Cell Activation;T-Lymphocyte;Therapeutic Intervention;Time;Tissues;United States;Update;Validation;Weight Gain;Writing;abacavir;adjudication;aged;antiretroviral therapy;candidate marker;cardiometabolism;cardiovascular disorder risk;case control;clinical care;clinical imaging;clinical risk;clinically relevant;cohort;comorbidity;design;hemodynamics;high risk;immunoregulation;improved;inflammatory marker;insight;kidney dysfunction;male;middle age;migration;monocyte;mortality;multidisciplinary;novel;overexpression;peripheral blood;power analysis;preservation;protein biomarkers;response;screening;senescence;targeted treatment;trafficking;transgender,Immunologic Inflammatory and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF),PROJECT NARRATIVEThe purpose of this application is to better understand heart failure among people with humanimmunodeficiency virus (HIV). People with HIV have much higher risks for heart failure than the generalpopulation for reasons that are not adequately understood. Our goal in this application is to fundamentallyimprove how heart failure is understood in HIV with the ultimate goal of improving heart failure prevention andtreatment in HIV.,NHLBI,10770358,1/19/2024 12:00:00 AM,PA-19-056,5R01HL156792-04,5,R01,HL,156792,04, ,"COADY, SEAN",2/25/2021 12:00:00 AM,1/31/2025 12:00:00 AM,HIV Comorbidities and Clinical Studies Study Section[HCCS], ,12551628,"FEINSTEIN, MATTHEW JOEL",Not Applicable,05,INTERNAL MEDICINE/MEDICINE,005436803,KG76WYENL5K1,005436803,KG76WYENL5K1,US,42.050479,-87.680046,6144650,NORTHWESTERN UNIVERSITY AT CHICAGO,CHICAGO,IL,SCHOOLS OF MEDICINE,606114579,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,837,Non-SBIR/STTR,2024,707690, ,NHLBI,565536,142154, ,707690,,707690.0 | |
| No NIH Category available,Accounting;Algorithms;Benign;Biological Markers;Blinded;Body Fluids;Cancer Etiology;Cessation of life;Chinese;Classification;Clinical;Clinical Research;Cohort Studies;Communities;Curative Surgery;Data;Death Rate;Development;Diagnosis;Diagnostic;Differential Diagnosis;Discrimination;Disease;Early Diagnosis;Environment;Excision;Future;General Population;Genes;Goals;Health;Incidence;Individual;Institution;Intervention;Magnetic Resonance Imaging;Malignant Neoplasms;Malignant neoplasm of pancreas;Minority;Nurses' Health Study;Operative Surgical Procedures;Organ;Outcome;Pancreas;Pancreatic Adenocarcinoma;Pancreatic Ductal Adenocarcinoma;Pathology;Patient Care;Patients;Performance;Persons;Phase;Population;Probability;Prognosis;Prospective Studies;Prospective cohort;Prospective cohort study;Proteins;Research;Resectable;Retrospective cohort;Risk;Risk Assessment;Sampling;Sensitivity and Specificity;Serum;Singapore;Site;Source;Specificity;Survival Rate;Symptoms;Testing;Training;Translations;Urine;Validation;Work;biomarker panel;candidate marker;care costs;clinical diagnosis;clinical translation;cohort;combinatorial;cost;early detection biomarkers;exosome;high risk;high risk population;improved;innovation;mortality;novel;novel diagnostics;patient subsets;prospective;protein biomarkers;screening;screening guidelines;specific biomarkers;surveillance strategy;tumor;urinary,Urine and serum biomarkers for early diagnosis and risk assessment of pancreatic cancer,NARRATIVEWe propose to develop a novel screening strategy to detect patients at high-risk for developing pancreatic cancerat least 6 months prior to the development of symptoms. The approach is based on following innovativepremises: (i) using urine biomarkers to better enrich the screening population and thereby identify the subsetof patients in whom more expensive and invasive surveillance strategies are warranted which shouldsignificantly reduce pancreatic cancer mortality and patient care costs; (ii) using urine exosomes rather than totalurine for some tests to further concentrate disease specific biomarkers and (iii) using samples collected beforediagnosis in prospective studies.,NCI,10770394,1/9/2024 12:00:00 AM,PA-19-056,5R01CA254036-04,5,R01,CA,254036,04, ,"YOUNG, MATTHEW R",2/3/2021 12:00:00 AM,1/31/2026 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,1873927,"LOKSHIN, ANNA E.","BATRA, SURINDER K.; BRAND, RANDALL ",12,PATHOLOGY,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,SCHOOLS OF MEDICINE,152133320,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,584995, ,NCI,477603,107392, ,584995,,584995.0 | |
| No NIH Category available,Algorithms;Bilateral;Biological Markers;Blinded;Blood;Blood Proteins;Blood Screening;Blood Tests;Blood specimen;CA-125 Antigen;Cancer Etiology;Cancerous;Carcinoma;Carcinoma in Situ;Cells;Cessation of life;Clinical;Collecting Cell;Collection;Data;Detection;Development;Diagnosis;Disease;Early Detection Research Network;Early Diagnosis;Endoscopes;Endoscopy;Epithelial Cells;Epithelial ovarian cancer;Epithelium;Family;Fertility;Genetic;Goals;Greater sac of peritoneum;Health;High Risk Woman;Histology;Human;Hysterectomy;Image;Image Analysis;Imaging Techniques;Instruction;Lead;Learning;Lesion;Malignant Neoplasms;Malignant neoplasm of ovary;Mammalian Oviducts;Metastatic Malignant Neoplasm to the Ovary;Methods;Morbidity - disease rate;Neoplasm Metastasis;Operative Surgical Procedures;Ovarian;Ovarian Serous Adenocarcinoma;Ovary;Patients;Pilot Projects;Predictive Value;Procedures;Proteomics;Recommendation;Recording of previous events;Research;Resolution;Risk;Risk Reduction;Salpingo-Oophorectomy;Sampling;Screening for Ovarian Cancer;Sensitivity and Specificity;Serous;Serum;Serum Markers;Serum Proteins;Survival Rate;Symptoms;System;Target Populations;Techniques;Technology;Test Result;Testing;Thinness;Time;Tissues;Transvaginal Ultrasound;Woman;Women's study;Work;biomarker validation;blood-based biomarker;cell preparation;classification algorithm;clinically actionable;fluorescence imaging;high resolution imaging;imaging biomarker;improved;in vitro Model;in vivo;miniaturize;minimally invasive;mortality;optical imaging;premalignant;protein biomarkers;prototype;screening;spectrograph,Ovarian Cancer Detection with Blood- and Imaging-Based Biomarkers,NARRATIVEThere is currently no acceptable screening method for ovarian cancer and most cases are detected when thedisease is widespread and likely to be deadly. We will develop a two-step blood-based biomarker followed by aminimally-invasive fallopian tube imaging and sampling technique as an effective method to detect ovariancancer at an early time when the disease is most curable.,NCI,10770413,1/5/2024 12:00:00 AM,PAR-19-264,5R01CA260399-03,5,R01,CA,260399,03, ,"MARQUEZ, GUILLERMO",1/1/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-SBIB-A(59)R], ,6525212,"BARTON, JENNIFER KEHLET","FISHMAN, DAVID A.; LOKSHIN, ANNA E.",07,BIOMEDICAL ENGINEERING,806345617,ED44Y3W6P7B9,806345617,ED44Y3W6P7B9,US,32.232844,-110.959467,490201,UNIVERSITY OF ARIZONA,TUCSON,AZ,BIOMED ENGR/COL ENGR/ENGR STA,857210158,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,714585, ,NCI,634626,79959, ,714585,,714585.0 | |
| No NIH Category available,Address;Benign;Biological Markers;Biopsy;Calibration;Cardiovascular Diseases;Cessation of life;Chronic Kidney Failure;Clinical;Clinical Protocols;Clinical Research;Data;Data Set;Detection;Diagnosis;Diagnostic;Disease;Early Diagnosis;Evaluation;Excision;Future;Glycolysis;Goals;Histology;Human;Image;Imaging Techniques;Imaging technology;Incidence;Incidental Discoveries;Indolent;Investigation;Kidney;Kidney Neoplasms;Lactate Dehydrogenase;Link;Local Therapy;Magnetic Resonance Imaging;Malignant - descriptor;Malignant Neoplasms;Malignant neoplasm of kidney;Maps;Measures;Mediating;Metabolic;Metabolism;Methods;Modeling;Motivation;Neoplasm Metastasis;Noise;Operative Surgical Procedures;Pathology;Pathway interactions;Patient Selection;Patients;Performance;Production;Prognosis;Pyruvate;Pyruvate Metabolism Pathway;RF coil;Reference Standards;Renal Carcinoma;Renal Cell Carcinoma;Reproducibility;Risk;Running;Safety;Scanning;Signal Transduction;Testing;Time;Translating;Unnecessary Surgery;Validation;Visualization;Work;clinical application;cohort;cost;imaging approach;imaging biomarker;improved;innovation;kinetic model;magnetic resonance imaging biomarker;metabolic imaging;metabolomics;molecular imaging;novel;overtreatment;pre-clinical;radiomics;response;risk stratification;standard of care;surgical risk;temporal measurement;tumor;tumor metabolism,Translating Hyperpolarized 13C Metabolic MRI to Predict Renal Tumor Aggressiveness,Project narrative:There has been a significant increase in incidentally discovered localized renal tumors and it remains achallenge to reliably and noninvasively differentiate benign tumors from renal cancers or differentiate low gradefrom high grade renal cancers. In this study we will apply a powerful imaging technology hyperpolarized 13Cmetabolic MRI to renal tumors for the first time to address an unmet need for noninvasive predictors of tumoraggressiveness. Successful completion of this work will aid in future management of patients with renal tumorsby reducing the current overdiagnosis and treatment of indolent tumors while enabling early detection ofaggressive renal cancers that require timely surgery.,NCI,10770419,12/20/2023 12:00:00 AM,PAR-19-264,5R01CA249909-04,5,R01,CA,249909,04, ,"ZHANG, HUIMING",1/1/2021 12:00:00 AM,12/31/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-SBIB-S(59)R], ,9115010,"WANG, ZHEN JANE","LARSON, PEDER ERIC ZUFALL",11,RADIATION-DIAGNOSTIC/ONCOLOGY,094878337,KMH5K9V7S518,094878337,KMH5K9V7S518,US,37.767442,-122.413937,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",SAN FRANCISCO,CA,SCHOOLS OF MEDICINE,941432510,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,603163, ,NCI,373476,229687, ,603163,,603163.0 | |
| No NIH Category available,Abbreviations;Acute Myelocytic Leukemia;Adult;Area;Arts;BCL2 gene;Basic Science;Biological Models;Biological Specimen Banks;Biomedical Engineering;Biometry;Cancer Biology;Cancer Center;Cancer Center Support Grant;Cancer Control;Catchment Area;Cellular biology;Chemoprevention;Chemotherapy and/or radiation;Childhood;Chronic Lymphocytic Leukemia;Clinical Treatment;Clinical Trials;Code;Collaborations;Colorectal;Comparative Pathology;Complex;Comprehensive Cancer Center;Computational Biology;Cryoelectron Microscopy;Cytotoxic Chemotherapy;DNA Damage;DNA Repair;Development;Diagnostic tests;Endometrial Carcinoma;Engineering;Epigenetic Process;Flow Cytometry;Funding;Future;Gene Expression Regulation;Gene Mutation;Genes;Genetic Predisposition to Disease;Genetic study;Genomics;Goals;Growth;Growth and Development function;Hereditary Nonpolyposis Colorectal Neoplasms;Hypoxia;Immunooncology;Incidence;Institution;Institutional Review Boards;International;Intramural Research Program;Knowledge;Knowledge acquisition;Machine Learning;Malignant Neoplasms;Malignant neoplasm of lung;Malignant neoplasm of thyroid;Manuscripts;Medicine;Microscopy;Mismatch Repair;Molecular Carcinogenesis;Mutate;Mutation;Natural Killer Cells;Neoplasm Metastasis;Non-Small-Cell Lung Carcinoma;Ohio;Oncology;Outcome;Participant;Pathway interactions;Peer Review;Pharmaceutical Chemistry;Population Study;Productivity;Proteomics;Public Health;Publications;Publishing;Research;Research Personnel;Resistance;Resource Sharing;Resources;Role;Sampling;Science;Services;Signal Transduction;Strategic Planning;T-Lymphocyte;Therapeutic;Therapeutic Trials;Tissue Engineering;Translating;Translational Research;Translations;Tumor Immunity;United States National Institutes of Health;Universities;Untranslated RNA;Vertebral column;Veterinary Medicine;Vision;Work;assay development;biomedical informatics;cancer cell;cancer initiation;cancer predisposition;cancer prevention;clinical translation;college;design;digital imaging;epigenomics;gene repair;genome wide association study;human tissue;improved;innovation;inter-institutional;kinase inhibitor;leukemia;leukemia tissue bank;leukemia treatment;member;metabolomics;mortality;new technology;novel;novel marker;novel therapeutics;pathology imaging;programs;radiation response;response;response biomarker;screening guidelines;targeted treatment;therapy resistant;transcriptomics;translational genomics;translational impact;translational scientist;translational therapeutics;tumor immunology;tumor progression;validation studies,Project 01: Cancer Biology (CB),,NCI,10770437,12/12/2023 12:00:00 AM,PAR-20-043,5P30CA016058-48,5,P30,CA,016058,48, , ,9/12/1997 12:00:00 AM,11/30/2025 12:00:00 AM,Cancer Centers Study Section (A)[NCI-A],7756,6184325,"RINGEL, MATTHEW D",Not Applicable,03,Unavailable,832127323,DLWBSLWAJWR1,832127323,DLWBSLWAJWR1,US,39.999598,-83.033131,6218701,OHIO STATE UNIVERSITY,COLUMBUS,OH,Domestic Higher Education,432101016,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM, ,Research Centers,2024, ,52154, ,33432,18722, , ,, | |
| No NIH Category available,Adopted;Antigens;Antitumor Response;Automobile Driving;Biological Markers;Biology;Blood;Body Weight decreased;CD14 gene;CD19 gene;CD22 gene;Cell Physiology;Cell-Mediated Cytolysis;Cells;Cellular immunotherapy;Cessation of life;Characteristics;Child;Childhood;Childhood Hematopoietic Neoplasm;Childhood Leukemia;Clinical;Clinical Trials;Collaborations;Coupled;Cytokine Signaling;Dangerousness;Data;Development;Disease;Dose;Engineering;Engraftment;Etiology;Excision;Functional disorder;Genetic Predisposition to Disease;Genetic Transcription;Grant;HIF1A gene;Hematopoietic Neoplasms;Hemophagocytic Lymphohistiocytoses;Histology;Human;IL18 gene;Immune;Immune system;Immunity;Immunotherapy;In Vitro;Individual;Inflammatory;Interferon Type II;Interferons;Interleukin-10;Interleukin-12;Investments;KLRB1 gene;Kinetics;Life;Machine Learning;Measures;Mediating;Medical;Myelogenous;Myeloproliferative disease;Nervous System Trauma;Neuroblastoma;Outcome;Patients;Pediatric Neoplasm;Peripheral Blood Mononuclear Cell;Phenotype;Play;Population;Production;Recording of previous events;Recurrence;Relapse;Research;Resources;Risk;Role;Safety;Sampling;Series;Serum;Signal Transduction;Solid Neoplasm;T-Lymphocyte;The Jackson Laboratory;Therapeutic;Time;Toxic effect;Treatment-related toxicity;Tumor Biology;Work;biomarker validation;blood treatment;blood-brain barrier crossing;chimeric antigen receptor;chimeric antigen receptor T cells;clinical biomarkers;clinical predictors;cohort;cytokine;cytokine release syndrome;experience;experimental study;humanized mouse;improved;improved outcome;insight;interleukin-18 receptor;leukemia;machine learning algorithm;monocyte;mouse model;neurotoxicity;novel;patient population;patient response;patient subsets;pediatric patients;predicting response;predictive marker;programs;response;side effect;success;survival prediction;trafficking;trend;trial design;tumor,The IL-18-IFN axis predicts response to immunotherapy,Project Narrative CAR T-cells have revolutionized the treatment of blood cancers but 50% of responsive patientseventually relapse and in ~50-70% of patients this therapy induces devastating side effects (i.e. neurotoxicity(NTX) and cytokine release syndrome (CRS)). By studying the pre-monocytic activation status and cytokineprofiles from the monocyte fraction of a patient this proposal will aim to validate that one can predict CAR Ttoxicity and efficacy. Through the use of a developed humanized mouse model we will investigate if this pre-inflammatory status is causative of toxicity outcomes.,NCI,10770486,3/22/2024 12:00:00 AM,PA-20-185,5R37CA266777-02,5,R37,CA,266777,02, ,"HU, ZHANG-ZHI",2/1/2023 12:00:00 AM,1/31/2028 12:00:00 AM,Special Emphasis Panel[ZRG1-OTC-D(08)F], ,12635935,"GUSTAFSON, HEATHER LEIGH HERD",Not Applicable,07,Unavailable,048682157,SZ32VTCXM799,048682157,LMAWH591NFK5; SZ32VTCXM799,US,47.66243,-122.282291,1531401,SEATTLE CHILDREN'S HOSPITAL,SEATTLE,WA,Independent Hospitals,981053901,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,395,Non-SBIR/STTR,2024,756160, ,NCI,503330,252830, ,756160,,756160.0 | |
| No NIH Category available,16 year old;Adrenal Cortex Hormones;Agreement;Algorithms;Antimetabolites;Appearance;Area;Biological Markers;Blindness;Cells;Clinical;Clinical Trials;Consensus;Cross-Sectional Studies;Data Set;Detection;Development;Disease;Early Diagnosis;Evaluation;Eye;Eye Development;Funding;Goals;Health;Image;Image Analysis;Immune system;Inflammation;Leukocytes;Longitudinal Studies;Masks;Measurement;Measures;Methodology;Methotrexate;Modeling;Monitor;Nature;Nomenclature;Ophthalmoscopy;Optical Coherence Tomography;Oral;Outcome;Outcome Measure;Panuveitis;Participant;Patients;Play;Posterior eyeball segment structure;Prediction of Response to Therapy;Randomized;Recommendation;Reproducibility;Research;Risk;Role;Signal Transduction;Specialist;Standardization;Steroids;Strategic Planning;System;Techniques;Training;Treatment Failure;United States Food and Drug Administration;Uveitis;Validation;Vision;Visit;Visual disability;Visual impairment;clinical examination;clinical practice;diagnostic tool;disability;follow-up;high risk;image processing;imaging biomarker;immunomodulatory therapies;improved;inflammatory marker;longitudinal analysis;mycophenolate mofetil;preservation;prevent;randomized clinical trials;research clinical testing;risk prediction;risk stratification;secondary analysis;slit lamp imaging;treatment response;vision development;working group,Objective quantification of vitreous inflammation using optical coherence tomography,PROJECT NARRATIVEUveitis involving the posterior segment of the eye accounts for the highest rate of vision impairment anddevelopment of ocular complications among patients with uveitis. Current clinical evaluation of intraocularinflammation using slit lamp biomicroscopy and indirect ophthalmoscopy is operator-dependent and semi-quantitative. We will evaluate the use of optical coherence tomography to objectively quantify inflammation inthese patients which can potentially enable better detection and surveillance of uveitis so that prompttreatment can be implemented to prevent blindness and disability.,NEI,10770507,1/24/2024 12:00:00 AM,PAR-19-260,5R21EY034543-02,5,R21,EY,034543,02, ,"EVERETT, DONALD F",2/1/2023 12:00:00 AM,1/31/2025 12:00:00 AM,ZEY1-VSN(01), ,16284329,"TSUI, EDMUND ",Not Applicable,36,OPHTHALMOLOGY,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,SCHOOLS OF MEDICINE,900952000,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,867,Non-SBIR/STTR,2024,196916, ,NEI,171183,25733, ,196916,,196916.0 | |
| No NIH Category available,Abbreviations;Address;Age;Algorithms;Anatomy;Animal Model;Animals;Antibodies;Biological Markers;Biomedical Research;Biometry;Board Certification;Breeding;Budgets;Cancer Biology;Cancer Center;Cancer Center Support Grant;Cancer Control;Cancer Hospital;Cancer Survivorship;Chemoprevention;Clinical Treatment;Clinical Trials;Comparative Pathology;Complement;Complex;Comprehensive Cancer Center;Computer software;Custom;Data Analyses;Development;Diagnostic;Engineering;Experimental Designs;Experimental Pathology;Flow Cytometry;Fostering;Funding;Genomics;Grant;Histology;Hour;Human;Human Pathology;IACUC;Image;Image Analysis;Immunofluorescence Immunologic;Immunohistochemistry;Immunologic Monitoring;Immunooncology;In Situ Hybridization;Informatics;Intervention;Intramural Research Program;Laboratories;Lesion;Machine Learning;Malignant Neoplasms;Medicine;Mentored Clinical Scientist Development Program;Microscopy;Minor;Molecular Carcinogenesis;Mus;NCI Center for Cancer Research;Names;Nutrient;Ohio;Pathologic;Pathologist;Pathology;Peer Review;Pharmaceutical Chemistry;Phenotype;Physiological;Phytochemical;Proteins;Proteomics;Publications;RNA;Research;Research Institute;Research Personnel;Resource Sharing;Sampling;Services;Slide;Stains;Surveys;Tissue Procurements;Tissues;Translational Research;Universities;Validation;Veterinary Medicine;Veterinary Pathology;Workload;animal imaging;animal tissue;biomedical informatics;cancer prevention;cancer therapy;carcinogenesis;clinical translation;college;comparative;digital imaging;experience;human tissue;improved;leukemia;leukemia tissue bank;meetings;member;open source;pathology imaging;pre-clinical;preclinical efficacy;preclinical toxicity;programs;quantitative imaging;recruit;tissue biomarkers;translational genomics;translational impact;translational study;translational therapeutics;treatment response;tumor progression,Shared Resource 06: Comparative Pathology and Digital Imaging (CPDISR),,NCI,10770517,12/12/2023 12:00:00 AM,PAR-20-043,5P30CA016058-48,5,P30,CA,016058,48, , ,9/12/1997 12:00:00 AM,11/30/2025 12:00:00 AM,Cancer Centers Study Section (A)[NCI-A],7783,3086533,"LA PERLE, KRISTA MARIE DUBRAY",Not Applicable,03,Unavailable,832127323,DLWBSLWAJWR1,832127323,DLWBSLWAJWR1,US,39.999598,-83.033131,6218701,OHIO STATE UNIVERSITY,COLUMBUS,OH,Domestic Higher Education,432101016,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM, ,Research Centers,2024, ,152572, ,97803,54769, , ,, | |
| No NIH Category available,Age;All of Us Research Program;Area;Assessment tool;Attention;Attenuated;Automation;Behavior;Behavior Therapy;Big Data Methods;Biomarker of Dietary Intake;Characteristics;Chronic Disease;Code;Cognition;Communities;Computers;Consumer Preferences;Controlled Study;Data;Data Analytics;Data Collection;Data Security;Data Storage and Retrieval;Devices;Diet;Diet Records;Dietary Assessment;Dietary intake;Dietitian;Dimensions;Disease;Disease Outcome;Domiciles;Eating;Eating Behavior;Effectiveness;Energy Intake;Engineering;Ensure;Epidemiologist;Food;Funding;Goals;Health;Hour;Human;Image;Image Analysis;Individual;Ingestion;Intake;Interview;Location;Machine Learning;Malignant Neoplasms;Measurement;Measures;Methods;Modernization;Monitor;Obesity;Outcome Study;Paper;Participant;Pattern;Performance;Persons;Policies;Population;Population Group;Population Heterogeneity;Precision Health;Procedures;Process;Randomized Controlled Trials;Reporting;Research;Research Design;Research Personnel;Resources;Sample Size;Sampling;Science;Scientist;Secure;Self Administration;Site;System;Technology;Telephone;Testing;Time;Translational Research;United States National Institutes of Health;Validation;Variant;Woman;Work;clinical center;comparative;cost;cost effective;data ecosystem;data exchange;data management;decision research;design;dietary;doubly-labeled water;effectiveness evaluation;electronic data;epidemiology study;evidence base;experience;feeding;improved;intervention program;medical specialties;men;multidisciplinary;novel;nutrition;personalized nutrition;precision nutrition;preference;response;scale up;sensor;social;tool;web-based tool,Traditional and New Dietary Assessment Methods (TANDAM) for Personalized Nutrition,PROJECT NARRATIVEElevating dietary assessment through harnessing the capabilities of computers mobile-based and image-based technology tools which offer an opportunity to reach a wide audience via cost-effective convenienttimely and familiar channels.,NCI,10771104,4/3/2024 12:00:00 AM,RFA-RM-21-004,5U24CA268228-03,5,U24,CA,268228,03, ,"REEDY, JILL",1/12/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-EMNR-H(55)R], ,7720115,"WILKENS, LYNNE R","DELP, EDWARD J; MCCRORY, MEGAN A",01,MISCELLANEOUS,965088057,NSCKLFSSABF2,965088057,NSCKLFSSABF2,US,21.299198,-157.820371,820005,UNIVERSITY OF HAWAII AT MANOA,HONOLULU,HI,SCHOOLS OF EDUCATION,968222234,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,393,Other Research-Related,2024,1431080, ,OD,1164312,269308, ,1431080,,1431080.0 | |
| No NIH Category available,3-Dimensional;Affect;African American;Air;Air Pollution;Alabama;Amendment;Area;Arsenic;Arts;Asthma;Authorization documentation;Biological;Biological Markers;Blood;Bronchoalveolar Lavage Fluid;Cadmium;Childhood Asthma;Chronic;Chronic Obstructive Pulmonary Disease;Chronic lung disease;Civil Rights;Coke;Communication;Communities;County;Data;Detection;Developed Countries;Development;Disease;Engineering;Environment;Environmental Engineering technology;Environmental Exposure;Environmental Health;Environmental Medicine;Environmental Science;Epidemiology;Equity;Excision;Exhalation;Exposure to;Fostering;Goals;Health;Heart;Heavy Metals;Home;Human;Hybrids;Incidence;Industrialization;Industry;Inhalation;Knowledge;Lead;Link;Low income;Lower Respiratory Tract Infection;Lung;Lung Diseases;Manganese;Measures;Metal exposure;Methodology;Methods;Mission;Modality;Molecular;National Institute of Environmental Health Sciences;Non-Invasive Detection;Nose;Optics;Organoids;Pathogenesis;Patients;Persons;Phenotype;Physical condensation;Poison;Pollution;Population;Post-Translational Protein Processing;Predisposition;Prevalence;Process;Public Health Schools;Research;Resources;Respiratory System;Risk;Risk Factors;Role;Schools;Science;Scientist;Services;Signal Recognition Particle;Site;Smoking;Socioeconomic Status;Soil;Specimen;Steel;Study Subject;Superfund;Surface;System;Technology;Tennessee;Toxic Environmental Substances;Toxicology;Training Programs;Translational Research;United States;United States Environmental Protection Agency;Universities;Work;aerosolized;biobank;biomarker validation;chronic respiratory disease;cigarette smoke;coal-fired power plant;college;community academic partnership;community engagement;cost effective;demographics;disease phenotype;disease registry;empowerment;human subject;improved;innovation;lung health;lung injury;medical schools;mortality;multidisciplinary;nano;next generation;novel;programs;remediation;respiratory health;response;superfund site;synergism;tool;toxicant,Impact of Airborne Heavy Metals on Lung Disease and the Environment,NARRATIVEThe University of Alabama at Birmingham (UAB) Superfund Research Program (UAB-SRP) will address airborne pollution with heavy metals in down town BirminghamAlabama. The UAB-SRP will work with the community and Superfund stakeholders tobetter define the issues related to the lung health of the residents of the North Birmingham35th Avenue site and the health of the environment. These innovative projects will addresslung disease in residents and define ways to mitigate environmental degradation andimprove human health.!,NIEHS,10771166,2/1/2024 12:00:00 AM,RFA-ES-18-002,5P42ES027723-05,5,P42,ES,027723,05, ,"CARLIN, DANIELLE J",3/15/2020 12:00:00 AM,1/31/2025 12:00:00 AM,ZES1-JAB-D(SF), ,6922208,"ANTONY, VEENA B.",Not Applicable,07,INTERNAL MEDICINE/MEDICINE,063690705,YND4PLMC9AN7,063690705,YND4PLMC9AN7,US,33.50591,-86.799772,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,BIRMINGHAM,AL,SCHOOLS OF MEDICINE,352940001,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,143,Research Centers,2024,1341574, ,NIEHS,929587,411987, ,1341574,,1341574.0 | |
| No NIH Category available,3-Dimensional;Activities of Daily Living;Address;Affect;Alabama;Amidines;Area;Arginine;Arginine deiminase;Arsenic;Atmosphere;Biological Markers;Cadmium;Calcium;Cell Physiology;Chronic Obstructive Pulmonary Disease;Chronic lung disease;Cities;Citrulline;Coke;Communities;Complex;County;Data;Development;Dimensions;Disease susceptibility;Environment;Environmental Exposure;Environmental Risk Factor;Enzymes;Exhalation;Exposure to;Fibroblasts;Fractals;Genetic;Heavy Metals;Human;In Vitro;Individual;Industrialization;Inhalation;Intermediate Filament Proteins;Lung;Lung Diseases;Macrophage;Manganese;Measurement;Mediating;Metal exposure;Mus;Particulate Matter;Pathogenesis;Pathway interactions;Patients;Phenotype;Phosphorylation;Physical condensation;Plasma;Pollution;Prevalence;Proteins;Pulmonary Emphysema;Reporting;Risk Factors;Role;Science;Site;Smoker;Smoking;Steel;Structure of parenchyma of lung;TLR4 gene;Testing;Toxic Environmental Substances;Untranslated RNA;Up-Regulation;Validation;Vimentin;Work;X-Ray Computed Tomography;airway remodeling;bronchiolar fibrosis;cigarette smoke;coal-fired power plant;cohort;comparison control;demographics;early detection biomarkers;fine particles;inhibitor;mortality;mouse model;non-smoker;novel;novel therapeutic intervention;pharmacologic;prospective test;smoking prevalence;superfund site;therapeutic target;tool,Project 1 Heavy Metal Induced Airway Remodeling and COPD,Project NarrativeInhaled particulate matter containing heavy metals such as arsenic manganese and cadmium are known tocause chronic obstructive pulmonary disease (COPD) however the mechanism remains unclear. Residents ofan EPA proposed superfund site live close to coke ovens and coal fired power plants in Birmingham AL andhave twice the prevalence of COPD than elsewhere and their lungs demonstrate the presence of abnormalproteins. We will work closely with the EPA and ATSDR in providing information to the community about COPDand about the science that informs our work.,NIEHS,10771180,2/1/2024 12:00:00 AM,RFA-ES-18-002,5P42ES027723-05,5,P42,ES,027723,05, , ,3/15/2020 12:00:00 AM,1/31/2025 12:00:00 AM,ZES1-JAB-D,5607,6922208,"ANTONY, VEENA B.",Not Applicable,07,Unavailable,063690705,YND4PLMC9AN7,063690705,YND4PLMC9AN7,US,33.50591,-86.799772,1288803,UNIVERSITY OF ALABAMA AT BIRMINGHAM,BIRMINGHAM,AL,Domestic Higher Education,352940001,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM, ,Research Centers,2024, ,254157, ,172484,81673, , ,, | |
| No NIH Category available,Affect;Area;Biological;Biological Markers;Caring;Cause of Death;Cessation of life;Characteristics;Clinical;Clinical Management;Clinical Trials;Complement;Consumption;Data;Development Plans;Diagnosis;Diagnostic;Discipline of obstetrics;Discrimination;Disease;Ectopic Pregnancy;Ethnic Origin;First Pregnancy Trimester;Funding;Gestational Age;Goals;Gynecologic;Hemorrhage;Human Chorionic Gonadotropin;Iatrogenesis;Interruption;Location;Machine Learning;Mammalian Oviducts;Medical;Medical Care Team;Methodology;Modeling;Morbidity - disease rate;National Institute of Child Health and Human Development;Pain;Pathway interactions;Patients;Performance;Physiology;Population;Predictive Value;Predictive Value of Tests;Pregnancy;Pregnancy Outcome;Procedures;Process;Productivity;Prospective Studies;Prospective cohort;Proteomics;Race;Recording of previous events;Research;Research Priority;Resources;Risk;Rupture;Sampling;Serum;Signs and Symptoms;Spontaneous abortion;Stress;Subgroup;Symptoms;System;Testing;Time;Uncertainty;United States National Institutes of Health;Uterus;Validation;Woman;Work;biomarker development;biomarker panel;biomarker performance;classification algorithm;clinical care;companion diagnostics;design;diagnostic tool;early pregnancy;early pregnancy loss;feature selection;health care delivery;improved;interest;machine learning algorithm;model building;novel;novel marker;pain symptom;population based;predictive marker;pregnancy failure;random forest;regression trees;screening;ultrasound,Clinical utility of novel biomarkers for prediction of early pregnancy failure,Project NarrativeIn this application we plan to finalize and externally validate two potential diagnostic aids based on novelbiomarkers to identify (1) location and (2) viability of an early gestation. With the inclusion of novel biomarkerswe plan to refine a serum multiple marker test and validate its performance in a population based prospectivecohort. We also plan to explore it use in combination with a patient sign and symptoms at presentation for careand it use in other populations.,NICHD,10771208,1/29/2024 12:00:00 AM,PA-20-185,5R01HD110448-02,5,R01,HD,110448,02, ,"SEN, ARITRO",2/1/2023 12:00:00 AM,1/31/2028 12:00:00 AM,Special Emphasis Panel[ZRG1-PSE-A(90)S], ,2086069,"BARNHART, KURT T",Not Applicable,03,OBSTETRICS & GYNECOLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,865,Non-SBIR/STTR,2024,671048, ,NICHD,491701,179347, ,671048,,671048.0 | |
| No NIH Category available,16S ribosomal RNA sequencing;Acceleration;Address;Affect;Age-associated memory impairment;Alzheimer's Disease;Alzheimer's disease related dementia;Alzheimer's disease risk;Alzheimer's disease therapy;Anti-Inflammatory Agents;Applications Grants;Award;Bacteria;Bacteroides;Biochemistry;Bioinformatics;Biology;Blood;Blood - brain barrier anatomy;Brain;Caring;Cause of Death;Central Nervous System;Chronology;Collaborations;Communication;Data;Dementia;Dependence;Development;Diagnosis;Diet;Disease;Episodic memory;Escherichia;Ethnic Origin;Ethnic Population;Etiology;Foundations;Framingham Heart Study;Functional disorder;Funding;Future;Genetic;Goals;Hispanic Populations;Human Microbiome;Individual;Inflammatory;Infrastructure;Learning;Link;Longitudinal Studies;Magnetic Resonance Imaging;Malignant Neoplasms;Mass Spectrum Analysis;Measures;Memory;Mentored Research Scientist Development Award;Mentors;Metabolic;Metabolism;Methods;Microvascular Dysfunction;Modeling;Neurocognitive;Neurodegenerative Disorders;Neuropsychology;Not Hispanic or Latino;Nutrient;Obesity;Outcome Measure;Pathogenicity;Pathology;Pharmaceutical Preparations;Physiology;Plasma;Population;Populations at Risk;Prevalence;Prevotella;Reporting;Research;Risk Factors;Role;Sex Differences;Shigella;Signal Transduction;South Texas;Structure;Testing;Texas;Therapeutic;Thinking;Time;bacterial community;bacterial metabolism;brain health;career;cerebral atrophy;cohort;drug development;endophenotype;ethnic difference;ethnoracial minority;executive function;experience;fecal microbiota;gut dysbiosis;gut microbes;gut microbiome;gut microbiota;high risk;innovation;insight;interest;lipidomics;magnetic resonance imaging biomarker;mathematical model;metabolome;metabolomics;microbial;microbial community;microbiome;microbiota;microbiota metabolites;microbiota-gut-brain axis;mild cognitive impairment;minority patient;modifiable risk;multi-ethnic;neuroimaging;neuroimaging marker;new therapeutic target;novel;novel marker;novel strategies;population stratification;prevent;processing speed;public health relevance;response;risk stratification;sex;structural biology;study population;systemic inflammatory response;targeted treatment;visual memory;white matter,Delineating the role of the gut microbiota and its derived metabolites in the development of dementia in multi-ethnic populations,Project Narrative / Public health relevanceNovel strategies are needed to prevent or delay the onset of Alzheimer's disease (AD) andAD-related dementias (AD/ADRD). This project aims to study the association between thegut microbiome an excellent modifiable risk factor and early markers of AD/ADRD.Understanding this link could help develop microbiome-targeted therapies for AD/ADRD.,NINDS,10771240,1/19/2024 12:00:00 AM,PAR-21-234,5K01NS126489-02,5,K01,NS,126489,02, ,"MCGAVERN, LINDA",2/1/2023 12:00:00 AM,1/31/2028 12:00:00 AM,ZNS1-SRB-L(10), ,12591290,"FONGANG, BERNARD ",Not Applicable,20,BIOCHEMISTRY,800772162,C3KXNLTAAY98,800772162,C3KXNLTAAY98,US,29.513091,-98.577742,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,SAN ANTONIO,TX,SCHOOLS OF MEDICINE,782293901,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Other Research-Related,2024,220142, ,NIA,204895,15247, ,220142,,220142.0 | |
| No NIH Category available,Affect;Age;Animal Model;Anti-Inflammatory Agents;Astrocytes;Autopsy;Autoradiography;Binding;Binding Sites;Biological Markers;Brain;Brain Diseases;Brain Injuries;Brain region;Central Nervous System;Contralateral;Data;Development;Diagnosis;Diagnostic Imaging;Disease;Economic Burden;Elements;Enzyme-Linked Immunosorbent Assay;Euthanasia;Family;Family member;Female;Goals;Human;Image;Immunofluorescence Immunologic;In Vitro;Inflammation;Inflammatory;Inflammatory Response;Injury;Intracarotid;Intracarotid Infusion;Ipsilateral;Lesion;Lysophospholipids;MPTP Poisoning;MRI Scans;Macaca;Magnetic Resonance Imaging;Measures;Membrane;Microglia;Movement Disorder Society Unified Parkinson's Disease Rating Scale;Multiple Sclerosis;Names;Nervous System Disorder;Neurodegenerative Disorders;Neuroglia;Neurons;Neurotoxins;Oligodendroglia;Parkinson Disease;Parkinsonian Disorders;Participant;Pathogenesis;Patients;Persons;Play;Positron-Emission Tomography;Quantitative Autoradiography;Reporting;Role;Scanning;Signal Transduction;Site;Sphingosine-1-Phosphate Receptor;Stains;Testing;Therapeutic;Tissues;Tracer;United States;Validation;brain tissue;brain volume;comparison control;dopaminergic neuron;dosimetry;frontal lobe;healthy volunteer;interest;longitudinal positron emission tomography;male;motor behavior;motor symptom;multiple sclerosis patient;neuroinflammation;neuroprotection;nonhuman primate;preclinical study;radioligand;radiotracer;receptor;response;safety study;sex;specific biomarkers;sphingosine 1-phosphate;success;targeted treatment;therapeutic development;therapeutic target;tool;uptake;white matter,Investigate neuroinflammation in the brain of PD using S1P1 radioligands,Project NarrativeParkinson disease (PD) is the second most common neurodegenerative disease with approximately 4-10 millionpeople affected worldwide and result in tremendous economic burden (14.4 billion/year in the United States).Neuroinflammation is a key element in the pathogenesis and progression of PD yet the lack of specificbiomarkers has hindered both targeted therapy and diagnostic imaging options. The success of this applicationmay lead to identification of a neuroinflammation biomarker and facilitate anti-inflammation therapeutics for PDand other neuroinflammatory diseases.,NINDS,10771872,2/19/2024 12:00:00 AM,PA-20-185,1R01NS134586-01,1,R01,NS,134586,01, ,"BABCOCK, DEBRA J",2/20/2024 12:00:00 AM,1/31/2029 12:00:00 AM,Clinical Neuroscience and Neurodegeneration Study Section[CNN], ,8576205,"TU, ZHUDE ","PERLMUTTER, JOEL SYNES",01,RADIATION-DIAGNOSTIC/ONCOLOGY,068552207,L6NFUM28LQM5,068552207,L6NFUM28LQM5,US,38.664368,-90.323797,9083901,WASHINGTON UNIVERSITY,SAINT LOUIS,MO,SCHOOLS OF MEDICINE,631304862,UNITED STATES,N,2/20/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,617783, ,NINDS,397288,220495, ,617783,,617783.0 | |
| No NIH Category available,Address;Aftercare;Amino Acids;Biological Assay;Biological Markers;Blood;Cancer Etiology;Cancer cell line;Cell Culture Techniques;Cell Line;Cell secretion;Cessation of life;Chemotherapy and/or radiation;Clinical;Combination Drug Therapy;Detection;Diameter;Disease;Early identification;Early treatment;Future;Human;Knowledge;Label;Liquid Chromatography;Local Therapy;Malignant neoplasm of pancreas;Mass Chromatography;Mass Spectrum Analysis;Measurement;Membrane;Methods;Monitor;Nature;Normal Cell;Patient-Focused Outcomes;Patients;Performance;Population;Preparation;Prognosis;Progression-Free Survivals;Prospective cohort;Protein Analysis;Proteins;Proteomics;Radiation therapy;Reproducibility;Research;Sampling;Serum;Serum Markers;Stable Isotope Labeling;Survival Rate;Therapeutic;Toxic effect;Treatment outcome;Unresectable;Variant;Vesicle;Work;X-Ray Computed Tomography;advanced disease;advanced pancreatic cancer;assay development;biomarker identification;biomarker panel;biomarker validation;cancer therapy;cancer type;chemoradiation;chemotherapy;cohort;exosome;high standard;imaging modality;improved;individual patient;microvesicles;minimally invasive;multiplex assay;nanosized;neoplastic cell;novel;novel marker;pancreatic cancer cells;pancreatic cancer patients;protein biomarkers;response;standard of care;tool;treatment response;tumor,Universal Internal Standard for Reproducible Accurate Quantification of Exosome Protein Markers,Narrative: Tumors release microvesicles called exosomes that reflect the protein content of the tumor itself. Wewill develop methods using a universal internal standard(UIS) for highly reproducible quantitative analysis of theprotein content of exosomes from patient serum during a course of treatment with chemotherapy and radiationtherapy. This method will be applied to a set of exosome protein markers from prior work for monitoring changesin protein cargo after treatment via a targeted mass spec-based approach.,NCI,10771956,1/12/2024 12:00:00 AM,PAR-20-053,5R01CA258240-03,5,R01,CA,258240,03, ,"OSSANDON, MIGUEL",1/14/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,1860975,"LUBMAN, DAVID M.","SHI, TUJIN ",06,SURGERY,073133571,GNJ7BBP73WE9,073133571,GNJ7BBP73WE9,US,42.275494,-83.743038,1506502,UNIVERSITY OF MICHIGAN AT ANN ARBOR,ANN ARBOR,MI,SCHOOLS OF MEDICINE,481091276,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,448610, ,NCI,359481,89129, ,448610,,448610.0 | |
| No NIH Category available,Adnexal Mass;Affect;Age;Antigens;Artificial Intelligence;Benign;Biological Markers;Biometry;Blood;CA-125 Antigen;Cancer Detection;Cancer Etiology;Cancer Patient;Cancerous;Cessation of life;Clinical;Clinical Research;Data;Data Set;Death Rate;Detection;Development;Diagnosis;Diagnostic;Diagnostic Procedure;Diagnostic Specificity;Disease;Early Diagnosis;Evaluation;Excision;Female;Future;Goals;Gynecologic Oncology;Histologic;Human;Image;Immune response;Immune system;Immunogenomics;Immunology;Lavage;Lesion;Life;Logistic Regressions;Low Prevalence;Malignant - descriptor;Malignant Neoplasms;Malignant neoplasm of ovary;Measures;Methods;Modeling;Neoplasm Metastasis;Operative Surgical Procedures;Ovarian;Ovarian Mass;Ovarian Serous Adenocarcinoma;Ovary;Patients;Pelvis;Performance;Peripheral;Pilot Projects;Planned Pregnancy;Process;Proliferating;Prostate Lung Colorectal and Ovarian Cancer Screening Trial;Public Domains;Reporter;Representational Oligonucleotide Microarray Analysis;Research Personnel;Risk;Role;Route;Sampling;Screening for Ovarian Cancer;Sensitivity and Specificity;Serum;Signal Transduction;Skates;Specificity;Specimen;Stage at Diagnosis;Symptoms;T cell receptor repertoire sequencing;T-Cell Receptor;T-Lymphocyte;T-cell receptor repertoire;Testing;Tissues;Training;Tumor Antigens;Tumor Markers;Ultrasonography;Unnecessary Surgery;Uterus;Vagina;Validation;Woman;accurate diagnosis;antigen-specific T cells;biobank;biomarker development;cancer biomarkers;cancer diagnosis;cohort;collaborative trial;detection method;detection sensitivity;diagnosis standard;diagnostic accuracy;diagnostic biomarker;diagnostic criteria;disease diagnosis;immunogenicity;improved;indexing;innovation;machine learning method;machine learning model;machine learning prediction;mortality;multimodality;multiplex assay;noninvasive diagnosis;novel;preservation;prospective;recruit;reproductive;screening;sequencing platform;software development;specific biomarkers;tool;transcriptome sequencing;tumor;tumor progression;young woman,Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer Diagnosis,Project NarrativeOvarian cancer is the deadliest female cancer in the world and currently there is no effective preoperativediagnostic biomarker. We have demonstrated that the circulating T cells can be used as indicators of cancerstatus and plan to prospectively collect an ovarian cancer patient cohort with matched immunogenomics dataand to train a machine learning model to obtain a novel TCR-based biomarker. Successful delivery of our Aimswill provide a validated independent ovarian cancer biomarker with improved diagnostic accuracy.,NCI,10771984,2/2/2024 12:00:00 AM,PA-20-185,5R01CA258524-04,5,R01,CA,258524,04, ,"PATRIOTIS, CHRISTOS F",1/1/2022 12:00:00 AM,12/31/2026 12:00:00 AM,Clinical Oncology Study Section[CONC], ,15395861,"LI, BO ","LEA, JAYANTHI S; SKATES, STEVEN J",03,Unavailable,073757627,G7MQPLSUX1L4,073757627,G7MQPLSUX1L4,US,39.946632,-75.196604,1499101,CHILDREN'S HOSP OF PHILADELPHIA,PHILADELPHIA,PA,Independent Hospitals,191462305,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,804864, ,NCI,557961,246903, ,804864,,804864.0 | |
| No NIH Category available,Acute Disease;Address;Aging;Alzheimer's disease patient;Alzheimer's disease related dementia;American;Area;Assessment tool;Attention;Award;Biological Markers;Clinical;Clinical Research;Clinical Treatment;Clinical Trials;Cognition;Data;Data Analyses;Data Set;Databases;Delirium;Development;Diagnosis;Discipline;Elderly;Ensure;Epidemiology;Event;Functional disorder;Future;Goals;Grant;Healthcare Systems;Human;Impaired cognition;Incidence;Individual;Infrastructure;Institution;Intensive Care;Interdisciplinary Study;Investigation;Knowledge;Life;Link;Long-Term Care;Measurement;Measures;Mental Depression;Mentorship;Meta-Analysis;Methods;National Institute on Aging;Outcome;Palliative Care;Paper;Participant;Pathway interactions;Patients;Pilot Projects;Prevention program;Principal Investigator;Public Health;Quality of Care;R24;Research;Research Design;Research Infrastructure;Research Personnel;Resources;Risk Factors;Science;Scientific Advances and Accomplishments;Scientist;Severities;Training;acute care;biomarker validation;career development;clinical epidemiology;clinical predictors;cost;data resource;design;effective therapy;epidemiology study;frailty;functional decline;improved outcome;innovation;interdisciplinary collaboration;interest;meetings;multiple chronic conditions;novel;outreach;prognostic;response;secondary analysis;support network;targeted therapy trials;therapeutic target;therapy development;treatment strategy;treatment trial;webinar;working group,NIDUS II: Advanced-Stage Development and Utilization of the NIDUS Research Infrastructure to Advance Interdisciplinary Aging Research in Delirium,Delirium an acute disorder of attention and cognition is a common life-threatening and costly condition forolder adults with strong links to Alzheimers Disease and Related Dementias (ADRD). The goal of the currentproposal is to advance foundational research to develop more effective treatments for delirium. This goal willbe accomplished by utilizing and expanding a research network the Network for Investigation of Delirium:Unifying Scientists (NIDUS II) to bring together investigators across disciplines and institutions to conductessential research to develop safe and effective treatments for delirium and ultimately to improve outcomes fordelirium in all older adults particularly those with ADRD.,NIA,10772012,2/16/2024 12:00:00 AM,PAR-20-071,5R33AG071744-04,5,R33,AG,071744,04, ,"ROBERTS, LUCI",6/1/2021 12:00:00 AM,2/28/2026 12:00:00 AM,ZAG1-ZIJ-D(J2), ,1889032,"INOUYE, SHARON K.","JONES, RICHARD N",08,Unavailable,030832075,WS29EMGEVEJ4,030832075,WS29EMGEVEJ4,US,42.296681,-71.130734,9512301,HEBREW REHABILITATION CENTER FOR AGED,BOSTON,MA,Independent Hospitals,021311000,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,805402, ,NIA,589936,215466, ,805402,,805402.0 | |
| No NIH Category available,Affect;Algorithms;Area;Asian;Award;Biological;Biometry;Black race;Cancer Etiology;Cancer Patient;Cancer Prognosis;Cancer Survivor;Carcinoma;Categories;Characteristics;Classification;Clinical;Clinical Data;Clinical Trials;Communication;Computational Biology;Data;Data Sources;Development;Diagnosis;Disease;Disease Management;Distress;Epithelial ovarian cancer;Event;Fostering;Foundations;Fright;Future;Gene Expression Profile;Gene Expression Profiling;Genetic Markers;Glean;Goals;Guidelines;Hispanic;Hospitalization;Individual;Intervention;Knowledge;Leadership;Link;Malignant Neoplasms;Malignant neoplasm of ovary;Medical Records;Mentorship;Molecular;Morbidity - disease rate;Operative Surgical Procedures;Ovarian;Pathology Report;Patient Care;Patients;Pattern;Performance;Population;Population Database;Probability;Prognosis;Prognostic Marker;Publishing;Recurrence;Research;Research Personnel;Research Project Grants;Resources;Risk;Risk Assessment;Risk Factors;Serous;Source;Systemic Therapy;Therapeutic;Tissue Sample;Training;Treatment Protocols;United States;Update;Utah;Validation;Woman;Work;World Health Organization;biobank;biomarker development;biomarker driven;brca gene;cancer diagnosis;cancer epidemiology;cancer recurrence;career development;clinical care;clinical decision-making;clinical remission;clinical risk;clinically relevant;cohort;data analysis pipeline;data streams;epithelial to mesenchymal transition;experience;follow-up;genetic epidemiology;high risk;improved;mortality;multiple data sources;patient biomarkers;patient prognosis;personalized approach;population based;prognostic;transcriptomics;treatment response;tumor,Identifying factors associated with ovarian cancer recurrence using a population-based approach,Project NarrativeOvarian cancer recurrence affects more than 50% of ovarian cancer survivors; however little is known aboutspecific factors contributing to ovarian cancer recurrence risk. The proposed research project will identifyrecurrence patterns on a population level and evaluate the associations of patient clinicopathologic factorsand gene expression signatures with patterns of ovarian cancer recurrence and mortality. Information gleanedfrom this proposal may improve identification of patients at higher risk for ovarian cancer recurrence therebyinforming clinical decision-making and leading to alternative therapeutic strategies and patient follow-up.,NCI,10772039,1/4/2024 12:00:00 AM,RFA-CA-21-060,5K99CA277580-02,5,K99,CA,277580,02, ,"RADAEV, SERGEY",2/1/2023 12:00:00 AM,1/31/2025 12:00:00 AM,ZCA1-RTRB-U(O1), ,14513483,"COLLIN, LINDSAY JANE",Not Applicable,01,INTERNAL MEDICINE/MEDICINE,009095365,LL8GLEVH6MG3,009095365,LL8GLEVH6MG3,US,40.764542,-111.850317,514002,UNIVERSITY OF UTAH,SALT LAKE CITY,UT,SCHOOLS OF MEDICINE,841129049,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,398,Other Research-Related,2024,139586, ,NCI,129246,10340, ,139586,,139586.0 | |
| No NIH Category available,Address;Adopted;American;Biological;Biological Markers;Brain;Categories;Chronic;Clinical;Cluster Analysis;Cognitive;Confusion;Data;Data Set;Development;Diagnosis;Diagnostic;Disease remission;Early Intervention;Electrophysiology (science);Frequencies;Functional disorder;Functional impairment;Future;Goals;Heterogeneity;Image;Individual;Intervention;Investigation;Longitudinal Studies;Measures;Modeling;Neurobiology;Outcome;Outcome Measure;Patients;Pattern;Phase;Population;Prevention;Psychiatry;Psychopathology;Psychoses;Reporting;Research;Risk Factors;Sampling;Schizophrenia;Stratification;Subgroup;Symptoms;Syndrome;Therapeutic Intervention;Validation;Variant;Work;affective psychoses;analytical method;biological heterogeneity;biotypes;brain based;clinical heterogeneity;clinical high risk for psychosis;clinical phenotype;clinically relevant;comparative;early psychosis;follow-up;functional outcomes;high risk;high risk population;multimodal data;multimodality;neuroimaging;non-affective psychoses;outcome prediction;phenotypic data;prevent;prospective;psychosis risk;supervised learning;treatment response,Identification of Distinct Biotypes in Clinical High Risk for Psychosis State Using Objective Brain-Based Biomarkers,Project Narrative: Our project tackles the heterogeneity in individuals at high-risk for psychosiswhich has been a long-standing challenge in the field of psychiatry. This challenge has hamperedinvestigation and therapeutic intervention for decades. Using objective biomarkers to parse thisheterogeneity in the early phase of the illness we seek to describe this population and itssubgroups predict outcome and provide the basis for personalized early therapeuticinterventions for the purpose of preventing the illness before it arises.,NIMH,10772165,1/12/2024 12:00:00 AM,PA-21-235,5R21MH133001-02,5,R21,MH,133001,02, ,"WIJTENBURG, ANDREA",2/1/2023 12:00:00 AM,1/31/2025 12:00:00 AM,"Neurological, Mental and Behavioral Health Study Section[NMBH]", ,78004108,"YASSINE, WALID ",Not Applicable,07,Unavailable,071723621,C1CPANL3EWK4,071723621,C1CPANL3EWK4,US,42.33982,-71.10568,758101,BETH ISRAEL DEACONESS MEDICAL CENTER,BOSTON,MA,Independent Hospitals,022155400,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,242,Non-SBIR/STTR,2024,155207, ,NIMH,129610,25597, ,155207,,155207.0 | |
| No NIH Category available,3-Dimensional;Antineoplastic Agents;Biological Assay;Biological Markers;Biological Models;Biology;Breast;Breast Adenocarcinoma;Breast Carcinoma;Cancer Biology;Cancer Model;Cancer cell line;Carcinoma;Cell Line;Cell Lineage;Cellular Structures;Characteristics;Classification;Clinical;Collaborations;Custom;Dependence;Development;Disease Progression;Ensure;Exhibits;Experimental Models;Funding;Genes;Genetic;Genetic Transcription;Genomics;Goals;Growth;Health;Health system;Human;In Vitro;Investigation;Malignant - descriptor;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of pancreas;Mammary Duct;Mammary Neoplasms;Mammary gland;Measurement;Mediating;Methodology;Methods;Microscopic;Modeling;Molecular;Molecular Profiling;Morphology;Oncologist;Organ;Organoids;Pancreas;Pancreatic Adenocarcinoma;Pancreatic carcinoma;Pancreatic duct;Pathologist;Patients;Pharmaceutical Preparations;Phenotype;Pregnancy;Primary Neoplasm;Procedures;Productivity;Program Research Project Grants;RNA Splicing;Reproducibility of Results;Research;Research Personnel;Resources;Sampling;Services;Specimen;Study models;Surgeon;Surrogate Markers;Technology;Testing;Therapeutic;Tissues;Traction;Training;Treatment Efficacy;Tumor Subtype;Validation;Variant;biobank;biomarker identification;cost effective;drug development;drug sensitivity;experimental study;genome annotation;genomic profiling;human model;in vitro Model;in vivo;innovation;insight;member;migration;molecular subtypes;mouse model;next generation;novel;pancreatic neoplasm;patient population;pharmacologic;programs;racial diversity;research study;response;self organization;stem;stem cells;therapeutic evaluation;transcriptome;transcriptomic profiling;transcriptomics;tumor;tumor microenvironment,Core B: Organoid Biobank,CORE B ORGANOID BIOBANKPROJECT NARRATIVETractable experimental models that accurately recapitulate human pancreatic and breast carcinoma biology arecritical to the overall goal of this Program Project Grant. Core B will provide all three Projects with access to alarge human patient-derived organoid biobank which includes hundreds of breast and pancreatic cancersamples. Expertise and methods for evaluating transcriptional and splicing dependencies will be provided toprovide deep insights into biomarkers and molecular mechanisms.,NCI,10773019,3/5/2024 12:00:00 AM,PAR-20-077,5P01CA013106-52,5,P01,CA,013106,52, , ,2/10/1997 12:00:00 AM,1/31/2028 12:00:00 AM,ZCA1-RPRB-8,8316,11852640,"DOS SANTOS, CAMILA ",Not Applicable,03,Unavailable,065968786,GV31TMFLPY88,065968786,GV31TMFLPY88,US,40.86755,-73.473456,4577101,COLD SPRING HARBOR LABORATORY,COLD SPRING HARBOR,NY,Research Institutes,117242209,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,211931, ,110381,101550, , ,, | |
| No NIH Category available,Apoptosis;Apoptotic;Automobile Driving;Biochemical;Bioinformatics;Biological;Biology;Cancer Patient;Candidate Disease Gene;Cell Adhesion Molecules;Cell Death;Cells;Clinical;Communication;Development;Disease;Down-Regulation;E-Cadherin;Epithelial Cells;Epithelium;Event;Future;Gastric Adenocarcinoma;Gene Mutation;Genes;Genetic Transcription;Genetically Engineered Mouse;Grant;Investigation;Iron;Lipid Peroxidation;Malignant - descriptor;Malignant Neoplasms;Mediating;Mesenchymal;Mesothelioma;Metabolism;Missense Mutation;Modality;Molecular;Mutate;Mutation;Neoplasm Metastasis;Neurofibromin 2;Oncogenic;Oncoproteins;Organoids;Pathologic;Pathway interactions;Patients;Play;Precision therapeutics;Predisposition;Property;Publishing;Regulation;Research;Resistance;Role;Signal Pathway;Signal Transduction;Structure;TFRC gene;Testing;The Cancer Genome Atlas;Therapeutic;Transcription Coactivator;Tumor Suppression;Tumor Suppressor Proteins;Validation;Work;Xenograft Model;Xenograft procedure;biomarker identification;cancer cell;cancer genomics;cancer therapy;carcinogenesis;clinically significant;effective therapy;gastric cancer cell;genetic approach;genome-wide;genomic data;in vivo;inhibitor;insight;loss of function;loss of function mutation;malignant stomach neoplasm;mouse model;mutant;novel;pharmacologic;pre-clinical;predicting response;predictive marker;promoter;screening;specific biomarkers;success;tumor;tumorigenesis,Ferroptosis and Cancer Cell Signaling,Narrative Success of the proposed research will unveil in-depth mechanisms of ferroptosis as well as its functionalcommunication with various cancer-relevant intercellular and intracellular molecular events. The proposedresearch will also lead to the identification of biomarkers that predict cancer responsiveness to future ferroptosis-inducing cancer therapy.,NCI,10773067,1/8/2024 12:00:00 AM,PA-20-185,5R01CA258622-03,5,R01,CA,258622,03, ,"SALNIKOW, KONSTANTIN",2/1/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Cancer Molecular Pathobiology Study Section[CAMP], ,8020423,"JIANG, XUEJUN ",Not Applicable,12,Unavailable,064931884,KUKXRCZ6NZC2,064931884,KUKXRCZ6NZC2,US,40.764045,-73.956024,5079202,SLOAN-KETTERING INST CAN RESEARCH,NEW YORK,NY,Research Institutes,100656007,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,396,Non-SBIR/STTR,2024,434191, ,NCI,245306,188885, ,434191,,434191.0 | |
| No NIH Category available,Address;Adopted;Aftercare;Age;Architecture;Biological;Biological Markers;Biology;Blood;Cancer Etiology;Cancer Patient;Cessation of life;Clinical;Clinical Data;Clinical Trials;Combined Modality Therapy;Data;Data Set;Diagnosis;Disease;Distant;Distant Metastasis;Evaluation;Evolution;Gender;Goals;Habitats;Heterogeneity;Histology;Image;Immune;In complete remission;Incidence;Individual;Knowledge;Localized Disease;Location;Machine Learning;Magnetic Resonance Imaging;Malignant Neoplasms;Measurement;Micrometastasis;Modality;Modeling;Morbidity - disease rate;Morphology;Neoadjuvant Therapy;Operative Surgical Procedures;Organ Preservation;Pathologic;Patient observation;Patient-Focused Outcomes;Patients;Performance;Prediction of Response to Therapy;Process;Prognosis;Prognostic Marker;Public Health;Quality of life;Recommendation;Rectal Cancer;Recurrence;Recurrent disease;Reproducibility;Research;Retrospective cohort;Risk;Risk Factors;Safety;Serial Magnetic Resonance Imaging;Statistical Models;Systemic disease;Testing;Total Mesorectal Excision;Toxic effect;Training;Treatment outcome;Validation;advanced disease;aggressive therapy;blood-based biomarker;chemoradiation;chemotherapy;clinical risk;clinical translation;clinically relevant;cohort;deep learning;deep learning model;design;disorder control;effective therapy;high risk;imaging biomarker;improved;improved outcome;individual patient;innovation;knowledge base;learning strategy;mortality;multimodal data;multitask;novel;novel strategies;outcome prediction;overtreatment;patient prognosis;personalized approach;personalized medicine;predicting response;predictive marker;predictive modeling;prognostic;prognostic model;prognostic value;prospective;radiological imaging;radiomics;response;serial imaging;standard care;standard of care;success;therapy outcome;tool;treatment response;treatment strategy;tumor;tumor DNA;tumor microenvironment,MRI and blood biomarkers of neoadjuvant therapy response and outcomes in rectal cancer,PROJECT NARRATIVERectal cancer is a major public health burden with a high incidence and mortality in the US andworldwide. In this project we propose to develop imaging biomarkers to predict treatment responseand prognosis of patients with rectal cancer. Success of our research may help guide surgery andidentify the most effective treatment for an individual patient which will improve quality of life andpatient outcomes.,NCI,10773747,2/9/2024 12:00:00 AM,PA-20-185,1R01CA285456-01,1,R01,CA,285456,01, ,"WANG, YISONG",2/1/2024 12:00:00 AM,1/31/2029 12:00:00 AM,Clinical Translational Imaging Science Study Section[CTIS], ,10933867,"LI, RUIJIANG ",Not Applicable,16,RADIATION-DIAGNOSTIC/ONCOLOGY,009214214,HJD6G4D6TJY5,009214214,HJD6G4D6TJY5,US,37.426852,-122.17047,8046501,STANFORD UNIVERSITY,STANFORD,CA,SCHOOLS OF MEDICINE,943052004,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,554345, ,NCI,359032,195313, ,554345,,554345.0 | |
| No NIH Category available,Acute;Address;Alleles;Alzheimer disease prevention;Alzheimer's Disease;Alzheimer's disease risk;Alzheimers disease biomarker;Amyloid;Chronic stress;Clinical Trials;Cognitive;Consensus;Distress;Endocrine;Executive Dysfunction;Failure;Foundations;Functional disorder;Future;Genes;Genetic Polymorphism;Genotype;Heterogeneity;Hormones;Human;Hydrocortisone;Impaired cognition;Individual;Intervention;Measures;Memory;Memory Loss;Memory impairment;Methods;Nerve Degeneration;Neurofilament-L;Outcome;Patients;Personality;Physiological;Plasma;Prevention trial;Production;Prospective Studies;Public Health;Research;Research Design;Risk;Sampling;Sex Differences;Stress;Stress Tests;Stressful Event;System;Translating;Trier Social Stress Test;Woman;acute stress;apolipoprotein E-4;biological adaptation to stress;blood-based biomarker;clinical application;cognitive testing;disease heterogeneity;endophenotype;executive function;follow-up;hypothalamic-pituitary-adrenal axis;interest;men;middle age;mild cognitive impairment;novel strategies;performance tests;polygenic risk score;response;saliva sample;sex;stressor;treatment trial;young adult,Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease,PROJECT NARRATIVEGiven the many recent failures of amyloid-lowering therapies in Alzheimers disease (AD) it is important toidentify new mechanisms which may inform treatment targets. This proposal could lay the foundation for futurelarge-scale AD prevention trials targeting HPA-axis reactivity in at-risk individuals.,NIA,10774198,2/1/2024 12:00:00 AM,PAR-18-877,5R01AG065171-03,5,R01,AG,65171,3, ,"HETTINGER, JANE CECELIA",2/1/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Special Emphasis Panel[ZRG1-BBBP-H(55)R], ,6202910,"MUNRO, CYNTHIA ANN",Not Applicable,7.0,PSYCHIATRY,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,650697, ,NIA,397372,253325, ,650697,,650697.0 | |
| No NIH Category available,APP-PS1;Affinity;Alzheimer's Disease;Alzheimer's disease model;Alzheimer's disease pathology;Alzheimers disease biomarker;Amyloid;Amyloid beta-Protein;Animals;Antibodies;Binding;Biodistribution;Blood Vessels;Brain;Chemical Structure;Custom;DAP kinase;Dependence;Deposition;Derivation procedure;Development;Disease Progression;Drug Kinetics;Dyes;Early Diagnosis;Environment;Enzymes;Fluorescence;Fluorescent Dyes;Fluorescent Probes;General Hospitals;Human;Image;Impaired cognition;In Vitro;Individual;International;Label;Leadership;Libraries;Magnetic Resonance Imaging;Massachusetts;Measures;Memory impairment;Mentored Research Scientist Development Award;Mentors;Methods;Microscope;Microscopic;Modeling;Monitor;Multi-modal optical imaging;Mus;Near-infrared optical imaging;Neurodegenerative Disorders;Neurofibrillary Tangles;Nonionizing Radiation;Optics;Pathologic;Pathway interactions;Patients;Penetration;Performance;Photons;Positron-Emission Tomography;Property;Quantitative Structure-Activity Relationship;Research;Research Personnel;Resolution;Resources;Scalp structure;Senile Plaques;Skin;Structure;System;Techniques;Testing;Therapeutic;Therapeutic Effect;Time;Tissues;Training;Transgenic Mice;Validation;Work;abeta accumulation;blood-brain barrier crossing;candidate identification;cost;cranium;efficacy study;extracellular;fluorophore;imaging approach;imaging biomarker;imaging modality;imaging study;imaging system;in vivo;in vivo evaluation;in vivo imaging;inhibitor;instrumentation;medical schools;microscopic imaging;molecular imaging;mouse model;multi-photon;multimodality;multiphoton microscopy;neurofibrillary tangle formation;neuropathology;non-invasive imaging;non-invasive monitor;non-invasive optical imaging;novel;optical imaging;optical spectra;pre-clinical;protein aggregation;simulation;single photon emission computed tomography;skills;small molecule libraries;tau Proteins;tau aggregation;theranostics;tool;treatment response;tumor,Optical probe and instrumentation development for in vivo near-infrared fluorescence imaging of Alzheimer's disease,PROJECT NARRATIVEAlzheimer's disease (AD) is progressive neurodegenerative disorder characterized by the extracellularaccumulation of amyloid (A) deposits and the formation of intracellular tau-containing neurofibrillary tanglesin the brain. This proposal aims to develop the near-infrared optical probes and instrumentation that will enablefor the first time the non-invasive monitoring of the dynamics of these pathological protein aggregates in ADmouse models with cellular resolution. The developed tools and techniques will represent a significant advancein our ability to assess therapeutic strategies when conducting preclinical mouse studies in AD.,NIA,10774216,1/31/2024 12:00:00 AM,PA-20-190,5K01AG072046-03,5,K01,AG,072046,03, ,"LUO, YUAN",2/1/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Career Development For Early Career Investigators Study Section [AGCD-2], ,14281587,"HOU, STEVEN SHUYU",Not Applicable,08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Other Research-Related,2024,127320, ,NIA,119000,8320, ,127320,,127320.0 | |
| No NIH Category available,Age;Atrophic;Biological Assay;Biological Markers;Blood;Blood Tests;Brain;Central Nervous System Diseases;Cerebrospinal Fluid;Characteristics;Clinical;Cytoskeletal Proteins;Data;Decision Making;Demyelinating Diseases;Diabetes Mellitus;Disability status;Disease;Electronics;Enhancing Lesion;Enrollment;Europe;Health;Healthcare;Hyperlipidemia;Hypertension;Image;Immune;Immunoassay;Immunotherapy;Inflammatory;Injury;Institution;Intervention;Lesion;Light;Magnetic Resonance Imaging;Measures;Mediating;Medical;Monitor;Multicenter Studies;Multiple Sclerosis;Nerve;Nervous System Disorder;Neurological disability;Neurons;Obesity;Outcome;Pathologic;Patient Care;Patients;Pharmaceutical Preparations;Proteins;Qualifying;Race;Radiology Specialty;Randomized Controlled Trials;Relapse;Research;Sampling;Serum;Severity of illness;Site;Smoking;Standardization;Technology;Treatment Efficacy;United States;Validation;Visit;aggressive therapy;biobank;blood-based biomarker;brain tissue;brain volume;cerebral atrophy;clinical practice;cohort;comorbidity;demographics;design;disability;disability risk;disorder subtype;follow-up;gray matter;illness length;interest;kidney dysfunction;multiple sclerosis patient;multiple sclerosis treatment;neurofilament;novel;prognostic;prospective;recruit;research clinical testing;sex;tool;treatment response,Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis,Project NarrativeIn this project we plan to show that a simple new blood test which measures smallamounts of proteins coming from nerves in the brain can be used to help predictthe severity of disease in people with multiple sclerosis. This also may be able tohelp determine whether MS drugs are working to protect the brain tissues.,NINDS,10774227,1/18/2024 12:00:00 AM,PAR-18-664,5U01NS111678-05,5,U01,NS,111678,05, ,"TAYLOR-BURDS, CAROL C",1/1/2020 12:00:00 AM,12/31/2024 12:00:00 AM,Neurological Sciences and Disorders B Study Section[NSD-B], ,6130429,"CALABRESI, PETER A",Not Applicable,07,NEUROLOGY,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,853,Non-SBIR/STTR,2024,1217659, ,NINDS,949402,268257, ,1217659,,1217659.0 | |
| No NIH Category available,Address;Adult;Anti-Inflammatory Agents;Attenuated;Biological;Biological Markers;Biology;Biometry;Bronchoalveolar Lavage Fluid;CD59 Antigen;Carbon Monoxide;Cessation of life;Chronic;Clinical;Clinical Trials;Communities;Data;Death Rate;Development Plans;Diffusion;Disease Progression;Docosahexaenoic Acids;Eicosanoid Production;Elderly;Epidemiology;Extracellular Matrix;Fatty Acids;Fibrosis;Foundations;Future;Gene Expression Profile;Goals;Hospitalization;Individual;Inflammatory;Intake;Interstitial Lung Diseases;K-Series Research Career Programs;Lead;Ligands;Light;Lung;Lung Transplantation;Matrilysin;Measures;Mediating;Medical;Mentors;Mentorship;Multi-Institutional Clinical Trial;Mus;Omega-3 Fatty Acids;Omega-6 Fatty Acids;Oxidative Stress;PPAR gamma;Participant;Pathogenesis;Pathway interactions;Patients;Phenotype;Phospholipids;Pilot Projects;Plasma;Polyunsaturated Fatty Acids;Positioning Attribute;Pre-Clinical Model;Production;Prognosis;Property;Prospective cohort;Pulmonary Fibrosis;Pulmonary Inflammation;Pulmonary Surfactant-Associated Protein D;Research;Research Personnel;Respiratory Failure;Risk;Risk Factors;Role;Sample Size;Sampling;Serum;Severity of illness;Therapeutic;Therapy Clinical Trials;Time;Training;Translational Research;Vital capacity;Walking;alveolar epithelium;antifibrotic treatment;beta-Chemokines;biobank;biomarker validation;career development;cell injury;clinical diagnosis;clinical translation;cohort;design;exercise capacity;fibrotic interstitial lung disease;fibrotic lung;hospitalization rates;idiopathic pulmonary fibrosis;lipid mediator;lung injury;modifiable risk;mortality;mouse model;novel;novel marker;participant enrollment;patient oriented research;personalized medicine;population based;pulmonary function;respiratory;secondary outcome;symptomatic improvement;transcriptome sequencing;transcriptomics;translational scientist,Role of polyunsaturated fatty acids in pulmonary fibrosis,PROJECT NARRATIVEIdiopathic pulmonary fibrosis (IPF) is a chronic form of interstitial lung disease in adults with few therapies thatleads to chronic respiratory failure with a high mortality rate. I propose to determine lower plasma phospholipidlevels of omega-3 fatty acids and their metabolites as a modifiable risk factor in adults with IPF. By achievingthe aims of my proposal this may lead to clinical trials of therapies that raise omega-3 fatty acid levels for thetreatment of IPF.,NHLBI,10774238,1/26/2024 12:00:00 AM,PA-19-119,5K23HL150301-04,5,K23,HL,150301,04, ,"GOMEZ, CHRISTIAN RENE",2/20/2021 12:00:00 AM,1/31/2026 12:00:00 AM,ZHL1-CSR-M(O1), ,15065520,"KIM, JOHN S",Not Applicable,05,INTERNAL MEDICINE/MEDICINE,065391526,JJG6HU8PA4S5,065391526,JJG6HU8PA4S5,US,38.050527,-78.500531,1526402,UNIVERSITY OF VIRGINIA,CHARLOTTESVILLE,VA,SCHOOLS OF MEDICINE,229044195,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,838,Other Research-Related,2024,171612, ,NHLBI,158900,12712, ,171612,,171612.0 | |
| No NIH Category available,3-Dimensional;Ablation;Address;Advanced Development;Anatomy;Applications Grants;Benchmarking;Biological Markers;Biomedical Engineering;Blood Vessels;Breast;Breast Cancer Patient;Breast Cancer Treatment;Breast Cancer therapy;Breast Magnetic Resonance Imaging;Cancer Center;Clinical;Clinical Trials;Clinical assessments;Collaborations;Computer Vision Systems;Contrast Media;Cosmetics;Data;Data Set;Development;Diagnosis;Dose;Early Diagnosis;Ensure;Environment;Female;Focused Ultrasound;Focused Ultrasound Therapy;Future;Gadolinium;Goat;Histopathology;Image;Image Analysis;Individual;International;Label;Literature;Magnetic Resonance;Magnetic Resonance Imaging;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;Methods;Modeling;Monitor;Oryctolagus cuniculus;Pathology;Patients;Pre-Clinical Model;Procedures;Protocols documentation;Radiology Specialty;Research Project Grants;Research Proposals;Safety;System;Techniques;Therapeutic;Thermal Ablation Therapy;Thermometry;Time;Tissue Viability;Tissues;Training;Translations;Treatment Efficacy;Treatment outcome;Udders;Validation;Work;convolutional neural network;deep learning;deep neural network;detection method;digital imaging;efficacious treatment;image registration;imaging biomarker;improved;in vivo;innovation;minimally invasive;model design;mortality;multidisciplinary;novel;overtreatment;patient population;predictive marker;professional atmosphere;radio frequency;reconstruction;treatment planning;treatment response;tumor;tumor ablation,A tissue viability imaging biomarker for use in non-invasive breast cancer therapy,NarrativeThe current treatment paradigms for minimally invasive ablative breast cancer therapies do not ensurecomplete tumor ablation or allow for immediate and accurate assessment of tissue viability. Although severalMRI contrasts are sensitive to thermal ablation no individual or combined MR contrasts have been able toaccurately predict tissue viability immediately after magnetic resonance guided focused ultrasound ablation.This proposal will develop a non-contrast deep neural network imaging biomarker that will provide both anaccurate assessment of tissue viability and a treatment outcome metric that will allow for iterative MRgFUSablation assessment ensuring efficacy of magnetic resonance guided focused ultrasound ablation treatmentsfor breast cancer.,NCI,10774280,1/9/2024 12:00:00 AM,PAR-19-158,5R01CA259686-03,5,R01,CA,259686,03, ,"BEIER, HOPE THOMAS",2/10/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Imaging Guided Interventions and Surgery Study Section[IGIS], ,11263447,"PAYNE, ALLISON ","JOSHI, SARANG ",01,RADIATION-DIAGNOSTIC/ONCOLOGY,009095365,LL8GLEVH6MG3,009095365,LL8GLEVH6MG3,US,40.764542,-111.850317,514002,UNIVERSITY OF UTAH,SALT LAKE CITY,UT,SCHOOLS OF MEDICINE,841129049,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,555975, ,NCI,363304,192671, ,555975,,555975.0 | |
| No NIH Category available,Adopted;Adult;Apoptosis;Apoptotic;BCL-2 Protein;BH3 Domain;BIM Bcl-2-binding protein;Binding;Biological Assay;Biological Markers;Cancer Etiology;Cancer Patient;Cell Line;Cellular Stress;Cessation of life;Chronic;Clinic;Clinical;Clinical Trials Design;Co-Immunoprecipitations;Combined Modality Therapy;Credentialing;Data;Death Domain;Dependence;Development;Diagnosis;Diagnostic tests;Environment;Exposure to;Family;Family member;Formalin;Genomics;Goals;Growth;Hematologic Neoplasms;Heterogeneity;In Situ;In Vitro;Infrastructure;Invaded;Knowledge;Ligation;Lymphocyte;MAP Kinase Gene;MCL1 gene;MEKs;Malignant Neoplasms;Measures;Mediating;Mitochondria;Mitogen-Activated Protein Kinase Inhibitor;Modeling;Mutation;Myeloid Leukemia;Neuroblastoma;Outcome;Paraffin Embedding;Pathway interactions;Patients;Pediatric Neoplasm;Pharmaceutical Preparations;Play;Primary Neoplasm;Process;Protein Family;Proteins;Public Health;Relapse;Research;Resistance;Role;Signal Transduction;Site;Slide;Solid Neoplasm;Stress;Tertiary Protein Structure;Testing;Therapeutic;Validation;Work;cancer care;cancer cell;cell growth;clinical care;clinical efficacy;clinical translation;cytochrome c;diagnostic assay;diagnostic tool;drug efficacy;genomic predictors;improved;in vivo;in-vitro diagnostics;inhibitor;inhibitor therapy;innovation;insight;mortality;neoplastic cell;novel diagnostics;patient derived xenograft model;patient subsets;precision medicine;predictive marker;predictive test;protein protein interaction;resistance mechanism;response;survival prediction;synergism;tumor,Mechanistic biomarkers to enable Bcl2 inhibitor therapies for neuroblastoma,Project Narrative The proposed research is relevant to public health since the resistance of tumors to available therapiesremains the major cause of cancer mortality. A better understanding of howresistance develops and the specificvulnerabilities each resistance mechanism poses will provide new treatment opportunities. The inclusion ofselective Bcl2 family inhibitors into clinical care driven by this fundamental knowledge will have broad reach inimproving cancer outcomes.,NCI,10775714,1/25/2024 12:00:00 AM,PA-19-056,5R01CA248501-04,5,R01,CA,248501,04, ,"DEY, SUMANA MUKHERJEE",2/18/2021 12:00:00 AM,1/31/2026 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,1901244,"HOGARTY, MICHAEL D",Not Applicable,03,Unavailable,073757627,G7MQPLSUX1L4,073757627,G7MQPLSUX1L4,US,39.946632,-75.196604,1499101,CHILDREN'S HOSP OF PHILADELPHIA,PHILADELPHIA,PA,Independent Hospitals,191462305,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,375256, ,NCI,236523,138733, ,375256,,375256.0 | |
| No NIH Category available,Acceleration;Address;Adsorption;Aggressive behavior;Air;Antibodies;Area;Automation;Benchmarking;Binding;Binding Proteins;Biological;Biological Assay;Biological Models;Biopsy;Cell Count;Cell Line;Cells;Chromatin;Chromatin Structure;Clinic;Clinical;Clinical Trials;Complex;Core Biopsy;Coupling;DNA;DNA Binding;DNA Methylation;DNA Sequence;DNA Sequence Alteration;DNA-Binding Proteins;Data;Development;Devices;Disease Progression;Dissociation;Ensure;Epigenetic Process;Exclusion;Fine needle aspiration biopsy;Force of Gravity;Frequencies;Future;GSTP1 gene;Gene Expression;Gene Silencing;Genes;Genetic Transcription;Genomics;Goals;Histone Acetylation;Histones;Human;Hypermethylation;Immune Evasion;Kinetics;Liquid substance;Magnetism;Malignant Neoplasms;Malignant neoplasm of prostate;Measurement;Measures;Methods;Methylation;Microfluidics;Minority;Modification;Molecular;Mutation;Nature;Needle biopsy procedure;Neoplasm Circulating Cells;Neoplasm Metastasis;Neurosecretory Systems;Oils;Patients;Pattern;Phase;Phenotype;Play;Pre-Clinical Model;Preparation;Primary Neoplasm;Procedures;Process;Proteins;Protocols documentation;Reaction;Reagent;Recovery;Research Personnel;Research Technics;Role;Sampling;Science;Solid Neoplasm;Speed;Surface;Surface Tension;Techniques;Technology;Translations;Tumor Cell Invasion;Variant;Wettability;aqueous;biomarker development;biomarker validation;bisulfite sequencing;cancer therapy;cell immortalization;chemotherapy;chromatin immunoprecipitation;diagnostic biomarker;epigenetic marker;epigenome;epigenomics;genomic aberrations;genomic biomarker;histone modification;hormonal signals;hormone therapy;improved;interest;magnetic field;microfluidic technology;new therapeutic target;novel therapeutic intervention;particle;precision medicine;preservation;promoter;prospective;protein complex;stem;success;targeted treatment;therapeutic target;therapy resistant;tumor;tumor DNA;tumor heterogeneity;tumor progression;tumorigenesis;validation studies;virtual,Enhancing Epigenetic Analysis Of Rare Cells With Multi-Phase Microfluidics,PROJECT NARRATIVEEpigenetic alterations have been identified as playing a critical role in the development andprogression of cancer. Current epigenetic assays require large numbers of cells (thousands tomillions) with limited capability to analyze rare cells or tumor heterogeneity. This proposal seeksto develop new microfluidic technologies to evaluate epigenetic alterations in rare cells that canbe used to improve our understanding of cancer develop new therapeutic interventions andsupport biomarker development.,NCI,10775716,1/31/2024 12:00:00 AM,PAR-19-158,5R01CA247479-05,5,R01,CA,247479,05, ,"OSSANDON, MIGUEL",2/3/2020 12:00:00 AM,1/31/2025 12:00:00 AM,Enabling Bioanalytical and Imaging Technologies Study Section[EBIT], ,1923039,"BEEBE, DAVID J","LANG, JOSHUA MICHAEL",02,PATHOLOGY,161202122,LCLSJAGTNZQ7,161202122,LCLSJAGTNZQ7,US,43.068519,-89.400858,578503,UNIVERSITY OF WISCONSIN-MADISON,MADISON,WI,SCHOOLS OF MEDICINE,537151218,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,602554, ,NCI,394249,208305, ,602554,,602554.0 | |
| No NIH Category available,Acceleration;Affect;Age;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimer's disease pathology;Alzheimer's disease risk;Amyloid;Amyloid beta-42;Amyloid beta-Protein;Apolipoprotein E;Automobile Driving;Autopsy;Bioinformatics;Biological;Biological Markers;Brain;Brain Diseases;Cell Physiology;Cell model;Cerebrospinal Fluid;Clinical;Data;Data Set;Dementia;Disease;Etiology;Gene Expression;Genes;Genetic;Genetic Variation;Genetic study;Genome Scan;Genomics;Genotype;Goals;Impaired cognition;In Vitro;Individual;Intervention;Magnetic Resonance Imaging;Measures;Mediation;Mendelian randomization;Methods;Myeloid Cells;National Institute on Aging;Nature;Nerve Degeneration;Neurofibrillary Tangles;Neuronal Injury;Outcome;Pathogenesis;Pathologic;Pathologic Processes;Pathology;Pathway interactions;Persons;Phase;Phenotype;Plasma;Positron-Emission Tomography;Preventive measure;Proxy;Public Health;Quantitative Trait Loci;Recommendation;Research;Research Subjects;Risk;Role;Sampling;Senile Plaques;Signal Transduction;Symptoms;Testing;Variant;abeta deposition;amyloid pathology;biomarker validation;clinical diagnosis;comorbidity;diagnostic value;effective therapy;endophenotype;experimental study;extracellular;fluorodeoxyglucose positron emission tomography;follow-up;genetic architecture;genetic association;genetic information;genetic variant;genome sequencing;genome wide association study;improved;interest;neuroimaging;neuropathology;novel;personalized medicine;polygenic risk score;population based;pre-clinical;prevent;rare variant;tau Proteins;tau-1;whole genome,Genetic Architecture of Alzheimers disease Proteinopathies,Project NarrativeAlzheimer's disease (AD) is a major public health problem. Currently there is no effective treatment for AD.Genetic studies aiming to improve our understanding of the pathogenesis of AD and underlying mechanismsmay contribute to personalized medicine goals and better therapies and/or preventive measures This study isfocused to delineate the genetic basis of two AD-specific proteinopathies amyloid-beta (A) and pathologic tauby whole-genome-sequencing. The successful completion of the proposed comprehensive study usingbiomarkers of two AD-specific proteinopathies in living people with well characterized amyloid-PET and CSFA42/tau datasets along with clinical outcomes of dementia followed by functional studies will make a majorcontribution to our understanding of the pathogenesis of AD and underlying mechanisms which may contributeto personalized medicine goals and better therapies and/or preventive measures.,NIA,10775757,2/19/2024 12:00:00 AM,PA-18-484,5R01AG064877-04,5,R01,AG,064877,04, ,"MILLER, MARILYN",4/15/2021 12:00:00 AM,2/28/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-GGG-B(02)M], ,1867465,"KAMBOH, M. ILYAS","CRUCHAGA, CARLOS ",12,GENETICS,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,SCHOOLS OF PUBLIC HEALTH,152133320,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,1817608, ,NIA,1481550,336058, ,1817608,,1817608.0 | |
| No NIH Category available, ,HRV-guided tDCS: Integrating a biomarker for clinical utility,PROJECT NARRATIVEThe integration of biomarker guidance with transcranial direct current stimulation (tDCS) could individualize andoptimize dosing to improve its clinical utility. We propose to develop a tDCS system that includes the collectionof the nonspecific biomarker of heart rate variability (HRV) by validating impedance-based heart rate (i-HR) andits clinical response to tDCS intervention in adults with depression. With the advantage of home-based datacollection this proposal rigorously builds a breakthrough system that includes wearable neuromodulation andmonitoring of vital signs linked to brain health.,NIBIB,10777098,8/5/2024 12:00:00 AM,PA-20-183,1R01EB035129-01,1,R01,EB,035129,01, ,"LASH, TIFFANI BAILEY",8/5/2024 12:00:00 AM,4/30/2028 12:00:00 AM,Special Emphasis Panel[ZRG1-NV-Q(91)S], ,77939948,"PILLONI, GIUSEPPINA ",Not Applicable,12,NEUROLOGY,121911077,M5SZJ6VHUHN8,121911077,M5SZJ6VHUHN8,US,40.669895,-73.974354,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NEW YORK,NY,SCHOOLS OF MEDICINE,10016,UNITED STATES,N,8/5/2024 12:00:00 AM,4/30/2025 12:00:00 AM,286,Non-SBIR/STTR,2024,730385, ,NIBIB,505051,225334, ,730385,,730385.0 | |
| No NIH Category available,Acetylcysteine;Age;Anatomy;Ancillary Study;Biological Markers;Blood;CCL18 gene;Cessation of life;Characteristics;Chicago;Clinical Trials;Collection;Cross-Sectional Studies;Data;Detection;Dimensions;Disease;Disease Marker;Disease Progression;FDA approved;Fibrosis;Foundations;Gender;Genes;Genetic Markers;Genetic Polymorphism;Image;Image Analysis;Length;Lung Transplantation;MUC5B gene;Measures;Methods;Modeling;Monitor;Morphology;Outcome Measure;Parents;Participant;Patients;Pattern;Performance;Pharmaceutical Preparations;Pharmacotherapy;Physiological;Physiology;Plasma;Plasma Proteins;Positioning Attribute;Predisposition;Prognostic Marker;Progression-Free Survivals;Proteins;Proteomics;Publishing;Pulmonary Fibrosis;Radiology Specialty;Registries;Regression Analysis;Role;Scanning;Severities;Severity of illness;TOLLIP gene;Texture;Therapeutic Trials;Time;Validation;Variant;Visual;Vital capacity;X-Ray Computed Tomography;clinical decision-making;cohort;drug development;efficacy testing;follow-up;genetic predictors;genetic variant;genome sequencing;genomic biomarker;high dimensionality;idiopathic pulmonary fibrosis;improved;molecular marker;novel marker;precision medicine;prognostic value;prognostication;prospective;protein biomarkers;pulmonary function;radiomics;recruit;response;risk variant;survival prediction;telomere;transcriptome;transcriptome sequencing;transcriptomics;treatment response;whole genome,The role of quantitative CT and radiomic biomarkers for precision medicine in pulmonary fibrosis,Project Narrative:This ancillary study proposal will incorporate computed tomography scanning with quantitative CT analysisusing Data-driven texture analysis as an outcome measure into the PRECISIONS trial. It will also assess theadditive value of genetic genomic and protein markers for disease progression. Validation will be achievedthrough replication in 2 external cohorts.,NHLBI,10777799,1/31/2024 12:00:00 AM,PA-20-185,1R01HL171918-01,1,R01,HL,171918,01, ,"VUGA, LOUIS J",2/5/2024 12:00:00 AM,1/31/2029 12:00:00 AM,Respiratory Integrative Biology and Translational Research Study Section[RIBT], ,8048081,"NOTH, IMRE ",Not Applicable,05,INTERNAL MEDICINE/MEDICINE,065391526,JJG6HU8PA4S5,065391526,JJG6HU8PA4S5,US,38.050527,-78.500531,1526402,UNIVERSITY OF VIRGINIA,CHARLOTTESVILLE,VA,SCHOOLS OF MEDICINE,229044195,UNITED STATES,N,2/5/2024 12:00:00 AM,1/31/2025 12:00:00 AM,838,Non-SBIR/STTR,2024,762272, ,NHLBI,543159,219113, ,762272,,762272.0 | |
| No NIH Category available,4D MRI;Abeta clearance;Acceleration;Address;Adoption;Affect;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimer's disease pathology;Alzheimer's disease risk;Alzheimers disease biomarker;Animal Model;Attention;Biological Markers;Blood Vessels;Blood capillaries;Blood flow;Caliber;Cardiac;Cardiovascular Diseases;Cause of Death;Cephalic;Cerebrovascular Circulation;Cerebrovascular Disorders;Clinical;Clinical Trials;Cognition;Cohort Studies;Complex;Data;Dementia;Development;Disease;Disease Marker;Early identification;FarGo;Frequencies;Functional disorder;Generations;Goals;Health;Hemodynamic Phenomena;Heterogeneity;Homeostasis;Human;Image;Impaired cognition;Institution;Knowledge;Link;Liquid substance;Longitudinal Studies;Longitudinal cohort study;Magnetic Resonance Imaging;Measures;Mediating;Methodology;Methods;Modeling;Motion;National Institute of Neurological Disorders and Stroke;Nature;Nerve Degeneration;Nervous System Disorder;Noise;Participant;Pathology;Patients;Perfusion;Physiologic pulse;Population;Population Study;Positioning Attribute;Predisposition;Prevalence;Protocols documentation;Regulation;Research;Resolution;Rest;Risk;Risk Factors;Role;Sampling;Sensitivity and Specificity;Specificity;Symptoms;Techniques;Technology;Testing;Therapeutic;Tissues;Translating;United States;Vascular Diseases;White Matter Hyperintensity;Wisconsin;Work;alternative treatment;arterial spin labeling;arterial stiffness;attenuation;capillary bed;cerebrovascular;cerebrovascular health;clinical translation;cohort;curative treatments;deep learning;dementia risk;elastography;endothelial dysfunction;hemodynamics;high risk;human subject;hypoperfusion;imaging biomarker;improved;individual patient;innovation;insight;mild cognitive impairment;neuroimaging;neuroinflammation;neuropathology;neurovascular;non-invasive imaging;novel;novel strategies;optical imaging;premature;progression marker;protective factors;recruit;technology validation;tool;vascular risk factor,Non-Invasive Imaging Markers to Elicit the Role of Vascular Involvement in Alzheimers Disease,NARRATIVEAlzheimer's disease is correlated with vascular disease; however the nature and mechanism by which thesediseases interact to develop clinical dementia remains relatively unknown. The novel MRI techniques in thisproject enable new insights into vascular health. The overarching objective is to enable characterization ofcerebrovascular involvement in Alzheimer's Disease pathology through the development and study integrationof a new battery of non-invasive cerebrovascular health measures including tools to image vascular stiffnessand flow oscillations.,NIA,10778526,2/1/2024 12:00:00 AM,PAR-19-070,5R01AG075788-03,5,R01,AG,075788,03, ,"HSIAO, JOHN",2/15/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Emerging Imaging Technologies in Neuroscience Study Section[EITN], ,10239723,"JOHNSON, KEVIN MICHAEL",Not Applicable,02,PHYSICS,161202122,LCLSJAGTNZQ7,161202122,LCLSJAGTNZQ7,US,43.068519,-89.400858,578503,UNIVERSITY OF WISCONSIN-MADISON,MADISON,WI,SCHOOLS OF MEDICINE,537151218,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,613810, ,NIA,403299,210511, ,613810,,613810.0 | |
| No NIH Category available,Address;Age;Aging;Antigen-Presenting Cells;Autophagocytosis;Baltimore;Behavior;Biological Markers;Biological Models;Biological Process;Biology;Blood;Body Fluids;Cardiovascular system;Cell Aging;Cell model;Cells;Chondrocytes;Clinical;Cohort Studies;Collaborations;Communication;Complex;Data;Data Set;Defect;Elderly;Exercise;Fibroblasts;Fluorescence;Funding;Funding Opportunities;Goals;Health;Hematopoietic stem cells;Hip Fractures;Hip region structure;Homeostasis;Human;Immune;Immune system;In Vitro;Individual;Inflammaging;Inflammation;Interleukin-6;Knowledge;Laboratories;Literature;Longevity;Mammalian Cell;Measures;Mediating;Mediator;Metabolic;Methodology;Methods;MicroRNAs;Microscopic;Mitochondria;Mus;Myocardial Ischemia;Natural Killer Cells;Nucleic Acids;Operative Surgical Procedures;Organism;Outcome;Oxidative Stress;PECAM1 gene;Parents;Participant;Patients;Phenotype;Physical Performance;Physical activity;Physiological;Plasma;Play;Population;Process;Production;Proteins;Proteome;RNA;Randomized;Recovery;Regenerative capacity;Regulation;Reperfusion Injury;Resolution;Resources;Role;Sampling;Serum;Sorting;Specimen;Surface;Testing;Tissues;United States National Institutes of Health;Validation;Vesicle;Video Microscopy;WI 38 cell;age related;aged;cell type;cohort;cytokine;data de-identification;epidemiology study;exercise intensity;exercise training;extracellular vesicles;follow-up;healthy aging;immune function;immunoregulation;immunosenescence;improved;insulin sensitivity;interest;milliliter;mode of exercise;muscle metabolism;nanoparticle;particle;peripheral blood;predictive marker;promote resilience;resilience;responders and non-responders;response;secondary analysis;senescence;specific biomarkers;stem cells;stressor;trafficking;vesicular release,Extracellular Vesicle Analyses to Develop Aging and Resilience Biomarkers,Project NarrativeExtracellular vesicles (EVs) are microscopic particles produced by all cells in the body that circulate in thetrillions in every milliliter of blood. EVs can potentially provide signatures of aging and resilience and carryproteins and other molecules that can communicate and have effects at a distance. Using large numbers ofalready collected precious human specimens from individuals aged 20 to over 90 years old this projectcharacterizes the types and role of these vesicles in aging and develops new blood biomarker tests for thesevesicles to better understand mechanisms of aging and the ability to recover from stressors with aging.,NIA,10778527,12/22/2023 12:00:00 AM,PA-17-088,5R01AG070146-04,5,R01,AG,070146,04, ,"RAGHAVACHARI, NALINI",1/1/2021 12:00:00 AM,12/31/2025 12:00:00 AM,Aging Systems and Geriatrics Study Section[ASG], ,1884264,"KRAUS, VIRGINIA ",Not Applicable,04,INTERNAL MEDICINE/MEDICINE,044387793,TP7EK8DZV6N5,044387793,TP7EK8DZV6N5,US,36.007766,-78.926475,2221101,DUKE UNIVERSITY,DURHAM,NC,SCHOOLS OF MEDICINE,277054673,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,619847, ,NIA,409546,210301, ,619847,,619847.0 | |
| No NIH Category available,Address;Adipose tissue;Age;Anatomy;Back;Biological Markers;Biology;Birth;Body mass index;Brain;Brain imaging;Breathing;Cerebrum;Chemical Shift Imaging;Cholesterol;Data;Development;Developmental Biology;Diet;Diffusion Magnetic Resonance Imaging;Disease;Drug or chemical Tissue Distribution;Dual-Energy X-Ray Absorptiometry;Early identification;Endocrine;Endocrine system;Enrollment;Environment;Equilibrium;Etiology;Exhibits;Fatty acid glycerol esters;Functional Magnetic Resonance Imaging;Funding Mechanisms;Genetic Risk;Gestational Age;Glucose;Graph;Growth;Health;High Density Lipoproteins;Homeostasis;Human;Hydrocortisone;Hypothalamic structure;Immune;Immune system;Individual;Individual Differences;Infant;Inflammatory;Insulin;Interleukin-6;Intervention;Knowledge;Life;Lipids;Logic;Machine Learning;Magnetic Resonance Imaging;Maternal-fetal medicine;Measures;Mediating;Mentors;Mentorship;Metabolic;Methods;Modeling;Neurologic;Neurosciences;Newborn Infant;Nonesterified Fatty Acids;Obesity;Outcome;Phase;Phenotype;Physics;Physiological;Pregnancy;Primary Prevention;Principal Component Analysis;Procedures;Process;Public Health;Research;Research Proposals;Rewards;Risk;Risk Factors;Role;Satiation;Scientific Advances and Accomplishments;Shapes;Standardization;Surface;System;TNF gene;Technology;Term Birth;Testing;Time;Training;Triglycerides;Validation;Variant;Weight;analytical method;brain circuitry;brain magnetic resonance imaging;career;career development;clinically significant;cohort;connectome;cost effective;data reduction;design;developmental plasticity;disorder risk;energy balance;fetal;fetal programming;gestational weight gain;gray matter;improved;infancy;infant adiposity;metabolic rate;neuroimaging;newborn adiposity;novel;obesity in children;obesity risk;obesogenic;obstetrical complication;population based;postnatal;predictive modeling;prenatal;prenatal stress;prepregnancy;programs;prospective;random forest;recruit;sex;skills;vector;white matter,Fetal Programming of Human Newborn Energy Homeostasis Brain Networks,This proposal describes a comprehensive plan for the applicant Dr. Jerod Rasmussen to obtain expert trainingand conduct research that aims to identify novel MRI-based measures of energy homeostasis-related brain circuitryin the human newborn identify their gestational biology determinants and determine the prospective associationof these measures with subsequent risk for childhood obesity. The identification of brain-related biomarkers ofchildhood obesity risk that predate the influence of the obesogenic environment will contribute to an improved understandingof the neurological underpinnings of obesity early identification of at-risk individuals and interventiontargets for primary prevention.,NICHD,10778590,1/8/2024 12:00:00 AM,PA-19-130,5R00HD100593-04,5,R00,HD,100593,04, ,"ILEKIS, JOHN V",2/1/2023 12:00:00 AM,1/31/2026 12:00:00 AM,NSS, ,14641759,"RASMUSSEN, JEROD MICHAEL",Not Applicable,47,PEDIATRICS,046705849,MJC5FCYQTPE6,046705849,MJC5FCYQTPE6,US,33.64852,-117.82136,577504,UNIVERSITY OF CALIFORNIA-IRVINE,IRVINE,CA,SCHOOLS OF MEDICINE,926970001,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,865,Non-SBIR/STTR,2024,245851, ,NICHD,157013,89497, ,245851,,245851.0 | |
| No NIH Category available,Americas;Animal Model;Animals;Biodiversity;Biological Markers;Blood;Blood specimen;Cessation of life;Chagas Disease;Chronic;Chronic Phase;Clinical;Data;Disease;Disease Progression;Early identification;Economics;Electrocardiogram;Fibronectins;Gene Expression Profile;Genetic Variation;Genotype;Human;Immune;Immune response;Immunology;In Vitro;Infection;Lead;Life;Macaca;Macaca mulatta;Measures;Megacolon;Methods;Monitor;Names;Parasites;Parasitic Diseases;Pathogenesis;Patient Care;Patients;Peripheral Blood Mononuclear Cell;Pharmaceutical Preparations;Plasma;Play;Predisposition;Prognosis;Risk;Role;Shapes;System;Testing;Time;Trypanosoma cruzi;Validation;Virulence;Work;burden of illness;candidate marker;chagasic cardiomyopathy;chronic infection;cohort;disability-adjusted life years;early detection biomarkers;follow-up;heart function;improved;in vivo;neglected tropical diseases;potential biomarker;response;single-cell RNA sequencing;transcriptomics;translational impact;vector;vector-borne;years of life lost,Intra-host Trypanosoma cruzi parasite dynamics in naturally-infected macaques and Chagas disease progression,PROJECT NARRATIVEChagas disease is a major vector borne parasitic disease caused by the protozoanparasite Trypanosoma cruzi and a major gap is that patients at increased risk ofdeveloping severe disease cannot be distinguished from those who may remain in theasymptomatic chronic stage making any prognosis uncertain and complicating patientcare and treatment. Our general objective is to determine the effects of T. cruzi parasitediversity on disease progression during the chronic phase by following naturally-infectedChagasic macaques and associating parasite genetic diversity with the immuneresponse and clinical disease progression over time. These studies will allow testing forthe role of parasite genetic diversity in shaping disease progression and are expected tolead to improved patient care and control of this important disease.,NIAID,10778616,1/12/2024 12:00:00 AM,PA-20-195,5R21AI175523-02,5,R21,AI,175523,02, ,"PESCE, JOHN T",2/6/2023 12:00:00 AM,1/31/2025 12:00:00 AM,Pathogenic Eukaryotes Study Section[PTHE], ,9338297,"DUMONTEIL, ERIC ",Not Applicable,01,INTERNAL MEDICINE/MEDICINE,053785812,XNY5ULPU8EN6,053785812,XNY5ULPU8EN6,US,29.935429,-90.12279,8424601,TULANE UNIVERSITY OF LOUISIANA,NEW ORLEANS,LA,SCHOOLS OF PUBLIC HEALTH,701185665,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,229500, ,NIAID,150000,79500, ,229500,,229500.0 | |
| No NIH Category available,Address;Affect;Aftercare;American;Aneuploidy;Benign;Binding;Biological Assay;Biological Markers;Biopsy;Blood;Classification;Clinical;Clinical Management;Complement;Computational algorithm;Cutaneous;DNA;DNA Markers;DNA Methylation;Data;Dermal;Detection;Development;Diagnosis;Diagnostic;Diffuse;Disease;Disease Management;Early Diagnosis;Early Intervention;Genes;Genetic Diseases;Genomics;Glucose;Goals;Haplotypes;Heterogeneity;Hypermethylation;Image;Individual;Information Systems;Inherited;Institution;Intervention;Intramuscular;Lesion;Link;Machine Learning;Magnetic Resonance Imaging;Malignant - descriptor;Malignant Neoplasms;Maps;Measures;Methylation;Modality;Monitor;Monitoring for Recurrence;Morbidity - disease rate;Mutation;Nerve Plexus;Nerve Tissue;Neurofibromatosis 1;Neurofibrosarcoma;Operative Surgical Procedures;Outcome;Pain;Patient-Focused Outcomes;Patients;Physicians;Plasma;Plexiform Neurofibroma;Population;Positron-Emission Tomography;Proliferating;Quality of life;Radiology Specialty;Recurrence;Recurrent disease;Reporting;Risk Assessment;Role;Sampling;Sarcoma;Source;Spinal;Survival Rate;Techniques;Technology;Testing;Therapeutic;Therapeutic Intervention;Tissues;Tumor Tissue;Validation;Variant;X-Ray Computed Tomography;accurate diagnosis;active method;cell free DNA;clinical biomarkers;clinically relevant;cohort;diagnostic panel;diagnostic tool;genome sequencing;high risk;imaging biomarker;imaging modality;improved;innovation;loss of function;methylation biomarker;methylome;mortality;multidisciplinary;multiparametric imaging;neoplastic cell;neural;neurofibroma;novel;post intervention;prospective;tool;treatment response;tumor;tumor DNA;tumor heterogeneity;whole genome,Use of Noninvasive Biomarkers and Advanced MRI for early detection of NF1-associated MPNSTs,Project NarrativeNeurofibromatosis type 1 (NF1) is an inherited genetic condition in which benign tumors develop along the nervetissues. Challenges for the clinical management of this disease include the surveillance patients must undergoa relative paucity of treatment options for late-stage disease and the monitoring for recurrence following surgicaltreatment. We propose to apply state of the art genomic technologies and novel computational algorithms toprofile blood combined with radiology to support noninvasive risk assessment early detection and post-treatment monitoring of this population and to improve patient outcomes.,NCI,10779151,3/11/2024 12:00:00 AM,PA-20-185,1R01CA285980-01,1,R01,CA,285980,01, ,"MAZURCHUK, RICHARD V",3/11/2024 12:00:00 AM,2/28/2029 12:00:00 AM,Molecular Cancer Diagnosis and Classification Study Section[MCDC], ,1879992,"TORRES, KEILA ENITT","SCHEET, PAUL A",09,SURGERY,800772139,S3GMKS8ELA16,800772139,S3GMKS8ELA16,US,29.706319,-95.397195,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,HOUSTON,TX,HOSPITALS,770304009,UNITED STATES,N,3/11/2024 12:00:00 AM,2/28/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,613597, ,NCI,413677,199920, ,613597,,613597.0 | |
| No NIH Category available,3-Dimensional;Acute;Acute myocardial infarction;Address;Adverse event;Algorithms;Artificial Intelligence;Attention;Board Certification;Cardiac;Cardiovascular Diseases;Characteristics;Classification;Clinical;Computer Analysis;Data;Data Set;Development;Diagnosis;Diagnostic;Dimensions;Discrimination;Echocardiography;Engineering;Evaluation;Foundations;Functional disorder;Goals;Grouping;Human;Image;Impairment;Individual;Institution;Investigation;Judgment;Learning;Machine Learning;Maps;Mechanics;Metadata;Mission;Modeling;Motion;Movement;Myocardial;Myocardium;Neural Network Simulation;Outcome;Patients;Pattern;Perception;Phenotype;Population;Prevention strategy;Primary Prevention;Prognosis;Public Health;Reader;Research;Research Project Grants;Risk Reduction;Secondary Prevention;Software Validation;Solid;Stress cardiomyopathy;Syndrome;Techniques;Therapeutic;Time;Training;Triage;Two-Dimensional Echocardiography;United States National Institutes of Health;Validation;Vendor;Visual;Work;bioimaging;clinical decision support;clinical diagnosis;clinical practice;clinical predictive model;convolutional neural network;data visualization;deep learning;deep learning model;deep neural network;diagnostic accuracy;diagnostic tool;diagnostic value;empowerment;imaging approach;imaging biomarker;improved;inattentional blindness;innovation;inter-institutional;learning network;neural model;noninvasive diagnosis;novel;open source tool;personalized medicine;precision medicine;predictive modeling;prevent;prognostic;prognostication;real-time images;recurrent neural network;scale up;spatiotemporal;support tools;therapeutically effective;tool,Implications of Spatiotemporal Deep Learning Neural Networks in Echocardiographic Diagnosis and Prognostication of Takotsubo Syndrome,Project NarrativeThis work can positively impact public heath by providing real time diagnosis and prognosis determination anddecision support for clinical patients with Takotsubo Syndrome with more objective and innovativespatiotemporal deep learning prediction models based on routinely available bedside imaging approaches. Thisproposed research is relevant to the NIH mission as it enables frontline clinicians to resolve time-sensitivediagnostic and therapeutic dilemmas and obtain advanced bioimaging markers to develop personalizedtreatment in patients with acute cardiovascular disorders.,NHLBI,10779357,12/28/2023 12:00:00 AM,PA-20-185,1R01HL171624-01,1,R01,HL,171624,01, ,"BRAZHNIK, OLGA",1/1/2024 12:00:00 AM,12/31/2027 12:00:00 AM,Emerging Imaging Technologies and Applications Study Section[EITA], ,8438058,"WU, XIAODONG ","LIU, KAN ; WANG, YI ",01,ENGINEERING (ALL TYPES),062761671,Z1H9VJS8NG16,062761671,Z1H9VJS8NG16,US,41.664405,-91.542152,3972901,UNIVERSITY OF IOWA,IOWA CITY,IA,BIOMED ENGR/COL ENGR/ENGR STA,522421320,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,837,Non-SBIR/STTR,2024,445798, ,NHLBI,290935,154863, ,445798,,445798.0 | |
| No NIH Category available,ARID1A gene;Address;Affect;Animal Model;Biological Assay;Biological Markers;Cancer Patient;Cell Survival;Cell model;Cells;Chromatin;Clinic;Clinical;Clinical Trials;Clinical Trials Cooperative Group;Combined Modality Therapy;Computer Models;DNA;DNA Damage;DNA Repair;DNA biosynthesis;DNA replication fork;Data;Dependence;Dimensions;Dose;Effectiveness;Epigenetic Process;Family;Future;Gene Expression;Gene Expression Alteration;Gene Mutation;Gene Proteins;Genes;Genetic Transcription;Genome;Genomics;Goals;High Prevalence;Human;Laboratories;Libraries;Link;Malignant Neoplasms;Malignant neoplasm of ovary;Mammalian Oviducts;Molecular;Molecular Profiling;Mutate;Mutation;Oncology Group;Outcome;Ovarian Clear Cell Tumor;Pathway interactions;Patient Selection;Patients;Pharmaceutical Preparations;Pharmacotherapy;Phase;Phase Ib Clinical Trial;Prediction of Response to Therapy;Protein Family;Protein Inhibition;Proteomics;Recurrence;Research;Research Personnel;Resistance;Running;Sample Size;Sampling;Selection for Treatments;Serous;Testing;Tumor Suppressor Proteins;Validation;biomarker signature;cancer cell;candidate marker;chemotherapy;cohort;deep learning;design;effective therapy;endometriosis;first-in-human;human model;member;molecular site;next generation;novel;novel marker;novel therapeutics;patient derived xenograft model;preclinical study;predicting response;predictive marker;prevent;response;response biomarker;standard of care;synergism;transcriptomics;treatment optimization;treatment response;tumor;tumor xenograft,Developing biomarkers of response for a new therapy in ovarian cancer,PROJECT NARRATIVEWe have identified a promising new active combination ATR and BET family protein inhibition that exploits acommon genetic alteration the ARID1A mutation. This mutation is found in ~50% of clear cell ovarian cancers(CCOC) which lack effective therapies. The genomic and proteomic studies described herein will validateARID1A mutation as a predictive biomarker for ATRi-BETi treatment of CCOC and will also identify additionalpredictive biomarkers of response to further optimize this therapy for future clinical trials.,NCI,10779400,2/15/2024 12:00:00 AM,PA-20-185,1R01CA285965-01,1,R01,CA,285965,01, ,"SONG, MIN-KYUNG H",2/15/2024 12:00:00 AM,12/31/2028 12:00:00 AM,Molecular Cancer Diagnosis and Classification Study Section[MCDC], ,10266428,"SIMPKINS, FIONA ","BROWN, ERIC J",03,OBSTETRICS & GYNECOLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,2/15/2024 12:00:00 AM,12/31/2024 12:00:00 AM,395,Non-SBIR/STTR,2024,692527, ,NCI,441601,250926, ,692527,,692527.0 | |
| No NIH Category available,4 year old;Acoustic Stimulation;Address;Affect;Anxiety;Attention;Attention deficit hyperactivity disorder;Behavior;Behavioral;Biological Markers;Brain;Caregivers;Categories;Child;Child Development;Classification;Complement;Computer software;Data;Development;Diagnosis;Disease;Electroencephalography;Functional disorder;Goals;Individual;Measurable;Measurement;Measures;Methods;Neurobiology;Neurodevelopmental Disorder;Neurons;Neurophysiology - biologic function;Output;Pilot Projects;Public Health;Publishing;Quality of life;Research;Risk;Sampling;Sensory;Sensory Process;Severities;Signal Transduction;Stimulus;Stratification;Subgroup;Symptoms;System;Testing;Time;Work;age group;autism spectrum disorder;autistic children;behavior observation;behavior prediction;behavioral phenotyping;behavioral response;biomarker development;biotypes;brain based;clinical diagnosis;clinical diagnostics;diagnostic development;endophenotype;functional outcomes;habituation;improved;individuals with autism spectrum disorder;innovation;neural;neural circuit;neuromechanism;novel;outcome prediction;personalized medicine;response;sensory input;sensory stimulus;social skills;tactile stimulation;time use;tool,Paradoxical Sensory Responses: A Clue Towards Understanding Biotypes in Autism Spectrum Disorder and Other Neurodevelopmental Disorders,NARRATIVEThe proposed research is relevant to public health because it will lead to development of biomarkers thatreflect granular neurobiological principles underlying ASD and related neurodevelopmental conditions. Amongthese individuals understanding and addressing challenges related to atypical sensory processing isrepeatedly noted as a common goal that would improve quality of life. In the long term by developingobjective brain-based measures of sensory processing (which has historically been a subjective phenomenon)this work has the potential to elevate research for a host of different diseases alongside a wide variety ofneurodevelopmental and sensory conditions.,NINDS,10779705,3/18/2024 12:00:00 AM,PA-21-201,1R01NS134948-01,1,R01,NS,134948,01, ,"HARDY, KRISTINA KOREN",4/1/2024 12:00:00 AM,3/31/2029 12:00:00 AM,Developmental Brain Disorders Study Section[DBD], ,10644155,"LEVIN, APRIL R.",Not Applicable,07,Unavailable,076593722,Z1L9F1MM1RY3,076593722,Z1L9F1MM1RY3,US,42.337481,-71.104964,1504801,BOSTON CHILDREN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021155724,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,510609, ,NINDS,292871,217738, ,510609,,510609.0 | |
| No NIH Category available,Affect;Attention;Auditory;Biological;Biological Markers;Bipolar Disorder;Brain;Calcium;Characteristics;Chronic;Clinical Data;Cognition;Cognitive Therapy;Cognitive deficits;Complement;Data;Development;Disease;Disparate;Equilibrium;Exhibits;First Degree Relative;Foundations;Functional Magnetic Resonance Imaging;Genetic;Goals;Human;Impairment;Individual;Investigation;Ketamine;Measures;Methods;Modality;Modeling;Motivation;Mus;National Institute of Mental Health;Neurobehavioral Manifestations;Neurocognitive;Neurons;Neurosciences;Patients;Penetrance;Phenotype;Photic Stimulation;Population;Prefrontal Cortex;Property;Psychoses;Public Health;Quality of life;Research;Rest;Risk;Role;Sampling;Schizophrenia;Selection for Treatments;Seminal;Sensory;Strategic Planning;Testing;Theoretical model;Translating;Translations;V1 neuron;Validation;Visual;Work;area striata;biophysical model;brain based;cognitive ability;cognitive performance;cognitive task;comparison control;connectome;early psychosis;effective therapy;experimental study;genetic variant;human data;imaging study;improved;indexing;large scale data;models and simulation;mouse model;neural;neurocognitive test;neuroimaging;neurophysiology;novel;novel strategies;novel therapeutics;pharmacologic;pre-clinical;preclinical study;predictive modeling;sensory cortex;theories;therapy development;young adult,Biophysical modeling as a translational bridge for understanding neural ensemble alterations in schizophrenia.,NARRATIVESchizophrenia represents a major public-health problem worldwide. In this proposal we aim to combine fMRIneurocognitive and clinical data across multiple large-scale datasets to provide an explanatory theoreticalmodel for understanding neural ensemble alterations in patients with schizophrenia and their relationship tocognitive deficits. In doing so we hope to elucidate their biological mechanisms and contribute to thedevelopment of novel therapeutics for cognitive deficits and brain-based biomarkers for treatment selectionand target engagement.,NIMH,10780619,4/1/2024 12:00:00 AM,PA-20-185,1R01MH134973-01,1,R01,MH,134973,01, ,"WIJTENBURG, ANDREA",4/1/2024 12:00:00 AM,1/31/2029 12:00:00 AM,Pathophysiological Basis of Mental Disorders and Addictions Study Section[PMDA], ,15907445,"WENGLER, KENNETH ",Not Applicable,13,PSYCHIATRY,078861598,C8H9CNG1VBD9,078861598,C8H9CNG1VBD9,US,40.790284,-73.946781,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NEW YORK,NY,SCHOOLS OF MEDICINE,100296574,UNITED STATES,N,4/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,242,Non-SBIR/STTR,2024,784835, ,NIMH,498994,285841, ,784835,,784835.0 | |
| No NIH Category available,Adjuvant;Adjuvant Chemotherapy;Adjuvant Therapy;Adopted;Adverse effects;Adverse event;Antibodies;Antigen Targeting;Antigens;Autoantibodies;Autoimmune Diseases;Autoimmunity;Biological Markers;Blinded;Cancer Etiology;Cessation of life;Clinical;Clinical Trials;Collaborations;Detection;Development;Evaluation;Goals;Human;Immune response;Immune system;Immunosuppression;Immunotherapy;Individual;Learning;Length;Life;Malignant Breast Neoplasm;Malignant Neoplasms;Measures;Mediating;Modeling;Neoadjuvant Therapy;Normal tissue morphology;Nucleic Acids;Organ;Outcome;Pathogenicity;Patient Monitoring;Patients;Performance;Physicians;Positive Lymph Node;Postoperative Period;Practice Guidelines;Prediction of Response to Therapy;Predictive Value;Protein Array;Proteins;Proteome;Randomized;Recurrence;Research Design;Residual state;Risk Estimate;Role;Safety;Sampling;Scientist;Serious Adverse Event;Serology;Serum;Site;Southwest Oncology Group;Symptoms;Technology;Testing;Therapeutic;Therapeutic Intervention;Toxic effect;Treatment Efficacy;Tumor Immunity;Validation;Woman;anti-PD-1;anti-PD1 antibodies;antibody detection;antibody test;arm;biomarker discovery;biomarker identification;biomarker validation;cancer cell;cancer diagnosis;cancer invasiveness;cancer recurrence;candidate identification;candidate marker;candidate validation;checkpoint therapy;chemotherapy;clinical predictors;clinically relevant;cohort;design verification;efficacy evaluation;efficacy testing;high risk;immune checkpoint blockade;immune-related adverse events;in silico;insight;outcome prediction;participant enrollment;pembrolizumab;phase III trial;predictive marker;predictive modeling;prospective;randomized trial;receptor;response;risk/benefit ratio;success;tissue archive;triple-negative invasive breast carcinoma;tumor initiation,Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer,Relevance Immunotherapy in combination with chemotherapy has proven highly effective for TNBC; howeversome patients develop severe adverse events and many may not benefit from treatment. We will investigateauto-antibody response in predicting adverse events and recurrence during and after single agentpembrolizumab therapy. Our split sample discovery and independent validation design using hundreds ofsamples from an FDA registration trial has the potential to introduce a clinically useful new biomarker thatcould optimize the use of immune checkpoint therapy in cancer.,NCI,10780788,12/18/2023 12:00:00 AM,PA-20-185,1R01CA286128-01,1,R01,CA,286128,01, ,"DEY, SUMANA MUKHERJEE",12/14/2023 12:00:00 AM,11/30/2028 12:00:00 AM,Molecular Cancer Diagnosis and Classification Study Section[MCDC], ,10665075,"QIU, JI ","PUSZTAI, LAJOS ",04,MISCELLANEOUS,943360412,NTLHJXM55KZ6,943360412,NTLHJXM55KZ6,US,33.423954,-111.940687,488301,ARIZONA STATE UNIVERSITY-TEMPE CAMPUS,TEMPE,AZ,ORGANIZED RESEARCH UNITS,852876011,UNITED STATES,N,12/14/2023 12:00:00 AM,11/30/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,671146, ,NCI,458634,212512, ,671146,,671146.0 | |
| No NIH Category available,Acute Pain;Affective;Anterior;Area;Assessment tool;Biological Markers;Brain;Brain region;Caregivers;Cerebrum;Chronic;Clinical;Clinical Treatment;Clinical Trials;Complex;Deep Brain Stimulation;Development;Diagnosis;Diffusion Magnetic Resonance Imaging;Esthesia;Functional Magnetic Resonance Imaging;Future;Goals;Graph;Human;Hyperalgesia;Image;Individual;Individual Differences;Injury;Interruption;Intervention;Life;Literature;Magnetic Resonance Imaging;Maintenance;Measures;Medial;Methods;Modification;Multimodal Imaging;Network-based;Neurobiology;Neurons;Neurostimulation procedures of spinal cord tissue;Nodal;Numeric Rating Scale;Opioid;Outcome;Pain;Pain Measurement;Pain management;Participant;Pathway Analysis;Pathway interactions;Patient Recruitments;Patient Self-Report;Patient-Focused Outcomes;Pattern;Persons;Phenotype;Population;Positron-Emission Tomography;Prefrontal Cortex;Process;Prognostic Marker;Protocols documentation;Public Health;Rehabilitation therapy;Research;Rest;Selection Criteria;Sensory;Sensory Disorders;Somatosensory Cortex;Spinal Cord;Spinal Ganglia;Spinal cord injury;Spinal cord injury patients;Spinothalamic Tracts;Structure;Techniques;Testing;Thalamic structure;Translational Research;Treatment outcome;Veterans;Work;allodynia;brain based;candidate selection;chronic neuropathic pain;chronic pain;cingulate cortex;clinical efficacy;clinical pain;connectome;diagnostic biomarker;dynamic system;effective therapy;endophenotype;experience;graph theory;improved;mathematical model;multimodal neuroimaging;multimodality;neural;neural network architecture;neurochemistry;neuroimaging;neuroimaging marker;neuroregulation;noninvasive diagnosis;pain processing;pain reduction;painful neuropathy;pharmacologic;post intervention;preclinical study;psychologic;psychosocial;risk prediction;sensory cortex;service member;side effect;spinal cord injury pain;statistics;tool,Neuroimaging and Connectome Analysis as a Diagnostic and Prognostic Biomarker of SCI Induced Neuropathic Pain,Relevance to Public Health: This work will directly benefit civilians caregivers as well as U.S. service mem-bers and veterans by: 1) unveiling potential neural targets of future pain reducing treatments; 2) developing anon-invasive diagnostic and predictive assessment of neuropathic pain and 3) unmasking the relationship be-tween quantitative connectome measures and psychosocial aspects of the pain experience after SCI. Havingan understanding of the mechanism of pain following SCI injury is critical to further provide a referral mecha-nism for intervention and/or modification of ongoing intervention that will aid to ameliorate the debilitatingconsequences of neuropathic pain in individuals with SCI.,NINDS,10780946,12/27/2023 12:00:00 AM,PA-20-185,1R01NS134987-01,1,R01,NS,134987,1, ,"GREENWELL, THOMAS",12/26/2023 12:00:00 AM,11/30/2028 12:00:00 AM,Neurobiology of Pain and Itch Study Section [NPI], ,16042037,"ALIZADEH, MAHDI ",Not Applicable,2.0,NEUROSURGERY,053284659,R8JEVL4ULGB7,053284659,R8JEVL4ULGB7,US,39.948207,-75.157825,4050801,THOMAS JEFFERSON UNIVERSITY,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191074418,UNITED STATES,N,12/26/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Non-SBIR/STTR,2024,576683, ,NINDS,396353,180330, ,576683,,576683.0 | |
| No NIH Category available,3-Dimensional;Achievement;Affect;Age;Aging;American;Award;Binding;Biochemical Markers;Biological Markers;Biomechanics;Body mass index;Bone Density;Cadaver;Chemicals;Clinical;Collagen;Cone;Control Groups;Development;Diagnosis;Diagnostic;Disease;Dual-Energy X-Ray Absorptiometry;Elasticity;Elderly woman;Ethnic Origin;Etiology;Evaluation;Failure;Femur;Fracture;Goals;Head and neck structure;Human;Image;Individual;Magnetic Resonance Imaging;Maps;Measurement;Measures;Metabolic Bone Diseases;Minerals;Modality;Modeling;Morphologic artifacts;Osteomalacia;Osteopenia;Osteoporosis;Participant;Patients;Physiologic pulse;Porosity;Predisposition;Property;Protons;Raman Spectrum Analysis;Recording of previous events;Recovery;Reference Standards;Relaxation;Renal Osteodystrophy;Roentgen Rays;Signal Transduction;Specimen;Techniques;Testing;Time;Validation;Water;Woman;Work;World Health Organization;accurate diagnosis;age group;biomechanical test;bone;bone imaging;chemical reduction;clinical practice;cohort;cortical bone;cost;crosslink;crystallinity;femur head;insight;mechanical properties;millisecond;mineralization;novel;older women;research clinical testing;substantia spongiosa,Ultrashort Echo Time (UTE) Magnetic Resonance Imaging of Bone,8. Project NarrativeThe goal of this project is to develop and combine novel 3D UTE MRI techniques to evaluate cortical andtrabecular bone offering full insight into bone characterization and correlation with function. In the cadaverichuman bone studies the 3D UTE MRI techniques will be compared with reference techniques including CThistomorphometry Raman spectroscopy and biomechanical testing as reference standard. In the humanstudies the 3D UTE MRI techniques will be applied to elderly women (age > 70y) with (n = 30) and without(n=30) osteoporosis with osteopenia (n = 30) and with ROD (n = 30) as well as a group of young healthywomen (age < 40y n = 30) to compare the 3D UTE biomarkers in the different groups and correlate theresults with BMD biochemical markers and fracture history.,NIAMS,10781991,3/6/2024 12:00:00 AM,PA-19-056,5R01AR068987-09,5,R01,AR,068987,09, ,"NICKS, KRISTY",9/17/2015 12:00:00 AM,2/28/2025 12:00:00 AM,Clinical Translational Imaging Science Study Section[CTIS], ,8906408,"DU, JIANG ",Not Applicable,50,RADIATION-DIAGNOSTIC/ONCOLOGY,804355790,UYTTZT6G9DT1,804355790,UYTTZT6G9DT1,US,32.876991,-117.24087,577507,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",LA JOLLA,CA,SCHOOLS OF MEDICINE,920930621,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,846,Non-SBIR/STTR,2024,559184, ,NIAMS,353914,205270, ,559184,,559184.0 | |
| No NIH Category available,Address;Adult;Age;Animal Model;Back;Biological Markers;C3HeB/FeJ Mouse;Child;Childhood;Clinical;Clinical Data;Clinical Trials;Collaborations;Communities;Critical Pathways;Data;Decision Making;Development;Dimensions;Disease;Dose;Drug Combinations;Drug Exposure;Drug Interactions;Equipment and supply inventories;Goals;Health;In Vitro;Inbred BALB C Mice;Knowledge;Lesion;Linezolid;Link;Methodology;Modeling;Moxifloxacin;Multidrug-Resistant Tuberculosis;Mus;Mycobacterium tuberculosis;Nature;Outcome;Output;Oxazolidinones;Pathway interactions;Patients;Pattern;Pharmaceutical Preparations;Pharmacodynamics;Pharmacology;Phase;Phase II/III Trial;Phase III Clinical Trials;Phenotype;Play;Pre-Clinical Model;Predictive Value;Predisposition;Probability;Protocols documentation;Provider;Pulmonary Tuberculosis;Pyrazinamide;Regimen;Relapse;Research;Research Personnel;Resistance;Resources;Rifamycins;Scientist;Testing;Translational Research;Translations;Treatment Protocols;Tuberculosis;Validation;Vertebral column;age related;clinical efficacy;clinical translation;cost effective;data warehouse;design;drug action;drug candidate;drug development;drug discovery;drug distribution;drug metabolism;early detection biomarkers;early phase clinical trial;efficacy study;experimental study;forgiveness;genomic platform;improved;in vitro Assay;in vitro Model;in vivo;mathematical model;member;metabolomics;mouse model;multidisciplinary;next generation;novel;novel marker;novel therapeutics;pharmacodynamic biomarker;pharmacometrics;phase III trial;portability;pre-clinical;pre-clinical research;preclinical efficacy;preclinical study;predict clinical outcome;prospective;research and development;research clinical testing;research study;simulation;success;tool;translational model;treatment duration;treatment optimization;tuberculosis drugs;tuberculosis treatment,Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium,PROJECT NARRATIVEDespite recent advances treatment of tuberculosis still requires giving 3-4 drugs for a minimum of 4-6 months.New drug candidates with potential to contribute to shorter simpler treatments are in various phases ofresearch and development but the most efficient path for research studies to determine which new and existingdrugs should be combined to create novel regimens with the highest probability of achieving this goal remainsuncertain. The overarching objective of this project is to unite a diverse group of researchers drug developersresearch sponsors and other stakeholders to develop and pursue a research agenda to develop a validatedpipeline of in vitro and mouse models that will inform mathematical models to predict clinical outcomes andenable early and accurate selection of the most promising new treatment regimens to move into clinical trials.,NIAID,10782298,3/26/2024 12:00:00 AM,RFA-AI-22-059,1UM1AI179699-01,1,UM1,AI,179699,01, ,"GARG, ANKITA",3/26/2024 12:00:00 AM,2/28/2029 12:00:00 AM,ZAI1-LG-M(S1), ,11061281,"SAVIC, RADOJKA ","DOOLEY, KELLY E.; NUERMBERGER, ERIC L; SCHNAPPINGER, DIRK ",11,PHARMACOLOGY,094878337,KMH5K9V7S518,094878337,KMH5K9V7S518,US,37.767442,-122.413937,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",SAN FRANCISCO,CA,SCHOOLS OF PHARMACY,941432510,UNITED STATES,N,3/26/2024 12:00:00 AM,2/28/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,7199999, ,NIAID,5811670,1388329, ,7199999,,7199999.0 | |
| No NIH Category available,Adverse event;Back;Biological Markers;Categories;Characteristics;Clinical;Clinical Treatment;Clinical Trials;Cohort Analysis;Cohort Studies;Data;Data Analyses;Development;Drug Evaluation;Early identification;Ensure;Frequencies;Generations;Grouping;Hypertension;Hypothyroidism;Immunotherapy;Individual;Lymphocyte;Malignant neoplasm of lung;Methods;Modernization;Non-Small-Cell Lung Carcinoma;Outcome;Pathway Analysis;Patients;Pharmaceutical Preparations;Platelet Count measurement;Precision therapeutics;Predictive Value;Progression-Free Survivals;PubMed;Reporting;Research;Risk;Risk-Benefit Assessment;Safety;Sample Size;Scientist;System;Testing;Time;Toxic effect;Treatment Protocols;Uncertainty;Validation;biomarker signature;cancer clinical trial;chemotherapy;clinical practice;clinical predictors;clinically relevant;cohort;experience;immune-related adverse events;improved;ineffective therapies;innovation;insight;neutrophil;novel;patient safety;precision medicine;predict clinical outcome;predictive marker;prevent;survival outcome;tool;translational study;treatment response;trend;user-friendly,Development of adverse event (AE) derived biomarkers for predicting clinical outcomes in lung cancer,PROJECT NARRATIVEThis highly translational study aims to change the paradigm of AE data usage from descriptive summary intomodern informative AE biomarkers to fulfill precision medicine.,NCI,10782335,1/12/2024 12:00:00 AM,PAR-22-216,1R21CA286417-01,1,R21,CA,286417,01, ,"OSSANDON, MIGUEL",1/12/2024 12:00:00 AM,12/31/2025 12:00:00 AM,ZCA1-TCRB-9(O2)S, ,8104006,"CHEN, DUNG-TSA ",Not Applicable,15,Unavailable,139301956,DVHKP4N619V9,139301956,DVHKP4N619V9,US,28.062583,-82.419596,3736101,H. LEE MOFFITT CANCER CTR & RES INST,TAMPA,FL,Research Institutes,336129497,UNITED STATES,N,1/12/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,196934, ,NCI,116875,80059, ,196934,,196934.0 | |
| No NIH Category available,Acceleration;Affect;Aging;Alzheimer's disease related dementia;Atrophic;Automobile Driving;Axon;Blood;Blood Vessels;Blood brain barrier dysfunction;Brain;Brain Injuries;Cerebrovascular Circulation;Chronic;Classification;Clinical;Clinical Research;Cognitive;Control Groups;Dementia;Deterioration;Development;Diffusion Magnetic Resonance Imaging;Disease;Elderly;Evolution;Exhibits;Functional disorder;Hospitalization;Human;Humanities;Image;Impaired cognition;Impairment;Individual;Injury;Investigation;Link;Magnetic Resonance Imaging;Measures;Microvascular Dysfunction;Modeling;Monitor;Morbidity - disease rate;Myelin;Myelin Water Imaging;Natural History;Nature;Nerve Degeneration;Neurodegenerative Disorders;Neurons;Neuropsychology;Outcome;Participant;Pathologic;Pathology;Patient Recruitments;Patient-Focused Outcomes;Pattern;Perfusion;Predictive Value;Process;Prognosis;Research;Risk Factors;Role;Survivors;TBI Patients;Techniques;Testing;Thick;Tissues;Traumatic Brain Injury;Water;Work;axon injury;blood-brain barrier permeabilization;brain magnetic resonance imaging;brain tissue;brain volume;cerebral atrophy;cerebrovascular reactivity;disability burden;effective therapy;endophenotype;extracellular;follow-up;functional decline;gray matter;hypoperfusion;imaging biomarker;improved;indexing;injury-related death;insight;long term recovery;morphometry;mortality;neuroimaging;neuron loss;neuronal cell body;neuropathology;new therapeutic target;normal aging;novel;outcome prediction;pre-clinical;pre-clinical research;prognostic significance;prognostic value;programs;progressive neurodegeneration;therapy development;time interval;vascular cognitive impairment and dementia;vascular injury;white matter,Longitudinal MRI Investigation of Traumatic Microvascular Injury,PROJECT NARRATIVEThis project will investigate the natural history and long-term prognostic significance of MRI-based measures ofmicrovascular dysfunction over the first 3 years after traumatic brain injury (TBI). Insights gained from this workwill provide a better understanding of TBI-related disease processes and contribute to the identification ofnovel therapeutic targets for TBI-related neurodegeneration and other Alzheimer's Disease RelatedDementias.,NINDS,10782527,2/8/2024 12:00:00 AM,PA-20-185,5R01NS125408-03,5,R01,NS,125408,03, ,"UMOH, NSINI ALEASE",2/15/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Acute Neural Injury and Epilepsy Study Section[ANIE], ,14208902,"WARE, JEFFREY B",Not Applicable,03,RADIATION-DIAGNOSTIC/ONCOLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,771006, ,NIA,536462,234544, ,771006,,771006.0 | |
| No NIH Category available,Adenocarcinoma;Benign Prostatic Hypertrophy;Bioinformatics;Biological Assay;Biological Markers;Biopsy;Cancer Histology;Cancer Patient;Castration;Cell surface;Clinic;Clinical;Clinical Trials;Cryopreservation;Cryopreserved Tissue;Databases;Development;Disease;Extracellular Matrix;Foundations;Fractionation;Future;Glycopeptides;Glycoproteins;Goals;Histologic;Human;Image;Immunodeficient Mouse;International;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Mass Spectrum Analysis;Measurement;Measures;Methods;Monitor;Monitoring for Recurrence;Mus;Neuroendocrine Prostate Cancer;Non-Invasive Detection;Pathologic;Patient Monitoring;Patient Selection;Patient Triage;Patients;Peptides;Pharmaceutical Preparations;Procedures;Prostate Adenocarcinoma;Protein Glycosylation;Protein Isoforms;Proteins;Proteomics;Quality of life;Reaction;Resistance;Resolution;Resources;Sampling;Sensitivity and Specificity;Series;Serum;Serum Proteins;Systemic Therapy;Testing;Time;Tumor Subtype;Tumor Tissue;Tumor Volume;Validation;Variant;androgen deprivation therapy;biomarker discovery;cancer biomarkers;candidate marker;candidate selection;candidate validation;chemotherapy;cohort;glycoproteomics;glycosylation;implantation;improved;individualized medicine;mass spectrometer;novel;novel strategies;novel therapeutics;patient derived xenograft model;patient response;potential biomarker;profiles in patients;programs;protein biomarkers;protein complex;resistance mechanism;response;specific biomarkers;standard of care;targeted treatment;therapy development;treatment response;tumor;tumor xenograft,Identification of serum protein biomarkers by profiling N-glycoproteomes of patient-derived xenografts of neuroendocrine prostate cancer,PROJECT NARRATIVECompared to biopsies serum biomarker measurements eliminate invasive procedures to patients are lessexpensive and most importantly may help identify neuroendocrine prostate cancer (PCa) a lethal variant ofPCa earlier so that new therapies can be started in a timely manner. N-glycoproteomic analyses of sera frompatient-derived xenografts (PDXs) represent a new paradigm of protein biomarker discovery that overcomesthe most challenging limitation of proteomic profiling based approaches. In this proposal we will identifyhuman-specific N-glycosylated proteins in a mouse background with high sensitivity using PCa PDX modelsand validate potential biomarkers associated with tumor volume in PCa patient sera.,NCI,10783009,12/15/2023 12:00:00 AM,PAR-20-292,5R21CA276896-02,5,R21,CA,276896,02, ,"MCKEE, TAWNYA C",2/15/2023 12:00:00 AM,1/31/2025 12:00:00 AM,ZCA1-TCRB-5(O1)S, ,1889210,"BROOKS, JAMES D.","PITTERI, SHARON ",16,UROLOGY,009214214,HJD6G4D6TJY5,009214214,HJD6G4D6TJY5,US,37.426852,-122.17047,8046501,STANFORD UNIVERSITY,STANFORD,CA,SCHOOLS OF MEDICINE,943052004,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,395,Non-SBIR/STTR,2024,171759, ,NCI,111031,60728, ,171759,,171759.0 | |
| No NIH Category available,Academic Medical Centers;Address;Algorithms;Anxiety;Artificial Intelligence;Benign;Biological Assay;Biological Markers;Blood;Blood Proteins;Cancer Detection;Cessation of life;Classification;Clinical;Clinical Data;Clinical Management;Clinical Markers;Community Hospitals;Data;Data Science;Data Sources;Diagnosis;Diagnostic;Discrimination;Disease;Dose;Early Diagnosis;Electronic Health Record;Enrollment;Funding;Goals;Health Care Costs;Healthcare;Image;Individual;Intervention;Joints;Lead;Lung;Lung nodule;Machine Learning;Malignant - descriptor;Malignant Neoplasms;Malignant neoplasm of lung;Measurement;Measures;Modeling;Modernization;Monitor;Morbidity - disease rate;Nodule;Oncology;Operative Surgical Procedures;Outcome;Patients;Pattern;Performance;Phenotype;Population;Predictive Value;Procedures;Prospective cohort;Radiation;Radiology Specialty;Research;Resources;Risk Assessment;Risk Estimate;Scanning;Series;Serum;Source;Structure;Testing;Thoracotomy;Time;Training;Validation;X-Ray Computed Tomography;biological specimen archives;biomedical informatics;blood-based biomarker;chest computed tomography;clinical predictive model;clinical predictors;cohort;computed tomography screening;convolutional neural network;cost;data mining;deep learning;deep learning model;demographics;diagnostic accuracy;early detection biomarkers;high risk population;imaging biomarker;improved;innovation;large scale data;longitudinal analysis;low dose computed tomography;lung cancer screening;lung lesion;machine learning method;molecular marker;mortality;neural network algorithm;noninvasive diagnosis;novel;patient oriented;predictive modeling;predictive signature;premalignant;programs;quantitative imaging;rate of change;research clinical testing;screening program;serial imaging;structural imaging,Novel Integrative Approach for the Early Detection of Lung Cancer using Repeated Measures,NARRATIVEMost lung cancers present as pulmonary nodules; so to improve survival from lung cancer we need to identifywith noninvasive strategies the disease early among a majority of benign nodules. This project focuses onestablishing an integrative approach to early detection leveraging repeated measures of chest CT imagingfeatures of lung nodules over time of the rate of change of a high sensitivity blood biomarker hsCYFRA 21-1and of longitudinal clinical patterns from the electronic health record. This research will inform the managementof lung nodules identified on lung cancer screening CT scans and should reduce the time to diagnosis and themortality of lung cancer.,NCI,10783015,2/7/2024 12:00:00 AM,PAR-19-264,5R01CA253923-04,5,R01,CA,253923,04, ,"MAZURCHUK, RICHARD V",1/1/2021 12:00:00 AM,12/31/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-SBIB-S(59)R], ,9875566,"MALDONADO, FABIEN ","LANDMAN, BENNETT A.",07,Unavailable,079917897,GYLUH9UXHDX5,079917897,GYLUH9UXHDX5,US,36.143784,-86.800995,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,NASHVILLE,TN,Independent Hospitals,372320011,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,624698, ,NCI,425378,199320, ,624698,,624698.0 | |
| No NIH Category available,Acute;Adult;Aging;Biological;Biological Assay;Biological Markers;Biology;Bone Density;Bone Development;Bone Diseases;Bone Resorption;C-terminal;Calories;Carbon;Caring;Center Core Grants;Clinical;Clinical Trials Design;Complication;Consumption;Cystic Fibrosis;DNA Sequence Alteration;Data;Development;Diabetes Mellitus;Diet;Diet Modification;Dietary Fiber;Dietary Intervention;Disease;Doctor of Philosophy;Dual-Energy X-Ray Absorptiometry;Educational workshop;Energy Intake;Energy Metabolism;Fasting;Fatty acid glycerol esters;Food;Fracture;Funding;Glucose;Goals;Grant;Guidelines;Heritability;Hour;Ingestion;Intake;International;Journals;Lead;Link;Long-Term Effects;Longitudinal Studies;Malnutrition;Mediating;Mentors;Metabolic;Methods;N-terminal;National Center for Advancing Translational Sciences;National Institute of Diabetes and Digestive and Kidney Diseases;Nutritional;Nutritional status;OGTT;Osteogenesis;Outcome;Pattern;Peripheral;Persons;Plasma;Population;Procollagen;Randomized;Randomized Controlled Trials;Research;Research Personnel;Resolution;Risk;Scholars Program;Secure;Site-Directed Mutagenesis;Statistical Methods;Technical Expertise;Testing;Training;Translations;Transplantation;United States National Institutes of Health;Universities;Update;Work;Writing;X-Ray Computed Tomography;biomarker validation;blood glucose regulation;bone;bone fragility;bone health;bone imaging;bone metabolism;bone turnover;career;cystic fibrosis related diabetes;dietary;effective therapy;evidence base;gastric inhibitory polypeptide receptor;glucagon-like peptide 1;high standard;imaging biomarker;improved;incretin hormone;innovation;insulin secretion;knowledgebase;meetings;novel;nutrition;prevent;programs;prospective;pulmonary function;randomized trial;response;stable isotope;standard of care;sugar;theories;trial design,Effects of an anti-diabetes diet on bone health in adults with cystic fibrosis,NARRATIVEBone disease is a concerning complication of cystic fibrosis (CF) since related fractures are associated withworsening pulmonary function and might contraindicate transplantation. Whereas genetic mutations leading toCF contribute to development of bone disease diabetes and nutritional status are also theorized to be majorcontributors. Determining the effect of an anti-diabetes diet on bone health in people with CF includingunderlying biological mechanisms will help expand the evidence-base to support updated nutrition standards-of-care for reducing the burden of CF-related metabolic complications namely diabetes and bone disease.,NIDDK,10783603,5/1/2024 12:00:00 AM,PA-20-190,1K01DK138233-01,1,K01,DK,138233,01, ,"EGGERMAN, THOMAS L",5/1/2024 12:00:00 AM,4/30/2028 12:00:00 AM,"Diabetes, Endocrinology and Metabolic Diseases B Study Section[DDK-B]", ,14443495,"KINDLER, JOSEPH ",Not Applicable,10,NUTRITION,004315578,NMJHD63STRC5,004315578,NMJHD63STRC5,US,33.931173,-83.378873,676602,UNIVERSITY OF GEORGIA,ATHENS,GA,SCH OF HOME ECON/HUMAN ECOLOGY,306021589,UNITED STATES,N,5/1/2024 12:00:00 AM,4/30/2025 12:00:00 AM,847,Other Research-Related,2024,155346, ,NIDDK,143839,11507, ,155346,,155346.0 | |
| No NIH Category available,Affect;Age;Animals;Atrophic;Biological Markers;Blood Vessels;Blood flow;Cardiovascular Diseases;Chronic;Chronic Kidney Failure;Clinical;Clinical Trials;Collaborations;Contrast Media;Data;Data Analyses;Development;Development Plans;Disease;Disease Progression;End stage renal failure;Enrollment;Environment;Erythrocytes;Evaluation;Fibrosis;Functional Imaging;Future;Gases;Glomerular Filtration Rate;Goals;Grant;Health;Histopathology;Hypoxia;Image;Image Analysis;Individual;Injury;Investigation;Iohexol;Japanese;Kidney;Kidney Diseases;Lead;Lesion;Link;Longevity;Measures;Mentors;Mentorship;Microbubbles;Microcirculation;Microvascular Dysfunction;Motion;Multicenter Studies;Outcome;Pathogenesis;Patients;Performance;Perfusion;Population;Positioning Attribute;Property;Proteinuria;Protocols documentation;Renal Blood Flow;Renal function;Reporting;Research;Research Personnel;Risk;Testing;Time;Training;Translations;Tubular formation;Ultrasonography;Universities;biomarker development;biomarker evaluation;biomarker selection;biomarker validation;cardiovascular disorder risk;career development;clinically relevant;contrast enhanced;disease phenotype;experience;glomerulosclerosis;healthy volunteer;high risk;high risk population;human data;imaging biomarker;imaging modality;improved;interstitial;kidney biopsy;kidney fibrosis;learning strategy;mortality;multidisciplinary;non-invasive imaging;novel;novel therapeutics;patient oriented research;premature;prognostic value;prospective;recruit;renal damage;research study;skill acquisition;skills;study population;tool;ultrasound,Non-Invasive Imaging Biomarkers to Identify a High-Risk Chronic Kidney Disease Phenotype,PROJECT NARRATIVEReductions in kidney blood flow can lead to permanent damage to the kidneys known as chronic kidneydisease which can progress to complete loss of kidney function and can shorten life span. We propose toinvestigate whether information about kidney blood flow that we will obtain from contrast enhanced ultrasoundwill help identify which individuals with chronic kidney disease are at high risk of experiencing progressive lossof kidney function. The high-risk individuals can then be included in future clinical trials to test new treatmentsfor chronic kidney disease.,NIDDK,10783826,2/9/2024 12:00:00 AM,PA-19-119,5K23DK120811-05,5,K23,DK,120811,05, ,"GREER, RAQUEL CHARLES",4/1/2020 12:00:00 AM,1/31/2025 12:00:00 AM,"Kidney, Urologic and Hematologic Diseases D Study Section[DDK-D]", ,12343484,"SRIVASTAVA, ANAND ",Not Applicable,07,INTERNAL MEDICINE/MEDICINE,098987217,W8XEAJDKMXH3,098987217,W8XEAJDKMXH3,US,41.871509,-87.667721,577703,UNIVERSITY OF ILLINOIS AT CHICAGO,Chicago,IL,SCHOOLS OF MEDICINE,606124305,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,847,Other Research-Related,2024,188970, ,NIDDK,174972,13998, ,188970,,188970.0 | |
| No NIH Category available,Acceleration;Address;Age;Antibodies;Antigens;Ataxia;Autoimmune;Autoimmune Diseases of the Nervous System;Autoimmune encephalitis;Axon;Bacteriophages;Biological Assay;Biological Markers;Brain Diseases;Cells;Cellular Assay;Cerebellar Ataxia;Characteristics;Clinic;Clinical;Clinical/Radiologic;Complementary DNA;Data;Degenerative Disorder;Diagnosis;Disease;Early Diagnosis;Early treatment;Encephalitis;Encephalopathies;Ethnic Origin;Future;Goals;Health;Hippocampus;Human;IL8 gene;Immune;Immune system;Immunofluorescence Immunologic;Immunoglobulin G;Immunologics;Immunoprecipitation;Incidence;Indirect Fluorescent Antibody Technique;Indirect Immunofluorescence;Infectious Encephalitis;Investigation;Laboratories;Length;Libraries;Mass Spectrum Analysis;Methods;Mission;Molecular;Movement Disorders;Mus;Neurologic;Neurological disability;Neurons;Nuclear;Ocular Motility Disorders;Outcome;Pathogenicity;Patients;Peptides;Phage ImmunoPrecipitation Sequencing;Phenotype;Prediction of Response to Therapy;Process;Protein Microchips;Proteins;Proteome;Public Health;Publishing;Radiology Specialty;Recombinant Proteins;Research;Research Personnel;Serum;Synapses;Techniques;Testing;Therapeutic Trials;Time;Tissues;Transfection;Translations;Undifferentiated;United States National Institutes of Health;Validation;Western Blotting;Work;amphiphysin;biomarker discovery;biomarker identification;biomarker validation;chemokine;clinical phenotype;clinical practice;cohort;cytokine;disability;disease mechanisms study;experience;innovation;neural;neuroimmunology;novel;novel marker;novel therapeutics;post-COVID-19;screening;sex;specific biomarkers;targeted treatment;therapeutic development;trial design,Seronegative Autoimmune Encephalopathies: Biomarker Discovery Validation & Deep Phenotyping,PROJECT NARRATIVEThe proposed research is relevant to public health because it focuses on characterizing poorly understoodbrain diseases caused by the immune system known as autoimmune encephalopathies through identificationand validation of new antibodies as disease biomarkers. Once this work has been completed thesebiomarkers have the potential to be informative in clinical practice for early diagnosis and immune treatmentdecisions and disease mechanism research. Thus the proposed research is relevant to the part of the NIH'smission that pertains to reducing illness and disability.,NINDS,10784648,1/20/2024 12:00:00 AM,PA-20-185,5R01NS126227-03,5,R01,NS,126227,03, ,"UTZ, URSULA",2/1/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Clinical Neuroimmunology and Brain Tumors Study Section[CNBT], ,9033307,"MCKEON, ANDREW ",Not Applicable,01,Unavailable,006471700,Y2K4F9RPRRG7,006471700,Y2K4F9RPRRG7,US,44.02432,-92.46011,4976101,MAYO CLINIC ROCHESTER,ROCHESTER,MN,Other Domestic Non-Profits,559050001,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,385575, ,NINDS,242500,143075, ,385575,,385575.0 | |
| No NIH Category available,Achievement;Adult;Aging;Alzheimer's Disease;Alzheimer's disease risk;Alzheimers disease biomarker;Amyloid;Attention;Bayesian Modeling;Biological;Clinical;Clinical Trials;Clinical assessments;Cognition;Cognition Disorders;Cognitive;Data Set;Dementia;Disease;Disease Progression;Elderly;Encapsulated;Equation;Evaluation;Goals;Impaired cognition;Impairment;Individual;International;Intervention;Intervention Studies;Measurement;Measures;Mentors;Minor;Modeling;Moods;Motivation;Nerve Degeneration;Noise;Outcome;Performance;Personality;Personality Assessment;Persons;Phenotype;Play;Positron-Emission Tomography;Prevention trial;Process;Research;Research Design;Research Technics;Secondary Prevention;Severities;Statistical Models;Stimulus;Techniques;Testing;Time;Training;Validation;Variant;advanced analytics;attentional control;behavior prediction;career development;cognitive change;cognitive function;cognitive performance;cognitive process;cognitive testing;cohort;design;disease phenotype;drug efficacy;experience;healthy aging;improved;in vivo;innovation;insight;intervention effect;longitudinal analysis;longitudinal design;magnetic resonance imaging biomarker;novel;pre-clinical;predictive modeling;psychologic;research clinical testing;risk prediction;tau Proteins;young adult,Within-person dynamics of cognition and personality in healthy aging and Alzheimer's disease.,Project NarrativeThe research and training in this application will provide additional training and experience applying advancedintensive longitudinal statistical techniques to the study of aging and dementia. Outcomes in aging andAlzheimer disease (AD) research rely critically on the measurement of cognitive change and the innovativeapproaches described herein will provide novel and more sensitive analyses of longitudinal change. Ultimatelywe will provide new cognitive endpoints for use in AD studies which will help establish the efficacy of candidatetreatments.,NIA,10784707,2/2/2024 12:00:00 AM,PA-20-190,5K01AG071847-04,5,K01,AG,071847,04, ,"STOECKEL, LUKE",4/15/2021 12:00:00 AM,1/31/2026 12:00:00 AM,Behavior and Social Science of Aging Study Section[NIA-S], ,11389259,"ASCHENBRENNER, ANDREW ",Not Applicable,01,NEUROLOGY,068552207,L6NFUM28LQM5,068552207,L6NFUM28LQM5,US,38.664368,-90.323797,9083901,WASHINGTON UNIVERSITY,SAINT LOUIS,MO,SCHOOLS OF MEDICINE,631304862,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Other Research-Related,2024,99952, ,NIA,92799,7153, ,99952,,99952.0 | |
| No NIH Category available,Affect;Algorithms;Architecture;Biological Markers;Clinic;Clinical;Computational algorithm;Computer software;Consensus;Data Set;Dependence;Diagnosis;Diagnostic;Differential Diagnosis;Disease;Early Diagnosis;Exhibits;External Beam Radiation Therapy;Funding Opportunities;Gland;Gleason Grade for Prostate Cancer;Goals;Histologic;Histology;Image;Imaging Device;Individual;Indolent;Libraries;Location;MRI Scans;Magnetic Resonance Imaging;Malignant Neoplasms;Malignant neoplasm of prostate;Maps;Measures;Methods;Microscopic;Modeling;Operative Surgical Procedures;Pathology;Patients;Pattern Recognition;Performance;Physicians;Population;Prognosis;Prostate;Prostate Cancer therapy;Prostatic Neoplasms;Protocols documentation;Radiation;Radiation therapy;Radical Prostatectomy;Radio;Radiology Specialty;Recurrence;Recurrent tumor;Risk;Sampling;Sensitivity and Specificity;Severity of illness;Stress Tests;System;Techniques;Technology;Testing;Therapeutic;Tissue Sample;Training;Translating;Validation;Vendor;cancer risk;clinical application;clinical decision-making;clinical imaging;clinically significant;disorder risk;evidence base;experimental study;high risk;image processing;imaging biomarker;imaging system;improved;individualized medicine;men;non-invasive imaging;overtreatment;personalized cancer therapy;predictive modeling;prostate cancer risk;quantitative imaging;resilience;response;screening;serial imaging;tool;treatment strategy;tumor,Prostate Cancer Radio-Pathomics for Differentiating Clinically Significant Disease,Project NarrativeThis project will provide a detailed understanding of how prostate tumors at the cellular level appear onmacroscopic imaging by examining post-surgical prostate tissue samples aligned with clinical MRI scans. Wewill develop computational algorithms that recognize patterns in MRI scans (i.e. radio-pathomics) which canthen be applied to patients to more fully understand the status of prostate tumors prior to surgery and duringtreatment. We expect that clinical decision-making will improve dramatically as a complete picture of pathomicfeatures underlying prostate cancer with high metastatic potential emerges from this proposal.,NCI,10784733,2/12/2024 12:00:00 AM,PAR-19-264,5R01CA249882-04,5,R01,CA,249882,04, ,"DARDZINSKI, BERNARD JOSEPH",3/1/2021 12:00:00 AM,2/28/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-SBIB-S(59)R], ,11436185,"LAVIOLETTE, PETER S",Not Applicable,04,RADIATION-DIAGNOSTIC/ONCOLOGY,937639060,E8VWJXMMUQ67,937639060,E8VWJXMMUQ67,US,43.04575,-88.020374,46001,MEDICAL COLLEGE OF WISCONSIN,MILWAUKEE,WI,SCHOOLS OF MEDICINE,532263548,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,564699, ,NCI,371205,193494, ,564699,,564699.0 | |
| No NIH Category available,Acceleration;Address;Adult;Advisory Committees;Age;Aging;Alzheimer's Disease;Alzheimer's disease risk;Alzheimers disease biomarker;Amyloid;Amyloid beta-Protein;Biological Assay;Biological Markers;Blood;Blood Pressure;Blood Vessels;Body mass index;Brain;Clinical Trials;Clinical Trials Design;Cognitive;Data;Early Diagnosis;Early Intervention;Elderly;Epidemiology;Foundations;Framingham Heart Study;Funding;Generations;Goals;Hypertension;Image;Impaired cognition;Individual;Intervention;K-Series Research Career Programs;Knowledge;Measures;Medial;Mediating;Mediation;Mentored Patient-Oriented Research Career Development Award;Mentorship;Methodology;Neocortex;Neurologist;Obesity;Outcome;Parietal;Participant;Pathogenesis;Pathologic;Pathology;Physicians;Pittsburgh Compound-B;Plasma;Populations at Risk;Positron-Emission Tomography;Prevalence;Prevention;Prevention trial;Research;Risk;Scientist;Statistical Methods;Surrogate Endpoint;Symptoms;Tauopathies;Techniques;Testing;Therapeutic;Training;Translating;United States National Institutes of Health;Work;abeta accumulation;age group;aging brain;amyloid pathology;asymptomatic Alzheimer's disease;career;causal model;clinical practice;cohort;cost;critical period;data harmonization;design;epidemiology study;improved;innovation;middle age;multimodality;neocortical;novel;pre-clinical;prospective;research study;sex;skills;synergism;tau Proteins;tau aggregation;tau mutation;tau-1;therapeutic target;vascular cognitive impairment and dementia;vascular contributions;vascular risk factor;-amyloid burden,Elevated systolic blood pressure body mass index and amyloid as drivers of tau and cognitive decline in preclinical Alzheimers disease: critical windows in mid- to late-life,PROJECT NARRATIVEVascular risk factors (particularly hypertension and obesity) are important contributors to Alzheimersdisease working with amyloid pathology in individuals without symptoms to accelerate the buildup ofabnormal tau proteins and drive cognitive decline. This study will provide important missing knowledge abouthow early and over what age range this interaction takes place and therefore can be intervened upon andwhether imaging or blood measures of tau pathology can detect this early and silent partnership betweenvascular risk and Alzheimers disease in midlife. Outcomes from this project will inform the design ofprevention trials targeting both amyloid and hypertension or obesity in asymptomatic Alzheimers diseaseby identifying individuals who are at risk and are most likely to benefit from early intervention and bydetermining whether we can use blood measures of tau pathology to improve accessibility and diversity ofthese clinical trials.,NIA,10784860,11/23/2023 12:00:00 AM,PA-20-205,1K23AG084868-01,1,K23,AG,84868,1, ,"HAAKENSON, CHELSEA MARIE",12/1/2023 12:00:00 AM,11/30/2028 12:00:00 AM,Career Development for Clinicians/Health Professionals Study Section [AGCD-3], ,16147547,"YAU, WAI-YING WENDY",Not Applicable,8.0,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,866,Other Research-Related,2024,194875, ,NIA,180440,14435, ,194875,,194875.0 | |
| No NIH Category available,Acceleration;Age;Applications Grants;Biological Markers;Blood typing procedure;Cancer Detection;Cancer Patient;Cessation of life;Clinical;Code;Cooperative Human Tissue Network;Correlative Study;DNA Methylation;DNA Transposable Elements;Data;Death Rate;Detection;Development;Diagnosis;Diagnostic Procedure;Disease;Early Diagnosis;Epigenetic Process;Ethnic Origin;Expression Profiling;Family;Feasibility Studies;Future;Genes;Genome Stability;Genomics;Germ Cells;Goals;Gynecologic Oncology Group;Health;Human;Maintenance;Malignant Female Reproductive System Neoplasm;Malignant Neoplasms;Malignant neoplasm of ovary;Mammalian Oviducts;Maps;Methods;MicroRNAs;Monitor;Ovarian;Ovarian Diseases;Ovarian Tissue;Patients;Play;Population Study;Professional Organizations;Prognosis;Proteins;Publishing;Quantitative Reverse Transcriptase PCR;RNA;Radiation therapy;Regulation;Research;Risk Assessment;Role;Sample Size;Sampling;Screening for Ovarian Cancer;Screening procedure;Serum;Small RNA;Somatic Cell;Survival Rate;Testing;Tissue Sample;Tissues;Tumor Debulking;Tumor Tissue;Untranslated RNA;Woman;Work;biobank;biomarker development;blood-based biomarker;cancer type;diagnostic biomarker;diagnostic tool;disorder risk;early detection biomarkers;epigenetic silencing;exosome;female reproductive system;genetic association;genomic locus;improved;innovation;member;next generation sequencing;novel;novel diagnostics;ovarian neoplasm;overexpression;patient biomarkers;piRNA;potential biomarker;response;screening;sequencing platform;tool;treatment response;tumorigenesis;validation studies,Explore piRNAs as a novel group of biomarkers for ovarian cancer early detection,Project NarrativeBoth genetic association studies and expression profiling analyses have suggested a role of Piwi-interactingRNAs (piRNAs) a new small noncoding RNA family in tumorigenesis. The proposed study aims to develop anovel piRNA-based diagnostic method for the early detection of ovarian cancer. This exploratory study willprovide proof of concept for future large population-based studies to further investigate the translational role ofpiRNAs in ovarian cancer.,NCI,10785263,4/25/2024 12:00:00 AM,PAR-22-216,1R21CA277412-01A1,1,R21,CA,277412,01,A1,"PATRIOTIS, CHRISTOS F",5/1/2024 12:00:00 AM,4/30/2026 12:00:00 AM,ZCA1-RTRB-S(O1), ,7803473,"ZHU, YONG ",Not Applicable,02,PUBLIC HEALTH & PREV MEDICINE,122452563,VDFYLZPJEAV6,122452563,VDFYLZPJEAV6,US,34.749005,-92.320097,1471106,UNIV OF ARKANSAS FOR MED SCIS,LITTLE ROCK,AR,SCHOOLS OF PUBLIC HEALTH,722057101,UNITED STATES,N,5/1/2024 12:00:00 AM,4/30/2026 12:00:00 AM,394,Non-SBIR/STTR,2024,411876, ,NCI,266275,145601, ,411876,,411876.0 | |
| No NIH Category available,Affect;Animal Model;Antiepileptogenic;Area;Atrophic;Axon;Big Data;Bioinformatics;Biological Markers;Brain;Brain imaging;Caring;Case Series;Chronic;Clinical;Clinical Trials;Craniocerebral Trauma;Data;Development;Diffuse;Diffuse Brain Injury;Diffusion Magnetic Resonance Imaging;Disease;Epilepsy;Epileptogenesis;Frequencies;Functional Magnetic Resonance Imaging;Future;Goals;Human Pathology;Image;Injury;K-Series Research Career Programs;Knowledge;Lesion;Location;Magnetic Resonance Imaging;Magnetism;Maps;Measurement;Measures;Mentors;Mentorship;Methods;Nervous System Disorder;Neurobiology;Neurology;Participant;Patient Care;Patients;Pennsylvania;Persons;Phenotype;Physicians;Play;Positioning Attribute;Post-Traumatic Epilepsy;Prevention trial;Process;Prognostic Marker;Records;Research;Rest;Risk;Role;Scientist;Seizures;Severities;Statistical Models;TBI Patients;Techniques;Temporal Lobe;Testing;Therapy Clinical Trials;Thick;Training;Traumatic Brain Injury;Universities;Work;animal data;axon injury;biomarker identification;brain magnetic resonance imaging;case control;cerebral atrophy;cohort;design;endophenotype;experience;experimental study;high risk;human data;improved;military injury;multimodal neuroimaging;multimodality;neural network;neuroimaging;prevent;preventable epilepsy;professor;prospective;risk prediction;risk stratification;skill acquisition;study population;tool;translational study,Neuroimaging Phenotypes of Post-Traumatic Epilepsy,Project NarrativeEpilepsy is a chronic debilitating neurological disorder that affects millions of people across the globe.Epilepsy due to head injury known as post-traumatic epilepsy represents an opportunity to understand thechanges in the brain that lead to epilepsy. This research will help us understand the unique structural andfunctional changes in the brain leading to post-traumatic epilepsy and develop tools for epilepsy riskstratification after head injurya prerequisite for feasible clinical trials of therapies for the prevention ofepilepsy.,NINDS,10785495,12/26/2023 12:00:00 AM,PA-20-205,1K23NS135101-01,1,K23,NS,135101,1, ,"CHURN, SEVERN BORDEN",1/1/2024 12:00:00 AM,12/31/2028 12:00:00 AM,NST-1 Study Section[NST-1], ,16302203,"GUGGER, JAMES J",Not Applicable,3.0,NEUROLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,853,Other Research-Related,2024,221505, ,NINDS,205097,16408, ,221505,,221505.0 | |
| No NIH Category available,Acceleration;Affect;Ankylosing spondylitis;Applications Grants;Award;Bioinformatics;Biological Markers;Blood Cells;Cells;Chronic;Clinical;Clinical Data;Clinical Markers;Clinical Trials;Collection;DNA;Data;Data Set;Development;Disease;Disease Progression;Environment;Foundations;Functional disorder;Funding;Future;Gene Expression;Gene Expression Profile;Genetic;Goals;Grant;Heterogeneity;Hyperostosis;Immune;Immunology;Inflammation;Inflammatory Arthritis;Infrastructure;Institution;Instruction;Interferon Type II;Knowledge;Longitudinal Studies;Medicine;Mentors;Mentorship;Methodology;Modeling;Molecular;Molecular Analysis;Molecular Profiling;Monitor;Morbidity - disease rate;Observational Study;Osteogenesis;Outcome;Outcome Study;Pathogenesis;Patient risk;Patients;Peripheral Blood Mononuclear Cell;Pharmaceutical Preparations;Pharmacological Treatment;Physical Function;Population;Preparation;Productivity;Prognosis;Prognostic Marker;Prospective Studies;Proteins;Proteomics;RNA;Research;Research Design;Research Personnel;Resources;Sacroiliac joint structure;Sampling;Scientist;Severities;Severity of illness;Spinal;Spinal Diseases;Spinal Fusion;Spondylarthritis;System;Systemic Scleroderma;T-Lymphocyte;Technology;Training;Transcript;Translational Research;United States National Institutes of Health;Validation;Vertebral column;Work;Writing;bioinformatics tool;biomarker identification;bone metabolism;career development;cell type;clinical biomarkers;clinical care;clinical phenotype;clinical predictors;cohort;design;disability;effective therapy;genetic signature;improved;molecular marker;molecular phenotype;monocyte;next generation;novel;peripheral blood;personalized approach;pharmacologic;physically handicapped;predictive modeling;predictive tools;prognostic model;prognostic signature;prognostication;programs;prospective;radiological imaging;recruit;rheumatologist;single-cell RNA sequencing;skills;spine bone structure;tool;transcriptome sequencing;transcriptomics;treatment strategy,Molecular Profiling of Spinal Disease Progression in Ankylosing Spondylitis,Ankylosing Spondylitis (AS) causes decreased physical functioning and disability due to aberrant bone formationand damage of the spine. In this proposal we will develop tools that can help prognosticate AS patients risk ofsevere spinal disease through molecular profiling and biomarker identification. Furthermore the results willprovide a foundation for studies investigating the pathophysiology of AS spinal disease and enhancerecruitment in clinical trials studying treatments for this disease-specific outcome.,NIAMS,10785663,2/12/2024 12:00:00 AM,PA-20-205,1K23AR083506-01,1,K23,AR,083506,01, ,"PARK, HEIYOUNG",2/12/2024 12:00:00 AM,1/31/2029 12:00:00 AM,ZAR1-FY(M1), ,15909946,"HWANG, MARK CHIAWEI",Not Applicable,18,INTERNAL MEDICINE/MEDICINE,800771594,ZUFBNVZ587D4,800771594,ZUFBNVZ587D4,US,29.703025,-95.403303,578417,UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON,HOUSTON,TX,SCHOOLS OF MEDICINE,770305400,UNITED STATES,N,2/12/2024 12:00:00 AM,1/31/2025 12:00:00 AM,846,Other Research-Related,2024,162540, ,NIAMS,150500,12040, ,162540,,162540.0 | |
| No NIH Category available,Address;Adult;Age;Aging;Alzheimer's Disease;Alzheimer's disease related dementia;Amyloidosis;Automobile Driving;Biological Markers;Brain;Cerebral small vessel disease;Cerebrospinal Fluid;Cerebrum;Characteristics;Clinical;Cognition;Cognitive;Collection;Complex;Cost utility;Data;Dementia;Deposition;Depressed mood;Device or Instrument Development;Disease;Disease Marker;Early Diagnosis;Early identification;Elderly;Enrollment;Etiology;Female;Heterogeneity;Impaired cognition;Incidence;Individual;Interview;Investigation;Laboratories;Longitudinal Studies;Longitudinal cohort;Measurable;Measures;Medical History;Memory;Methods;Microvascular Dysfunction;Modeling;Modification;Nerve Degeneration;Neuropsychology;Outcome;Participant;Pathologic;Pathologic Processes;Pathology;Pathway interactions;Patient Self-Report;Performance;Population;Prevention;Procedures;Process;Prospective cohort;Protocols documentation;Public Health;Questionnaires;Research;Research Personnel;Resources;Risk;Specificity;Spinal Puncture;Symptoms;Testing;Therapeutic;Thinking;Time;Training;Validation;Variant;Work;biomarker validation;brain magnetic resonance imaging;cohort;cost effective;dementia risk;detection method;early detection biomarkers;feature selection;follow-up;high dimensionality;improved;innovation;multimodality;neuroimaging;neuropathology;neuropsychiatric symptom;neuropsychiatry;novel;pre-clinical;prospective;sex;tau Proteins;tau aggregation;tool;tool development;white matter injury,Subjective Cognitive Decline in OIder Adults,Alzheimers disease (AD) and AD-related dementias (ADRD) are an increasingly important public health issuewith the rapid aging of the population. Early detection of individuals prior to overt or irreversible symptoms is animportant step in managing this growing crisis. This preclinical stage represents an ideal time for targetedprevention and therapeutics when available.,NIA,10786074,1/26/2024 12:00:00 AM,PA-19-056,5R01AG062826-05,5,R01,AG,062826,05, ,"ROBERTS, LUCI",2/15/2020 12:00:00 AM,1/31/2025 12:00:00 AM,Clinical Neuroscience and Neurodegeneration Study Section[CNN], ,10941361,"GIFFORD, KATHERINE A.",Not Applicable,07,Unavailable,079917897,GYLUH9UXHDX5,079917897,GYLUH9UXHDX5,US,36.143784,-86.800995,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,NASHVILLE,TN,Independent Hospitals,372320011,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,818031, ,NIA,495913,322118, ,818031,,818031.0 | |
| No NIH Category available,Adolescent;Adult;Algorithms;Bacille Calmette-Guerin vaccination;Biological Assay;Biological Markers;Blood;Blood specimen;CD4 Lymphocyte Count;Characteristics;Child;Childhood;Communities;Country;Data;Decision Making;Detection;Diagnosis;Diagnostic;Diagnostic Sensitivity;Diagnostic Specificity;Diagnostic tests;Disease;Disease Progression;Enrollment;Evaluation;Exposure to;Failure;Gene Expression Profile;Genes;Genetic;Genetic Determinism;Genetic Transcription;Geography;HIV;HIV/TB;Health;Household;Immune;Immune response;Immune system;Incidence;Individual;Inflammatory;Interferon Type II;Interferons;Investigation;Laboratories;Measures;Micro Array Data;Modeling;Monitor;Morbidity - disease rate;Mycobacterium tuberculosis;Mycobacterium tuberculosis antigens;Pathogenesis;Patients;Performance;Population;Preventive therapy;Prognosis;Public Health;Publishing;Quantitative Reverse Transcriptase PCR;RNA;Research Personnel;Risk;Sampling;South African;Specificity;Standardization;T-Cell Activation;T-Lymphocyte;Testing;Translating;Tuberculosis;Tuberculosis Vaccines;Tuberculosis diagnosis;Validation;Variant;Whole Blood;accurate diagnosis;antigen-specific T cells;authority;biomarker performance;candidate marker;cohort;cost;cost effective;cost effectiveness;curative treatments;epidemiological model;experience;genetic signature;genetic variant;improved;industry partner;mortality;novel;novel diagnostics;novel marker;novel strategies;performance tests;point of care;prognostic;prognostic assays;prognostic performance;progression risk;respiratory;response;response biomarker;sample collection;screening;screening program;targeted biomarker;tool;treatment response,Host blood biomarkers for the diagnosis prognosis and treatment response of childhood TB,Project NarrativeThe root cause of systemic failure to identify and treat childhood TB worldwide is the challenge ofaccurate diagnosis. Two novel biomarker approaches based on host blood RNA signatures and asimplified T cell Antigen-Specific Activation assay that target complementary aspects of the hostimmune response have been discovered and validated in adults and offer promise as biomarkers ofchildhood TB. We will evaluate diagnostic and prognostic performance of these biomarkers for pediatricTB disease to inform feasibility and potential impact of biomarker-targeted TB screening strategies forchildren.,NIAID,10786090,2/14/2024 12:00:00 AM,PA-18-484,5R01AI143636-05,5,R01,AI,143636,05, ,"LACOURCIERE, KAREN A",2/20/2019 12:00:00 AM,1/31/2025 12:00:00 AM,Clinical Research and Field Studies of Infectious Diseases Study Section[CRFS], ,8843109,"HATHERILL, MARK ",Not Applicable,,Unavailable,568227214,NN5NML6VUCF9,568227214,NN5NML6VUCF9,SF,-33.96333,18.47639,1147601,UNIVERSITY OF CAPE TOWN,RONDEBOSCH, ,Unavailable,7700,SOUTH AFRICA,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,806919, ,NIAID,761993,44926, ,806919,,806919.0 | |
| No NIH Category available,Actins;Agreement;Algorithmic Software;Algorithms;Artificial Intelligence;Biological Assay;Biological Markers;Biopsy;CD34 gene;Carcinoma;Cell-Matrix Junction;Cells;Classification;Clinical;Clinical Pathways;Clinical Research;Consensus;Cytology;Cytopathology;Data;Data Sources;Databases;Dental;Diagnosis;Diagnostic;Disease;Disease Progression;Early Diagnosis;Early identification;Epidermal Growth Factor Receptor;Evolution;Excision;F-Actin;Goals;Health;Histopathology;Image;Image Cytometry;Incidence;Individual;Institution;Intraepithelial Neoplasia;Lesion;Lip structure;Literature;Localized Malignant Neoplasm;Longitudinal cohort study;Malignant - descriptor;Malignant neoplasm of pharynx;Measurement;Measures;Medical Surveillance;Microfluidics;Modeling;Monitor;National Institute of Dental and Craniofacial Research;Nuclear;Operative Surgical Procedures;Oral cavity;Pathway interactions;Patient Monitoring;Patient-Focused Outcomes;Patients;Performance;Persons;Phenotype;Ploidies;Population;Population Surveillance;Predictive Value;Prospective cohort study;Protocols documentation;Quality of life;Questionnaires;Recording of previous events;Recurrence;Risk;Sampling;Series;Severity of illness;Specimen;Speed;Surveys;System;Technology;Time;Treatment outcome;Trust;Validation;Visit;Visual;biomarker identification;cancer diagnosis;cancer recurrence;cancer risk;cell type;cellular imaging;data acquisition;data streams;deep learning;deep learning algorithm;diagnostic technologies;diagnostic tool;experience;high risk;imaging agent;improved;indexing;individual patient;insight;instrument;malignant mouth neoplasm;mouth squamous cell carcinoma;multimodality;oral care;oral cavity epithelium;oral dysplasia;oral lesion;patient population;personalized diagnostics;point of care;portability;predictive modeling;preference;prognostic value;programmed cell death ligand 1;prospective;rate of change;risk prediction;scalpel;single cell analysis;targeted imaging;tertiary care;time use;tool,Oral Dysplasia and Oral Cavity Cancer Risk in Dental and Medical Surveillance Settings Using a Chairside Chip-Based Cytopathology Tool,PROJECT NARRATIVELip oral cavity and pharyngeal cancers are a significant health problem afflicting approximately 530000 peopleglobally every year. This multi-institution prospective longitudinal cohort study will assess for the first time theperformance of a point-of-care oral cytology tool (POCOCT) for its use in both secondary and tertiary caresettings where high risk patients will be longitudinally monitored and their risk trajectory established over timeusing personalized cellular image signatures. This effort has potential for more accurate oral lesion diagnosiswhile improving patient survival and overall quality of life.,NIDCR,10786108,2/13/2024 12:00:00 AM,PAR-18-787,5R01DE031319-03,5,R01,DE,031319,03, ,"CHEN, ZHONG",4/7/2022 12:00:00 AM,2/28/2027 12:00:00 AM,"Oral, Dental and Craniofacial Sciences Study Section[ODCS]", ,8231604,"MCDEVITT, JOHN T",Not Applicable,10,DENTISTRY,041968306,NX9PXMKW5KW8,041968306,NX9PXMKW5KW8,US,40.729659,-73.997018,5998301,NEW YORK UNIVERSITY,NEW YORK,NY,SCHOOLS OF DENTISTRY/ORAL HYGN,100122300,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,121,Non-SBIR/STTR,2024,725131, ,NIDCR,573985,151146, ,725131,,725131.0 | |
| No NIH Category available,Age;Aging;Alzheimer disease detection;Alzheimer disease screening;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimer's disease diagnostic;Alzheimer's disease patient;Alzheimers disease biomarker;Amyloid deposition;Anatomy;Animal Model;Animals;Autopsy;Barrett Epithelium;Barrett Esophagus;Biological Markers;Cellular Structures;Central Nervous System;Cerebrospinal Fluid;Cervical;Cervix Uteri;Characteristics;Clinical;Clinical Research;Cone;Crystalline Lens;Data;Data Analyses;Dementia;Descriptor;Detection;Development;Devices;Diagnosis;Diagnostic;Discrimination;Disease;Epithelium;Esophagus;Evaluation;Exclusion Criteria;Eye diseases;Functional impairment;Future;Ganglion Cell Layer;Glaucoma;Goals;Health;Human;Image;Impaired cognition;Individual;Interferometry;Investigation;Label;Link;Machine Learning;Measurement;Measures;Meta-Analysis;Methods;Morphology;Neurodegenerative Disorders;Neurology;Nuclear;Onset of illness;Ophthalmology;Optic Nerve;Optical Coherence Tomography;Pathologic;Pathology;Patients;Photophobia;Photoreceptors;Population;Positron-Emission Tomography;Premalignant Cell;Probability;Prospective Studies;Recording of previous events;Research;Resolution;Retina;Rod;Scanning;Senile Plaques;Spinal Puncture;Structure;System;Techniques;Technology;Technology Assessment;Testing;Thick;Thinness;Tissues;Translating;Work;adaptive optics;biomarker development;biomarker validation;brain tissue;cellular imaging;clinical biomarkers;clinical diagnostics;cost;detection method;diagnostic platform;diagnostic tool;early onset;in vivo;light scattering;machine learning algorithm;mouse model;nephelometry;new technology;novel;organizational structure;prevent;retinal imaging;retinal nerve fiber layer,Retinal Light Scattering Measurements as a Clinical Biomarker of Alzheimer's Disease,Project NarrativeThe proposed research will develop a new measurements of the retina. This new technology will be built into existing devices that arecurrently used to image disease in the retina providing a simple way for clinicians to evaluate patientsusing a simple retinal scan. This would have significant implications for detecting and managingdiagnostic that can be widely used at a lower cost than current methods.,NIA,10788366,3/22/2024 12:00:00 AM,PA-20-185,5R01AG072732-03,5,R01,AG,072732,03, ,"ST HILLAIRE-CLARKE, CORYSE",6/15/2022 12:00:00 AM,2/28/2027 12:00:00 AM,Special Emphasis Panel[ZRG1-ETTN-P(81)S], ,6272819,"WAX, ADAM ",Not Applicable,04,BIOMEDICAL ENGINEERING,044387793,TP7EK8DZV6N5,044387793,TP7EK8DZV6N5,US,36.007766,-78.926475,2221101,DUKE UNIVERSITY,DURHAM,NC,BIOMED ENGR/COL ENGR/ENGR STA,277054673,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,491598, ,NIA,316875,174723, ,491598,,491598.0 | |
| No NIH Category available,AR gene;Acceleration;Acetates;Alkaline Phosphatase;Androgen Antagonists;Androgen Receptor;Androgens;Biological Markers;Biology;Cancer Etiology;Cessation of life;Clinic;Clinical;Clinical Research;Clinical Trials;Costs and Benefits;DNA Markers;DNA Sequence Alteration;Data;Detection;Development;Disease;Eligibility Determination;Enrollment;Future;Generations;Genetic;Genomics;Goals;Heterogeneity;Individual;Kinetics;Lactate Dehydrogenase;Ligand Binding Domain;Malignant neoplasm of prostate;Measurement;Measures;Medical Genetics;Metastatic Prostate Cancer;Modeling;Mutation;Neoplasm Circulating Cells;Outcome;Patients;Pattern;Phase;Phenotype;Physicians;Plasma;Prediction of Response to Therapy;Predictive Value;Prevalence;Prior Therapy;Prognosis;RNA Splicing;Research Design;Resistance;Resistance development;Risk;Serum;Speed;Symptoms;Testing;Toxic effect;Treatment outcome;United States;Validation;Variant;abiraterone;androgen biosynthesis;angiokines;care delivery;castration resistant prostate cancer;chemotherapy;circulating biomarkers;clinical phenotype;design;direct patient care;disease heterogeneity;enzalutamide;genomic aberrations;genomic predictors;hormone therapy;improved;improved outcome;inhibitor;inhibitor therapy;insight;man;men;men's group;novel;novel strategies;objective response rate;patient variability;phase III trial;predictive marker;predictive modeling;prognostic;prognostic model;prognostic value;radiological imaging;resistance mechanism;response;targeted treatment;taxane;therapy outcome;tumor;tumor DNA,Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC,PROJECT NARRATIVEThe goal of this project is to develop prognostic models of clinical outcomes that will incorporate baseline AR andnon-AR ctDNA aberrations in men with mCRPC (A031201). In addition we identify potential predictivebiomarkers for overall survival benefit with combined abiraterone acetate and enzalutamide versusenzalutamide treatment alone from men with mCRPC enrolled in a phase III trial on the Alliance Trial A031201.,NCI,10788372,1/9/2024 12:00:00 AM,PA-19-056,5R01CA256157-04,5,R01,CA,256157,04, ,"SONG, MIN-KYUNG H",9/16/2020 12:00:00 AM,12/31/2025 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,2794302,"HALABI, SUSAN ","ARMSTRONG, ANDREW J; DEHM, SCOTT M.",04,BIOSTATISTICS & OTHER MATH SCI,044387793,TP7EK8DZV6N5,044387793,TP7EK8DZV6N5,US,36.007766,-78.926475,2221101,DUKE UNIVERSITY,DURHAM,NC,SCHOOLS OF MEDICINE,277054673,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,395,Non-SBIR/STTR,2024,612180, ,NCI,481002,131178, ,612180,,612180.0 | |
| No NIH Category available,Address;Adult;Advocacy;Altruism;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimer's disease pathology;Alzheimer's disease related dementia;Alzheimers disease biomarker;Amyloid;Area;Awareness;Basic Science;Behavioral Symptoms;Biological;Biological Markers;Biology;Blood;Brain;Caregivers;Caring;Clinic;Clinical;Clinical Course of Disease;Clinical Data;Clinical Research;Clinical assessments;Cognition;Cognition Disorders;Cognitive;Collaborations;Communication;Communities;Data;Data Collection;Databases;Dedications;Dementia;Development;Early Diagnosis;Early treatment;Education;Environment;Etiology;Evaluation;Evolution;Faculty;Family;Foundations;Functional disorder;Funding;Genetic;Goals;Grant;Healthcare;Heterogeneity;Human Resources;Image;Imaging technology;Individual;Infrastructure;Institution;International;Investments;Leadership;MRI Scans;Methodology;Methods;Motivation;Natural History;Nerve Degeneration;Neurobehavioral Manifestations;Outcome;Participant;Pathogenesis;Pathologic;Pathologic Processes;Patient Care;Patients;Pharmaceutical Preparations;Physicians;Positron-Emission Tomography;Process;Productivity;Protocols documentation;Psychoses;Public Health;Qualifying;Research;Research Personnel;Risk Factors;Role;Sampling;Scientist;Solid;Standardization;Students;Symptoms;Testing;Tracer;Training;Training Programs;Training and Education;Universities;Validation;career;cohort;data management;design;disease phenotype;education research;effective therapy;efficacious treatment;genetic risk factor;health care delivery;improved;innovation;insight;interdisciplinary approach;international center;member;mild cognitive impairment;multidisciplinary;neurogenetics;neuroimaging;neuropathology;neuropsychiatry;novel;novel therapeutics;outreach;outreach program;programs;recruit;research study,Alzheimer's Disease Research Center,Overall NarrativeThe principal goal of the University of Pittsburgh Alzheimers Disease Research Center (PITT-ADRC) is toperform and promote research that increases our understanding of the etiology and pathogenesis ofAlzheimers disease (AD) and related dementias in order to ultimately advance new therapies. The PITT-ADRC provides the infrastructure to investigate the mechanisms underlying cognitive and behavioralsymptoms and to develop strategies for effective early diagnoses and treatments of AD. We will accomplishthis goal with our own research involving investigators at the University of Pittsburgh and nearby institutions inclinical and basic research and with collaborations with other national and international centers of excellencein an environment that supports innovative research and enhances training and educational opportunities forpatients caregivers students scientists and clinicians,NIA,10788389,3/6/2024 12:00:00 AM,RFA-AG-20-004,5P30AG066468-05,5,P30,AG,066468,05, ,"SILVERBERG, NINA B",5/15/2020 12:00:00 AM,2/28/2025 12:00:00 AM,ZAG1-ZIJ-G(J1), ,2097508,"LOPEZ, OSCAR L.",Not Applicable,12,NEUROLOGY,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,SCHOOLS OF MEDICINE,152133320,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,866,Research Centers,2024,3098848, ,NIA,1997769,1101079, ,3098848,,3098848.0 | |
| No NIH Category available,Adherence;Affect;Anatomy;Area;Autopsy;Biological Markers;Cancer Patient;Cells;Chronic;Clinic;Clinical;Clinical Trials;DNA;DNA Damage;Data;Data Set;Detection;Development;Diagnosis;Effectiveness;Epidermis;Erythema;Evolution;Feedback;Future;Genes;Genomic DNA;Genomic Segment;Genomics;Growth;Human;Individual;Intervention;Kinetics;Knowledge;Lesion;Life;Malignant Neoplasms;Measurement;Measures;Methods;Modeling;Mus;Mutagenesis;Mutate;Mutation;NOTCH1 gene;Normal tissue morphology;Oncology;Patient risk;Patients;Pattern;Photography;Play;Prevention;Prevention approach;Prevention strategy;Preventive measure;Preventive treatment;Process;Recording of previous events;Redness;Resolution;Risk;Role;Sampling;Signal Transduction;Skin;Skin Cancer;Skin Squamous Cell;Somatic Mutation;Sun Exposure;Sun protection factor;Sunburn;Sunscreening Agents;TP53 gene;Technology;Testing;Textiles;Time;Training;UV Radiation Exposure;UV carcinogenesis;UV induced;UVB induced;Ultraviolet B Radiation;Ultraviolet Rays;Validation;Work;aged;biomarker identification;biomarker panel;cancer care;cancer prevention;cancer risk;care outcomes;clinically relevant;cohort;computerized tools;dosage;effectiveness evaluation;efficacy evaluation;genetic variant;genotoxicity;high dimensionality;improved;indexing;irradiation;machine learning model;mouse model;photoprotection;pre-clinical;predictive panel;premalignant;prevent;research clinical testing;skin cancer prevention;skin damage;skin squamous cell carcinoma;standard of care;sun damage;sun protection;sunlight-induced;targeted sequencing;therapy design;treatment response;treatment strategy;tumor,Advancing skin cancer prevention by tackling UV-induced clonogenic mutations,UV-induced clonogenic mutations (CMs) can be used to evaluate an individual's overall sunexposure and the status of sun-induced genotoxicity in the skin which can profoundly impacthow we diagnosis and treat early stage skin cancer. CMS can be used to evaluate therapeuticresponse to field treatments for skin cancer. CMS can be used to rapidly evaluate strategies forthe prevention of skin cancer such as the genoprotective efficacy of sunscreens or anindividual's adherence to sunscreen application.,NCI,10788394,1/19/2024 12:00:00 AM,PA-19-056,5R01CA255242-04,5,R01,CA,255242,04, ,"WANG, WENDY",2/3/2021 12:00:00 AM,1/31/2026 12:00:00 AM,Cancer Prevention Study Section[CPSS], ,14446591,"WEI, LEI ","PARAGH, GYORGY ",26,Unavailable,824771034,YDWAYVVQHNK5,824771034,YDWAYVVQHNK5,US,42.873378,-78.869243,3934901,ROSWELL PARK CANCER INSTITUTE CORP,BUFFALO,NY,Independent Hospitals,142630001,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,568214, ,NCI,337820,230394, ,568214,,568214.0 | |
| No NIH Category available,Access to Information;Aging;Algorithms;Alzheimer disease prevention;Alzheimer's Disease;Alzheimer's disease patient;Alzheimer's disease related dementia;Alzheimer's disease risk;Amyloid;Area;Autopsy;Biological Markers;Brain;Classification;Clinical;Cognitive;Collaborations;Communities;Consensus;Data;Databases;Detection;Diagnosis;Diagnostic;Disease;Education;Educational process of instructing;Evaluation;Family;Feedback;Fibroblasts;Frontotemporal Lobar Degenerations;Genetic;Genetic Polymorphism;Harvest;Image;Image Analysis;Imaging technology;Joints;Knowledge;Laboratories;Liquid substance;MRI Scans;Measures;Medical Students;Mentors;Microscopy;Mission;Molecular;Nerve Degeneration;Neurobiology;Neurodegenerative Disorders;Participant;Pathologic;Pathology;Phenotype;Positron-Emission Tomography;Process;Protocols documentation;Psychoses;Recommendation;Recording of previous events;Research;Research Personnel;Research Project Grants;Resources;Role;Scanning;Secure;Slice;Systems Analysis;Technical Expertise;Technology;Time;Tissue Banks;Tissue Sample;Tissues;Triage;United States National Institutes of Health;Universities;Update;Variant;Vascular Diseases;alpha synuclein;amyloid imaging;brain tissue;clinical diagnosis;clinical phenotype;cohort;comorbidity;computational pipelines;data management;data sharing;diagnostic criteria;digital;digital imaging;education research;endophenotype;histological image;human tissue;imaging agent;imaging approach;imaging biomarker;imaging study;improved;in vivo;instrumentation;interest;mild cognitive impairment;neuroimaging;neuroinflammation;neuropathology;novel;personalized diagnostics;protein TDP-43;psychiatric comorbidity;repository;research study;resilience;skills;statistics;tau Proteins;therapeutic target;tool;treatment response;web app;whole slide imaging,Neuropathology Core,,NIA,10788397,3/6/2024 12:00:00 AM,RFA-AG-20-004,5P30AG066468-05,5,P30,AG,066468,05, , ,5/15/2020 12:00:00 AM,2/28/2025 12:00:00 AM,ZAG1-ZIJ-G,9374,9681819,"KOFLER, JULIA K",Not Applicable,12,Unavailable,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,Domestic Higher Education,152133320,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Research Centers,2024, ,284671, ,179038,105633, , ,, | |
| No NIH Category available,Alzheimer disease detection;Alzheimer's Disease;Alzheimer's disease patient;Alzheimer's disease therapy;Alzheimers disease biomarker;Amyloid beta-Protein;Ancillary Study;Archives;Biological Assay;Biological Markers;Blood;Blood specimen;Cerebrospinal Fluid;Clinical;Collection;Complex;Country;DNA;DNA Library;Data;Dementia;Deposition;Development;Early Diagnosis;Enzyme-Linked Immunosorbent Assay;Funding;Future;Genes;Genetic;Genetic Diseases;Genetic Markers;Genetic Polymorphism;Genetic Risk;Genetic study;Genomics;Genotype;Goals;Grant;Image;Immunoprecipitation;Individual;International;Late Onset Alzheimer Disease;Light;Magnetic Resonance Imaging;Mass Spectrum Analysis;Measures;Medical;Medical Device;Methods;Multicenter Trials;Nerve Degeneration;Neuronal Injury;Participant;Pathologic;Performance;Phenotype;Pittsburgh Compound-B;Plasma;Play;Positron-Emission Tomography;Publications;Qualifying;RNA;Research;Research Personnel;Research Project Grants;Resources;Risk Marker;Role;Sample Size;Sampling;Site;Standardization;Techniques;Testing;Universities;Validation;Variant;blood-based biomarker;case control;cost;data management;endophenotype;genetic architecture;genome wide association study;mass spectrometer;neurofilament;neurofilament protein L;neurogenetics;neuroimaging;neuropathology;novel;research clinical testing;tau Proteins,Biomarker and Neurogenetics Core,,NIA,10788404,3/6/2024 12:00:00 AM,RFA-AG-20-004,5P30AG066468-05,5,P30,AG,066468,05, , ,5/15/2020 12:00:00 AM,2/28/2025 12:00:00 AM,ZAG1-ZIJ-G,9377,1867465,"KAMBOH, M. ILYAS",Not Applicable,12,Unavailable,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,Domestic Higher Education,152133320,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Research Centers,2024, ,265832, ,167190,98642, , ,, | |
| No NIH Category available,Address;Affect;Alzheimer disease screening;Alzheimer's Disease;Alzheimer's disease patient;Alzheimer's disease therapeutic;Alzheimers disease biomarker;Area;Biochemical;Biological Markers;Biophysics;Blood specimen;Brain scan;Calibration;Cancer Detection;Cerebrospinal Fluid;Cerebrospinal Fluid Proteins;Clinical Trials;Cognition Disorders;Cognitive;Consumption;DNA Folding;Dementia;Development;Devices;Disease;Disease Progression;Drug Targeting;Enrollment;Future;Individual;Investigation;Lab On A Chip;Label;Light;Light-Scattering Spectroscopy;Mass Spectrum Analysis;Measures;Modality;Modeling;Molecular Conformation;Monitor;Nervous System Disorder;Neurodegenerative Disorders;Optics;Parkinson Disease;Participant;Performance;Persons;Plasma;Polymers;Positron-Emission Tomography;Property;Proteins;Raman Spectrum Analysis;Reproducibility;Research;Sampling;Spinal Puncture;Standardization;Structure;System;Techniques;Testing;Time;Validation;biomarker panel;cohort;cost;cost effective;design;detection platform;drug action;drug candidate;experimental study;fabrication;manufacture;miniaturize;misfolded protein;nanophotonic;nanoscale;novel;novel marker;photonics;polymerization;protein structure;prototype;screening;skills;stem cell differentiation;targeted biomarker;therapeutic development;two-photon;waveguide,A lab-on-a-chip device for measuring multiple biochemical and biophysical biomarkers of Alzheimers disease,PROJECT NARRATIVEThese exploratory studies could lead to the development of a mass producible device that uses a simple bloodsample to identify people most suited for clinical trials of Alzheimers disease therapeutics. The same devicecould also be used for monitoring disease progression throughout the trial.,NIA,10788635,4/29/2024 12:00:00 AM,PAR-24-022,1R21AG085089-01,1,R21,AG,085089,01, ,"LUO, YUAN",5/1/2024 12:00:00 AM,4/30/2027 12:00:00 AM,Special Emphasis Panel[ZRG1-BBBT-M(82)S], ,16597709,"COUGHLAN, MARK ",Not Applicable,07,Unavailable,071723621,C1CPANL3EWK4,071723621,C1CPANL3EWK4,US,42.33982,-71.10568,758101,BETH ISRAEL DEACONESS MEDICAL CENTER,BOSTON,MA,Independent Hospitals,022155400,UNITED STATES,N,5/1/2024 12:00:00 AM,4/30/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,236022, ,NIA,150000,86022, ,236022,,236022.0 | |
| No NIH Category available,7 year old;Acceleration;Acute;Adult;Alleles;Biological Assay;Biological Markers;Blood;Brain Neoplasms;Cancer Burden;Caring;Cessation of life;Chemoresistance;Chest;Child;Childhood;China;Clinical;Clinical Trials;Codon Nucleotides;Collaborations;Communities;Cystic Neoplasm;Detection;Development;Diagnosis;Diagnostic;Disease;Dose;Early Diagnosis;Embryonic Development;Enrollment;Excision;Face;Future;Industrialization;Infant;International;Intervention;Kidney Neoplasms;Malignant Childhood Neoplasm;Malignant Neoplasms;Malignant neoplasm of lung;Measures;Metastatic malignant neoplasm to brain;Methods;Minnesota;Missense Mutation;Molecular;Monitor;Morbidity - disease rate;Mutation;Operative Surgical Procedures;Pathogenesis;Pathogenicity;Pathologic;Pediatric Hospitals;Pediatric Oncology;Pleuropulmonary Blastoma;Preclinical Drug Development;Predisposition;Prognosis;Progressive Disease;Radiation;Radiation therapy;Rare Diseases;Recurrence;Recurrent disease;Recurrent tumor;Registries;Research;Residual Neoplasm;Rhabdomyosarcoma;Ribonucleases;Risk;Sarcoma;Scanning;Schedule;Sedation procedure;Sensitivity and Specificity;Site;Solid;Solid Neoplasm;Technology;Testing;Toxic effect;Translations;Treatment-related toxicity;Tumor Burden;Validation;Variant;Work;X-Ray Computed Tomography;biomarker validation;blood-based biomarker;cancer cell;cell free DNA;chemotherapy;chest computed tomography;clinical practice;clinically significant;companion diagnostics;data registry;design;digital;early childhood;high risk;improved;improved outcome;liquid biopsy;mortality risk;mutant;new technology;novel;novel marker;novel therapeutics;ovarian neoplasm;radiation risk;rare cancer;risk minimization;risk stratification;side effect;specific biomarkers;therapy resistant;thyroid neoplasm;translational study;treatment response;tumor;tumor DNA;young adult,Detecting DICER1: A global partnership to cure pediatric lung cancer,"NARRATIVEClinical validation and translation of blood-based biomarkers is the next necessary step in ourefforts to cure PPB and other DICER1-related cancers. This global partnership focuses on theclinical validation of novel circulating tumor DNA-based ""liquid biopsy"" assays for quantificationof tumor burden and detection of treatment response in DICER1-related cancers. Developmentof novel biomarkers will improve outcomes for children and adults with DICER1-related cancersthrough early diagnosis risk stratification and intervention and development of novel therapies.",NCI,10789853,2/12/2024 12:00:00 AM,PAR-18-530,5R37CA244940-05,5,R37,CA,244940,05, ,"MCKEE, TAWNYA C",2/15/2020 12:00:00 AM,1/31/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-SBIB-Q(57)R], ,10742430,"SCHULTZ, KRIS ANN PINEKENSTEIN",Not Applicable,05,Unavailable,078689619,JR53UMNS5Y87,078689619,JR53UMNS5Y87,US,44.956627,-93.261846,4940001,CHILDREN'S HOSPITALS AND CLINICS,MINNEAPOLIS,MN,Independent Hospitals,554044518,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,362047, ,NCI,293878,68169, ,362047,,362047.0 | |
| No NIH Category available,Alzheimer's Disease;Alzheimer's disease brain;Alzheimer's disease diagnosis;Alzheimer's disease related dementia;Alzheimers disease biomarker;Antibodies;Autopsy;Biological Assay;Biological Markers;Biological Specimen Banks;Brain;Brain imaging;Brain region;Cerebrospinal Fluid;Characteristics;Clinical;Cognitive;Communities;Dementia;Development;Diagnosis;Diagnostic;Diagnostic Specificity;Diagnostic tests;Differential Diagnosis;Disease;Early Diagnosis;Enzyme-Linked Immunosorbent Assay;Frequencies;Goals;Healthcare;Human;Image;Imaging Device;Impaired cognition;Intervention;Medical;Methods;Microscopic;Monitor;Neurology;Pathologic;Patients;Performance;Persons;Pharmacotherapy;Plasma;Positron-Emission Tomography;Process;Progressive Disease;Radioactive Tracers;Rare Diseases;Registries;Sampling;Scanning;Senile Plaques;Sensitivity and Specificity;Severity of illness;Site;Symptoms;Tauopathies;Technology;Testing;Time;Translating;Translations;United States;Work;biobank;biomarker panel;biomarker validation;brain tissue;clinical diagnosis;cohort;cost;detection test;early detection biomarkers;effectiveness evaluation;human old age (65+);improved;mild cognitive impairment;minimally invasive;molecular array;molecular marker;neurocognitive test;novel;repository;screening;single molecule;tau Proteins;tau aggregation;tau-1;technology development,New biomarkers for early Alzheimer's diagnosis and tauopathy differentiation,Project NarrativeDeveloping easy-to-use and low-cost assays with high sensitivity and specificity to detect earlyAlzheimer's disease (AD) and differentiate AD from other related dementias is urgent unmetneed. We will develop novel biofluid misfolded tau protein-based molecular biomarkers for earlyAD diagnosis and for differentiating AD from other tauopathies. Our work may lead to significantclinical and translational advances in AD and ADRD medical diagnosis and related healthcare.,NIA,10790509,2/8/2024 12:00:00 AM,PAS-19-392,1R03AG085058-01,1,R03,AG,085058,01, ,"LUO, YUAN",2/15/2024 12:00:00 AM,11/30/2025 12:00:00 AM,Clinical Neuroscience and Neurodegeneration Study Section[CNN], ,12178008,"WU, LING ",Not Applicable,04,NONE,783691801,L1DXXP1KGP77,783691801,L1DXXP1KGP77,US,35.97467,-78.898054,578213,NORTH CAROLINA CENTRAL UNIVERSITY,DURHAM,NC,UNIVERSITY-WIDE,277073129,UNITED STATES,N,2/15/2024 12:00:00 AM,11/30/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,150000, ,NIA,100000,50000, ,150000,,150000.0 | |
| No NIH Category available,Address;Affect;Africa South of the Sahara;African;Amines;Anabolism;Anatomy;Bacteria;Bacterial Physiology;Bacterial Vaginosis;Bacteriology;Biochemical;Biogenic Amines;Bioinformatics;Biological Markers;Biology;Cadaverine;Cell Proliferation;Cellular Metabolic Process;Chemicals;Chemistry;Clinical;Clinical Markers;Collaborations;Communicable Diseases;Communities;Data;Development Plans;Disease;Environment;Enzymatic Biochemistry;Enzyme Inhibitor Drugs;Enzymes;Functional disorder;General Hospitals;Genomics;Goals;HIV;HIV risk;Health;Imidazole;Immune response;Immunologics;Immunology;In Vitro;Inflammation;Inflammatory;Inflammatory Response;Knowledge;Lactobacillus;Link;Malignant Neoplasms;Malignant neoplasm of cervix uteri;Massachusetts;Measures;Mediating;Mediator;Medicine;Mentors;Metabolic;Metagenomics;Methods;Microbial Biofilms;Mucositis;Mucous Membrane;Outcome;Pathogenesis;Pathogenicity;Pathway interactions;Physicians;Population;Premature Birth;Prevalence;Production;Propionates;Putrescine;Reproducibility;Research;Research Personnel;Role;Scientist;Site;Smell Perception;Source;South African;Symptoms;Testing;Therapeutic;Tissues;Training;Universities;Vagina;Vaginal Diseases;Validation;Woman;bacterial community;candidate identification;candidate marker;career;career development;cohort;cytokine;diagnostic criteria;eIF-5A;enzyme activity;experience;experimental study;high volume manufacturing;immunoregulation;in vivo;inhibitor;innovation;instructor;interest;medical schools;metabolome;metabolomics;metagenome;metatranscriptomics;microbial;microbiome;microbiome composition;microbiota;multiple omics;novel;novel therapeutic intervention;novel therapeutics;pharmacologic;potential biomarker;prevent;reproductive outcome;reproductive tract;skills;targeted treatment;translation factor;vaginal fluid;vaginal microbiome;vaginal microbiota,Mechanistic characterization of vaginal microbiome-metabolome associations and metabolite-mediated host inflammation,Project NarrativeThe vaginal microbiome is linked to important health conditions including bacterial vaginosis (BV) preterm birthHIV and cervical cancer but reasons for these links are unclear and current BV-directed therapies do not workwell. We will study how metabolites in vaginal fluid including the potentially harmful molecules putrescine andimidazole propionate are produced by the microbiome how they cause inflammation in the vagina and whetherthey can be blocked by pharmacological agents. The results will provide important new knowledge about causesof BV and vaginal diseases and will help to find new therapies for preventing and treating these diseases inwomen globally.,NIAID,10791863,2/15/2024 12:00:00 AM,PA-20-203,5K08AI171166-02,5,K08,AI,171166,02, ,"CHUANG, ELEANORE JENNIFER",2/17/2023 12:00:00 AM,1/31/2028 12:00:00 AM,Microbiology and Infectious Diseases B Research Study Section[MID-B], ,10791264,"BLOOM, SETH MICHAEL",Not Applicable,08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,855,Other Research-Related,2024,182304, ,NIAID,168800,13504, ,182304,,182304.0 | |
| No NIH Category available,Address;Animal Model;Biopsy;Blood - brain barrier anatomy;Brain;Brain Neoplasms;Brain imaging;Cancer Patient;Cell Size;Clinic;Clinical;Computer Assisted;Contrast Media;Cranial Irradiation;Development;Diagnosis;Diffusion;Dimensions;Early Diagnosis;Edema;Enhancing Lesion;Foundations;Gadolinium;Image;Lesion;Liquid substance;Magnetic Resonance Imaging;Malignant Neoplasms;Malignant neoplasm of brain;Metastatic malignant neoplasm to brain;Metastatic/Recurrent;Methods;Monitor;Morbidity - disease rate;Necrosis Induction;Neoplasm Metastasis;Non-Small-Cell Lung Carcinoma;Operative Surgical Procedures;Patients;Process;Protocols documentation;Radiation;Radiation Oncology;Radiation necrosis;Radiosurgery;Recurrence;Recurrent tumor;Scanning;Signal Transduction;Source;Specificity;Spectrum Analysis;Structure;Techniques;Testing;Time;Validation;Variant;Work;accurate diagnosis;brain abnormalities;brain cell;brain tissue;cancer cell;cell type;clinical imaging;common treatment;diagnostic accuracy;diffusion anisotropy;effective therapy;imaging approach;imaging biomarker;imaging modality;improved;kidney dysfunction;multidisciplinary;non-invasive imaging;novel strategies;perfusion imaging;pre-clinical;reduce symptoms;standard of care;tumor;tumor progression;vasogenic edema,Differentiation of tumor progression from radiation necrosis using MR cell size imaging,PROJECT NARRATIVE This R21 proposal seeks to develop a cell-size-based MRI technique Selective Size MR Imaging usingFilters via diffusion Times (SSIFT) as a novel approach for imaging brain metastases in patients with highspecificity and to evaluate its potential to differentiate recurrent metastatic brain cancer from radiation necrosisinduced by stereotactic radiosurgery.,NCI,10791886,4/17/2024 12:00:00 AM,PAR-20-292,5R21CA270731-02,5,R21,CA,270731,02, ,"KIM, BOKLYE",4/1/2023 12:00:00 AM,3/31/2025 12:00:00 AM,ZCA1-RTRB-U(J2)S, ,10454911,"XU, JUNZHONG ",Not Applicable,07,Unavailable,079917897,GYLUH9UXHDX5,079917897,GYLUH9UXHDX5,US,36.143784,-86.800995,10040927,VANDERBILT UNIVERSITY MEDICAL CENTER,NASHVILLE,TN,Independent Hospitals,372320011,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,194304, ,NCI,111031,83273, ,194304,,194304.0 | |
| No NIH Category available,Acoustics;Affect;Anatomy;Aphasia;Associative aphasia;Behavioral;Biological Markers;Brain Injuries;Communication;Communication Disability;Communication impairment;Complex;Computer Models;Data;Death Rate;Diagnosis;Diffusion Magnetic Resonance Imaging;Dorsal;Effectiveness;Electroencephalography;Electrophysiology (science);Event-Related Potentials;Family;Feedback;Functional Magnetic Resonance Imaging;Generations;Goals;Human;Impairment;Individual;Knowledge;Language;Language Disorders;Left;Lesion;Life;Life Expectancy;Location;MRI Scans;Measures;Mission;Modality;Modeling;Motor;Motor output;National Institute of Neurological Disorders and Stroke;Neuronal Plasticity;Outcome;Outcome Measure;Patients;Pattern;Play;Population;Positioning Attribute;Procedures;Process;Production;Public Health;Quality of life;Receptive aphasia;Regression Analysis;Rehabilitation Outcome;Research;Resolution;Role;Sensorimotor functions;Sensory;Signal Transduction;Source;Speech;Speech Disorders;Speech Therapy;Stream;Stroke;Time;Training;Translating;Treatment outcome;United States;United States National Institutes of Health;Validation;Visual;Voice;acute stroke;auditory feedback;base;behavior measurement;biomarker identification;chronic stroke;comprehension deficit;disability;experience;improved;indexing;individualized medicine;innovation;insight;motor control;multimodality;neural;neuroimaging;neuromechanism;neurophysiology;novel;response;sensory feedback;sensory input;sensory integration;social;stroke patient;stroke-induced aphasia;targeted treatment;tractography;treatment strategy;visual feedback;white matter,Neural Bases of Vocal Sensorimotor Impairment in Aphasia,Project NarrativeAphasia is an acquired speech/language deficit most commonly resulting from left-hemisphere stroke and is aleading cause of communication disability in the United States posing a significant barrier to professionalsocial and family participations. Our proposed research meets public health needs by providing uniqueinsights into the neural bases of vocal sensorimotor deficits that underlie impaired communication in aphasia.This knowledge will inform targeted treatment of sensorimotor mechanisms to help enhance communicationability and improve the quality of life in affected individuals.,NIDCD,10791888,5/2/2024 12:00:00 AM,PA-18-334,5R01DC018523-05,5,R01,DC,018523,05, ,"KOPF, LISA MARIE",3/1/2021 12:00:00 AM,2/28/2026 12:00:00 AM,Sensorimotor Integration Study Section[SMI], ,11307615,"BEHROOZMAND, ROOZBEH ",Not Applicable,24,PSYCHOLOGY,800188161,EJCVPNN1WFS5,800188161,EJCVPNN1WFS5,US,32.991725,-96.743697,578409,UNIVERSITY OF TEXAS DALLAS,RICHARDSON,TX,SCH ALLIED HEALTH PROFESSIONS,750803021,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,173,Non-SBIR/STTR,2024,701141, ,NIDCD,505102,196039, ,701141,,701141.0 | |
| No NIH Category available,Address;Affect;American;Amputation;Ancillary Study;Area;Biological Markers;CCR;Caring;Clinic;Clinical;Clinical Research;Collection;Communities;Data;Data Collection;Diabetes Mellitus;Diabetic Foot;Diabetic Foot Ulcer;Education;Enrollment;Feasibility Studies;Funding;General Hospitals;Goals;Healthcare Systems;Hospitals;Impaired healing;Individual;Infrastructure;Interdisciplinary Study;Link;Lower Extremity;Medical center;Minority Groups;Morbidity - disease rate;Multicenter Studies;National Institute of Diabetes and Digestive and Kidney Diseases;Observational Study;Outcome;Parents;Patient-Focused Outcomes;Patients;Persons;Podiatry;Population;Population Heterogeneity;Prevalence;Protocols documentation;Provider;Public Health;Quality of life;Recurrence;Research;Research Personnel;Risk Factors;San Francisco;Site;Specimen;Technology;United States;Vascular Diseases;biobank;biomarker development;biomarker validation;c-myc Genes;candidate marker;clinical care;clinical center;experience;health data;health equity;improved;mortality;multidisciplinary;performance site;recruit;social health determinants;socioeconomics;standard of care;wound care,UCSF Diabetic Foot Clinical Research Unit,PROJECT NARRATIVEThis proposal is a renewal for the UCSF Diabetic Foot Clinical Research Unit one of the original centers withinthe NIDDK Diabetic Foot Consortium. In the next funding cycle our multi-disciplinary team will continue torecruit subjects from our two academic hospitals (UCSF Medical Center and ZSFGH) into the DFC trialsoperationalize a new master protocol to enable the study of all patients with active diabetic foot ulcers (DFU)expand our infrastructure through an existing partnership with affiliated Bay Area podiatry clinics and initiatethe study of social determinants of health (SDOH) within the DFC. This research directly addresses a majorpublic health burden in the Bay Area nation and global community.,NIDDK,10792624,1/18/2024 12:00:00 AM,RFA-DK-22-509,5U01DK119100-06,5,U01,DK,119100,06, ,"LI, YAN",9/15/2018 12:00:00 AM,12/31/2027 12:00:00 AM,ZDK1-GRB-1(J2), ,1926137,"CONTE, MICHAEL S",Not Applicable,11,SURGERY,094878337,KMH5K9V7S518,094878337,KMH5K9V7S518,US,37.767442,-122.413937,577508,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",SAN FRANCISCO,CA,SCHOOLS OF MEDICINE,941432510,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,765842, ,NIDDK,488014,277828, ,765842,,765842.0 | |
| No NIH Category available,Acceleration;Benchmarking;Biochemical Genetics;Biological;Biological Assay;Biological Markers;Bioluminescence;Cellularity;Cerebrospinal Fluid;Characteristics;Chemotherapy and/or radiation;Clinic;Clinical;Clinical Management;Clinical Trials;Combined Modality Therapy;Core Facility;Data;Detection;Devices;Diagnosis;Diagnostic;Disease;Disease Progression;Disease Surveillance;Excision;Glioma;Histologic;Human;Image;Individual;Laboratories;Lesion;Linear Regressions;Location;Magnetic Resonance Imaging;Magnetic Resonance Spectroscopy;Mass Spectrum Analysis;Measurement;Measures;Metabolic;Microdialysis;Minor;Modeling;Molecular;Monitor;Monitoring for Recurrence;Mus;Newly Diagnosed;Ommaya Reservoir;Operative Surgical Procedures;Outcome;Patients;Performance;Phase;Postoperative Period;Pre-Clinical Model;Production;Progressive Disease;Property;Recurrence;Recurrent disease;Recurrent tumor;Residual Neoplasm;Resistance;Sampling;Sensitivity and Specificity;Series;Site;Spectrum Analysis;Spinal Puncture;Stereoisomer;Testing;Therapeutic;Time;Tumor Tissue;Tumor Volume;Validation;Ventricular;biomarker discovery;burden of illness;cancer cell;candidate marker;cohort;epigenomics;extracellular;follow-up;individual patient;individualized medicine;metabolic phenotype;metabolomics;mutant;neurosurgery;new therapeutic target;radiation effect;radiological imaging;response;survival outcome;translational progress;translational therapeutics;treatment response;tumor;tumor progression;young adult,Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.,Narrative:Translational progress for IDH-mutant gliomas is slowed by protracted disease course and lack of biomarkersand remain ultimately uniformly fatal. Tumors produce high levels of the metabolite D-2-hydroxyglutarate(D2-HG) within the local tumor tissue that is also reliably detectable within cerebrospinal fluid. We propose aseries of studies in preclinical models and human patients undergoing surgery and monitoring for IDH-mutantglioma to determine the utility of (D2-HG) as a monitoring biomarker benchmarked against gold-standardimaging and clinical outcomes.,NINDS,10792628,2/15/2024 12:00:00 AM,PAR-19-315,5R61NS122096-03,5,R61,NS,122096,03, ,"TAYLOR-BURDS, CAROL C",3/15/2022 12:00:00 AM,2/28/2025 12:00:00 AM,Neurological Sciences and Disorders A Study Section[NSD-A], ,11196938,"BURNS, TERRY ",Not Applicable,01,Unavailable,006471700,Y2K4F9RPRRG7,006471700,Y2K4F9RPRRG7,US,44.02432,-92.46011,4976101,MAYO CLINIC ROCHESTER,ROCHESTER,MN,Other Domestic Non-Profits,559050001,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,385574, ,NINDS,242499,143075, ,385574,,385574.0 | |
| No NIH Category available,Acceleration;Adoption;Affinity;Alzheimer's Disease;Alzheimer's disease brain;Alzheimer's disease related dementia;Alzheimer's disease risk;Amyloid deposition;Biological Assay;Biological Markers;Blood - brain barrier anatomy;Blood Proteins;Brain;Brain Mapping;Brain region;Cerebrospinal Fluid;Cerebrospinal Fluid Proteins;Chronic Disease;Clinical;Compensation;Complement;Consensus;Consumption;Custom;Data;Dementia;Detection;Development;Diagnosis;Diagnostic tests;Disease;Disease Progression;Flow Cytometry;Functional disorder;Genetic Risk;Goals;Human;Impaired cognition;Individual;Infrastructure;Injury;Intercellular Fluid;Lipoproteins;Liquid substance;Logic;Mass Spectrum Analysis;Medicine;Methods;Mission;Molecular;Molecular Profiling;Monitor;Multiplexed Ion Beam Imaging;Neurodegenerative Disorders;Neurofibrillary Tangles;Neuronal Injury;Neuropsychological Tests;Neurosciences;Pathogenicity;Pathologic;Pathway interactions;Patients;Peripheral;Process;Protein Engineering;Proteins;Proteomics;Protocols documentation;Public Health;Reagent;Reproducibility;Research;Research Personnel;Resources;Sampling;Specimen;System;Technology;Transportation;United States National Institutes of Health;Validation;Work;clinical diagnostics;clinically relevant;data dissemination;data sharing;diagnostic value;extracellular vesicles;improved;in vivo;innovation;molecular imaging;new technology;next generation;novel;outcome prediction;particle;precision medicine;programs;protein biomarkers;response to injury;therapeutic target;translational applications;translational proteomics;treatment response,Next Generation Translational Proteomics for Alzheimer's and Related Dementias,Project NarrativeAlzheimer's disease (AD) is a chronic illness whose ultimate clinical expression as dementia follows years ifnot decades of injury response to injury consumption of reserve and compensation. Genetic risk for AD nowclearly highlights the potential for multiple molecular drivers and perhaps multiple pathogenic pathways. Tomonitor AD progression or response to treatment cerebrospinal fluid (CSF) represents the preferred fluid toreflect brain pathophysiology. We propose to enable precision medicine for AD by developing a cooperativeresearch program that will unite a unique research team with the specific goal of vastly improving the molecularcharacterization of CSF as predictors of cognitive decline and AD pathophysiology.,NIA,10792929,1/31/2024 12:00:00 AM,PAR-18-296,5U19AG065156-05,5,U19,AG,065156,05, ,"HSIAO, JOHN",2/15/2020 12:00:00 AM,1/31/2025 12:00:00 AM,ZAG1-ZIJ-6(O1), ,6676500,"MACCOSS, MICHAEL ","MONTINE, THOMAS J",07,GENETICS,605799469,HD1WMN6945W6,605799469,HD1WMN6945W6,US,47.660307,-122.315168,9087701,UNIVERSITY OF WASHINGTON,SEATTLE,WA,SCHOOLS OF MEDICINE,981959472,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,3132122, ,NIA,2350498,781624, ,3132122,,3132122.0 | |
| No NIH Category available,Alternative Splicing;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimer's disease patient;Alzheimer's disease related dementia;Amyloid;Amyloid beta-Protein;Amyloid beta-Protein Precursor;Bathing;Behavior;Biochemical;Biological;Biological Assay;Biological Markers;Cause of Death;Cell Death;Cell Separation;Central Nervous System;Cerebral cortex;Cerebrospinal Fluid;Cessation of life;Clinical;Computer software;Data;Dementia;Deposition;Development;Disease;Disease Management;Ensure;Event;Goals;Guidelines;Hand;Impaired cognition;Injury;Laboratories;Lipoproteins;Liquid Chromatography;Liquid substance;Mediator;Methods;Molecular Conformation;Molecular Weight;Monitor;Neurodegenerative Disorders;Neurofibrillary Tangles;Neuronal Dysfunction;Neurons;Outcome;Pathologic;Patients;Phosphorylation Site;Post-Translational Protein Processing;Procedures;Process;Proteins;Proteomics;Reproducibility;Research Personnel;Sampling;Senile Plaques;Speed;Synapses;Tissue imaging;Validation;abeta deposition;amyloid formation;biomarker discovery;brain tissue;clinical translation;differential expression;experience;extracellular vesicles;gene product;gray matter;interest;mild cognitive impairment;multiplex assay;neuron loss;next generation;novel;novel marker;protein aggregation;regional atrophy;success;tandem mass spectrometry;tau Proteins;tau-1;translational proteomics;verification and validation,Project 3: Development of multiplex assays for clinical monitoring of disease,,NIA,10792939,1/31/2024 12:00:00 AM,PAR-18-296,5U19AG065156-05,5,U19,AG,065156,05, , ,2/15/2020 12:00:00 AM,1/31/2025 12:00:00 AM,ZAG1-ZIJ-6,9800,2110147,"HOOFNAGLE, ANDREW N",Not Applicable,07,Unavailable,605799469,HD1WMN6945W6,605799469,HD1WMN6945W6,US,47.660307,-122.315168,9087701,UNIVERSITY OF WASHINGTON,SEATTLE,WA,Domestic Higher Education,981959472,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,608188, ,391118,217070, , ,, | |
| No NIH Category available,Acceleration;Address;Affect;Age;Aging;Behavioral;Biological;Biological Aging;Biological Markers;Biological Process;Black Populations;Blood;Blood Cells;Brain;Cell Aging;Cells;Characteristics;Chronology;Clinical;Cognitive;Complex;DNA Methylation;Degenerative polyarthritis;Development;Disease;Disparity population;Elderly;Epigenetic Process;Ethnic Origin;Ethnic Population;Florida;Future;Gerontology;Goals;Health;Heterogeneity;Individual;Intervention;Knee Osteoarthritis;Knowledge;Length;Leukocytes;Longevity;Measures;Methods;Modeling;Morbidity - disease rate;Not Hispanic or Latino;Outcome;Pain;Pain Free;Pain Measurement;Pain intensity;Pattern;Performance;Personality Traits;Persons;Phase II Clinical Trials;Physical Function;Physiological;Population Group;Process;Reporting;Research;Residual state;Risk;System;Therapeutic;Time;Tissues;Underrepresented Minority;Universities;Validation;Visit;Work;age related;aging brain;biobehavior;biological heterogeneity;biopsychosocial;candidate marker;chronic pain;clinical pain;clinically relevant;cognitive function;comparison control;disability;disorder risk;ethnic difference;ethnic disparity;experience;follow-up;functional decline;functional disability;functional outcomes;improved;in vivo;inter-individual variation;knee pain;loss of function;middle age;mortality;mosaic;neuroimaging;non-opioid analgesic;novel;osteoarthritis pain;pain inhibition;pain relief;pain sensitivity;personalized predictions;predictive marker;predictive modeling;prospective;psychologic;psychosocial;racial difference;racial disparity;racial population;social;telomere;trait,Biobehavioral basis of knee osteoarthritis pain,Project NarrativeOur recent cross-sectional findings suggest that chronic pain is associated with multiple biological agingbiomarkers where a greater pain burden is associated with accelerated aging processes. Thus the goal of theproposed study is to determine the brain and bodily aging mechanisms whereby pain prospectively impactsfunction in aging and whether these are different across racial/ethnic groups. Findings will contribute towardsincreased understanding of pain and biological aging processes with the potential to reduce race/ethnic groupdisparities and improve pain-related health outcomes.,NIA,10793573,2/22/2024 12:00:00 AM,PA-18-141,5R01AG067757-05,5,R01,AG,067757,05, ,"FRANKOWSKI, DAVID WITT",5/15/2020 12:00:00 AM,2/28/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-RPHB-W(02)M], ,11196759,"CRUZ-ALMEIDA, YENISEL ",Not Applicable,03,DENTISTRY,969663814,NNFQH1JAPEP3,969663814,NNFQH1JAPEP3,US,29.643443,-82.349637,513806,UNIVERSITY OF FLORIDA,GAINESVILLE,FL,SCHOOLS OF DENTISTRY/ORAL HYGN,326115500,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,504192, ,NIA,336680,167512, ,504192,,504192.0 | |
| No NIH Category available,Adolescence;Adolescent;Affect;Affective;Age;Age of Onset;Amygdaloid structure;Anterior;Behavior;Behavior assessment;Behavioral;Biological;Biological Markers;Biosensor;Bipolar Disorder;Brain;Categories;Childhood;Clinical;Clinical assessments;Cognition;Cognitive;Corpus striatum structure;Development;Diagnosis;Dimensions;Disease;Disease Marker;Disease Progression;Early Diagnosis;Emotions;Evaluation;Functional impairment;Future;Gender;Hospitals;Impairment;Individual;Inpatients;Intervention;Length;Linear Models;Longitudinal Studies;Machine Learning;Magnetic Resonance Imaging;Manic;Matched Group;Measures;Modeling;Mood Disorders;Moods;Morbidity - disease rate;Multimodal Imaging;Neurocognitive;Neurophysiology - biologic function;Onset of illness;Outcome;Outpatients;Parietal;Patient Self-Report;Pattern Recognition;Physical activity;Polysomnography;Population;Prefrontal Cortex;Proxy;Puberty;Resources;Rest;Rewards;Risk;Sampling;Severities;Sleep;Specific qualifier value;Stimulus;Structure;Suicide;Symptoms;Syndrome;Testing;Thick;Time;Training;Uncertainty;Validation;Variant;Ventral Striatum;Work;Youth;actigraphy;aged;behavior measurement;biomarker identification;brain behavior;childhood bipolar disorder;cingulate cortex;clinical predictors;cognitive testing;comorbidity;computerized;cost;digital;experience;follow-up;gray matter;high risk;high risk population;high-risk adolescents;hypomania;imaging modality;improved;machine learning classifier;machine learning model;mobile application;mood symptom;multimodality;neural;neural network;neuroimaging;neuropsychiatry;novel;outcome prediction;personalized intervention;predictive marker;predictive modeling;recruit;response;reward processing;treatment planning;two-dimensional;white matter;young adult,From Manic Symptoms to Bipolar Disorder: Neural-behavioral Markers Using Two Analytic Models,PROJECT NARRATIVEAdolescents may experience manic symptoms that may or may not progress into bipolar disorder.This proposed longitudinal study would be the first of its kind and could shed light on the neural andbehavioral markers of disease progression in high-risk adolescents with manic symptoms. Identifyingsuch markers for bipolar disorder has important clinical implications such as improving early detectionof illness and informing treatment planning and personalized interventions.,NIMH,10793574,1/12/2024 12:00:00 AM,PA-19-056,5R01MH121451-05,5,R01,MH,121451,05, ,"FRIEDMAN-HILL, STACIA",3/1/2020 12:00:00 AM,1/31/2025 12:00:00 AM,"Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]", ,10048932,"DILER, RASIM SOMER","BERTOCCI, MICHELE A",12,PSYCHIATRY,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,SCHOOLS OF MEDICINE,152133320,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,242,Non-SBIR/STTR,2024,665224, ,NIMH,433065,232159, ,665224,,665224.0 | |
| No NIH Category available,Address;Adipose tissue;Adult;Affect;American Heart Association;Body mass index;Breathing;Cardiovascular Diagnostic Techniques;Cardiovascular Diseases;Cardiovascular system;Caring;Centers for Disease Control and Prevention (U.S.);Classification;Clinical;Clinical Management;Compensation;Development;Diagnostic;Diagnostic Imaging;Diameter;Dyslipidemias;Echocardiography;Epidemic;Equipment;Face;Functional impairment;Goals;Healthcare;Heart Diseases;Heart failure;Hispanic;Hypertension;Image;Image Enhancement;Incidence;Individual;Institution;Link;Machine Learning;Magnetic Resonance Imaging;Methods;Modality;Morbid Obesity;Morphologic artifacts;Myocardial tissue;Non-Insulin-Dependent Diabetes Mellitus;Obesity;Obesity Epidemic;Outcome;Patients;Physiologic pulse;Physiological;Population;Prevalence;Prognosis;Protocols documentation;Radiation;Radiation Dose Unit;Radiology Specialty;Reference Standards;Reporting;Reproducibility;Risk;Risk Factors;Safety;Scanning;Severities;Signal Transduction;Stroke;Structure;Symptoms;System;Techniques;Testing;Validation;Walking;Weight;Work;X-Ray Computed Tomography;absorption;accurate diagnosis;attenuation;black women;cardiac magnetic resonance imaging;cardiovascular disorder risk;cardiovascular imaging;clinical care;data acquisition;denoising;design;diagnostic accuracy;diagnostic value;efficacy evaluation;experience;flexibility;head-to-head comparison;healthy volunteer;image reconstruction;imaging modality;imaging system;implantable device;innovation;interest;lifetime risk;magnetic field;magnetic resonance imaging biomarker;men;mortality risk;non-invasive imaging;novel;obese patients;prognostic value;reconstruction;single photon emission computed tomography;statistics;tool;ultrasound,Development and validation of cardiovascular MRI techniques on a low-field ultra-wide bore system to assess patients with severe obesity,Project NarrativeThe prevalence of severe obesity continues to rise and is strongly linked to many forms of cardiovasculardisease; unfortunately cardiovascular imaging is challenging in these patients as their large size limitsaccessibility to some imaging modalities and leads to poor image quality in others reducing diagnostic accuracy.The use of cardiac magnetic resonance imaging (MRI) is currently limited by the narrow bore and table weightlimits of standard MRI machines operating at 1.5T and 3.0T. In this project we will develop cardiac MRItechniques for a new low-field 0.55T MRI machine with an ultra-wide 80 cm patient bore and 700 lb. tableweight limit to provide a robust diagnostic cardiovascular imaging option for severely obese patients.,NHLBI,10793577,1/25/2024 12:00:00 AM,PA-20-185,5R01HL161618-03,5,R01,HL,161618,03, ,"DANTHI, NARASIMHAN",2/15/2022 12:00:00 AM,1/31/2027 12:00:00 AM,Emerging Imaging Technologies and Applications Study Section[EITA], ,8671610,"SIMONETTI, ORLANDO PAUL",Not Applicable,03,INTERNAL MEDICINE/MEDICINE,832127323,DLWBSLWAJWR1,832127323,DLWBSLWAJWR1,US,39.999598,-83.033131,6218701,OHIO STATE UNIVERSITY,COLUMBUS,OH,SCHOOLS OF MEDICINE,432101016,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,837,Non-SBIR/STTR,2024,589435, ,NHLBI,418023,171412, ,589435,,589435.0 | |
| No NIH Category available,Acceleration;Address;Adherence;Adult;Affect;American;American Indian Population;American Indians;Amputation;Ancillary Study;Arizona;Bioinformatics;Biological Markers;Blood Glucose;Blood Vessels;Blood flow;Caring;Cells;Chairperson;Clinical;Clinical Research;Clinical Trials;Clinical Trials Network;Collaborations;Collection;Communities;Community Actions;Complex;Data;Debridement;Dedications;Diabetes Mellitus;Diabetic Foot;Diabetic Foot Ulcer;Education;Educational Status;Environment;Ethnic Origin;FDA approved;Foundations;Funding;Grant;Health;Heterogeneity;Hispanic;Hispanic Populations;Human;Individual;Infrastructure;Institution;International;Intervention;Latino;Limb Salvage;Lower Extremity;Medical;Medicine;Minority;Mission;National Institute of Diabetes and Digestive and Kidney Diseases;Native Americans;Operative Surgical Procedures;Pathologic;Pathology;Patient Care;Patient Recruitments;Patients;Persons;Physicians;Podiatry;Population;Positioning Attribute;Prevalence;Problem Solving;Publications;Recommendation;Recording of previous events;Recurrence;Reporting;Research;Resource Sharing;Role;Sampling;Services;Site;Socioeconomic Status;Source;Surgeon;Techniques;Testing;Tissues;Trauma;United States;United States Indian Health Service;United States National Institutes of Health;Universities;Work;academic program;bench to bedside;biomarker identification;biomarker validation;chronic wound;clinical care;clinical center;clinical research site;college;comorbidity;compliance behavior;contextual factors;demographics;design;diabetic;diabetic patient;diabetic wound healing;drug candidate;experience;healing;higher education;improved;innovation;interdisciplinary approach;limb amputation;mortality;multidisciplinary;open wound;outcome prediction;outreach;outreach program;patient population;predictive marker;prevent;programs;provider adherence;recruit;single-cell RNA sequencing;social;social deprivation;social factors;social health determinants;standard of care;treatment planning;wound;wound care;wound healing,The University of Arizona Wound Care Center Clinical Research Unit,PROJECT NARRATIVEAt Stanford over the last decade the Gurtner group has used NIDDK funding to identify the best treatment plansto improve blood flow decrease blood glucose and enhance the body's ability to heal wounds and preventamputations. With Dr. Gurtner recently assuming the position of Chair of Surgery at the University of Arizona(UArizona) College of Medicine-Tucson the entire team has moved and worked tirelessly to seamlessly transferall the existing Diabetic Foot Consortium (DFC) studies to UArizona. In this proposal we will continue theseimportant studies at UArizona to collect a large range of samples from a diverse patient population to improvebiomarker identification and standard of care efforts for DFUs as well as demonstrate our potential for theaddition of various satellite sites throughout the Southwest.,NIDDK,10793580,1/18/2024 12:00:00 AM,RFA-DK-22-509,5U01DK119094-07,5,U01,DK,119094,07, ,"LI, YAN",9/15/2018 12:00:00 AM,12/31/2027 12:00:00 AM,ZDK1-GRB-1(J2), ,7053106,"GURTNER, GEOFFREY C","ZHOU, WEI ",07,SURGERY,806345617,ED44Y3W6P7B9,806345617,ED44Y3W6P7B9,US,32.232844,-110.959467,490201,UNIVERSITY OF ARIZONA,TUCSON,AZ,SCHOOLS OF MEDICINE,857210158,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,733314, ,NIDDK,576074,276100, ,733314,,733314.0 | |
| No NIH Category available,Abate;Acute;Adjuvant;Algorithms;American;Award;Benchmarking;Biological Markers;Blood Vessels;Bone Injury;Bone Tissue;Cancer Survivorship;Caring;Categories;Chronic;Clinical;Clinical Research;Communities;Complication;Computer software;Data;Data Analyses;Deglutition;Deglutition Disorders;Dental;Development;Diagnosis;Disease;Disease Surveillance;Dose;Drug Kinetics;Drug Monitoring;Early Diagnosis;Ensure;Epidemic;Exhibits;Exposure to;Fracture;Funding;Habilitation;Head and Neck Cancer;Health;Healthcare;Human Papillomavirus;Image;Incidence;Individual;Injury;Institution;Intervention;Investigation;Knowledge;Letters;Life Expectancy;Longevity;Magnetic Resonance Imaging;Malignant Neoplasms;Mandible;Mandibular Injuries;Masticatory muscles;Measures;Medical;Mission;Monitor;Morbidity - disease rate;Muscle;National Institute of Dental and Craniofacial Research;Natural History;Necrosis;Normal tissue morphology;Oral;Organ;Organ Preservation;Osteoradionecrosis;Outcome;Outcome Measure;Parotid Gland;Patients;Performance;Prevention;Preventive;Process;Prognosis;Public Health;Qualifying;Quality of life;Radiation;Radiation therapy;Research;Research Design;Resolution;Risk;Salivary Glands;Secure;Soft Tissue Injuries;Source;Staging;Standardization;Statistical Models;Structure;Surrogate Endpoint;Surrogate Markers;Survivors;Symptoms;System;Testing;Therapeutic Intervention;Tissues;Tooth Diseases;Toxic effect;Translating;Treatment-related toxicity;United States National Institutes of Health;Validation;Work;Xerostomia;biomarker validation;bone;bone healing;cancer therapy;candidate marker;clinical practice;contrast enhanced;craniofacial;diagnostic biomarker;disorder control;effectiveness evaluation;environmental agent;experience;imaging biomarker;improved;in vivo;innovation;interest;long-term sequelae;mortality;multimodality;open source;oral HPV-positive head and neck cancers;patient biomarkers;patient population;patient stratification;population based;predicting response;programs;prospective;quantitative imaging;radiation effect;side effect;soft tissue;standard of care;surrogacy;survivorship;tissue injury;tool;treatment response;treatment strategy;usability;validation studies;working group,Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI),PROJECT NARRATIVEThe proposed clinical research aims to validate the use of dynamic contrast-enhanced magnetic resonanceimaging (DCE-MRI) parameters as FDA BEST-defined monitoring biomarkers to monitor the natural historyof radiation-associated bone and soft tissue injury and subsequent long-term oral morbidity due to radiation-associated damage (e.g. dry mouth swallowing difficulty and jawbone injury/fracture). The work is relevant topublic health because of (1) the epidemic rise in HPV-associated oral malignancies and because this represents(2) the development of the first FDA BEST-defined monitoring biomarker of any kind for oral sequelae of cancertherapy generally and the first-ever validated FDA BEST-defined monitoring imaging biomarker of any dentaldisease process. The innovative research described in this proposal can drive significant change in clinicalpractice for head and neck cancer by improving survivorship through normal tissue sparing and prevention oflong-term toxicity while maintaining excellent disease control which always represents a major healthcarechallenge.,NIDCR,10793625,1/4/2024 12:00:00 AM,PAR-20-060,5U01DE032168-02,5,U01,DE,032168,02, ,"CHEN, ZHONG",4/1/2023 12:00:00 AM,1/31/2028 12:00:00 AM,ZDE1-YM(07), ,1880052,"LAI, STEPHEN Y","FULLER, CLIFTON DAVID",09,SURGERY,800772139,S3GMKS8ELA16,800772139,S3GMKS8ELA16,US,29.706319,-95.397195,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,HOUSTON,TX,HOSPITALS,770304009,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,121,Non-SBIR/STTR,2024,687801, ,NIDCR,584281,316573, ,687801,,687801.0 | |
| No NIH Category available, ,Analytical characterization and validation of blood-biomarkers for monitoring TBI evolution,Project NarrativeThis proposal will investigate 7 promising neurotrauma biomarkers to be practically adopted for use in multi-institutional clinical studies in acute and subacute TBI with rapid reliable results. The goal of this study is todevelop reference materials which will allow laboratories the ability to report consistent biomarker results withage-specific reference intervals throughout the lifespan that will allow discrimination from normal values. Finallywe propose to develop preliminary information on how biomarker levels are affected by injury severity whetherthey can be used to monitor incipient secondary injury and whether they have promise as prognostic biomarkersof persistent post-concussive symptoms.,NINDS,10793739,8/9/2024 12:00:00 AM,PAR-21-056,1U01NS131740-01A1,1,U01,NS,131740,01,A1,"TAYLOR-BURDS, CAROL C",8/10/2024 12:00:00 AM,7/31/2028 12:00:00 AM,Neurological Sciences and Disorders A Study Section[NSD-A], ,9766815,"PUCCIO, AVA M.","DIAZ-ARRASTIA, RAMON ; HUTCHISON, JAMIE SANDERS; MONDELLO, STEFANIA ; WANG, KEVIN KA WANG; WELLINGTON, CHERYL LEA",12,NEUROSURGERY,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,SCHOOLS OF MEDICINE,152133320,UNITED STATES,N,8/10/2024 12:00:00 AM,7/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,1444308, ,NINDS,1242787,201521, ,1444308,,1444308.0 | |
| No NIH Category available,Address;Affect;Age;Aging;Antipsychotic Agents;Behavior;Bioinformatics;Biological;Biological Markers;Biometry;Brain;Case/Control Studies;Cells;Cognition;Cognitive;Cognitive deficits;Complex;Data;Dementia;Deterioration;Development;Diagnosis;Disease;Doctor of Philosophy;Ecological momentary assessment;Elderly;Event;Executive Dysfunction;Foundations;Future;Gene Expression;General Population;Genomics;Goals;Hypoxia;Immune;Impaired cognition;Inflammation;Inflammatory;Interferon Type II;Intervention;Intervention Trial;Investigation;Link;National Institute of Mental Health;Neurocognitive;Neuropsychology;Obesity;Obstructive Sleep Apnea;Onset of illness;Outcome;Participant;Pathway interactions;Persons;Pharmaceutical Preparations;Physiology;Psychoneuroimmunology;Questionnaires;Reporting;Research;Research Personnel;Restless Legs Syndrome;Risk;Risk Factors;Role;Schizophrenia;Severities;Sleep;Sleep Apnea Syndromes;Sleep Disorders;Sleep disturbances;Sleeplessness;Smoking;Strategic Planning;Surrogate Markers;Symptoms;Vulnerable Populations;Work;career;cognitive disability;cognitive function;cognitive reserve;cognitive testing;comorbidity;comparison group;design;disability;effective intervention;effective therapy;executive function;experience;functional decline;high risk;high risk population;human old age (65+);improved;innovation;lifestyle intervention;male;middle age;modifiable risk;molecular marker;novel;pharmacologic;positive airway pressure;prevent;promoter;sedentary lifestyle;sex;stem;targeted treatment;transcription factor;treatment trial,Cognitive Consequences of Obstructive Sleep Apnea in Schizophrenia: An Investigation of Inflammatory Mechanisms,PROJECT NARRATIVE Middle-aged and older people with schizophrenia have high rates of cognitive impairment and associateddisability however there is a lack of effective interventions. Obstructive sleep apnea may be a potentiallytreatable contributor to cognitive problems in people with schizophrenia. This project proposes to lay thegroundwork for future intervention trials by clarifying the impact of sleep apnea on cognition examining the roleof inflammation as a surrogate biomarker and identifying key risk factors that contribute to cognition in thishigh-risk and understudied group.,NIMH,10793821,2/1/2024 12:00:00 AM,RFA-MH-22-270,1R01MH135147-01,1,R01,MH,135147,01, ,"ROWLAND, LAURA",2/1/2024 12:00:00 AM,11/30/2028 12:00:00 AM,ZMH1-ERB-S(06), ,14514294,"LEE, ELLEN EUN-OK",Not Applicable,50,PSYCHIATRY,804355790,UYTTZT6G9DT1,804355790,UYTTZT6G9DT1,US,32.876991,-117.24087,577507,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",LA JOLLA,CA,SCHOOLS OF MEDICINE,920930621,UNITED STATES,N,2/1/2024 12:00:00 AM,11/30/2024 12:00:00 AM,242,Non-SBIR/STTR,2024,759737, ,NIMH,506758,252979, ,759737,,759737.0 | |
| No NIH Category available,Adolescence;Adolescent;Beds;Biological Markers;Central Nervous System Diseases;Chemosensitization;Chronic;Classification;Clinic;Clinical;Clinical Research;Data;Data Correlations;Databases;Development;Diagnosis;Diagnostic;Diagnostic tests;Disabling;Disease;Disorders of Excessive Somnolence;Drowsiness;Foundations;Functional disorder;Future;GABA Receptor;Grant;Hour;Hypersomnias;Idiopathic Hypersomnolence;International;Judgment;Knowledge;Measures;Methods;Modeling;Muscle Tonus;Narcolepsy;Nervous System Disorder;Obstructive Sleep Apnea;Occupational;Outcome;Pathology;Patients;Performance;Persons;Phase;Population;Process;Prospective Studies;Protocols documentation;Recommendation;Records;Reporting;Research;Resources;Risk;Safety;Sensitivity and Specificity;Severities;Signal Transduction;Site;Sleep;Sleep Disorders;Sleep Stages;Specific qualifier value;Specificity;Surveys;Symptoms;Testing;Therapeutic;Time;Treatment Efficacy;Validation;Validity and Reliability;Work;accurate diagnosis;biomarker development;biomarker discovery;biomarker signature;burden of illness;circadian;clinical care;clinical heterogeneity;clinical trial enrollment;cohort;diagnostic accuracy;diagnostic criteria;drug development;effective therapy;heart rate variability;improved;improvement on sleep;meetings;multidisciplinary;multimodality;neurophysiology;non rapid eye movement;novel;statistics;success;supervised learning;trait,Development and Validation of a Nocturnal Sleep Signature for the Diagnosis of Idiopathic Hypersomnia,Project NarrativeSymptoms of idiopathic hypersomnia are debilitating and pose safety concerns and thus thereis a critical need to improve diagnostic accuracy. Using sleep neurophysiological biomarkers todiagnose this neurological disease is novel given most clinicians focus on measuring daytimesleepiness to establish diagnosis and treatment efficacy. The idiopathic hypersomnia nocturnalsleep traits we identify will also serve as the foundation for development and testing of therapiesthat improve sleep pathology and reduce disease burden.,NINDS,10794044,5/3/2024 12:00:00 AM,PAR-22-089,1R61NS130215-01A1,1,R61,NS,130215,01,A1,"TAYLOR-BURDS, CAROL C",6/1/2024 12:00:00 AM,5/31/2027 12:00:00 AM,Neurological Sciences and Disorders A Study Section[NSD-A], ,10419575,"MASKI, KIRAN PRASAD",Not Applicable,07,Unavailable,076593722,Z1L9F1MM1RY3,076593722,Z1L9F1MM1RY3,US,42.337481,-71.104964,1504801,BOSTON CHILDREN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021155724,UNITED STATES,N,6/1/2024 12:00:00 AM,5/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,785153, ,NINDS,517801,267352, ,785153,,785153.0 | |
| No NIH Category available,Acceleration;Address;Animal Model;Behavior;Biological Markers;CDKL5 disorder;Clinical;Clinical Research;Clinical Trials;Communication;Consensus;Cyclin-Dependent Kinases;Data;Data Reporting;Databases;Development;Disease;Electroencephalography;Ensure;Epilepsy;Equipment and supply inventories;Evoked Potentials;Family;Foundations;Future;Genes;Genetic;Goals;Hand functions;Impaired cognition;International;Interview;Knowledge;Maps;Measurement;Measures;Methods;Modification;Motor;Multi-Institutional Clinical Trial;National Institute of Neurological Disorders and Stroke;Outcome;Outcome Measure;Parents;Pathogenicity;Patients;Phenotype;Population;Positioning Attribute;Protocols documentation;Qi;Quality of life;Reporting;Reproducibility;Research;Rest;Rett Syndrome;Severities;Site;Sleep;Structure;Symptoms;Testing;Therapeutic;Training;Treatment Failure;Validation;Variant;Work;biomarker validation;cerebral visual impairment;clinical outcome measures;clinical trial protocol;clinical trial readiness;disability;epileptic encephalopathies;experience;gene therapy;implementation evaluation;motor disorder;motor impairment;novel therapeutics;potential biomarker;tool,Multi-Site Validation of Biomarkers and Core Clinical Outcome Measures for Clinical Trials Readiness in CDKL5 Deficiency Disorder,Project Narrative: Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD MIM 300672 105830) a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating there is a critical barrier for clinical trial readiness that may result in failure of these therapies not due to lack of efficacy but due to lack of validated outcome measures and biomarkers. The measures and biomarkers validated here will be adaptable to other developmental and epileptic encephalopathies.,NINDS,10794267,2/8/2024 12:00:00 AM,PAR-19-220,5U01NS114312-04,5,U01,NS,114312,04, ,"WHITTEMORE, VICKY R",2/15/2021 12:00:00 AM,1/31/2026 12:00:00 AM,ZNS1-SRB-A(34), ,1866075,"BENKE, TIMOTHY A","DOWNS, JENNY ; LEONARD, HELEN M; MARSH, ERIC D",06,PEDIATRICS,041096314,MW8JHK6ZYEX8,041096314,MW8JHK6ZYEX8,US,39.745098,-104.837605,1199905,UNIVERSITY OF COLORADO DENVER,Aurora,CO,SCHOOLS OF MEDICINE,800452571,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,859629, ,NINDS,773820,85809, ,859629,,859629.0 | |
| No NIH Category available,Abbreviations;Abruptio Placentae;Acute;Adult;Affect;Animal Model;Antioxidants;Area;Axon;Biochemical;Birth;Brain;Brain Hypoxia-Ischemia;Brain Injuries;Brain region;Cell Culture Techniques;Cell Physiology;Cerebral Palsy;Childhood;Cholera Toxin;Clinical;Clinical Trials;Communities;Country;Dancing;Developed Countries;Development;Diffusion;Disease;Dose;Electron Spin Resonance Spectroscopy;Electrophysiology (science);Endoplasmic Reticulum;Endothelium;Enzyme Inhibition;Equation;Ethidium;Facilities and Administrative Costs;Family;Fetal Distress;Fetus;Fiber;Financial cost;Free Radicals;Future;Generations;Genetic;High Pressure Liquid Chromatography;Human;Injury;Laboratories;Location;Magnetic Resonance Imaging;Measures;Methodology;Modeling;Molecular;Morbidity - disease rate;Mothers;Motor;Motor disability;Muscle Hypertonia;Nature;Nervous System Disorder;Neuronal Injury;Neurons;Neuroprotective Agents;Nitric Oxide;Nitric Oxide Synthase Type I;Nitric Oxide Synthetase Inhibitor;Nitrogen Oxides;Oryctolagus cuniculus;Outcome;Oxidants;Oxidation-Reduction;Oxidative Stress;Parents;Pathway interactions;Patients;Perinatal;Perinatal Hypoxia;Pharmaceutical Preparations;Phase;Phenotype;Placental Insufficiency;Pregnancy;Premature Labor;Prevalence;Prevention;Prevention therapy;Preventive;Property;Propidium Diiodide;Reactive Nitrogen Species;Reactive Oxygen Species;Reperfusion Therapy;Resource-limited setting;Resources;Rhodamine 123;Rodent Model;Siblings;Societies;Sorting;Specificity;Speed;Stress;Sum;Superoxide Dismutase;Superoxides;Surrogate Markers;System;Techniques;Testing;Therapeutic;Time;Tissues;Translating;Translations;Western Blotting;antenatal;brain cell;burden of illness;cell injury;cost;drug action;drug candidate;effective therapy;fetal;gray matter;hydroethidine;in vivo;indexing;inhibitor;innovation;interest;magnetic resonance imaging biomarker;mortality;motor deficit;neonatal hypoxic-ischemic brain injury;neuroprotection;nitrosative stress;novel;novel therapeutics;oxidation;perinatal period;postnatal;prevent;response;severe injury;white matter;white matter injury,Neuroprotection by nNOS inhibitors in perinatal hypoxia-ischemia,PROJECT NARRATIVE There is a paucity of effective treatments for cerebral palsy and this proposal tests new promising drugsaimed at a preventive cure for this disease. These are new drugs aimed at inhibiting an enzyme present inbrain called neuronal nitric oxide synthase. New information about how these drugs act how they affect braincells and how effective they are in an animal model of cerebral palsy will be very valuable for future translationto clinical use in humans throughout the world.,NINDS,10794380,5/22/2024 12:00:00 AM,PA-19-056,5R01NS114972-05,5,R01,NS,114972,05, ,"KOENIG, JAMES I",5/1/2020 12:00:00 AM,2/28/2025 12:00:00 AM,Developmental Brain Disorders Study Section[DBD], ,1899884,"TAN, SIDHARTHA ",Not Applicable,13,PEDIATRICS,001962224,M6K6NTJ2MNE5,001962224,M6K6NTJ2MNE5,US,42.357466,-83.065294,9110501,WAYNE STATE UNIVERSITY,DETROIT,MI,SCHOOLS OF MEDICINE,482024000,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,594586, ,NINDS,457235,137351, ,594586,,594586.0 | |
| No NIH Category available,Address;Age;Autoimmune;Autoimmune Diabetes;Beta Cell;Biological Assay;Biological Markers;Cells;Clinical;Clinical Data;Clinical Trials;Complex;DNA;DNA redundancy;Data;Data Collection;Data Set;Development;Diabetes Mellitus;Diagnosis;Disease;Disease Progression;E-learning;Economics;Elasticity;Etiology;Future;Gender;Goals;Heterogeneity;Immune system;Immunologics;Individual;Insulin;Insulin-Dependent Diabetes Mellitus;Intervention Trial;Kinetics;Knowledge;Machine Learning;Mediating;Metabolic;Modeling;Monitor;Morbidity - disease rate;Natural History;Newly Diagnosed;Partial Remission;Patients;Performance;Persons;Play;Proteins;RNA;Randomized;Regulation;Replacement Therapy;Risk;Series;Societies;Stratification;Testing;Training;Validation;Wing;Youth;biomarker identification;biomarker panel;clinical development;clinical diagnosis;clinically actionable;clinically relevant;cohort;economic cost;effective therapy;efficacy evaluation;experience;feature selection;high throughput screening;improved;improved outcome;machine learning algorithm;member;mortality;multimodality;peripheral blood;predictive modeling;protein function;recruit;responders and non-responders;social;tool;transcriptome,"Multimodal analysis of the ""honeymoon period"" in autoimmune diabetes",Type 1 diabetes causes significant increases in morbidity and mortality and is responsible for considerablesocial and economic costs. A cure is urgently needed but current gaps in our knowledge of its etiology anda paucity of mechanistic biomarkers are major impediments. This study proposes to fill these gaps byidentifying biomarkers that can predict rates of future disease progression.,NIDDK,10794412,3/1/2024 12:00:00 AM,PA-20-185,5R01DK129310-03,5,R01,DK,129310,03, ,"SPAIN, LISA M",4/1/2022 12:00:00 AM,3/31/2027 12:00:00 AM,Human Studies of Diabetes and Obesity Study Section[HSDO], ,7621561,"DAVIDSON, HOWARD W",Not Applicable,06,PEDIATRICS,041096314,MW8JHK6ZYEX8,041096314,MW8JHK6ZYEX8,US,39.745098,-104.837605,1199905,UNIVERSITY OF COLORADO DENVER,Aurora,CO,SCHOOLS OF MEDICINE,800452571,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,847,Non-SBIR/STTR,2024,495495, ,NIDDK,318646,176849, ,495495,,495495.0 | |
| No NIH Category available,Address;Affect;Age;Assessment tool;Award;Biological Markers;Blindness;Brain;CLN3 gene;Cessation of life;Child;Childhood;Clinical;Clinical Trials;Clinical assessments;Collaborations;Complex;Cross-Sectional Studies;Data;Decision Making;Development;Disease;Disease Progression;Ensure;Epilepsy;European;Evaluation;Event;Face;Fostering;Foundations;Future;Germany;Image;Impaired cognition;Individual;International;Life;Magnetic Resonance Imaging;Manuals;Measurable;Measurement;Measures;Modeling;Multicenter Trials;Natural History;Nerve Degeneration;Neuronal Ceroid-Lipofuscinosis;New York;Outcome;Patients;Phase;Phenotype;Preparation;Process;Qualifying;Rare Diseases;Readiness;Reproducibility;Research;Sampling;Severity of illness;Signs and Symptoms;Site;Spielmeyer-Vogt Disease;Staging System;Symptoms;Testing;Therapeutic;Therapeutic Effect;Therapeutic Trials;Thick;Time;Training Programs;United States Food and Drug Administration;Universities;Visit;biomarker validation;brain volume;clinical care;clinical outcome assessment;clinical phenotype;clinical trial implementation;clinical trial readiness;design;drug development;gray matter;inclusion criteria;indexing;interest;juvenile neuronal ceroid lipofuscinosis;longitudinal analysis;motor disorder;neuroimaging;neuroimaging marker;neuropathology;novel therapeutics;optimism;phase II trial;premature;programs;prospective;time interval;timeline;tool;tool development;white matter,Meaningful Outcomes and Multi-Site Readiness for Clinical Trials in Juvenile Neuronal Ceroid Lipofuscinosis,Juvenile Neuronal Ceroid Lipofuscinosis (CLN3 disease) is a rare fatal pediatric disease that lacks disease- modifying treatments. Several candidate compounds are advancing through the therapeutic pipeline but will face barriers to development resulting from for unmet research needs. This project will overcome these barriers to validate sensitive measures of how patients feel and function validate neuroimaging biomarkers of disease progression and prepare these tools for multi-site use immediately setting the stage for rigorous and efficient clinical trials in CLN3 disease.,NINDS,10794925,3/6/2024 12:00:00 AM,PAR-18-534,5U01NS101946-05,5,U01,NS,101946,05, ,"MENDOZA-PUCCINI, MARIA CAROLINA",4/1/2019 12:00:00 AM,1/31/2025 12:00:00 AM,ZNS1-SRB-A(18), ,9568426,"AUGUSTINE, ERIKA ",Not Applicable,25,NEUROLOGY,041294109,F27KDXZMF9Y8,041294109,F27KDXZMF9Y8,US,43.131774,-77.63546,7047101,UNIVERSITY OF ROCHESTER,ROCHESTER,NY,SCHOOL OF MEDICINE & DENTISTRY,146113847,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,610733, ,NINDS,430674,180059, ,610733,,610733.0 | |
| No NIH Category available,Affect;Age;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimer's disease pathology;Alzheimer's disease patient;Alzheimer's disease therapy;American;Amyloid beta-Protein;Autopsy;Binding;Biological Markers;Blood Glucose;Brain;Brain Diseases;Clinic;Clinical;Clinical Trials;Communities;Coupled;Data;Dementia;Development;Diagnostic;Disease;Disease Progression;Event;FDA approved;Fasting;Female;Fluorine;Frontotemporal Dementia;Glycoproteins;Goals;Half-Life;Hippocampus;Human;Image;Impaired cognition;In Vitro;Individual;Institution;Investigation;Keppra;Kinetics;Label;Levetiracetam;Limbic System;Measures;Medical Imaging;Membrane Proteins;Methods;Molecular Target;Monitor;Multi-Institutional Clinical Trial;Multicenter Trials;Nervous System Disorder;Neurodegenerative Disorders;Neurofibrillary Tangles;Neurons;Pathogenesis;Pathology;Patients;Persons;Pharmaceutical Preparations;Positron-Emission Tomography;Preventive;Production;Property;Protein Isoforms;Proteins;Protocols documentation;Radioisotopes;Regulation;Reproducibility;Research;Resolution;Scanning;Senile Plaques;Signal Transduction;Site;Synapses;Synaptic Vesicles;Synaptophysin;Testing;Tracer;Treatment Efficacy;Treatment Protocols;Treatment outcome;Validation;Vesicle;abeta oligomer;amyloid imaging;analog;cell cortex;cognitive function;density;entorhinal cortex;fluorodeoxyglucose;glucose metabolism;human subject;imaging agent;imaging biomarker;imaging properties;in vivo;in vivo imaging;kinetic model;male;mild cognitive impairment;neuroimaging;neuroimaging marker;neuropsychiatric disorder;pre-clinical;presynaptic;quantitative imaging;radioligand;radiotracer;synaptic failure;tomography;tool;trafficking;uptake;virtual;white matter,Validation of Fluorine-18 radioligand for PET imaging of synaptic density in Alzheimer's disease,In this application we propose to validate a positron emission tomography (PET) imaging agent as biomarkerfor synaptic density. As many brain disorders are thought of as synaptic diseases the use of PET imaging todetect synaptic density and its changes in diseases will provide a potentially paradigm-shifting tool toinvestigate and diagnose Alzheimer's disease and other neurologic disorders and monitor treatmentoutcomes.,NIA,10794935,1/12/2024 12:00:00 AM,PA-19-056,5R01AG065474-05,5,R01,AG,065474,05, ,"ROVESCALLI, ALESSANDRA C",1/1/2020 12:00:00 AM,12/31/2024 12:00:00 AM,Clinical Neuroscience and Neurodegeneration Study Section[CNN], ,9137850,"HUANG, YIYUN HENRY","VAN DYCK, CHRISTOPHER H",03,RADIATION-DIAGNOSTIC/ONCOLOGY,043207562,FL6GV84CKN57,043207562,FL6GV84CKN57,US,41.310925,-72.926428,9420201,YALE UNIVERSITY,NEW HAVEN,CT,SCHOOLS OF MEDICINE,065208327,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,764364, ,NIA,456337,308027, ,764364,,764364.0 | |
| No NIH Category available,Accident and Emergency department;Acute;Address;Advanced Development;Affect;Antibodies;Bacteremia;Bar Codes;Biological Markers;Biology;Blood;Blood Cells;Blood Vessels;Cell Physiology;Cell surface;Cells;Cellular Indexing of Transcriptomes and Epitopes by Sequencing;Clinical;Data;Data Set;Development;Diagnostic;Diagnostic Procedure;Disease;Early Diagnosis;Endothelium;Etiology;Exhibits;Extravasation;Flow Cytometry;Functional disorder;Future;Gene Expression Profile;Gene Expression Profiling;Genes;Goals;Health;Heterogeneity;Human;Human body;Immune;Immune System Diseases;Immune response;Individual;Infection;Intervention;Investigation;Life;Longitudinal cohort;Maps;Measures;Membrane Proteins;Modeling;Molecular;Molecular Profiling;Mus;Nature;Organ;Outcome;Pathway interactions;Patient-Focused Outcomes;Patients;Phenotype;Pilot Projects;Proteome;Rapid diagnostics;Resolution;Risk;Role;Sampling;Sepsis;Signs and Symptoms;Site;Stimulus;Surface;Syndrome;Technology;Testing;Therapeutic;Translating;Urinary tract infection;Validation;Variant;Vascular Endothelial Cell;Vascular Permeabilities;Work;biomarker identification;biomarker panel;clinically relevant;cohort;diagnostic tool;effective therapy;gene function;genomic profiling;human disease;improved;in silico;insight;monocyte;new therapeutic target;novel therapeutics;patient stratification;patient subsets;predictive marker;response;septic patients;single cell genomics;single-cell RNA sequencing;therapeutic development;transcriptome;transcriptomics,Single-cell genomic profiling to identify immune signatures of bacterial sepsis in humans,Sepsis is a prevalent and life-threatening disease of humans characterized by organ dysfunctionthat is due to an overly aggressive immune response to an infection; despite the importance ofthis disease currently there are no diagnostic methods that can rapidly and accurately identifypatients that have this disease. Our goals are to identify and characterize biomarkers in sepsisand to gain insights into the mechanisms leading to inappropriate immune responses. We willdo this by applying state-of-the-art technology in ways that have not been used previously toanalyze individual immune cells in the blood of patients with sepsis; the insights gained from theproposed work have the potential to lead to rapid diagnostic tools for sepsis.,NIAID,10794964,2/1/2024 12:00:00 AM,PA-20-185,5R01AI153142-04,5,R01,AI,153142,04, ,"MINNICOZZI, MICHAEL",3/3/2021 12:00:00 AM,2/28/2026 12:00:00 AM,"Surgery, Anesthesiology and Trauma Study Section[SAT]", ,1894282,"GOLDBERG, MARCIA B","FILBIN, MICHAEL ; HACOHEN, NIR ",08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,1012832, ,NIAID,718819,294013, ,1012832,,1012832.0 | |
| No NIH Category available,Adenocarcinoma;Antibodies;Automobile Driving;Benign;Binding;Biological;Biological Assay;Biological Markers;Biology;Biopsy;Biotin;Cancer Etiology;Cells;Cessation of life;Characteristics;Clinical;Clinical Data;Computer software;Cytoplasm;Data;Data Set;Development;Diagnosis;Disease;Ectopic Expression;Elements;Fluorescence Resonance Energy Transfer;Fluorescent in Situ Hybridization;Fractionation;Health;Histologic;Human;Immunoprecipitation;Immunotherapy;In Vitro;Knowledge;Label;Liquid Chromatography;Lung;Lung nodule;Malignant - descriptor;Malignant Neoplasms;Malignant neoplasm of lung;Measures;Molecular;Mutation;Non-Small-Cell Lung Carcinoma;Nuclear;Oligonucleotides;Oncogenic;Patients;Pattern;Plasma;Play;Prognosis;Protein Inhibition;Proteins;Publications;RNA-Binding Proteins;Research;Role;Sensitivity and Specificity;Solid;Specific qualifier value;Specificity;Squamous cell carcinoma;Structure of parenchyma of lung;Survival Rate;Tertiary Protein Structure;Testing;Tissues;United States;biomarker validation;deep sequencing;improved;knock-down;mutant;novel;novel therapeutic intervention;protein activation;protein complex;protein expression;protein function;tandem mass spectrometry;targeted treatment;tumorigenesis,Identify the target proteins of one ADC-specific and two SCC-specific pfeRNAs and investigate the mechanisms underlying the pfeRNA-protein interaction.,Project Narrative:Despite the development of novel targeted treatment and immune therapies that have prolonged survival insome patients with non-small cell lung cancer (NSCLC) NSCLC is still the leading cause of cancer-relateddeath in the U.S. We will identify the target proteins of an ADC-specific and two SCC-specific pfeRNAs anddecipher the machinimas underlying their interaction opening a new window of understanding in the sncRNAfield and providing new evidence on NSCLC oncogenesis.,NCI,10794971,2/22/2024 12:00:00 AM,PAR-20-052,5R03CA259658-02,5,R03,CA,259658,02, ,"AMIN, ANOWARUL",3/1/2023 12:00:00 AM,2/28/2025 12:00:00 AM,ZCA1-TCRB-Q(O1)S, ,12219997,"MEI, YUPING ",Not Applicable,07,NEUROSURGERY,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,396,Non-SBIR/STTR,2024,81875, ,NCI,50000,31875, ,81875,,81875.0 | |
| No NIH Category available,Address;Aftercare;Back;Biological Assay;Biological Markers;Blood specimen;Bromodomains and extra-terminal domain inhibitor;CCNE1 gene;Cancer Model;Cell Line;ChIP-seq;Chemicals;Clinic;Clinical;Clinical Trials;Combined Modality Therapy;Complement;DNA Methyltransferase Inhibitor;Data;Drug Combinations;Epigenetic Process;Future;Gene Expression;Genes;Genetic Transcription;Histone Deacetylase Inhibitor;In Vitro;Knowledge;Malignant neoplasm of ovary;Measures;Methods;Molecular;Patients;Pharmaceutical Preparations;Phase I/II Clinical Trial;Phase I/II Trial;Phenotype;Platinum;Poly(ADP-ribose) Polymerase Inhibitor;Positioning Attribute;Pre-Clinical Model;Publishing;Regimen;Repression;Resistance;Surrogate Markers;Testing;Therapeutic;Toxic effect;Translational Research;Validation;antitumor effect;cancer cell;carcinogenesis;cell type;chemotherapy;clinical development;clinically relevant;companion diagnostics;design;effective therapy;epigenetic drug;epigenetic therapy;gene function;gene repression;genome-wide;homologous recombination;homologous recombination deficiency;in vivo;inhibitor;inhibitor therapy;innovation;insight;mutant;patient derived xenograft model;pre-clinical;preclinical development;prognostic;response;response biomarker;transcriptome sequencing;translational approach;tumor,Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer,Poly ADP ribose polymerase inhibitor (PARPi) have changed treatment paradigms with greatest clinical benefitsin BRCA mutant homologous recombination (HR) deficient ovarian cancer. A critical clinical problem ischemotherapy drugs including PARPi are far less effective in BRCA wild-type HR proficient ovarian cancer (e.g.CCNE1 amplification/gain). This proposal will apply an innovative translational research approach to determinethe potential benefits of PARPi-epigenetic drug combinations for the treatment of poor prognostic ovarian cancer.,NCI,10794977,4/15/2024 12:00:00 AM,PA-19-056,5R01CA243511-06,5,R01,CA,243511,06, ,"KONDAPAKA, SUDHIR B",7/1/2020 12:00:00 AM,2/28/2025 12:00:00 AM,Developmental Therapeutics Study Section[DT], ,7605639,"KHABELE, DINEO ",Not Applicable,01,OBSTETRICS & GYNECOLOGY,068552207,L6NFUM28LQM5,068552207,L6NFUM28LQM5,US,38.664368,-90.323797,9083901,WASHINGTON UNIVERSITY,SAINT LOUIS,MO,SCHOOLS OF MEDICINE,631304862,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,395,Non-SBIR/STTR,2024,412827, ,NCI,304525,108302, ,412827,,412827.0 | |
| No NIH Category available,Address;Adopted;Bioinformatics;Biological Assay;Biological Markers;Biopsy;Blood specimen;Brain Neoplasms;Caring;Cell Line;Cells;Central Nervous System;Cessation of life;Clinical;Clinical Protocols;Clinical Research;Data;Detection;Development;Diagnosis;Diagnostic;Disease;Drug resistance;Early Diagnosis;Ensure;Evolution;Excision;General Hospitals;Glioma;Goals;Heterogeneity;Human;Image;Industry;Laboratories;Longitudinal Studies;Magnetic Resonance Imaging;Malignant Glioma;Malignant Neoplasms;Massachusetts;Mean Survival Times;Measures;Membrane;Messenger RNA;Methods;Modeling;Molecular;Molecular Analysis;Molecular Profiling;Monitor;Nucleic Acids;Operative Surgical Procedures;Outcome;Outcomes Research;Patients;Performance;Progression-Free Survivals;Protein Analysis;Proteins;Quality Control;Radiation therapy;Readiness;Regression Analysis;Reproducibility;Resistance;Resistance development;Resources;Risk;Sampling;Sampling Biases;Sampling Errors;Specificity;Specimen;Standardization;Systems Biology;Testing;Time;Tissues;Translations;Treatment outcome;Tumor Burden;Vesicle;biobank;cancer biomarkers;cancer cell;chemotherapy;clinical care;clinical diagnostics;clinical translation;cohort;comorbidity;comparative efficacy;design;diagnostic strategy;diagnostic value;digital;exosome;experience;extracellular vesicles;follow-up;improved;individualized medicine;innovation;instrument;liquid biopsy;mRNA Expression;minimally invasive;molecular subtypes;multidisciplinary;nanoscale;new technology;novel;particle;patient stratification;peripheral blood;plasmonics;predictive modeling;pressure;prognostic;programs;screening;statistics;success;technology validation;temozolomide;therapy resistant;tool;translational impact;treatment response;treatment strategy;tumor;tumor heterogeneity;tumor progression,Imaging and Liquid Biopsy for Glioma Diagnosis and Treatment Monitoring,We propose to assess the diagnostic power of a liquid biopsy for glioma detection and treatmentmonitoring. Specifically we will advance a clinical assay for comprehensive high-throughputmolecular profiling of extracellular vesicles (EVs). The developed assay will be applied to analyzepatient blood samples. EVs' clinical utility will be integrated with standard imaging (MRI).,NCI,10795020,2/1/2024 12:00:00 AM,PA-18-629,5R01CA239078-05,5,R01,CA,239078,05, ,"MCKEE, TAWNYA C",3/1/2020 12:00:00 AM,2/28/2025 12:00:00 AM,Cancer Biomarkers Study Section[CBSS], ,1939877,"CARTER, BOB S","LEE, HAKHO ",08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,578593, ,NCI,372150,206443, ,578593,,578593.0 | |
| No NIH Category available,Address;Benign;Biological Markers;Biophotonics;Blood Tests;Cancer Biology;Cancer Control;Cancer Detection;Cancer Diagnostics;Cancer Patient;Chemicals;Clinical;Clinical Management;Complex;Coupled;Data;Detection;Devices;Diagnosis;Diagnostic;Discrimination;Discrimination Learning;Disease;Early Diagnosis;Electromagnetics;Engineering;Equity;Female;Fingerprint;Functional disorder;Funding;Future;Goals;Grant;Health;Image;Imaging technology;Label;Lasers;Light;Lipids;Machine Learning;Malignant Neoplasms;Malignant neoplasm of ovary;Measurement;Medical;Methods;Modality;Modeling;Molecular;Non-Invasive Cancer Detection;Non-Invasive Detection;Nucleic Acids;Optics;Outcome;Pathologic;Patient Monitoring;Patients;Pattern;Pelvis;Performance;Peritoneal Fluid;Physiological;Population;Population Group;Population Heterogeneity;Postmenopause;Proteins;Protocols documentation;Raman Spectrum Analysis;Recommendation;Research;Research Personnel;Retrieval;Sampling;Screening for cancer;Serum;Signal Transduction;Socioeconomic Factors;Spectrometry;Spectrum Analysis;Survival Rate;Symptoms;System;Techniques;Technology;Temperature;Testing;Tissues;United States National Institutes of Health;Validation;absorption;advanced analytics;burden of illness;cancer health disparity;cancer risk;cancer type;chemical fingerprinting;cohort;cost;cost effective;data analysis pipeline;design;detection platform;diagnostic biomarker;imaging approach;improved;infrared spectroscopy;innovation;instrumentation;liquid biopsy;machine learning method;machine learning model;manufacture;mid infrared spectrometry;mortality;multiple omics;nano;nanophotonic;novel;novel diagnostics;photonics;plasmonics;portability;preclinical study;quantum;real world application;screening;screening program;spectrograph;survival outcome;tool,Metasurface enhanced and machine learning aided spectrochemical liquid biopsy,PROJECT NARRATIVENew bioanalytical and computational technologies that can accurately identify cancer risks early are needed toimprove cancer outcomes equitably. Here we propose to develop an innovative spectrochemical liquid biopsyplatform based on metasurface-enhanced mid-infrared absorption spectroscopy and machine-learningdiscrimination models. While the proposed research will optimize the novel imaging-based on-chip chemicalfingerprinting technology using ovarian cancer samples the developed diagnostic modality can be applied todetect a broad spectrum of disease-associated spectral patterns from biofluids in the future.,NIBIB,10795078,2/7/2024 12:00:00 AM,PAR-20-084,5R21EB034411-02,5,R21,EB,034411,02, ,"ANDERSON, AFROUZ AZARI",3/1/2023 12:00:00 AM,2/28/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-BST-D(81)S], ,16448077,"YESILKOY, FILIZ ",Not Applicable,02,BIOMEDICAL ENGINEERING,161202122,LCLSJAGTNZQ7,161202122,LCLSJAGTNZQ7,US,43.068519,-89.400858,578503,UNIVERSITY OF WISCONSIN-MADISON,MADISON,WI,BIOMED ENGR/COL ENGR/ENGR STA,537151218,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,286,Non-SBIR/STTR,2024,223260, ,NIBIB,150000,73260, ,223260,,223260.0 | |
| No NIH Category available,Affect;Algorithms;Angiography;Arteries;Artificial Intelligence;Attention;Biological Markers;Biomedical Research;Blindness;Blood Vessels;Blood capillaries;Chicago;Classification;Clinical;Clinical Data;Clinical Management;Consensus;Data;Data Compromising;Data Reporting;Data Set;Democracy;Detection;Diabetic Retinopathy;Diagnosis;Diagnostic;Disease;Early Diagnosis;Educational Curriculum;Exposure to;Goals;Illinois;Individual;Institution;Intellectual Property;Intervention;Investigation;Learning;Machine Learning;Measures;Modeling;North Carolina;Ophthalmologist;Optical Coherence Tomography;Pathway interactions;Patients;Performance;Population;Prognosis;Protocols documentation;Research;Research Personnel;Retina;Retinal Diseases;Risk Assessment;Secure;Standardization;Taiwan;Techniques;Testing;Texture;Training;Translating;Treatment outcome;Universities;Validation;Veins;Vision;Work;clinical biomarkers;clinical practice;cohort;data modeling;data privacy;data sharing;deep learning model;design;diabetic;diabetic patient;diagnostic accuracy;diagnostic algorithm;distributed model;diverse data;experience;federated learning;firewall;heterogenous data;imaging biomarker;imaging capabilities;improved;innovation;insight;machine learning model;macular edema;model building;novel;patient privacy;predictive marker;prevent;prognostic model;proliferative diabetic retinopathy;public health relevance;repository;rural area;social;success;trend;undergraduate student;underserved area,Distributed approaches to train machine learning models in diabetic retinopathy,Public Health Relevance StatementDiabetic retinopathy (DR) is a retinal disease that is a leading cause of severe vision lossworldwide. We are developing artificial intelligence (AI) based techniques tocollaboratively build diagnostic/prognostic models using multi-institutional data cohortswith a diverse sub-population. Distributed model training (federated learning) will be usedto build robust models to improve clinical management of DR.,NEI,10795486,2/22/2024 12:00:00 AM,PAR-21-155,1R15EY035804-01,1,R15,EY,035804,01, ,"GAO, JAMES",3/1/2024 12:00:00 AM,2/28/2027 12:00:00 AM,Clinical Data Management and Analysis Study Section[CDMA], ,78148710,"ALAM, MINHAJ NUR ",Not Applicable,12,ENGINEERING (ALL TYPES),066300096,JB33DT84JNA5,066300096,JB33DT84JNA5,US,35.301652,-80.731452,578202,UNIVERSITY OF NORTH CAROLINA CHARLOTTE,CHARLOTTE,NC,BIOMED ENGR/COL ENGR/ENGR STA,282230001,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2027 12:00:00 AM,867,Non-SBIR/STTR,2024,459516, ,NEI,334936,124580, ,459516,,459516.0 | |
| No NIH Category available,15 year old;21 year old;Age;Antigen Presentation;Autoantibodies;Autoimmune Responses;Autoimmunity;Beta Cell;Biological Assay;Biological Markers;Biological Process;Case/Control Studies;Child;Clinical;Coagulation Process;Complement;Cross-Sectional Studies;Data;Development;Diabetes Mellitus;Disease;Expectancy;Extracellular Matrix;Individual;Inflammatory;Insulin;Insulin-Dependent Diabetes Mellitus;Knowledge;Machine Learning;Measures;Metabolic Diseases;Monitor;Nested Case-Control Study;Participant;Pathway interactions;Pattern;Phase;Plasma;Play;Process;Proteins;Proteomics;Quality of life;Regulation;Risk;Role;Sampling;Signal Transduction;Single Nucleotide Polymorphism;Structure of beta Cell of islet;Time;autoimmune pathogenesis;biomarker identification;biomarker panel;biomarker signature;biomarker validation;candidate marker;clinical biomarkers;cohort;endocrine pancreas development;follow-up;insulin dependent diabetes mellitus onset;islet;islet autoimmunity;lipid metabolism;longitudinal analysis;metabolomics;novel marker;predictive marker;prevent;preventive intervention;progression marker;protein biomarkers;seroconversion;therapy development;virome,Systematic validation of biomarkers predictive of IA and T1D and their relationship with disease development,NarrativeType 1 diabetes results from the loss of pancreatic beta cells due to an autoimmune destruction. Stopping theautoimmune response and preventing the beta cell loss is attractive for the development of therapies but thebottleneck of this approach is the lack of validated biomarkers that can predict the autoimmunity onset and type1 diabetes development. Here we propose to systematically validate biomarker candidates and determine theirrelationship with disease development.,NIDDK,10795697,1/17/2024 12:00:00 AM,RFA-DK-22-021,1R01DK138335-01,1,R01,DK,138335,01, ,"SECHI, SALVATORE",1/17/2024 12:00:00 AM,12/31/2026 12:00:00 AM,ZDK1-GRB-S(O3), ,10522487,"NAKAYASU, ERNESTO SATOSHI","METZ, THOMAS O; REWERS, MARIAN J; WEBB-ROBERTSON, BOBBIE-JO MARY",04,Unavailable,032987476,CWKJEXDG79A7,032987476,CWKJEXDG79A7,US,46.280405,-119.290503,685903,BATTELLE PACIFIC NORTHWEST LABORATORIES,RICHLAND,WA,Research Institutes,993520999,UNITED STATES,N,1/17/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,730660, ,NIDDK,468000,262660, ,730660,,730660.0 | |
| No NIH Category available,Address;Adoption;Biological;Biological Markers;Blood;Canada;Characteristics;Clinical;Collaborations;Custom;Data;Development;Diagnosis;Disease;Disease Outcome;Early identification;Etiology;Foundations;Genomics;Goals;Incidence;Interstitial Lung Diseases;Intervention;Investigation;Knowledge;Length;Leukocytes;Machine Learning;Malignant Neoplasms;Mediator;Nature;Outcome;Pathway Analysis;Patients;Performance;Plasma;Population;Positioning Attribute;Productivity;Prognostic Marker;Proteins;Proteomics;Pulmonary Fibrosis;Qualifying;Radiology Specialty;Sampling;Sensitivity and Specificity;Specificity;Testing;Therapeutic Intervention;Transplantation;Validation;Work;X-Ray Computed Tomography;antifibrotic treatment;biobank;biomarker development;blood-based biomarker;clinical implementation;clinically actionable;clinically relevant;cohort;comparative;fibrotic interstitial lung disease;idiopathic pulmonary fibrosis;improved;machine learning algorithm;new therapeutic target;novel;novel marker;performance tests;peripheral blood;prevent;prospective;protein biomarkers;proteomic signature;pulmonary function decline;radiomics;recruit;telomere;therapeutic target;tool;treatment disparity,Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung Disease,Project NarrativeIn this proposal we will identify proteins that predict progression in patients with non-idiopathic pulmonaryfibrosis forms of interstitial lung disease. We will then use these proteins to develop a blood-based tool toaccurately predict progression in those with early/mid-stage disease as these patients are most likely tobenefit from early therapeutic intervention.,NHLBI,10796267,12/20/2023 12:00:00 AM,PA-20-185,1R01HL166290-01A1,1,R01,HL,166290,01,A1,"VUGA, LOUIS J",1/1/2024 12:00:00 AM,12/31/2028 12:00:00 AM,Cardiovascular and Respiratory Diseases Study Section[CRD], ,9401210,"OLDHAM, JUSTIN M",Not Applicable,06,INTERNAL MEDICINE/MEDICINE,073133571,GNJ7BBP73WE9,073133571,GNJ7BBP73WE9,US,42.275494,-83.743038,1506502,UNIVERSITY OF MICHIGAN AT ANN ARBOR,ANN ARBOR,MI,SCHOOLS OF MEDICINE,481091276,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,838,Non-SBIR/STTR,2024,762646, ,NHLBI,490809,271837, ,762646,,762646.0 | |
| No NIH Category available,Acute;Adult;Analgesics;Antibiotics;Archives;Behavioral;Binding;Biological;Biological Availability;Biological Markers;Brain;Central Nervous System Diseases;Chronic;Collaborations;Communities;Complex;Consumption;Data;Development;Disease;Dose;Ensure;Environment;Epilepsy;Etiology;Funding Mechanisms;Future;Generations;Human;Hyperalgesia;Inflammation;Inflammatory;Institution;Intervention;Length of Stay;Malignant Neoplasms;Mammals;Modeling;Molecular;Morphine;Mus;Natural Immunity;Neuroimmune;Neurotransmitters;Nociception;Non-Insulin-Dependent Diabetes Mellitus;Opioid;Opioid Analgesics;Opioid Receptor;Oral;Pain;Pathology;Patients;Peptides;Persons;Pharmaceutical Preparations;Pharmacology;Phenotype;Physical Dependence;Play;Postoperative Pain;Probiotics;Reporting;Research;Rewards;Risk;Risk Reduction;Role;Safety;Sampling;Science;Sister;Structure;Supplementation;Testing;Therapeutic;Ventilatory Depression;addiction;antinociception;biomarker validation;chronic pain management;chronic painful condition;dysbiosis;gut dysbiosis;gut homeostasis;gut microbiome;gut microbiota;gut-brain axis;immunoregulation;improved;microbial;microbial community;microbiome;microbiome analysis;microbiome composition;morphine administration;morphine tolerance;mouse model;opioid abuse;opioid mortality;opioid overdose;opioid use;opioid use disorder;overdose death;pain patient;pain relief;pathogen;predictive marker;prescription opioid;response;side effect;skills;stem;student training;therapeutic development;trend;undergraduate student,Probiotic neuroimmune modulation of morphine tolerance,Chronic opioid use produces analgesic tolerance and opioid use disorder (OUD) in only a subset of bothhumans and mice. Identifying and validating the biomarkers that predict liability for OUD could improvetherapeutic utility and reduce risk.,NIDA,10796314,3/14/2024 12:00:00 AM,PAR-21-155,1R15DA058187-01A1,1,R15,DA,058187,01,A1,"ANANTHAN, SUBRAMANIAM",4/1/2024 12:00:00 AM,3/31/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-BN-R(86)A], ,7541961,"WHISTLER, CHERYL ALLYNE",Not Applicable,01,BIOCHEMISTRY,111089470,GBNGC495XA67,111089470,GBNGC495XA67,US,43.1304,-70.9767,830102,UNIVERSITY OF NEW HAMPSHIRE,DURHAM,NH,EARTH SCIENCES/RESOURCES,038242620,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2026 12:00:00 AM,279,Non-SBIR/STTR,2024,479535, ,NIDA,356368,123167, ,479535,,479535.0 | |
| No NIH Category available,Acute;Affect;Age;Ancillary Study;Area;Biological Markers;Case Report Form;Clinical;Clinical Management;Clinical Trials;Collaborations;Common Data Element;Communities;Conduct Clinical Trials;Consent;Data;Data Collection;Data Coordinating Center;Data Management Resources;Data Set;Databases;Development;Devices;Disabling;Disease;Documentation;Elderly;Emergency Situation;Enrollment;Ensure;Equipment and supply inventories;Feasibility Studies;Funding;Future;Grant;Health Resources;Individual;Infant;Information Management;Infrastructure;Intervention;Leadership;Libraries;Management Information Systems;Medical;Methods;Mission;Monitor;National Institute of Neurological Disorders and Stroke;Network Infrastructure;Online Systems;Participant;Patient Representative;Patients;Pharmaceutical Preparations;Phase;Population;Prevention;Principal Investigator;Process;Public Health;Publications;Quality Control;Recovery;Recurrence;Regulation;Reporting;Research;Research Design;Research Infrastructure;Research Personnel;Research Priority;Role;Safety;Scientist;Site;Societies;South Carolina;Standardization;Statistical Methods;Stroke;Stroke prevention;StrokeNet clinical trials;System;Testing;Training;United States National Institutes of Health;Universities;adjudication;arm;biomarker validation;central database;clinical practice;clinical research site;data dissemination;data management;data quality;data sharing;design;digital communication;electronic data;experience;improved;industry partner;innovation;multi-site trial;multidisciplinary;neuroimaging;novel therapeutics;operation;pre-clinical;protocol development;recruit;stroke clinical trials;stroke incidence;stroke recovery;stroke rehabilitation;stroke therapy;stroke trials;telerehabilitation;tool;trial design;validation studies,Stroke Trials Network National Data Management Center (NDMC),PROJECT NARRATIVEThe NIH Stroke Net is a research network infrastructure to efficiently conduct clinical trials to identify intervention for: (1) acute treatment of stroke; (2) prevention of stroke recurrence; and (3) recovery and rehabilitation after stroke. The National Data Management Center (NDMC) of the NIH Stroke Net offers economies of scale through its centralized clinical management system to conduct multiple stroke clinical trials simultaneously and efficiently. This is expected to have an impact on the public health by potentially reducing stroke occurrences and the burden of stroke to the individuals as well as to the society.,NINDS,10796320,12/15/2023 12:00:00 AM,RFA-NS-23-008,2U01NS087748-10,2,U01,NS,087748,10, ,"AFZAL, MARIAM MASHEEB",4/1/2014 12:00:00 AM,11/30/2028 12:00:00 AM,ZNS1-SRB-W(16), ,8854947,"ELM, JORDAN J.","DILLON, CATHERINE R.; ZHAO, WENLE ",06,PUBLIC HEALTH & PREV MEDICINE,183710748,NHV3GTWSALA7,183710748,NHV3GTWSALA7,US,32.786754,-79.947265,7575301,MEDICAL UNIVERSITY OF SOUTH CAROLINA,CHARLESTON,SC,SCHOOLS OF MEDICINE,294074636,UNITED STATES,N,12/15/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Non-SBIR/STTR,2024,1454897, ,NINDS,966260,488637, ,1454897,,1454897.0 | |
| No NIH Category available,Acute;Address;Advisory Committees;Advocacy;Age;Agreement;Ancillary Study;Applications Grants;Area;Biological Markers;COVID-19 pandemic;COVID-19 patient;Caring;Cause of Death;Cerebrovascular Disorders;Clinical;Clinical Investigator;Clinical Research;Clinical Trials;Collaborations;Communities;Conceptions;Continuing Education;Contracts;Country;Dedications;Development;Devices;Education;Elderly;Enrollment;Ensure;Ethnic Origin;Feasibility Studies;Feedback;Funding;Gender;Grant;Hospitals;Image;Incidence;Institutional Review Boards;International;K-Series Research Career Programs;Leadership;Methodology;Minority Recruitment;Multi-Institutional Clinical Trial;National Institute of Neurological Disorders and Stroke;Outcome;Participant;Patient Representative;Patients;Pediatrics;Pharmaceutical Preparations;Pharmacy facility;Phase;Population;Populations at Risk;Prevention;Process;Professional Education;Race;Recovery;Rehabilitation therapy;Research;Research Personnel;Resources;SARS-CoV-2 infection;Science;Series;Site;Standardization;Stroke;StrokeNet trials;Testing;Training;Training and Education;United States National Institutes of Health;Universities;Work;Working stroke;aging population;base;biomarker validation;career development;clinical practice;clinical research site;community partners;design;disability;electronic consent;equity diversity and inclusion;experience;improved;industry partner;innovation;member;multi-site trial;multidisciplinary;next generation;novel strategies;participant retention;patient population;payment;pre-clinical;prevent;recruit;sex;stroke rehabilitation;stroke trials;symposium;telerehabilitation;thrombotic;timeline;trial design;validation studies;working group,NIH StrokeNet National Clinical Coordinating Center (NCC),PROJECT NARRATIVEStroke is the second leading cause of death and a leading cause of major disability globally and is becoming more frequent with the aging population. NIH Stroke Net is a network of clinical sites and experts across the country working together to develop and complete multi-site clinical trials the final step in proving that new potential treatments will work and to train the next generation of clinical researchers. The National Coordinating Center leads and manages this network to test new ways to treat prevent and aid in recovery and rehabilitation from stroke.,NINDS,10796607,12/11/2023 12:00:00 AM,RFA-NS-23-009,2U01NS086872-11,2,U01,NS,086872,11, ,"AFZAL, MARIAM MASHEEB",9/30/2013 12:00:00 AM,11/30/2028 12:00:00 AM,ZNS1-SRB-W(16), ,8779645,"KHATRI, POOJA ","BRODERICK, JOSEPH PAUL",01,NEUROLOGY,041064767,DZ4YCZ3QSPR5,041064767,DZ4YCZ3QSPR5,US,39.129719,-84.520554,1523902,UNIVERSITY OF CINCINNATI,CINCINNATI,OH,SCHOOLS OF MEDICINE,452210001,UNITED STATES,N,12/11/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Non-SBIR/STTR,2024,2863371, ,NINDS,1846828,1016543, ,2863371,,2863371.0 | |
| No NIH Category available,Acceleration;Adjuvant;Adult;Africa;Age;Asthma;Australasia;Bacteria;Bioinformatics;Biological Assay;Biological Markers;Biological Models;Birth;Blood Donations;Blood Volume;Cells;Childhood;Clinical;Communicable Diseases;Coupled;Data;Development;Disease;Enrollment;Epigenetic Process;Goals;Greek;Growth;Health;Human;Human body;Immune;Immune system;Immunity;Immunologics;Immunomodulators;In Vitro;Individual;Infant;Infection;Innate Immune Response;Intervention;Knowledge;Life;Liquid substance;Measures;Mediating;Medical;Memory;Modeling;Molecular;Molecular Profiling;Mucous Membrane;Newborn Infant;North America;Nose;Organ;PRTN3 gene;Pathway interactions;Pattern;Pediatric cohort;Phenotype;Physiological;Plasma;Positioning Attribute;Predisposition;Prognostic Marker;Protective Agents;Proteins;Proteomics;Publishing;Resistance;Respiratory Disease;Respiratory Tract Infections;Risk;Sampling;Shapes;System;Systems Biology;Testing;Training;Translating;Vaccines;Validation;adaptive immune response;age related;biobank;bioinformatics tool;clinical phenotype;cohort;experience;gut microbiome;high risk;in silico;in utero;in vitro Model;infancy;infection risk;insight;inter-individual variation;metabolomics;microbiome;multiple omics;novel strategies;predictive marker;prevent;programs;prospective;respiratory;response;risk prediction;specific biomarkers;tool;vaccine response,Immune development in early life (IDEAL) shapes vaccine response respiratory infectious diseaseand asthma,Immune development in early life (IDEAL) shapes vaccine response respiratory infectious diseaseand asthma,NIAID,10796875,3/7/2024 12:00:00 AM,RFA-AI-20-078,5U19AI168643-03,5,U19,AI,168643,03, ,"PRABHUDAS, MERCY R",3/10/2022 12:00:00 AM,2/28/2027 12:00:00 AM,ZAI1-MMF-X(J1), ,1928111,"LEVY, OFER ",Not Applicable,07,Unavailable,076593722,Z1L9F1MM1RY3,076593722,Z1L9F1MM1RY3,US,42.337481,-71.104964,1504801,BOSTON CHILDREN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021155724,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,1542768, ,NIAID,1161744,381024, ,1542768,,1542768.0 | |
| No NIH Category available,3 year old;Adjuvant;Africa;Age;Antibody Response;Asthma;Canada;Child;Child Health;Clinical;Clinical Trials;Communicable Diseases;Data;Development;Disease;Functional disorder;Future;Geography;Goals;Growth;Health;Hypersensitivity;Immune;Immune System Diseases;Immune response;Immune system;Immunologic Memory;Immunologics;Immunology procedure;Impairment;Incidence;Infant;Infection;Infection prevention;Intervention;Intestines;Investigation;Lead;Life;Longitudinal cohort study;Measures;Modernization;Molecular;Mucous Membrane;Nasopharynx;Papua New Guinea;Phenotype;Population;Predisposition;Prospective cohort;Proteins;Proteomics;Respiratory Tract Infections;Sampling;Secure;Shapes;Systems Biology;Testing;Vaccination;Vaccines;Validation;Variant;biobank;biomarker development;biomarker discovery;clinical phenotype;cohort;data exchange;early childhood;immune modulating agents;metabolomics;microbiome research;mortality;multiple omics;predictive marker;prevent;prospective;recruit;respiratory;tool;transcriptomics;vaccine response;vaccine-induced antibodies,Clinical Core: IDEAL shapes vaccine response susceptibility to respiratory infectious disease and asthma,,NIAID,10796880,3/7/2024 12:00:00 AM,RFA-AI-20-078,5U19AI168643-03,5,U19,AI,168643,03, , ,3/10/2022 12:00:00 AM,2/28/2027 12:00:00 AM,ZAI1-MMF-X,7847,1946165,"PICHICHERO, MICHAEL E",Not Applicable,07,Unavailable,076593722,Z1L9F1MM1RY3,076593722,Z1L9F1MM1RY3,US,42.337481,-71.104964,1504801,BOSTON CHILDREN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021155724,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,356182, ,314162,42020, , ,, | |
| No NIH Category available,Affect;Aliquot;Antibody Response;Asthma;Biological;Biological Markers;Birth;Blood;COVID-19;COVID-19 patient;Cells;Child;Childhood;Clinical;Communicable Diseases;Complement;Consumption;Data;Development;Diagnosis;Dimensions;Disease;Early treatment;Epigenetic Process;Exhibits;Extravasation;Frequencies;Goals;Growth;Health;Hospitalization;Hour;Human;Immune;Immune system;Immunologics;Immunology;Immunophenotyping;Impairment;In Vitro;Infant;Infection;Infrastructure;Intervention;Life;Maps;Measurement;Methods;Microbe;Molecular;Molecular Profiling;Mucous body substance;Nasal cavity;Nasopharynx;National Institute of Allergy and Infectious Disease;Newborn Infant;Nose;Outcome;PRTN3 gene;Pathway interactions;Pattern;Pharyngeal structure;Phenotype;Plasma;Predisposition;Prevention;Process;Prognosis;Proteins;Proteome;Proteomics;Publishing;Research;Resolution;Respiratory System;Respiratory Tract Infections;Risk;Role;Sampling;Services;Shapes;System;Testing;Time;Tissues;Vaccination;Vaccines;biomarker identification;chemokine;clinical phenotype;clinically relevant;comorbidity;cytokine;data management;early childhood;endophenotype;high risk;immunoregulation;infancy;insight;interest;liquid chromatography mass spectrometry;metabolome;metabolomics;neonate;novel strategies;pathogen;respiratory;vaccine immunogenicity;vaccine response,Proteomics and Metabolomics Core: IDEAL shapes vaccine response susceptibility to respiratory infectious disease and asthma,,NIAID,10796883,3/7/2024 12:00:00 AM,RFA-AI-20-078,5U19AI168643-03,5,U19,AI,168643,03, , ,3/10/2022 12:00:00 AM,2/28/2027 12:00:00 AM,ZAI1-MMF-X,5364,8529307,"STEEN, HANNO ",Not Applicable,07,Unavailable,076593722,Z1L9F1MM1RY3,076593722,Z1L9F1MM1RY3,US,42.337481,-71.104964,1504801,BOSTON CHILDREN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021155724,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,264457, ,140562,123895, , ,, | |
| No NIH Category available,6 year old;Address;Asthma;Automobile Driving;Biological;Biological Markers;Biological Process;Categories;Childhood;Classification;Clinical;Collection;Communicable Diseases;Complex;Data;Data Discovery;Development;Disease;Ensure;Environmental Exposure;Epigenetic Process;Etiology;Future;Genetic;Growth;Health;Heterogeneity;Human;Immune;Immune Targeting;Immunity;Immunization;Immunologics;In Vitro;Individual;Infection;Life;Machine Learning;Molecular;Molecular Target;Multiomic Data;Natural Immunity;Outcome;Pathway interactions;Phenotype;Play;Predisposition;Process;Proteome;Proteomics;Research;Respiratory Tract Infections;Role;Shapes;Systems Biology;Validation;Variant;Vitamin D;adaptive immunity;antenatal;clinical phenotype;cohort;epigenome;ethnic diversity;follow-up;metabolome;metabolomics;microbiome;multiple omics;novel;precision medicine;programs;prospective;respiratory;statistics;targeted biomarker;therapeutic target;transcriptome;transcriptomics;vaccination outcome;vaccine response,Project 1: Multi-omic endotyping of vaccine response susceptibility to respiratory infectious disease and asthma,,NIAID,10796885,3/7/2024 12:00:00 AM,RFA-AI-20-078,5U19AI168643-03,5,U19,AI,168643,03, , ,3/10/2022 12:00:00 AM,2/28/2027 12:00:00 AM,ZAI1-MMF-X,5365,9348007,"LASKY-SU, JESSICA A",Not Applicable,07,Unavailable,076593722,Z1L9F1MM1RY3,076593722,Z1L9F1MM1RY3,US,42.337481,-71.104964,1504801,BOSTON CHILDREN'S HOSPITAL,BOSTON,MA,Independent Hospitals,021155724,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,172130, ,172130,0, , ,, | |
| No NIH Category available,Adult;Affect;African American population;Ascorbic Acid;Asia;Asian;Atherosclerosis Risk in Communities;Bacteria;Beverages;Biological Markers;Biology;Black race;Branched-Chain Amino Acids;Butyrates;Caring;Case Study;Cholesterol;Citric Acid;Clinical;Coffee;Country;Dairying;Data;Development;Diet;Disease;Emergency department visit;Estrone;Estrone-Sulfate;Etiology;Flare;Follow-Up Studies;Foundations;Fructose;Funding;Gas Chromatography;Gene Expression;Generations;Genome;Gonadal Steroid Hormones;Gout;Health Professional;Heart;High Prevalence;Hormones;Hospitalization;Hyperuricemia;Immunity;Individual;Inflammation;Inflammatory;Inflammatory Arthritis;Intestines;Ketone Bodies;Life Style;Liquid Chromatography;Mass Spectrum Analysis;Medical;Mendelian randomization;Metabolic;Metagenomics;Microbe;Nested Case-Control Study;Network-based;Nonesterified Fatty Acids;Nurses' Health Study;Pain;Pathogenesis;Pathway interactions;Patients;Plasma;Precipitation;Predisposition;Prevalence;Prevention;Prevention strategy;Primary Prevention;Prospective cohort study;Pyrrolidonecarboxylic Acid;Recurrence;Regulation;Research;Resources;Risk;Risk Factors;Role;Sampling;Secondary Prevention;Sex Differences;Statistical Methods;Steroids;Taxonomy;Testing;Testosterone;Training;United States National Institutes of Health;Urate;Validation;Woman;Women's study;androgenic;biobank;burden of illness;cardiometabolism;cohort;coronary event;dehydroepiandrosterone;dietary;equol;follow-up;genetic risk factor;genetic variant;genome wide association study;gut microbiome;gut microbiota;hormone regulation;insight;joint injury;lifestyle data;male;men;metabolome;metabolomics;microbial;microbiome;microbiota;monocyte;novel;phenome;population based;predictive tools;prospective;sex;sociodemographics;stool sample;success;trait;western diet,NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUT,NARRATIVEGout a metabolic condition causing the most common inflammatory arthritis leads to painful flares and jointdamage; fundamental questions remain about its development. Building on the advances made in ourpreceding NIH-funded research and leveraging the unique resources of ongoing prospective cohort studieswith decades of follow-up confirmed incident gout cases and rich dietary lifestyle biomarker and medicaldata we propose to determine the role of metabolites and gut microbiota in the pathogenesis of gout(particularly hyperuricemia becoming gout) and gouts distinctive sex predilection. We anticipate this rigorousapproach will provide novel mechanistic insights in gout thereby laying a foundation for new preventionstrategies as well as novel predictive tools.,NIAMS,10796891,4/2/2024 12:00:00 AM,PA-20-185,5R01AR065944-08,5,R01,AR,065944,08, ,"PARK, HEIYOUNG",9/20/2013 12:00:00 AM,2/28/2026 12:00:00 AM,"Neurological, Aging and Musculoskeletal Epidemiology Study Section[NAME]", ,8095993,"CHOI, HYON K",Not Applicable,08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,846,Non-SBIR/STTR,2024,723144, ,NIAMS,534128,189016, ,723144,,723144.0 | |
| No NIH Category available,Address;Age;Apoptosis;Autoantibodies;Autoimmune;Autoimmune Diseases;Autoimmunity;Automobile Driving;Avidity;B-Cell Activation;B-Lymphocytes;Benign;Bioinformatics;Biological Markers;Cell Count;Cells;Cellular Immunology;Cellular Indexing of Transcriptomes and Epitopes by Sequencing;Cessation of life;Characteristics;Chronic;Classification;Clinical;Clinical Data;Collaborations;Collection;Data;Development;Disease;Disease Progression;Early Diagnosis;Epigenetic Process;Epitope spreading;Exhibits;Female of child bearing age;Flare;Frequencies;Functional disorder;Future;Genes;Genetic;Genetic Transcription;Genomics;Immune;Immune Targeting;Immunology;Impairment;Individual;Inflammatory;Innate Immune Response;Interferon Type I;Knowledge;Link;Lupus;Lymphopenia;Measures;Mediating;Mediator;Medical;Metabolic;Metabolism;Minority Groups;Mitochondria;Molecular;Morbidity - disease rate;Myeloid Cells;Natural History;Nucleic Acids;Onset of illness;Organ;Participant;Pathogenesis;Pathway interactions;Patients;Peripheral;Phenotype;Population;Prevention;Prevention trial;Process;Production;Productivity;Proliferating;Publishing;Questionnaires;RNA;Regulation;Research;Research Personnel;Risk;Risk Assessment;Risk Factors;Risk Reduction;Role;Sampling;Science;Scientist;Sentinel;Signal Transduction;Source;Specificity;System;Systemic Lupus Erythematosus;T-Lymphocyte;TLR7 gene;Testing;Time;Tissues;Treatment-related toxicity;Validation;Viral;adaptive immune response;autoreactive T cell;biomarker identification;clinical investigation;clinical predictive model;cohort;cytokine;data integration;dysbiosis;extracellular;high risk population;imaging approach;improved;longitudinal design;member;metabolomics;microbial;microbiome;microbiota;mitochondrial metabolism;monocyte;mortality;multiple omics;novel therapeutics;pre-clinical;predictive modeling;prevent;programs;response;restraint;sample collection;single cell ATAC-seq;systemic autoimmune disease;transcriptome sequencing;virome;young woman,Autoimmune Drivers and Protectors Team Science (ADAPTS),Project NarrativeAutoimmune diseases afflict up to 12% of the US and lupus as one autoimmune disease remains a leadingcause of medical death in young women of child-bearing age. This program is testing a number of potentialdrivers and protectors of autoimmune disease using unique patient cohorts and broad investigator expertise.,NIAID,10796915,2/6/2024 12:00:00 AM,RFA-AI-22-012,5U01AI176244-02,5,U01,AI,176244,02, ,"GUERAU, MIREIA",3/1/2023 12:00:00 AM,2/29/2028 12:00:00 AM,ZAI1-PT-I(J1), ,1877799,"JAMES, JUDITH A","RATHMELL, JEFFREY C.",05,Unavailable,077333797,NGCNCJ1X6XA4,077333797,NGCNCJ1X6XA4,US,35.482988,-97.49781,6239601,OKLAHOMA MEDICAL RESEARCH FOUNDATION,OKLAHOMA CITY,OK,Research Institutes,731045005,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,1288071, ,NIAID,982403,305668, ,1288071,,1288071.0 | |
| No NIH Category available,Address;Affinity;Anisotropy;Architecture;Area;Binding;Binding Proteins;Biological;Biological Assay;Biological Markers;Biosensor;Cells;Clinical;Complex;Crowding;Detection;Deterioration;Development;Diagnostic;Disease;Elements;Engineering;Epidermal Growth Factor Receptor;Event;Fingerprint;Fluorescence Polarization;Formulation;Goals;Healthcare;Human;Impairment;Kinetics;Knowledge;Label;Libraries;Liquid substance;Malignant Neoplasms;Mammalian Cell;Masks;Measurement;Membrane Proteins;Methods;Microelectrodes;Modification;Molecular;Names;Nanostructures;Nature;Noise;Outcome;Output;Performance;Physiologic pulse;Pore Proteins;Property;Protein Engineering;Proteins;Proteome;Proteomics;Reading;Reagent;Reporter;Research;Resolution;Sampling;Sensitivity and Specificity;Serum;Signal Transduction;Structure;Surface;Techniques;Technology;Therapeutic;Time;Validation;Variant;Work;antibody mimetics;biomarker discovery;biomarker performance;combinatorial;design;detection limit;detector;disease prognostic;high throughput technology;improved;next generation;operation;polypeptide;preservation;protein biomarkers;protein expression;scaffold;sensor;sensor technology;targeted biomarker;time use;tool;trait,Development of Modular Synthetic Sensors for Protein Biomarker Detection,Project NarrativeProtein identification and quantification in challenging heterogeneous biofluids have pivotal significance inbiomarker discovery. These proposed studies will impact healthcare by providing technological tools forultrasensitive protein detection in biomedical diagnostics quantitative proteomics and molecular therapeutics.,NIBIB,10796997,2/13/2024 12:00:00 AM,PA-20-185,5R01EB033412-02,5,R01,EB,033412,02, ,"MULVANEY, SHAWN PATRICK",3/1/2023 12:00:00 AM,2/28/2027 12:00:00 AM,Biomaterials and Biointerfaces Study Section[BMBI], ,8258796,"MOVILEANU, LIVIU ",Not Applicable,22,PHYSICS,002257350,C4BXLBC11LC6,002257350,C4BXLBC11LC6,US,43.041575,-76.133784,1520301,SYRACUSE UNIVERSITY,SYRACUSE,NY,SCHOOLS OF ARTS AND SCIENCES,132441200,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,286,Non-SBIR/STTR,2024,379576, ,NIBIB,280256,99320, ,379576,,379576.0 | |
| No NIH Category available,Adjuvant;Area;Biological;Biology;CD8B1 gene;Cancer Control;Cell Physiology;Cells;Cessation of life;Characteristics;Chemopreventive Agent;Clinical;Clinical Trials;Clinical Trials Design;Collaborations;Controlled Environment;Cytoplasm;Development;Diagnosis;Disease;Dose;Drug usage;Epidemiologic Methods;Epidemiologist;Epidemiology;FOXP3 gene;Foundations;Functional disorder;Genetic Transcription;Goals;Health;Helper-Inducer T-Lymphocyte;Heterogeneity;Immune;Immune response;Immunosuppression;Immunotherapy;Malignant Neoplasms;Malignant neoplasm of prostate;Measurement;Mediating;Medical Oncology;Meditation;Mentors;Methods;Molecular;Nature;Neoplasm Metastasis;Nuclear Protein;Nuclear Translocation;Observational Study;Operative Surgical Procedures;Outcome;Pathologic;Pathway interactions;Pharmaceutical Preparations;Pharmacology;Phase;Phosphorylation;Placebos;Prostate;Prostate Cancer therapy;Prostatectomy;Prostatic Neoplasms;Proteins;Randomized;Regulatory T-Lymphocyte;Research;Research Project Grants;Risk;Risk Reduction;Sampling;Schedule;Science;T cell response;Testing;Therapeutic;Time;Tissue Microarray;Tissues;Training;Training Programs;Translations;Tumor Antigens;Uncertainty;Work;advanced prostate cancer;anti-cancer research;anti-tumor immune response;biomarker validation;cancer biomarkers;cancer epidemiology;career;cohort;density;epidemiology study;evidence base;experience;immunoregulation;improved;men;multidisciplinary;novel;oncology trial;pleiotropism;population based;population health;progression risk;prostate cancer progression;protective effect;randomized trial;response;tissue archive;tissue biomarkers;tumor;tumor microenvironment;validation studies,Treg functional changes: a novel immune regulatory effect underlying the benefit of statin drug use on lethal prostate cancer,PROJECT NARATIVEThis study will examine a novel immune-modulatory mechanism through which statins impede the progressionof lethal prostate cancer. The research plan includes the construction of tumor microarray (TMA) set from aclinical cohort of men sampled based on their statin use at the time of prostatectomy and a proof-of-principlepre-prostatectomy randomized trial to test the effect of statins on this pathway in men diagnosed with prostatecancer schedule for prostatectomy. The research project is complemented by a comprehensive trainingprogram that will prepare the applicant for an independent research career as a translational cancerepidemiologist.,NCI,10797017,4/10/2024 12:00:00 AM,RFA-CA-19-030,5R00CA246097-05,5,R00,CA,246097,05, ,"SONG, MIN-KYUNG H",3/9/2020 12:00:00 AM,2/28/2026 12:00:00 AM,ZCA1-TCRB-T(O2), ,14324590,"MARRONE, MICHAEL THOMAS",Not Applicable,06,PUBLIC HEALTH & PREV MEDICINE,183710748,NHV3GTWSALA7,183710748,NHV3GTWSALA7,US,32.786754,-79.947265,7575301,MEDICAL UNIVERSITY OF SOUTH CAROLINA,CHARLESTON,SC,SCHOOLS OF MEDICINE,294074636,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,398,Non-SBIR/STTR,2024,26341, ,NCI,18936,7405, ,26341,,26341.0 | |
| No NIH Category available,Age;Alcohol consumption;Algorithms;Applications Grants;Award;Barrett Esophagus;Biological Assay;Biological Markers;Biopsy Specimen;Businesses;Chronic;Clinic Visits;Clinical;Columnar Epithelium;DNA;Detection;Development;Devices;Diagnosis;Disease Progression;Dysplasia;Early Diagnosis;Endoscopy;Enrollment;Esophageal Adenocarcinoma;Esophageal Neoplasms;Esophagus;Feedback;Focus Groups;Foundations;Funding;Future;Gastroesophageal reflux disease;Grant;Health system;High grade dysplasia;Histologic;Incidence;Individual;Interobserver Variability;Interview;Licensing;Malignant Neoplasms;Market Research;Marketing;Methylation;Modeling;Multivariate Analysis;Neoplasms;Obesity;Outcome;Pathologist;Pathway interactions;Patient-Focused Outcomes;Patients;Phase;Physicians;Porifera;Precancerous Conditions;Predictive Value;Primary Care Physician;Productivity;Prognostic Marker;Prospective Studies;Recommendation;Risk;Risk Assessment;Sampling;Specimen;Surveillance Program;Symptoms;Testing;Time;Tissues;Training;Update;Upper digestive tract structure;Validation;Weight;cancer risk;clinical practice;cohort;commercialization;diagnostic assay;diagnostic biomarker;follow-up;gastrointestinal;high risk;improved;indexing;industry partner;innovation;male;model building;population based;prognostic;prognostic assays;prognostic value;progression marker;progression risk;prospective;recruit;response;screening;success;tobacco exposure;tool;treatment planning;tumor progression;usability;validation studies,Academic-Industrial Partnership for Barrett's Esophagus Detection and Risk Assessment,We will devise nonendoscopic early BE and EAC detection strategies and develop biomarkers to predictneoplastic progression in BE by 1. Analytically and clinically validating and commercializing the EsoPredictassay for personalized BE risk assessment; 2. Developing validating and commercializing the EsoDetectassay for noninvasive BE diagnosis; and 3. Conducting a prospective study of EsoPredict in tissues andsponge samples from BE patients.,NCI,10797282,2/16/2024 12:00:00 AM,PAR-21-166,9R01CA287294-06,9,R01,CA,287294,06, ,"TATA, DARAYASH B",3/1/2024 12:00:00 AM,2/28/2029 12:00:00 AM,Special Emphasis Panel[ZRG1-ISB-S(57)R], ,1891510,"MELTZER, STEPHEN J",Not Applicable,07,INTERNAL MEDICINE/MEDICINE,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,791370, ,NCI,532454,258916, ,791370,,791370.0 | |
| No NIH Category available,Acceleration;Affect;American;Antibody Response;Autoantibodies;Autoantigens;Autoimmune Diseases;Autoimmune Process;Biological Assay;Biological Markers;Blinded;Blood Glucose;Blood specimen;Budgets;Caring;Cells;Clinical;Complement;Complex;Continuous Glucose Monitor;Data;Data Analyses;Data Set;Development;Diabetes Mellitus;Diagnostic;Disease;Disease Pathway;Disease Progression;Endocrine;Environmental Risk Factor;Event;Evolution;Excess Mortality;Exclusion;Exocrine pancreas;Family;Fostering;Funding;Future;Generations;Genetic Predisposition to Disease;Genetic Transcription;Glycosylated hemoglobin A;Heterogeneity;Hormones;Immune;Immune response;Immunologic Markers;Immunologics;Immunology;Incidence;Individual;Insulin;Insulin Infusion Systems;Insulin-Dependent Diabetes Mellitus;Intervention;Intervention Studies;Investigation;Kidney Failure;Longevity;Measurement;Mediating;Metadata;MicroRNAs;Modality;Modeling;Modification;Myocardial Infarction;Natural History;Nested Case-Control Study;Outcome;Pathogenesis;Pathway interactions;Peripheral Blood Mononuclear Cell;Phase;Phenotype;Positioning Attribute;Prevalence;Prevention;Public Health;Records;Research;Research Design;Research Personnel;Risk;Sampling;Secure;Series;Serum;Serum Proteins;Societies;Staging;Stratification;Stroke;Structure of beta Cell of islet;Study of serum;Symptoms;Technology;Therapeutic;Time;Treatment Protocols;United States;Validation;Viral;blood glucose regulation;carbohydrate metabolism;case control;cohort;commensal bacteria;data dissemination;data integration;data mining;data resource;design;diabetes management;diabetes pathogenesis;diabetes risk;distributed data;genetic risk factor;genome-wide;glycemic control;high throughput analysis;improved;insight;insulin dependent diabetes mellitus onset;insulin secretion;islet;lipid metabolism;longitudinal dataset;metabolome;novel;novel marker;potential biomarker;prevent;prognostic;prohormone;prophylactic;protein metabolism;psychologic;public health relevance;risk stratification;sample collection;technology platform;therapy development;transcriptomics,The KQ1 serum study: soluble biomarkers for T1D risk development & progression,No modifications to Public Health RelevanceReferences1. Christoffersson G. Coppieters K.T. von Herrath M.G. and Homann D. (2022). Autoimmunity and Autoimmune Diseases. In Pauls Fundamental Immunology M. Flajnik N.J. Singh and S.M. Holland eds. (Lippincott Williams & Wilkins). 2. Atkinson M.A. Eisenbarth G.S. and Michels A.W. (2014). Type 1 diabetes. Lancet 383 69-82. 10.1016/S0140-6736(13)60591-7. 3. Chiang J.L. Kirkman M.S. Laffel L.M. Peters A.L. and Type 1 Diabetes Sourcebook A. (2014). Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37 2034-2054. 10.2337/dc14-1140. 4. Pociot F. and Lenmark A. (2016). Genetic risk factors for type 1 diabetes. Lancet 387 2331-2339. 5. Rewers M.J. and Ludvigsson J. (2016). Environmental risk factors for type 1 diabetes. Lancet 387 2340-2348. 6. Lind M. Svensson A.M. Kosiborod M. Gudbjornsdottir S. Pivodic A. Wedel H. Dahlqvist S. Clements M. and Rosengren A. (2014). Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 371 1972-1982. 10.1056/NEJMoa1408214. 7. Insel R.A. Dunne J.L. Atkinson M.A. Chiang J.L. Dabelea D. Gottlieb P.A. Greenbaum C.J. Herold K.C. Krischer J.P. Lernmark A. et al. (2015). Staging presymptomatic type 1 diabetes: a scientific statement of JDRF the Endocrine Society and the American Diabetes Association. Diabetes Care 38 1964-1974. 10.2337/dc15-1419. 8. Battaglia M. Anderson M.S. Buckner J.H. Geyer S.M. Gottlieb P.A. Kay T.W.H. Lernmark A. Muller S. Pugliese A. Roep B.O. et al. (2017). Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 10.1007/s00125-017-4384-2.2. Atkinson M.A. Eisenbarth G.S. and Michels A.W. (2014). Type 1 diabetes. Lancet 383 69-82. 10.1016/S0140-6736(13)60591-7.3. Chiang J.L. Kirkman M.S. Laffel L.M. Peters A.L. and Type 1 Diabetes Sourcebook A. (2014). Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37 2034-2054. 10.2337/dc14-1140.4. Pociot F. and Lenmark A. (2016). Genetic risk factors for type 1 diabetes. Lancet 387 2331-2339.5. Rewers M.J. and Ludvigsson J. (2016). Environmental risk factors for type 1 diabetes. Lancet 387 2340-2348.6. Lind M. Svensson A.M. Kosiborod M. Gudbjornsdottir S. Pivodic A. Wedel H. Dahlqvist S. Clements M. and Rosengren A. (2014). Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 371 1972-1982. 10.1056/NEJMoa1408214.7. Insel R.A. Dunne J.L. Atkinson M.A. Chiang J.L. Dabelea D. Gottlieb P.A. Greenbaum C.J. Herold K.C. Krischer J.P. Lernmark A. et al. (2015). Staging presymptomatic type 1 diabetes: a scientific statement of JDRF the Endocrine Society and the American Diabetes Association. Diabetes Care 38 1964-1974. 10.2337/dc15-1419.8. Battaglia M. Anderson M.S. Buckner J.H. Geyer S.M. Gottlieb P.A. Kay T.W.H. Lernmark A. Muller S. Pugliese A. Roep B.O. et al. (2017). Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia. 10.1007/s00125-017-4384-2.,NIDDK,10797494,1/30/2024 12:00:00 AM,RFA-DK-22-021,1R01DK138369-01,1,R01,DK,138369,01, ,"SPAIN, LISA M",2/1/2024 12:00:00 AM,1/31/2027 12:00:00 AM,ZDK1-GRB-S(O3), ,2214443,"HOMANN, DIRK ","SPEAKE, CATE ",13,INTERNAL MEDICINE/MEDICINE,078861598,C8H9CNG1VBD9,078861598,C8H9CNG1VBD9,US,40.790284,-73.946781,3839801,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,NEW YORK,NY,SCHOOLS OF MEDICINE,100296574,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,847,Non-SBIR/STTR,2024,1230771, ,NIDDK,979739,251032, ,1230771,,1230771.0 | |
| No NIH Category available,Academic Medical Centers;Acute;Adult;Agreement;Ally;Area;Award;Biological Markers;Blood Vessels;Brain hemorrhage;Career Mobility;Caring;Cause of Death;Cessation of life;Chicago;Child;Clinical;Clinical Trials;Clinical Trials Network;Clinical and Translational Science Awards;Collaborations;Community Outreach;County;Data Coordinating Center;Development;Diagnostic;Education;Elderly;Emergency Care;Emergency Medicine;Enrollment;Ensure;Environment;Ethnic Population;Faculty;Fellowship;Fostering;Funding;Future;Geography;Growth and Development function;Hospitals;Illinois;Individual;Industry;Infrastructure;Institution;Institutional Review Boards;International;Intervention;Lead;Leadership;Medical center;Medicine;Mentors;Mentorship;National Institute of Neurological Disorders and Stroke;Neurology;Patient Recruitments;Patients;Pediatric Hospitals;Pediatric Neurology;Persons;Population Heterogeneity;Prevention;Prevention trial;Procedures;Process;Program Development;Qualifying;Recording of previous events;Recovery;Rehabilitation therapy;Research;Research Personnel;Resources;Role;Sample Size;Site;Societies;Standardization;Stroke;Stroke prevention;System;Training Programs;United States;United States Department of Veterans Affairs;United States National Institutes of Health;Universities;Vulnerable Populations;Wisconsin;Work;acute stroke;aging population;base;career;clinical biomarkers;cooking;cost;disability;effective therapy;experience;future implementation;high risk;improved;innovation;medical schools;metropolitan;multi-ethnic;multidisciplinary;neurological rehabilitation;neuroprotection;neurosurgery;novel;patient population;phase III trial;programs;public health relevance;recruit;response;skills;statistics;stroke patient;stroke rehabilitation;stroke therapy;stroke trials;telerehabilitation;translational medicine;trial enrollment;validation studies,Chicago Stroke Trials Consortium,PUBLIC HEALTH RELEVANCEStroke remains the 5th leading cause of death in the United States (US) and a leading cause of adult disability. In the past decade there have been tremendous strides in discovery of beneficial approaches to treat and prevent stroke aided in part by conduct of large-scale clinical trials in StrokeNet. Leveraging our prior contributions to trial enrollment proposal development and trainee education our renewal application as a regional coordinating center (RCC) in StrokeNet seeks to provide continued access to a diverse stroke patient population consolidated multidisciplinary and multi-institutional expertise and leadership for StrokeNet trials and ensure mentoring for trainees and junior faculty seeking academic careers in stroke. These efforts will identify new stroke treatments that reduce death and disability from stroke.,NINDS,10797720,11/28/2023 12:00:00 AM,RFA-NS-23-010,2U24NS107233-06,2,U24,NS,107233,06, ,"AFZAL, MARIAM MASHEEB",8/15/2018 12:00:00 AM,11/30/2028 12:00:00 AM,ZNS1-SRB-W(17), ,9766607,"PRABHAKARAN, SHYAM ",Not Applicable,01,NEUROLOGY,005421136,ZUE9HKT2CLC9,005421136,ZUE9HKT2CLC9,US,41.789554,-87.601172,1413601,UNIVERSITY OF CHICAGO,CHICAGO,IL,SCHOOLS OF MEDICINE,606372612,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Other Research-Related,2024,437470, ,NINDS,266750,170720, ,437470,,437470.0 | |
| No NIH Category available,Academic Medical Centers;Acceleration;Achievement;Acute;Address;Adherence;Adult;African American;African American population;Aging;American;Award;California;Cause of Death;Cerebrovascular Disorders;Cessation of life;Child;Clinical Research;Clinical Trials Network;Collaborations;Communities;County;Dedications;Disease;Emergency Department Physician;Emergency Medicine;Ensure;Faculty;Funding;Geographic Locations;Goals;Grant;Hispanic Americans;Hospitals;Impairment;Individual;Infrastructure;Inpatients;Intervention;Investments;Leadership;Los Angeles;Medical;Medical Students;Medical center;Mentors;Mentorship;Minority Groups;Multi-Institutional Clinical Trial;National Institute of Neurological Disorders and Stroke;Neurologist;Neurology;Neurosurgeon;New Mexico;Nurses;Oranges;Outcome Measure;Paramedical Personnel;Patient Dropouts;Patient Noncompliance;Patients;Pediatric Hospitals;Performance;Phase;Physical Medicine;Physical Rehabilitation;Physicians;Population;Premedical Students;Prevention;Prevention trial;Preventive;Recovery;Rehabilitation Centers;Rehabilitation therapy;Research;Research Personnel;Resources;Self Perception;Stroke;Stroke prevention;System;Testing;Time;Training;Translational Research;Underserved Population;United States;United States National Institutes of Health;Universities;Validation;Woman;acute stroke;arm;biomarker validation;career;career development;cerebrovascular;decision-making capacity;disability;educational atmosphere;experience;follow-up;mid-career faculty;neurosurgery;neurovascular;novel;outreach;performance site;post stroke;programs;randomized clinical trials;recruit;rehabilitative care;research study;safety net;stroke recovery;stroke rehabilitation;stroke therapy;stroke trials;success;treatment trial;validation studies,Los Angeles - Southern California (LASC) NIH StrokeNet Regional Coordinating Center,Project NarrativeStroke is the leading cause of combined death and severe disability in the United States. It is imperative that new treatments for stroke prevention acute therapy and recovery be efficiently developed. This application is to renew a large-scale regional clinical trial network to accelerate testing and validation of promising new stroke preventive acute and reparative therapies.,NINDS,10797802,12/5/2023 12:00:00 AM,RFA-NS-23-010,2U24NS107321-06,2,U24,NS,107321,06, ,"AFZAL, MARIAM MASHEEB",9/1/2018 12:00:00 AM,11/30/2028 12:00:00 AM,ZNS1-SRB-W(17), ,3047775,"SAVER, JEFFREY L","SUNG, GENE YONG",36,NEUROLOGY,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,SCHOOLS OF MEDICINE,900952000,UNITED STATES,N,12/5/2023 12:00:00 AM,11/30/2024 12:00:00 AM,853,Other Research-Related,2024,444991, ,NINDS,354388,90603, ,444991,,444991.0 | |
| No NIH Category available,Acceleration;Affect;Afghanistan;Alzheimer's Disease;Alzheimer's disease pathology;Animal Model;Anxiety;Area;Autopsy;Axon;Behavior;Behavior assessment;Behavioral;Biochemistry;Bioenergetics;Biological Markers;Blast Injuries;Brain;Brain imaging;Cells;Classification;Cognitive;Cognitive deficits;Defect;Department of Defense;Development;Discipline;Economic Burden;Etiology;Evaluation;Exposure to;Family;Human;Human Resources;Imaging Techniques;Immunohistochemistry;Impairment;Injury;Intention;Investigation;Iraq;Laboratories;Lead;Link;Long term disability;Mediating;Membrane;Metabolic;Military Personnel;Missouri;Mitochondria;Molecular;Molecular Biology;Mus;Myelin;Neurodegenerative Disorders;Neurologic Deficit;Outcome;Oxidative Stress;Pathogenesis;Pathologic;Pathology;Patients;Plasma;Positioning Attribute;Positron-Emission Tomography;Prevention;Prevention strategy;Prone Position;Protocols documentation;Reporting;Reproducibility;Research;Research Personnel;Role;Rupture;Scanning;Services;Sex Differences;Societies;Speed;Stains;System;Systems Biology;Tauopathies;Techniques;Testing;Time;Training;Transgenic Mice;Transmission Electron Microscopy;Traumatic Brain Injury;Universities;Validation;Veterans;Veterans Hospitals;War;biological adaptation to stress;biomarker discovery;blast exposure;brain tissue;cell type;chronic traumatic encephalopathy;combat;disability;functional outcomes;hTau Mice;head impact;in vivo;in vivo imaging;inhibitor;insight;instrumentation;metabolic profile;meter;mild traumatic brain injury;mitochondrial dysfunction;molecular imaging;mortality;mouse model;neuropathology;neuropsychiatric disorder;pressure sensor;research facility;response;service member;single photon emission computed tomography;socioeconomics;tau Proteins;tau aggregation;tau expression;tau-1;treatment strategy;white matter;wound,CTBI: Tauopathy in Mice and Human: Effects of Open-Field Low-Intensity Blast on Brain Ultrastructure and Outcomes in Mild Traumatic Brain Injury,Project NarrativeBlast-induced mild traumatic brain injury (mTBI) can cause long-term disabilities in service personnel exposedto blast in combat or during military training. These disabilities impose socioeconomic burdens on patientsfamilies and society. Using an established highly reproducible open-field blast mouse model our studiesdemonstrated ability for the high-energy blast waves to rupture membranes and intracellular components in thebrain tissue. This project is aimed at investigating mechanism(s) of the signature invisible injury sustained inaffected service personnel. Using a transgenic mouse model expressing human tau studies will furtherexamine the role of tau on key linkages between low-level blast exposure(s) and underlying ultrastructuraldamage as well as molecular changes reflecting oxidative stress and mitochondrial dysfunction. Understandingof the pathogenesis of mTBI-induced cognitive deficits due to blast will advance opportunities for preventativeand treatment strategies.,VA,10798101,10/6/2023 12:00:00 AM,RFA-BX-18-006,5I01BX004313-05,5,I01,BX,004313,05, , ,10/1/2019 12:00:00 AM,9/30/2024 12:00:00 AM,ZRD1-NURD-C(01)1, ,6767953,"GU, ZEZONG ",Not Applicable,03,Unavailable,082263013,LW3JC7WVEP78,082263013,LW3JC7WVEP78,US,38.93751,-92.328601,481123,HARRY S. TRUMAN MEMORIAL VA HOSPITAL,COLUMBIA,MO,Independent Hospitals,652015275,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,AIDS prevention;Address;Adherence;Antibody-mediated protection;Automobile Driving;Behavioral;Biological Assay;Biometry;Case/Control Studies;Clinical Data;Clinical Trials;Clinical Trials Network;Collaborations;Computational Biology;Data;Data Analyses;Data Coordinating Center;Data Element;Drug Kinetics;Encapsulated;Engineering;Ensure;Epidemiology;Epitopes;Ethics;Evaluation;Futility;Genes;Genetic;Goals;Good Clinical Practice;HIV;HIV Infections;HIV Vaccine Trials Network;HIV vaccine;HIV-1;HIV-1 vaccine;HIV/AIDS;Human;Immune;Immune response;Immunologics;Immunology;Incidence;Infant;Infection;Information Systems;Information Technology;Injectable;Intervention;Laboratories;Leadership;Licensure;Measures;Mediator;Methodology;Methods;Modality;Modeling;Modification;Monitor;Monoclonal Antibodies;National Institute of Allergy and Infectious Disease;Noise;Oral;Persons;Phase;Phenotype;Population;Practice Management;Prevention;Procedures;Protocols documentation;Qualifying;Quality Control;Regimen;Research;Research Activity;Research Design;Research Personnel;Resource-limited setting;Resources;Risk;Risk Assessment;Risk Behaviors;Risk Reduction;Safety;Secure;Signal Transduction;Specific qualifier value;Standardization;Statistical Methods;Statistical Models;Surrogate Endpoint;System;Testing;Time;Tuberculosis Vaccines;Underrepresented Minority;Vaccination;Vaccine Clinical Trial;Vaccine Design;Vaccines;Validation;Variant;Viremia;Virus;analysis pipeline;antiretroviral therapy;biomarker development;clinically relevant;cost efficient;data acquisition;data analysis pipeline;data exchange;data management;design;efficacy trial;first-in-human;high throughput analysis;immune function;immunogenicity;innovation;neutralizing antibody;neutralizing monoclonal antibodies;novel;novel vaccines;operation;pandemic disease;pediatric human immunodeficiency virus;pharmacokinetic model;phase III trial;pre-exposure prophylaxis;predictive modeling;prevent;programs;response biomarker;screening;tool;trial design;vaccine efficacy;vaccine evaluation;vaccine immunogenicity;vaccine trial;vaccine-induced antibodies;vaccinology;virology,SDMC: HIV Vaccine Trials Network,PROJECT NARRATIVEDespite recent advances in biomedical interventions that reduce the risk of HIV acquisition worldwide anestimated 1.7 million people acquired HIV in 2018. Eliminating the pandemic will require a safe and effectiveHIV vaccine. Only through human clinical trials held to the highest scientific ethical and regulatory standards willthe goal of an HIV vaccine be realized.,NIAID,10798117,11/16/2023 12:00:00 AM,RFA-AI-19-002,5UM1AI068635-19,5,UM1,AI,068635,19, ,"RENZULLO, PHILIP O",6/29/2006 12:00:00 AM,11/30/2027 12:00:00 AM,ZAI1-CD-A(S1), ,1941165,"GILBERT, PETER B.","HUANG, YUNDA ; JANES, HOLLY ",07,Unavailable,806433145,TJFZLPP6NYL6,806433145,TJFZLPP6NYL6,US,47.626482,-122.329606,10068583,FRED HUTCHINSON CANCER CENTER,SEATTLE,WA,Other Domestic Non-Profits,981094433,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,855,Non-SBIR/STTR,2024,31992488, ,NIAID,27572576,6770746, ,31992488,,31992488.0 | |
| No NIH Category available,Address;Behavior;Behavioral;Biological Markers;Caring;Chronic Disease;Clinical;Clinical Research;Complex;Computer software;Data;Data Set;Dependence;Development;Diagnostic;Discharge Plannings;Disease;Ensure;Equipment;Goals;Healthcare;Healthcare Systems;Hospitalization;Hospitals;Human;Individual;Informatics;Inpatients;Intelligence;Interview;Judgment;Knowledge;Linear Models;Measurement;Measures;Medical;Mental Health;Mental Health Services;Mental disorders;Methods;Mission;Modality;Modeling;Monitor;Names;National Institute of Mental Health;Outcome;Patients;Population;Process;Protocols documentation;Proxy;Psychiatry;Psychotic Disorders;Readiness;Research;Resource Allocation;Self Perception;Shapes;Social Environment;Symptoms;System;Technology;Telemedicine;Testing;Time;Universities;Validation;Work;acceptability and feasibility;behavior measurement;behavioral health;biomarker development;care delivery;clinical care;clinical decision-making;clinical encounter;clinical practice;computer framework;cost;fundamental research;health assessment;improved;insight;longitudinal dataset;multimodality;neural model;non-verbal;novel;novel strategies;predict clinical outcome;predictive marker;prognostic;provider behavior;psychiatric symptom;remote sensing;scaffold;severe mental illness;social;trustworthiness,SCH: INT: Collaborative Research: Context-Adaptive Multimodal Informatics for Psychiatric Discharge Planning,Charting mental illness trajectories to determine when where and how to intervene is a key objective of the NIMH mission to transform the understanding and treatment of mental illness. This project will: (1) deepen our understanding of the trajectory leading to hospitalization discharge with knowledge about behavioral biomarkers and their relationship to symptoms and discharge-readiness; (2) contribute to the knowledge on how social context impacts patient's behaviors since some symptoms or predictive biomarkers may only be seen in a specific context such as social or solitary interactions; and (3) contribute a credible objective framework for behavioral measurement by defining interpretable biomarkers and latent factors for symptoms and discharge assessment. The project will also enable a judicious use of remote sensing and non-direct clinical encounters (e.g. telemedicine) which are increasingly viewed as essential capabilities in the medical fields to reduce costs while maintaining or elevating care standards.,NIMH,10798135,2/26/2024 12:00:00 AM,PAR-20-004,5R01MH125740-04,5,R01,MH,125740,04, ,"FERRANTE, MICHELE",4/15/2021 12:00:00 AM,2/28/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-MOSS-V(50)], ,6414577,"BAKER, JUSTIN T","DE LA TORRE, FERNANDO ",05,Unavailable,046514535,MCKWJYCWNVN3,046514535,MCKWJYCWNVN3,US,42.393619,-71.191142,1876801,MCLEAN HOSPITAL,BELMONT,MA,Independent Hospitals,024781064,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,242,Non-SBIR/STTR,2024,276671, ,NIMH,225600,51071, ,276671,,276671.0 | |
| No NIH Category available,Address;Adjuvant Chemotherapy;Adopted;Aftercare;Age;Algorithms;Architecture;Biological;Blood;Cancer Etiology;Chemotherapy-Oncologic Procedure;Clinical;Clinical Data;Clinical Markers;Clinical Trials;Curative Surgery;Data;Development;Disease;Disease Surveillance;Distant;Evaluation;Failure;Gender;Goals;Habitats;Heterogeneity;Histologic;Histology;Image;Imaging technology;Immune;Immunotherapy;Incidence;Individual;Integration Host Factors;Knowledge;Localized Disease;Location;Machine Learning;Malignant Neoplasms;Minority Groups;Modality;Modeling;Monitor;Morphology;Neoadjuvant Therapy;Operative Surgical Procedures;PET/CT scan;Pathologic;Patient-Focused Outcomes;Patients;Performance;Population;Prediction of Response to Therapy;Process;Prognosis;Protocols documentation;Public Health;Recurrence;Reproducibility;Research;Risk;Risk Factors;Selection for Treatments;Serum Markers;Solid Neoplasm;Staging;Statistical Models;Systemic disease;Testing;Toxic effect;Training;Uncertainty;Underserved Population;Validation;Work;X-Ray Computed Tomography;advanced disease;burden of illness;cancer therapy;chemotherapy;clinical translation;clinically relevant;clinically significant;cohort;community setting;deep learning;deep learning model;design;effective therapy;follow-up;imaging approach;imaging biomarker;improved;improved outcome;individual patient;ineffective therapies;innovation;knowledge base;longitudinal analysis;malignant stomach neoplasm;minority communities;mortality;multimodal data;multitask;new therapeutic target;novel;performance tests;personalized medicine;predicting response;predictive modeling;prognostic;prognostic model;prognostic value;prospective;prospective test;radiological imaging;radiomics;response;risk prediction;risk stratification;serial imaging;side effect;standard care;success;survival outcome;survival prediction;therapy outcome;translational model;treatment response;tumor;tumor microenvironment,Computational imaging approaches to personalized gastric cancer treatment,PROJECT NARRATIVEGastric cancer (i.e. stomach cancer) is a major public health burden with a high incidence andmortality worldwide. In this project we propose to develop computational imaging approaches to theprediction of treatment response and prognosis of gastric cancer. Success of our research may helpselect the most effective treatment for an individual patient which will not only improve outcomes forpatients in the US but also have global impact.,NCI,10798183,2/22/2024 12:00:00 AM,PA-20-185,5R01CA269559-02,5,R01,CA,269559,02, ,"SALVADOR MORALES, CAROLINA",3/1/2023 12:00:00 AM,2/29/2028 12:00:00 AM,Emerging Imaging Technologies and Applications Study Section[EITA], ,10933867,"LI, RUIJIANG ",Not Applicable,16,RADIATION-DIAGNOSTIC/ONCOLOGY,009214214,HJD6G4D6TJY5,009214214,HJD6G4D6TJY5,US,37.426852,-122.17047,8046501,STANFORD UNIVERSITY,STANFORD,CA,SCHOOLS OF MEDICINE,943052004,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,547185, ,NCI,354395,192790, ,547185,,547185.0 | |
| No NIH Category available,Accelerometer;Address;Adult;Affect;Age;Behavior;Biological Markers;Biomedical Research;Body mass index;Characteristics;Chronic;Classification;Clinical;Complex;Complex Mixtures;Computer software;Data;Data Set;Databases;Demographic Factors;Devices;Dietary intake;Energy Intake;Ensure;Ethnic Origin;Evaluation;Failure;Fatty acid glycerol esters;Food;Frequencies;Health;Intake;Intervention;Life Style;Linear Regressions;Measurement;Measures;Methodology;Methods;Modeling;Monitor;National Health and Nutrition Examination Survey;Noise;Non-Insulin-Dependent Diabetes Mellitus;Nutrient;Obesity;Outcome;Patient Self-Report;Pattern;Performance;Physical activity;Population Heterogeneity;Precision Health;Process;Property;Public Health;Questionnaires;Race;Recommendation;Regression Analysis;Research;Research Personnel;Role;Sampling;Sensitivity and Specificity;Statistical Data Interpretation;Statistical Methods;Statistical Models;Subgroup;Testing;Validation;Variant;Vulnerable Populations;Work;analytical method;design;discrete time;effective intervention;health outcome disparity;high dimensionality;improved;indexing;insight;modifiable behavior;novel;risk minimization;semiparametric;sex;simulation;software development;time interval;wearable device,Measurement error correction approaches to wearable device-based measures of physical activity and self-reported measures of dietary intake in obesity and type 2 diabetes research,Many current recommendations for dietary intake (DI) and physical activity (PA) to maintain optimal healthand minimize risks for chronic health conditions such as obesity and type 2 diabetes (T2D) are based onstatistical analyses of data prone to measurement error including those collected from self-reportedquestionnaires and wearable devices. To overcome these barriers we will develop new and robust statisticalmethods to 1) identify latent groups of PA patterns based on device-based functional curves prone toheteroscedastic measurement errors and determine the association between the identified PA patternswith T2D status adjusting for PA biomarkers age sex and race/ethnicity; 2) better reduce the impact ofmeasurement error-related biases in PA and DI data on the quantile functions of body mass index and fatmass index; and 3) correct for measurement error biases associated with device-based PA and self-reported DI when evaluating their influences on T2D status. These newly developed models and relatedsoftware will be widely applicable in studies of objective measures of PA and DI in chronic health conditionswhich can lead to more targeted and effective interventions and address health outcomes disparities amongvulnerable populations in various biomedical contexts.,NIDDK,10798189,3/7/2024 12:00:00 AM,PA-18-856,5R01DK132385-03,5,R01,DK,132385,03, ,"UNALP-ARIDA, AYNUR",4/15/2022 12:00:00 AM,2/28/2026 12:00:00 AM,Biostatistical Methods and Research Design Study Section[BMRD], ,12158533,"TEKWE, CARMEN D.",Not Applicable,09,NONE,006046700,YH86RTW2YVJ4,006046700,YH86RTW2YVJ4,US,39.172055,-86.523157,577805,TRUSTEES OF INDIANA UNIVERSITY,BLOOMINGTON,IN,UNIVERSITY-WIDE,474013654,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,847,Non-SBIR/STTR,2024,564126, ,NIDDK,383131,180995, ,564126,,564126.0 | |
| No NIH Category available,Address;Affect;Anatomy;Angiography;Animals;Antipsychotic Agents;Area;Biological Markers;Blood Vessels;Brain;Cell Physiology;Cells;Cellular biology;Central Nervous System;Cerebrum;Cessation of life;Chronic;Chronic Disease;Chronic Schizophrenia;Clinical;Cognition;Cognitive;Collaborations;Consensus;Data;Development;Diagnostic;Diameter;Dimensions;Dropout;Ear;Early Intervention;Electroretinography;Eye;Functional Imaging;Functional disorder;Functional impairment;Ganglion Cell Layer;Goals;Health Care Costs;Histologic;Human;Imaging Device;Imaging technology;Impaired cognition;Infrastructure;Injury;Inner Plexiform Layer;Israel;Lateral Geniculate Body;Link;Magnetic Resonance Imaging;Measures;Medical center;Medicine;Meta-Analysis;Methods;Morphology;Nerve Degeneration;Nerve Fibers;Neurosciences;Nuclear;Occipital lobe;Ophthalmology;Optical Coherence Tomography;Outcome;Pathology;Patients;Perfusion;Phenotype;Photoreceptors;Physiologic Intraocular Pressure;Population;Process;Psychiatry;Psychopathology;Psychoses;Psychotic Disorders;Research;Resolution;Resources;Retina;Retinal Ganglion Cells;Retrograde Degeneration;Role;Schizophrenia;Selection for Treatments;Structural defect;Structure;Structure-Activity Relationship;Symptoms;Synapses;Technology;Testing;Thalamic structure;Thick;Thinness;Time;Tissues;Training;Training Programs;Trans-Synaptic Degeneration;Universities;Visual;Visual Cortex;Visual Pathways;Visual System;Visual impairment;Work;biological research;biomarker validation;brain magnetic resonance imaging;brain volume;cerebral atrophy;clinically relevant;comorbidity;comparison control;cost effective;disabling disease;disease classification;experience;functional loss;ganglion cell;gray matter;imaging approach;imaging study;in vivo;indexing;injured;multidisciplinary;multimodality;neuroimaging;neuropsychiatry;novel;outcome prediction;outer plexiform layer;personalized intervention;psychotic symptoms;responsible research conduct;retinal imaging;retinal nerve fiber layer;structural imaging;therapy resistant;tool;treatment response;venule;vision science;visual processing,Retinal Layer Microvascular and Electroretinographic Determinants of Early Course Schizophrenia,Project NarrativeSchizophrenia is a chronic disorder and is among the most highly disabling diseases in all of medicineimpacting approximately 1.5% of the population. This study will use novel state-of-the-art electroretinographyoptical coherence tomography and angiography imaging to capture retinal biomarkers that informpathophysiology and clinical associations in early course schizophrenia. This study is expected to have animpact on the growing consensus in psychiatry and neuro-ophthalmology that the retina provides a window intothe brain that can be useful for understanding brain pathophysiology and for developing biomarkers of illnessprogression and possibly treatment response.,NIMH,10798201,4/17/2024 12:00:00 AM,PA-19-119,5K23MH122701-04,5,K23,MH,122701,04, ,"CHAVEZ, MARK",4/1/2021 12:00:00 AM,3/31/2025 12:00:00 AM,"Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]", ,15028475,"LIZANO, PAULO L",Not Applicable,07,Unavailable,071723621,C1CPANL3EWK4,071723621,C1CPANL3EWK4,US,42.33982,-71.10568,758101,BETH ISRAEL DEACONESS MEDICAL CENTER,BOSTON,MA,Independent Hospitals,022155400,UNITED STATES,N,4/17/2024 12:00:00 AM,3/31/2025 12:00:00 AM,242,Other Research-Related,2024,192024, ,NIMH,177800,14224, ,192024,,192024.0 | |
| No NIH Category available,3' Untranslated Regions;3-Dimensional;Address;Age related macular degeneration;Architecture;Binding;Biological Assay;Blindness;Cell Cycle;Cell Physiology;Cell Proliferation;Cell Reprogramming;Cells;Cyclin D1;Data;Development;Disease;Disease Progression;Electrophysiology (science);Enzymes;Fishes;Gene Expression;Gene Expression Profile;Generations;Genes;Goals;In Vitro;Ions;Lead;Malignant Neoplasms;Measures;Messenger RNA;MicroRNAs;Molecular;Monitor;Morphology;Muller's cell;Mus;Natural regeneration;Neural Retina;Neuroglia;Neurons;Organism;Pathologic;Photoreceptors;Play;Postdoctoral Fellow;Proliferating;Property;Regenerative Medicine;Regulation;Reporter;Resources;Retina;Retinal Degeneration;Retinal Diseases;Retinitis Pigmentosa;Rod;Role;Source;Supplementation;Testing;Therapeutic Agents;Therapeutic Uses;Tissues;Validation;Visual impairment;Visualization;Work;antagonist;biomarker identification;candidate selection;cell behavior;cell fate specification;cell replacement therapy;cell type;experimental study;in vivo;innovation;overexpression;patch clamp;postnatal;postnatal development;preservation;prevent;programs;repaired;restoration;retinal neuron;retinal progenitor cell;retinal regeneration;retinal rods;retinogenesis;sensor;sight restoration;single-cell RNA sequencing;stem cell therapy;stem cells;therapy development;tool;transcription factor;transplantation therapy,The Role of Retinal Progenitor microRNAs for Late-stage Progenitor Cell State and Muller Glia Reprogramming,PROJECT NARRATIVERetinal diseases lead to visual impairment or blindness and we are in search of approaches to regenerate theretina and restore vision. This project examines microRNAs as key regulators of retinal progenitor cell state andsubsequent neuronal cell fate specification in postnatal retinal development. The results will reveal microRNAcandidates that can not only function as reprogramming factors to convert endogenous retinal glia cells intoneurons but also can serve as therapy to prevent cell degeneration in order to restore or preserve normal retinalfunction.,NEI,10798265,3/1/2024 12:00:00 AM,PA-20-185,5R01EY032532-03,5,R01,EY,032532,03, ,"NEUHOLD, LISA",3/1/2022 12:00:00 AM,2/28/2027 12:00:00 AM,Biology and Development of the Eye Study Section[BDE], ,11498310,"WOHL, STEFANIE G",Not Applicable,12,NONE,152652764,Z8BHM18YGG86,152652764,Z8BHM18YGG86,US,40.752951,-73.978673,5992605,STATE COLLEGE OF OPTOMETRY,NEW YORK,NY,UNIVERSITY-WIDE,100368005,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,867,Non-SBIR/STTR,2024,405000, ,NEI,250000,155000, ,405000,,405000.0 | |
| No NIH Category available,16S ribosomal RNA sequencing;Aftercare;Anti-Inflammatory Agents;Bacteria;Biological Factors;Biological Markers;Brain;Butyrates;Cancer Patient;Cancer Survivor;Clinical;Cognition;Complex;Data;Development;Dietary Fiber;Distress;Eating;Fatigue;Fermentation;Goals;Head and Neck Cancer;High Prevalence;Homeostasis;Human;Human papilloma virus infection;Impaired cognition;Incidence;Individual;Inflammation;Inflammatory;Link;Longitudinal Studies;Malignant Neoplasms;Mass Fragmentography;Mediating;Mental Depression;Mucositis;Mus;Neuropsychology;Oral cavity;Outcome;Pain;Pathway interactions;Patient-Focused Outcomes;Patients;Peripheral;Phase;Phenotype;Plasma;Play;Production;Proteins;Radiation therapy;Regulation;Research;Role;Signal Pathway;Sleep;Sleep Disorders;Symptoms;Time;Transcriptional Regulation;Validation;Volatile Fatty Acids;Work;Xerostomia;active method;blood-brain barrier crossing;cancer therapy;chemoradiation;commensal bacteria;depressive symptoms;dysbiosis;experience;fecal microbiome;gut bacteria;gut microbiome;gut microbiota;gut-brain axis;head and neck cancer patient;high risk;immunoregulation;improved;metagenomic sequencing;microbial;microbiome;neuroinflammation;new therapeutic target;prognostic;protein biomarkers;restoration;side effect;symptom management;targeted treatment;therapeutic target;transcriptome;treatment response;trend,The Role of the Gut Microbiome and Short Chain Fatty Acids in the Regulation of Inflammation and Neuropsychological Symptoms in Patients with Head and Neck Cancer,PROJECT NARRATIVE:Neuropsychological symptoms such as fatigue depressive symptoms cognitive dysfunction sleep problemsand pain are among the most common debilitating and long-lasting side effects from cancer and its treatmentand are prognostic to survival. The proposed research will examine the association between gut microbiomeand neuropsychological symptoms through the role of short chain fatty acids and inflammation in the gut-brainaxis among patients with head and neck cancer receiving radiotherapy. The findings may indicate newbiomarkers and novel therapeutic targets for neuropsychological symptoms in cancer survivors.,NINR,10798341,2/27/2024 12:00:00 AM,PA-20-185,5R01NR020188-03,5,R01,NR,020188,03, ,"TYUS, NADRA",5/9/2022 12:00:00 AM,2/28/2026 12:00:00 AM,"Biobehavioral Mechanisms of Emotion, Stress and Health Study Section[MESH]", ,11439329,"XIAO, CANHUA ","FEDIRKO, VERONIKA ",05,NONE,066469933,S352L5PJLMP8,066469933,S352L5PJLMP8,US,33.791247,-84.3249,2384501,EMORY UNIVERSITY,ATLANTA,GA,SCHOOLS OF NURSING,303221007,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,361,Non-SBIR/STTR,2024,755208, ,NINR,561610,193598, ,755208,,755208.0 | |
| No NIH Category available,Acceleration;Affect;Affinity Chromatography;Alternative Splicing;Automobile Driving;Benchmarking;Biological;Biological Assay;Biological Markers;Biology;Cancer Patient;Cancer cell line;Cell Line;Colorectal Cancer;Communities;Coupled;DNA Sequence Alteration;Data Set;Drug Targeting;Event;Gene Targeting;Genes;Genetic Heterogeneity;Genomic approach;Genotype;Germ-Line Mutation;Immunotherapy;Individual;Joints;Knowledge;Lead;Length;Link;Literature;Malignant Neoplasms;Mass Spectrum Analysis;Mediating;Melanoma;Methods;Mutation;Network-based;Nucleic Acid Regulatory Sequences;Paper;Pathway interactions;Patients;Phenotype;Play;Prevalence;Production;Prognosis;Property;Protein Isoforms;Proteins;Proteomics;Publications;RNA Splicing;Reporting;Resolution;Resources;Role;Sampling;Signal Transduction;Silent Mutation;Somatic Mutation;Surveys;System;Systems Biology;Technology;Tissues;Validation;cancer biomarkers;cancer genome;cancer genomics;cancer heterogeneity;cancer therapy;computer framework;disease model;driver mutation;exome sequencing;genome sequencing;innovation;insight;neoantigens;new therapeutic target;novel;patient population;precision medicine;protein aminoacid sequence;protein expression;protein protein interaction;proteogenomics;synergism;targeted cancer therapy;targeted treatment;transcriptome sequencing;tumor;tumor progression,An integrated functional proteomics platform for accelerated discovery of isoform-specific determinants of cancer,Cancers are highly heterogeneous and the underlying mechanisms are driven in large part through mutationsthat are silent but cause changes to protein isoform expression. This proposal will develop innovative broadlyapplicable technologies to systematically link silent cancer mutations to splicing events and the functionalimpacts of their consequent protein isoforms. Such information will reveal highly specific cancer biomarkersnovel drug targets and systems-biology-driven cancer treatments.,NCI,10798690,2/27/2024 12:00:00 AM,RFA-CA-23-003,1R33CA281919-01A1,1,R33,CA,281919,01,A1,"AMIN, ANOWARUL",3/1/2024 12:00:00 AM,2/28/2027 12:00:00 AM,ZCA1-TCRB-Q(O1), ,10600844,"SHEYNKMAN, GLORIA ","YI, S. STEPHEN ",05,PHYSIOLOGY,065391526,JJG6HU8PA4S5,065391526,JJG6HU8PA4S5,US,38.050527,-78.500531,1526402,UNIVERSITY OF VIRGINIA,CHARLOTTESVILLE,VA,SCHOOLS OF MEDICINE,229044195,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,396,Non-SBIR/STTR,2024,412365, ,NCI,304296,108069, ,412365,,412365.0 | |
| No NIH Category available,Address;Agreement;Attention;Automation;Biological Assay;Biological Markers;Blood;Blood Plasma Volume;Blood Volume;CCR;Cancer Center;Cancer Detection;Cancer Etiology;Cancer Patient;Cellular Phone;Cessation of life;Clinical;Collaborations;DNA;DNA Markers;Detection;Devices;Diagnosis;Diagnostic;Emerging Technologies;Endoscopic Biopsy;Enzyme-Linked Immunosorbent Assay;Fluorescence;Heterogeneity;Hybrids;Immune;Individual;Industry;Laboratories;Letters;Light;Magnetic Resonance Imaging;Malignant Neoplasms;Malignant neoplasm of pancreas;Measurement;Measures;Methods;Microfluidic Microchips;Molecular;Pancreatic Ductal Adenocarcinoma;Patients;Performance;Phenotype;Plasma;Proteins;RNA;Reaction;Research;Resolution;Sampling;Sensitivity and Specificity;Specificity;Staging;Technology;Telecommunications;Testing;Training;United States;Work;biomarker panel;clinical translation;cohort;design;detection limit;detector;diagnostic value;digital;disease diagnosis;disorder control;experimental study;extracellular vesicles;improved;innovation;instrumentation;laboratory equipment;liquid biopsy;microelectronics;molecular diagnostics;multimodality;nano;new technology;operation;precision oncology;prospective;recruit;research clinical testing;screening;single molecule;success;targeted cancer therapy;technology development;technology platform;technology validation;tumor DNA,High Throughput Digital Droplet Assays for Ultrasensitive Multimodal (DNA RNA and Protein) Diagnostics,NarrativeWe propose to develop a new technology to ultrasensitively quantify proteins DNA and singleextracellular vesicles in an integrated device directly in patient blood to address critical issuesin multimodal diagnostics. In collaboration with the Abramson Cancer Center and building onprior work together on multi-modal diagnostics we focus our attention on Pancreaticductal adenocarcinoma -the third leading cause of cancer-related death in the United Stateswith an overall 5-year survival of only 9%. In the proposed work we will develop our technologyto a level of maturity that it can measure multi-modal panels of relevant PDAC biomarkers atultra-high sensitivity high linearity and dynamic range in plasma to diagnose PDAC at earlierstages and to more accurately guide the treatment of patients with PDAC than is currentlypossible.,NCI,10798798,3/7/2024 12:00:00 AM,RFA-CA-23-003,1R33CA287135-01,1,R33,CA,287135,01, ,"MCKEE, TAWNYA C",3/7/2024 12:00:00 AM,2/28/2027 12:00:00 AM,ZCA1-TCRB-Q(O1), ,10223439,"ISSADORE, DAVID AARON",Not Applicable,03,BIOMEDICAL ENGINEERING,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,BIOMED ENGR/COL ENGR/ENGR STA,191046205,UNITED STATES,N,3/7/2024 12:00:00 AM,2/28/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,389746, ,NCI,248999,140747, ,389746,,389746.0 | |
| No NIH Category available,Address;Adoptive Transfer;Adult;B-Cell Lymphomas;B-Lymphocytes;Biological Markers;Biological Models;Cells;Chemoresistance;Classification;Clinical;Complex;Congenic Mice;Cytometry;Data;Development;Elements;Ensure;Gene Expression;Generations;Genetic;Genetic Models;Genetic Variation;Goals;Grant;Hematologic Neoplasms;Histologic;Human;Image;Immune;Immune Targeting;Immune checkpoint inhibitor;Immunohistochemistry;Immunophenotyping;Immunotherapy;In Vitro;Institution;International Prognostic Index;Link;Lymphoma;Malignant Neoplasms;Mediating;Methods;Modeling;Molecular;Molecular Profiling;Monitor;Mus;Mutation;Nature;Non-Hodgkin's Lymphoma;Non-Malignant;Oncogenic;Outcome;Parents;Pathologist;Patient-Focused Outcomes;Patients;Phenotype;Pre-Clinical Model;Preclinical Testing;Prognostic Marker;Publishing;Recurrence;Research;Resolution;Role;Sample Size;Sampling;Structure;Subgroup;Systems Biology;Technology;Testing;Tissues;Tumor Markers;Validation;biomarker identification;cancer cell;cancer type;candidate marker;candidate validation;cohort;exome sequencing;human disease;in vitro Model;in vivo Model;insight;large cell Diffuse non-Hodgkin's lymphoma;mosaic analysis;mouse model;neoplastic cell;next generation;novel;novel strategies;parent grant;parent project;pre-clinical;predictive marker;programmed cell death ligand 1;protein biomarkers;recombinase-mediated cassette exchange;response;standard care;survival prediction;targeted agent;targeted cancer therapy;targeted treatment;transcriptomics;tumor;tumor growth;tumor-immune system interactions,Generation of novel murine B-cell lymphoma models using mosaic analysis by dual recombinase-mediated cassette exchange (MADR) to more closely resemble human B-cell lymphomas,PROJECT NARRATIVEAggressive B cell lymphomas are a very common type of cancer with varied outcomes for patientssome arecured with standard treatment but others are not. The goal of this research is to identify biomarkers that canidentify which patients are likely to be cured and which patients might need new treatments. The biomarkersmay also tell us if certain types of immune targeting therapies would be useful for certain types of patients.,NCI,10799433,1/30/2024 12:00:00 AM,RFA-CA-23-006,3R01CA266544-02S1,3,R01,CA,266544,02,S1,"BHARTI, SANITA",8/1/2022 12:00:00 AM,7/31/2027 12:00:00 AM,ZCA1-TCRB-5(O2), ,7648857,"MERCHANT, AKIL ",Not Applicable,30,Unavailable,075307785,NCSMA19DF7E6,075307785,NCSMA19DF7E6,US,34.076544,-118.380004,1225501,CEDARS-SINAI MEDICAL CENTER,LOS ANGELES,CA,Independent Hospitals,900481804,UNITED STATES,N,1/1/2024 12:00:00 AM,7/31/2024 12:00:00 AM,394,Non-SBIR/STTR,2024,118869, ,NCI,71179,47690, ,118869,,118869.0 | |
| No NIH Category available,Achievement;Automobile Driving;Biological Markers;Cancer Patient;Cancer Prognosis;Clinical;Clinical Treatment;Code;Computer Models;Data;Decision Making;Dimensions;Disease;Disease Progression;Family;Future;Genes;Genetic;Goals;HPV oropharyngeal cancer;Habitats;Head and Neck Cancer;Heterogeneity;Human Papillomavirus;Image;Imaging Techniques;Incidence;International;Machine Learning;Medical Imaging;Methodology;MicroRNAs;Modeling;Nature;Oncogenic;Oropharyngeal Neoplasms;Oropharyngeal Squamous Cell Carcinoma;Outcome;Patients;Phenotype;Play;Prognosis;Prognostic Marker;Proteins;Research;Retrospective Studies;Risk;Role;Site;Survival Rate;Techniques;Testing;Therapeutic;Treatment Failure;Treatment outcome;Uncertainty;United States;Untranslated RNA;Validation;Variant;biomarker identification;cancer biomarkers;cancer epidemiology;cancer therapy;cancer type;clinical application;clinical biomarkers;clinical decision-making;clinically relevant;cohort;effective therapy;high dimensionality;high risk;imaging biomarker;improved;individualized medicine;malignant oropharynx neoplasm;microRNA biomarkers;mortality risk;multimodality;non-invasive imaging;novel;outcome prediction;patient biomarkers;patient prognosis;patient stratification;patient subsets;precision oncology;predictive modeling;prognostic;prognostic model;prognostic value;response;tool;treatment strategy;tumor,Multimodal Biomarkers For Oropharyngeal Cancer,NarrativeThe achievement of this project forms a basis of combining non-invasive imaging biomarkers with miRNAsHPV clinical and histopathologic biomarkers for accurate cancer prognosis and discovering the correlationwith genetic mechanisms leading to specific tumor phenotypes. This clinical decision-making tool can provideuseful information to support patient stratification and individualized treatment. We anticipate that many of themethodological improvements established in this proposal will improve oropharyngeal squamous cellcarcinoma treatment and tumor response assessment and treatment in other disease sites as well.,NCI,10799539,11/28/2023 12:00:00 AM,PA-18-484,5R01CA233873-06,5,R01,CA,233873,06, ,"TANDON, PUSHPA",2/1/2022 12:00:00 AM,11/30/2025 12:00:00 AM,Biomedical Computing and Health Informatics Study Section[BCHI], ,9017498,"LI, HUA ",Not Applicable,01,RADIATION-DIAGNOSTIC/ONCOLOGY,068552207,L6NFUM28LQM5,068552207,L6NFUM28LQM5,US,38.664368,-90.323797,9083901,WASHINGTON UNIVERSITY,SAINT LOUIS,MO,SCHOOLS OF MEDICINE,631304862,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,369462, ,NCI,294890,74572, ,369462,,369462.0 | |
| No NIH Category available,16S ribosomal RNA sequencing;Acceleration;Anaerobic Bacteria;Anatomy;Antibiotic Therapy;Antibiotics;Atherosclerosis;Bacteria;Big Data;Big Data Methods;Biological;Biometry;COVID-19 pandemic;Caring;Cefepime;Cessation of life;Circulation;Cirrhosis;Clinical;Clinical Data;Clinical Management;Clinical Research;Clinical Sciences;Clinical Treatment;Communicable Diseases;Communities;Computerized Medical Record;Data;Data Analyses;Development;Disease;Enterobacteriaceae;Enterobacteriaceae Infections;Environment;Foundations;Future;Goals;Growth;Health;Hospitalization;Immune response;Immunologics;Infection;Inflammation;Interleukin-6;International;Intestinal permeability;Intestines;Knowledge;Learning;Length of Stay;Malignant Neoplasms;Master of Science;Measures;Mentors;Mentorship;Metabolic;Methods;Michigan;Modeling;Molecular;Natural experiment;Nosocomial Infections;Organ;Outcome;Pathogenicity;Patients;Pharmaceutical Preparations;Physicians;Physiological;Physiology;Piperacillin-Tazobactam;Positioning Attribute;Prospective Studies;Prospective cohort study;Publishing;Research;Research Design;Research Infrastructure;Research Personnel;Research Priority;Resources;Retrospective cohort study;Sampling;Serum;Shock;Site;Skin;Statistical Methods;Techniques;Testing;Time;Training;Training Support;Translating;Translational Research;Universities;Upper respiratory tract;Veterans;Work;antimicrobial;biomarker validation;career development;clinical center;data warehouse;digital;experience;gut microbiome;host microbiome;improved;intestinal fatty acid binding protein;lipopolysaccharide-binding protein;microbiome;microbiome composition;microbiome research;microbiota;mortality;patient oriented;prospective;research and development;skills;systemic inflammatory response;translational pipeline;treatment optimization,Impact of anti-anaerobic antibiotics on clinical outcomes and the microbiome in hospitalized Veterans,Thousands of hospitalized Veterans receive inappropriate antibiotic treatment with a class of antibiotics knownas anti-anaerobic antibiotics. Recent research suggests that this class of antibiotics is particularly disruptiveto the gut microbiome and that this disruption may increase mortality in hospitalized Veterans. This proposalwill use a big-data analysis of electronic medical record data to determine if anti-anaerobic antibiotics mayincrease mortality in hospitalized Veterans. It will also look at the impact of anti-anaerobic antibiotics on themicrobiome and inflammation in hospitalized Veterans. As a result of this research physicians can make betterdecisions about their antibiotic use and avoid harm related to antibiotic treatment. This research will alsosupport the training and development of Dr. Rishi Chanderraj a VA researcher who will combine big-dataanalysis advanced statistical methods and molecular techniques to improve our understanding of the impactof antibiotic treatment on the microbiome and Veteran health.,VA,10799973,4/9/2024 12:00:00 AM,RFA-CX-23-023,1IK2CX002766-01,1,IK2,CX,002766,01, , ,3/1/2024 12:00:00 AM,2/28/2029 12:00:00 AM,ZRD1-INFB-K(01), ,15262761,"CHANDERRAJ, RISHI ",Not Applicable,06,Unavailable,096318480,EM8LUADP6D31,096318480,EM8LUADP6D31,US,42.286121,-83.716708,481045,VETERANS HEALTH ADMINISTRATION,ANN ARBOR,MI,Independent Hospitals,481052303,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,999,Other,2024, , , , , , , ,, | |
| No NIH Category available,Address;Adipose tissue;Adult;Algorithms;American;American Heart Association;Assessment tool;Atherosclerosis;Biological Markers;Black race;Body Composition;Body mass index;Calcium;Cardiology;Cardiovascular system;Categories;Cause of Death;Cessation of life;Chest;Clinic;Clinical;Clinical Data;Computerized Medical Record;Coronary;Data;Data Element;Dedications;Dependence;Equation;Ethnic Origin;Event;Future;Gender;Goals;Graph;Health system;Image;Individual;Manuals;Methods;Minority Groups;Modeling;Morbidity - disease rate;Myocardial Infarction;Myocardial Ischemia;Nature;Obesity;Patients;Performance;Population;Population Heterogeneity;Prevention;Prevention strategy;Preventive;Preventive therapy;Primary Prevention;Prognostic Marker;Race;Recommendation;Reporting;Risk;Risk Assessment;Risk Estimate;Scanning;Scientist;Semantics;Site;Skeletal Muscle;Slice;Stroke;Techniques;Technology;Therapeutic;Thoracic aorta;Training;United States;Universities;Validation;Visceral;Work;X-Ray Computed Tomography;cardiovascular disorder risk;chest computed tomography;clinical practice;cohort;college;coronary artery calcium;deep learning;deep learning model;demographics;design;experience;experimental study;falls;imaging Segmentation;imaging biomarker;insurance plan;middle age;minority patient;mortality;multidisciplinary;multimodality;muscle form;novel;patient population;patient screening;predictive tools;preventive intervention;prognostic;prognostic performance;racial bias;radiologist;risk prediction;risk prediction model;risk stratification;screening;social health determinants;subcutaneous;tool,Opportunistic Screening for ASCVD using a Multimodal Deep Learning Risk Prediction Model,PROJECT NARRATIVERoutine chest CT examinations contain prognostic information that is often underutilized for its value in primaryprevention of atherosclerotic cardiovascular disease (ASCVD) leaving missed opportunities for incidentalscreening to predict future cardiovascular events such as heart attack and stroke. Current risk assessment toolssuch as Pooled Cohort Equations (PCE) are poor predictors of ASCVD due to data limitations most notably thestatic nature of the data and lack of model complexity resulting in misestimation in minority groups. A graph-based multimodal fusion model that integrates imaging and electronic medical record data is essential toaddressing the data limitations of outdated tools and creating more sophisticated technology that supportsopportunistic screening of a larger more diverse population of patients as well as earlier prevention strategiesand therapeutics.,NHLBI,10800203,12/11/2023 12:00:00 AM,PA-20-185,1R01HL167811-01A1,1,R01,HL,167811,01,A1,"ANAYA, GABRIEL",12/15/2023 12:00:00 AM,11/30/2028 12:00:00 AM,Clinical Informatics and Digital Health Study Section[CIDH], ,6665396,"PATEL, BHAVIK NATVAR","GICHOYA, JUDY ",01,Unavailable,153665211,ULMJJBL7ZXX3,153665211,ULMJJBL7ZXX3,US,33.589113,-111.79394,4976104,MAYO CLINIC ARIZONA,SCOTTSDALE,AZ,Other Domestic Non-Profits,852595499,UNITED STATES,N,12/15/2023 12:00:00 AM,11/30/2024 12:00:00 AM,837,Non-SBIR/STTR,2024,698520, ,NHLBI,501434,197086, ,698520,,698520.0 | |
| No NIH Category available,Affect;Africa;African;African ancestry;Antibiotic Therapy;Antimycobacterial Agents;Antisense Oligonucleotide Therapy;Antisense Oligonucleotides;Automobile Driving;Bioinformatics;Biology;Cessation of life;Code;Communicable Diseases;Data;Development;Disease;Drug Targeting;Elements;Epigenetic Process;Gene Expression;Generations;Genes;Genetic;Genetic Transcription;Genome;Genotype;Goals;Growth;Heritability;Heterogeneity;Host Defense;Host resistance;Human;Immune response;Investigation;Knowledge;Macrophage;MicroRNAs;Multidrug Resistance Induction;Mycobacterium tuberculosis;Outcome;Partner in relationship;Pathogenesis;Pathogenicity;Pathway interactions;Patients;Pharmaceutical Preparations;Pharmacotherapy;Population;Predisposition;Public Health;Publishing;Quantitative Trait Loci;RNA;Research;Resources;Role;Sampling;Shapes;Site;South Africa;South African;Southern Africa;System;Systems Biology;Techniques;Testing;Transcript;Tuberculosis;Uganda;Untranslated RNA;Validation;Variant;antimicrobial;chronic infection;cohort;design;diagnostic biomarker;differential expression;gene interaction;genetic architecture;genetic variant;human disease;in silico;inter-individual variation;knock-down;loss of function;monocyte;multidimensional data;mycobacterial;novel;novel therapeutic intervention;pathogen;resilience;response;targeted delivery;transcriptome;transcriptomics;treatment strategy;tuberculosis treatment,Targeting non-coding RNAs as host-directed drug therapy for tuberculosis,NARRATIVEMycobacterium tuberculosis (Mtb) the causative agent of tuberculosis (TB) causes 1.6 million deaths peryear globally and thus there is an urgent need to develop new treatment approaches. Our proposed researchis significant to public health because a better understanding of the host non-coding RNA landscape drivingsusceptibility to tuberculosis disease could lead to the development of better diagnostic biomarkers andadjunctive host-that seeks fundamental knowledge on the causes of pathogenicity that helps to reduce the burden of humandiseases.,NIAID,10800676,4/10/2024 12:00:00 AM,PAR-20-108,5R01AI160501-04,5,R01,AI,160501,04, ,"ROBINSON, RICHARD THOMAS",4/19/2021 12:00:00 AM,3/31/2026 12:00:00 AM,Clinical Research and Field Studies of Infectious Diseases Study Section[CRFS], ,10886813,"GULER, RETO ","HIDE, WINSTON ALEXANDER",,Unavailable,568227214,NN5NML6VUCF9,568227214,NN5NML6VUCF9,SF,-33.96333,18.47639,1147601,UNIVERSITY OF CAPE TOWN,RONDEBOSCH, ,Unavailable,7700,SOUTH AFRICA,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,131718, ,NIAID,124766,6952, ,131718,,131718.0 | |
| No NIH Category available,3-Dimensional;Aortic Valve Stenosis;Big Data;Biological Markers;Cardiac;Chronic Obstructive Pulmonary Disease;Clinical;Clinical Data;Clinical Trials;Code;Communities;Complex;Computer software;Data;Development;Diabetes Mellitus;Diagnosis;Diagnostic;Dimensions;Disease;Disparate;EFRAC;Economic Burden;Electronic Health Record;Environmental Risk Factor;Failure;Goals;Heart;Heart failure;Hospitalization;Hypertension;Image;Image Analysis;Knowledge;Laboratories;Learning;Life Style;Machine Learning;Magnetic Resonance;Malignant Neoplasms;Measurement;Methods;Modeling;Morbidity - disease rate;Morphology;Nature;Obesity Epidemic;Organ;Outcome;Patient imaging;Patients;Performance;Pharmaceutical Preparations;Phenotype;Physicians;Pilot Projects;Population;Prevalence;Procedures;Prognosis;Psychological reinforcement;Public Health;Publishing;Quality of life;Radiology Specialty;Recommendation;Recording of previous events;Reporting;Research;Resources;Sepsis;Series;Source Code;Surface;Symptoms;Syndrome;Techniques;Therapeutic;Treatment Efficacy;Validation;Work;aging population;automated analysis;biomarker identification;cardiac magnetic resonance imaging;clinical decision support;clinical efficacy;clinical investigation;clinically significant;comorbidity;computerized data processing;deep learning;deep reinforcement learning;effective therapy;electronic health information;feature extraction;heart imaging;image processing;imaging biomarker;improved;individualized medicine;lifestyle factors;longitudinal analysis;magnetic resonance imaging biomarker;mortality;multimodality;novel;novel therapeutics;open data;optimal treatments;personalized medicine;preservation;reconstruction;recurrent neural network;risk stratification;shape analysis;symposium;targeted treatment;treatment optimization;treatment planning;treatment strategy;trend,Deep learning Based Phenotyping and Treatment Optimization for Heart Failure with Preserved Ejection Fraction,PROJECT NARRATIVEHeart failure with preserved ejection fraction is a major public health problem that is rising in prevalence with theaging population. By performing deep phenotyping of the patients from their Cardiac Magnetic Resonanceimages and Electronic Health Record simultaneously we aim to provide phenotypic-specific individualizedtreatment optimization based on the current massive amount of clinical data using deep learning.,NHLBI,10800686,2/27/2024 12:00:00 AM,PA-20-185,5R01HL159183-03,5,R01,HL,159183,03, ,"FARAHANI, KEYVAN",3/15/2022 12:00:00 AM,2/28/2026 12:00:00 AM,Clinical Data Management and Analysis Study Section[CDMA], ,9340938,"LI, QUANZHENG ",Not Applicable,08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,837,Non-SBIR/STTR,2024,578505, ,NHLBI,344348,234157, ,578505,,578505.0 | |
| No NIH Category available,10 year old;17 year old;18 year old;Adrenal Cortex Hormones;Adverse event;Age of Onset;Antibodies;Biological;Biological Markers;Biological Products;Caring;Child;Chronic;Chronic Disease;Clinical;Clinical Trials;Computer software;Crohn's disease;Data;Development;Disease;Disease remission;Dose;Drug Exposure;Drug Kinetics;Drug Monitoring;Drug Targeting;Drug usage;Effectiveness;Enrollment;Exposure to;Flare;Fostering;Goals;Growth;Hospitalization;Immunosuppressive Agents;Incidence;Individual;Intervention;Intestines;Kidney Transplantation;Label;Leukocyte L1 Antigen Complex;Logistics;Maintenance;Maintenance Therapy;Measures;Modeling;Modification;Monitor;Monoclonal Antibodies;Natural History;North America;Online Systems;Operative Surgical Procedures;Outcome;Patients;Pediatric Crohn's disease;Pharmaceutical Preparations;Pharmacodynamics;Phase;Physicians;Population;Prednisone;Publishing;Quality of life;Randomized;Randomized Controlled Trials;Recurrent disease;Regimen;Relapse;Reporting;Risk;Serum;Severities;Statistical Computing;Symptoms;TNF gene;Testing;Therapeutic;Treatment Failure;United States Food and Drug Administration;Validation;adalimumab;arm;clinical decision support;clinical remission;cohort;conventional dosing;dashboard;drug clearance;early adolescence;gastrointestinal symptom;gut inflammation;healing;improved;improved outcome;infliximab;innovation;learning progression;multidisciplinary;neutrophil;novel;novel therapeutics;patient population;peripheral blood;pharmacodynamic biomarker;pharmacokinetic model;pharmacokinetics and pharmacodynamics;pragmatic implementation;randomized clinical trials;response;support tools;treatment arm;young adult,Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease,Project NarrativeCrohn's disease is a chronic remitting and relapsing illness that results in intestinal inflammation unwantedgastrointestinal symptoms and can lead to serious complications including surgery hospitalizations growthdelays and poor quality of life. As there are limited treatment options approved for use in children and relapsesare common we will conduct a cluster-randomized clinical trial in children and young adults with moderate tosevere Crohn's disease starting infliximab (anti-TNF). We will assess patient reported and disease modifyingoutcomes (endoscopic healing) between patients who received infliximab using an innovative precision dosingstrategy (treat-to-target) and those who received infliximab with the conventional dosing approach.,NIDDK,10800687,5/3/2024 12:00:00 AM,PA-20-183,5R01DK132408-03,5,R01,DK,132408,03, ,"LOH, KATRINA SHUEH WEN",6/1/2022 12:00:00 AM,3/31/2027 12:00:00 AM,"Digestive System Host Defense, Microbial Interactions and Immune and Inflammatory Disease Study Section[DHMI]", ,11100620,"MINAR, PHILLIP P",Not Applicable,01,Unavailable,071284913,JZD1HLM2ZU83,071284913,JZD1HLM2ZU83,US,39.140663,-84.501007,615001,CINCINNATI CHILDRENS HOSP MED CTR,CINCINNATI,OH,Independent Hospitals,452293039,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,847,Non-SBIR/STTR,2024,642469, ,NIDDK,482954,159515, ,642469,,642469.0 | |
| No NIH Category available,Biochemical;Biological;Biological Factors;Biological Markers;Biomechanics;Body Weight decreased;Cadaver;Caring;Cartilage;Cells;Characteristics;Clinical;Cluster Analysis;Computer Models;Data;Degenerative polyarthritis;Development;Dinoprostone;Environment;Flow Cytometry;Future;Goals;Health;Image;Immune;Individual;Inflammation Mediators;Inflammatory;Joints;Knee;Knee Osteoarthritis;Lateral;Lead;Machine Learning;Macrophage;Magnetic Resonance Imaging;Maps;Matrix Metalloproteinases;Measures;Medial;Medial meniscus structure;Meniscus structure of joint;Metabolic;Methods;Nonpharmacologic Therapy;Operative Surgical Procedures;Orthopedic Procedures;Participant;Pathway interactions;Patient-Focused Outcomes;Patients;Pharmacologic Substance;Phenotype;Physical Rehabilitation;Physical therapy;Play;Procedures;Public Health;Risk;Roentgen Rays;Role;Serum;Speed;Subgroup;Synovial Fluid;Techniques;Thick;Time;Tissues;Validation;Walking;articular cartilage;biomechanical test;cartilage degradation;clinical phenotype;demographics;disability;early onset;high risk;imaging biomarker;improved;improved outcome;in vivo;joint destruction;joint inflammation;joint injury;meniscus injury;predictive modeling;prevent;primary outcome;radiological imaging;random forest;rehabilitation strategy;response;targeted treatment;three-dimensional modeling;treadmill,Biomechanical and Biological Predictors of Cartilage Health Following Meniscus Injury,Project NarrativeMeniscus injuries are very common and frequently lead to early onset osteoarthritis a leading cause of disability.This project will identify biomechanical and biological predictors of cartilage degeneration after meniscus injuryand partial meniscectomy. Our findings will be utilized to improve care and outcomes for patients suffering frommeniscus injuries.,NIAMS,10800712,3/29/2024 12:00:00 AM,PA-20-185,5R01AR079184-04,5,R01,AR,079184,04, ,"ZHENG, XINCHENG",4/5/2021 12:00:00 AM,3/31/2026 12:00:00 AM,Musculoskeletal Rehabilitation Sciences Study Section[MRS], ,8190828,"MCNULTY, AMY L","DEFRATE, LOUIS E.; GOODE, ADAM ",04,ORTHOPEDICS,044387793,TP7EK8DZV6N5,044387793,TP7EK8DZV6N5,US,36.007766,-78.926475,2221101,DUKE UNIVERSITY,DURHAM,NC,SCHOOLS OF MEDICINE,277054673,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,846,Non-SBIR/STTR,2024,649601, ,NIAMS,403479,246122, ,649601,,649601.0 | |
| No NIH Category available,Academic Medical Centers;Ally;American College of Surgeons Oncology Group;Basic Science;Bioinformatics;Biological Markers;Cancer Patient;Cancer Therapy Evaluation Program;Cancer and Leukemia Group B;Cessation of life;Clinic;Clinical;Clinical Research;Clinical Trials;Clinical Trials Design;Collaborations;Community Practice;Computer software;Conduct Clinical Trials;Correlative Study;Data;Data Collection;Data Coordinating Center;Development;Discipline;Ensure;Evaluation;Faculty;Goals;Information Systems;Information Technology;Infrastructure;International;Leadership;Location;Manuscripts;Medical;Medidata;Meta-Analysis;Methodology;Methods;Mission;Monitor;North Central Cancer Treatment Group;Oncologist;Oncology;Oncology Group;Operative Surgical Procedures;Paper;Pathologist;Patients;Phase I Clinical Trials;Policies;Positioning Attribute;Precision Medicine Initiative;Preparation;Procedures;Process;Publications;Publishing;Radiation;Randomized;Regulation;Reporting;Research;Research Personnel;Resource Allocation;Retrospective Studies;Sample Size;Scheme;Science;Scientist;Secure;Source;Statistical Methods;Structure;Support System;Surrogate Endpoint;System;Technology;Time;Training Programs;Translational Research;Translations;United States;anti-cancer research;cancer clinical trial;clinical practice;data centers;data management;data quality;data sharing;design;editorial;electronic data;flexibility;follow-up;genomic biomarker;genomic predictors;improved outcome;individual patient;innovation;instrument;member;novel;novel therapeutics;operation;programs;prospective;quality assurance;radiologist;statistical center;statistics;timeline;tool;treatment trial,Alliance Statistics and Data Management Center,Alliance Statistics and Data Management CenterPROJECT NARRATIVEThe Alliance Statistics and Data Management Center is responsible for the statisticaldata management and information technology activities that support the scientificagenda of the Alliance for Clinical Trials in Oncology a national cancer researchorganization. Successful execution of these activities had led to and will continue to leadto the translation of basic and clinical research into trials of new therapies that have thepotential to change clinical practice resulting in improved outcomes for cancer patientsworld-wide.,NCI,10800739,2/19/2024 12:00:00 AM,RFA-CA-17-057,5U10CA180882-11,5,U10,CA,180882,11, ,"MOONEY, MARGARET M",4/17/2014 12:00:00 AM,2/28/2025 12:00:00 AM,ZCA1-GRB-S(O1), ,7992524,"MANDREKAR, SUMITHRA JAY",Not Applicable,1.0,Unavailable,006471700,Y2K4F9RPRRG7,006471700,Y2K4F9RPRRG7,US,44.02432,-92.46011,4976101,MAYO CLINIC ROCHESTER,ROCHESTER,MN,Other Domestic Non-Profits,559050001,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,395,Other Research-Related,2024,8068048, ,NCI,5249512,2818536, ,8068048,,8068048.0 | |
| No NIH Category available,American College of Surgeons Oncology Group;Basic Science;Bioinformatics;Biological Markers;Cancer Patient;Cancer and Leukemia Group B;Cessation of life;Clinic;Clinical Research;Clinical Trials;Clinical Trials Design;Collaborations;Computer software;Correlative Study;Data;Data Coordinating Center;Development;Evaluation;Faculty;Information Systems;Information Technology;Infrastructure;International;Leadership;Location;Manuscripts;Medidata;Methodology;Methods;Mission;Monitor;North Central Cancer Treatment Group;Oncology;Oncology Group;Paper;Patients;Phase I Clinical Trials;Positioning Attribute;Precision Medicine Initiative;Preparation;Procedures;Publications;Publishing;Reporting;Retrospective Studies;Source;Surrogate Endpoint;System;Technology;Translations;anti-cancer research;cancer clinical trial;clinical practice;data management;data quality;editorial;follow-up;genomic biomarker;genomic predictors;improved outcome;individual patient;innovation;member;novel;novel therapeutics;operation;programs;prospective;statistics;timeline;tool;treatment trial,Administrative Core,The Alliance Statistics and Data Management Center is responsible for the statisticaldata management and information technology activities that support the scientificagenda of the Alliance for Clinical Trials in Oncology a national cancer researchorganization. Successful execution of these activities had led to and will continue to leadto the translation of basic and clinical research into trials of new therapies that have thepotential to change clinical practice resulting in improved outcomes for cancer patientsworld-wide.,NCI,10800744,2/19/2024 12:00:00 AM,RFA-CA-17-057,5U10CA180882-11,5,U10,CA,180882,11, , ,4/17/2014 12:00:00 AM,2/28/2025 12:00:00 AM,ZCA1-GRB-S,5825,7992524,"MANDREKAR, SUMITHRA JAY",Not Applicable,1.0,Unavailable,006471700,Y2K4F9RPRRG7,006471700,Y2K4F9RPRRG7,US,44.02432,-92.46011,4976101,MAYO CLINIC ROCHESTER,ROCHESTER,MN,Other Domestic Non-Profits,559050001,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Other Research-Related,2024, ,477862, ,299532,178330, , ,, | |
| No NIH Category available,American College of Surgeons Oncology Group;Basic Science;Bioinformatics;Biological Markers;Cancer Patient;Cancer and Leukemia Group B;Cessation of life;Clinic;Clinical Research;Clinical Trials;Clinical Trials Design;Collaborations;Computer software;Correlative Study;Data;Data Collection;Data Coordinating Center;Development;Evaluation;Experimental Designs;Faculty;Information Systems;Information Technology;Infrastructure;International;Leadership;Location;Manuscripts;Medidata;Methodology;Methods;Mission;Monitor;North Central Cancer Treatment Group;Oncology;Oncology Group;Paper;Patients;Phase I Clinical Trials;Positioning Attribute;Precision Medicine Initiative;Preparation;Process;Publications;Publishing;Randomized;Reporting;Research;Retrospective Studies;Sample Size;Scheme;Source;Surrogate Endpoint;System;Technology;Translations;Validation;anti-cancer research;cancer clinical trial;clinical practice;data management;data quality;design;editorial;follow-up;genomic biomarker;genomic predictors;improved outcome;individual patient;innovation;member;multidimensional data;novel;novel therapeutics;prospective;statistics;timeline;tool;treatment trial,Statistics Core,The Alliance Statistics and Data Management Center is responsible for the statisticaldata management and information technology activities that support the scientificagenda of the Alliance for Clinical Trials in Oncology a national cancer researchorganization. Successful execution of these activities had led to and will continue to leadto the translation of basic and clinical research into trials of new therapies that have thepotential to change clinical practice resulting in improved outcomes for cancer patientsworld-wide.,NCI,10800748,2/19/2024 12:00:00 AM,RFA-CA-17-057,5U10CA180882-11,5,U10,CA,180882,11, , ,4/17/2014 12:00:00 AM,2/28/2025 12:00:00 AM,ZCA1-GRB-S,5827,7992524,"MANDREKAR, SUMITHRA JAY",Not Applicable,01,Unavailable,006471700,Y2K4F9RPRRG7,006471700,Y2K4F9RPRRG7,US,44.02432,-92.46011,4976101,MAYO CLINIC ROCHESTER,ROCHESTER,MN,Other Domestic Non-Profits,559050001,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Other Research-Related,2024, ,3441114, ,2349269,1091845, , ,, | |
| No NIH Category available,American College of Surgeons Oncology Group;Basic Science;Bioinformatics;Biological Markers;Cancer Patient;Cancer and Leukemia Group B;Cessation of life;Clinic;Clinical Research;Clinical Trials;Clinical Trials Design;Collaborations;Computer software;Correlative Study;Data;Data Collection;Data Coordinating Center;Development;Ensure;Evaluation;Faculty;Information Systems;Information Technology;Infrastructure;International;Leadership;Location;Manuscripts;Medidata;Methodology;Methods;Mission;Monitor;North Central Cancer Treatment Group;Oncology;Oncology Group;Paper;Patients;Phase I Clinical Trials;Policies;Positioning Attribute;Precision Medicine Initiative;Preparation;Procedures;Process;Publications;Publishing;Regulation;Reporting;Retrospective Studies;Secure;Source;Support System;Surrogate Endpoint;System;Technology;Training Programs;Translational Research;Translations;anti-cancer research;cancer clinical trial;clinical practice;data management;data quality;design;editorial;electronic data;follow-up;genomic biomarker;genomic predictors;improved outcome;individual patient;innovation;instrument;member;novel;novel therapeutics;prospective;quality assurance;statistics;timeline;tool;treatment trial,Data Management Core,The Alliance Statistics and Data Management Center is responsible for the statisticaldata management and information technology activities that support the scientificagenda of the Alliance for Clinical Trials in Oncology a national cancer researchorganization. Successful execution of these activities had led to and will continue to leadto the translation of basic and clinical research into trials of new therapies that have thepotential to change clinical practice resulting in improved outcomes for cancer patientsworld-wide.,NCI,10800753,2/19/2024 12:00:00 AM,RFA-CA-17-057,5U10CA180882-11,5,U10,CA,180882,11, , ,4/17/2014 12:00:00 AM,2/28/2025 12:00:00 AM,ZCA1-GRB-S,5829,7992524,"MANDREKAR, SUMITHRA JAY",Not Applicable,1.0,Unavailable,006471700,Y2K4F9RPRRG7,006471700,Y2K4F9RPRRG7,US,44.02432,-92.46011,4976101,MAYO CLINIC ROCHESTER,ROCHESTER,MN,Other Domestic Non-Profits,559050001,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Other Research-Related,2024, ,4149072, ,2600711,1548361, , ,, | |
| No NIH Category available,Address;Adult;Age;Alcohol Phenotype;Alcohol consumption;Alcohols;Behavior;Behavioral;Biological;Brain;Cellular Phone;Characteristics;Chronic;Circadian Rhythms;Classification;Clinical;Communication;Computers;Cost Analysis;Dairying;Data;Data Collection;Development;Diagnosis;Digital biomarker;Dimensions;Disease;Distal;Environment;Equation;Ethnic Origin;Factor Analysis;Functional disorder;Goals;Heavy Drinking;Heterogeneity;Hour;Incidence;Individual Differences;Intervention;Longitudinal Studies;Machine Learning;Maps;Measurement;Measures;Mental disorders;Methods;Modeling;National Institute of Mental Health;National Institute on Alcohol Abuse and Alcoholism;Neurobiology;Neuropsychology;Online Systems;Outcome;Participant;Patient Self-Report;Persons;Phenotype;Population;Precision Medicine Initiative;Prediction of Response to Therapy;Psychiatry;Public Health;Questionnaires;Race;Recommendation;Reporting;Research;Research Domain Criteria;Risk;Science;Sleep;Social Processes;Statistical Models;Surveys;Symptoms;System;Targeted Research;Telephone;Testing;Translating;Treatment outcome;Work;World Health Organization;addiction;alcohol misuse;alcohol related consequences;alcohol research;alcohol risk;alcohol use disorder;circadian;clinical heterogeneity;college;cost;deter alcohol use;diagnostic strategy;diaries;digital;digital data;disorder risk;drinking;emotional functioning;executive function;follow-up;improved;incentive salience;innovation;neurobehavioral;novel;precision medicine;psychologic;sensor;sensor technology;sex;social;time use;transition to adulthood;treatment response;validation studies;young adult;young adult alcohol use,Deep Phenotyping of Heavy Drinking in Young Adults with Behavioral Scales Neuropsychological Tasks and Smartphone Sensing Technology,PUBLIC HEALTH NARRATIVEThis study seeks to better characterize the longitudinal variability in heavy drinking and alcohol use disorder risk in young adults via a multimethod approach that takes advantage of the latest innovations in web-based neuropsychological assessment smartphone sensing and machine learning and statistical modeling. The results will help advance alcohol use disorder precision medicine initiatives targeting this vulnerable developmental transition from adolescence to adulthood.,NIAAA,10800805,12/13/2023 12:00:00 AM,PA-20-185,5R01AA030136-02,5,R01,AA,030136,02, ,"ZHA, WENXING",3/5/2023 12:00:00 AM,12/31/2027 12:00:00 AM,Adult Psychopathology and Disorders of Aging Study Section[APDA], ,8619862,"FUCITO, LISA M","DEMARTINI, KELLY S",03,PSYCHIATRY,043207562,FL6GV84CKN57,043207562,FL6GV84CKN57,US,41.310925,-72.926428,9420201,YALE UNIVERSITY,NEW HAVEN,CT,SCHOOLS OF MEDICINE,065208327,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,273,Non-SBIR/STTR,2024,657555, ,NIAAA,458577,198978, ,657555,,657555.0 | |
| No NIH Category available,Acute;Admission activity;Affect;Aftercare;Algorithms;Anatomy;Angiography;Area;Arizona;Blood Vessels;Blood flow;Brain;Brain Edema;Brain hemorrhage;Brain imaging;Brain region;Bypass;Cause of Death;Cerebrovascular Circulation;Cerebrovascular Disorders;Cerebrovascular system;Cessation of life;Clinical;Clinical Trials;Collateral Circulation;Complex;Data;Data Set;Databases;Development;Diagnosis;Diameter;Distal;Elasticity;Evaluation;Family;Functional disorder;Future;Geometry;Goals;Hemorrhage;Hour;Image;Infarction;Intravenous;Investigation;Ischemia;Ischemic Stroke;Knowledge;Lasso;Length;Longterm Follow-up;Machine Learning;Magnetic Resonance Angiography;Malignant - descriptor;Measures;Medical;Modeling;Morphology;National Institute of Biomedical Imaging and Bioengineering;National Institute of Neurological Disorders and Stroke;Operative Surgical Procedures;Outcome;Pathway interactions;Patient Selection;Patients;Pattern;Pennsylvania;Performance;Population;Prediction of Response to Therapy;Prospective cohort;Provider;Race;Recurrence;Regional Perfusion;Reperfusion Therapy;Risk;Role;Scanning;Site;Specific qualifier value;Stroke;Surgical Decompression;System;Texas;Time;Tissues;Training;Validation;Variant;Vascular blood supply;algorithmic bias;automated algorithm;cerebrovascular;clinical biomarkers;cohort;convolutional neural network;data harmonization;demographics;disability;endovascular thrombectomy;functional outcomes;imaging biomarker;improved;improved outcome;indexing;machine learning algorithm;metropolitan;neural network algorithm;outcome prediction;post stroke;predicting response;prediction algorithm;predictive modeling;prospective;radiological imaging;recruit;response;restoration;sex;stroke outcome;stroke patient;stroke risk;stroke therapy;thrombolysis;treatment response,Dynamic cerebrovascular morphology changes in acute ischemic stroke,PROJECT NARRATIVEThe objective of this proposal is to develop a fully automatic algorithm to extract geometric features from brainvessels of stroke patients in real-time and the effects of ischemic stroke on vascular alterations. We will usethese features to improve the prediction of major complications and long-term outcomes after stroke and acutereperfusion therapies.,NINDS,10801086,4/18/2024 12:00:00 AM,PA-20-184,1R01NS131554-01A1,1,R01,NS,131554,01,A1,"HEWETT, SANDRA JEANNE",4/19/2024 12:00:00 AM,3/31/2029 12:00:00 AM,Emerging Imaging Technologies in Neuroscience Study Section[EITN], ,12493984,"LAKSARI, KAVEH ","TAHSILI FAHADAN, POUYA ",39,ENGINEERING (ALL TYPES),627797426,MR5QC5FCAVH5,627797426,MR5QC5FCAVH5,US,33.972585,-117.350361,577506,UNIVERSITY OF CALIFORNIA RIVERSIDE,RIVERSIDE,CA,BIOMED ENGR/COL ENGR/ENGR STA,925210001,UNITED STATES,N,4/19/2024 12:00:00 AM,3/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,661270, ,NINDS,511655,149615, ,661270,,661270.0 | |
| No NIH Category available,Adherence;Adoption;Benefits and Risks;Biological Markers;Blood specimen;Cancer Center;Cancer Patient;Caring;Clinical;Collaborations;Data;Development;Disease;Disease Progression;Early Diagnosis;Early treatment;Equipment and supply inventories;Event;Frequencies;Genes;Genetic Polymorphism;Haplotypes;Health Status;Hospitalization;Hospitals;Immune checkpoint inhibitor;Immune system;Immunotherapy;Incidence;Institution;Interruption;Intervention;Knowledge;Life;Link;Malignant Neoplasms;Measures;Modeling;Monitor;Morbidity - disease rate;National Cancer Institute;Nomograms;Online Systems;Organ;Outcome;Outcome Measure;Patient Outcomes Assessments;Patient risk;Patients;Physicians;Pilot Projects;Precision Health;Prevention;Public Health;Quality of life;RNA;Recommendation;Reporting;Research Personnel;Risk;Risk Assessment;Risk Estimate;Risk Reduction;Symptoms;T cell receptor repertoire sequencing;Testing;Therapeutic;Translating;Treatment Factor;Treatment Side Effects;Treatment outcome;United States National Institutes of Health;University of Texas M D Anderson Cancer Center;Visit;adverse event monitoring;associated symptom;beta Chain Antigen T Cell Receptor;biomarker validation;cancer care;cancer therapy;clinical practice;cohort;comorbidity;daily functioning;disability;effective therapy;experience;immune activation;immune-related adverse events;immunological intervention;improved;innovation;interdisciplinary approach;member;mortality;novel;patient oriented;peripheral blood;predictive marker;predictive modeling;risk mitigation;risk prediction;risk prediction model;side effect;socioeconomics;surveillance strategy;tool;treatment adherence;tumor;tumor progression;web app;web-based tool,Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events,PROJECT NARRATIVE Identifying the risk for severe immune-related adverse events will have a major public health impact as riskassessment-based monitoring will facilitate early detection and prompt management of immune-related ad-verse events minimizing the progression to life-threatening or fatal events. Thus this approach will reducetreatment-induced symptom burden and mortality while significantly improving treatment adherence and treat-ment outcome. This strategy aligns with NCI Cancer Moonshot Blue Ribbon Panel 2016 recommendations tosystematically gather patient-reported outcomes and develop innovative patient-based approaches to facilitateadherence to effective therapies and improve patients quality of life.,NCI,10801113,1/19/2024 12:00:00 AM,PA-20-185,1R01CA279749-01A1,1,R01,CA,279749,01,A1,"FILIPSKI, KELLY",1/19/2024 12:00:00 AM,12/31/2028 12:00:00 AM,Interdisciplinary Clinical Care in Specialty Care Settings Study Section[ICSC], ,9035497,"NAING, AUNG ",Not Applicable,09,INTERNAL MEDICINE/MEDICINE,800772139,S3GMKS8ELA16,800772139,S3GMKS8ELA16,US,29.706319,-95.397195,578407,UNIVERSITY OF TX MD ANDERSON CAN CTR,HOUSTON,TX,OVERALL MEDICAL,770304009,UNITED STATES,N,1/19/2024 12:00:00 AM,12/31/2024 12:00:00 AM,393,Non-SBIR/STTR,2024,657119, ,NCI,405629,251490, ,657119,,657119.0 | |
| No NIH Category available,Address;Animals;Back;Benchmarking;Biology;Calibration;Cancer Biology;Cell Proliferation;Clinical;Communities;Computer software;Coupled;Custom;Detection;Disease;Disease Progression;Evaluation;Exercise;FDA approved;Fatty acid glycerol esters;Feasibility Studies;Frequencies;Generations;Glioblastoma;Glioma;Gluconeogenesis;Glycolysis;Goals;Hand;Heart Diseases;Human;Image;Magnetic Resonance Imaging;Malignant Breast Neoplasm;Malignant Neoplasms;Metabolic;Metabolic Pathway;Metabolism;Methods;Mitochondria;Multicenter Trials;Noise;Nuclear;Oxidative Phosphorylation;Performance;Physiologic pulse;Play;Positron-Emission Tomography;Prevalence;Production;Protons;Pyruvate;Pyruvate Metabolism Pathway;Reproducibility;Research;Resolution;Role;Series;Signal Transduction;Site;Stroke;Surveys;System;Techniques;Technology;Testing;Thinking;Time;Validation;Vendor;Water;aerobic glycolysis;aqueous;cancer therapy;cell growth;clinical imaging;clinical translation;cost;cost effective;density;design;detection sensitivity;early phase clinical trial;first-in-human;imaging biomarker;imaging capabilities;improved;in vivo;in vivo imaging;malignant stomach neoplasm;metabolic imaging;millisecond;novel;prototype;radio frequency;response;success;transmission process,Plug-and-play Hyperpolarized MRI of Metabolism on Clinical Scanners,PROJECT NARRATIVE (3-sentence limit)Recent advances in hyperpolarized metabolic imaging pioneered by our team and others allow real-time in vivotracking of metabolic conversions of injected hyperpolarized 13C-pyruvate to downstream metabolites in multiplemetabolic pathways resulting in new imaging biomarkers to indicate aberrant cellular metabolism inform dis-ease progression and guide treatment decisions. One of the major hurdles for widespread clinical translation ofthis novel technique is most standard clinical scanners have only proton imaging capabilities and cannot detect13C signals. In this feasibility study our team will develop and validate a simple smart cost-effective scanneradd-on module that will enable the transfer of polarization-enhanced signals from 13C to proton and enablemetabolic imaging of hyperpolarized 13C compounds on a standard clinical MRI scanner via indirect 1H detection.,NIBIB,10801163,1/17/2024 12:00:00 AM,PA-20-185,1R01EB034197-01A1,1,R01,EB,034197,01,A1,"LIU, GUOYING",1/18/2024 12:00:00 AM,12/31/2027 12:00:00 AM,Imaging Technology Development Study Section[ITD], ,10988339,"ROSEN, MATTHEW SCOT","CHEKMENEV, EDUARD ",08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,1/18/2024 12:00:00 AM,12/31/2024 12:00:00 AM,286,Non-SBIR/STTR,2024,566997, ,NIBIB,405300,161697, ,566997,,566997.0 | |
| No NIH Category available,Address;Affect;Affective;Animal Model;Anxiety;Anxiety Disorders;Attention;Behavior;Behavioral;Biological Markers;Brain;Categories;Chronic;Chronic Disease;Clinical;Clinical Data;Cognitive Therapy;Complex;Computer Models;Control Groups;Cues;Data;Diagnosis;Diagnostic;Dimensions;Disabling;Disease;Disease susceptibility;Electroencephalography;Electrophysiology (science);Emotional;Etiology;Evidence based intervention;Evidence based treatment;Exposure to;Frequencies;Functional disorder;Goals;Individual;Individual Differences;Intervention;Knowledge;Link;Machine Learning;Measures;Mental Health;Mental disorders;Methods;Modeling;Molecular;National Institute of Mental Health;Neurobiology;Obsessive compulsive behavior;Parameter Estimation;Participant;Patient Self-Report;Patients;Pattern;Perception;Pharmaceutical Preparations;Population;Prediction of Response to Therapy;Predictive Value;Prevalence;Process;Psychopathology;Reporting;Research;Research Domain Criteria;Resistance;Role;Sampling;Sensory;Sensory Process;Severities;Social Anxiety Disorder;Stimulus;Symptoms;System;Techniques;Testing;Treatment Protocols;Treatment outcome;Validity of Results;Visual;Visual Cortex;Visual Perception;Visual attention;Visual evoked cortical potential;Woman;Work;anxiety spectrum disorders;biomarker validation;clinical practice;clinical predictors;comorbidity;computer framework;conditioned fear;data reduction;epidemiology study;indexing;individualized medicine;men;neural;neuromechanism;neurophysiology;novel;novel strategies;prognostic;response;selective attention;societal costs;success;temporal measurement,Visual perception and attention in the obsessive-compulsive/anxiety spectrum: Neurophysiological characterization predictive value and computational modeling,Narrative Many psychiatric disorders are characterized by dysregulation of perception and attention for instancethe hypervigilance seen in individuals with obsessive-compulsive or anxiety disorders when they are exposedto potentially threatening situations. The proposed research examines how novel measures of visual activityobtained with electroencephalography can be used to predict symptoms of obsessive-compulsive and anxietydisorders. Establishing reliable and valid quantitative indices of perception and attention that vary systematicallywith self-reported symptoms is a necessary step towards objective assessment of the brain circuits underlyingemotional dysfunction in these disorders and ultimately to inform evidence-based intervention and treatmentefforts.,NIMH,10801223,11/15/2023 12:00:00 AM,PA-20-185,1R01MH135426-01,1,R01,MH,135426,01, ,"ROWLAND, LAURA",12/1/2023 12:00:00 AM,10/31/2028 12:00:00 AM,Special Emphasis Panel[ZRG1-BP-Y(02)M], ,1884731,"MATHEWS, CAROL A","KEIL, ANDREAS ",03,PSYCHIATRY,969663814,NNFQH1JAPEP3,969663814,NNFQH1JAPEP3,US,29.643443,-82.349637,513806,UNIVERSITY OF FLORIDA,GAINESVILLE,FL,SCHOOLS OF MEDICINE,326115500,UNITED STATES,N,12/1/2023 12:00:00 AM,10/31/2024 12:00:00 AM,242,Non-SBIR/STTR,2024,684381, ,NIMH,461631,222750, ,684381,,684381.0 | |
| No NIH Category available,Address;Antibodies;Antigen Presentation;Architecture;Automobile Driving;Biological;Biomedical Research;Biopsy;Cancer Prognosis;Cellular Morphology;Clinic;Clinical;Collaborations;Communities;Complete Blood Count;Computing Methodologies;DNA Sequence Alteration;Data;Data Set;Decision Making;Diagnosis;Disease;Disease-Free Survival;Disparate;Dreams;Endometrial Carcinoma;Genes;Genetic Transcription;Glioblastoma;Hematology;Histologic;Histology;Histopathology;Image;Immunohistochemistry;Immunophenotyping;Individual;Intuition;KRAS2 gene;Knowledge;Knowledge Discovery;Learning;Malignant Neoplasms;Malignant neoplasm of lung;Measurement;Medical;Methods;Mitotic;Modeling;Molecular;Molecular Profiling;Morphology;Multiomic Data;Mutation;National Cancer Institute;Neural Network Simulation;Nuclear;Outcome;PIK3CA gene;Pathologic;Pathologist;Pathology;Pathway interactions;Patients;Pattern;Performance;Process;Prognosis;Proteins;Proteomics;Regulatory Pathway;Research;Resolution;Role;Stains;TP53 gene;Tissues;Training;Trust;Tumor Biology;Tumor Pathology;Tumor stage;Urine;Validation;Visual;Visualization;Work;ZFHX3 gene;cancer therapy;cancer type;clinical practice;clinical predictors;convolutional neural network;data integration;deep learning;deep learning model;density;diagnostic biomarker;diagnostic tool;diagnostic value;differential expression;illness length;imaging platform;immune cell infiltrate;improved;interest;machine learning model;machine learning prediction;multiple omics;novel;personalized diagnostics;predict clinical outcome;predictive signature;proteogenomics;reconstitution;tool;transcriptomics;tumor;tumor heterogeneity;tumorigenesis,Deep-learning Integration of Histopathology and Proteogenomics at a Pan-cancer Level - Resubmission,PROJECT NARRATIVEWe propose to develop machine learning models that predict a wide range of clinical histological and molecularoutcomes directly from histopathology images. Importantly we will connect biomedical research and clinicalefforts through the identification of enriched regulatory pathways responsible for worsening cancer outcomes.Ultimately such efforts would augment clinical practice by giving pathologists additional diagnostic tools andmolecular pathway information not previously available.,NCI,10802110,1/31/2024 12:00:00 AM,PA-21-049,5F30CA271622-02,5,F30,CA,271622,02, ,"DAMICO, MARK W",3/1/2023 12:00:00 AM,6/30/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-F05-D(21)L], ,15582991,"WANG, JOSHUA ",Not Applicable,12,BIOCHEMISTRY,121911077,M5SZJ6VHUHN8,121911077,M5SZJ6VHUHN8,US,40.669895,-73.974354,5998304,NEW YORK UNIVERSITY SCHOOL OF MEDICINE,NEW YORK,NY,SCHOOLS OF MEDICINE,10016,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,398,"Training, Individual",2024,41300, ,NCI,41300,0, ,41300,,41300.0 | |
| No NIH Category available,Adherence;Adoption;Affect;American;Amputation;Ancillary Study;Bioinformatics;Biological;Biological Markers;Caring;Cells;Clinic;Clinical;Clinical Data;Clinical Protocols;Clinical Research;Clinical Skills;Complications of Diabetes Mellitus;Data;Data Collection;Death Rate;Diabetes Mellitus;Diabetic Foot;Diabetic Foot Ulcer;Eligibility Determination;Ensure;Evolution;Funding;Future;Genomics;Goals;Health Care Costs;Health system;Healthcare;Heterogeneity;Human;Image;Image Analysis;Incidence;Infrastructure;Interdisciplinary Study;Lead;Leadership;Lower Extremity;Machine Learning;Methods;Michigan;Molecular;Molecular Analysis;Multi-site clinical study;National Institute of Diabetes and Digestive and Kidney Diseases;Outcome;Participant;Patient Outcomes Assessments;Patient Recruitments;Patients;Performance;Persons;Phenotype;Podiatry;Policies;Precision Health;Prevalence;Prevention;Protocols documentation;Publications;Recommendation;Records;Recurrence;Research;Research Infrastructure;Rest;Risk;Role;Sampling;Science;Site;Standardization;Techniques;Training;Translating;Translational Research;Treatment Cost;United States;Universities;Water;Work;Writing;bench to bedside;biobank;biological standardization;biomarker discovery;biomarker validation;c-myc Genes;clinical practice;clinical research site;comorbidity;cost;data mining;design;diabetes management;driving force;economic impact;foot;genetic analysis;healing;ineffective therapies;instrument;interdisciplinary approach;large datasets;member;metagenomic sequencing;microbiome;microbiome analysis;mortality;novel;novel therapeutics;pandemic disease;patient engagement;personalized medicine;point of care;prediction algorithm;predictive marker;public health relevance;recruit;sample collection;social health determinants;socioeconomics;standard care;success;team-based care;tool;transcriptomics;treatment as usual;treatment strategy;wound;wound care;wound healing;wound treatment,NIDDK Diabetic Foot Consortium Clinical Research Unit,PROJECT NARRATIVEThis project has major public health relevance because diabetic foot ulcers (DFUs) remain one of the mostcommon complications of diabetes and are the leading cause of lower extremity amputations in the US. Currenttreatments are ineffective and given the recent surge in major lower extremity amputations in patients withdiabetes despite the previous decades of decline identification of novel treatment avenues is of criticalimportance. The main objectives of the Diabetic Foot Clinical Research Unit at the University of Michigan are toexpand the work and activities initiated during the first DFC cycle by integrating the robust DFC infrastructurewe built at Michigan with the highly skilled clinical and translational research team to: finalize the ongoing DFUbiomarkers protocols implement the DFC master protocol and its various substudies continue our highrecruitment performance across all biomarker studies recruit train and supervise satellite sub sites developnew methods to stimulate participants engagement collect all data sets from large and standardized clinicalsamples collections phenotyping genomic molecular and microbiome analyses from DFUs samples andwound image analyses to patient reported outcomes and social determinants of health analyze how DFUrecommended standards of care are implemented into usual care to facilitate evolution of clinical practice andparticipate in biomarker validation analyses and any new wound healing projects undertaken by the Consortiumthrough active and effective participation in its self-governing committees.,NIDDK,10802197,1/18/2024 12:00:00 AM,RFA-DK-22-509,5U01DK119083-07,5,U01,DK,119083,07, ,"LI, YAN",9/15/2018 12:00:00 AM,12/31/2027 12:00:00 AM,ZDK1-GRB-1(J2), ,7645423,"BUSUI (POP-BUSUI), RODICA ","HOLMES, CRYSTAL MURRAY",06,INTERNAL MEDICINE/MEDICINE,073133571,GNJ7BBP73WE9,073133571,GNJ7BBP73WE9,US,42.275494,-83.743038,1506502,UNIVERSITY OF MICHIGAN AT ANN ARBOR,ANN ARBOR,MI,SCHOOLS OF MEDICINE,481091276,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,727080, ,NIDDK,493000,234080, ,727080,,727080.0 | |
| No NIH Category available,Address;Affect;Affective;Anisotropy;Area;Atrophic;Axon;Biological;Biological Assay;Biological Markers;Clinical;Clinical Trials;Cognitive;Complex;Confidence Intervals;Data;Diffusion Magnetic Resonance Imaging;Disabling;Disease;Educational workshop;Elderly;Guidelines;Humanities;Image;Impaired cognition;Injury;Laboratories;Light;MRI Scans;Magnetic Resonance Imaging;Maintenance;Measures;Methods;Mitochondria;Molecular;Morbidity - disease rate;Natural regeneration;Nerve Degeneration;Nervous System Trauma;Neurodegenerative Disorders;Neurological outcome;Observational Study;Participant;Pathologic;Phase;Population Study;Pre-Clinical Model;Process;Prognostic Marker;Proteins;Receiver Operating Characteristics;Recommendation;Reference Standards;Risk Factors;Sampling;Scanning;Serum;Techniques;Testing;Therapy Clinical Trials;Translations;Traumatic Brain Injury;United States National Institutes of Health;Validation;axon injury;axonal degeneration;biomarker validation;cerebral atrophy;clinical trial participant;comorbidity;disability burden;drug development;early phase clinical trial;effective intervention;follow-up;improved;indexing;individual patient;injury-related death;mortality;neurofilament;neuroimaging;novel therapeutic intervention;participant enrollment;patient subsets;peripheral blood;pharmacodynamic biomarker;precision medicine;promote resilience;resilience;specific biomarkers;targeted therapy trials;white matter,Clinical Validation of Serum Neurofilament Light as a Biomarker of Traumatic Axonal Injury,Project Narrative Traumatic brain injury (TBI) is one the leading causes of mortality and morbidity affecting humanity and arecognized risk factor for late-life neurodegenerative disorders. The absence of validated biomarkers in theneurotrauma field is a barrier to drug development in this area and there are currently no disease-modifyingtherapies that limit the burden of TBI. This proposal addresses this gap by aiming to validate serum neurofilamentlight (NF-L) a biomarker of TAI which can be useful in early-phase clinical trials of therapies aimed at improvingaxonal resilience and regeneration.,NINDS,10802203,2/23/2024 12:00:00 AM,PAR-18-664,5U01NS114140-04,5,U01,NS,114140,04, ,"TAYLOR-BURDS, CAROL C",3/15/2020 12:00:00 AM,2/28/2026 12:00:00 AM,Neurological Sciences and Disorders A Study Section[NSD-A], ,1876248,"DIAZ-ARRASTIA, RAMON ",Not Applicable,03,NEUROLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,701723, ,NINDS,520787,180936, ,701723,,701723.0 | |
| No NIH Category available,Address;Age;Algorithms;Amyloid;Amyloidosis;Attention;Biological Assay;Biological Markers;Biology;Biopsy;Blood;Blood specimen;Boston;Brain;Cardiac;Caring;Cells;Certification;Cessation of life;Chromosome abnormality;Clinical;Clinical Laboratory Improvement Amendments;Congo Red;Cyclin D1;Cytogenetics;Data;Data Collection;Databases;Death Rate;Decision Making;Dependence;Deposition;Diagnosis;Disease;Disparity;Early Diagnosis;Early Intervention;Enrollment;Failure;Future;Genes;Goals;Heart;Heart failure;Hepatic;Immunoglobulin Variable Region;Immunoglobulins;Investigation;Kidney;Kidney Failure;Knowledge;Laboratories;Light;Marrow;Modeling;Molecular Biology;Monoclonal Gammapathies;Multiple Myeloma;N-terminal;Pathologic;Patient Care;Patients;Peripheral Nervous System Diseases;Phase;Plasma Cells;Population;Process;Proteins;Provider;Public Health;Regulation;Research Personnel;Retrospective Studies;Risk;Risk Assessment;Role;Series;Site;Specimen;Stains;Statistical Algorithm;Statistical Models;Support Groups;Symptoms;Systemic Therapy;Techniques;Testing;Training;Universities;Validation;Work;advanced disease;base;biomarker identification;design;design verification;improved;kappa opioid receptors;member;mortality;next generation;next generation sequencing;novel marker;overexpression;participant enrollment;patient screening;precision medicine;primary amyloidosis of light chain type;prohormone;prospective;saluretic;screening;standard of care;statistics;sulfated glycoprotein 2;tool;validation studies,Screening for AL Amyloidosis in Smoldering Multiple Myeloma,Public Health StatementOur objective is to develop tools that improve early diagnosis of systemic light-chain (AL) amyloidosis adisease that causes heart and kidney failure and early death in patients with smoldering multiple myeloma adisease in which patients make immunoglobulin free light chains but are relatively asymptomatic. By studyingpatients with smoldering myeloma and analyzing their light chain levels the genes in their myeloma cells and acertain heart-related protein we will be able to establish the likelihood that they have or will get AL.,NCI,10802231,2/27/2024 12:00:00 AM,PA-20-185,1R01CA279808-01A1,1,R01,CA,279808,01,A1,"BHARTI, SANITA",3/1/2024 12:00:00 AM,2/28/2029 12:00:00 AM,Molecular Cancer Diagnosis and Classification Study Section[MCDC], ,9799532,"COMENZO, RAYMOND LUKE",Not Applicable,07,Unavailable,079532263,MY2ERHGDV956,079532263,MY2ERHGDV956,US,42.349512,-71.063308,130301,TUFTS MEDICAL CENTER,BOSTON,MA,Independent Hospitals,021111552,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,861956, ,NCI,573855,288101, ,861956,,861956.0 | |
| No NIH Category available,Adoption;Biological Markers;Biological Process;Blood Vessels;Brain;Central Vein;Chronic;Clinic;Clinical;Clinical Research;Data;Detection;Development;Diagnosis;Diagnostic;Diffuse;Disease;Disease Progression;Etiology;Functional disorder;Future;Goals;Heterogeneity;Histopathology;Horns;Image;Image Analysis;Individual;Lesion;Location;Magnetic Resonance Imaging;Measures;Methods;Microglia;Monitor;Morphology;Multimodal Imaging;Multiple Sclerosis;Multiple Sclerosis Lesions;Myelin;Neurologist;Outcome;Pathology;Patients;Pattern;Phase;Phenotype;Predisposition;Process;Research;Sequence Analysis;Severities;Signal Transduction;Statistical Data Interpretation;Statistical Methods;System;T2 weighted imaging;Techniques;Therapeutic;Time;Tissues;Translating;Translations;Validation;Ventricular;Visit;Visual;Work;analysis pipeline;automated analysis;burden of illness;clinical decision-making;clinical practice;clinically relevant;density;detection method;diagnostic accuracy;disability;education resources;gray matter;illness length;imaging biomarker;imaging study;improved;indexing;individual patient;infancy;ischemic lesion;magnetic resonance imaging biomarker;multimodality;multiparametric imaging;neuroimaging;neuropathology;novel;older patient;precision medicine;radiologist;radiomics;repaired;research study;software development;statistics;stem;targeted treatment;tissue injury;tissue repair;tool;white matter,Advanced Statistical Analytics of MRI in MS,PROJECT NARRATIVEOur overarching goals are to develop statistical methods for the analysis of imaging acquired on multiplescanners for the study of multiple sclerosis (MS). We will develop and validate statistical methods for identifyingindividual lesions and quantifying the central vein in MS lesions for improved MS diagnostics as well astechniques for automatically identifying lesion phenotypes in a novel coordinate system. Finally we will developmethods that allow for the study of patterns of neuropathological change across an image to study diffusechanges in the normal-appearing white and gray matter of the brain.,NINDS,10802294,1/16/2024 12:00:00 AM,PA-19-056,5R01NS112274-05,5,R01,NS,112274,05, ,"UTZ, URSULA",4/1/2020 12:00:00 AM,1/31/2025 12:00:00 AM,Emerging Imaging Technologies in Neuroscience Study Section[EITN], ,11429276,"SHINOHARA, RUSSELL TAKESHI",Not Applicable,03,BIOSTATISTICS & OTHER MATH SCI,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,549768, ,NINDS,365401,184367, ,549768,,549768.0 | |
| No NIH Category available,Africa;Architecture;Area;Asia;Biological Markers;Biometry;Biotechnology;Brazil;COVID-19;China;Clinical;Clinical Research;Clinical Trials;Cohort Studies;Collaborations;Collection;Common Data Element;Communication;Country;Data;Data Collection;Data Element;Development;Diagnostic;Diagnostics Research;Elements;Ensure;Epidemiology;Feedback;Foundations;Generations;Geographic Locations;Goals;Grant;HIV/TB;Human;Immunology;India;Indonesia;International;Intervention Studies;Korea;Laboratories;Leadership;Logistics;Mentors;Monitor;Observational Study;Performance;Pharmaceutical Preparations;Population;Proteomics;Protocols documentation;Publishing;Quality Control;Research;Research Design;Research Methodology;Research Personnel;Research Support;Review Committee;Science;Site;South Africa;South America;Specimen;Structure;Technology;Translational Research;Treatment outcome;Tuberculosis;Vaccines;Validation;biobank;biomarker evaluation;data centers;data harmonization;data hub;data management;data standards;design;electronic data;falls;frontier;innovation;insight;learning materials;multiple omics;nano-string;novel diagnostics;predictive marker;programs;prospective;response;sample collection;tool;transcriptomics;tuberculosis diagnostics;working group,TB-RICC 3.0,New tools are necessary for tuberculosis control. The Regional ProspectiveObservational Research on tuberculosis (RePORT) coordinating center (TB-RICC 3.0)will discover predictors of development of TB and poor treatment outcomes and showthat they are applicable across three continents. TB-RICC 3.0 will further supportdevelopment of a network of sites to study promising new diagnostics vaccines anddrugs.,NIAID,10802316,3/30/2024 12:00:00 AM,RFA-AI-21-078,5U01AI174268-02,5,U01,AI,174268,02, ,"ESPY, NICOLE JOY",4/1/2023 12:00:00 AM,3/31/2028 12:00:00 AM,ZAI1-CD-A(S1), ,1888883,"ELLNER, JERROLD J.","ANDRADE, BRUNO DE BEZERRIL; STERLING, TIMOTHY R",10,INTERNAL MEDICINE/MEDICINE,090299830,YVVTQD8CJC79,090299830,YVVTQD8CJC79,US,40.520984,-74.473247,10034168,RUTGERS BIOMEDICAL AND HEALTH SCIENCES,Newark,NJ,SCHOOLS OF MEDICINE,071073001,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,855,Non-SBIR/STTR,2024,3960184, ,NIAID,3432892,527292, ,3960184,,3960184.0 | |
| No NIH Category available,Age;Algorithms;Alzheimer disease screening;Alzheimer's Disease;Alzheimer's disease patient;Alzheimer's disease related dementia;Alzheimers disease biomarker;Amyloid;Amyloid beta-42;Biological Markers;Blood specimen;Brain;Caregivers;Caring;Categories;Chemicals;Classification;Clinical;Clinical Markers;Clove;Cognition;Cognitive;Communities;Complex;Comprehensive Health Care;Counseling;Data;Dementia;Detection;Diagnostic tests;Disease;Disease Marker;Dreams;Early Intervention;Ensure;Evaluation;Family;Functional disorder;Future;Goals;Health;Hippocampus;Home;Individual;Infrastructure;Intervention;Lavandula;Life;Machine Learning;Measurement;Measures;Methods;Mind;Monitor;Nerve Degeneration;Neuroanatomy;Neurocognition;Neurocognitive;Neurologic;Odors;Olfactory dysfunction;Outcome;Pathology;Patients;Pattern;Pennsylvania;Performance;Persons;Phenotype;Plasma;Population;Positron-Emission Tomography;Predictive Value;Process;Public Health;Questionnaires;Registries;Research;Risk;Services;Smell Perception;Specificity;Techniques;Testing;Time;Triage;United States;Universities;Validation;Volatile Oils;Woman;Work;aging population;burden of illness;clinical trial enrollment;clinically relevant;clinically significant;cognitive testing;cohort;cost effective;dementia risk;design;early phase clinical trial;early screening;exercise capacity;frailty;functional decline;functional status;human old age (65+);improved;interest;machine learning algorithm;medical specialties;men;mild cognitive impairment;novel;piriform cortex;point of care;pre-clinical;predictive marker;predictive modeling;primary care setting;response;screening;statistics;tau Proteins;tau-1;underserved community,Olfactory Phenotypes as Non-Invasive Biomarkers for Alzheimer's Disease: A Machine Learning Approach,PROJECT NARRATIVEWe predict that olfactory dysfunction testing using AROMA a novel essential oil-based objective test ofolfaction and machine learning algorithms using this data will accurately classify Alzheimers disease stage(including asymptomatic individuals); be strongly associated with and predictive of conventional biomarkers ofdisease; and predict longitudinal functional trajectory. The ability to effectively screen for ADRD using a non-invasive and accessible test is critical to public health and our ability to identify people early when diseasecourse is most likely to still be modifiable. Accurate prediction of future functional decline will also meaningfullyinform comprehensive care planning and improved counseling of patients and their families.,NIA,10802324,3/5/2024 12:00:00 AM,PAR-19-070,5R01AG072624-03,5,R01,AG,072624,03, ,"ST HILLAIRE-CLARKE, CORYSE",6/15/2022 12:00:00 AM,2/28/2027 12:00:00 AM,Special Emphasis Panel[ZRG1-BDCN-F(55)R], ,16086016,"VILLWOCK, JENNIFER ",Not Applicable,03,OTOLARYNGOLOGY,016060860,YXJGGNC5J269,016060860,YXJGGNC5J269,US,39.026584,-94.636347,1484303,UNIVERSITY OF KANSAS MEDICAL CENTER,KANSAS CITY,KS,SCHOOLS OF MEDICINE,661608500,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,756254, ,NIA,487906,268348, ,756254,,756254.0 | |
| No NIH Category available,Address;Affect;Area;Binding Proteins;Biological Assay;Biological Markers;Biological Process;Blinded;Blood;Blood Tests;Brain;Brain Aneurysms;Brain hemorrhage;Caring;Cerebral Aneurysm;Cerebral Ischemia;Cerebral hemisphere hemorrhage;Characteristics;Clinical;Clinical Research;Clinical Trials Design;Clinical stratification;Complex;Complication;Data;Detection;Development;Exposure to;Focal Neurologic Deficits;Functional disorder;GDF8 gene;Glycoproteins;Goals;Health;Hemorrhage;Hospitals;Hour;Individual;Intensive Care Units;Interferon Type II;Intervention;Intervention Studies;Investigation;Lead;Leucine;Logistic Regressions;Measures;Morbidity - disease rate;Neurologic Deficit;Patients;Pattern;Performance;Phase;Plasma;Plasma Proteins;Population;Preparation;Process;Prospective cohort;Proteins;Proteomics;Public Health;Reproducibility;Research;Resource Allocation;Resources;Risk;Rupture;Sampling;Sensitivity and Specificity;Series;Specificity;Subarachnoid Hemorrhage;Subarachnoid Space;Technology;Testing;Treatment Side Effects;United States National Institutes of Health;biomarker identification;biomarker signature;biomarker validation;candidate identification;candidate marker;candidate validation;cohort;detection assay;detection method;effective therapy;growth differentiation factor 5;guanylate;high risk;improved;individualized medicine;innovation;machine learning model;member;minimally invasive;neurexophilin;novel;patient stratification;prevent;prognostic;prognostic assays;prognostic performance;prognostic value;prognostication;prospective;protein biomarkers;randomized clinical trials;response;risk stratification;scavenger receptor;screening;statistical and machine learning;validation studies,Discovery of Plasma Biomarkers of Delayed Cerebral Ischemia after Subarachnoid Hemorrhage,NARRATIVEThis study will discover plasma protein biomarkers associated with delayed cerebral ischemia (DCI) aftersubarachnoid hemorrhage (SAH). The aims of this study are consistent with the goals of the NIH and NINDsR61/R3 PAR-19-315 and it will have a significant impact on public health and will improve SAH care.,NINDS,10802430,2/22/2024 12:00:00 AM,PAR-19-315,5R61NS119640-03,5,R61,NS,119640,03, ,"TAYLOR-BURDS, CAROL C",3/15/2022 12:00:00 AM,2/28/2025 12:00:00 AM,Neurological Sciences and Disorders A Study Section[NSD-A], ,10995777,"CHOI, HUIMAHN ALEX","SAVARRAJ, JUDE PJ",18,NEUROSURGERY,800771594,ZUFBNVZ587D4,800771594,ZUFBNVZ587D4,US,29.703025,-95.403303,578417,UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON,HOUSTON,TX,SCHOOLS OF MEDICINE,770305400,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,466647, ,NINDS,299133,167514, ,466647,,466647.0 | |
| No NIH Category available,Acute;Acute myocardial infarction;Affect;American;Aorta;Award;Biological Markers;Blood;Blood flow;Cardiac;Cardiac Output;Cardiogenic Shock;Cardiopulmonary;Cardiovascular Physiology;Cardiovascular system;Chronic;Clinical;Clinical Management;Clinical Trials;Complication;Conduct Clinical Trials;Critical Care;Data;Death Rate;Devices;Diameter;Diastolic blood pressure;EFRAC;Echocardiography;Emergency Medicine;Enrollment;Equilibrium;Etiology;Extracorporeal Membrane Oxygenation;Failure;Future;Goals;Heart;Heart Ventricle;Hour;Injury;Intervention;Intra-Aortic Balloon Pumping;K-Series Research Career Programs;Knowledge;Left;Left ventricular structure;Lung;Measures;Mechanics;Mediating;Methods;Morbidity - disease rate;Myocardial;National Heart Lung and Blood Institute;Observational Study;Outcome;Pathway interactions;Patient-Focused Outcomes;Patients;Perfusion;Phase;Physiological;Physiology;Pulmonary Capillary Wedge Pressure;Pulse Pressure;Randomized;Recovery;Refractory;Research Personnel;Sample Size;Selection Bias;Stretching;Target Populations;Testing;Training;Troponin;United States National Institutes of Health;Universities;Utah;Validation;Ventricular;Ventricular Remodeling;Weaning;Work;arm;biomarker validation;cytokine;design;hemodynamics;improved;innovation;long term recovery;mechanical circulatory support;mid-career faculty;mortality;myocardial injury;novel;novel strategies;participant enrollment;predictive marker;primary outcome;secondary outcome;standard of care;trial design,Physiology of Unloading VA ECMO Trial,PROJECT NARRATIVEVeno-arterial extracorporeal membrane oxygenation (VA ECMO) may enable survival of patients with severeacute cardiogenic shock (CS) which kills 80000 Americans each year but may also cause harm to the failingheart. A clinical management change of unloading/decompressing the heart during VA ECMO for CS mayimprove survival for these patients. Understanding the physiologic effects of unloading on the heart is animportant step towards conducting clinical trials of unloading during VA ECMO for CS and improving patientoutcomes during ECMO and CS.,NHLBI,10803163,2/9/2024 12:00:00 AM,PA-20-183,1R01HL168510-01A1,1,R01,HL,168510,01,A1,"FINE, LARRY",2/9/2024 12:00:00 AM,1/31/2029 12:00:00 AM,Special Emphasis Panel[ZRG1-RCCS-R(02)], ,14414891,"TONNA, JOSEPH EDWARD",Not Applicable,01,SURGERY,009095365,LL8GLEVH6MG3,009095365,LL8GLEVH6MG3,US,40.764542,-111.850317,514002,UNIVERSITY OF UTAH,SALT LAKE CITY,UT,SCHOOLS OF MEDICINE,841129049,UNITED STATES,N,2/9/2024 12:00:00 AM,1/31/2025 12:00:00 AM,837,Non-SBIR/STTR,2024,658132, ,NHLBI,504371,153761, ,658132,,658132.0 | |
| No NIH Category available,Address;Affect;Alcoholic Liver Diseases;Biological;Biological Markers;Biopsy;Breathing;Caring;Cell surface;Cessation of life;Cicatrix;Cirrhosis;Clinic;Clinical;Clinical Research;Clinical Trials;Clinical assessments;Collagen;Deposition;Development;Differentiation Antigens;Early Diagnosis;Evaluation;Family suidae;Fibrosis;Foundations;Future;Goals;Health;Hepatic Fibrogenesis;Hepatic Stellate Cell;Hepatocyte;Hepatology;Hepatotoxicity;Histologic;Histology;Human;Image;Immunohistochemistry;Inflammation;Knowledge;Liver;Liver Failure;Liver Fibrosis;Liver diseases;Magnetic Resonance Elastography;Magnetic Resonance Imaging;Malignant neoplasm of liver;Measurement;Measures;Methods;Miniature Swine;Modeling;Monitor;Motion;Mus;Non-Invasive Detection;Outcome;Pain;Pathologic Processes;Patients;Persons;Pharmaceutical Preparations;Positioning Attribute;Positron-Emission Tomography;Qualifying;Radiolabeled;Research;Risk;Sampling;Serology;Serum Markers;Specimen;Standardization;Techniques;Time;Tissues;Transplantation;Validation;Wisconsin;biomarker development;chronic liver disease;clinical implementation;drug development;drug discovery;effective therapy;elastography;fibroblast-activating factor;fibrogenesis;hepatocellular injury;hepatotoxin;imaging biomarker;improved;in vivo;inhibitor;innovation;liver imaging;liver inflammation;liver injury;liver stiffness;multidisciplinary;novel strategies;porcine model;pre-clinical;pre-clinical assessment;preclinical evaluation;prevent;prognostic;protein expression;public health relevance;radiotracer;specific biomarkers;treatment response;uptake,Development of FAPI PET as a Non-invasive Biomarker of Liver Fibrogenesis,PROJECT NARRATIVE / PUBLIC HEALTH RELEVANCE STATEMENT The broad long-term objective of our research is to improve the health of the ~1.5 billion people in the worldwith chronic liver disease that can progress to liver failure liver cancer and liver-related death. We seek todevelop and validate non-invasive methods of assessing the activity of chronic liver disease. These methodswill reduce the need for biopsy permit earlier diagnosis and facilitate more effective treatment thereby pre-venting the serious long-term complications of chronic liver disease.,NIDDK,10803164,1/18/2024 12:00:00 AM,PA-20-185,1R01DK136007-01A1,1,R01,DK,136007,01,A1,"SHERKER, AVERELL H",2/1/2024 12:00:00 AM,1/31/2029 12:00:00 AM,Hepatobiliary Pathophysiology Study Section[HBPP], ,14352901,"PIRASTEH, ALI ",Not Applicable,02,RADIATION-DIAGNOSTIC/ONCOLOGY,161202122,LCLSJAGTNZQ7,161202122,LCLSJAGTNZQ7,US,43.068519,-89.400858,578503,UNIVERSITY OF WISCONSIN-MADISON,MADISON,WI,SCHOOLS OF MEDICINE,537151218,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,847,Non-SBIR/STTR,2024,683258, ,NIDDK,439394,243864, ,683258,,683258.0 | |
| No NIH Category available,Address;Adult;Affect;Amino Acids;Architecture;Area;Autoimmune Diseases;Biochemical;Biological Markers;Biometry;Biopsy;Biopsy Specimen;Child;Clinical;Collagen;Complex;Core Biopsy;Data;Development;Diagnosis;Diagnostic;Disease;Disease Outcome;End stage renal failure;Hematoxylin and Eosin Staining Method;Histologic;Histology;Histopathology;Human;Image;Kidney;Label;Leucocytic infiltrate;Lipids;Lupus Nephritis;Machine Learning;Maps;Measurement;Measures;Metabolic;Methods;Microscopy;Modality;Molecular;Morphology;Mouse Strains;Mus;Nucleic Acids;Paraffin Embedding;Pathologist;Pathology;Patient Care;Patients;Preparation;Prognosis;Proteins;Quantitative Evaluations;Resolution;Sampling;Secondary Protein Structure;Spatial Distribution;Speed;Stains;Structure;Surface;Systemic Lupus Erythematosus;Techniques;Thinness;Time;Tissue Embedding;Tissue Preservation;Tissue Sample;Tissues;Training;United States;Urine;Validation;Variant;Visualization;accurate diagnosis;alpha helix;beta pleated sheet;deep learning;design;diagnosis standard;diagnostic accuracy;diagnostic value;disease heterogeneity;disease phenotype;efficacy validation;feature selection;human data;human subject;imaging biomarker;imaging modality;improved;instrumentation;interstitial;kidney biopsy;molecular imaging;mouse model;multimodality;optical imaging;preservation;small molecule;spectroscopic imaging;structural imaging;tissue processing;ultraviolet,Improving the Accuracy of Lupus Nephritis Diagnosis using Biomarkers Derived from Ultraviolet and Mid-infrared Spectroscopic Imaging,PROJECT NARRATIVEDiagnosis of lupus nephritis (LN) using conventional histopathology is challenging and fraught with pitfalls. Wepropose combining histopathology with information from two independent optical imaging modalities that provideadditional biochemical and macromolecular context to LN diagnosis. We develop a multi-modal histologyplatform to collect co-registered images and combine data using a deep learning architecture to improve theaccuracy of LN diagnosis.,NIDDK,10803337,12/29/2023 12:00:00 AM,PA-20-185,1R01DK135870-01A1,1,R01,DK,135870,01,A1,"CHAN, KEVIN E",1/1/2024 12:00:00 AM,11/30/2028 12:00:00 AM,Enabling Bioanalytical and Imaging Technologies Study Section[EBIT], ,14084289,"REDDY, ROHITH ",Not Applicable,18,ENGINEERING (ALL TYPES),036837920,QKWEF8XLMTT3,036837920,QKWEF8XLMTT3,US,29.718091,-95.336483,1449402,UNIVERSITY OF HOUSTON,HOUSTON,TX,BIOMED ENGR/COL ENGR/ENGR STA,772042610,UNITED STATES,N,1/1/2024 12:00:00 AM,11/30/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,629842, ,NIDDK,434998,194844, ,629842,,629842.0 | |
| No NIH Category available,Acids;Alternative Therapies;Amines;Aminoisobutyric Acids;Anatomy;Animals;Atherosclerosis;Behavioral;Bile Acids;Biological;Biological Markers;Blood;Body Weight;Body Weight Changes;Body Weight decreased;Brain;Branched-Chain Amino Acids;Cardiometabolic Disease;Cardiovascular Diseases;Cessation of life;Circulation;Clinical Data;Coupled;Data;Diet;Disease;Disease remission;Eating;Environmental Exposure;Environmental Risk Factor;Epigenetic Process;Ethnic Population;Etiology;Future;Gastrectomy;Gastric Bypass;Genes;Genetic;Genetic Predisposition to Disease;Genomics;Goals;Health;Hormones;Human;Incidence;Individual;Joints;Kynurenine;Lecithin;Link;Lipids;Liquid Chromatography;Literature;Mass Fragmentography;Measures;Mediating;Mediation;Mediator;Medical;Mendelian randomization;Metabolic;Metabolic Pathway;Metabolism;Methods;Modeling;Molecular;Monounsaturated Fatty Acids;Morbidity - disease rate;National Institute of Diabetes and Digestive and Kidney Diseases;Non-Insulin-Dependent Diabetes Mellitus;Obesity;Operative Surgical Procedures;Organ;Oxides;Participant;Pathway Analysis;Pathway interactions;Physiological;Prevalence;Prevention strategy;Proteomics;Public Health;Regulation;Resolution;Risk;Risk Marker;Risk Reduction;Role;Sample Size;Sampling;Signal Pathway;Signal Transduction;Testing;Tissues;Validation;Variant;Weight;Xenobiotics;bariatric surgery;biomarker identification;cardiometabolism;cardiovascular disorder risk;circulating biomarkers;cohort;differential expression;disorder risk;effective therapy;energy balance;genetic association;genome wide association study;gut microbiota;high risk population;improved;intestine surgery;metabolomics;microbiome;mortality;novel;obesity treatment;phenotypic data;population based;predictive signature;small molecule;success;therapeutic target;transcriptome;transcriptomics,Defining the pathways of cardiometabolic health after weight loss,PROJECT NARRATIVEWeight loss surgery can effectively reduce the risk of cardiovascular disease and type 2 diabetes leading causesof illness and death in the US but it is invasive and produces variable results. This project seeks to identify thebiomarkers and pathways responsible for better cardiometabolic health after weight loss surgery. The findingsmay be used to develop nonsurgical methods to improve cardiometabolic health.,NIDDK,10803759,3/29/2024 12:00:00 AM,PA-20-185,1R01DK136134-01A1,1,R01,DK,136134,01,A1,"CASTLE, ARTHUR",4/1/2024 12:00:00 AM,12/31/2028 12:00:00 AM,Kidney Endocrine and Digestive Disorders Study Section[KEDD], ,11903722,"THAKER, VIDHU V.",Not Applicable,13,PEDIATRICS,621889815,QHF5ZZ114M72,621889815,QHF5ZZ114M72,US,40.8415,-73.9414,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NEW YORK,NY,SCHOOLS OF MEDICINE,100323725,UNITED STATES,N,4/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,744286, ,NIDDK,465255,279031, ,744286,,744286.0 | |
| No NIH Category available,Acceleration;Algorithms;Area;Artificial Intelligence;Bacteria;Biological Markers;Characteristics;Chest imaging;Clinical;Data Set;Death Rate;Detection;Development;Diagnosis;Diagnostic;Disease;Disease Progression;Early Diagnosis;Early treatment;Epidemiology;Evolution;Gene Expression Profile;Goals;High Resolution Computed Tomography;Household;Image;Imaging Device;Individual;Infection;Intervention;Knowledge;Lesion;Machine Learning;Methods;Microscopic;Morbidity - disease rate;Mycobacterium tuberculosis;Onset of illness;Pathologic;Pathology;Pattern;Performance;Persons;Phenotype;Predictive Value;Preventive therapy;Preventive treatment;ROC Curve;Regimen;Research;Resolution;Risk;Scanning;Signs and Symptoms;Sputum;Symptoms;Testing;Texture;Thoracic Radiography;Training;Treatment Protocols;Tuberculosis;Validation;X-Ray Computed Tomography;case finding;clinically relevant;computer aided detection;detection platform;digital;disability;disease transmission;effective therapy;high resolution imaging;image guided;imaging biomarker;imaging modality;improved;meetings;personalized diagnostics;personalized medicine;predictive modeling;prevent;progression marker;progression risk;prospective;radiomics;risk prediction;targeted treatment;tool;transfer learning;transmission process;treatment response;tuberculosis drugs;tuberculosis treatment,Imaging signatures of early tuberculosis,PROJECT NARRATIVEDetecting and treating tuberculosis (TB) before it becomes infectious or leads to disability iscritical to TB control. We propose to use artificial intelligence combined with digital chestimaging (computed tomography and chest-X-rays) to develop a high-precision imaging toolsetto characterize and diagnose early TB disease.,NIAID,10804028,11/9/2023 12:00:00 AM,PA-20-185,1R01AI175555-01A1,1,R01,AI,175555,01,A1,"LACOURCIERE, KAREN A",11/9/2023 12:00:00 AM,10/31/2028 12:00:00 AM,Population based Research in Infectious Disease Study Section[PRID], ,14985673,"XIE, YINGDA LINDA",Not Applicable,10,INTERNAL MEDICINE/MEDICINE,090299830,YVVTQD8CJC79,090299830,YVVTQD8CJC79,US,40.520984,-74.473247,10034168,RUTGERS BIOMEDICAL AND HEALTH SCIENCES,Newark,NJ,SCHOOLS OF MEDICINE,071073001,UNITED STATES,N,11/9/2023 12:00:00 AM,10/31/2024 12:00:00 AM,855,Non-SBIR/STTR,2024,682110, ,NIAID,526495,155615, ,682110,,682110.0 | |
| No NIH Category available,3-Dimensional;Address;Brain Mapping;Categories;Code;Cognition Disorders;Communities;Computer software;Data;Data Analyses;Data Set;Databases;Diagnostic;Disease;Educational workshop;Equation;Funding;Goals;Guidelines;Human;Image;Java;Learning;Location;Machine Learning;Mango - dietary;Manuals;Mental disorders;Meta-Analysis;Metabolic;Metadata;Methods;Mining;Modeling;Multivariate Analysis;Output;Parameter Estimation;Peer Review;Phase;Physiology;Plug-in;Property;Publications;Publishing;Regional Disease;Research Domain Criteria;Resources;Retrieval;Site;Software Framework;Surface;Symptoms;Taxonomy;Texas;Training;Uncertainty;Validation;biomarker discovery;case control;cognitive neuroscience;cohort;computerized tools;connectome;data submission;data tools;data visualization;design;disease model;experimental study;graph theory;hemodynamics;independent component analysis;learning materials;lectures;morphometry;network models;neuroimaging;simulation;webinar,Meta-analysis in human brain mapping,The overall goal of the BrainMap Project is to provide the human neuroimaging community with curated datasets metadata computational tools and related resources that enable coordinate-based meta-analyses(CBMA) meta-analytic connectivity modeling (MACM) meta-data informed interpretation (decoding) ofimaging results and meta-analytic priors for mining (including machine learning) primary (per-subject)neuroimaging data.,NIMH,10804592,4/25/2024 12:00:00 AM,PA-19-056,5R01MH074457-17,5,R01,MH,074457,17, ,"BENNETT, YVONNE",9/15/2006 12:00:00 AM,1/31/2025 12:00:00 AM,Special Emphasis Panel[ZRG1-ETTN-N(02)M], ,6382050,"FOX, PETER THORNTON",Not Applicable,20,RADIATION-DIAGNOSTIC/ONCOLOGY,800772162,C3KXNLTAAY98,800772162,C3KXNLTAAY98,US,29.513091,-98.577742,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,SAN ANTONIO,TX,SCHOOLS OF MEDICINE,782293901,UNITED STATES,N,4/25/2024 12:00:00 AM,1/31/2025 12:00:00 AM,242,Non-SBIR/STTR,2024,575925, ,NIMH,426493,149432, ,575925,,575925.0 | |
| No NIH Category available,Active Sites;Address;American;Amputation;Area;Award;Biological Markers;Caring;Clinical;Clinical Research;Communication;Darkness;Dedications;Diabetes Mellitus;Diabetic Foot;Diabetic Foot Ulcer;Discipline;Enrollment;Ensure;Environment;Exclusion Criteria;Extramural Activities;Foot Ulcer;Fostering;Funding;Goals;Health;Health system;Home;Hospitals;Human Resources;Indiana;Individual;Infrastructure;Institution;Interdisciplinary Education;Interdisciplinary Study;Leadership;Methodist Church;Mission;Monitor;National Institute of Diabetes and Digestive and Kidney Diseases;Nomenclature;Participant;Patient Recruitments;Patient-Focused Outcomes;Patients;Performance;Podiatry;Procedures;Productivity;Protocols documentation;Qualifying;Readiness;Recurrence;Resources;Rights;Safety;Schedule;Secure;Site;Time;Training;Translational Research;Travel;United States National Institutes of Health;Universities;Visit;Water;biobank;biomarker validation;c-myc Genes;care delivery;care providers;clinical center;clinical research site;cost;experience;healing;improved;innovation;medical schools;pandemic disease;patient oriented;patient population;patient retention;programs;recruit;response;social health determinants;success;wound;wound care;wound healing,Diabetic Foot Consortium Clinical Research Unit,Project NarrativeAmong patients with diabetes 15% develop a foot ulcer and 12-24% of individuals with a foot ulcer requireamputation. This proposal seeks continuation of an established Clinical Research Unit (CRU) participating inthe NIH Diabetic Foot Consortium (DFC). DFC conducts clinical research on Americans with diabetic foot ulcer(DFU) with the goal to improve care and minimize amputation.,NIDDK,10804694,1/18/2024 12:00:00 AM,RFA-DK-22-509,5U01DK119099-08,5,U01,DK,119099,08, ,"LI, YAN",9/21/2018 12:00:00 AM,12/31/2027 12:00:00 AM,ZDK1-GRB-1(J2), ,6355716,"SEN, CHANDAN K","GORDILLO, GAYLE M; ROY, SASHWATI ",12,INTERNAL MEDICINE/MEDICINE,004514360,MKAGLD59JRL1,004514360,MKAGLD59JRL1,US,40.440909,-79.959125,2059802,UNIVERSITY OF PITTSBURGH AT PITTSBURGH,PITTSBURGH,PA,SCHOOLS OF MEDICINE,152133320,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Non-SBIR/STTR,2024,781757, ,NIDDK,738303,435599, ,781757,,781757.0 | |
| No NIH Category available,Address;Affect;Agreement;Autoimmune Diseases;Benzene;Biological Markers;Biopsy;Caring;Cellular Phone;Classification;Clinical;Clinical Trials;Clinical assessments;Cutaneous;Cutaneous sclerosis;Dermal;Devices;Disease;Disease Marker;Disease Progression;Early Intervention;Edema;Enrollment;Evaluation;Evolution;Frequencies;Histologic;Histology;Image Analysis;Impairment;Interobserver Variability;Life;Link;Lung;Lung Diseases;Machine Learning;Measurement;Measures;Mechanics;Morbidity - disease rate;Multi-site clinical study;Organ;Outcome Measure;Pathology;Patient Outcomes Assessments;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Physicians;Predictive Value;Protocols documentation;Provider;Quality of life;Reproducibility;Rheumatism;Scleroderma;Services;Severities;Severity of illness;Skin;Staging;Standardization;Structure;Systemic Scleroderma;Testing;Therapy Clinical Trials;Thick;Time;Tissue Model;Tissues;Ultrasonography;Validation;Veterans;chronic graft versus host disease;clinical phenotype;cohort;contaminated water;diagnostic biomarker;disability;graft vs host disease;handheld equipment;improved;insight;instrument;mortality;novel therapeutics;primary outcome;response;skin disorder;skin fibrosis;subcutaneous;systemic autoimmune disease;tool;treatment response;ultrasound;user-friendly,Quantitative assessment of cutaneous systemic sclerosis.,Systemic sclerosis (SSc) is a life-altering autoimmune disease that is overrepresented in Veteransdue to service-related exposures. It has a progressive and mostly devastating course with thehighest mortality of all rheumatologic diseases. Although SSc affects many organs of the bodyhardening of the skin is the most common and distinct feature and a primary cause of disability anddecreased quality of life. Importantly skin changes guide treatment. Recently promising newtherapies have emerged for SSc but clinical trials of these therapies are hampered by the lack ofreliable ways to measure the complexities of skin changes. To tackle this important clinical challengewe propose a handheld device the Myoton that noninvasively and rapidly measures manymechanical attributes of the skin. We will rigorously validate the Myoton as a practical and objectivetool to aid with SSc staging and evaluation in Veterans with this debilitating disease.,VA,10804755,2/26/2024 12:00:00 AM,RFA-CX-23-001,1I01CX002721-01,1,I01,CX,002721,01, , ,1/1/2024 12:00:00 AM,12/31/2027 12:00:00 AM,ZRD1-IMMA-G(01), ,9357041,"TKACZYK, ERIC R",Not Applicable,05,Unavailable,156385783,M4CNTUL3N9L7,156385783,M4CNTUL3N9L7,US,35.9273,-86.381058,481084,VETERANS HEALTH ADMINISTRATION,NASHVILLE,TN,Independent Hospitals,372122637,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Ablation;Acute;Adolescence;Adult;Age;Animal Model;Astrocytes;Autoradiography;Back;Binding;Biological Models;Blood;Brain;Brain Diseases;Brain imaging;Cell Communication;Cell surface;Cells;Characteristics;Clinical;Clinical Research;Corpus striatum structure;Cross-Sectional Studies;Data;Data Collection;Decision Making;Development;Diet;Disease;Dopamine;Down-Regulation;Drug Kinetics;Elements;Embryonic Development;Environmental Risk Factor;Extracellular Matrix;Functional disorder;Gene Expression Profile;Genes;Genetic;Genetic Models;Genetic Predisposition to Disease;Glutamates;Hippocampus;Human;Image;Immune;Immune response;Immunocompetent;Impaired cognition;Impairment;Individual;Infiltration;Inflammation;Inflammatory;Interview;Learning;Lipopolysaccharides;Lymphocyte;Macrophage;Macrophage Colony-Stimulating Factor Receptor;Maintenance;Measures;Microglia;Modeling;Monitor;Morphology;Mus;Neuronal Plasticity;Neurons;Neuropsychology;Patients;Performance;Peripheral;Phenotype;Population;Positioning Attribute;Positron-Emission Tomography;Prefrontal Cortex;Property;Proteins;Psychoses;Publishing;Receptor Protein-Tyrosine Kinases;Receptor Signaling;Reporting;Role;Sampling;Schizophrenia;Short-Term Memory;Signal Transduction;Stress;Structure;Surface;Temporal Lobe;Therapeutic;Translational Research;Validation;Viral;brain parenchyma;brain shape;brain tissue;cell type;cognitive control;comparison control;cytokine;design;glial activation;imaging agent;imaging biomarker;immune activation;in vivo;molecular imaging;mouse model;neural circuit;neuroepithelium;neuroimaging;neuroinflammation;neurotransmission;nonhuman primate;offspring;pharmacologic;postnatal;prenatal;presynaptic;radiotracer;receptor;response;targeted imaging;tool;translational study;trend;uptake;white matter,Imaging microglial dysfunction in schizophrenia,PROJECT NARRATIVEThis project aims to study a marker expressed by microglia the resident immune cells in the brain using a newimaging agent [11C]CPPC. The availability of this microglial marker in the striatum and dorsolateral prefrontalcortex in brains of those with recent onset of schizophrenia and healthy controls will be compared. We will alsoassess the relationship between the microglial imaging marker and clinical signs characteristic of SZ.,NIMH,10805535,11/17/2023 12:00:00 AM,PA-21-235,1R21MH133015-01A1,1,R21,MH,133015,01,A1,"WIJTENBURG, ANDREA",11/17/2023 12:00:00 AM,10/31/2025 12:00:00 AM,"Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]", ,10581205,"COUGHLIN, JENNIFER MARIE",Not Applicable,07,PSYCHIATRY,001910777,FTMTDMBR29C7,001910777,FTMTDMBR29C7,US,39.325256,-76.605131,4134401,JOHNS HOPKINS UNIVERSITY,BALTIMORE,MD,SCHOOLS OF MEDICINE,212182680,UNITED STATES,N,11/17/2023 12:00:00 AM,10/31/2024 12:00:00 AM,242,Non-SBIR/STTR,2024,243139, ,NIMH,150000,93139, ,243139,,243139.0 | |
| No NIH Category available,Address;Affect;Age;Aging;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimer's disease related dementia;Amyloid beta-Protein;Autopsy;Behavior;Behavioral;Biological Markers;Brain;Brain Stem;Cells;Cessation of life;Characteristics;Circadian Dysregulation;Circadian Rhythms;Clinical;Cognition;Cognitive;Data;Dementia;Deposition;Diagnosis;Disease;Early identification;Elderly;Frontotemporal Dementia;Goals;Hour;Hypothalamic structure;Individual;Lewy Body Dementia;Life;Lobe;Measures;Memory;Napping;Nature;Nerve Degeneration;Nervous System Disorder;Neurodegenerative Disorders;Neurons;Optics;Parkinson Disease;Pathologic;Pathology;Patients;Pattern;Persons;Phase;Play;Process;Proteins;REM Sleep Behavior Disorder;Research;Rest;Role;Sampling;Sleep;Sleep Fragmentations;Sleep disturbances;Structure;Testing;Time;Validation;Vasopressins;Work;Wrist;actigraphy;alpha synuclein;circadian;cohort;demented;endophenotype;falls;hypocretin;locus ceruleus structure;nerve supply;neurodegenerative dementia;neuron loss;neuronal survival;neuropathology;normal aging;pre-clinical;preoptic nucleus;preservation;prospective;protein TDP-43;sleep regulation;specific biomarkers;suprachiasmatic nucleus;symptomatology;synucleinopathy;tau-1;tool,Wake-sleep Circuitry in Neurodegenerative Dementias,Project NarrativeOlder people sleep less have more fragmented sleep and nap more during the day but the cause of thesechanges is not known. However we now know that neurodegenerative processes deposit the hallmarkproteins for Alzheimers disease (Abeta and phospho-tau) Parkinsons disease (phospho--synuclein) andfronto-temporal lobe dementia (phospho-TDP-43) in neurons in the brain for many years before theneurological disorder can be diagnosed. We will investigate whether the aging changes in sleep are due to thedeposition of these pathological proteins in neurons in the wake-sleep and circadian circuitry in the brain andmay serve as a biomarker for these disorders.,NIA,10805582,11/16/2023 12:00:00 AM,PAR-22-093,1R01AG082016-01A1,1,R01,AG,082016,01,A1,"MACKIEWICZ, MIROSLAW",12/1/2023 12:00:00 AM,11/30/2028 12:00:00 AM,Clinical Neuroscience and Neurodegeneration Study Section[CNN], ,1901374,"SAPER, CLIFFORD B",Not Applicable,07,Unavailable,071723621,C1CPANL3EWK4,071723621,C1CPANL3EWK4,US,42.33982,-71.10568,758101,BETH ISRAEL DEACONESS MEDICAL CENTER,BOSTON,MA,Independent Hospitals,022155400,UNITED STATES,N,12/1/2023 12:00:00 AM,11/30/2024 12:00:00 AM,866,Non-SBIR/STTR,2024,900121, ,NIA,601467,298654, ,900121,,900121.0 | |
| No NIH Category available,Autoradiography;BRCA mutations;Binding;Biological Assay;Biological Markers;Breast;Cancer Center;Cancer Patient;Chemistry;Clinical;Clinical Data;Clinical Trials;Data;Defect;Development;Diagnosis;Diagnostic;Elements;Formalin;Freezing;Future;Gene Mutation;Good Manufacturing Process;Image;Immunofluorescence Immunologic;Immunohistochemistry;In Vitro;Label;Lead;Licensing;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of ovary;Measures;Methodology;Methods;Multicenter Trials;Ovarian;PET/CT scan;Paraffin Embedding;Patients;Pennsylvania;Pharmaceutical Preparations;Phase;Poly(ADP-ribose) Polymerase Inhibitor;Poly(ADP-ribose) Polymerases;Polymerase;Positron-Emission Tomography;Principal Investigator;Production;Prostate;Protocols documentation;Radiopharmaceuticals;Reference Standards;Research;Site;Specific qualifier value;Standardization;Testing;Time;Tissue Embedding;Tissues;Toxic effect;Tracer;Universities;Validation;Washington;analog;clinical translation;commercialization;design;diagnostic accuracy;homologous recombination;imaging biomarker;improved;in vivo;industry partner;inhibitor therapy;manufacture;neoplastic cell;novel therapeutics;phase 3 study;phase II trial;phase III trial;predicting response;programs;prospective;targeted treatment;trial comparing;trial design;tumor;uptake;wasting,Breast Cancer PARP PET Imaging AIP to Support FDA Approval & Commercialization,Narrative:Poly polymerase inhibitor drugs (PARPi's) have emerged as important new therapeutic agents targeting abroadening class of gene mutations present in breast ovarian prostate and a host of other cancers. To furtherthe development clinical translation and commercialization of [18F]Fluorthanatrace ([18F]FTT) a PET tracer ofPARP1 expression and drug binding we propose an Academic Industrial Partnership (AIP) comprised of TheUniversity of Pennsylvania (lead academic partner) MD Anderson Cancer Center and Washington Universitywith Trevarx Biomedical Inc. The proposed effort by the AIP will generate elements to design and implement apivotal Phase 3 trial for [18F]FTT FDA approval as well as support [18F]FTT commercial supply andongoing/future research evaluating the value of [18F]FTT PET/CT for guiding PARP inhibitor treatment to thebenefit of many cancer patients.,NCI,10806137,2/27/2024 12:00:00 AM,PAR-20-155,5R01CA258717-04,5,R01,CA,258717,04, ,"SALVADOR MORALES, CAROLINA",3/24/2021 12:00:00 AM,2/28/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-SBIB-Q(57)R], ,1891470,"MANKOFF, DAVID A.","LIN, LILIE LEMING; MCDONALD, ELIZABETH ",03,RADIATION-DIAGNOSTIC/ONCOLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,538137, ,NCI,419618,118519, ,538137,,538137.0 | |
| No NIH Category available,Alzheimer's Disease;Anatomy;Animal Experimentation;Animals;Architecture;Award;BRAIN initiative;Biological;Boston;Brain;Cell Physiology;Cells;Chemicals;Cognition;Cues;Data;Deep Brain Stimulation;Diffusion;Diffusion Magnetic Resonance Imaging;Dimensions;Early Diagnosis;Foundations;Functional Magnetic Resonance Imaging;Funding;Hippocampus;Human;Image;Imaging technology;Individual;Institution;Knowledge;Learning;Link;Magnetic Resonance Imaging;Maps;Memory;Memory impairment;Mentors;Methodology;Methods;Modeling;Molecular;Neurites;Neuroanatomy;Neurobiology;Neuronal Plasticity;Pathologic;Performance;Phase;Physiology;Property;Protocols documentation;Research;Resolution;Rodent;Role;Route;Signal Transduction;Specificity;Structure;System;Techniques;Technology;Time;Training;Universities;Validation;behavior test;cognitive neuroscience;connectome;density;dentate gyrus;design;diagnostic tool;efficacy evaluation;expectation;gray matter;in vivo;magnetic resonance imaging biomarker;mathematical model;memory encoding;millimeter;neural;neuroimaging;neuronal cell body;next generation;non-invasive imaging;programs;reconstruction;repair function;repaired;response;skills;spatial memory;tool;way finding,Revealing the Functional and Microstructural Response of Human Hippocampus to Spatial Learning with High-Gradient Strength Diffusion MRI,Revealing the Functional and Microstructural Response of Human Hippocampus to Spatial Learning with High-Gradient Strength Diffusion MRI,NINDS,10806311,2/8/2024 12:00:00 AM,RFA-NS-19-043,1K99NS132984-01A1,1,K99,NS,132984,01,A1,"JOHNSON, KARI ANNE",2/10/2024 12:00:00 AM,1/31/2026 12:00:00 AM,ZMH1-ERB-P(02), ,15804385,"RAMOS LLORDEN, GABRIEL ",Not Applicable,08,Unavailable,073130411,FLJ7DQKLL226,073130411,FLJ7DQKLL226,US,42.363198,-71.068772,4907701,MASSACHUSETTS GENERAL HOSPITAL,BOSTON,MA,Independent Hospitals,021142621,UNITED STATES,N,2/10/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Other Research-Related,2024,163327, ,NINDS,151229,12098, ,163327,,163327.0 | |
| No NIH Category available,Accounting;Address;Adult;Bioinformatics;Biological Markers;California;Caring;Chronic;Clinical;Clinical Data;Clinical Management;Clinical Trials;Communities;Controlled Clinical Trials;Data;Deglutition Disorders;Devices;Diagnosis;Diagnostic;Diagnostic Procedure;Digestive System Disorders;Disease;Double-Blind Method;Dysphonia;Ensure;Environment;Esophageal Diseases;Esophagus;Expenditure;Fluoroscopy;Future;Gastroesophageal reflux disease;Generations;Goals;Grant;Health;Health Care Costs;Inferior esophageal sphincter structure;Inflammation;Infrastructure;Institution;International;Knowledge;Larynx;Manometry;Measures;Mentored Patient-Oriented Research Career Development Award;Mentors;Mentorship;Metagenomics;Methods;Modernization;National Institute of Diabetes and Digestive and Kidney Diseases;Observational Study;Operative Surgical Procedures;Oral;Oral Characters;Outcomes Research;Pathway interactions;Patient Care;Patient-Focused Outcomes;Patients;Pepsin A;Pharyngeal structure;Phenotype;Physicians;Physiological;Physiology;Proton Pump Inhibitors;Randomized;Randomized Controlled Trials;Reflux;Research;Research Design;Research Institute;Research Personnel;Research Training;Resources;Salivary;Scientist;Screening procedure;Self-Help Devices;Seminal;Shotgun Sequencing;Signs and Symptoms;Source;Symptoms;Syndrome;Techniques;Testing;Therapeutic;Training;Translational Research;Treatment outcome;United States National Institutes of Health;Universities;Upper Esophageal Sphincter;Visit;Voice Disorders;Work;arm;authority;career;career development;clinical translation;colorectal cancer screening;constriction;cost;design;diagnostic biomarker;electric impedance;experience;gut microbiome;health care service utilization;healthcare burden;improved;indexing;innovation;laryngopharyngeal reflux;microbial;microbiome;microbiome research;microbiome sequencing;multidisciplinary;novel;novel diagnostics;novel therapeutics;oral microbial community;oral microbiome;poor health outcome;primary outcome;recruit;research facility;response;secondary outcome;skill acquisition;skills;supportive environment;targeted biomarker;tool;treatment strategy;trial design;validation studies,Mechanism Guided Therapy for Laryngopharyngeal Reflux,PROJECT NARRATIVEGeneralized approaches for laryngopharyngeal reflux (LPR) a prevalent syndrome in which laryngealsymptoms are attributed to gastroesophageal reflux disease have resulted in poor patient outcomesinappropriate utilization of healthcare resources and tremendous expenditure. Information from this biomarkertargeted randomized sham-controlled clinical trial of the upper esophageal sphincter assist device will beanalyzed using novel latent class and microbiomics methods in order to define a phenotype guided treatmentapproach for LPR and inform the mechanistic understanding of reflux associated oral microbiome changes asa source of chronic inflammation in LPR. These findings will ultimately contribute to developing modernpractice paradigms for LPR in order to optimize patient care as well as provide fundamental knowledge aboutmechanistic pathways and symptom generation in LPR.,NIDDK,10807014,4/19/2024 12:00:00 AM,PA-20-206,5K23DK125266-04,5,K23,DK,125266,04, ,"OSGANIAN, VOULA",5/7/2021 12:00:00 AM,3/31/2026 12:00:00 AM,Digestive Diseases and Nutrition C Study Section[DDK-C], ,14148302,"YADLAPATI, RENA HIREN",Not Applicable,50,INTERNAL MEDICINE/MEDICINE,804355790,UYTTZT6G9DT1,804355790,UYTTZT6G9DT1,US,32.876991,-117.24087,577507,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",LA JOLLA,CA,SCHOOLS OF MEDICINE,920930621,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,847,Other Research-Related,2024,192205, ,NIDDK,178116,14089, ,192205,,192205.0 | |
| No NIH Category available,Adenoid Cystic Carcinoma;Bioinformatics;Biological Markers;Biology;Breast;C-terminal;Cell Line;Cell model;Cells;Characteristics;Chimeric Proteins;Chromosomes;Clinic;Clinical;Data;Denmark;Development;Distant Metastasis;Enhancers;Epigenetic Process;Event;Gene Expression;Gene Expression Profile;Gene Expression Profiling;Genes;Genetic Transcription;Genomics;Glean;Goals;Growth;Heterogeneity;Human;Institution;Laboratories;Lacrimal gland structure;Lead;Learning;Length;MYB gene;MYBL1 gene;Methods;Molecular;Molecular Biology;Morbidity - disease rate;Morphology;Mus;Mutation;N-terminal;NFIB gene;Oncogenic;Oncoproteins;Operative Surgical Procedures;Paper;Patients;Positioning Attribute;Prognosis;Proteins;Publishing;Radiation;Reconstructive Surgical Procedures;Recurrence;Relapse;Research;Role;Salivary Gland Adenoid Cystic Carcinoma;Salivary Gland Neoplasms;Salivary Glands;Sampling;Shapes;Skin;Subgroup;Testing;Tissues;Training;Translating;Validation;Work;biomarker development;cohort;driver mutation;follow-up;high risk;migration;novel therapeutic intervention;overexpression;patient derived xenograft model;patient prognosis;patient subsets;promoter;relapse risk;sample archive;transcription factor;transcriptome sequencing;tumor;usability,Mutations and Target Genes in Adenoid Cystic Carcinoma,Narrative Adenoid Cystic Carcinoma (ACC) is a slow-growing salivary gland tumor that is treated by surgery andradiation often leaving patients disfigured and with significant morbidity. Many ACC patients survive more than10 years after the standard therapy of surgery and radiation but a fraction succumb much more quickly andothers acquire distant metastases or relapse 5 or more years after the initial treatment. This project will usedetailed RNA sequencing analyses to learn more about the biology of ACC tumors to identify the patients athighest risk of relapse and to translate our findings to clinical laboratories so the information can besuccessfully used to help patients.,NIDCR,10807057,1/17/2024 12:00:00 AM,PA-20-185,5R01DE023222-11,5,R01,DE,023222,11, ,"CHEN, ZHONG",9/10/2012 12:00:00 AM,2/29/2028 12:00:00 AM,"Oral, Dental and Craniofacial Sciences Study Section[ODCS]", ,8661961,"PALANISAMY, VISWANATHAN ",Not Applicable,01,INTERNAL MEDICINE/MEDICINE,829868723,G389MFAYJNG9,829868723,G389MFAYJNG9,US,35.090968,-106.617544,10021612,UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR,ALBUQUERQUE,NM,SCHOOLS OF MEDICINE,871310001,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,121,Non-SBIR/STTR,2024,428710, ,NIDCR,281121,147589, ,428710,,428710.0 | |
| No NIH Category available,Accident and Emergency department;Address;Allergic Disease;Anaphylaxis;Automobile Driving;Basophils;Biological Markers;Biological Products;Biology;Biometry;Cardiovascular system;Caring;Characteristics;Child;Clinical;Communities;Consensus;Crowding;Data;Derivation procedure;Development;Dose;Emergency Care;Emergency department visit;Enrollment;Epinephrine;Exhibits;Funding;Goals;Guidelines;Health Care Costs;Healthcare Systems;Histamine;Home;Hospitalization;Hour;Human;IL8 gene;IgE;Immunologics;Immunology;Infant;Infrastructure;Investigation;Knowledge;Life;Machine Learning;Measures;Mediating;Mediation;Mentored Patient-Oriented Research Career Development Award;Mission;Modeling;National Institute of Allergy and Infectious Disease;Neutrophil Activation;Outcome;Pathogenesis;Pathway interactions;Patient risk;Patient-Focused Outcomes;Patients;Peroxidases;Phase;Plasma;Prognostic Marker;Prospective Studies;Prospective cohort;Reaction;Refractory;Research;Research Personnel;Resolution;Retrospective cohort;Risk;Risk Factors;Role;S100A12 gene;Serum;Severities;Symptoms;System;Testing;Therapeutic;Time;Training;Tryptase;Urine;Wait Time;Wheezing;biomedical informatics;career development;clinical care;clinical predictive model;clinically actionable;cohort;diagnostic accuracy;diagnostic biomarker;hands-on learning;health care service utilization;improved;infrastructure development;mast cell;neutrophil;novel;novel therapeutics;patient stratification;pediatric emergency;personalized care;predictive modeling;prevent;prognostic;research and development;risk stratification;skills;success;tool;translational approach;translational scientist;treatment response;validation studies,Improving Anaphylaxis Outcomes Through Personalized Care Strategies,Project NarrativePediatric emergency department visits for anaphylaxis have tripled during the past decade with mandatoryprolonged observation periods driving emergency department overcrowding and excessive healthcare costs.There is a need for personalized clinical prediction models and the discovery of prognostic biomarkers toenhance patient risk stratification optimize observation periods and prevent unnecessary hospitalizations. Theresearch goals of this K23 award are consistent with the mission of NIAID to better understand treat andultimately prevent allergic diseases and will improve patient outcomes and optimize healthcare utilization.,NIAID,10807412,2/20/2024 12:00:00 AM,PA-20-205,1K23AI175525-01A1,1,K23,AI,175525,01,A1,"GONDRE-LEWIS, TIMOTHY A",2/20/2024 12:00:00 AM,1/31/2029 12:00:00 AM,"Allergy, Immunology, and Transplantation Research Committee[AITC]", ,16597395,"DRIBIN, TIMOTHY ERICK",Not Applicable,01,Unavailable,071284913,JZD1HLM2ZU83,071284913,JZD1HLM2ZU83,US,39.140663,-84.501007,615001,CINCINNATI CHILDRENS HOSP MED CTR,CINCINNATI,OH,Independent Hospitals,452293039,UNITED STATES,N,2/20/2024 12:00:00 AM,1/31/2025 12:00:00 AM,855,Other Research-Related,2024,192252, ,NIAID,178100,14152, ,192252,,192252.0 | |
| No NIH Category available,Adult;Applied Skills;Arsenic;Arsenicals;Bioinformatics;Biological;Biological Factors;Biological Markers;Biometry;Cardiovascular Diseases;Cardiovascular system;Cluster Analysis;Cohort Studies;Complex;DNA Methylation;DNA Methylation Regulation;Data;Development;Disease;Disease Outcome;Environmental Epidemiology;Environmental Risk Factor;Epigenetic Process;Ethnic Population;Etiology;Excretory function;Face;Family Study;Foundations;Genes;Genetic;Genetic Transcription;Genetic Variation;Health;Heart;Hepatic;Incidence;Individual;Ingestion;Link;Machine Learning;Measures;Mediating;Mediation;Mediator;Mentorship;Messenger RNA;Methods;Methylation;MicroRNAs;Molecular;Molecular Epidemiology;Morbidity - disease rate;Multiomic Data;Native American community;Native Americans;Outcome;Pathway Analysis;Pathway interactions;Phase;Phenotype;Population;Post-Transcriptional Regulation;Privatization;Process;Public Health;Quantitative Trait Loci;Regulation;Research;Research Personnel;Risk;Role;Signal Transduction;Testing;Toxic effect;Toxin;Training;United States;Urine;Work;anthropogenesis;biomarker development;biomarker validation;burden of chronic illness;candidate identification;carcinogenicity;cardiovascular disorder risk;cardiovascular risk factor;career;career development;circulating microRNA;cohort;disorder risk;drinking water;epigenetic marker;epigenetic regulation;epigenome-wide association studies;gene interaction;genetic epidemiology;high dimensionality;insight;machine learning method;methylation biomarker;microRNA biomarkers;mortality;multiple omics;posttranscriptional;prospective;public health intervention;recruit;rural Americans;rural residence;urinary,Epigenetic and genetic regulation of arsenic methylation and arsenic-relatedcardiovascular disease risk,Epigenetic and genetic regulation of arsenic methylation and arsenic-relatedcardiovascular disease risk,NIEHS,10807890,3/29/2024 12:00:00 AM,PA-20-188,1K99ES035109-01A1,1,K99,ES,035109,01,A1,"TYSON, FREDERICK L",4/1/2024 12:00:00 AM,3/31/2026 12:00:00 AM,ZES1-BWD-D(K9), ,12508479,"BOZACK, ANNE KRISTINA",Not Applicable,16,INTERNAL MEDICINE/MEDICINE,009214214,HJD6G4D6TJY5,009214214,HJD6G4D6TJY5,US,37.426852,-122.17047,8046501,STANFORD UNIVERSITY,STANFORD,CA,SCHOOLS OF MEDICINE,943052004,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,113,Other Research-Related,2024,125847, ,NIEHS,116525,9322, ,125847,,125847.0 | |
| No NIH Category available,ATPase inhibitory protein;Acceleration;Accounting;Address;Adult;Affect;Age;Age Months;Area;Biological Markers;Brain natriuretic peptide;Cardiac;Cardiac Death;Cardiac Myocytes;Cardiac Surgery procedures;Cessation of life;Characteristics;Child;Childhood;Clinical;Clinical Data;Clinical Research;Collaborations;Complex;Deformity;Development;Digoxin;Disease;Doctor of Philosophy;Dose;Drug Combinations;Drug Exposure;Drug Kinetics;Echocardiography;Environment;Equation;Event;Failure;Goals;Growth;Half-Life;Heart Transplantation;Heart failure;Hospitalization;Image;Infant;Infant Mortality;Injury to Kidney;Kidney;Knowledge;Measures;Metabolic;Morbidity - disease rate;Myocardium;N-terminal;National Institute of Child Health and Human Development;Network Infrastructure;Outcome;Pathologic;Patients;Pharmaceutical Preparations;Pharmacodynamics;Pharmacologic Substance;Pharmacotherapy;Physiological;Plasma;Population;Principal Investigator;Public Health;Recording of previous events;Renal function;Research;Research Institute;Retrospective Studies;Science;Single ventricle congenital heart disease;Surrogate Markers;Symptoms;Therapeutic;Therapeutic Index;Treatment Failure;Validation;data access;dosage;drug action;drug development;drug disposition;experience;glomerular filtration;heart function;heart imaging;imaging biomarker;improved;infancy;member;model development;mortality;multidisciplinary;neonate;novel strategies;pediatric heart failure;pharmacodynamic model;pharmacokinetics and pharmacodynamics;pharmacologic;predictive modeling;prospective;response;skills;therapeutic development,Digoxin Pharmacodynamics in Infants with Heart Failure due to Single Ventricle Congenital Heart Disease,Identifying efficacious drugs for the treatment of heart failure will save infant lives but successful drugdevelopment in this population is dependent upon integration of growth maturation and disease specificinfluences on drug disposition and response. These factors are often ignored in infant heart failure trials. Ourmultidisciplinary team will systematically and efficiently characterize and validate the exposure-responserelationship of the heart failure probe drug digoxin in infants with heart failure from single ventricle congenitalheart disease; this disruptive approach is translatable to other therapeutics to broadly impact outcomes in thispopulation.,NICHD,10807963,2/29/2024 12:00:00 AM,PAR-20-300,5R01HD106588-03,5,R01,HD,106588,03, ,"PILEGGI, ANTONELLO",4/1/2022 12:00:00 AM,2/28/2026 12:00:00 AM,Special Emphasis Panel[ZRG1-EMNR-S(55)R], ,12233776,"HORNIK, CHRISTOPH ",Not Applicable,04,PEDIATRICS,044387793,TP7EK8DZV6N5,044387793,TP7EK8DZV6N5,US,36.007766,-78.926475,2221101,DUKE UNIVERSITY,DURHAM,NC,SCHOOLS OF MEDICINE,277054673,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,865,Non-SBIR/STTR,2024,629432, ,NICHD,433248,196184, ,629432,,629432.0 | |
| No NIH Category available,Address;Advocate;Anatomy;Bayesian Method;Biochemical;Biological Markers;Brain;Brain Neoplasms;Brain imaging;Brain scan;Cell Nucleus;Central Nervous System;Central Nervous System Diseases;Cerebrospinal Fluid;Chronic;Clinical;Clinical Protocols;Communities;Coupling;Data;Detection;Development;Diagnosis;Energy Metabolism;Environment;Evaluation;Excision;Functional disorder;Generations;Goals;Homeostasis;Human;Image;Intervention;Ion Pumps;Lesion;MRI Scans;Magnetic Resonance Imaging;Maps;Measures;Methodology;Monitor;Na(+)-K(+)-Exchanging ATPase;Nature;Noise;Pathologic;Pathology;Patients;Performance;Positron-Emission Tomography;Property;Protocols documentation;Protons;Relaxation;Research;Resolution;Scheme;Signal Transduction;Slice;Sodium;System;Techniques;Tissues;Validation;brain tissue;clinical implementation;clinically relevant;data acquisition;detection sensitivity;experience;follow-up;gray matter;human imaging;image reconstruction;imaging system;improved;in vivo;magnetic field;neuroimaging;novel;novel strategies;reconstruction;research clinical testing;sodium ion;success;tissue biomarkers;white matter,Anatomically Guided Sodium MRI: Accurately Monitoring Chronic Ion Pump Dysfunction in the Human Brain,PROJECT NARRATIVE:This project will develop new methodology for improving the resolution of sodium images from the humanbrain. There have been approaches for generating sodium images of the brain using imaging times that aresuitable for routine clinical use however these images suffer from significant blur as a result of the demandingnature of this brain imaging application (much weaker signal than conventional MRI vanishing very quickly afterit has been generated). Our approach seeks to reduce the deleterious effects of this blur through the use ofanatomical information from concurrently acquired high-resolution conventional MRI scans of the brain.,NIBIB,10808128,5/1/2024 12:00:00 AM,PA-20-185,5R01EB031199-03,5,R01,EB,031199,03, ,"BARRY, ROBERT LEO II",5/1/2022 12:00:00 AM,1/31/2026 12:00:00 AM,Emerging Imaging Technologies in Neuroscience Study Section[EITN], ,1865581,"BOADA, FERNANDO E",Not Applicable,16,RADIATION-DIAGNOSTIC/ONCOLOGY,009214214,HJD6G4D6TJY5,009214214,HJD6G4D6TJY5,US,37.426852,-122.17047,8046501,STANFORD UNIVERSITY,STANFORD,CA,SCHOOLS OF MEDICINE,943052004,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,286,Non-SBIR/STTR,2024,557250, ,NIBIB,394750,162500, ,557250,,557250.0 | |
| No NIH Category available,Address;Appearance;Automobile Driving;Biological Markers;Biopsy;DNA Methylation;Data;Dental;Disease;Disease Progression;Epigenetic Process;Event;Gene Targeting;Genomic Segment;Genomics;Goals;Head and Neck Squamous Cell Carcinoma;Health;High grade dysplasia;Human;Incidence;Intervention;Knowledge;Left;Lesion;Logistic Regressions;Longitudinal Studies;Longterm Follow-up;Malignant - descriptor;Malignant Neoplasms;Medical;Methods;Methylation;Minority;Modeling;Modification;Morphology;Mucous Membrane;Mutation;Nucleotides;Oral;Outcome;Output;Patients;Prevention strategy;Proteins;Public Health;Reporting;Research;Resolution;Risk;Risk Assessment;Sampling;Site;Testing;Tobacco;Training;Treatment Side Effects;Validation;Visit;Width;bisulfite sequencing;cancer prevention;cancer risk;carcinogenicity;evidence base;gene environment interaction;gene function;high risk;improved;learning algorithm;machine learning algorithm;malignant mouth neoplasm;methylome;mouth squamous cell carcinoma;novel;oral cancer prevention;oral carcinogenesis;oral cavity epithelium;oral dysplasia;personalized strategies;predictive marker;predictive modeling;premalignant;preservation;programs;random forest;risk prediction;risk prediction model;screening;sequencing platform;side effect;whole genome,Discovery of New DNA Methylation Biomarkers for Predicting the Malignant Outcome of Low-Grade Oral Dysplasia,PROJECT NARRATIVEThis project will discover new DNA methylation targets that can be used as biomarkers to predict the risk oflow-grade oral premalignant lesions (OPLs) in becoming oral cancers. It is relevant to public health becausethe obtained information will allow the implementation of evidence-based personalized strategies for OPLtreatment and oral cancer prevention as well as advancing our knowledge on the epigenetic mechanismsdriving the malignant progression of OPLs.,NIDCR,10808193,3/6/2024 12:00:00 AM,PA-20-195,5R21DE032821-02,5,R21,DE,032821,02, ,"BACCAGLINI, LORENA",4/1/2023 12:00:00 AM,3/31/2025 12:00:00 AM,Cancer Genetics Study Section[CG], ,7932542,"TSAI, ROBERT Y",Not Applicable,10,INTERNAL MEDICINE/MEDICINE,835607441,HFT7XTHB6563,835607441,HFT7XTHB6563,US,30.551654,-96.242881,8266910,TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR,COLLEGE STATION,TX,OVERALL MEDICAL,778454375,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,121,Non-SBIR/STTR,2024,189981, ,NIDCR,125400,64581, ,189981,,189981.0 | |
| No NIH Category available,Address;Advanced Development;Animals;Biochemical;Biochemistry;Biological Assay;Biological Markers;Biology;Biomedical Engineering;Biomedical Research;Breast Cancer cell line;Cancer Detection;Cell Culture Techniques;Cell Line;Cells;Cellular Metabolic Process;Characteristics;Chemicals;Chemistry;Collaborations;Color;Creativeness;Cyclotrons;Dependence;Detection;Development;Diabetes Mellitus;Diagnostic;Dietary Sugars;Discrimination;Disease;Disease Progression;Early Diagnosis;Education;Engineering;Environment;Fingerprint;Flow Cytometry;Fluorescence;Fostering;Foundations;Fructose;GLUT-2 protein;Glucose;Glucose Transporter;Goals;Growth;Health;Image;Imaging Techniques;Knowledge;Label;Link;Literature;Malignant Breast Neoplasm;Malignant Neoplasms;Mammalian Cell;Measures;Metabolic;Metabolic Diseases;Metabolism;Methods;Michigan;Mission;Modeling;Molecular;Molecular Probes;Molecular Target;Monitor;Normal Cell;Nutritional;Obesity;Onset of illness;Organic Chemistry;Organic Synthesis;Outcomes Research;Oxidative Stress;Patients;Positron-Emission Tomography;Radiolabeled;Research;Research Personnel;Research Project Grants;SLC2A1 gene;SLC2A12 gene;Scientist;Stimulus;Strategic Planning;Structure;Students;Supervision;Testing;Therapeutic;United States National Institutes of Health;Universities;Validation;Visualization;Work;Yeasts;analog;cancer cell;cancer diagnosis;cancer type;cell type;cellular imaging;design;disease diagnosis;educational atmosphere;experience;hands on research;imaging agent;imaging probe;improved;in vivo;in vivo imaging;innovation;interest;molecular modeling;multidisciplinary;next generation;non-invasive imaging;novel;programs;pyranose;radiotracer;real time monitoring;response;screening;sugar;targeted agent;therapeutic target;treatment response;undergraduate student;uptake,Molecular probes for targeting facilitative fructose transporters (GLUTs) in biochemical and biomedical applications,PROJECT NARRATIVEAlterations in sugar uptake and activity of facilitative sugar transporters GLUTs - arise as a biomarker ofmetabolic diseases such as obesity diabetes and cancer. Understanding the differences the composition andactivity of GLUTs between cells provides the grounds for distinguishing cell types and subtypes and for moreaccurate detection of metabolically compromised cells. The current research established GLUT-specificfluorescently-labeled molecular probes for application in biochemical and biomedical research and cancerdetection.,NCI,10808247,12/6/2023 12:00:00 AM,PAR-21-155,2R15CA242401-02A1,2,R15,CA,242401,02,A1,"WANG, WENDY",7/3/2019 12:00:00 AM,11/30/2026 12:00:00 AM,Chemical Biology and Probes Study Section[CBP], ,12078290,"TANASOVA, MARINA ",Not Applicable,01,CHEMISTRY,065453268,GKMSN3DA6P91,065453268,GKMSN3DA6P91,US,47.116169,-88.53931,5230701,MICHIGAN TECHNOLOGICAL UNIVERSITY,HOUGHTON,MI,SCHOOLS OF ARTS AND SCIENCES,499311295,UNITED STATES,N,12/6/2023 12:00:00 AM,11/30/2026 12:00:00 AM,394,Non-SBIR/STTR,2024,455433, ,NCI,300000,155433, ,455433,,455433.0 | |
| No NIH Category available,3-Dimensional;Academia;Acute;Address;Admission activity;Age;Animal Model;Anti-Inflammatory Agents;Autopsy;Biochemical;Biological Markers;Blinded;Blood;Blood - brain barrier anatomy;Blood Pressure;Brain;Brain Ischemia;Brain hemorrhage;Cerebral Ischemia;Cerebral hemisphere hemorrhage;Cerebrospinal Fluid;Cessation of life;Clinical Research;Clinical Trials;Clinical Trials Design;Complex;Conduct Clinical Trials;DNA;Data;Diffusion Magnetic Resonance Imaging;Disabled Persons;Disease;Edema;Endothelium;Event;Extravasation;Future;Gatekeeping;Generations;Goals;Hemorrhage;Histology;Histones;Hospitalization;Hospitals;Hour;Image;Industry;Infarction;Infiltration;Inflammation;Injury;Innate Immune Response;Intercellular adhesion molecule 1;International;Ischemia;Ischemic Stroke;Length of Stay;Lesion;Leukoaraiosis;Light;Magnetic Resonance Imaging;Measurement;Measures;Mediating;Mediator;Mentors;Microvascular Dysfunction;Modeling;Nervous System Disorder;Neuronal Injury;Outcome;Outcome Measure;Participant;Patient Recruitments;Patients;Pennsylvania;Peroxidases;Pharmaceutical Preparations;Plasma;Process;Prospective Studies;Prospective cohort;Proteins;Reporting;Research;Resolution;Sample Size;Scientist;Serum;Severities;Stroke;Subarachnoid Hemorrhage;Survivors;Symptoms;TRAP Complex;Testing;Therapeutic;Thrombosis;Thrombus;Time;Tissues;Universities;Work;biomarker validation;brain magnetic resonance imaging;brain tissue;career;cerebral microbleeds;disability;effective therapy;extracellular;imaging biomarker;innovation;ischemic lesion;magnetic resonance imaging biomarker;migration;molecular marker;mortality;neurofilament;neuroimaging;neuron loss;neutrophil;novel;novel therapeutics;observational cohort study;pathogen;prevent;prospective;recruit;response;success;therapeutic target;tissue injury;treatment trial;trial design;usability,Neutrophil extracellular traps and high-precision MRI measures of tissue injury after intracerebral hemorrhage,PROJECT NARRATIVEA deeper understanding of injury processes in spontaneous intracerebral hemorrhage (ICH) a severe form ofhemorrhagic stroke for which there are no effective treatments is critical. Through serum plasma andcerebrospinal fluid measures of maladaptive neutrophil inflammation (neutrophil extracellular traps NETs)transendothelial neutrophil migration (soluble intercellular adhesion molecule-1) and brain tissue injury(neurofilament light chain NfL) and by using an innovative high-resolution brain MRI approach in a prospectivecohort of patients with ICH the goal of this proposal is to acquire expertise in biomarker validation clinical studyconduct and the use of imaging markers as endpoints in clinical trials in patients with ICH. This proposal willidentify the contribution of NETs to local (edema) and remote (ischemic lesions) tissue injury both associatedwith poor outcome after ICH which may define novel treatment targets for patients with ICH at the level ofneutrophil migration activation or generation of NETs (NETosis).,NINDS,10808669,2/15/2024 12:00:00 AM,PA-20-205,1K23NS131588-01A1,1,K23,NS,131588,01,A1,"KOENIG, JAMES I",3/1/2024 12:00:00 AM,2/28/2029 12:00:00 AM,NST-1 Study Section[NST-1], ,14594900,"WITSCH, JENS JULIAN",Not Applicable,03,NEUROLOGY,042250712,GM1XX56LEP58,042250712,GM1XX56LEP58,US,39.953462,-75.193983,6463801,UNIVERSITY OF PENNSYLVANIA,PHILADELPHIA,PA,SCHOOLS OF MEDICINE,191046205,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,853,Other Research-Related,2024,231255, ,NINDS,214125,17130, ,231255,,231255.0 | |
| No NIH Category available,Acute Respiratory Distress Syndrome;Address;Affect;Alveolar;Angiopoietin-2;Animals;Biodistribution;Bioinformatics;Biological;Biostatistics Core;Blood;Blood Vessels;California;Carbon Dioxide;Cell Fraction;Cell Separation;Cells;Classification;Clinical;Complication;Critical Care;Data;Data Set;Development;Disease;Doctor of Philosophy;Endothelial Cells;Endothelium;Epithelium;Functional disorder;Future;Gases;Genetic Transcription;Goals;Heterogeneity;Human;Infection;Inflammatory Response;Injury;Intervention Studies;Knowledge;Lobar;Los Angeles;Lung;Lung Diseases;Malignant Neoplasms;Measures;Mechanical ventilation;Mediating;Mediation;Medicine;Mentored Patient-Oriented Research Career Development Award;Mentors;Methodology;Nature;Operative Surgical Procedures;Organ;Outcome;Oxygen;PTPRC gene;Pathogenesis;Pathologic;Pathway Analysis;Pathway interactions;Patients;Peripheral Blood Mononuclear Cell;Pharmacologic Substance;Physicians;Physiological;Plasma;Play;Pneumonia;Population;Protein C;Proteins;Proteomics;Public Health;RNA;Research;Research Personnel;Resistance;Respiratory Failure;Role;Sampling;Science;Sepsis;Severities;Severity of illness;Signal Pathway;Signal Transduction;Source;Survivors;Syndrome;System;Techniques;Testing;Thrombomodulin;Training;Translational Research;Trauma;Universities;Validation;Vasculitis;Work;absorption;biobank;career;career development;circulating biomarkers;clinical trial recruitment;cohort;design;effective therapy;endothelial dysfunction;experience;graft dysfunction;hypoperfusion;individualized medicine;innovation;insight;large datasets;lung injury;mortality;multidisciplinary;novel;novel marker;novel therapeutics;observational cohort study;patient oriented research;peripheral blood;post-transplant;prospective;protein biomarkers;pulmonary function;single-cell RNA sequencing;therapeutic target;tool;transcriptome;transcriptome sequencing;transcriptomics;translational scientist;tumor immunology;vascular injury;ventilation;von Willebrand Factor,Investigating the Role of Vascular Injury and Physiologic Dead Space in the Acute Respiratory Distress Syndrome,Project NarrativeThe proposed research is relevant to public health because acute respiratory distress syndrome (ARDS) is a seriouscomplication of several conditions including respiratory failure from pneumonia other infection cancer organdysfunction surgery and trauma requiring mechanical ventilation and can lead to mortality in as much as 50% of thoseaffected. ARDS has been described for over 50 years however its heterogeneity has precluded the identification ofeffective treatments and thus categorizing the syndrome based on what signaling cascades are affected may allow for thedisease to be classified into subtypes. In deciphering the subtype of ARDS that involves lung vascular function essentialfor absorption of oxygen from the lungs and expulsion of carbon dioxide from the body we may identify therapies thatmay not have worked for a non-differentiated population of ARDS patients.,NHLBI,10808804,12/29/2023 12:00:00 AM,PA-20-205,1K23HL165149-01A1,1,K23,HL,165149,01,A1,"KALANTARI, ROYA",1/1/2024 12:00:00 AM,12/31/2028 12:00:00 AM,NHLBI Mentored Patient-Oriented Research Study Section[MPOR(OA)], ,15962694,"COSTA MONTEIRO, ANA CAROLINA ",Not Applicable,36,INTERNAL MEDICINE/MEDICINE,092530369,RN64EPNH8JC6,092530369,RN64EPNH8JC6,US,34.070199,-118.45102,577505,UNIVERSITY OF CALIFORNIA LOS ANGELES,LOS ANGELES,CA,SCHOOLS OF MEDICINE,900952000,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,838,Other Research-Related,2024,181980, ,NHLBI,168500,13480, ,181980,,181980.0 | |
| No NIH Category available,Acceleration;African American;Aging;Alzheimer's Disease;Alzheimer's Disease Pathway;Alzheimers disease biomarker;American;Amyloid beta-Protein;Autopsy;Biological;Biological Markers;Blood;Blood specimen;Brain;Brain region;Cell Nucleus;Cerebrospinal Fluid;Clinic;Clinical;Clinical Research;Cognitive;Collection;Communities;Complex;DNA Methylation;Data;Data Set;Diagnosis;Diagnostic;Discipline;Disease;Disease Progression;Education and Outreach;Environment;Epigenetic Process;Ethnic Population;Functional disorder;Funding;Future;Generations;Genetic;Image;Impaired cognition;Individual;Institution;Knowledge;Latino;Link;Liquid substance;Measures;Molecular;Molecular Profiling;Multiomic Data;Nerve Degeneration;Not Hispanic or Latino;Office of Administrative Management;Onset of illness;Outcome;Participant;Pathologic;Pathology;Pathway interactions;Pattern;Peripheral;Phenotype;Population;Process;Prognosis;Prognostic Marker;Proteome;Public Health;Publishing;Research;Resources;Sampling;Therapeutic;Translations;Underrepresented Populations;United States National Institutes of Health;Validation;Vascular Diseases;Work;biomarker discovery;biomarker validation;blood-based biomarker;brain cell;cell type;clinical biomarkers;clinical phenotype;cohort;comorbidity;data sharing;diagnostic biomarker;endophenotype;insight;knowledge base;lipidome;metabolome;multi-ethnic;multidimensional data;multimodality;multiple omics;neuroimaging;neuropathology;new therapeutic target;next generation;open data;precision medicine;predictive signature;prognostic;recruit;specific biomarkers;targeted treatment;tau Proteins;therapeutic target;transcriptome sequencing;transcriptomics;trial readiness;validation studies,Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations,Project Narrative (3 sentences):There is a clear and immediate need for the discovery of peripheral molecular signatures linked to centraldisease processes core and co-pathologies in Alzheimers Disease (AD) that will serve as precision medicineblood-based biomarkers for diagnostic prognostic theragnostic and therapeutic purposes. AD is a complexdisorder in which many biological pathways are disrupted due to multi-omic perturbations which can bedetected in brain and reflected in blood i.e. centrally-linked peripheral molecular signatures (CLPMS). ThisU19 will leverage deeply phenotyped longitudinal NIH-funded multi-ethnic cohorts and cross-disciplinaryexpertise for multi-omics data generation and its integration with harmonized AD endophenotypes will sharethese data and utilize them in integrated U19 projects to discover CLPMS that will serve as the next generationof AD biomarkers.,NIA,10808852,4/15/2024 12:00:00 AM,PAR-19-374,5U19AG074879-02,5,U19,AG,074879,02, ,"ARUNKUMAR, NANDINI",3/15/2023 12:00:00 AM,2/29/2028 12:00:00 AM,ZAG1-ZIJ-G(O2), ,6917017,"ERTEKIN-TANER, NILUFER ","CARRASQUILLO, MINERVA MARIA; NHO, KWANGSIK TIMOTHY; SAYKIN, ANDREW J",05,Unavailable,153223151,GKPBCFV1QMM3,153223151,GKPBCFV1QMM3,US,30.264703,-81.444793,4976105,MAYO CLINIC JACKSONVILLE,JACKSONVILLE,FL,Other Domestic Non-Profits,322241865,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,8291222, ,NIA,6729848,1561374, ,8291222,,8291222.0 | |
| No NIH Category available,Acceleration;Accountability;African American;African American population;Aging;Agreement;Algorithms;Alzheimer's Disease;Alzheimer's disease model;Alzheimer's disease therapeutic;Alzheimers disease biomarker;American;Autopsy;Biological Markers;Blood;Blood Vessels;Blood specimen;Brain;Cell Nucleus;Cerebrospinal Fluid;Clinic;Collaborations;Communication;Communities;Complex;DNA Methylation;Data;Data Set;Dementia;Diagnostic;Discipline;Disease;Education and Outreach;Ensure;Ethnic Population;Etiology;Feedback;Funding;Future;Generations;Goals;Hematological Disease;Indiana;Individual;Institution;Institutional Review Boards;Knowledge;Knowledge Portal;Latino;Leadership;Link;Medicine;Michigan;Molecular;Molecular Profiling;Multiomic Data;Not Hispanic or Latino;Outcome;Participant;Peripheral;Phenotype;Proteome;Reproducibility;Research;Research Personnel;Resources;Sampling;Scholars Program;Scientist;Training;Training Programs;Underrepresented Populations;United States National Institutes of Health;Universities;Washington;Work;candidate marker;career;cohort;data integration;data sharing;endophenotype;epigenome;insight;lipidome;material transfer agreement;meetings;metabolome;multi-ethnic;multiple omics;neuroimaging;neuropathology;next generation;open data;outreach;prognostic;programs;repository;resilience;success;symposium;transcriptome;transcriptome sequencing;trial readiness;working group,Administrative Core,,NIA,10808853,4/15/2024 12:00:00 AM,PAR-19-374,5U19AG074879-02,5,U19,AG,74879,2, , ,3/15/2023 12:00:00 AM,2/29/2028 12:00:00 AM,ZAG1-ZIJ-G,6417,6917017,"ERTEKIN-TANER, NILUFER ",Not Applicable,5.0,Unavailable,153223151,GKPBCFV1QMM3,153223151,GKPBCFV1QMM3,US,30.264703,-81.444793,4976105,MAYO CLINIC JACKSONVILLE,JACKSONVILLE,FL,Other Domestic Non-Profits,322241865,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,477413, ,412581,64832, , ,, | |
| No NIH Category available,Alzheimer's Disease;Alzheimer's disease risk;Alzheimers disease biomarker;Amyloid;Amyloid beta-Protein;Autopsy;Biological Markers;Biometry;Blood;Brain;Calibration;Clinical;Cognition;Cognitive;Communities;Complex;Computational Biology;Computing Methodologies;DNA Methylation;Data;Data Analyses;Databases;Deposition;Development;Diffusion Magnetic Resonance Imaging;Disease Progression;Documentation;Environment;Ethnic Population;Functional Magnetic Resonance Imaging;Genetic;Genetic Transcription;Genetic study;Genotype;Goals;Image;Institution;Link;Magnetic Resonance Imaging;Measures;Methods;Molecular;Molecular Profiling;Multiomic Data;Nerve Degeneration;Neurofibrillary Tangles;Pathway Analysis;Peripheral;Phenotype;Positron-Emission Tomography;Process;Proteomics;Research Personnel;Rest;Risk;Sampling;Science;Senile Plaques;Standardization;System;Systems Biology;Team Process;Tissues;Visualization;Work;advanced system;brain tissue;cerebrovascular;cohort;computerized data processing;data analysis pipeline;data framework;data harmonization;data integration;data mining;data visualization;deep learning;endophenotype;fluorodeoxyglucose positron emission tomography;genetic association;genome wide association study;high dimensionality;high throughput analysis;interoperability;lipidomics;metabolomics;method development;multi-ethnic;multidimensional data;multidisciplinary;multimodal neuroimaging;multimodality;multiple omics;neuroimaging;neuropathology;novel;phenome;phenotypic data;polygenic risk score;risk prediction;risk stratification;tau Proteins;transcriptome sequencing;whole genome,Analytics Core,,NIA,10808855,4/15/2024 12:00:00 AM,PAR-19-374,5U19AG074879-02,5,U19,AG,074879,02, , ,3/15/2023 12:00:00 AM,2/29/2028 12:00:00 AM,ZAG1-ZIJ-G,6419,10941211,"NHO, KWANGSIK TIMOTHY",Not Applicable,05,Unavailable,153223151,GKPBCFV1QMM3,153223151,GKPBCFV1QMM3,US,30.264703,-81.444793,4976105,MAYO CLINIC JACKSONVILLE,JACKSONVILLE,FL,Other Domestic Non-Profits,322241865,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,1104026, ,1037732,66294, , ,, | |
| No NIH Category available,African American;Aging;Alzheimer's Disease;Alzheimer's disease brain;Alzheimer's disease pathology;Alzheimer's disease related dementia;Alzheimers disease biomarker;American;Autopsy;Biological;Biological Markers;Blood;Blood Vessels;Blood specimen;Brain;Brain region;Cell Nucleus;Cerebrospinal Fluid;Clinic;Clinical;Cognition;Cognitive;Collaborations;Communities;Complex;Data;Diagnosis;Diagnostic;Disease;Disease Progression;Early Diagnosis;Epigenetic Process;Ethnic Population;Florida;Functional disorder;Future;Gene Expression Profile;Genes;Genetic;Genome;Image;Individual;Knowledge;Latino;Link;Longitudinal cohort;Measures;Molecular;Molecular Profiling;Multiomic Data;Natural Immunity;Outcome;Participant;Pathway Analysis;Pathway interactions;Pattern;Peripheral;Phenotype;Population;Population Heterogeneity;Proteins;Proteome;RNA;Resources;Sampling;Symptoms;Synapses;Testing;Therapeutic;Therapeutic Intervention;Transcript;Translations;advanced analytics;artificial neural network;biomarker discovery;blood-based biomarker;brain cell;cell type;cohort;comparative;cost effective;disease phenotype;disorder subtype;lipidome;metabolome;methylome;multi-ethnic;multiple omics;myelination;neuroimaging;neuropathology;novel;patient stratification;peripheral blood;personalized medicine;precision medicine;preservation;prognostic;random forest;single nucleus RNA-sequencing;transcriptome;transcriptome sequencing;transcriptomic profiling;translational approach;translational study;validation studies,Discovering Centrally Linked Peripheral Molecular Signatures of Alzheimer's Disease,,NIA,10808858,4/15/2024 12:00:00 AM,PAR-19-374,5U19AG074879-02,5,U19,AG,074879,02, , ,3/15/2023 12:00:00 AM,2/29/2028 12:00:00 AM,ZAG1-ZIJ-G,6420,6917017,"ERTEKIN-TANER, NILUFER ",Not Applicable,05,Unavailable,153223151,GKPBCFV1QMM3,153223151,GKPBCFV1QMM3,US,30.264703,-81.444793,4976105,MAYO CLINIC JACKSONVILLE,JACKSONVILLE,FL,Other Domestic Non-Profits,322241865,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,834045, ,566009,268036, , ,, | |
| No NIH Category available,Address;Attention;Award;Biological Markers;Brain;Chronic;Clinical;Cognitive;Cognitive deficits;Coupling;Cues;Data;Development;Effectiveness of Interventions;Electroencephalography;Etiology;Event;Exhibits;Frequencies;Functional impairment;Future;Goals;Illness impact;Impaired cognition;Impairment;Individual;Intervention;Learning;Link;Literature;Maintenance;Measurement;Measures;Memory;Memory impairment;National Institute of Mental Health;Participant;Perception;Performance;Persons;Phase;Play;Population;Process;Protocols documentation;Psychophysiology;Psychoses;Psychotic Disorders;Research Personnel;Role;Series;Short-Term Memory;Signal Transduction;Specificity;Training;Validation;Variant;Visual;Work;candidate marker;clinical biomarkers;cognitive ability;design;effective intervention;first episode psychosis;improved;memory consolidation;memory process;memory retention;neural;neurobiological mechanism;neurofeedback;novel;peer;personalized intervention;psychotic symptoms;remediation;response;severe mental illness;therapy development,Measurement and manipulation of oscillatory biomarker of working memory in psychosis,Project NarrativeAlthough it is widely known that people with psychosis have reduced cognitive ability compared to theirpsychiatrically healthy peers the neurobiological mechanisms that give rise to this impairment remain poorlyunderstood. In this project we will evaluate the role of a promising candadite biomarker of working memorydysfunctiona core cognitive deficit commonly observed in people with psychosis. Using EEG we will (1)isolate a core psychophysiological process involved in working memory; (2) measure the impact of psychosisand illness chronicity on this biomarker; and (3) manipulate this biomarker using neurofeedback and measurethe effects of this manipulation on working memory capacity.,NIMH,10808860,1/18/2024 12:00:00 AM,PA-19-055,5R01MH121671-05,5,R01,MH,121671,05, ,"MORRIS, SARAH E",3/5/2020 12:00:00 AM,1/31/2025 12:00:00 AM,Adult Psychopathology and Disorders of Aging Study Section[APDA], ,11882675,"ERICKSON, MOLLY ",Not Applicable,01,PSYCHIATRY,005421136,ZUE9HKT2CLC9,005421136,ZUE9HKT2CLC9,US,41.789554,-87.601172,1413601,UNIVERSITY OF CHICAGO,CHICAGO,IL,SCHOOLS OF MEDICINE,606372612,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,242,Non-SBIR/STTR,2024,564079, ,NIMH,384225,179854, ,564079,,564079.0 | |
| No NIH Category available,Acceleration;African;Alzheimer's Disease;Alzheimer's disease model;Alzheimer's disease related dementia;Alzheimers disease biomarker;American;Amyloid;Artificial Intelligence;Biological;Biological Markers;Blood;Blood Vessels;Brain;Clinical;Clinical Trials;Cognition;Cognitive;Cohort Studies;Collaborations;Communities;Coupled;DNA;DNA Methylation;Data;Data Set;Dementia;Diagnostic;Disease;Disease Progression;Early Diagnosis;Epigenetic Process;Ethnic Population;Functional Magnetic Resonance Imaging;Functional disorder;Funding;Future;Genes;Genetic;Genetic Transcription;Goals;Heterogeneity;Immune;Immunity;Indiana;Latino;Length;Link;Liquid substance;Machine Learning;Magnetic Resonance Imaging;Modality;Modeling;Molecular;Molecular Profiling;Multimodal Imaging;Multiomic Data;Mus;Nerve Degeneration;Outcome;Participant;Pathway interactions;Patients;Peripheral;Population;Positron-Emission Tomography;Process;Proteomics;RNA;Research;Risk;Sampling;Site;Synapses;Testing;Therapeutic;Time;Transcript;Validation;Variant;biomarker identification;brain tissue;candidate marker;causal model;cerebrovascular;cognitive change;cognitive performance;cohort;design;differential expression;endophenotype;follow-up;genome sequencing;induced pluripotent stem cell;insight;lipidomics;longitudinal analysis;metabolomics;multi-ethnic;multimodal neuroimaging;multiple omics;myelination;neuroimaging;novel;open data;peripheral blood;polygenic risk score;precision medicine;predictive marker;predictive modeling;tau Proteins;telomere;therapeutic biomarker;therapeutic target;transcriptome sequencing;transcriptomics;translational approach;validation studies;whole genome,Longitudinal Blood-based Transcriptomic Changes in AD: Relation to Clinical and Biomarker Data,,NIA,10808861,4/15/2024 12:00:00 AM,PAR-19-374,5U19AG074879-02,5,U19,AG,074879,02, , ,3/15/2023 12:00:00 AM,2/29/2028 12:00:00 AM,ZAG1-ZIJ-G,6421,1959346,"SAYKIN, ANDREW J",Not Applicable,05,Unavailable,153223151,GKPBCFV1QMM3,153223151,GKPBCFV1QMM3,US,30.264703,-81.444793,4976105,MAYO CLINIC JACKSONVILLE,JACKSONVILLE,FL,Other Domestic Non-Profits,322241865,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,676346, ,676346,0, , ,, | |
| No NIH Category available,Address;Adopted;Advanced Malignant Neoplasm;Biological;Biological Assay;Biological Markers;Biopsy;Blood;Blood Tests;Cancer Patient;Caring;Clinical;Clinical Trials;Communities;Complement;DNA analysis;Dana-Farber Cancer Institute;Data;Development;Diagnostic;Drug Targeting;Drug resistance;Effectiveness;Epidermal Growth Factor Receptor;FDA approved;Generations;Genomics;Genotype;Grant;Image;Immuno-Chemotherapy;Immunotherapy;Institution;Intuition;Investigational Therapies;KRAS2 gene;Malignant Neoplasms;Malignant neoplasm of lung;Measurement;Measures;Methods;Molecular;Monitor;Mutation;Nature;Non-Small-Cell Lung Carcinoma;Oncogenes;Oral;Outcome;Patient Care;Patients;Performance;Pharmaceutical Preparations;Plasma;Positioning Attribute;ROS1 gene;Research Personnel;Specimen;Testing;Therapeutic Trials;Translating;Treatment outcome;Validation;Variant;cancer care;cancer imaging;cancer therapy;chemotherapy;clinical application;clinical trial analysis;cohort;effective therapy;experience;improved;innovation;insight;liquid biopsy;mutant;next generation sequencing;novel diagnostics;novel therapeutics;pembrolizumab;radiological imaging;response;response biomarker;targeted treatment;tool;treatment effect;treatment response;tumor;tumor DNA,Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer,Project NarrativeGenomic analysis of plasma circulating tumor DNA has been adopted widely for genotyping of advancedcancer to select targeted therapies. This noninvasive biomarker also offers clear potential for evaluatingtreatment response though no rigorous criteria have been established for determining when to assessresponse in plasma and how much change is meaningful. In this grant we will identify a criterion for plasmaresponse and evaluate its utility in clinical trial analysis and in guiding the care of lung cancer patients receivingfirst-line immunotherapy.,NCI,10808863,1/12/2024 12:00:00 AM,PA-18-629,5R01CA240592-05,5,R01,CA,240592,05, ,"OSSANDON, MIGUEL",2/15/2020 12:00:00 AM,1/31/2025 12:00:00 AM,Clinical Oncology Study Section[CONC], ,11726277,"PAWELETZ, CLOUD PETER",Not Applicable,07,Unavailable,076580745,DPMGH9MG1X67,076580745,DPMGH9MG1X67,US,42.337593,-71.108279,1464901,DANA-FARBER CANCER INST,BOSTON,MA,Independent Hospitals,022155450,UNITED STATES,N,2/1/2024 12:00:00 AM,1/31/2025 12:00:00 AM,394,Non-SBIR/STTR,2024,326540, ,NCI,187226,139314, ,326540,,326540.0 | |
| No NIH Category available,Address;African American population;Alcohol consumption;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimer's disease patient;Alzheimer's disease risk;Alzheimers disease biomarker;American;Amyloid;Autopsy;Biological;Biological Markers;Biomedical Research;Blood;Blood Vessels;Blood specimen;Brain;California;Characteristics;Clinic;Clinical;Clinical Trials;Cognition;Cognitive;Cohort Analysis;Collection;Community Outreach;Data;Dementia;Development;Diabetes Mellitus;Diagnosis;Disease;Disease Progression;Disparity;Education;Epigenetic Process;Ethnic Population;Evaluation;Exhibits;Frequencies;Funding;Genes;Genetic;Genetic Risk;Genetic Variation;Genotype;Goals;High Prevalence;Hypertension;Impaired cognition;Incidence;Indiana;Individual;Institution;Knowledge;Latino;Link;Measures;Methylation;Michigan;Molecular;Molecular Profiling;Multiomic Data;Nerve Degeneration;Not Hispanic or Latino;Participant;Pathway interactions;Pattern;Peripheral;Phenotype;Plasma;Population;Preventive therapy;Prognostic Marker;Research;Resources;Sample Size;Sampling;Sensitivity and Specificity;Smoking;Subgroup;Testing;Time;Transcript;Translations;Underrepresented Populations;Universities;Validation;cerebrovascular;clinical diagnosis;cohort;comorbidity;comparative;data analysis pipeline;data archive;dementia risk;diagnostic biomarker;differential expression;endophenotype;genetic variant;genomic locus;image archival system;improved;lifestyle factors;longitudinal analysis;methylome;mild cognitive impairment;minimally invasive;multi-ethnic;multiple omics;neuroimaging;neuron loss;novel;outreach program;polygenic risk score;potential biomarker;precision medicine;predictive marker;preventive intervention;recruit;research study;risk variant;sample collection;tau Proteins;therapy design;therapy development;transcriptome;transcriptome sequencing;transcriptomics;trial readiness;whole genome,Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse Cohorts,,NIA,10808864,4/15/2024 12:00:00 AM,PAR-19-374,5U19AG074879-02,5,U19,AG,074879,02, , ,3/15/2023 12:00:00 AM,2/29/2028 12:00:00 AM,ZAG1-ZIJ-G,6422,9336199,"CARRASQUILLO, MINERVA MARIA",Not Applicable,05,Unavailable,153223151,GKPBCFV1QMM3,153223151,GKPBCFV1QMM3,US,30.264703,-81.444793,4976105,MAYO CLINIC JACKSONVILLE,JACKSONVILLE,FL,Other Domestic Non-Profits,322241865,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM, ,Non-SBIR/STTR,2024, ,498377, ,349528,148849, , ,, | |
| No NIH Category available,Affect;Automobile Driving;Biological Assay;Biological Markers;Biological Models;British Columbia;Cancer Patient;Castration;Cell Death;Cell Line;Clinic;Clinical;Clinical Trials;Collaborations;DNA Sequence Alteration;Data;Death Rate;Disease;Drug Combinations;Epithelium;Event;Family;Foundations;Future;Genetic;Genetically Engineered Mouse;Immunohistochemistry;In Vitro;Individual;Investigation;Iron;Knowledge;Lipid Peroxidation;Malignant Breast Neoplasm;Malignant Neoplasms;Malignant neoplasm of lung;Malignant neoplasm of prostate;Modeling;Molecular;Neoplasm Metastasis;Neurosecretory Systems;Outcome;Pathologic;Pathway interactions;Patients;Personal Satisfaction;Preclinical Testing;Prostate Adenocarcinoma;RB1 gene;Research;Resistance;Role;Safety;Sampling;Stains;Technology;Testing;Therapeutic;Translations;Universities;Up-Regulation;Validation;Work;Xenograft Model;biomarker development;biomarker identification;cancer therapy;castration resistant prostate cancer;design;drug candidate;experience;improved;in vivo;in vivo evaluation;insight;interdisciplinary approach;men;mouse model;novel;novel therapeutic intervention;novel therapeutics;patient derived xenograft model;pre-clinical;preclinical study;prostate cancer cell;prostate cancer model;rational design;targeted treatment;therapeutically effective;tumor;tumor xenograft,Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer,Project NarrativeLoss of RB function is a dominant mechanism driving prostate cancer lethality. It is therefore critical to identifypotential therapeutic strategies targeting this disease mechanism to reduce prostate cancer mortality rates andimprove the well-being of patients and their families who are experiencing the impact of the disease. Our workwill delineate downstream effectors of the RB/E2F pathway and provide novel insights into the contributions ofRB to ferroptosis as well as the preclinical data regarding efficacy safety and biomarkers required for the rationaldesign of future clinical trials targeting ferroptosis as a therapeutic approach to treating lethal RB1-deficientprostate cancer.,NCI,10808914,3/8/2024 12:00:00 AM,PA-20-185,5R01CA269211-03,5,R01,CA,269211,03, ,"VENKATACHALAM, SUNDARESAN",4/1/2022 12:00:00 AM,3/31/2027 12:00:00 AM,Mechanisms of Cancer Therapeutics - 1 Study Section[MCT1], ,6774848,"CHEN, MING ",Not Applicable,04,PATHOLOGY,044387793,TP7EK8DZV6N5,044387793,TP7EK8DZV6N5,US,36.007766,-78.926475,2221101,DUKE UNIVERSITY,DURHAM,NC,SCHOOLS OF MEDICINE,277054673,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,395,Non-SBIR/STTR,2024,399133, ,NCI,251626,147507, ,399133,,399133.0 | |
| No NIH Category available,Acetylcysteine;Archives;Area;Biological Markers;Blindness;Certification;Characteristics;Clinical;Clinical Trials;Collaborations;Computer software;Custom;Cysteine;Data;Databases;Disease;Disease Progression;Electronics;Ensure;Eye;Goals;Group Meetings;Health;Human Resources;Image;Infrastructure;Inherited;Length;Manuals;Measures;Methods;Modernization;Optical Coherence Tomography;Phase;Photoreceptors;Placebos;Process;Protocols documentation;Public Health;Publications;Quality Control;Reader;Reading;Reproducibility;Research Personnel;Resources;Retina;Retinal Diseases;Retinitis Pigmentosa;Scanning;Secure;Site;Software Validation;Standardization;System;Testing;Time;Training;Width;adaptive optics;clinical research site;comparison control;cost;data exchange;data submission;deep learning algorithm;design;electronic data;imaging modality;novel;programs;randomized placebo controlled trial;recruit;retinal imaging;social;software development;software systems;time use;transmission process;web platform,NAC Attack a phase-3 multicenter randomized placebo-controlled trial with retinitis pigmentosa: OCT Reading Center,Project NarrativeRetinitis pigmentosa is a group of blinding diseases and is the most common cause ofinherited retinal diseases causing vision loss. Modern retinal imaging methods can non-invasively measure the progression of these disorders. The proposed project isimportant to public health because we will accurately quantify biomarkers of disease onretinal images to determine whether a novel treatment N-acetyl cysteine cansignificantly slow the progression of this devastating condition which would therebyreduce personal financial social and health burden costs.,NEI,10808922,2/23/2024 12:00:00 AM,PAR-21-043,5UG1EY033287-03,5,UG1,EY,033287,03, ,"EVERETT, DONALD F",3/17/2022 12:00:00 AM,2/28/2027 12:00:00 AM,ZEY1-VSN(02), ,1933399,"JAFFE, GLENN ","FARSIU, SINA ",04,OPHTHALMOLOGY,044387793,TP7EK8DZV6N5,044387793,TP7EK8DZV6N5,US,36.007766,-78.926475,2221101,DUKE UNIVERSITY,DURHAM,NC,SCHOOLS OF MEDICINE,277054673,UNITED STATES,N,3/1/2024 12:00:00 AM,2/28/2025 12:00:00 AM,867,Other Research-Related,2024,259193, ,NEI,166100,93093, ,259193,,259193.0 | |
| No NIH Category available,10 year old;20 year old;Acute Lymphocytic Leukemia;Address;Adolescent and Young Adult;Adult;Affect;Age;Ambulatory Blood Pressure Monitoring;Angiotensin-Converting Enzyme Inhibitors;Anti-Hypertensive Agents;Attenuated;Autoimmune Diseases;Award;Biological Markers;Biology;Blood;Blood Vessels;Bone necrosis;Cessation of life;Child;Childhood Acute Lymphocytic Leukemia;Clinic;Clinical;Clinical Investigator;Clinical Trials;Clinical Trials Design;Combination Drug Therapy;Data;Development;Development Plans;Diagnosis;Echocardiography;Elasticity;Endothelium;Enrollment;Evaluation;Functional disorder;Future;Genetic study;Glucocorticoids;Glutamates;Goals;Grant;Health;Height;Hip region structure;Hodgkin Disease;Human;Hypertension;Impairment;Institution;Intervention;Joints;K-Series Research Career Programs;Knee;Knowledge;Left;Lesion;Link;Long-Term Survivors;Magnetic Resonance Imaging;Malignant Childhood Neoplasm;Malignant Neoplasms;Measures;Mentorship;Modeling;Modernization;Morbidity - disease rate;Mus;Nitric Oxide Synthase;Operative Surgical Procedures;Orthopedic Surgery;Outcome;Pain;Patient Outcomes Assessments;Patients;Perfusion;Physical activity;Physiologic pulse;Physiological;Physiology;Plasminogen Activator Inhibitor 1;Population;Prevention;Quality of life;Randomized;Randomized Controlled Trials;Regimen;Regression Analysis;Replacement Arthroplasty;Reporting;Research;Research Personnel;Risk;Risk Factors;Scientist;Severities;Site;Stratification;Structure;Symptoms;Testing;Time;Toxin;Training;Training Support;Translating;Treatment-related toxicity;Validation;Variant;Vascular Diseases;Vasodilator Agents;Vasomotor;Ventricular;acute toxicity;arm;biomarker identification;blood pressure control;bone;career;career development;chemotherapy;cohort;didactic education;disability;experience;follow-up;genetic variant;health related quality of life;high risk;histological specimens;hypertension control;hypertensive;improved;leukemia;leukemia treatment;mouse model;normotensive;novel;patient stratification;pre-clinical;pressure;prevent;prospective;radiological imaging;receptor;reduce symptoms;sex;side effect;skills;tool;treatment arm;trial planning;von Willebrand Factor;young adult,Hypertension Intervention to Reduce Osteonecrosis in Children with Acute Lymphoblastic Leukemia,Project NarrativeThis project will test a novel intervention (intensive antihypertensive control) to determine if it will decreaseosteonecrosis in children with acute lymphoblastic leukemia (ALL) while also identifying biomarkers ofosteonecrosis risk. This can reduce a side-effect of therapy causing lifelong disability a crucial goal becausemore than 90% of children with ALL will become long-term survivors. Identification of both interventions andbiomarkers for osteonecrosis will have broad significance as this side-effect complicates therapy not only ofALL but for other cancers and autoimmune diseases which use glucocorticoids.,NCI,10808924,2/27/2024 12:00:00 AM,PA-19-116,5K08CA250418-05,5,K08,CA,250418,05, ,"RADAEV, SERGEY",4/1/2020 12:00:00 AM,3/31/2025 12:00:00 AM,Career Development Study Section (J)[NCI-J], ,14779709,"KAROL, SETH EVAN",Not Applicable,09,Unavailable,067717892,JL4JHE9SDRR3,067717892,JL4JHE9SDRR3,US,35.155607,-90.045279,7893501,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,MEMPHIS,TN,Independent Hospitals,381053678,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,398,Other Research-Related,2024,224070, ,NCI,207472,16598, ,224070,,224070.0 | |
| No NIH Category available,3-Dimensional;Affect;Age;Aneurysm;Aneurysmal Subarachnoid Hemorrhages;Angiography;Arteries;Blood;Blood - brain barrier anatomy;Catheters;Cerebral Infarction;Cerebral Ischemia;Cerebral hemisphere hemorrhage;Cerebrovascular Spasm;Cerebrum;Clinical;Clinical Trials;Clip;Coagulation Process;Cognitive;Complication;Derivation procedure;Diagnosis;Early treatment;Endothelin Receptor Antagonist;Enrollment;FDA approved;Future;Gene Expression;Genes;Hemorrhage;Human;Image;Inflammation;Inflammatory;Ischemia;Ischemic Stroke;Machine Learning;Measures;Medical;Meta-Analysis;Modeling;Morbidity - disease rate;Myocardial dysfunction;Neurologic;Nimodipine;Outcome;Pathway interactions;Patients;Peripheral;Pharmaceutical Preparations;Phase;Placebos;Prevention;Pulmonary Edema;Quantitative Reverse Transcriptase PCR;Resource Allocation;Sensitivity and Specificity;Societies;Stroke;Subarachnoid Hemorrhage;Survivors;Systemic Inflammatory Response Syndrome;Thrombosis;Training;Validation;Vasospasm;Whole Blood;Work;biomarker signature;care costs;cerebral microvasculature;cohort;cost;improved;improved outcome;mortality;outcome prediction;patient stratification;peripheral blood;prevent;randomized clinical trials;repaired;spreading depression;stroke patient;support vector machine;transcriptome;transcriptome sequencing;treatment trial;vascular inflammation;vascular risk factor;whole genome,Biomarker Signatures for Delayed Cerebral Ischemia and Outcome Following Subarachnoid Hemorrhage,Narrative This proposal will perform RNAseq on blood of a derivation cohort of subarachnoid hemorrhage (SAH)patients to determine those genes that best predict Delayed Cerebral Ischemia (DCI) between 4 and 14 daysand that predict median Rankin Scores (mRS) outcomes at 90 days using cross-correlation. These genes arethen measured in an independent validation cohort of SAH patients to predict who develops DCI by 14d and topredict their mRS at 90 days after SAH. The studies will direct early treatment for DCI identify treatmenttargets for DCI and help stratify patients for future DCI treatment trials.,NINDS,10809562,2/6/2024 12:00:00 AM,PAR-19-315,4R33NS119345-04,4,R33,NS,119345,04, ,"TAYLOR-BURDS, CAROL C",1/1/2021 12:00:00 AM,1/31/2026 12:00:00 AM,Neurological Sciences and Disorders A Study Section[NSD-A], ,1862644,"SHARP, FRANK R","ANDER, BRADLEY PEARCE; STAMOVA, BORYANA ",04,NEUROLOGY,047120084,TX2DAGQPENZ5,047120084,TX2DAGQPENZ5,US,38.543366,-121.72946,577503,UNIVERSITY OF CALIFORNIA AT DAVIS,DAVIS,CA,SCHOOLS OF MEDICINE,956186153,UNITED STATES,N,2/15/2024 12:00:00 AM,1/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,599599, ,NINDS,458454,141145, ,599599,,599599.0 | |
| No NIH Category available,Alcohol consumption;Amino Acids;Anti-viral Agents;Anti-viral Therapy;Ascites;Bile Acids;Biological;Biological Markers;Biology;Blood;Caring;Ceramides;Cessation of life;Cirrhosis;Clinical;Development;Disease;Enrollment;Ensure;Esophagus;Etiology;Event;Fibrosis;Future;Goals;HCV Cirrhosis;HIV;HIV/HCV;Health;Health Personnel;Hemorrhage;Hepatic;Hepatic Encephalopathy;Hepatitis C;Hepatitis C Therapy;Hepatitis C co-infection;Hepatitis C virus;Knowledge;Laboratories;Lecithin;Lipids;Liver;Liver Fibrosis;Liver diseases;Mediating;Membrane Lipids;Metabolic;Metabolic syndrome;Modeling;Nested Case-Control Study;Obesity;Observational Study;Pathogenesis;Pathway interactions;Patients;Peripheral;Peritonitis;Persons;Pilot Projects;Plasma;Primary carcinoma of the liver cells;Proteins;Proteomics;Residual state;Risk;Site;Sphingomyelins;Subgroup;Testing;Tissues;Transcript;Translational Research;United States;United States Department of Veterans Affairs;Validation;Veterans;Viral;acylcarnitine;biomarker validation;biosignature;case control;clinical predictors;co-infection;cohort;comorbidity;design;fatty acid oxidation;follow-up;high dimensionality;high risk;improved;lipid metabolism;liver cancer model;liver injury;metabolic profile;metabolomics;military veteran;mortality;multiple omics;new therapeutic target;non-alcoholic fatty liver disease;novel;novel marker;novel therapeutics;peripheral blood;predict clinical outcome;predictive modeling;prognostic;prospective;response;risk prediction;risk stratification;therapeutic target;transcriptomics,Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy,This VA Merit Review Application is highly relevant to the health of Veterans as it seeks to develop novelbiomarkers to improve risk stratification of Veterans with significant liver disease who have achieved HCV cure.The Department of Veterans Affairs is the single largest hepatitis C virus infection health care provider in theUnited States. Since the introduction of direct acting antivirals for the treatment of HCV infection in 2014 VA hascured over 100000 Veterans. Due to the high rate of comorbidities in the veteran population including HIV co-infection alcohol use and obesity and metabolic syndrome rates of severe liver fibrosis prior to DAA therapyare high and likely to persist despite cure. To date there are no reliable laboratory tests or biomarkers todifferentiate patients with the greatest risk of post-SVR decompensation events HCC and liver-related death.This is a critical unmet clinical need that is highly relevant to clinicians who care for Veterans cured of their HCVinfection but with significant residual liver disease and/or ongoing liver injury.,VA,10809572,11/6/2023 12:00:00 AM,RFA-CX-20-001,5I01CX002147-03,5,I01,CX,002147,03, , ,10/1/2021 12:00:00 AM,9/30/2025 12:00:00 AM,ZRD1-GAST-L(01)1, ,10462486,"NAGGIE, SUSANNA ","MOYLAN, CYNTHIA A",04,Unavailable,043241082,FWJ7MMLUN2M1,043241082,FWJ7MMLUN2M1,US,36.00896,-78.937364,481065,DURHAM VA MEDICAL CENTER,DURHAM,NC,Independent Hospitals,277053875,UNITED STATES,N,10/1/2023 12:00:00 AM,9/30/2024 12:00:00 AM,999,Non-SBIR/STTR,2024, , , , , , , ,, | |
| No NIH Category available,Affect;African American;African American population;African Caribbean;Age;Aging;Alzheimer's Disease;Alzheimer's disease diagnosis;Alzheimers disease biomarker;Amyloid;Amyloid beta-42;Amyloid beta-Protein;Autopsy;Biological;Biological Markers;Blood;Brain imaging;Caribbean Hispanic;Cerebrospinal Fluid;Cerebrovascular Disorders;Classification;Classification Scheme;Clinical;Cognition;Cognitive;Communities;Community Networks;Cross-Sectional Studies;Cyclotrons;DNA;Data;Data Set;Dementia;Development;Diagnosis;Disease;Early Diagnosis;Education;Elderly;Environment;Epidemiology;Ethnic Origin;Ethnic Population;Genetic;Genetic Predisposition to Disease;Genetic Research;Genotype;Goals;Height;Hemorrhage;Image;Impaired cognition;Individual;Infarction;Investigation;Life Cycle Stages;Light;Magnetic Resonance Imaging;Measures;Mexican Americans;Mind;Molecular;Neighborhoods;Nerve Degeneration;Not Hispanic or Latino;Observational Study;Observational epidemiology;Occupations;Outcome;Participant;Phenotype;Plasma;Population;Positron-Emission Tomography;Psychosocial Factor;Quantitative Trait Loci;Race;Risk Factors;SNP array;SNP genotyping;Sampling;Socioeconomic Status;Therapeutic Trials;Thick;Time;Universities;Variant;Vascular Diseases;Washington;White Matter Hyperintensity;Whole Blood;base;blood-based biomarker;brain magnetic resonance imaging;brain volume;cerebral atrophy;clinical diagnosis;cohort;endophenotype;epidemiology study;exome;follow-up;genetic analysis;genetic predictors;genome sequencing;genome-wide;health care availability;health disparity;imaging biomarker;improved;indexing;longitudinal analysis;magnetic resonance imaging biomarker;metabolic abnormality assessment;mild cognitive impairment;molecular imaging;multi-ethnic;neurofilament;neuroimaging marker;neuropathology;phenotypic data;polygenic risk score;prospective;protective factors;psychosocial;racial population;sex;social;social health determinants;tau Proteins;tau-1,Epidemiological and Genetic Investigations of Blood-Based Biomarkers for Alzheimer's Disease in the Multiethnic Washington Heights Inwood Columbia Aging Project (WHICAP),PROJECT NARRATIVE (RELEVANCE)The availability of new blood-based biomarkers provides an opportunity to investigate the application of A/T/Nbiomarker profile in community-based observational study and provide endophenotypes that can be used toidentify genetic research. The Washington Heights Inwood Columbia Aging Project study is one of the fewcohorts where these newly-established blood-based biomarkers (A40 A42 total tau phosporylated-tau217neurofilament light chain or NFL) and well-established neuroimaging biomarkers for AD can be used toinvestigate the application of A/T/N biomarker profile across race/ethnic groups and by age and sex.,NIA,10809607,4/15/2024 12:00:00 AM,PAR-19-070,5R01AG072474-04,5,R01,AG,072474,04, ,"BENNANI-BAITI, MICHAEL",6/1/2021 12:00:00 AM,3/31/2026 12:00:00 AM,"Neurological, Aging and Musculoskeletal Epidemiology Study Section[NAME]", ,1861947,"MAYEUX, RICHARD P","BRICKMAN, ADAM M; MANLY, JENNIFER JAIE",13,NEUROLOGY,621889815,QHF5ZZ114M72,621889815,QHF5ZZ114M72,US,40.8415,-73.9414,1833205,COLUMBIA UNIVERSITY HEALTH SCIENCES,NEW YORK,NY,SCHOOLS OF MEDICINE,100323725,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,866,Non-SBIR/STTR,2024,2833085, ,NIA,1748818,1084267, ,2833085,,2833085.0 | |
| No NIH Category available,Affinity;Age;Antibodies;Benchmarking;Biological Assay;Biological Markers;Biology;Blood;Calibration;Categories;Classification;Clinical;Clinical Data;Clinical Trials;Complement;Cox Models;Data;Decision Making;Diagnostic;Discrimination;Disease;Disease Progression;Duchenne muscular dystrophy;Ensure;Evaluation;Future;Genes;Goals;Intervention;Knowledge;Literature;Mass Spectrum Analysis;Measurement;Measures;Methods;Modeling;Monitor;Muscle;Myopathy;Netherlands;Outcome Measure;Pathogenesis;Patients;Performance;Phase;Physicians;Program Development;Proteins;Proteomics;Publishing;Reproducibility;Sampling;Sensitivity and Specificity;Serum;Serum Proteins;Severity of illness;Signal Transduction;Specificity;Statistical Methods;Testing;Time;Training;Translating;Validation;Vital capacity;aptamer;bench to bedside;biomarker discovery;biomarker signature;blood-based biomarker;burden of illness;candidate marker;clinical biomarkers;clinical predictors;cohort;drug development;effective therapy;follow-up;performance tests;prognostic;prospective;protein biomarkers;response;screening;tandem mass spectrometry;tool,Biomarker Signatures for Duchenne Muscular Dystrophy,PROJECT NARRATIVEBlood-based biomarkers are urgently needed as alternative outcome measures in DMD. In this study we seekto define monitoring biomarker signatures for DMD to assess disease course and changes in disease. We willuse longitudinal serum samples including clinical data collected from well defined and well annotated cohortsand apply our internally developed and validated quantitative proteomics assays to develop such biomarkersignatures. Finally the signatures developed will be validated in external samples.,NINDS,10809611,3/11/2024 12:00:00 AM,PAR-19-315,5R61NS119639-03,5,R61,NS,119639,03, ,"TAYLOR-BURDS, CAROL C",4/1/2022 12:00:00 AM,3/31/2025 12:00:00 AM,Neurological Sciences and Disorders B Study Section[NSD-B], ,7937510,"HATHOUT, YETRIB ","DANG, UTKARSH J",19,PHARMACOLOGY,090189965,NQMVAAQUFU53,090189965,NQMVAAQUFU53,US,42.09521,-75.964561,5992621,"STATE UNIVERSITY OF NY,BINGHAMTON",BINGHAMTON,NY,SCHOOLS OF PHARMACY,139026000,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,853,Non-SBIR/STTR,2024,535668, ,NINDS,450280,85388, ,535668,,535668.0 | |
| No NIH Category available,Address;Adopted;Adrenal Cortex Hormones;Animal Model;Archives;Asthma;Beds;Bioinformatics;Biological;Biological Products;Birth Weight;Blindness;Blood;Blood specimen;Body Weight;Bronchopulmonary Dysplasia;Childhood;Chronic;Clinical;Clinical Research;Clinical Trials;Coughing;Coupled;Custom;Data;Development;Diagnosis;Disease;Double-Blind Method;Education;Exposure to;FDA approved;Future;Gene Expression;Genes;Genomic approach;Genomics;Goals;Health Care Costs;Health Sciences;Hospitalization;Human;Hyperoxia;Immunity;Immunology;Impairment;Inflammation;Injury;Institution;Instruction;Knowledge;Learning;Life;Lung;Lung Diseases;Medicine;Mental deficiency;Mentored Patient-Oriented Research Career Development Award;Mentors;Modality;Modeling;Monoclonal Antibodies;Morbidity - disease rate;Mutation;Neonatal;Neonatal Intensive Care Units;Outcome;Papio;Pathologic Processes;Pathway interactions;Patient Care;Patients;Persons;Pharmaceutical Preparations;Physicians;Physiology;Predisposition;Pregnancy;Prevention;Prevention strategy;Preventive;Primary Prevention;Process;Pulmonary Hypertension;Recurrence;Research;Respiratory Tract Infections;Risk;Risk Factors;Safety;Scientist;Secondary to;Severities;Severity of illness;Site;Symptoms;T-Lymphocyte;Technology;Testing;Texas;Time;Tissues;Training;Universities;Validation;Ventilator;Ventilator-induced lung injury;Wheezing;biobank;biomarker discovery;career;clinically significant;cohort;disability;efficacy testing;eosinophil;experience;extreme prematurity;genetic signature;genomic profiles;genomic signature;genomic tools;improved;innovation;lung development;lung injury;mortality;nano-string;neonatal lung disease;neonate;novel;novel strategies;patient oriented;peripheral blood;predictive signature;preterm newborn;prevent;professor;prospective;pulmonary function;randomized clinical trials;respiratory;risk stratification;skills;surfactant;text searching;therapeutic target;tool;transcriptome sequencing;transcriptomics;translational genomics;whole genome,Genomic determinants of bronchopulmonary dysplasia development in humans and an animal model,PROJECT NARRATIVEaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaBronchopulmonary dysplasia (BPD) is the most common lung disease in premature neonatescharacterized by long-term respiratory disability frequent hospitalizations and high healthcare costs.This proposal will validate a genomic tool that may predict which neonates are at risk for developingBPD. Moreover we will examine whether an FDA-approved biologic can mitigate genetic changesfound to be associated with BPD risk.,NICHD,10809616,3/22/2024 12:00:00 AM,PA-19-119,5K23HD101701-04,5,K23,HD,101701,04, ,"GUMINA, DIANE LAURA",4/23/2021 12:00:00 AM,3/31/2025 12:00:00 AM,Pediatrics Study Section[CHHD-A], ,14163923,"MOREIRA, ALVARO G",Not Applicable,20,PEDIATRICS,800772162,C3KXNLTAAY98,800772162,C3KXNLTAAY98,US,29.513091,-98.577742,578418,UNIVERSITY OF TEXAS HLTH SCIENCE CENTER,SAN ANTONIO,TX,SCHOOLS OF MEDICINE,782293901,UNITED STATES,N,4/1/2024 12:00:00 AM,3/31/2025 12:00:00 AM,865,Other Research-Related,2024,163080, ,NICHD,151000,12080, ,163080,,163080.0 | |
| No NIH Category available,Accounting;Adherence;Adverse event;Ancillary Study;Architecture;Area;Bioinformatics;Biological Markers;Budgets;Caring;Characteristics;Chronic Disease;Clinical;Clinical Research;Collaborations;Collection;Communication;Complex;Complications of Diabetes Mellitus;Contracts;Data;Data Analyses;Data Analytics;Data Collection;Data Coordinating Center;Databases;Diabetes Mellitus;Diabetic Foot;Diabetic Foot Ulcer;Diagnostic;Ensure;Esapent;FDA approved;Foot Ulcer;Foundations;Future;Goals;Health;Heterogeneity;Infrastructure;Institutional Review Boards;Knowledge;Laboratories;Leadership;Learning;Measurement;Methods;Michigan;Modeling;Monitor;National Institute of Diabetes and Digestive and Kidney Diseases;Observational Study;Online Systems;Outcome;Patient-Focused Outcomes;Patients;Physicians;Process;Protocols documentation;Qualifying;Recurrence;Reporting;Reproducibility;Research Personnel;Sampling Biases;Science;Scientist;Scoring Method;Secure;Services;Site;Statistical Methods;Subgroup;System;Techniques;Therapeutic;Time;Translations;Universities;bench to bedside;biobank;biomarker discovery;biomarker validation;comorbidity;data integration;data management;design;experience;healing;improved;knowledge base;machine learning method;meetings;operation;patient subsets;payment;predictive marker;prevent;repository;safety outcomes;safety study;social health determinants;standard care;standard of care;study population;success;tool;treatment adherence;validation studies;web site;webinar;wound,University of Michigan Data Coordinating Center for the Diabetic Foot Consortium,The Diabetic Foot Consortium aims to validate biomarkers that promote healing and prevent recurrence ofdiabetic foot ulcers and leverage their growing database of patient wound therapies and biomarkercharacteristics to advance standard care. Proper design of biomarker validation studies and analyses usingadvanced machine learning methods are critical to accomplish these goals. With more than 23 years ofexperience the University of Michigan data coordinating center will continue to apply cutting-edge statisticaland operational methods to these studies maximizing the clinical impact of the consortium in this complex andchallenging therapeutic area.,NIDDK,10809721,1/18/2024 12:00:00 AM,RFA-DK-21-505,5U24DK122927-06,5,U24,DK,122927,06, ,"LI, YAN",7/1/2019 12:00:00 AM,12/31/2027 12:00:00 AM,ZDK1-GRB-1(J2), ,9313677,"SPINO, CATHERINE A",Not Applicable,06,BIOSTATISTICS & OTHER MATH SCI,073133571,GNJ7BBP73WE9,073133571,GNJ7BBP73WE9,US,42.275494,-83.743038,1506502,UNIVERSITY OF MICHIGAN AT ANN ARBOR,ANN ARBOR,MI,SCHOOLS OF PUBLIC HEALTH,481091276,UNITED STATES,N,1/1/2024 12:00:00 AM,12/31/2024 12:00:00 AM,847,Other Research-Related,2024,3861668, ,NIDDK,2984784,876884, ,3861668,,3861668.0 | |
| No NIH Category available,Acute;Age;Algorithms;Anatomy;Attenuated;Biological Markers;Brain;Brain Injuries;Brain region;Cerebrum;Child;Childhood;Chronic;Clinical;Cognitive;Data;Development;Erythrocyte Transfusion;Evaluation;Executive Dysfunction;Exposure to;Functional Imaging;Functional Magnetic Resonance Imaging;Functional disorder;Future;Goals;Impaired cognition;Infarction;Injury;Intervention;Ischemia;Link;MRI Scans;Magnetic Resonance Imaging;Measures;Mediating;Mentored Patient-Oriented Research Career Development Award;Metabolic;Metabolic stress;Metabolism;Nervous System Trauma;Outcome;Oxygen;Participant;Patient Care;Patients;Primary Prevention;Rest;Screening procedure;Sickle Cell Anemia;Stroke;Structure;Techniques;Testing;Time;Transcranial Doppler Ultrasonography;Transfusion;Treatment Efficacy;Vulnerable Populations;biomarker development;biomarker validation;brain magnetic resonance imaging;cognitive function;cognitive testing;cohort;comparison control;connectome;disability;efficacy evaluation;executive function;experience;improved;improved outcome;innovation;insight;neuroimaging;neuroimaging marker;novel;patient population;predictive marker;prevent;prospective;recruit;risk prediction model;risk stratification;stroke risk;treatment effect;white matter,The Impact of Cerebral Metabolic Stress on the Development of the Structural and Functional Connectome in Pediatric Sickle Cell Anemia,PROJECT NARRATIVEChildren with sickle cell anemia suffer from progressive cognitive decline as they age yet the pathophysiologyof this cognitive dysfunction is poorly understood which poses a barrier to the development of predictivebiomarkers. Through longitudinal cognitive testing and brain MRIs evaluating metabolic stress structuralconnectivity and functional connectivity we aim to determine the mechanism of cognitive dysfunction inchildren with SCA and develop neuroimaging biomarkers predictive of both acutely reversible injury and long-term cognitive trajectories. The impact of this proposal lies in the potential improvement of ris |
View raw
(Sorry about that, but we can’t show files that are this big right now.)
View raw
(Sorry about that, but we can’t show files that are this big right now.)
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment